0001060736-22-000052.txt : 20220728 0001060736-22-000052.hdr.sgml : 20220728 20220728172044 ACCESSION NUMBER: 0001060736-22-000052 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220728 DATE AS OF CHANGE: 20220728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seagen Inc. CENTRAL INDEX KEY: 0001060736 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911874389 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32405 FILM NUMBER: 221116286 BUSINESS ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4255274000 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: SEATTLE GENETICS INC /WA DATE OF NAME CHANGE: 20001116 10-Q 1 sgen-20220630.htm 10-Q sgen-20220630
false2022Q2000106073612/31http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent00010607362022-01-012022-06-3000010607362022-07-25xbrli:shares00010607362022-06-30iso4217:USD00010607362021-12-31iso4217:USDxbrli:shares0001060736us-gaap:ProductMember2022-04-012022-06-300001060736us-gaap:ProductMember2021-04-012021-06-300001060736us-gaap:ProductMember2022-01-012022-06-300001060736us-gaap:ProductMember2021-01-012021-06-300001060736us-gaap:RoyaltyMember2022-04-012022-06-300001060736us-gaap:RoyaltyMember2021-04-012021-06-300001060736us-gaap:RoyaltyMember2022-01-012022-06-300001060736us-gaap:RoyaltyMember2021-01-012021-06-300001060736us-gaap:LicenseAndServiceMember2022-04-012022-06-300001060736us-gaap:LicenseAndServiceMember2021-04-012021-06-300001060736us-gaap:LicenseAndServiceMember2022-01-012022-06-300001060736us-gaap:LicenseAndServiceMember2021-01-012021-06-3000010607362022-04-012022-06-3000010607362021-04-012021-06-3000010607362021-01-012021-06-300001060736us-gaap:CommonStockMember2020-12-310001060736us-gaap:AdditionalPaidInCapitalMember2020-12-310001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001060736us-gaap:RetainedEarningsMember2020-12-3100010607362020-12-310001060736us-gaap:RetainedEarningsMember2021-01-012021-03-3100010607362021-01-012021-03-310001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001060736us-gaap:CommonStockMember2021-01-012021-03-310001060736us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001060736us-gaap:CommonStockMember2021-03-310001060736us-gaap:AdditionalPaidInCapitalMember2021-03-310001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001060736us-gaap:RetainedEarningsMember2021-03-3100010607362021-03-310001060736us-gaap:RetainedEarningsMember2021-04-012021-06-300001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001060736us-gaap:CommonStockMember2021-04-012021-06-300001060736us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001060736us-gaap:CommonStockMember2021-06-300001060736us-gaap:AdditionalPaidInCapitalMember2021-06-300001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001060736us-gaap:RetainedEarningsMember2021-06-3000010607362021-06-300001060736us-gaap:CommonStockMember2021-12-310001060736us-gaap:AdditionalPaidInCapitalMember2021-12-310001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001060736us-gaap:RetainedEarningsMember2021-12-310001060736us-gaap:RetainedEarningsMember2022-01-012022-03-3100010607362022-01-012022-03-310001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001060736us-gaap:CommonStockMember2022-01-012022-03-310001060736us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001060736us-gaap:CommonStockMember2022-03-310001060736us-gaap:AdditionalPaidInCapitalMember2022-03-310001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001060736us-gaap:RetainedEarningsMember2022-03-3100010607362022-03-310001060736us-gaap:RetainedEarningsMember2022-04-012022-06-300001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001060736us-gaap:CommonStockMember2022-04-012022-06-300001060736us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001060736us-gaap:CommonStockMember2022-06-300001060736us-gaap:AdditionalPaidInCapitalMember2022-06-300001060736us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001060736us-gaap:RetainedEarningsMember2022-06-30sgen:segment00010607362021-01-012021-12-310001060736srt:WeightedAverageMember2022-01-012022-06-300001060736sgen:AdcetrisMemberus-gaap:ProductMember2022-04-012022-06-300001060736sgen:AdcetrisMemberus-gaap:ProductMember2021-04-012021-06-300001060736sgen:AdcetrisMemberus-gaap:ProductMember2022-01-012022-06-300001060736sgen:AdcetrisMemberus-gaap:ProductMember2021-01-012021-06-300001060736us-gaap:ProductMembersgen:PadcevMember2022-04-012022-06-300001060736us-gaap:ProductMembersgen:PadcevMember2021-04-012021-06-300001060736us-gaap:ProductMembersgen:PadcevMember2022-01-012022-06-300001060736us-gaap:ProductMembersgen:PadcevMember2021-01-012021-06-300001060736us-gaap:ProductMembersgen:TukysaMember2022-04-012022-06-300001060736us-gaap:ProductMembersgen:TukysaMember2021-04-012021-06-300001060736us-gaap:ProductMembersgen:TukysaMember2022-01-012022-06-300001060736us-gaap:ProductMembersgen:TukysaMember2021-01-012021-06-300001060736us-gaap:ProductMembersgen:TIVDAKMember2022-04-012022-06-300001060736us-gaap:ProductMembersgen:TIVDAKMember2021-04-012021-06-300001060736us-gaap:ProductMembersgen:TIVDAKMember2022-01-012022-06-300001060736us-gaap:ProductMembersgen:TIVDAKMember2021-01-012021-06-30utr:sqft00010607362021-06-012021-06-30utr:acrexbrli:puresgen:term0001060736us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001060736us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001060736us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001060736us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:FairValueMeasurementsRecurringMember2022-06-300001060736us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001060736us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001060736us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001060736us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:OtherNoncurrentAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:FairValueMeasurementsRecurringMember2021-12-310001060736us-gaap:USTreasurySecuritiesMember2022-06-300001060736us-gaap:USTreasurySecuritiesMember2021-12-310001060736us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001060736us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001060736us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001060736us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001060736us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-012022-06-300001060736us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300001060736us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-06-300001060736us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300001060736sgen:LongTermIncentivePlansMember2022-06-3000010607362022-05-152022-05-150001060736sgen:PatentInfringementMember2020-12-232021-01-22sgen:petition0001060736sgen:PatentInfringementMember2022-04-082022-04-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 0-32405 
SEAGEN INC.
(Exact name of registrant as specified in its charter) 
Delaware 91-1874389
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
21823 30th Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code): (425) 527-4000
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001SGENThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer ☒  Accelerated filer ☐
Non-accelerated filer ☐   Smaller reporting company ☐
Emerging growth company ☐   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐ No  ☒
As of July 25, 2022, there were 184,435,456 shares of the registrant’s common stock outstanding.

Seagen Inc.
Quarterly Report on Form 10-Q
For the Quarter Ended June 30, 2022
INDEX
2
PART I. FINANCIAL INFORMATION
Item 1.    Condensed Consolidated Financial Statements
Seagen Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except par value)
June 30, 2022December 31, 2021
Assets
Current assets:
Cash and cash equivalents$364,874 $424,834 
Short-term investments1,485,448 1,735,202 
Accounts receivable, net438,041 389,256 
Inventories319,354 200,663 
Prepaid expenses and other current assets170,938 119,239 
Total current assets2,778,655 2,869,194 
Property and equipment, net218,901 210,073 
Operating lease right-of-use assets51,942 57,889 
Intangible assets, net249,149 260,593 
Goodwill274,671 274,671 
Other non-current assets57,025 47,184 
Total assets$3,630,343 $3,719,604 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$128,872 $114,824 
Accrued liabilities and other479,649 454,030 
Total current liabilities608,521 568,854 
Long-term liabilities:
Operating lease liabilities, long-term50,205 56,665 
Other long-term liabilities38,805 28,946 
Total long-term liabilities89,010 85,611 
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued
— — 
Common stock, $0.001 par value, 250,000 shares authorized; 184,369 shares issued and outstanding at June 30, 2022 and 183,381 shares issued and outstanding at December 31, 2021
184 183 
Additional paid-in capital4,747,481 4,607,816 
Accumulated other comprehensive income507 1,179 
Accumulated deficit(1,815,360)(1,544,039)
Total stockholders’ equity2,932,812 3,065,139 
Total liabilities and stockholders’ equity$3,630,343 $3,719,604 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
Seagen Inc.
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
(In thousands, except per share amounts)
 Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Revenues:
Net product sales$431,714 $347,338 $814,800 $649,926 
Royalty revenues39,109 36,296 67,290 63,514 
Collaboration and license agreement revenues26,679 4,844 41,872 7,020 
Total revenues497,502 388,478 923,962 720,460 
Costs and expenses:
Cost of sales106,100 78,090 193,726 142,225 
Research and development304,254 234,861 601,913 465,286 
Selling, general and administrative220,259 165,130 394,484 324,972 
Total costs and expenses630,613 478,081 1,190,123 932,483 
Loss from operations(133,111)(89,603)(266,161)(212,023)
Investment and other (loss) income , net(1,609)5,027 (3,799)6,027 
Loss before income taxes(134,720)(84,576)(269,960)(205,996)
Provision for income taxes107 — 1,361 — 
Net loss$(134,827)$(84,576)$(271,321)$(205,996)
Net loss per share - basic and diluted$(0.73)$(0.47)$(1.48)$(1.14)
Shares used in computation of per share amounts - basic and diluted184,145 181,628 183,897 181,390 
Comprehensive loss:
Net loss$(134,827)$(84,576)$(271,321)$(205,996)
Other comprehensive income (loss):
Unrealized loss on securities available-for-sale, net of tax (2,736)(213)(3,597)(47)
Foreign currency translation gain2,819 511 2,925 274 
Total other comprehensive income (loss)83 298 (672)227 
Comprehensive loss$(134,744)$(84,278)$(271,993)$(205,769)
The accompanying notes are an integral part of these condensed consolidated financial statements.

4
Seagen Inc.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
(In thousands)
Common stock
SharesAmountAdditional
paid-in capital		Accumulated other comprehensive incomeAccumulated deficitTotal stockholders' equity
Balances as of December 31, 2020180,902 $181 $4,356,922 $565 $(869,568)$3,488,100 
Net loss— — — — (121,420)(121,420)
Other comprehensive loss— — — (71)— (71)
Issuance of common stock for stock option exercises and employee stock purchase plan341 — 19,791 — — 19,791 
Restricted stock vested during the period, net
80 — — — — — 
Share-based compensation— — 38,224 — — 38,224 
Balances as of March 31, 2021181,323 181 4,414,937 494 (990,988)3,424,624 
Net loss— — — — (84,576)(84,576)
Other comprehensive income— — — 298 — 298 
Issuance of common stock for stock option exercises and employee stock purchase plan359 1 13,200 — — 13,201 
Restricted stock vested during the period, net
184 — — — — — 
Share-based compensation— — 37,727 — — 37,727 
Balances as of June 30, 2021181,866 $182 $4,465,864 $792 $(1,075,564)$3,391,274 
Balances as of December 31, 2021183,381 $183 $4,607,816 $1,179 $(1,544,039)$3,065,139 
Net loss— — — — (136,494)(136,494)
Other comprehensive loss— — — (755)— (755)
Issuance of common stock for stock option exercises and employee stock purchase plan463 1 26,663 — — 26,664 
Restricted stock vested during the period, net
48 — — — — — 
Share-based compensation— — 43,913 — — 43,913 
Balances as of March 31, 2022183,892 184 4,678,392 424 (1,680,533)2,998,467 
Net loss— — — — (134,827)(134,827)
Other comprehensive income— — — 83 — 83 
Issuance of common stock for stock option exercises and employee stock purchase plan298 — 14,960 — — 14,960 
Restricted stock vested during the period, net179 — — — — — 
Share-based compensation— — 54,129 — — 54,129 
Balances as of June 30, 2022184,369 $184 $4,747,481 $507 $(1,815,360)$2,932,812 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Seagen Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
 Six Months Ended June 30,
 20222021
Operating activities:
Net loss$(271,321)$(205,996)
Adjustments to reconcile net loss to net cash used by operating activities
Share-based compensation98,042 75,951 
Depreciation22,867 19,603 
Amortization of intangible assets11,444 11,451 
Amortization of right-of-use assets
6,140 6,356 
Amortization of premiums, accretion of discounts, and (gains) losses on debt securities
484 11,802 
Losses (gains) on equity securities7,078 (4,929)
Deferred income taxes(557)— 
Changes in operating assets and liabilities
Accounts receivable, net(48,785)(54,752)
Inventories(118,691)(47,048)
Prepaid expenses and other assets(37,249)(46,122)
Lease liability(8,533)(7,481)
Other liabilities50,499 43,395 
Net cash used by operating activities(288,582)(197,770)
Investing activities:
Purchases of securities(1,489,327)(1,788,967)
Proceeds from maturities of securities1,735,000 1,831,500 
Payments for lessor-owned assets(13,756)— 
Purchases of property and equipment(32,161)(22,403)
Net cash provided by investing activities199,756 20,130 
Financing activities:
Proceeds from exercise of stock options and employee stock purchase plan41,624 32,992 
Net cash provided by financing activities41,624 32,992 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(2,809)(342)
Net decrease in cash, cash equivalents, and restricted cash(50,011)(144,990)
Cash, cash equivalents, and restricted cash at beginning of period424,834 558,424 
Cash, cash equivalents, and restricted cash at end of period$374,823 $413,434 
The accompanying notes are an integral part of these condensed consolidated financial statements.

6
Seagen Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Summary of significant accounting policies
Basis of presentation
The accompanying unaudited condensed consolidated financial statements reflect the accounts of Seagen Inc. and its wholly-owned subsidiaries (collectively “Seagen,” “we,” “our,” or “us”). All intercompany transactions and balances have been eliminated. Management has determined that we operate in one segment: the development and sale of pharmaceutical products on our own behalf or in collaboration with others. Substantially all of our assets and revenues are related to operations in the U.S.; however, we have multiple subsidiaries in foreign jurisdictions, including several subsidiaries in Europe.
The condensed consolidated balance sheet data as of December 31, 2021 were derived from audited financial statements not included in this quarterly report on Form 10-Q. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and generally accepted accounting principles in the United States of America, or GAAP, for unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position and results of our operations as of and for the periods presented.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.
The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The results of our operations for the three and six month period ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other interim period.
Non-cash activities
We had $9.4 million and $9.9 million of accrued capital expenditures as of June 30, 2022 and December 31, 2021, respectively. Accrued capital expenditures are treated as a non-cash investing activity and, accordingly, have not been included in the condensed consolidated statement of cash flows until such amounts have been paid in cash.
Investments
We hold certain equity securities which are reported at estimated fair value based on quoted market prices. Changes in the fair value of equity securities are recorded in income or loss. The cost of equity securities for purposes of computing gains and losses is based on the specific identification method.
We invest our available cash primarily in debt securities. These debt securities are classified as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains, realized losses and declines in the value of debt securities judged to be other-than-temporary are included in investment and other income (loss), net. The cost of debt securities for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Amortization of premiums and accretion of discounts on debt securities are included in investment and other income (loss), net. Interest and dividends earned are included in investment and other income (loss), net. Accrued interest receivable as of June 30, 2022 and December 31, 2021, were $2.2 million and $0.4 million, respectively, and were included in prepaid expenses and other current assets. We classify investments in debt securities maturing within one year of the reporting date, or where management’s intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments.
If the estimated fair value of a debt security is below its carrying value, we evaluate whether it is more likely than not that we will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. We also evaluate whether or not we intend to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, we consider whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in investment and other income (loss), net.
7
Restricted Cash
As of June 30, 2022, we had $9.9 million cash held in escrow restricted by a contractual agreement related to our Everett, Washington building construction project. The restricted cash was recorded in prepaid expenses and other current assets in the condensed consolidated balance sheet. We determine classification based on the expected duration of the restriction.
Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:
(dollars in thousands)June 30, 2022December 31, 2021June 30, 2021December 31, 2020
Cash and cash equivalents$364,874 $424,834 $413,434 $558,424 
Restricted cash included in prepaid expenses and other current assets9,949 — — — 
Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows$374,823 $424,834 $413,434 $558,424 
Intangible assets, net
Our intangible assets are primarily comprised of acquired TUKYSA technology. The following table presents the balances of our finite-lived intangible assets for the periods presented:
(dollars in thousands)June 30, 2022December 31, 2021
Gross carrying value$305,650 $305,650 
Less: accumulated amortization(56,501)(45,057)
Total$249,149 $260,593 
The following table presents our amortization expense related to acquired TUKYSA technology costs, included in cost of sales in our condensed consolidated statements of comprehensive loss, for the periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Amortization expense$5,753 $5,757 $11,444 $11,451 
The weighted average remaining useful life of our finite-lived intangible assets was approximately 11 years as of June 30, 2022, and estimated future amortization expense related to acquired TUKYSA is $11.6 million for the six months ending December 31, 2022, and TUKYSA technology costs is $23.1 million for each of the years ending December 31, 2023 through December 31, 2027.
Revenue recognition - Net product sales
We sell our products primarily through a limited number of specialty distributors and specialty pharmacies in the U.S, and to a lesser extent, internationally. The delivery of our products represents a single performance obligation for these transactions and we record net product sales at the point in time when control is transferred to the customer, which generally occurs upon receipt by the customer. The transaction price for net product sales represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. We reflect these accruals as either a reduction in the related account receivable from the distributor or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management’s estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment.
Outside of the U.S., the transaction price for net product sales represents the amount we expect to receive, which is net of estimated discounts, estimated government mandated rebates, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. These estimates involve judgment in estimating net product sales.
U.S. government-mandated rebates and chargebacks: We have entered into a Medicaid Drug Rebate Agreement, or MDRA, with the Centers for Medicare & Medicaid Services. This agreement provides for a rebate based on covered purchases of our products. Medicaid rebates are invoiced to us by the various state Medicaid programs. We estimate Medicaid rebates using the expected value approach, based on a variety of factors, including payor mix and our experience to-date.
8
We have a Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible purchases of our products. In addition, we have entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services, which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS, to receive discounts on their qualified purchases of our products. Under these agreements, eligible customers receive an applicable discount which is processed through the distributor as a chargeback. We estimate expected chargebacks for FSS and PHS purchases based on the expected value of each entity’s eligibility for the FSS and PHS programs. We also review historical rebate and chargeback information to further refine these estimates.
Distribution fees, product returns and other deductions: Our distributors charge a volume-based fee for distribution services that they perform for us. We allow for the return of product that is within a specified number of days of its expiration date or that is damaged. We estimate product returns based on our experience to-date using the expected value approach. We provide financial assistance to qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through our patient support programs. Estimated contributions for commercial coinsurance under Seagen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as necessary to reflect our actual experience.
Revenue recognition - Royalty revenues
Royalty revenues primarily reflect amounts earned under the ADCETRIS collaboration with Takeda Pharmaceutical Company Limited, or Takeda. These royalties include commercial sales-based milestones and sales royalties that relate predominantly to the license of intellectual property. Sales royalties are based on a percentage of Takeda’s net sales of ADCETRIS, with rates that range from the mid-teens to the mid-twenties based on annual net sales tiers. Takeda bears a portion of low single digit third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenues. Amounts owed to our third-party licensors related to Takeda’s sales of ADCETRIS are recorded in cost of sales. These amounts are recognized in the period in which the related sales by Takeda occur. Royalty revenues also reflect amounts from Genentech, Inc., a member of the Roche Group, or Genentech, earned on net sales of Polivy, and amounts from GlaxoSmithKline earned on net sales of Blenrep.
Revenue recognition - Collaboration and license agreement revenues
We have collaboration and license agreements for our technology with a number of biotechnology and pharmaceutical companies. Under these agreements, we typically receive or are entitled to receive upfront cash payments and progress- and sales-dependent milestones for the achievement by our licensees of certain events, and annual maintenance fees and support fees for research and development services and materials provided under the agreements. We also are entitled to receive royalties on net sales of any resulting products incorporating our technology. Generally, our licensees are solely responsible for research, product development, manufacturing and commercialization of any product candidates under these collaborations, which includes the achievement of the potential milestones. Since we may not take a substantive role or control the research, development or commercialization of any products generated by some of our licensees, we may not be able to reasonably estimate when, if at all, any potential future milestone payments or royalties may be payable to us by our licensees. As such, the potential future milestone payments associated with certain of our collaboration and license agreements involve a substantial degree of uncertainty and risk that they may never be received.
Collaboration and license agreements are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to future reversal of cumulative revenue and, therefore, should be included in the transaction price. Assessing the recognition of variable consideration requires significant judgment. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaboration and license agreements, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract.
9
We have concluded that the license of intellectual property in certain collaboration and license agreements is not distinct from the perspective of our customers at the time of initial transfer, since we often do not license intellectual property without related technology transfer and research and development support services. Such evaluation requires significant judgment since it is made from the customer's perspective. Our performance obligations under our collaborations may include such things as providing intellectual property licenses, performing technology transfer, performing research and development consulting services, providing reagents, ADCs, and other materials, and notifying the customer of any enhancements to licensed technology or new technology that we discover, among others. We determined our performance obligations under certain collaboration and license agreements as evaluated at contract inception were not distinct and represented a single performance obligation. Upfront payments are amortized to revenue over the performance period. Upfront payment contract liabilities resulting from our collaborations do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. For agreements beyond the initial performance period, we have no remaining performance obligations. We may receive license maintenance fees and potential milestones and royalties based on collaborator development and regulatory progress, which are recorded in the period achieved in the case of milestones, and during the period of the related sales for royalties.
When no performance obligations are required of us, or following the completion of the performance obligation period, such amounts are recognized upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as collaboration and license agreement revenues. Sales-based milestones and royalties are recognized as royalty revenue in the period the related sale occurred.
We generally invoice our collaborators and licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.

2. Revenue from contracts with customers
The following table presents our disaggregated revenue for the periods presented.
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
ADCETRIS$201,939 $181,912 $382,928 $344,484 
PADCEV123,577 82,405 223,784 152,163 
TUKYSA88,989 83,021 179,464 153,279 
TIVDAK17,209 — 28,624 — 
Net product sales$431,714 $347,338 $814,800 $649,926 
Royalty revenues$39,109 $36,296 $67,290 $63,514 
Collaboration and license agreement revenues$26,679 $4,844 $41,872 $7,020 
Total revenues$497,502 $388,478 $923,962 $720,460 

3. Leases
We have operating leases for our office and laboratory facilities with terms that expire from 2022 through 2029. We recorded $0.2 million and $7.1 million right-of-use assets in exchange for lease liabilities, respectively, during the six months ended June 30, 2022 and 2021, respectively. All of our significant leases include options for us to extend the lease term. None of our options to extend the rental term of any existing leases were considered reasonably certain as of June 30, 2022.
In June 2021, we entered into a lease agreement for an approximately 258,000 square feet building complex to be constructed by the landlord on approximately 20.5 acres of land in Everett, Washington. We intend to use the building for future manufacturing, laboratory, and office space. Under the terms of the lease, base rent is payable at an initial rate of $4.0 million per year, subject to annual escalations of 3% during the initial term of 20 years. The lease commences on the date when construction and delivery of the building shell and related improvements by the landlord have been substantially completed. We will record a lease liability and right-of-use assets on our condensed consolidated balance sheet on the lease commencement date, which has not commenced as of June 30, 2022. We have an option to renew the lease for two additional terms of ten years each. In addition, we have an option to purchase the premises in the future.
10
Supplemental operating lease information was as follows:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Operating lease cost$3,947 $4,063 $8,142 $8,077 
Variable lease cost1,249 1,151 2,321 2,138 
Total lease cost$5,196 $5,214 $10,463 $10,215 
Cash paid for amounts included in measurement of lease liabilities$4,196 $4,199 $8,749 $8,057 
As of June 30,
20222021
Weighted average remaining lease term5.6 years6.3 years
Weighted average discount rate5 %5.1 %
Operating lease liabilities were recorded in the following captions of our condensed consolidated balance sheet as follows:
(dollars in thousands)June 30, 2022December 31, 2021
Accrued liabilities and other$13,700 $13,905 
Operating lease liabilities, long-term50,205 56,665 
Total$63,905 $70,570 

4. Net loss per share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and dilutive potential common shares outstanding during the period. Potentially dilutive common shares include incremental common shares issuable upon the vesting of unvested restricted stock units and the exercise of outstanding stock options, calculated using the treasury stock method.
We excluded the potential shares of common stock from the computation of diluted net loss per share because their effect would have been antidilutive. The following table presents the weighted average number of shares that have been excluded for all periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2022202120222021
Stock options and RSUs9,824 9,992 10,077 10,229 

5. Fair value
We have certain assets that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:
Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2:  Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.
Level 3:  Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. We consider observable data to be market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.
11
The fair value hierarchy of assets carried at fair value and measured on a recurring basis was as follows: 
 Fair value measurement using:
(dollars in thousands)Quoted prices
in active
markets for
identical assets
(Level 1)		Other
observable
inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)		Total
June 30, 2022
Short-term investments—U.S. Treasury securities$1,485,448 $— $— $1,485,448 
Other non-current assets—equity securities6,931 — — 6,931 
Total$1,492,379 $— $— $1,492,379 
December 31, 2021
Short-term investments—U.S. Treasury securities$1,735,202 $— $— $1,735,202 
Other non-current assets—equity securities14,009 — — 14,009 
Total$1,749,211 $— $— $1,749,211 
Our short-term debt investments portfolio only contains investments in U.S. Treasury and other U.S. government-backed securities. We review our portfolio based on the underlying risk profile of the securities and have a zero loss expectation for these investments. We also regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three and six months ended June 30, 2022 and 2021, we recognized no year-to-date credit loss related to our short- and long-term investments, and had no allowance for credit loss recorded as of June 30, 2022 or December 31, 2021.
Our debt securities consisted of the following:
(dollars in thousands)Amortized
cost		Gross
unrealized
gains		Gross
unrealized
losses		Fair
value
June 30, 2022
U.S. Treasury securities$1,489,231 $30 $(3,813)$1,485,448 
Contractual maturities (at date of purchase):
Due in one year or less$1,473,502 $1,469,688 
Due in one to two years15,729 15,760 
Total$1,489,231 $1,485,448 
December 31, 2021
U.S. Treasury securities$1,735,388 $12 $(198)$1,735,202 
Contractual maturities (at date of purchase):
Due in one year or less$1,635,307 $1,635,118 
Due in one to two years100,081 100,084 
Total$1,735,388 $1,735,202 

6. Investment and other income (loss), net
Investment and other income (loss), net consisted of the following:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
(Loss) gain on equity securities$(4,299)$4,670 $(7,078)$4,929 
Investment and other income, net2,690 357 3,279 1,098 
Total investment and other (loss) income, net$(1,609)$5,027 $(3,799)$6,027 
(Loss) gain on equity securities includes the realized and unrealized holding gains and losses on our equity securities. At times, we hold equity investments in certain companies acquired in relation to a strategic partnership. Shares held at the end of reporting periods are marked to market in our condensed consolidated financial statements, which can result in unrealized gains and losses.
12

7. Inventories
Inventories consisted of the following:
(dollars in thousands)June 30, 2022December 31, 2021
Raw materials$15,541 $12,181 
Work in process259,805 152,635 
Finished goods44,008 35,847 
Total$319,354 $200,663 
We capitalize our commercial inventory costs. Inventory that is deployed into clinical, research or development use is charged to research and development expense when it is no longer available for use in commercial sales.

8. Accrued liabilities
Accrued liabilities consisted of the following: 
(dollars in thousands)June 30, 2022December 31, 2021
Employee compensation and benefits$107,585 $139,052 
Clinical trial and related costs169,425 122,468 
Contract manufacturing24,211 21,867 
Gross-to-net deductions and third-party royalties95,094 81,316 
Other 83,334 89,327 
Total$479,649 $454,030 

9. Share-based compensation
The following table presents our total share-based compensation expense for the periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Research and development$23,446 $17,232 $46,522 $34,196 
Selling, general and administrative30,683 20,495 51,520 41,755 
Total share-based compensation expense$54,129 $37,727 $98,042 $75,951 
As of June 30, 2022, there was $105.7 million of unrecognized compensation cost related to unvested options and restricted stock unit awards, excluding our LTIPs and performance-based awards, net of forfeitures. The estimated unrecognized compensation expense related to our performance-based LTIPs was approximately $71 million as of June 30, 2022.
On May 15, 2022, we entered into a separation agreement with our former CEO which modified certain terms of his previously granted equity awards. The agreement provided for the following equity considerations: acceleration of his outstanding and unvested restricted stock unit and stock option awards by an additional 18 months following his separation; the exercisability of his vested options would be extended to December 31, 2023 (or, if earlier, their 10-year expiration); and 5/6 of his outstanding and unvested restricted stock units subject to performance-based vesting conditions granted in 2019 remain eligible to vest on March 13, 2023, based on actual performance through December 31, 2022. Accounting for the equity awards impacted by the separation agreement resulted in $7.3 million of share-based compensation expense recorded in the quarter ended June 30, 2022, net of forfeitures for equity awards that will not vest, other than in the event that a change of control occurs on or prior to December 31, 2023.

13
10. Income taxes
For the three and six months ended June 30, 2022, we had taxable profits in the U.S. as a result of amendments to IRC Section 174, which took effect January 1, 2022 pursuant to the 2017 Tax Cuts and Jobs Act. We recorded an income tax provision for the three and six months ended June 30, 2022 of $0.1 million and $1.4 million, respectively, primarily related to estimated state tax liabilities for which there were limitations on the use of existing state tax carryforwards. We had existing federal tax carryforwards sufficient to offset any federal liability. Our income tax provision also reflected taxable profits in foreign jurisdictions partially offset by a foreign valuation allowance release. Our effective tax rate for the three and six months ended June 30, 2022 of approximately 0.1% and 0.5%, respectively, differed from the federal statutory rate primarily because we have provided a valuation allowance against substantially all our deferred tax assets.
For the three and six months ended June 30, 2021, we did not record any income tax provision.

11. Legal matters
We are engaged in multiple legal disputes with Daiichi Sankyo Co. Ltd., or Daiichi Sankyo.
Dispute over ownership of intellectual property
We are in a dispute with Daiichi Sankyo regarding the ownership of certain technology used by Daiichi Sankyo in its cancer drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) and certain product candidates. We believe that the linker and other ADC technology used in ENHERTU and these drug candidates are improvements to our ADC technology, the ownership of which we contend was assigned to us under the terms of a 2008 collaboration agreement between us and Daiichi Sankyo. On November 12, 2019, we submitted an arbitration demand to the American Arbitration Association seeking, among other remedies, a declaration that we are the owner of the intellectual property rights under dispute, monetary damages, and a running royalty. On April 27, 2020, the arbitrator confirmed the dispute should be resolved in arbitration. The arbitration hearing was conducted in June 2021. Recently, the arbitration hearing record was reopened by the arbitrator to consider additional evidence. A decision in the arbitration case is expected in mid-2022.
On November 4, 2019, Daiichi Sankyo filed a declaratory judgment action in the United States District Court for the District of Delaware, alleging that we are not entitled to the intellectual property rights under dispute, in an attempt to have the dispute adjudicated in federal court. The case has been stayed and administratively closed by court order.
Patent infringement
On October 19, 2020, we filed a complaint in the United States District Court for the Eastern District of Texas to commence an action for infringement of our U.S. Patent No. 10,808,039, or the '039 Patent, by Daiichi Sankyo’s importation into, offer for sale, sale, and use in the United States of the cancer drug ENHERTU. The remedies sought in this action include, among other remedies, a judgment that Daiichi Sankyo infringed one or more valid and enforceable claims of the '039 Patent, monetary damages and a running royalty.
Daiichi Sankyo (as well as Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals, LP, or AstraZeneca) subsequently filed an action on November 13, 2020 in the U.S. District Court for the District of Delaware seeking a declaratory judgment that ENHERTU does not infringe the ‘039 Patent. The Delaware action has been stayed by court order.
Daiichi Sankyo, Inc. and AstraZeneca also filed two petitions for post-grant review on December 23, 2020 and January 22, 2021 with the U.S. Patent and Trademark Office, or USPTO, seeking to have claims of the ‘039 Patent cancelled as unpatentable. On June 24, 2021, the USPTO issued a decision denying both petitions for post-grant review. On April 7, 2022, the USPTO granted a request on rehearing and instituted two post-grant review proceedings, but on July 15, 2022, the USPTO issued a new decision denying post-grant review of the claims asserted in the patent infringement action.
On April 8, 2022, a jury in the United States District Court for the Eastern District of Texas found that Daiichi Sankyo willfully infringed the asserted claims of the '039 Patent with its ENHERTU product, and also found that the asserted claims were not invalid. The jury further awarded damages of $41.8 million for infringement from October 20, 2020 through March 31, 2022. The U.S. District Court for the Eastern District of Texas also denied Daiichi Sankyo’s claim that the ‘039 Patent should be unenforceable under the equitable theory of prosecution laches, entered judgment in favor of Seagen based on the jury’s verdict that Daiichi Sankyo willfully infringed the ‘039 Patent consisting of pre-trial damages in the sum of $41.8 million, and awarded Seagen pre- and post-trial interest and costs. We will record an amount of awarded damages in our condensed consolidated financial statements when we have determined the payment to be realized or realizable under ASC 450. We intend to request a royalty on Daiichi Sankyo's future sales of ENHERTU in the United States through November 5, 2024.
14
As a result of these disputes, we have incurred and will continue to incur litigation expenses. In addition, from time to time, we may become involved in other lawsuits, claims and proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent or other intellectual property rights and our contractual rights. These proceedings are costly and time consuming, and they may subject us to claims which may result in liabilities or require us to take or refrain from certain actions. Additionally, successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use our proprietary technologies without a license from us or our collaborators.

15
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Quarterly Report on Form 10-Q, including the following discussion of our financial condition and results of operations, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are “forward-looking statements” for purposes of these provisions, including those relating to future events or our future financial performance and financial guidance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend” or “continue,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements except as required by law. Any or all of our forward-looking statements in this document may turn out to be wrong. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and other factors in this Quarterly Report on Form 10-Q in greater detail under the heading “Part II Item 1A—Risk Factors.” We caution investors that our business and financial performance are subject to substantial risks and uncertainties.
Overview
Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. We are commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TUKYSA®, or tucatinib, for the treatment of certain metastatic HER2-positive breast cancers, and TIVDAK®, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS, PADCEV and TIVDAK, are based on our antibody drug conjugate, or ADC, technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Second quarter 2022 highlights and recent developments
Corporate
•Achieved 24% growth in net product sales for the quarter ended June 30, 2022 compared to the quarter ended June 30, 2021.
•Announced Roger Dansey, M.D., Seagen’s Chief Medical Officer since 2018, was appointed interim CEO following the resignation of Clay Siegall, Ph.D., our former President and CEO.
•Announced plans to build a new facility in Everett, WA, designed to expand our biomanufacturing capacity and to enable greater control and flexibility over the production of our products. The new facility is intended to add to our existing manufacturing site in the Bothell, WA area.
•Received a $12.0 million milestone payment under our ADC technology licensing agreement with AbbVie following the initiation of a phase 3 study of AbbVie's telisotuzumab vedotin for the treatment of non-small cell lung cancer.
PADCEV
•Announced positive topline results for combination of PADCEV with pembrolizumab as first-line treatment for advanced urothelial cancer.
•Received European Commission, or EC, approval for PADCEV in previously treated metastatic urothelial cancer and received approval from other jurisdictions, including Australia, Brazil, Great Britain and Singapore.
TUKYSA
•Presented positive results from the pivotal phase 2 MOUNTAINEER trial evaluating TUKYSA in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium in July 2022. A supplemental New Drug Application based on these data was submitted to the U.S. Food and Drug Administration, or FDA, in July 2022.
16
•In July 2022, the FDA granted TUKYSA Breakthrough Therapy designation for use in combination with trastuzumab for the treatment of adult patients with unresectable or metastatic HER2-positive colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The designation is based on results of the MOUNTAINEER trial.
ADCETRIS
•ADCETRIS combination data from longer-term follow-up of the ECHELON-1 phase 3 trial demonstrating statistically significant improvement in overall survival for patients with advanced Hodgkin lymphoma were published in the New England Journal of Medicine in July 2022. We expect to submit the data to the FDA in a supplemental Biologics License Application, or sBLA, submission during the balance of 2022.
•The Children's Oncology Group presented results of ADCETRIS plus standard of care demonstrating superior event-free survival versus standard of care alone in children and young adults with previously untreated high-risk Hodgkin lymphoma. Based on these data, we submitted a sBLA to the FDA for review. The sBLA was granted Priority Review with a Prescription Drug User Fee Act, or PDUFA, target action date of November 16, 2022.
TIVDAK
•Reported interim data from the innovaTV 205 trial, which included data evaluating TIVDAK in combination with KEYTRUDA (Cohort E) in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy showing encouraging and durable anti-tumor activity for the combination.
17

Our Medicines
Our approved medicines include the following:
Product*
Therapeutic AreaU.S. Approved Indication
sgen-20220630_g1.jpg
Hodgkin LymphomaPreviously untreated Stage III/IV classical Hodgkin lymphoma, or cHL, in combination with doxorubicin, vinblastine and dacarbazine
cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation, or auto-HSCT, consolidation
cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
T-cell LymphomaPreviously untreated systemic anaplastic large cell lymphoma, or sALCL, or other CD30-expressing peripheral T-cell lymphoma, or PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin and prednisone
sALCL after failure of at least one prior multi-agent chemotherapy regimen
Primary cutaneous anaplastic large cell lymphoma, or pcALCL, or CD30-expressing mycosis fungoides who have received prior systemic therapy
sgen-20220630_g2.jpg
Urothelial Cancer
Locally advanced or metastatic urothelial cancer for patients who:
•have previously received a programmed death receptor-1 (or PD-1) or a programmed death-ligand 1 (or PD-L1) inhibitor and platinum-containing chemotherapy, or
•are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
sgen-20220630_g3.jpg
Breast Cancer
In combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
sgen-20220630_g4.jpg
Cervical CancerRecurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
*ADCETRIS, PADCEV, TUKYSA and TIVDAK are only indicated for use in adults.

18
ADCETRIS®
ADCETRIS is an ADC targeting CD30, which is a protein located on the surface of cells and highly expressed in Hodgkin lymphoma, certain T-cell lymphomas as well as other cancers. ADCETRIS first received U.S. Food and Drug Administration, or FDA, approval in 2011 and is now approved in a total of six indications to treat Hodgkin lymphoma and certain T-cell lymphomas in various settings including as frontline therapy.
ADCETRIS has received approval in more than 75 countries worldwide. We commercialize ADCETRIS in the U.S. and its territories and in Canada, and we collaborate with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Takeda has commercial rights in the rest of the world and pays us a royalty. Takeda has received regulatory approvals for ADCETRIS as monotherapy or in combination with other agents in various settings for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas in Europe and many countries throughout the rest of the world and is pursuing additional regulatory approvals.

PADCEV®
PADCEV is an ADC targeting Nectin-4, a protein expressed on the surface of cells and highly expressed in bladder cancer as well as other cancers. PADCEV was granted accelerated approval by the FDA in December 2019 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery in the locally advanced or metastatic setting. FDA approval of PADCEV was supported by data from a single-arm pivotal phase 2 clinical trial called EV-201.
In July 2021, the FDA converted PADCEV's accelerated approval to regular approval in the U.S., in addition to granting regular approval for a new indication for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. The conversion to regular approval was supported by the pivotal phase 3 clinical trial called EV-301, and the expanded indication was supported by data from the second cohort in the EV-201 trial. The FDA reviewed the application for regular approval under the Oncology Center of Excellence's, or OCE's, Real Time Oncology Review, or RTOR, pilot program.
In April 2022, the European Commission approved PADCEV as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The approval is applicable in the European Union member states, as well as Iceland, Norway and Liechtenstein.
PADCEV is also approved in other countries including Brazil, Canada, Japan, Great Britain and Switzerland in previously treated metastatic urothelial cancer.
PADCEV is being co-developed and jointly commercialized with Astellas Pharma, Inc., or Astellas. In the U.S., we and Astellas are jointly promoting PADCEV. We record net sales of PADCEV in the U.S. and are responsible for all U.S. distribution activities. We and Astellas each bear the costs of our own sales organizations in the U.S., equally share certain other costs associated with commercializing PADCEV in the U.S., and equally share in any profits realized in the U.S. Outside the U.S., we have commercialization rights in all other countries in North and South America, and Astellas has commercialization rights in the rest of the world, including Europe, Asia, Australia and Africa. The agreement is intended to provide that we and Astellas will effectively equally share in costs incurred and any profits realized in all of these markets. Cost and profit sharing in Canada, the United Kingdom, Germany, France, Spain and Italy will be based on product sales and costs of commercialization. In the remaining markets, the commercializing party will bear costs and will pay the other party a royalty rate applied to net sales of the product based on a rate intended to approximate an equal profit share for both parties.
TUKYSA®
TUKYSA is an oral, small molecule tyrosine kinase inhibitor, or TKI, that is highly selective for HER2, a growth factor receptor overexpressed in certain cancers. HER2 mediates cell growth, differentiation and survival. Tumors that over-express HER2 are generally more aggressive and historically have been associated with poor overall survival, compared with HER2-negative cancers. In April 2020, TUKYSA received approval from the FDA in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. FDA approval of TUKYSA was supported by data from the HER2CLIMB trial.
19
The application for approval was reviewed under the FDA's RTOR pilot program. We also participated in the Project Orbis initiative of the FDA OCE which provides a framework for concurrent submission and review of oncology products among international partners. Under this program we have received approval in the U.S., Canada, Australia, Singapore, and Switzerland. In February 2021, the EC granted marketing authorization for TUKYSA in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens. This approval is valid in all countries of the European Union as well as Norway, Liechtenstein, Iceland and Northern Ireland. In Europe, we have begun marketing TUKYSA in Austria, France, Germany and Switzerland. Additionally, in February 2021, the UK Medicines and Healthcare products Regulatory Agency, or MHRA, granted a Great Britain marketing authorization for TUKYSA.
We are responsible for commercializing TUKYSA in the U.S., Canada and Europe. In September 2020, we entered into a license and collaboration agreement, or the TUKYSA Agreement, with Merck & Co., Inc., or Merck, pursuant to which we granted exclusive rights to Merck to commercialize TUKYSA in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. The collaboration is intended to accelerate global availability of TUKYSA.
TIVDAK®
TIVDAK is an ADC targeting tissue factor, a protein expressed on the surface of cells that has increased levels of expression on multiple solid tumors. The FDA granted accelerated approval of TIVDAK in September 2021 for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. FDA approval was supported by data from the innovaTV 204 trial where it was evaluated in patients with recurrent or metastatic cervical cancer who had received no more than two prior systemic regimens in the recurrent or metastatic setting, including at least one prior platinum-based chemotherapy regimen. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
TIVDAK is being co-developed with Genmab A/S, or Genmab, under an agreement in which the companies share all costs and profits for the product on a 50:50 basis. Under a joint commercialization agreement, we and Genmab co-promote TIVDAK in the U.S. and we record net sales of TIVDAK in the U.S. and are responsible for leading U.S. distribution activities. The companies will each maintain 50% of the sales representatives and medical science liaisons, equally share those and certain other costs associated with commercializing TIVDAK in the U.S., and equally share in any profits realized in the U.S. Outside the U.S., we have commercialization rights in the rest of the world except for Japan, where Genmab has commercialization rights. In Europe, China, and Japan, we and Genmab will equally share 50% of the costs associated with commercializing TIVDAK as well as any profits realized in these markets. In markets outside the U.S. other than Europe, China, and Japan, aside from certain costs specified in the agreement, we will be solely responsible for all costs associated with commercializing TIVDAK, and will pay Genmab a royalty based on a percentage of aggregate net sales.
Clinical Development and Regulatory Status
ADCETRIS (brentuximab vedotin)
Beyond our current labeled indications, we are evaluating ADCETRIS as monotherapy and in combination with other agents in ongoing trials, including several potential registration-enabling trials such as the phase 3 ECHELON-3 clinical trial in relapsed or refractory diffuse large B-cell lymphoma. In addition to our corporate-sponsored trials there are numerous investigator-sponsored trials of ADCETRIS in the United States. The investigator-sponsored trials include the use of ADCETRIS in a number of malignant hematologic indications and in solid tumors.
In February 2022, we announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival, or OS, (p=0.009) in patients with advanced Hodgkin lymphoma following treatment with ADCETRIS in combination with chemotherapy. With approximately six years median follow up, patients receiving ADCETRIS plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in the frontline setting had a 41 percent reduction in the risk of death (HR 0.59; [95% CI: 0.396 to 0.879]) compared with patients receiving doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The safety profile of ADCETRIS was consistent with previous studies and no new safety events were observed. In July 2022, these results were published in the New England Journal of Medicine. We expect to submit the data to the FDA in a sBLA submission during the balance of 2022.
In June 2022, we announced results from a phase 3 Children’s Oncology Group study trial evaluating ADCETRIS in children and young adults with high-risk, previously untreated classical Hodgkin lymphoma. The trial showed ADCETRIS in combination with standard of care showed a clinically meaningful and statistically significant 59% reduction in the risk of disease progression or relapse, second malignancy or death and achieved superior event-free survival compared to the current standard of care. Based on these data, we submitted a sBLA to the FDA for review. The sBLA was granted Priority Review with a PDUFA target action date of November 16, 2022.

20
PADCEV (enfortumab vedotin-ejfv)
In addition to jurisdictions where PADCEV is currently approved, applications are under review for approval in the previously treated metastatic urothelial cancer setting in Australia, under the FDA's Project Orbis program, as well as in Singapore, Brazil and other countries. In collaboration with Astellas we are conducting or planning to conduct clinical trials across the spectrum of bladder cancer including ongoing trials in frontline metastatic urothelial cancer and muscle invasive bladder cancer. We are planning to conduct a trial in non-muscle invasive bladder cancer. In addition, we are conducting a trial in a range of other solid tumors.
PADCEV is being investigated in first-line metastatic urothelial cancer and earlier stages of bladder cancer. We and Astellas are conducting a phase 1b/2 clinical trial, called EV-103, that is a multi-cohort, open-label trial of PADCEV alone or in combination with other agents. The trial is evaluating safety, tolerability and activity in locally advanced and first- and second-line metastatic urothelial cancer, and was expanded to include muscle invasive bladder cancer, or MIBC.
In February 2020, based on the positive initial results of the dose-escalation cohort and the expansion Cohort A of the EV-103 trial, the FDA granted Breakthrough Therapy designation for PADCEV in combination with Merck's anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. In April 2020, we announced that, based on discussions with the FDA, data from the randomized Cohort K in the EV-103 trial, along with other data from the EV-103 trial, could potentially support registration under the FDA's accelerated approval pathway. The primary endpoint is confirmed objective response rate. In October 2021, we completed enrollment in Cohort K.
In July 2022, we and Astellas announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV in combination with pembrolizumab as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy. In patients treated with PADCEV and pembrolizumab, results demonstrated a 64.5% confirmed objective response rate, or ORR, (95% CI: 52.7 to 75.1) per blinded independent central review, or BICR, the primary endpoint of Cohort K. The median duration of response per BICR was not reached. The most frequently reported treatment-emergent adverse events Grade 3 or greater that occurred in more than 5% of patients were rash maculo-papular, anemia, lipase increased, urinary tract infection, hyperglycemia, fatigue, neutropenia, hematuria, diarrhea, acute kidney injury, hyponatremia, chronic kidney disease, weight decreased, syncope, hypophosphatemia, pneumonitis, sepsis, and alanine aminotransferase increased. Overall, the results are generally consistent with previously reported efficacy and safety results of EV-103 dose escalation and expansion Cohort A. Data will be presented at a future medical conference and will be discussed with the FDA with the intention of submitting a sBLA later in 2022 under the FDA's Accelerated Approval Program.
In addition to the potential accelerated approval pathway based on the EV-103 trial, we are conducting a global, registrational phase 3 trial, called EV-302, in frontline metastatic urothelial cancer in collaboration with Astellas and Merck. We, Astellas and Merck are jointly funding EV-302 and the trial is being conducted by us. EV-302 is an open-label, randomized phase 3 clinical trial evaluating the combination of PADCEV and pembrolizumab versus chemotherapy alone in patients with previously untreated locally advanced or metastatic urothelial cancer. The trial includes metastatic urothelial cancer patients who are either eligible or ineligible for cisplatin-based chemotherapy. The trial has dual primary endpoints of progression free survival and OS and is intended to support global regulatory submissions and potentially serve as a confirmatory trial if accelerated approval is granted based on EV-103.
In April 2020, we and Astellas entered into an agreement with Merck to evaluate PADCEV in MIBC. Merck has amended its ongoing phase 3 KEYNOTE-905/EV-303 registrational trial in cisplatin-ineligible patients with MIBC to include an arm evaluating PADCEV in combination with pembrolizumab. In October 2020, we and Astellas entered into an agreement with Merck to evaluate PADCEV in combination with pembrolizumab in a phase 3 trial, called KEYNOTE-B15/EV-304, to be conducted by Merck in cisplatin-eligible patients with MIBC. This trial was initiated in the first quarter of 2021.
In January 2022, we enrolled the first patient in a phase 1 trial, called EV-104, evaluating PADCEV in patients with BCG unresponsive non-muscle invasive bladder cancer.
In January 2020, we and Astellas also initiated a phase 2 clinical trial, called EV-202, to evaluate PADCEV monotherapy in solid tumors that have high-levels of Nectin-4 expression, including non-small cell lung, head and neck, gastric/esophageal and breast cancers. Astellas is conducting the trial and has obtained topline results in some cohorts. We and Astellas will be reviewing the results and discussing future direction.
21
TUKYSA (tucatinib)
We are conducting a broad clinical development program for TUKYSA including ongoing and planned trials in earlier lines of breast cancer and in other HER2-positive cancers. The positive results of the HER2CLIMB trial served as the basis for approval in the U.S., Canada, the European Union as well as other countries. Merck is co-funding a portion of the TUKYSA global development plan.
In December 2021, we presented new data at the San Antonio Breast Cancer Symposium from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in OS was maintained after an additional 15.6 months of follow-up when TUKYSA was combined with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases. After a median follow-up of 29.6 months, the TUKYSA regimen improved OS for patients with brain metastases by 9.1 months compared to trastuzumab and capecitabine alone (21.6 months vs. 12.5 months) (HR: 0.60; [95% CI: 0.44, 0.81]). The benefit extended to patients with active or stable brain metastases.
In October 2019, we initiated a phase 3 randomized trial, called HER2CLIMB-02, evaluating TUKYSA versus placebo, each in combination with T-DM1, for patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have had prior treatment with a taxane and trastuzumab. In June 2022, we completed enrollment in the HER2CLIMB-02 trial.
We are supporting a U.S. cooperative group, the Alliance for Clinical Trials in Oncology, that is conducting a phase 3 randomized trial, called CompassHER2 RD, which is evaluating TUKYSA in combination with T-DM1 in the adjuvant setting for patients with high-risk, HER2-positive breast cancer.
We are also conducting a phase 2 trial, called HER2CLIMB-04, evaluating TUKYSA in combination with trastuzumab deruxtecan in previously treated locally-advanced or metastatic HER2-positive breast cancer.
We have also initiated a phase 3 trial, called HER2CLIMB-05, evaluating TUKYSA compared to placebo in combination with trastuzumab and pertuzumab in the frontline maintenance setting for patients with metastatic HER2-positive breast cancer.
We are conducting a phase 2 trial, called MOUNTAINEER, evaluating TUKYSA in combination with trastuzumab in patients with HER2-positive, RAS wild-type metastatic colorectal cancer after treatment with first- and second-line standard-of-care therapies. In July 2022, we presented positive results from the pivotal phase 2 MOUNTAINEER trial investigating TUKYSA in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer. The combination of TUKYSA and trastuzumab was generally well-tolerated with durable responses in patients assigned to receive the combination demonstrating a 38.1% confirmed response rate after a median duration of follow-up of 20.7 months. In these patients, the median DOR was 12.4 months. Median progression-free survival was 8.2 months, and median overall survival was 24.1 months. The most common (greater than or equal to 20%) treatment-emergent adverse events, or TEAEs, in patients assigned to receive tucatinib and trastuzumab were diarrhea (Grade 1 or 2: 60.5%, Grade 3: 3.5%), fatigue (Grade 1 or 2: 41.9%, Grade 3: 2.3%), nausea (Grade 1 or 2: 34.9%) and infusion-related reaction (Grade 1 or 2: 20.9%). We believe the trial could potentially support an application for accelerated approval in the U.S. In July 2022, a supplemental New Drug Application was submitted to the FDA under the accelerated approval program.
In July 2022, the FDA granted TUKYSA Breakthrough Therapy designation for use in combination with trastuzumab for the treatment of adult patients with unresectable or metastatic HER2-positive colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The designation is based on results of the MOUNTAINEER trial.
We are conducting a phase 2/3 trial, called MOUNTAINEER-02, in combination with trastuzumab, ramucirumab and paclitaxel in second-line HER2-positive metastatic gastroesophageal cancer. In addition, we have initiated a phase 3 trial, called MOUNTAINEER-03, in combination with trastuzumab and mFOLFOX6 in first-line HER2-positive metastatic colorectal cancer. We have also initiated a phase 1b trial evaluating TUKYSA in combination with trastuzumab and oxaliplatin based chemotherapy in first-line HER2-positive unresectable or metastatic colorectal, gastric, esophageal and gallbladder cancers.
TIVDAK (tisotumab vedotin-tftv)
In collaboration with Genmab, we are developing TIVDAK for metastatic cervical cancer and are evaluating it as a potential therapy in other solid tumors.
In January 2021, we and Genmab initiated a phase 3 clinical trial, called innovaTV 301, to evaluate TIVDAK compared to chemotherapy in patients with recurrent or metastatic cervical cancer who have received one or two prior lines of therapy. innovaTV 301 is intended to support global regulatory applications for potential approvals in regions where innovaTV 204 does not support approval and to serve as a confirmatory trial in the U.S.
22
We are also conducting a phase 2 clinical trial, called innovaTV 205, evaluating TIVDAK as monotherapy and in combination with certain other anti-cancer agents for first- and second-line treatment of patients with recurrent or advanced cervical cancer. In September 2021, interim results were presented at the European Society for Medical Oncology Annual Congress from two cohorts of the phase 1b/2 innovaTV 205 trial, evaluating TIVDAK as combination therapy for recurrent or metastatic cervical cancer. Both combinations showed encouraging, durable anti-tumor activity and demonstrated a manageable and acceptable safety profile. Additionally, in June 2022, we announced interim data from the innovaTV 205 trial, which included data evaluating TIVDAK in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy. This combination cohort enrolled 33 patients with recurrent or metastatic cervical cancer who had not received any prior systemic therapy. At the time of data cutoff, the confirmed objective response rate among 32 evaluable patients was 41% with 16% of patients achieving complete responses and 25% of patients achieving partial responses. Median DOR was not reached with median follow-up of 18.8 months. Median progression-free survival was 5.3 months. In this cohort, the most common TEAEs were alopecia (61%), diarrhea (55%), epistaxis (49%), conjunctivitis (45%), and nausea (46%).
We are conducting a phase 2 clinical trial, called innovaTV 207, for patients with relapsed, locally advanced or metastatic solid tumors. In February 2022, initial data from the innovaTV 207 phase 2 trial of TIVDAK in solid tumors was presented at the Multidisciplinary Head and Neck Cancers Symposium. The results demonstrated a manageable safety profile and promising preliminary antitumor activity in patients with squamous cell carcinoma of the head and neck with 16 percent of patients (95% CI: 5.5 to 33.7) achieving the primary endpoint of confirmed objective response rate per investigator.
Disitamab vedotin
In September 2021, we and RemeGen entered into an exclusive license agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC, which has shown anti-tumor activity in several solid tumor types across a spectrum of HER2 levels, including urothelial, gastric and breast cancer, in all countries outside of RemeGen’s territory of Asia, excluding Japan and Singapore. We have a broad clinical development program planned including an ongoing phase 2 trial evaluating disitamab vedotin as monotherapy in previously treated HER2-expressing metastatic urothelial cancer.
Ladiratuzumab vedotin
We are developing ladiratuzumab vedotin, or LV, an ADC targeting LIV-1, which is currently being evaluated in phase 1 and phase 2 clinical trials both as monotherapy and in combination with other agents for patients with metastatic breast cancer and select solid tumors with high LIV-1 expression. In September 2020, we and Merck entered into a license and collaboration agreement, or the LV Agreement, under which the companies will jointly develop and share future costs and profits worldwide for LV.
Other clinical and early-stage product candidates
We are advancing a pipeline of early-stage clinical candidates as well as multiple preclinical and research-stage programs that employ our proprietary technologies. We advanced several product candidates into clinical development in 2021, and we plan to submit additional Investigational New Drug, or IND, applications to the FDA during the remainder of 2022.
Antibody-Drug Conjugate technology license agreements
We have active technology license agreements for our ADC technology with a number of biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd., or AbbVie; Genentech, Inc., a member of the Roche Group, or Genentech; and GlaxoSmithKline LLC, or GSK, as well as collaboration agreements with Astellas and Genmab. Genentech and GSK have received approval for ADC drugs that utilize our technology, Polivy® (polatuzumab vedotin-piic) and Blenrep® (belantamab mafodotin-blmf), respectively, in the U.S., European Union and other countries. Under our ADC license agreements with Genentech and GSK, we are entitled to receive royalties on net sales of Polivy and Blenrep worldwide.
23
COVID-19
We are continuing to closely monitor the impact of the evolving effects of the COVID-19 pandemic on our business. We are continuing to take proactive steps designed to protect the health and safety of our workforce, patients and healthcare professionals, to continue our business operations and to advance our goal of bringing important medicines to patients as rapidly as possible. Earlier in the pandemic, we instituted a mandatory work-from-home policy for employees who could perform their jobs offsite, but continued our essential research, manufacturing, and laboratory activities on site. More recently, we began to allow additional U.S. office-based employees who have been fully vaccinated to return to the office. We maintain a number of precautionary measures designed to protect our on-site employees, such as enhanced facilities cleaning, lower concentrations of staff, contact tracing and making testing available. After pausing most in-person customer interactions in healthcare settings earlier in the pandemic, our field-based personnel are now using a mix of in-person interactions and electronic communications, such as emails, phone calls and video conferences, to support healthcare professionals and patients. We believe that the measures we have implemented are appropriate and are helping to reduce transmission of COVID-19, and we will continue to monitor conditions and related guidance from governmental authorities and adjust our activities as appropriate.
Outlook
We recognize product sales revenue from ADCETRIS in the U.S. and Canada, from PADCEV and TIVDAK in the U.S., and from TUKYSA in the U.S., Europe and Canada. We expect growth in net product sales in 2022 from 2021 to be primarily driven by sales growth of PADCEV and, to a lesser extent, TIVDAK and ADCETRIS. While we anticipate that sales of ADCETRIS will increase modestly in 2022 as compared to 2021, we have experienced continued impacts associated with the COVID-19 pandemic, which appear to have led to a reduction in the rate of Hodgkin lymphoma diagnoses and may further adversely affect the rate of Hodgkin lymphoma diagnoses in the future. We have also experienced an increase in gross-to-net deductions for ADCETRIS since the beginning of the pandemic, which has been driven by the proportion of ADCETRIS sales subject to discounts through the federal 340B drug discount program, as well as increases in discount rates. We believe that the increase in gross-to-net deductions is, in part, due to a shift in the locations where ADCETRIS is administered. We may further experience additional increases in gross-to-net deductions for ADCETRIS and the rest of our portfolio in the future based on market and site-of-care dynamics. Subject to potentially securing additional labels, we anticipate that the rate of growth of PADCEV and TUKYSA sales will decelerate in 2022 compared to 2021 as we expect to continue to more fully penetrate the markets for their currently approved labels within the U.S.
Our ability to maintain or continue to grow net product sales and to realize the anticipated benefits of our investments in our products depends on a number of factors including:
•our and our collaborators’ ability to demonstrate to the medical community the efficacy, safety and value of our products and their potential advantages compared to existing and future therapeutics in their approved indications;
•the extent to which we and our collaborators are able to obtain regulatory and other approvals of our products in additional territories and/or in additional indications, including any approvals for PADCEV in the frontline metastatic urothelial cancer setting and any approvals for TUKYSA in earlier lines of breast cancer and/or other HER2-positive cancers;
•our and our collaborators’ ability to successfully launch, market and commercialize our products in any new markets or new indications, if regulatory approval is obtained, including Astellas' ability to successfully launch, market and commercialize PADCEV in the European Union and its other markets;
•competition from other therapies and changing market dynamics, as further described in "Business—Competition" in Part I of our Annual Report on Form 10-K for the year ended December 31, 2021; for example, the approval of ENHERTU for second-line HER2-positive metastatic breast cancer has resulted and is expected to continue to result in increased competition for TUKYSA;
•the extent to which we are able to successfully work with Astellas to jointly market and commercialize PADCEV in the U.S., and with Genmab to jointly market and commercialize TIVDAK in the U.S.;
•our ability to successfully market and commercialize TUKYSA in our territories outside the U.S.;
•the extent to which coverage and adequate levels of reimbursement for our products are available from governments and other third-party payors;
•the extent to which we and our collaborators are able to obtain required pricing and reimbursement approvals of our products in additional territories, most notably with respect to TUKYSA and PADCEV;
•the impact of current and future healthcare reform measures, including measures that could result in more rigorous coverage criteria or reduce the price that we receive for our products;
24
•the incidence flow of patients eligible for treatment in our products’ approved indications;
•our and our collaborators’ ability to accurately predict and supply product demand;
•duration of therapy for patients receiving our products;
•our and our collaborators' ability to successfully comply with rigorous post-marketing requirements, including requirements related to a confirmatory trial as a result of TIVDAK’s accelerated approval by the FDA, and to convert TIVDAK's accelerated approval to regular approval in the U.S.;
•with respect to TIVDAK, the acceptance of TIVDAK and its required eye care by the medical community and patients; and
•impacts related to the COVID-19 pandemic, including potential further adverse effects on the rate of Hodgkin lymphoma diagnoses and potential adverse impacts on diagnosis rates for other cancers.
As a result of these and other factors, our future net product sales for each of our products can be difficult to accurately predict from period to period. We cannot assure you that sales of any of our products will continue to grow or that we can maintain sales of any of our products at or near current levels.
The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. Drug prices are under significant scrutiny and we expect drug pricing and other healthcare costs to continue to be subject to intense political and societal pressures on a global basis. For example, in July 2021, the Biden administration announced an Executive Order that includes initiatives aimed at lowering prescription drug costs and implementing Canadian drug importation, and in response to President Biden’s Executive Order, in September 2021, the U.S. Department of Health and Human Services released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition to pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally.
We expect that amounts received from our collaboration agreements, including royalties, will continue to be an important source of our revenues and cash flows. These revenues and cash flows will be impacted by future development funding and the achievement of development, clinical and commercial success by our collaborators under our existing collaboration and license agreements, as well as by entering into potential new collaboration and license agreements.
Our ongoing research, development, manufacturing and commercial activities will require substantial amounts of capital and may not ultimately be successful. We expect that we will incur substantial expenses, and we will require significant financial resources and additional personnel in order to advance the development of, to pursue, obtain and maintain regulatory approvals for, and to commercialize our products and product candidates, and expand our pipeline. In addition, we may pursue new operations or continue the expansion of our existing operations, including with respect to the continued development of our commercial infrastructure in Europe and our plans to otherwise continue to expand our operations internationally. As a result, we may need to raise additional capital, and our operating expenses may fluctuate as a result of such activities. We may also incur substantial milestone payment obligations to certain of our licensors, including RemeGen, as our product candidates progress through clinical trials towards potential commercialization.
25
We are closely evaluating the impacts of the evolving effects of the COVID-19 pandemic on our ability and the ability of our collaborators to effectively market, sell and distribute our products and to develop our products and product candidates. Our field-based personnel are using a mix of in-person interactions and electronic communications, such as emails, phone calls and video conferences, to support healthcare providers and patients. Many healthcare professionals are facing additional demands on their time during the ongoing COVID-19 pandemic. We expect the different quality of electronic interactions as compared with in-person interactions, as well as the reduced quantity of interactions during the COVID-19 pandemic, to reduce the effectiveness of our sales personnel, as well as those of our collaborators, which could negatively affect our product sales and those of our collaborators, as well as physician awareness of our products. In this regard, we believe that the need to conduct some of our activities virtually is negatively impacting our ability to connect with key customers, including those familiar with competitive products, and our ability to conduct payor engagements. We face a number of challenges that will limit our ability to fully resume in-person interactions, including increasing COVID-19 infection rates due to coronavirus mutations and/or low vaccination rates in different areas or otherwise, the need to navigate varying restrictions for entering healthcare facilities and the pandemic's impacts on employee childcare arrangements. In addition, we may subsequently decide or be forced to resume a more restrictive remote work model, whether as a result of further spikes or surges in COVID-19 infection or hospitalization rates or otherwise. Moreover, the long-term effects of the COVID-19 pandemic are also unknown and it is possible that following the pandemic, healthcare institutions could alter their policies with respect to in person visits by pharmaceutical company representatives. Future COVID-19 related restrictions could also present product distribution challenges. The evolving effects of the COVID-19 pandemic appear to have negatively affected and may continue to negatively affect our product sales due to challenges in patient access to healthcare settings, loss of individual health insurance coverage, and inability to access government healthcare programs due to backlogs, some or all of which appear to have negatively affected diagnosis rates, may affect side effect management and course of treatment and may increase enrollment in our patient support programs. In this regard, impacts associated with the COVID-19 pandemic appear to have led to a reduction in the rate of Hodgkin lymphoma diagnoses, may have adversely affected diagnosis rates of other cancers, and may further adversely affect rates of cancer diagnoses in the future. We also expect that the conversion of medical conferences to a virtual format may reduce our ability to effectively disseminate scientific information about our products, which may result in decreased physician awareness of our products, their approved indications and their efficacy and safety.
Some of the sites participating in our clinical trials are affected by site closings, reduced capacity, staffing shortages, or other effects of the COVID-19 pandemic. At some sites, we are experiencing impacts to our ability to monitor patients, activate sites, screen and enroll patients, complete site monitoring and manage samples. The extent of the impact on a particular clinical trial depends on the current stage of activities at a given site, for example study start up versus post-enrollment, and the number of impacted sites participating in that trial. Impacts on diagnosis rates associated with the COVID-19 pandemic may also negatively impact enrollment. While we do not at this time anticipate the need to revise our publicly reported projected clinical milestone dates as a result of the effects of the COVID-19 pandemic, there may continue to be adverse impacts to our clinical study timelines, which, depending upon the duration and severity of the evolving effects of the COVID-19 pandemic, could ultimately delay data availability. Due to the suspension of data monitoring activities at sites that do not currently allow remote monitoring, as well as impacts on the ability to monitor patients, maintain patient treatment according to the trial protocols and manage samples, there is also the potential for negative impacts on data quality. While we are actively utilizing digital monitoring measures and other mitigations designed to prevent negative data quality impacts, if there were in fact a negative impact on data quality, we or our collaborators could be required to repeat, extend the duration of, or increase the size of clinical trials, which could significantly delay potential commercialization and require greater expenditures. We expect that similar factors will impact clinical studies operationalized by our collaborators. In addition, many of our non-essential on-site research activities are currently significantly reduced as a result of the COVID-19 pandemic, which may negatively impact the number of IND candidates entering our clinical pipeline in future years.
The extent to which the evolving effects of the COVID-19 pandemic impact our business will depend on future developments that are highly uncertain, such as coronavirus variants that may prove to be especially contagious or virulent, the ultimate duration and severity of the pandemic, government actions, such as travel restrictions, quarantines and social distancing requirements in the U.S. and in other countries, business closures or business disruptions and the effectiveness of vaccine programs and other actions taken to contain and treat the disease. For more information on the risks and uncertainties associated with the evolving effects of the COVID-19 pandemic on our business, our ability to generate sales of and revenues from our approved products, and our clinical development and regulatory efforts, see “Part II Item 1A—Risk Factors.”
Because of the above and other factors, our results of operations may vary substantially from year to year and from quarter to quarter and, as a result, we believe that period to period comparisons of our operating results may not be meaningful and should not be relied upon as being indicative of our future performance.

26
Financial summary
For the six months ended June 30, 2022, our total revenues increased to $924 million, compared to $720 million for the same period in 2021. This increase was primarily driven by $165 million or 25% higher net product sales, due to growth from each of our approved medicines, and to a lesser extent, higher collaboration and license agreement revenues, and higher royalty revenues.
For the six months ended June 30, 2022, total costs and expenses increased to $1,190 million, compared to $932 million for the same period in 2021. The increase was due mainly to higher research and development expenses, and to a lesser extent, higher sales, general, and administrative expenses, and higher cost of sales.
As of June 30, 2022, we had approximately $1.9 billion in cash, cash equivalents and investments and $2.9 billion in total stockholders’ equity.

Results of operations
Net product sales
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
ADCETRIS$201,939 $181,912 11 %$382,928 $344,484 11 %
PADCEV123,577 82,405 50 %223,784 152,163 47 %
TUKYSA88,989 83,021 7 %179,464 153,279 17 %
TIVDAK17,209 — NM28,624 — NM
Net product sales$431,714 $347,338 24 %$814,800 $649,926 25 %
NM: No amount in comparable period or not a meaningful comparison.
Our net product sales increased during the three and six months ended June 30, 2022 as compared to the comparable periods in 2021, driven by growth from each of our marketed products.
PADCEV net product sales grew primarily due to higher penetration in its approved indications, and to a lesser extent, higher sales in the current periods of drug product to another company for use in its clinical trials. ADCETRIS net product sales grew primarily due to higher net selling prices, and to a lesser extent, growth in volumes of vials sold. TUKYSA net product sales grew due to increased sales volume in our European markets following its commercial launches commencing in 2021 and higher net selling prices in the U.S. We began commercializing TIVDAK in the U.S. following FDA approval in September 2021.
We expect growth in net product sales in 2022 as compared to 2021 to be primarily driven by sales growth of PADCEV, and to a lesser extent, TIVDAK and ADCETRIS. Refer to “Overview—Outlook” above for additional information.
Gross-to-net deductions, net of related payments and credits, were as follows:
(in thousands)Rebates and
chargebacks		Distribution fees,
product returns
and other		Total
Balance as of December 31, 2021$74,889 $16,818 $91,707 
Provision related to current period sales273,174 22,603 295,777 
Adjustment for prior period sales(6,070)(532)(6,602)
Payments/credits for current period sales(213,394)(15,318)(228,712)
Payments/credits for prior period sales(40,998)(3,886)(44,884)
Balance as of June 30, 2022$87,601 $19,685 $107,286 
Government-mandated rebates and chargebacks are the most significant component of our total gross-to-net deductions and the discount changes over time. The most significant portion of our gross-to-net accrual balances as of June 30, 2022 and 2021 was for ADCETRIS Medicaid rebates. We expect future gross-to-net deductions to fluctuate based on the volume of purchases eligible for government mandated discounts and rebates, as well as changes in the discount percentage which is impacted by potential future price increases, the rate of inflation, and other factors. We expect gross-to-net deductions to increase in 2022 as compared to 2021, driven by anticipated growth in our gross product sales.

27
Royalty revenues
Royalty revenues primarily reflect royalties earned under the ADCETRIS collaboration with Takeda. These royalties include commercial sales-based milestones and sales royalties. Sales royalties are based on a percentage of Takeda’s net sales of ADCETRIS, with rates that range from the mid-teens to the mid-twenties based on annual net sales tiers. Takeda bears third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenues. Royalty revenues also reflect, to a lesser extent, amounts from Genentech earned on net sales of Polivy beginning in 2019 and amounts from GlaxoSmithKline earned on net sales of Blenrep beginning in 2020, both of which utilizes technology that we have licensed to them, as well as royalties on TUKYSA sales by Merck in its territory, and royalties on disitamab vedotin sales by RemeGen in its territory.
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
Royalty revenues$39,109 $36,296 8 %$67,290 $63,514 6 %
Royalty revenues increased slightly for the three and six months ended June 30, 2022 from the comparable periods in 2021, primarily due to higher royalties earned on net sales of Polivy by Genentech.
We expect that royalty revenues will increase in 2022 as compared to 2021 primarily due to higher royalties from anticipated growth in ADCETRIS sales volume by Takeda, and to a lesser extent, anticipated growth of our other licensees' net product sales.

Collaboration and license agreement revenues
Collaboration and license agreement revenues reflect amounts earned under certain of our license and collaboration agreements. These revenues reflect license fees, payments received by us for technology access and maintenance fees, sales of drug supply to our collaborators, milestone payments, and reimbursement payments for research and development support that we provide to our collaborators.
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
Collaboration and license agreement revenues$26,679 $4,844 451 %$41,872 $7,020 496 %
Collaboration and license agreement revenues increased for the three and six months ended June 30, 2022 compared to the prior periods due to a $12.0 million milestone received from AbbVie during the second quarter of 2022, higher amounts received from Astellas profit share or royalty contributions, and increased revenues from drug product supplied to collaborators, The increase in collaboration and license agreement revenues for the six months ended June 30, 2022 compared to the prior period was also due to an upfront license payment received from Sanofi during the first quarter 2022.
We expect that collaboration and license agreements revenues will increase in 2022 as compared to 2021 primarily driven by the AbbVie and Sanofi revenues in 2022. Our collaboration and license agreement revenues are impacted by the term and duration of those agreements and by progress-dependent milestones, annual maintenance fees, and reimbursement of materials and support services. Collaboration and license agreement revenues may vary substantially from year to year and quarter to quarter depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved, the amount of drug supplied to our collaborators, and whether we enter into potential additional collaboration and license agreements.

Collaboration and license agreements
Takeda ADCETRIS collaboration
We have an agreement with Takeda for the global co-development of ADCETRIS and the commercialization of ADCETRIS by Takeda in its territory. We recognize payments from Takeda, including progress-dependent development and regulatory milestone payments, reimbursement for drug supplied, and net development cost reimbursement payments, as collaboration and license agreement revenues upon transfer of control of the goods or services over the development period. When the performance of development activities under the collaboration results in us making a reimbursement payment to Takeda, that payment reduces collaboration and license agreement revenues. We also recognize royalty revenues based on a percentage of Takeda's net sales of ADCETRIS in its territories, ranging from the mid-teens to the mid-twenties based on annual net sales tiers, as well as sales-based milestones. Takeda bears a portion of third-party royalty costs owed on its sales of ADCETRIS, which is included in royalty revenues.
28
Astellas PADCEV collaboration
We have a collaboration agreement with Agensys, Inc., which subsequently became an affiliate of Astellas, to jointly research, develop and commercialize ADCs for the treatment of several types of cancer. Under this collaboration, we and Astellas are equally co-funding all development and certain commercialization costs for PADCEV. In the U.S., we and Astellas jointly promote PADCEV. We record sales of PADCEV in the U.S. and are responsible for all U.S. distribution activities. The companies each bear the costs of their own sales organizations in the U.S., equally share certain other costs associated with commercializing PADCEV in the U.S., and equally share in any profits realized in the U.S. Gross profit share payments owed to Astellas in the U.S. under the joint commercialization agreement are recorded in cost of sales. Outside the U.S., we have commercialization rights in all countries in North and South America, and Astellas has commercialization rights in the rest of the world, including Europe, Asia, Australia and Africa.
Astellas or its affiliates are responsible for manufacturing PADCEV for development and commercial use. However, we are responsible for packaging and labeling in countries in which we sell PADCEV. In addition, if the parties determine that a second source is required, we will be responsible for establishing such second source whether internally or through a third party.
Genmab TIVDAK collaboration
We have an agreement with Genmab to develop and commercialize ADCs for the treatment of several types of cancer, under which we previously exercised a co-development option for TIVDAK. Under this collaboration, we and Genmab are co-funding all development costs for TIVDAK. In the U.S., we and Genmab co-promote TIVDAK. We record sales of TIVDAK in the U.S. and are responsible for leading U.S. distribution activities. The companies will each maintain 50% of the sales representatives and medical science liaisons, equally share those and certain other costs associated with commercializing TIVDAK in the U.S., individually bear the costs of certain other personnel in the U.S., and equally share in any profits realized in the U.S. Outside the U.S., we have commercialization rights in the rest of the world except for Japan, where Genmab has commercialization rights. In Europe, China, and Japan, we and Genmab equally share 50% of the costs associated with commercializing TIVDAK as well as any profits realized in these markets. In markets outside the U.S. other than Europe, China, and Japan, aside from certain costs specified in the agreement, we are solely responsible for all costs associated with commercializing TIVDAK and will pay Genmab a royalty based on a percentage of aggregate net sales ranging from the mid-teens to mid-twenties.
Merck LV collaboration
In 2020, we entered into the LV Agreement with a subsidiary of Merck. We are pursuing a broad joint development program evaluating LV as monotherapy and in combination setting, including with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. Under the terms of the LV Agreement, we granted Merck a co-exclusive worldwide development and commercialization license for LV, and agreed to jointly develop and commercialize LV on a worldwide basis. We received an upfront cash payment, and we are eligible to receive milestone payments upon the initiation of certain clinical trials, regulatory approval in certain major markets and achievement of specified annual global net sales thresholds of LV. Each company is responsible for 50% of global costs to develop and commercialize LV and will receive 50% of potential future profits.
We recognize such cost sharing proportionately with the performance of the underlying activities, while recording Merck’s reimbursement of our expenses as a reduction of research and development expenses.
29
Merck TUKYSA collaboration
In 2020, we entered into the TUKYSA Agreement with a subsidiary of Merck. We granted exclusive rights to commercialize TUKYSA in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Under the terms of the TUKYSA Agreement, Merck is responsible for marketing applications for approval in its territory, supported by the positive results from the HER2CLIMB clinical trial. We retained commercial rights in, and will record sales in, the U.S., Canada and Europe. Merck is also co-funding a portion of the TUKYSA global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers. We will continue to lead ongoing TUKYSA global development operational execution. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. We are eligible to receive progress-dependent milestone payments, and are entitled to receive tiered royalties on sales of TUKYSA by Merck that begin in the low twenty percent range and escalate based sales volume by Merck in its territory.
We recognize such cost sharing proportionately with the performance of the underlying activities, while recording Merck’s reimbursement of our expenses as a reduction of research and development expenses. Sales of TUKYSA drug product supplied is included in collaboration and license agreement revenues. The $85.0 million prepayment received for global development cost-sharing was recorded as a co-development liability in accrued liabilities and other or other long-term liabilities on our condensed consolidated balance sheet as of June 30, 2022. As joint development expenses are incurred, we recognize the portion of Merck’s prepayment as a reduction of our research and development expenses on our condensed consolidated statements of comprehensive loss. As of June 30, 2022 and December 31, 2021, $39.3 million and $55.3 million was recorded as the remaining co-development liability, respectively.
RemeGen disitamab vedotin license agreement
Effective in September 2021, we and RemeGen entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. Disitamab vedotin combines the drug-linker technology originally developed by Seagen with RemeGen’s novel HER2 antibody. Disitamab vedotin received FDA Breakthrough Therapy designation in 2020 for use in second-line treatment of patients with HER2-expressing, locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy. Also in 2020, RemeGen announced FDA’s clearance of an IND application for a phase II clinical trial in locally advanced or metastatic urothelial cancer. Disitamab vedotin is conditionally approved for treating locally advanced metastatic gastric cancer in China, and in July 2021 the National Medical Products Administration of China also accepted a NDA for disitamab vedotin in locally advanced or metastatic urothelial cancer.
Under the terms of the agreement, we made a $200.0 million upfront payment to obtain exclusive license rights to disitamab vedotin for global development and commercialization, outside of RemeGen’s territory. RemeGen retains development and commercialization rights for Asia, excluding Japan and Singapore. We will lead global development and RemeGen will fund and operationalize the portion of global clinical trials attributable to its territory. RemeGen will also be responsible for all clinical development and regulatory submissions specific to its territory. We will pay RemeGen up to $195.0 million in potential milestone payments across multiple indications and products based upon the achievement of specified development goals, and up to $2.2 billion in potential milestone payments based on the achievement of specified regulatory and commercialization goals. RemeGen will be entitled to a tiered, high single digit to mid-teen percentage royalty based on net sales of disitamab vedotin in our territory.
Other technology collaboration and license agreements
We have other collaboration and license agreements for our ADC technology with a number of biotechnology and pharmaceutical companies. We typically receive upfront cash payments and progress- and sales-dependent milestones for the achievement by our licensees of certain events, and annual maintenance fees and support fees for research and development services and materials provided under the agreements. These amounts are recognized as revenue over the performance obligation period if the license is determined not to be distinct from other goods and services provided, or, if there is no performance obligation, upon transfer of control of the goods or services to the customer.

Cost of sales
Cost of sales includes manufacturing and distribution costs of product sold, gross profit share with Astellas and Genmab pursuant to those respective collaborations, amortization of acquired technology license costs, royalties owed on our PADCEV net product sales, and royalties owed on global ADCETRIS, TUKYSA, and TIVDAK net product sales.
30
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
Cost of sales$106,100 $78,090 36 %$193,726 $142,225 36 %
Cost of sales increased for the three and six months ended June 30, 2022 from the comparable periods in 2021, driven by higher gross profit sharing owed to our collaboration partners, and to a lesser extent, higher product costs from sales volume increases. The gross profit share owed to collaborators totaled $65.5 million and $118.3 million for the three and six months ended June 30, 2022, respectively, as compared to $38.6 million and $71.1 million for the comparable periods in 2021.
We expect cost of sales to increase in 2022 as compared to 2021 as a result of the net product sales growth of our marketed products, contributing to higher anticipated gross profit sharing with our collaborators, higher manufacturing costs for products sold, and increased royalties owed on certain net sales of our products.

Research and development
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
Research and clinical development$232,679 $164,869 41 %$462,328 $338,873 36 %
Process sciences and manufacturing71,575 69,992 2 %139,585 126,413 10 %
Total research and development$304,254 $234,861 30 %$601,913 $465,286 29 %
Research and clinical development expenses include personnel, occupancy and laboratory expenses, technology access fees, preclinical translational biology and in vitro and in vivo studies, IND-enabling pharmacology and toxicology studies, and external clinical trial costs including costs for clinical sites, clinical research organizations, contractors and regulatory activities associated with conducting human clinical trials. The increases for the three and six months ended June 30, 2022 from the comparable period in 2021 was due mainly to higher employee-related costs and clinical trial costs mainly to support our early- and late-stage pipeline of product candidates.
Process sciences and manufacturing expenses include personnel and occupancy expenses, manufacturing costs for the scale-up and pre-approval manufacturing of product candidates used in research and our clinical trials, and costs for drug product supplied to our collaborators. Process sciences and manufacturing expenses also include quality control and assurance activities, and storage and shipment of our product candidates. The increases for the three and six months ended June 30, 2022 from the comparable period in 2021 primarily reflected higher employee-related costs and the timing of manufacturing costs of our product candidates for use in clinical trials.
We utilize our employee and infrastructure resources across multiple research and development projects. We track human resource efforts expended on many of our programs for purposes of billing our collaborators for time incurred at agreed upon rates and for resource planning. We do not account for actual costs on a project basis as it relates to our infrastructure, facility, employee and other indirect costs; however, we do separately track significant third-party costs including clinical trial costs, manufacturing costs and other contracted service costs on a project basis. To that end, the following table shows third-party costs incurred for research, manufacturing of our product candidates and clinical and regulatory services, as well as development milestone payments for in-licensed technology for our products and certain of our clinical-stage product candidates. The table also presents other costs and overhead consisting of third-party costs for our preclinical stage programs, personnel, facilities, manufacturing, and other indirect costs not directly charged to development programs, as well as cost reimbursements received from or payments made to collaborators related to our product candidates.
31
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)2022202120222021
TUKYSA (tucatinib)$48,947 $32,241 $92,542 $62,233 
PADCEV (enfortumab vedotin-ejfv)17,836 19,213 42,605 35,500 
ADCETRIS (brentuximab vedotin)25,015 16,838 38,867 33,914 
TIVDAK (tisotumab vedotin)10,758 9,384 18,690 21,388 
Ladiratuzumab vedotin4,484 6,955 7,743 11,800 
Disitamab vedotin
7,500 — 17,879 — 
Other clinical stage programs23,422 13,314 45,027 34,929 
Total third-party costs for clinical stage programs137,962 97,945 263,353 199,764 
Other costs, overhead, and net cost-sharing with collaborators166,292 136,916 338,560 265,522 
Total research and development$304,254 $234,861 $601,913 $465,286 
N/A: No amount in comparable period or not a meaningful comparison.

Third-party costs for TUKYSA increased for the three and six months ended June 30, 2022 as compared to the 2021 periods, due primarily to higher clinical trials expenses.
Third-party costs for PADCEV decreased slightly for the three months ended June 30, 2022 as compared to the 2021 period, and increased for the six months ended June 30, 2022 as compared to the 2021 period, due to the timing of clinical trials expenses and manufacturing costs.
Third-party costs for ADCETRIS increased for the three and six months ended June 30, 2022 as compared to the 2021 periods, due primarily to higher manufacturing and clinical trials expenses.
Third-party costs for TIVDAK increased for the three months ended June 30, 2022 as compared to the 2021 period, and decreased for the six months ended June 30, 2022 as compared to the 2021 period, due to the timing of clinical trials expenses.
Third-party costs for ladiratuzumab decreased for the three and six months ended June 30, 2022 as compared to the 2021 periods, due primarily to lower clinical trials expenses.
We obtained exclusive license rights to disitamab vedotin for global development and commercialization outside of RemeGen’s territory in September 2021.
Third-party costs for other clinical stage programs increased for the three and six months ended June 30, 2022 as compared to the 2021 periods due to higher clinical trial expenses.
Other costs, overhead, and net cost-sharing reimbursements from or payments made to collaborators increased for the three and six months ended June 30, 2022 from the comparable periods in 2021, due to higher employee-related costs. During the three months ended June 30, 2022 and 2021, net cost-sharing reimbursements from collaborators were $21.1 million and $19.0 million, respectively. During the six months ended June 30, 2022 and 2021, net cost-sharing reimbursements from collaborators were $44.3 million and $40.3 million, respectively.
In order to advance our product candidates toward commercialization, the product candidates are tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical trials for those product candidates that take several years or more to complete. The length of time varies substantially based upon the type, complexity, novelty and intended use of a product candidate. We will also need to conduct additional clinical trials in order to expand labeled indications of use for our commercial products. The outcome of our clinical trials is uncertain. The cost of clinical trials may vary significantly as a result of a variety of factors, including the number of patients enrolled, patient site costs, quantity and source of drug supply required, safety and efficacy of the product candidate, and extent of regulatory efforts, among others. 
We anticipate that our total research and development expenses in 2022 will increase compared to 2021 primarily due to higher costs for the continued development of our approved products and product candidates, offset in part by the $200.0 million RemeGen upfront license payment in 2021.
32
The risks and uncertainties associated with our research and development projects are discussed more fully in “Part II Item 1A—Risk Factors.” As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates, or when and to what extent we will receive cash inflows from the commercialization and sale of our products in any additional approved indications or of any of our product candidates.

Selling, general and administrative 
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
Selling, general and administrative$220,259 $165,130 33 %$394,484 $324,972 21 %
Selling, general and administrative expenses increased for the three and six months ended June 30, 2022 from the comparable periods in 2021, reflecting investments to support our ongoing European TUKYSA launches and the U.S. commercial launch of TIVDAK, $11.1 million in one-time expenses related to the separation agreement with our former CEO in the second quarter of 2022, and higher legal expenses,
We anticipate that selling, general and administrative expenses will increase in 2022 as compared to 2021 as we continue our commercial activities in support of our product launches, and invest in infrastructure to support our continued growth in the U.S. and Europe.

Investment and other (loss) income , net
 Three months ended June 30,Six months ended June 30,
(dollars in thousands)20222021% Change20222021% Change
(Loss) gain on equity securities$(4,299)$4,670 (192)%$(7,078)$4,929 (244)%
Investment and other income, net2,690 357 654 %3,279 1,098 199 %
Total investment and other (loss) income, net$(1,609)$5,027 (132)%$(3,799)$6,027 (163)%
NM: No amount in comparable period or not a meaningful comparison.
Investment and other (loss) income, net includes other non-operating income and loss, such as unrealized holding gains and losses on equity securities, realized gains and losses on equity and debt securities, and amounts earned on our investments in U.S. Treasury securities.
The loss on equity securities for the three and six months ended June 30, 2022 was due to unrealized holding losses resulting from a decline in the share price of securities held during the respective periods.

Provision for income taxes

Our provision for income taxes was $0.1 million and $1.4 million for the three and six months ended June 30, 2022, respectively, compared with $0 for the three and six months ended June 30, 2021. The provision for income taxes in the 2022 periods primarily related to taxable profits in the U.S. as a result of amendments to IRC Section 174, which took effect January 1, 2022 pursuant to the 2017 Tax Cuts and Jobs Act. We had existing federal tax carryforwards sufficient to offset any federal liability; however, there were limitations on the use of existing state tax carryforwards. Our income tax provision also reflected taxable profits in foreign jurisdictions partially offset by a foreign valuation allowance release.
Liquidity and capital resources
(in thousands)June 30, 2022December 31, 2021
Cash, cash equivalents, and investments$1,850,322 $2,160,036 
Working capital2,170,134 2,300,340 
Stockholders’ equity2,932,812 3,065,139 
33
 Six months ended June 30,
(in thousands)20222021
Cash provided (used) by:
Operating activities$(288,582)$(197,770)
Investing activities199,756 20,130 
Financing activities41,624 32,992 
The change in net cash from operating activities for the six months ended June 30, 2022 as compared to the comparable period in 2021 was primarily related to an increase in net loss and increases in net working capital.
The change in net cash from investing activities for the six months ended June 30, 2022 as compared to the comparable period in 2021 reflected differences between the amounts used for purchases of securities and proceeds from maturities of securities, and the difference for purchases of property, plant, and equipment.
The change in net cash from financing activities for the six months ended June 30, 2022 as compared to the comparable period in 2021 was driven by the higher proceeds from the exercise of stock options and employee stock purchase plan.
We primarily have financed our operations through the issuance of our common stock, collections from commercial sales of our products, amounts received pursuant to license and collaboration agreements, and royalty revenues. To a lesser degree, we also have financed our operations through investment income. These financing and revenue sources have allowed us to maintain adequate levels of cash and investments.
Our cash, cash equivalents, and investments are held in a variety of non-interest bearing bank accounts and interest-bearing instruments subject to investment guidelines allowing for holdings in U.S. government and agency securities, corporate securities, taxable municipal bonds, commercial paper and money market accounts. Our investment portfolio is structured to provide for investment maturities and access to cash to fund our anticipated working capital needs. However, if our liquidity needs should be accelerated for any reason in the near term, or investments do not pay at maturity, we may be required to sell investment securities in our portfolio prior to their scheduled maturities, which may result in a loss. As of June 30, 2022, we had $1.9 billion held in cash, cash equivalents and investments.
At our currently planned spending rates, we believe that our existing financial resources, together with product and royalty revenues, and reimbursements and profit sharing we expect to receive under our existing collaboration and license agreements, will be sufficient to fund our operations for at least the next twelve months from the date of this filing.
We expect to make additional capital outlays and to increase operating expenditures over the next several years as we hire additional employees, and support our development, commercialization, invest in our facilities, and expand globally, which may require us to raise additional capital. In addition, we may pursue new operations or continue the expansion of our existing operations, including with respect to the continued development of our commercial infrastructure in Europe and our plans to otherwise continue to expand our operations internationally. Our commitment of resources to the continuing development, regulatory and commercialization activities for our products, the continued research, development and manufacturing of our product candidates, our pursuit of regulatory approvals for and preparing to potentially launch and commercialize our product candidates, and the anticipated expansion of our pipeline and operations may require us to raise additional capital. Further, we actively evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary products, technologies or businesses, and we may require significant additional capital in order to complete or otherwise provide funding for such transactions. We may seek additional capital through some or all of the following methods: corporate collaborations, licensing arrangements, and public or private debt or equity financings. We have no committed sources of funding and do not know whether additional capital will be available when needed, or that, if available, we will obtain financing on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to scale back our operations, delay, reduce the scope of, or eliminate development programs enter into collaboration or license agreements on terms that are not favorable to us, sell or relinquish rights to certain assets, proprietary technologies or product candidates or forego strategic opportunities.
Material Cash Requirements
Our material cash requirements in the short- and long-term consist of the following operational, capital, and manufacturing expenditures, a portion of which contain contractual or other obligations. We plan to fund our material cash requirements with our current financial resources together with our anticipated receipts of accounts receivable, product sales and royalty revenues, and reimbursements we expect to receive under our existing collaboration and license agreements.
34
Operating expenditures. Our primary uses of cash and operating expenses relate to paying employees and consultants, administering clinical trials, marketing our products, and providing technology and facility infrastructure to support our operations. Our research and development expenses for the six months ended June 30, 2022 were $601.9 million and we expect to increase our investment in research and development expenses in 2022 as compared to 2021. Our sales, general and administrative expenses were $394.5 million for the six months ended June 30, 2022, and we expect to increase our sales, general, and administrative expenses to support our business growth in 2022 as compared to 2021. On a long-term basis, we manage future cash requirements relative to our long-term business plans.
Operating costs also relate to our building leases for our office and laboratory facilities expiring in 2022 through 2029 that contain rate escalations and options for us to extend the leases. Our future minimum lease payments as of June 30, 2022 totaled $16.5 million related to short-term lease liabilities, and $57.1 million related to long-term lease liabilities. We signed a 20-year lease in June 2021 for a building complex in Everett, Washington that has not commenced as of June 30, 2022, and therefore rent payments are not included in lease liability balances as of June 30, 2022. Refer to Note 3 in the Notes to Financial Statements in Item 1 for further detail of our lease obligations.
Capital expenditures. We make investments in our office, laboratory, and manufacturing facilities to enable continued expansion of our business. These include leasehold and building improvements at our approximately 1 million square feet of leased and owned properties, installation of laboratory and manufacturing equipment, computers, software, and office equipment. Our purchases for property and equipment for the six months ended June 30, 2022 were $32.2 million, and we anticipate these investments to grow in 2022 as compared to 2021 to support our anticipated business growth and long-term facility needs, including a significant multi-year investment in a building complex being constructed in Everett, Washington, which is expected to provide us additional manufacturing, laboratory, and office space in the future. We expect our capital expenditures for this Everett facility to be approximately $350 million to $400 million through 2024.
Manufacturing costs, and supply agreements. Some of our inventory components and products require long lead times to manufacture. Therefore, we make substantial and often long-term investments in our supply chain in order to ensure we have enough drug product to meet current and future revenue forecasts, as well as clinical trial needs. Supply agreements primarily include non-cancelable obligations under our manufacturing, license and collaboration, and technology agreements. Further, a substantial portion of those non-cancelable obligations include minimum payments related to manufacturing our product candidates for use in our clinical trials and for commercial operations in the case of ADCETRIS. There have been no material changes related to our future minimum contractual commitments under these arrangements as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 filed February 9, 2022.
Royalties, milestones and profit-sharing associated with our licensed technology and collaboration agreements. Some of our license and collaboration agreements provide for periodic maintenance fees over specified time periods, profit share payments, and/or payments by us upon the achievement of development and regulatory milestones. Some of our licensing agreements also obligate us to pay royalties based on net sales of products utilizing licensed technology. Such royalties and profit share payments are dependent on future product sales and are contingent on events that have not yet occurred. Royalties and profit share payments totaled $118.3 million for the six months ended June 30, 2022 and are expected to increase in future periods. Milestone payments generally become due and payable upon the achievement of certain events. There have been no material changes related to our future milestone payments potentially owed related to in-licensed technology as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 filed February 9, 2022.
Critical accounting policies
The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the amounts reported in our financial statements and accompanying notes. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates. Our critical accounting policies, those with the more significant judgments and estimates, used in the preparation of our financial statements for the six months ended June 30, 2022 were consistent with those in Part II Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021.


Item 3.    Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our market risk disclosures as set forth in Part II Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2021.
35

Item 4.    Controls and Procedures
(a) Evaluation of disclosure controls and procedures. Our management, with the participation of our Interim Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this quarterly report. Based on that evaluation, our Interim Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level.
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met.
(b) Changes in internal control over financial reporting. There have not been any changes in our internal control over financial reporting during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
36
Part II. Other Information
Item 1.    Legal Proceedings
The information required to be set forth under this Item 1 is incorporated by reference to “Note 11. Legal matters” of the Notes to Condensed Consolidated Financial Statements included in Part 1 Item 1 of this Quarterly Report on Form 10-Q.
Item 1A.    Risk Factors
You should carefully consider the following risk factors, in addition to the other information contained in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and related notes. If any of the events described in the following risk factors occurs, our business, operating results and financial condition could be seriously harmed. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report on Form 10-Q.
Risk Factor Summary
Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks that we face, follows this summary. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties.
•Our success depends on our ability to effectively commercialize our products. If we and our collaborators are unable to effectively commercialize our products and to expand their utilization, our ability to generate significant revenue and our prospects for profitability will be adversely affected.
•Our success also depends on our ability to obtain regulatory approvals for our product candidates and for our current products in additional territories, as well as our ability to expand the labeled indications of use for our current products. Our inability to do so could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
•Reports of adverse events or safety concerns involving our products or product candidates could delay or prevent us from obtaining or maintaining regulatory approvals or could negatively impact sales of our products or the prospects for our product candidates.
•Clinical trials and product development are expensive, time consuming and uncertain, may take longer than we expect and may not be successful. Our failure to effectively advance our development programs in a timely manner or at all could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
•The successful commercialization of our products will depend, in part, on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.
•The successful commercialization of our products will also depend in part on the acceptance of our products by the medical community, patients and third-party payors.
•Any failures or setbacks in our antibody-drug conjugate, or ADC, development program or our other platform technologies could negatively affect our business and financial position.
•We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
•Our products and any future approved products remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in penalties and significant additional expense and could negatively impact our and our collaborators’ ability to commercialize our current and any future approved products.
•Healthcare law and policy changes may negatively impact our business, including by decreasing the prices that we and our collaborators receive for our products.
•We are subject to various state, federal and international laws and regulations, including healthcare, data privacy and information security laws and regulations, that may impact our business and could subject us to significant fines and penalties or other negative consequences.
•Our collaborators and licensees may not perform as expected, which may negatively affect our ability to develop and commercialize our products and product candidates and/or generate revenues through technology licensing, and may otherwise negatively affect our business.
37
•We currently rely on third-party manufacturers and other third parties for production of our drug products, and our dependence on these third parties may impair the continued development and commercialization of our products and product candidates.
•If we are unable to enforce our intellectual property rights or if we fail to sustain and further procure additional intellectual property rights, we may not be able to successfully commercialize our products or any future products and competitors may be able to develop competing therapies.
•We and our collaborators rely on license agreements for certain aspects of our products and product candidates and technologies such as our ADC technology. Failure to maintain these license agreements or to secure any required new licenses could prevent us from continuing to develop and commercialize our products and product candidates.
•We have been and may in the future be subject to litigation, which could result in substantial expenses and damages and may divert management’s time and attention from our business.
•The evolving effects of the COVID-19 pandemic and associated global economic instability could have further adverse effects on our business, including our commercialization efforts, supply chain, regulatory activities, clinical development activities and other business operations.
•If we are unable to manage our growth, our business, results of operations, financial condition and growth prospects may be adversely affected.
•Risks associated with our expanding operations in countries outside the U.S. could materially adversely affect our business.
•Our operating results are difficult to predict and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.
•We have a history of net losses. We expect to continue to incur net losses and may not achieve future sustained profitability for some time, if at all.
•Our stock price is volatile and our shares may suffer a decline in value.
•Our existing stockholders have significant control of our management and affairs.
Risks Related to Our Products, Product Candidates and Research and Development
Our success depends on our ability to effectively commercialize our products. If we and our collaborators are unable to effectively commercialize our products and to expand their utilization, our ability to generate significant revenue and our prospects for profitability will be adversely affected.
Our ability to generate revenue from product sales and our prospects for profitability are substantially dependent on our and our collaborators’ ability to effectively commercialize our products and expand their utilization. We may not be able to fully realize the commercial potential of our products, and/or commercial sales of our products may be lower than our projections, for a number of reasons, including:
•we and our collaborators may be unable to effectively launch, market and commercialize our products, including in any new markets or in any new indications;
•we and our collaborators may not be able to establish or demonstrate to the medical community the efficacy, safety and value of our products and their potential advantages compared to existing and future therapeutics in their approved indications;
•we and our collaborators may not be able to obtain and maintain regulatory and other required governmental approvals to market our products in any additional territories or for any additional indications;
•new competitive therapies in the approved indications for our products have been approved by regulatory authorities or may be approved or submitted to regulatory authorities for approval in the near term;
•there may continue to be new adverse results, adverse events or safety concerns reported in connection with the use of our products, including in clinical trials;
•there may be additional changes to the labeling for our products that further restrict how we market and sell our products, including as a result of data collected from clinical trials and/or as a result of the use of our products;
•the incidence rate of new patients or the duration of therapy in the approved indications for our products may be lower than our projections;
38
•negative impacts related to the COVID-19 pandemic, including potential further impacts on cancer diagnosis rates, may increase or become more severe;
•we may encounter challenges in joint decision making and joint execution with our collaborators that adversely affect product sales;
•co-promotion arrangements, such as the joint commercialization of PADCEV with Astellas in the U.S. and the joint commercialization of TIVDAK with Genmab in the U.S., may not be successful;
•our products may be impacted by adverse reimbursement and coverage policies from government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators, or may be subject to pricing pressures enacted by industry organizations or state and federal governments, including as a result of increased scrutiny over pharmaceutical pricing, the cost of alternative treatment options or otherwise;
•we and our collaborators may not be able to obtain favorable pricing and reimbursement approvals in additional territories in a timely manner or at all;
•physicians may be reluctant to prescribe our products due to side effects associated with their use or until longer term efficacy and safety data exist;
•regulatory restrictions may change or increase;
•we and our collaborators may not have adequate financial or other resources to effectively commercialize our products; and
•we and our collaborators may not be able to accurately predict demand for our products and obtain adequate commercial supplies of our products to meet demand at an acceptable cost.
Our ability to grow our product sales in future periods is also dependent on price increases, and we periodically increase the price of our products. Price increases on our products, as well as negative publicity regarding drug pricing and increases in drug prices generally, whether on our products or products distributed by other pharmaceutical companies, could negatively affect market acceptance of, and sales of, our products. In any event, we cannot assure you that price increases we have taken or may take in the future will not negatively affect our future product sales.
If we and our collaborators are unable to successfully commercialize our products or if sales of a product do not reach the levels we expect, then our business, results of operation, financial condition and growth prospects could be adversely affected.
Our success also depends on our ability to obtain regulatory approvals for our product candidates and for our current products in additional territories, as well as our ability to expand the labeled indications of use for our current products. Our inability to do so could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
We and our collaborators are required to obtain marketing approvals from applicable regulatory authorities in order to market our products or to expand the labeled indications of use for our current marketed products. However, regulatory review is a lengthy and expensive process, and approval is highly uncertain.
The FDA and other regulatory agencies have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained. Clinical trial data are subject to differing interpretations. Even if we believe data are promising, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. For example, although we presented positive results from the MOUNTAINEER trial and submitted a supplemental New Drug Application for TUKYSA under the FDA's accelerated approval program based on the results of the MOUNTAINEER trial, the FDA or its advisors may disagree with our interpretation of the data from the trial. We cannot be certain that the supplemental New Drug Application we submitted for TUKYSA in July 2022 will be accepted or approved in a timely manner or at all. Similarly, although we and Astellas announced positive topline results from Cohort K of the EV-103 trial, the FDA or its advisors may disagree with our interpretation of the data from this cohort, and PADCEV may otherwise never be approved for use in any first-line setting or any other additional indications. In addition, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.
Any approval that a product does receive may be more restricted than anticipated. For example, regulatory authorities may approve a product for fewer indications or narrower indications than requested. Further, regulatory agencies may impose safety monitoring, educational requirements or risk evaluation and mitigation strategies, or REMS. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate or the dosing or delivery methods.
39
The regulatory review process may also take significantly longer than expected, which may delay or eliminate any potential revenues from sales of the affected product or product candidate. Target action dates and regulatory timelines may be subject to substantial delays. Although the FDA and EMA have programs to facilitate expedited development and accelerated approval processes, these programs may not result in faster review or approval than conventional procedures and do not assure ultimate approval. In addition, although the FDA granted Breakthrough Therapy designation to each of PADCEV, TUKYSA and disitamab vedotin in a specified treatment setting, these Breakthrough Therapy designations do not increase the likelihood that PADCEV, TUKYSA or disitamab vedotin will receive marketing approval in the specified settings or in any other settings in a timely manner or at all. Disruptions at the FDA and other agencies due to reduced funding levels, government shutdowns, impacts associated with the COVID-19 pandemic or other factors, may also lead to delays in the regulatory review process. These disruptions may also slow our other interactions with regulatory agencies, which may slow our other product development efforts.
If a product candidate fails to receive regulatory approvals, we will not have the anticipated revenues from that product candidate to fund our operations, and we may not recoup or receive any return on our investment in that product candidate. Similarly, if regulatory authorities do not approve product labeling that is necessary or desirable for the successful commercialization of an approved product, or if they do not approve an application to expand a product’s labeled indications of use or market the product in a new territory, then our anticipated revenue from that product may be adversely affected. Any of these events could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
Even if regulatory approval is achieved, the launch of a new product or of an existing product in a new indication or territory is subject to a number of risks and uncertainties and may not be successful.
Sales of a new product and sales of an existing product in a new indication or territory are subject to significant risks and uncertainties and can be particularly difficult to predict. For example, the commercialization of TIVDAK is at an early stage and may not be successful. In addition to commercialization risks described elsewhere in these "Risk Factors", impacts related to the COVID-19 pandemic, including restrictions on in-person interactions and resulting impacts on our ability to connect with key customers and conduct payor engagements, could limit our and our collaborators' abilities to effectively launch and commercialize a new product or to launch and commercialize an existing product in a new indication or territory. A proposed launch, including the launch of PADCEV and TUKYSA in countries in Europe where they have not yet launched, could also be delayed or impaired due to a variety of factors, including supply constraints, delays in arranging a commercial infrastructure, delays in obtaining or failure to obtain pricing and reimbursement approvals, or other factors. These risks could be heightened by impacts related to the COVID-19 pandemic. Delays or other difficulties due to any of these factors could negatively impact anticipated revenue from the affected product. In addition, prior to TUKYSA, we had no prior experience as an organization launching or commercializing a product outside the U.S. and Canada, which could adversely affect our ability to maximize the commercial potential of TUKYSA. If we and our collaborators are unable to successfully launch and commercialize any newly approved products and/or to successfully launch and commercialize our existing products in new indications or territories, then our business, results of operation, financial condition and growth prospects could be adversely affected.
Reports of adverse events or safety concerns involving our products or product candidates could delay or prevent us from obtaining or maintaining regulatory approvals or could negatively impact sales of our products or the prospects for our product candidates.
Reports of adverse events or safety concerns involving our products and product candidates could result in the limitation, denial or withdrawal of regulatory approval by the FDA or other regulatory authorities for any or all indications, the need to conduct additional trials, implementation of a REMS or the inclusion of unfavorable information in our product labeling and, in turn, could delay or prevent us from commercializing the applicable product or product candidate. There are no assurances that patients receiving our products will not experience serious adverse events, including fatal events, in the future, whether the serious adverse events are disclosed in the prescribing information or are newly reported. Further, there are no assurances that patients receiving our products with co-morbid diseases not previously studied, such as autoimmune diseases, will not experience new or different serious adverse events in the future.
40
The prescribing information for each of our products includes warnings and precautions for various toxicities and reactions, including certain fatal reactions. The prescribing information for ADCETRIS also includes a boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy and death can occur in patients receiving ADCETRIS. The prescribing information for PADCEV also includes a boxed warning related to the risk that severe and fatal cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, may occur in patients receiving PADCEV. The prescribing information for TIVDAK also includes a boxed warning related to the risk that ocular toxicity may occur in patients receiving TIVDAK, and the boxed warning includes requirements for ophthalmic exams at baseline, prior to each dose, and as clinically indicated, as well as premedication and eye care. We have updated the prescribing information for our products from time to time in the past, based on reports of adverse events or safety concerns, and we may be required to further update the prescribing information for our products, including boxed warnings, limitations of use, contraindications, warnings and precautions, and adverse reactions, or to implement a REMS in the future. Side effects and toxicities associated with our products, as well as the warnings, precautions and requirements listed in the prescribing information for our products, could affect the willingness of physicians to prescribe, and patients to utilize, our products and thus harm commercial sales of our products. Implementation of a REMS could advantage products that compete with ours or make it more difficult or expensive for us to distribute our products.
Likewise, reports of adverse events or safety concerns involving our products and product candidates could interrupt, delay or halt clinical trials of our products and product candidates, including the post-approval confirmatory studies that regulatory agencies have required us or our collaborators to complete. There have been serious side effects and, in some cases, deaths in clinical trials for our products and product candidates that were deemed to be treatment-related by the investigators in those trials, and additional and/or unexpected side effects may be observed in these or other trials in the future. In addition, in response to prior safety events observed in our clinical trials, including serious side effects and patient deaths, we have in the past, and may in the future, institute additional precautionary safety measures such as dosing caps and delays, enhanced monitoring for side effects, and modified patient inclusion and exclusion criteria. Additional and/or unexpected safety events could be observed in these or other trials that could delay or prevent us from advancing the clinical development of, or obtaining regulatory approvals for, our products and product candidates, could require us to alter the approved labeling of our products, may cause a trial to be redone or terminated, may affect patient recruitment or may affect the ability of enrolled patients to complete a trial. As a result, such safety events could adversely affect our business, results of operations, financial condition and growth prospects.
Clinical trials and product development are expensive, time consuming and uncertain, may take longer than we expect and may not be successful. Our failure to effectively advance our development programs in a timely manner or at all could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
Our long-term success will depend upon the successful development of new products, as well as developing our existing products for new indications. However, only a small number of development programs result in the commercialization of a product. It is possible that none of our product candidates will ever become commercial products and that none of our existing products will obtain regulatory approval in any additional indications or territories. We and our collaborators are currently conducting multiple clinical trials for our products and product candidates, and we plan to commence additional trials in the future. Each of these trials requires the investment of substantial expense and time. However, there can be no assurance that the design or conduct of these trials, or any data collected from them, will be sufficient to support advancement to the next stage of development, any regulatory approvals or commercial viability.
Many of our clinical trials were initiated based on limited data. Encouraging preclinical, preliminary or interim data, and/or positive early-stage clinical trial results do not ensure that full, larger scale, later stage or confirmatory trials will be successful or that regulatory approval will be obtained. For example, despite the positive initial results we and Astellas reported from the dose-escalation cohort and expansion Cohort A of the EV-103 trial and the positive topline results we and Astellas announced from Cohort K of the EV-103 trial, we cannot be certain that PADCEV will demonstrate sufficient efficacy or a favorable safety profile in other trials, including the EV-302 trial. Many companies in the pharmaceutical and biotechnology industries, including us, have suffered significant setbacks in late-stage clinical trials after achieving encouraging or positive results in early-stage development. We cannot be certain that we will not face similar setbacks in our ongoing or planned clinical trials, including ongoing pivotal and confirmatory trials.
41
There may still be important facts about the safety, efficacy, and risk versus benefit of our products and product candidates, as single agents or in combination with other agents, that are not known to us at this time and that may negatively impact our ability to develop and commercialize them. Safety events or concerns, or negative or inconclusive trial results, could adversely affect the development timeline and the regulatory approval and commercialization prospects for our products and product candidates, or cause us to cease further development of a product or product candidate, any of which may materially and adversely affect our business, results of operations, financial condition and growth prospects. In addition, we may make a strategic decision to discontinue development if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to prioritize other opportunities in our pipeline. We also face intense competition, and it is possible that a clinical trial may meet its safety and efficacy endpoints but we may choose not to advance the development of a product or product due to changes in the competitive environment.
From time to time, the commencement, continuation and completion of our clinical trials have been subject to delays, and we are likely to experience additional delays in the future. Factors that could lead to the delay, suspension, termination or need to modify clinical trials of our products and product candidates include:
•adverse medical events or side effects, including fatalities, in treated patients or other safety issues or concerns;
•deficiencies in the conduct of the clinical trial, including failure to conduct the clinical trial in accordance with regulatory requirements, Good Clinical Practice, or GCP, or study protocols;
•problems, errors or other deficiencies with respect to data collection, data processing and analysis;
•action by competent authorities to place a clinical hold or partial clinical hold on a trial or compound;
•the time required to determine efficacy may be longer than expected;
•unfavorable scientific results or insufficient data to support safety and effectiveness;
•inadequate supply or deficient quality of the applicable product or product candidate or of other materials necessary to complete the trials;
•inability to reach agreement on acceptable terms with prospective trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different trial sites;
•delay or failure to obtain institutional review board, or IRB, or ethics committee approval to conduct a clinical trial at a prospective site;
•decisions by competent authorities, IRBs, ethics committees, our collaborators or us, or recommendation by a data monitoring committee, to suspend or terminate a clinical trial for safety issues, futility or any other reason or to demand variations in the protocols or conduct of clinical trials;
•changes in governmental regulations or administrative actions that adversely affect the ability to continue to conduct or to complete a clinical trial;
•budgetary constraints or prohibitively high clinical trial costs;
•difficulties in identifying and enrolling patients who meet trial eligibility criteria;
•lower than anticipated retention rates for patients who have initiated a clinical trial;
•the risks and evolving effects of the COVID-19 pandemic; and
•risks related to the ongoing military conflict between Russia and Ukraine, and sanctions imposed against Russia by the international community.
Additionally, patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials, perceived side effects and the availability of alternative or new treatments. We have experienced enrollment-related delays in clinical trials in the past, and we will likely continue to experience similar delays in our current and future trials. Many of our future and ongoing clinical trials are being or will be coordinated or conducted with collaborators. If we and these collaborators fail to collaborate effectively, we may experience delays or adverse effects on the commencement, continuation or completion of these trials. In addition, our collaborators have operational control over some of the studies we conduct jointly and we do not have full visibility into these studies run by our collaborators. We also conduct clinical trials in countries outside the U.S., which may subject us to additional expenses, regulatory requirements and potential delays, as well as risks associated with different standards of medical care.
42
If a product candidate or a potential new indication fails at any stage of development, or if we or our collaborators otherwise discontinue development of a product candidate or indication for any reason, we will not have the anticipated revenues from that product candidate or indication to fund our operations and we may not recoup or receive any return on our investment in that product candidate or indication. Failure to effectively advance our development programs in a timely manner or at all could have a material adverse effect on our business, results of operations, financial condition and prospects.
The successful commercialization of our products will depend, in part, on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.
Successful sales of our current and any future approved products will depend, in part, on the extent to which coverage and reimbursement for our products will be available from government and health administration authorities, private health insurers and other third-party payors. To manage healthcare costs, many governments and third-party payors increasingly scrutinize the pricing of new products and require increasing levels of evidence of favorable clinical outcomes and cost-effectiveness before extending coverage. In light of this pricing scrutiny, we cannot be sure that we and our collaborators will achieve and maintain coverage for our products and any product candidates that we or our collaborators commercialize and, if available, that the reimbursement rates will be adequate and grant access to all eligible patients. If we or our collaborators are unable to obtain and maintain coverage and adequate levels of reimbursement for our current and any future approved products that we or our collaborators commercialize, their marketability will be negatively and materially impacted. For example, we cannot be certain that third-party payors will continue to provide coverage and adequate reimbursement for ADCETRIS in the frontline Hodgkin lymphoma indication based on the relative price and perceived benefit of ADCETRIS as compared to alternative treatment options, which may materially harm our ability to maintain or increase sales of ADCETRIS or may otherwise negatively affect future ADCETRIS sales. Similarly, we cannot be certain that third-party payors will provide coverage and adequate reimbursement for PADCEV, TUKYSA or TIVDAK based on their relative price and perceived benefits as compared to alternative treatment options or otherwise, which may materially harm our and our collaborators’ ability to successfully commercialize PADCEV, TUKYSA and TIVDAK in our respective designated territories. In addition, we have also experienced an increase in gross-to-net deductions for ADCETRIS since the beginning of the COVID-19 pandemic, which has been driven by the proportion of ADCETRIS sales subject to discounts through the federal 340B drug discount program, as well as increases in discount rates. We believe that the increase in gross-to-net deductions is, in part, due to a shift in the locations where ADCETRIS is administered. We may further experience additional increases in gross-to-net deductions for ADCETRIS and the rest of our portfolio in the future based on market and site-of-care dynamics.
In many jurisdictions, including many countries in Europe, the proposed pricing for a drug must be approved in an individual country before it may be lawfully marketed, which could delay entry of a product into a market or, if pricing is not approved, may prevent us or our collaborators from selling a product in a country where it has received regulatory approval. In European countries where TUKYSA and PADCEV have obtained regulatory approval, we will seek additional pricing and reimbursement agreements for TUKYSA, and work with Astellas to seek additional pricing and reimbursement agreements for PADCEV, in accordance with local timelines. As an organization, we did not have any experience applying for pricing and reimbursement approvals in jurisdictions outside the U.S. and Canada prior to our applications with respect to TUKYSA. Further, authorities in Europe have substantial discretion in the pricing and reimbursement approval process and in determining when or whether coverage will be available for a product in its initial indication or for any additional indications or in additional territories. In addition, in some cases, they may lower the price for a medicine after the price has been established. If we or our collaborators are unable to obtain favorable pricing and reimbursement approvals in the countries that represent significant potential markets, our anticipated revenue from and growth prospects for PADCEV and/or TUKYSA in those regions would be negatively affected.
Eligibility for coverage and reimbursement does not imply that payors will pay for a drug in all cases or at a rate that (i) captures the value delivered to patients, payors and the overall healthcare system; (ii) allows for continued investment in innovative treatments for cancer patients; or (iii) covers our costs, including research, development, manufacture, sale and distribution. In addition, obtaining and maintaining adequate coverage and reimbursement status is time-consuming and costly. Third-party payors may deny coverage and reimbursement status altogether for a given product, or they may cover the product but establish prices at levels that are too low to enable us to realize an appropriate return on our investment in product development or limit access to select patient populations, reducing revenue potential. Further, in the U.S., there is no uniform policy of coverage and reimbursement among third-party payors. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided is made on a payor-by-payor basis. One payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Because the rules and regulations regarding coverage and reimbursement change frequently, in some cases at short notice, even when there is favorable coverage and reimbursement, future changes may occur that adversely impact the favorable status.
43
The unavailability or inadequacy of third-party coverage and reimbursement could have a material adverse effect on the market acceptance of our current and any future approved products and the future revenues we may expect to receive from those products. In addition, we are unable to predict what additional legislation or regulation relating to the healthcare industry or third-party coverage and reimbursement may be upheld or enacted in the future, or what effect such legislation or regulation would have on our business. Continuing negative publicity regarding pharmaceutical pricing practices and ongoing governmental and societal scrutiny create significant uncertainty regarding regulation of the healthcare industry and third-party coverage and reimbursement in the U.S. and other jurisdictions. If additional healthcare policies or reforms intended to curb healthcare costs are implemented or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical products generally, the prices that we charge for our current and any future approved products may be limited, and our revenues from sales of our current and any future approved products may be negatively impacted.
The successful commercialization of our products will also depend in part on the acceptance of our products by the medical community, patients and third-party payors.
The degree of market acceptance among patients, physicians, and third-party payors is important to our ability to successfully commercialize our current and any future approved products. The degree of acceptance will depend on a number of factors including the clinical benefits of our products, the effectiveness of our marketing, sales and distribution strategy and operations, the perceived advantages and relative cost, safety and efficacy of alternative treatments, and the acceptance and degree of adoption of our products by institutional treatment pathways and institutional, local, and national clinical guidelines. In the U.S., many oncology practices and healthcare providers rely on the National Comprehensive Cancer Networks® Clinical Practice Guidelines in Oncology or other institutional practice pathways in decisions related to treatment of patients and utilization of medicines. To the extent that our current or any future approved products are not included or positioned favorably in such treatment guidelines and pathways, the full utilization potential of our products may not be reached, which may harm our ability to successfully commercialize our current or any future approved products.
Any failures or setbacks in our ADC development program or our other platform technologies could negatively affect our business and financial position.
ADCETRIS, PADCEV, TIVDAK and our ladiratuzumab vedotin and disitamab vedotin product candidates are all based on antibody-drug conjugate, or ADC, technology, which utilizes proprietary stable linkers and potent cell-killing synthetic agents. Our ADC technology is also the basis of our license agreements with AbbVie Biotechnology Ltd., or AbbVie, Astellas, Genentech, Inc., a member of the Roche Group, or Genentech, and GlaxoSmithKline LLC, or GSK, and our collaboration agreements with Takeda, Astellas, Genmab and Merck. Any failures or setbacks in our ADC development program or with respect to our additional proprietary technologies, including adverse effects resulting from the use of this technology in human clinical trials and/or the imposition of clinical holds on our trials of our product candidates, could have a detrimental impact on the continued commercialization of our products in their current or any potential future approved indications and on our product candidate pipeline, as well as our ability to maintain and/or enter into new corporate collaborations regarding our ADC technology, which would negatively affect our business and financial position.
We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies and intense competition. Many third parties compete with us in developing various approaches to treating cancer. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
44
With respect to ADCETRIS, there are several other FDA approved drugs for its approved indications. Bristol-Myers Squibb’s, or BMS's, nivolumab and Merck’s pembrolizumab are approved for the treatment of certain patients with relapsed or refractory classical Hodgkin lymphoma, and Acrotech Biopharma’s pralatrexate and belinostat are approved for relapsed or refractory systemic anaplastic large cell lymphoma, or sALCL, among other T-cell lymphomas. Celgene's romidepsin is approved for cutaneous T-cell lymphoma. Kyowa Kirin’s mogamulizumab is approved for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome. The competition ADCETRIS faces from these and other therapies is intensifying. Additionally, Merck conducted a phase 3 clinical trial in relapsed or refractory classical Hodgkin lymphoma comparing pembrolizumab to ADCETRIS. An interim analysis of this clinical trial demonstrated a statistically significant improvement in progression-free survival for pembrolizumab compared with ADCETRIS, resulting in a label expansion to an earlier line of therapy, and we expect increased competition from pembrolizumab in this indication. We are also aware of multiple investigational agents currently being studied that, if successful, may compete with ADCETRIS in the future, such as camidanlumab tesirine being studied in a phase 2 study in relapsed/refractory classical Hodgkin lymphoma. Merck is conducting a phase 2 study in newly diagnosed classical Hodgkin lymphoma. Data have also been presented on several developing technologies, including bispecific antibodies and CAR modified T-cell therapies that may compete with ADCETRIS in the future. Further, there are many competing approaches used in the treatment of patients in ADCETRIS’ approved indications, including autologous hematopoietic stem cell transplant, allogeneic hematopoietic stem cell transplant and chemotherapy, in addition to clinical trials with experimental agents.
With respect to PADCEV, other treatments in pretreated metastatic urothelial cancer include sacituzumab govitecan (a Trop-2-directed antibody and topoisomerase inhibitor conjugate), checkpoint inhibitor monotherapy, generic chemotherapy and, for patients with select FGFR genetic alterations, Janssen’s erdafitinib. Front line metastatic urothelial cancer has traditionally been treated with chemotherapy alone but is evolving to include checkpoint inhibitors for cisplatin-ineligible patients with high PD-L1 expression in addition to patients who are ineligible for platinum therapy. Several trials of investigational agents in combination with chemotherapy or other novel agents are ongoing. Continued development of PD-(L)1 targeted therapies across early-stage bladder cancer and in metastatic bladder cancer in frontline combinations with chemotherapy, in frontline maintenance with the recent approval of avelumab, and in pretreated disease, could potentially impact PADCEV usage and enrollment in PADCEV clinical trials.
With respect to TUKYSA, there are multiple marketed products which target HER2, including the antibodies trastuzumab and pertuzumab and the antibody drug conjugate T-DM1. In addition, lapatinib is an EGFR/HER2 oral kinase inhibitor for the treatment of metastatic breast cancer, and neratinib is an irreversible pan-HER kinase inhibitor indicated for extended adjuvant treatment and treatment of metastatic breast cancer in patients who received two or more prior anti-HER2-based regimens. Daiichi Sankyo and AstraZeneca have fam-trastuzumab deruxtecan-nxki which was approved by the FDA for patients who have received one or more prior anti-HER2-based regimens in the metastatic breast cancer setting and in the HER2 positive gastric cancer setting post-trastuzumab-based therapy. The agent was also granted conditional marketing authorization by the EMA for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. The sequence of therapies patients receive for HER2+ breast cancer is likely to change in both the U.S. and EU, with greater fam-trastuzumab deruxtecan-nxki use in second line. This has resulted and is expected to continue to result in increased competition for TUKYSA, which is approved by the FDA for patients who have received one or more prior anti-HER2-based regimens in the metastatic breast cancer setting, including in patients with brain metastases. MacroGenics has a HER2 targeted, Fc-optimized antibody, margetuximab, which is approved by the FDA for patients who have received at least two previous anti-HER2 regimens. Additionally, Byondis has an antibody drug conjugate, SYD985, and has released results from its pivotal trial in metastatic breast cancer patients treated with multiple anti-HER2-based regimens; this drug may be approved in this patient segment in 2022.
With respect to TIVDAK, in October 2021, the FDA approved Merck’s pembrolizumab in first line in combination with chemotherapy, with or without bevacizumab, for the treatment of recurrent or metastatic cervical cancer whose tumors express PD-L1 and was granted full approval in second line as a monotherapy for recurrent or metastatic cervical cancer patients with disease progression on or after chemotherapy in patients whose tumors express PD-L1. In April 2022, the European Commission approved pembrolizumab as first-line therapy in combination with chemotherapy, with or without bevacizumab, for treatment of persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1. We are also aware of other companies that currently have products in development for the treatment of late-stage cervical cancer which could be competitive with TIVDAK, including Agenus, BMS, Iovance Biotherapeutics, Merck, Regeneron Pharmaceuticals, Sanofi-Aventis and Roche. Cemiplimab is being reviewed in several countries outside the U.S. for the treatment of patients with recurrent or metastatic cervical cancer following progression on platinum-based chemotherapy. A supplemental Biologics License Application for cemiplimab was withdrawn in the U.S. in January 2022. In March 2022, Sanofi received Canadian approval for cemiplimab for the treatment of patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy.
Many other pharmaceutical and biotechnology companies are developing and/or marketing therapies for the same types of cancer that our product candidates are designed and being developed to treat. In addition, we are aware of a number of other
45
companies that have ADC and other technologies that may be competitive with ours. We are also aware of a number of companies developing monoclonal antibodies directed at the same antigen targets or for the treatment of the same diseases as our product candidates. In addition, our ADC collaborators may develop compounds utilizing our technology that may compete with product candidates that we are developing.
The risk of biosimilar or generic challenges has also been increasing in our industry. In the U.S. and the EU, after a period of exclusivity for an innovator’s approved biological product or branded drug has passed, there are abbreviated pathways for approval of biosimilar products or generic drugs. In addition, it is not possible to predict changes in law that might reduce regulatory exclusivity. As a result, and due to uncertainties regarding patent protection, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. Absent patent protection or regulatory exclusivity for our products, it is possible, both in the United States and elsewhere, that biosimilar, interchangeable or generic versions of those products may be approved and marketed, which would likely result in substantial and rapid reductions in revenues from sales of those products.
It is also possible that our competitors will succeed in developing technologies that are more effective than our products and product candidates or that would render our technology obsolete or noncompetitive, or will succeed in developing biosimilar, interchangeable or generic products for our products and product candidates. We anticipate that we will continue to face increasing competition in the future as new companies enter our market and scientific developments surrounding biosimilars and other cancer therapies continue to accelerate. We cannot predict to what extent the entry of biosimilars or other competing products will impact potential future sales of our products and product candidates.
Risks Related to Regulatory Oversight, and Other Legal Compliance Matters
Our products and any future approved products remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in penalties and significant additional expense and could negatively impact our and our collaborators’ ability to commercialize our current and any future approved products.
Any product that has received regulatory approval remains subject to extensive ongoing obligations and continued review from applicable regulatory agencies. These obligations include, among other things, drug safety reporting and surveillance, submission of other post-marketing information and reports, pre-clearance of certain promotional materials, manufacturing processes and practices, product labeling, confirmatory or post-approval clinical research, import and export requirements and record keeping. These obligations may result in significant expense and limit our and our collaborators’ ability to commercialize our current and any future approved products. Any violation of ongoing regulatory obligations could result in restrictions on the applicable product, including the withdrawal of the applicable product from the market.
If FDA approval is granted via the accelerated approval pathway or a product receives conditional marketing authorization from another comparable regulatory agency, we and our collaborators may be required to conduct a post-marketing confirmatory trial in support of full approval and to comply with other additional requirements. For example, in connection with ADCETRIS’s conditional marketing authorization in relapsed Hodgkin lymphoma, relapsed cutaneous T-cell lymphoma, and both relapsed and frontline sALCL in the EU, Takeda is subject to certain post-approval requirements, including the requirement to conduct clinical trials to confirm clinical benefit. The FDA’s accelerated approval of TIVDAK also included a requirement for a confirmatory trial. An unsuccessful post-marketing study or failure to complete such a study with due diligence could result in the withdrawal of marketing approval. Post-marketing studies may also suggest unfavorable safety information that could require us to update the product’s prescribing information or limit or prevent the product’s widespread use. In addition, the labeling, advertising and promotion of products that have received accelerated approval from the FDA, including TIVDAK, are subject to additional regulatory requirements, which entail significant expense and could negatively impact the product’s commercialization.
Regulatory authorities may also impose additional post-marketing commitments, including requirements for companion diagnostics. For example, the FDA’s approval of ADCETRIS in the frontline peripheral T-cell lymphoma indication included a post-marketing commitment to develop an in-vitro diagnostic device for the selection of patients with CD30-expressing PTCL, not including SALCL, for treatment with ADCETRIS in this indication. We and Takeda have a collaboration with Ventana Medical Systems, Inc., or Ventana, under which Ventana is working to develop such a diagnostic device.
We and the manufacturers of our current and any future approved products are also required, or will be required, to comply with current Good Manufacturing Practices, or cGMP, regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our products and product candidates, and these facilities are subject to ongoing regulatory inspections. In addition, any approved product, its manufacturer and the manufacturer’s facilities are subject to continual regulatory review and inspections, including periodic unannounced inspections. Failure to comply with applicable FDA and other regulatory requirements may subject us to administrative or judicially imposed sanctions and other consequences, including:
46
•issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies;
•imposition of fines and other civil penalties;
•criminal prosecutions;
•injunctions, suspensions or revocations of regulatory approvals;
•suspension of any ongoing clinical trials;
•total or partial suspension of manufacturing;
•delays in regulatory approvals and commercialization;
•refusal by the FDA to approve pending applications or supplements to approved applications submitted by us;
•refusals to permit drugs to be imported into or exported from the U.S.;
•restrictions on operations, including costly new manufacturing requirements;
•product recalls or seizures or withdrawal of the affected product from the market; and
•reputational harm.
The policies of the FDA and other regulatory agencies may change and additional laws and regulations may be enacted that could prevent or delay regulatory approval of our product candidates or of our products in any additional indications or territories, or further restrict or regulate post-approval activities. Any problems with a product or any violation of ongoing regulatory obligations could result in restrictions on the applicable product, including the withdrawal of the applicable product from the market. If we are not able to maintain regulatory compliance, we or our collaborators might not be permitted to commercialize our current or any future approved products and our business would suffer.
Healthcare law and policy changes may negatively impact our business, including by decreasing the prices that we and our collaborators receive for our products.
In recent years, there have been a number of legislative and regulatory actions and executive orders that have made reforms to the U.S. healthcare system. The implementation of certain of these policy changes has decreased our revenues and increased our costs, and federal and state legislatures, governments in countries outside the U.S., health agencies and third-party payors continue to focus on containing the cost of healthcare. Further legislative and regulatory changes, and increasing pressure from social sources, are likely to further influence the manner in which our products are priced, reimbursed, prescribed and purchased. Such additional reforms could result in further reductions in coverage and levels of reimbursement for our products, expansion of U.S. government rebate and discount programs, increases in the rebates and discounts payable under these programs, requests for additional or supplemental rebates, and additional downward pressure on the prices that we and our collaborators receive for our products.
The federal government has implemented reforms to government healthcare programs in the U.S., including changes to the methods for, and amounts of, Medicare reimbursement and changes to the Medicaid Drug Rebate Program. For example, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On November 15, 2021, President Biden signed the Infrastructure Investment and Jobs Act, which included changes to the Medicare Part B program requiring rebates for some discarded drug products that are expected to increase future rebates for ADCETRIS, PADCEV and TIVDAK with a target implementation date of the first quarter of 2023. The Biden administration also recently announced an Executive Order that includes initiatives to support the implementation of Canadian drug importation and reduce drug prices. In response to President Biden’s Executive Order, on September 9, 2021, the U.S. Department of Health and Human Services released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other healthcare reform initiatives.
Some states are also considering legislation, or have passed laws, that would control the prices and coverage and reimbursement levels of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases.
In addition, governments in countries outside the U.S. control the costs of pharmaceuticals. Many European countries and Canada have established pricing and reimbursement policies that contain costs by referencing the price of the same or similar products in other countries. In these instances, if coverage or the level of reimbursement is reduced, limited or eliminated in one or more countries, we may be unable to obtain or maintain anticipated pricing or reimbursement in other
47
countries or in new markets. This may create the opportunity for third-party cross-border trade or may influence our decision whether to sell a product in one or more countries, thus adversely affecting our geographic expansion plans.
It is also possible that governments may take additional action to reform the healthcare system in response to the evolving effects of the COVID-19 pandemic.
We cannot assure you as to the ultimate content, timing, or effect of future healthcare law and policy changes, nor is it possible at this time to estimate the impact of any such potential changes; however, such changes or the ultimate impact of changes could materially and adversely affect our revenue or sales of our current and or potential future products, as well as those of our collaborators.
We are subject to various state, federal and international laws and regulations, including healthcare laws and regulations, that may impact our business and could subject us to significant fines and penalties or other negative consequences.
Our operations may be directly or indirectly subject to various healthcare laws, including, without limitation, the federal Anti-Kickback Statute, federal civil and criminal false claims laws, regulations prohibiting off-label promotions and federal transparency requirements. These laws may impact, among other things, the sales, marketing and education programs for our products and any future approved products. In addition, the number and complexity of healthcare laws and regulations applicable to our business continue to increase.
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willingly soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as the Medicare and Medicaid programs. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a criminal conviction for violation of the federal Anti-Kickback Statute requires mandatory exclusion from participation in federal healthcare programs.
The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, persons or entities from knowingly presenting, or causing to be presented, a false claim to, or the knowing use of false statements to obtain payment from or approval by, the federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease, or conceal an obligation to pay money to the federal government. Many pharmaceutical and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing, promotion or other activities.
The FDA and other governmental authorities also actively investigate allegations of off-label promotion activities in order to enforce regulations prohibiting these types of activities. In recent years, private whistleblowers have also pursued False Claims Act cases against a number of pharmaceutical companies for causing false claims to be submitted as a result of off-label promotion. If we are found to have promoted an approved product for off-label uses, we may be subject to significant liability, including significant civil and administrative financial penalties and other remedies as well as criminal penalties and other sanctions. Even when a company is not determined to have engaged in off-label promotion, the allegation from government authorities or market participants that a company has engaged in such activities could have a significant impact on the company’s sales, business and financial condition. The U.S. government has also required companies to enter into complex corporate integrity agreements, deferred prosecution agreements and/or non-prosecution agreements that impose significant reporting and other burdens on the affected companies.
The federal transparency requirements under the Physician Payments Sunshine Act require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program to annually report information related to certain payments or other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year plus up to an aggregate of $1 million per year for “knowing failures,” as adjusted for inflation.
48
In addition, there has been increased scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments of reimbursement support offerings, clinical education programs and promotional speaker programs. If we or our vendors are deemed to fail to comply with laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Further, in connection with civil settlements related to these laws and regulations, the U.S. government has and may in the future require companies to enter into complex corporate integrity agreements that impost significant reporting and other requirements.
Other healthcare laws and regulations that may affect our ability to operate include, among others, the federal civil monetary penalties statute and the healthcare fraud provisions of the federal Health Insurance Portability and Accountability Act, or HIPAA. In addition, many states and jurisdictions outside the U.S. have similar laws and regulations, such as anti-kickback, anti-bribery and corruption, false claims and transparency, to which we are currently and/or may in the future, be subject. Additional information about these requirements is provided under “Government Regulation – Healthcare Regulation” in our Annual Report on Form 10-K for the year ended December 31, 2021.
We are also subject to numerous other laws and regulations that while not specific to the healthcare industry, do apply to the healthcare industry in important ways. For example, we are subject to antitrust regulations with respect to interactions with other participants in the markets we currently serve or may serve in the future. These antitrust laws are vigorously enforced in the U.S. and in other jurisdictions in which we operate.
In an effort to comply with applicable laws and regulations, we have implemented a compliance program designed to actively identify, prevent and mitigate risk by implementing policies and systems and promoting a culture of compliance. We also actively work to revise and evolve our compliance program in an effort to keep pace with evolving compliance risks and the growing scale of our business. However, we cannot guarantee that our compliance program will be sufficient or effective, that we will be able to integrate the operations of newly formed affiliates or acquired businesses into our compliance program effectively or on a timely basis, that our employees will comply with our policies, that our employees will notify us of any violation of our policies, that we will have the ability to take appropriate and timely corrective action in response to any such violation, or that we will make decisions and take actions that will limit or avoid liability for whistleblower claims or actions by governmental authorities. If we are found to be in violation of any of the laws and regulations described above or other applicable laws, we may be subject to penalties, including significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, administrative burdens, imprisonment, diminished profits and future earnings, exclusion from government healthcare reimbursement programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and/or the curtailment or restructuring of our operations. Any of these outcomes could have a material adverse effect on our business, results of operations, financial condition and growth prospects. Regardless of whether we have complied with the law, a government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses. Moreover, achieving and sustaining compliance with applicable federal, state and healthcare laws outside the U.S. is costly and time-consuming for our management.
We are subject to stringent and changing obligations related to data privacy and information security. Our actual or perceived failure to comply with such obligations could lead to governmental investigations or actions, litigation, fines and penalties, a disruption of our business operations, reputational harm and other adverse business impacts.
We are subject to numerous privacy and data protection laws and regulations governing personal information, including healthcare information. In addition, the legislative and regulatory landscape for privacy and data protection continues to evolve.
In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. The laws are not consistent, and states frequently amend existing laws, requiring attention to constantly changing regulatory requirements. For example, the California Consumer Privacy Act, or CCPA, became effective on January 1, 2020, and the California Privacy Rights Act, or CPRA, will take effect in January 2023 (with a look back for certain rights to January 2022). The CPRA will significantly modify the CCPA, including by expanding consumers’ rights with respect to certain sensitive personal information. We may also be subject to additional U.S. privacy regulations in the future, including the Virginia Consumer Data Protection Act and the Colorado Privacy Act, both of which become effective in 2023. In addition, at the federal level, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations impose additional obligations on certain types of individuals and entities with respect to the security, privacy and transmission of individually identifiable health information.
EU member countries and other jurisdictions, including Switzerland, the United Kingdom, or the U.K., and Canada, have also adopted data protection laws and regulations which impose significant compliance obligations. For example, the EU’s General Data Protection Regulation, or GDPR, imposes a range of requirements relating to the collection, use, handling and protection of personal data. Violations of the GDPR can result in significant penalties, including potential fines of up to €20
49
million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The GDPR has increased our responsibility and potential liability in relation to all types of personal data that we process, including clinical trial data and employee information. In addition, local data protection authorities can have different interpretations of the GDPR, leading to compliance challenges as a result of potential inconsistencies amongst various EU member states.
Among other requirements, the GDPR regulates transfers of personal data to countries that have not been found to provide adequate protection to such personal data, including the U.S. This includes transfers between us and our subsidiaries. In July 2020, the Court of Justice of the EU, or the CJEU, invalidated one of the primary safeguards enabling U.S. companies to import personal information from Europe, the EU-U.S. Privacy Shield. The same decision also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the EC’s Standard Contractual Clauses, or SCCs, provide sufficient protection for personal data transfers without analyzing each transfer and implementing supplementary measures to protect the data. As a result of the CJEU’s decision, the EC issued new SCCs in June 2021 that repeal and replace the previous clauses. Companies relying on the SCCs for transfers have until December 2022 to implement the new clauses. Following recommendations from the European Data Protection Board, we are reviewing personal data transfers from the EU and adding the new SCCs and supplementary measures, when required. Since local data protection authorities can interpret GDPR and the CJEU’s decision differently, there is no definitive set of controls that can ensure GDPR compliance across our business operations. In addition, authorities in Switzerland and the U.K., whose data protection laws are similar to those of the EU, also invalidated the use of privacy shields. Additional compliance efforts may be needed to respond to evolving regulatory guidance. If our compliance solutions are found to be insufficient, we could face substantial fines under European data protection laws as well as injunctions against processing and/or transferring personal information from Europe. The inability to import personal information from Europe could restrict our clinical trial activities in Europe, limit our ability to collaborate with contract research organizations, service providers, contractors and other companies subject to European data protection laws, interfere with our ability to hire employees in Europe and require us to increase our data processing capabilities in Europe at significant expense.
In addition, we may be subject to other foreign data privacy and security laws. For example, China’s Personal Information Protection Law, or PIPL, which took effect in November 2021, imposes various requirements related to personal information processing, similar to the GDPR and CCPA. In particular, the PIPL sets out personal information localization requirements, along with rules regarding the transfer of personal information outside of China. Such transfers may require assessment and/or approval by China’s Cyberspace Administration, certification by professional institutions or entering into contracts with and supervising overseas recipients. Violations of the PIPL may lead to an administrative fine of up to RMB 50 million or 5% of turnover in the last year.
Any failure or alleged failure to comply with legal or contractual obligations, policies and industry standards relating to personal information, and any incident resulting in the unauthorized access to, or acquisition, release or transfer of, personal information, may result in governmental investigations or enforcement actions, litigation, fines, penalties, damage to our reputation and other adverse consequences. In addition, we expect that laws, regulations, policies and industry standards relating to privacy and data protection will continue to evolve. These changes may require us to modify our practices and may increase our costs of doing business. In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these standards, even if no personal information is compromised, we may incur significant fines or experience a significant increase in costs.
Product liability and product recalls could harm our business, and we may not be able to obtain adequate insurance to protect us against product liability losses.
The testing, manufacturing, marketing, and sale of products and product candidates expose us to product liability claims. As a result, it is possible that we may be named as a defendant in product liability suits that may allege that drug products we manufactured for BMS resulted in injury to patients. While we have obtained product liability insurance, it may not provide adequate coverage against all potential liabilities. In addition, we may not be able to maintain insurance coverage on acceptable terms or at all. If a product liability claim or series of claims is brought against us, we may experience substantial financial losses, including uninsured liabilities or liabilities in excess of insured amounts, and may be required to limit further development and commercialization of our products, either of which could have a material adverse effect on our business, results of operations, financial condition and growth prospects. Additionally, product liability claims, regardless of their merits, could be costly, could divert management’s attention and could adversely affect our reputation and the demand for our products.
Product recalls may be issued at our discretion, or at the discretion of government agencies and other entities that have regulatory authority for pharmaceutical sales. Any recall of our products could materially adversely affect our business by rendering us unable to sell our products for some time and by adversely affecting our reputation.
50
Our operations involve hazardous materials and are subject to environmental, health and safety laws and regulations.
We are subject to environmental, health and safety laws and regulations, including those governing the use and disposal of hazardous materials, and we spend considerable time complying with such laws and regulations. Our business activities involve the controlled use of hazardous materials, and although we take precautions to prevent accidental contamination or injury from these materials, we cannot completely eliminate the risk of using these materials. In this regard, with respect to our manufacturing facility, we may incur substantial costs to comply with environmental laws and regulations and may become subject to the risk of accidental contamination or injury from the use of hazardous materials in our manufacturing process. It is also possible that our manufacturing facility may expose us to environmental liabilities associated with historical site conditions that we are not currently aware of and did not cause. Some environmental laws impose liability for contamination on current owners or operators of affected sites, regardless of fault. In the event of an accident or environmental discharge, or new or previously unknown contamination is discovered or new cleanup obligations are otherwise imposed in connection with any of our currently or previously owned or operated facilities, we may be held liable for remediation obligations, damages or fines, which may exceed our insurance coverage and materially harm our business, financial condition and results of operations. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.
Risks Related to Our Reliance on Third Parties
Our collaborators and licensees may not perform as expected, which may negatively affect our ability to develop and commercialize our products and product candidates and/or generate revenues through technology licensing, and may otherwise negatively affect our business.
We have established collaborations with third parties to develop and market each of our products and some of our current and potential future product candidates. These include our collaborations with Takeda for ADCETRIS, with Astellas for PADCEV, with Merck for TUKYSA and with Genmab for TIVDAK. We also have established clinical trial collaborations to develop certain of our products or product candidates in combination with the products or product candidates of third parties. Our dependence on these collaboration and licensing arrangements subjects us to a number of risks, including:
•we are not able to control the amount or timing of resources our collaborators and licensees devote to the development or commercialization of our programs, products or product candidates;
•the interests of our collaborators may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition;
•with respect to products or product candidates under joint control, we may encounter challenges in joint decision making and joint execution, including with respect to any joint development or commercialization plans or co-promotion activities, which may delay or otherwise harm the research, development, launch or commercialization of the applicable products and product candidates;
•disputes may arise between us and our collaborators or licensees, including with respect to the achievement and payment of milestones or ownership of rights to technology developed, that could result in litigation or arbitration;
•any failure on the part of our collaborators to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings;
•any improper conduct or actions on the part of our collaborators, licensees or other third parties could subject us to civil or criminal investigations and monetary penalties and injunctions, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation;
•business combinations or significant changes in a collaborator’s business strategy may adversely affect such party’s willingness or ability to complete its obligations under any arrangement;
•a collaborator could independently move forward with competing products, therapeutic approaches or technologies, either independently or in collaboration with others, including with our competitors; and
•our collaboration agreements may be terminated, breached or allowed to expire, or our collaborators may reduce the scope of our agreements with them.
If our collaborative and license arrangements are not successful, then our ability to advance the development and commercialization of the applicable products and product candidates, or to otherwise generate revenue from these arrangements, will be adversely affected, and our business and business prospects may be materially harmed. If any of our
51
collaborators terminates our collaboration or opts out of their obligations, we may have to engage another collaborator, or we may have to complete the development process and undertake commercializing the applicable product or product candidate in our collaborator’s current territories ourselves. This could significantly disrupt or delay the development and commercialization of the applicable product or product candidate and substantially increase our costs. Any of these events could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
A substantial portion of our revenue results from payments made under agreements with our collaborators. The loss of any of our collaborators, changes in product development or business strategies of our collaborators, or the failure of our collaborators to perform their obligations under their agreements with us for any reason, including paying license or technology fees, milestone payments, royalties or reimbursements, could have a material adverse effect on our business, results of operations, financial condition and growth prospects. Payments under our existing and potential future collaboration agreements are also subject to significant fluctuations in both timing and amount, which could cause our revenue to fall below the expectations of securities analysts and investors and cause a decrease in our stock price.
In addition to collaboration agreements, we also have ADC license agreements that allow our licensees to use our proprietary ADC technology. Our ADC licensees conduct all research, product development, manufacturing and commercialization of any product candidates under these agreements. Any delay or termination of the development and commercialization of a licensed product or product candidate by the licensee could adversely affect our business, results of operations, financial condition and growth prospects by reducing or eliminating the potential for us to receive applicable milestones and royalties.
We currently rely on third-party manufacturers and other third parties for production of our drug products, and our dependence on these third parties may impair the continued development and commercialization of our products and product candidates.
We own a biologics manufacturing facility located in Bothell, Washington, which we use to support our clinical supply needs, as well as for commercial production of PADCEV antibody, for which the facility was recently approved by the FDA. We have also signed a lease for a site in Everett, Washington, where we are constructing a new manufacturing facility that we intend to use for future biologics manufacturing. We have made and plan to continue to make significant investments in these facilities with no assurance that these investments will be recouped. We may experience cost overruns, delays or other difficulties in construction, obtaining regulatory approvals and permits or in otherwise bringing the Everett facility online. In addition, we rely and expect to continue to rely on collaborators, contract manufacturers and other third parties to produce and store sufficient quantities of drug product for both our clinical and commercial programs. In some cases, we rely on contract manufacturers and other third parties that are single-source suppliers to complete steps in the manufacturing process. If any of the parties in our supply chain cease or interrupt production or otherwise fail to deliver materials, products or services on a timely basis, with sufficient quality, and at commercially reasonable prices, and we fail to find replacements or to develop our own manufacturing capabilities, we may bear costly losses or be required to delay or suspend clinical trials or otherwise delay or discontinue development, production and sale of our products. As a result, our business, results of operations, financial condition and growth prospects could be materially and adversely affected.
There are a limited number of facilities in which each of our products and product candidates can be produced. Any interruption of the operation of those facilities, due to equipment malfunction or failure, damage to the facility, natural disasters, regulatory actions, contractual disputes or other events, could result in delays, cancellation of shipments, loss of product in the manufacturing process, or a shortfall in supply. Further, we and our collaborators depend on outside vendors for the supply of raw materials used to produce our products and product candidates. If these suppliers were to cease production or otherwise fail to supply quality raw materials and we or our collaborators were unable to contract with alternative suppliers for these raw materials on acceptable terms, our ability to have our products manufactured to meet clinical and commercial requirements would be adversely affected. In an effort to increase the availability of needed medical and other supplies and products in connection with the COVID-19 pandemic, we and our suppliers may elect to, or governments may require us or our suppliers to, allocate raw materials used in manufacturing or manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our ability to have our products manufactured to meet clinical and commercial requirements. In addition, if any of the parties in our supply chain are adversely impacted by the evolving effects of the COVID-19 pandemic, such as staffing shortages, productions slowdowns and/or disruptions in delivery systems, there could be disruptions and delays in the manufacturing and supply of our products and product candidates.
52
While we believe that the existing supplies of our products and our and our collaborators’ contract manufacturing relationships will be sufficient to accommodate current clinical and commercial needs, we or our collaborators may need to obtain additional manufacturing arrangements or increase manufacturing capability to meet potential future commercial needs, which could require additional capital investment or cause delays. We cannot assure you that we can enter into additional manufacturing arrangements on commercially reasonable terms or at all. Forecasting demand for a new product or for a newly-approved territory or indication for an existing product can be challenging. If demand for a product exceeds our estimates or if our commercial manufacturers are unable or unwilling to increase production capacity commensurate with demand, our commercialization of the affected product could be negatively impacted by short-term product supply challenges. Supply challenges would adversely impact our revenues and could negatively affect our relationships with patients and healthcare professionals. In addition, any failures or delays in manufacturing adequate product supplies and in putting in place or expanding our manufacturing and supply infrastructure could delay or impede our and collaborators’ ability to launch and commercialize our products, including PADCEV and TUKYSA, in additional markets where they have obtained regulatory approval.
In order to obtain regulatory approval of any product candidate or regulatory approval of any product in a new jurisdiction, the suppliers for that product or product candidate must obtain approval to manufacture and supply product. In addition, the facilities utilized to manufacture the product or product candidate will be subject to pre-approval regulatory inspections. Any delay or failure in generating the chemistry, manufacturing and control data required in connection with any application for regulatory approval, or challenges in the regulatory inspection process, could negatively impact our ability to meet our anticipated regulatory submission dates, delay any approval decisions and/or negatively affect our ability to obtain regulatory approval at all. Any failure of us, our collaborators or a manufacturer to obtain approval to manufacture and supply product in a jurisdiction, or to obtain and distribute adequate supplies of the product, on a timely basis or in accordance with applicable specifications and local requirements could negatively impact our ability to successfully launch and commercialize the applicable product in that jurisdiction and to generate sales of that product at the levels we expect. We or our collaborators may also encounter difficulties in meeting the regulatory requirements applicable to the manufacturing process for these agents, in managing the additional complexity of manufacturing for a number of markets outside the U.S. or in responding to changes in the amount or timing of supply needs. Any failures or delays in meeting these requirements could substantially delay or impede our ability to obtain regulatory approvals for and to market these agents, which could negatively impact our operating results and adversely affect our business.
We are dependent upon a small number of distributors for a significant portion of our net sales, and the loss of, or significant reduction or cancellation in sales to, any one of these distributors could adversely affect our revenues and increase our costs.
We sell ADCETRIS, PADCEV and TIVDAK through a limited number of specialty distributors. Healthcare providers order ADCETRIS, PADCEV and TIVDAK through these distributors. We receive orders from distributors and generally ship product directly to the healthcare provider. We sell TUKYSA through a distribution network of specialty pharmacies, integrated delivery network hospitals and practices that dispense in the office. These distributors and distribution network partners do not set or determine demand for our products; however, our ability to effectively commercialize our products will depend, in part, on their performance. If we lost a major distributor or partner, revenue during any period of disruption could suffer and we might incur additional costs. In addition, business disruptions arising from the COVID-19 pandemic could negatively affect the ability of some of our distributors or distribution network partners to pay amounts owed to us in a timely manner or at all.
We are dependent on third parties such as contract research organizations, medical institutions and clinical investigators to assist with the design, review, management and conduct of our clinical trials and other activities.
We also depend on third parties such as contract research organizations, medical institutions and clinical investigators to assist with the design, review, management and conduct of our clinical trials and other activities. Our reliance on these third parties reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with regulatory requirements, GCP and study protocols. To the extent these third parties fail to successfully carry out their contractual duties or meet expected deadlines, our clinical trials and regulatory filings may be negatively impacted including possible impacts to data, results, or conclusions, increased costs, and delays to regulatory timelines, which may harm our reputation and business.
Risks Related to Intellectual Property and Litigation
If we are unable to enforce our intellectual property rights or if we fail to sustain and further procure additional intellectual property rights, we may not be able to successfully commercialize our products or any future products and competitors may be able to develop competing therapies.
Our success depends, in part, on obtaining and maintaining patent protection and successfully enforcing these patents and defending them against third-party challenges in the U.S. and other countries. We own multiple U.S. and foreign patents and pending patent applications for our technologies. We also have rights to issued U.S. patents, patent applications, and their
53
foreign counterparts, relating to our monoclonal antibody, linker and drug-based technologies. Our rights to these patents and patent applications are derived in part from worldwide licenses from third parties.
The standards that the U.S. Patent and Trademark Office, or USPTO, and patent offices in other countries use to grant patents are not always applied predictably or uniformly and can change. Consequently, our pending patent applications may not be allowed and, if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, patents may have a shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our technology or similar technology or from copying our products. Similarly, the standards that courts use to interpret patents are not always applied predictably or uniformly and may evolve, particularly as new technologies develop. For example, the U.S. Federal Circuit Court of Appeals and the U.S. Supreme Court have modified some legal standards applied by the USPTO in examination of U.S. patent applications, which may decrease the likelihood that we will be able to obtain patents and may increase the likelihood of challenges to patents we obtain or license. These changes and any future changes to the patent system in the U.S. or in other countries could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, results of operations, financial condition and growth prospects. In addition, changes to patent laws may be applied retroactively to affect the validity, enforceability, or term of our patents. Patent protection outside the U.S. is particularly uncertain and costly. The laws of some countries may not protect our intellectual property rights to the same extent as U.S. laws, and many companies in our industry have encountered significant difficulties in protecting and defending such rights in these jurisdictions.
We rely on external agents to perform certain activities to maintain our patents. Although we carefully select and oversee these agents, the failure of an agent to properly perform these maintenance activities, whether through mistake or otherwise, could adversely affect our intellectual property rights. Additionally, if we do not control all of the intellectual property rights in-licensed to us with respect to a drug candidate and the entity that controls the intellectual property rights does not adequately protect those rights, our rights may be impaired, which may impact our ability to develop, market and commercialize the in-licensed drug candidate.
We rely on trade secrets and other proprietary information where we believe patent protection is not appropriate or obtainable. However, trade secrets and other proprietary information are difficult to protect. We have taken measures to protect our unpatented trade secrets and know-how, including the use of confidentiality and assignment of inventions agreements with our employees, consultants and certain contractors. It is possible, however, that these persons may breach the agreements or that our competitors may independently develop or otherwise discover our trade secrets or other proprietary information. Our research collaborators may also publish confidential data or other restricted information to which we have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations, then our ability to receive patent protection or protect our proprietary information may be impaired. In addition, under proposed or adopted policies in the EU, information related to clinical trials and clinical trial data that historically were considered confidential are now increasingly subject to public disclosure. The move toward public disclosure of this information could adversely affect our business in many ways, such as by requiring the disclosure of confidential methodologies for product development, preventing us from obtaining intellectual property right protection for innovations, requiring significant resources to prevent others from violating our intellectual property rights, adding complexity to compliance with applicable data privacy regulations, and enabling competitors to use our data to gain approvals for their own products.
We may incur substantial costs and lose important rights or may not be able to continue to commercialize our products or to commercialize any of our product candidates that may be approved for commercial sale as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be required to obtain patent and other intellectual property rights from others.
We may face potential lawsuits by companies, academic institutions or others alleging infringement of their intellectual property. Due to the amount of intellectual property in our field, we cannot be certain that we do not infringe intellectual property rights of competitors or that we will not infringe intellectual property rights of competitors granted or created in the future. In addition, we are monitoring the progress of multiple pending patent applications of other organizations that, if granted, may require us to license or challenge their enforceability in order to continue commercializing our products or to commercialize our product candidates that may be approved for commercial sale. Our challenges to patents of other organizations may not be successful, which may affect our ability to commercialize our products or product candidates. If it is ultimately determined that our products infringe a third-party’s intellectual property rights, we may be required to pay substantial damages, including lost profits, royalties, treble damages, attorneys’ fees and costs. Even if infringement claims against us are without merit, the results may be unpredictable. In addition, defending lawsuits takes significant time, may be expensive and may divert management’s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products unless and until we obtain a license from the owner of the relevant technology or other intellectual property rights, or we may be forced to undertake costly design-arounds, if feasible. If such a license is available at all, it may require us to pay substantial royalties or other fees.
54
We are or may be from time to time involved in the defense and enforcement of our patent or other intellectual property rights in a court of law, USPTO interference, inter partes review, or IPR, post-grant review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. For example, we are involved in multiple disputes with Daiichi Sankyo Co. Ltd., or Daiichi Sankyo. In connection with one of these disputes, Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals, LP, or AstraZeneca, filed two petitions for post-grant review with the USPTO, and on April 7, 2022, the USPTO instituted two post-grant review proceedings, but on July 15, 2022, the USPTO issued a new decision denying post-grant review of the claims asserted in the patent infringement action. See the risk factor below titled, “We have been and may in the future be subject to litigation, which could result in substantial expenses and damages and may divert management’s time and attention from our business.” In addition, if we choose to go to court to stop a third party from infringing our patents, that third party has the right to ask the court to rule that these patents are invalid, not infringed and/or should not be enforced. Under the America Invents Act, a third party may also have the option to challenge the validity of certain patents at the Patent Trial and Appeal Board, or PTAB, of the USPTO whether they are accused of infringing our patents or not, and certain entities associated with hedge funds, pharmaceutical companies and other entities have challenged valuable pharmaceutical patents through the IPR process. These lawsuits and administrative proceedings are expensive and consume time and other resources, and we may not be successful in these proceedings or in stopping infringement. In addition, there is a risk that a court will decide that these patents are not valid or not infringed or otherwise not enforceable, or that the PTAB will decide that certain patents are not valid, and that we do not have the right to stop a third party from using the patented subject matter. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use our proprietary technologies without a license from us or our collaborators, which may also result in loss of future royalty payments. Furthermore, if such challenges to our rights are not resolved promptly in our favor, our existing business relationships may be jeopardized and we could be delayed or prevented from entering into new collaborations or from commercializing potential products, which could adversely affect our business, results of operations, financial condition and growth prospects. In addition, we may challenge the patent or other intellectual property rights of third parties and if we are unsuccessful in actions we bring against the rights of such parties, through litigation or otherwise, and it is determined that we infringe the intellectual property rights of such parties, we may be prevented from commercializing potential products in the relevant jurisdiction, or may be required to obtain licenses to those rights or develop or obtain alternative technologies, any of which could harm our business.
We and our collaborators rely on license agreements for certain aspects of our products and product candidates and technologies such as our ADC technology. Failure to maintain these license agreements or to secure any required new licenses could prevent us from continuing to develop and commercialize our products and product candidates.
We have entered into agreements with third-party commercial and academic institutions to license technology for use in ADCETRIS, TUKYSA, our product candidates and technologies such as our ADC technology. Currently, we have license agreements with BMS, the University of Miami and Array BioPharma, Inc., among others. In addition to royalty provisions and other payment obligations, some of these license agreements contain diligence and milestone-based termination provisions, in which case our failure to meet any agreed upon royalty or diligence requirements or milestones may allow the licensor to terminate the agreement. Many of our license agreements grant us exclusive licenses to the underlying technologies. In addition, Astellas has agreements to license technology for use in PADCEV. We rely on Astellas to maintain these license agreements. If Astellas fails to maintain these license agreements, if our licensors terminate our license agreements or if we or our collaborators are unable to maintain the exclusivity of our exclusive license agreements, we may be unable to continue to develop and commercialize our products or product candidates. Further, we have had in the past, and we or our collaborators may in the future have, disputes with our licensors, which may impact our ability to develop and commercialize our products or product candidates or require us to enter into additional licenses. An adverse result in potential future disputes with our or our collaborators’ licensors may impact our ability to develop and commercialize our products and product candidates, or may require us to enter into additional licenses or to incur additional costs in litigation or settlement. In addition, continued development and commercialization of our products and product candidates will likely require us to secure licenses to additional technologies. We may not be able to secure these licenses on commercially reasonable terms, if at all.
55
We have been and may in the future be subject to litigation, which could result in substantial expenses and damages and may divert management’s time and attention from our business.
We are engaged in multiple legal disputes with Daiichi Sankyo. We are in a dispute with Daiichi Sankyo regarding the ownership of certain technology used by Daiichi Sankyo in its cancer drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) and certain product candidates. A decision in the arbitration case is expected in mid-2022. In addition, we filed a complaint in the U.S. District Court for the Eastern District of Texas to commence an action for infringement of our U.S. Patent No. 10,808,039, or the ‘039 Patent, by Daiichi Sankyo’s importation into, offer for sale, sale, and use in the U.S. of ENHERTU. Daiichi Sankyo (as well as Daiichi Sankyo, Inc. and AstraZeneca) subsequently filed an action in the U.S. District Court for the District of Delaware seeking a declaratory judgment that ENHERTU does not infringe the ‘039 Patent. The Delaware action has been stayed by court order. Daiichi Sankyo, Inc. and AstraZeneca also filed two petitions for post-grant review with the USPTO seeking to have claims of the ‘039 Patent cancelled as unpatentable. On June 24, 2021, the USPTO issued a decision denying both petitions for post-grant review. On April 7, 2022, the USPTO granted a request on rehearing and instituted two post-grant review proceedings, but on July 15, 2022, the USPTO issued a new decision denying post-grant review of the claims asserted in the patent infringement action. On April 8, 2022, a jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo willfully infringed the asserted claims of the '039 Patent with its ENHERTU product, and also found that the asserted claims were not invalid. The U.S. District Court for the Eastern District of Texas also denied Daiichi Sankyo’s claim that the ‘039 Patent should be unenforceable under the equitable theory of prosecution laches, entered judgment in favor of Seagen based on the jury’s verdict that Daiichi Sankyo willfully infringed the ‘039 Patent consisting of pre-trial damages in the sum of $41.8 million, and awarded us pre- and post-trial interest and costs. We intend to request a royalty on Daiichi Sankyo's future sales of ENHERTU in the United States through November 5, 2024. As a result of these disputes, we have incurred and will continue to incur litigation expenses. In addition, from time to time, we may become involved in other lawsuits, claims and proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent or other intellectual property rights and our contractual rights.
These and other potential future litigations are subject to inherent uncertainties, and the actual costs to be incurred relating to litigations may be impacted by unknown factors. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the course of these and potential future litigations, we may be subject to additional claims and counterclaims that may result in liabilities or require us to take or refrain from certain actions, and we may not prevail. Monitoring, defending against and pursuing legal actions can be time-consuming for our management and detract from our ability to fully focus our internal resources on our business activities, which could result in delays of our clinical trials or our development and commercialization efforts. In addition, we may incur substantial legal fees and costs in connection with these and potential future litigations. Decisions adverse to our interests in these and potential future litigations could result in the payment of substantial damages, or possibly fines, or affect our intellectual property rights and could have a material adverse effect on our business, results of operations, financial condition and growth prospects. Successful challenges to our patent or other intellectual property rights could result in a loss of rights in the relevant jurisdiction and may allow third parties to use our proprietary technologies without a license from us or our collaborators. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.
Risks Related to Our Operations, Managing Our Growth and Other Risks
The evolving effects of the COVID-19 pandemic and associated global economic instability could have further adverse effects on our business, including our commercialization efforts, supply chain, regulatory activities, clinical development activities and other business operations.
Our business is currently being adversely affected and could be materially and adversely affected in the future by the evolving effects of the COVID-19 pandemic. Our ongoing increased reliance on personnel working from home may present operational and workplace culture challenges, negatively impact productivity or disrupt, delay or otherwise adversely impact our business. This could also increase our cybersecurity risk, create data accessibility concerns and make us more susceptible to communication disruptions, any of which could adversely impact our business operations. Our field-based personnel are using a mix of in-person interactions and electronic communications, such as emails, phone calls and video conferences, to support healthcare providers and patients. Many healthcare professionals are facing additional demands on their time during the ongoing COVID-19 pandemic. We expect the different quality of electronic interactions as compared with in-person interactions, as well as the reduced quantity of interactions during the COVID-19 pandemic, to reduce the effectiveness of our sales personnel, as well as those of our collaborators, which could negatively affect our product sales and those of our collaborators, as well as physician awareness of our products. In this regard, we believe that the need to conduct some of our activities virtually is negatively impacting our ability to connect with key customers, including those familiar with competitive products, and our ability to conduct payor engagements.
56
We face a number of challenges that will limit our ability to fully resume in-person interactions, including increasing COVID-19 infection rates due to coronavirus mutations and/or low vaccination rates in different areas or otherwise, the need to navigate varying restrictions for entering healthcare facilities and the pandemic's impacts on employee childcare arrangements. In addition, we may subsequently decide or be forced to resume a more restrictive remote work model, whether as a result of further spikes or surges in COVID-19 infection or hospitalization rates or otherwise. Moreover, the long-term effects of the COVID-19 pandemic are also unknown and it is possible that following the pandemic, healthcare institutions could alter their policies with respect to in person visits by pharmaceutical company representatives. Future COVID-19 related restrictions could also present product distribution challenges.
The evolving effects of the COVID-19 pandemic appear to have negatively affected and may continue to negatively affect our product sales due to challenges in patient access to healthcare settings, loss of individual health insurance coverage, and inability to access government healthcare programs due to backlogs, some or all of which appear to have negatively affected diagnosis rates, may affect side effect management and course of treatment and may increase enrollment in our patient support programs. In this regard, impacts associated with the COVID-19 pandemic appear to have led to a reduction in the rate of Hodgkin lymphoma diagnoses, may have adversely affected diagnosis rates of other cancers, and may further adversely affect rates of cancer diagnoses in the future. We also expect that the conversion of medical conferences to a virtual format may reduce our ability to effectively disseminate scientific information about our products, which may result in decreased physician awareness of our products, their approved indications and their efficacy and safety.
Some of the sites participating in our clinical trials are affected by site closings, reduced capacity, staffing shortages or other effects of the COVID-19 pandemic. At some sites, we are experiencing impacts to our ability to monitor patients, activate sites, screen and enroll patients, complete site monitoring and manage samples. The extent of the impact on a particular clinical trial depends on the current stage of activities at a given site, for example study start up versus post-enrollment, and the number of impacted sites participating in that trial. Impacts on diagnosis rates associated with the COVID-19 pandemic may also negatively impact enrollment. While we do not at this time anticipate the need to revise our publicly reported projected clinical milestone dates as a result of the effects of the COVID-19 pandemic, there may continue to be adverse impacts to our clinical study timelines, which, depending upon the duration and severity of the evolving effects of the COVID-19 pandemic, could ultimately delay data availability. Due to the suspension of data monitoring activities at sites that do not currently allow remote monitoring, as well as impacts on the ability to monitor patients, maintain patient treatment according to the trial protocols and manage samples, there is also the potential for negative impacts on data quality. While we are actively utilizing digital monitoring measures and other mitigations designed to prevent negative data quality impacts, if there were in fact a negative impact on data quality, we or our collaborators could be required to repeat, extend the duration of, or increase the size of clinical trials, which could significantly delay potential commercialization and require greater expenditures. We expect that similar factors will impact clinical studies operationalized by our collaborators. In addition, many of our non-essential on-site research activities are currently significantly reduced as a result of the COVID-19 pandemic, which may negatively impact the number of investigational new drug application, or IND, candidates entering our clinical pipeline in future years.
The effects of the COVID-19 pandemic continue to rapidly evolve. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, economic instability resulting from the effects of the COVID-19 pandemic could materially affect our business and the value of our common stock.
The extent to which the evolving effects of the COVID-19 pandemic impact our business will depend on future developments that are highly uncertain, such as coronavirus variants that may prove to be especially contagious or virulent, the ultimate duration and severity of the pandemic, government actions, such as travel restrictions, quarantines and social distancing requirements in the U.S. and in other countries, business closures or business disruptions and the effectiveness of vaccine programs and other actions taken to contain and treat the disease. Accordingly, we do not yet know the full extent of potential effects from the pandemic. However, these effects could materially and adversely affect our business, results of operations, financial condition and growth prospects. In addition, the evolving effects of the COVID-19 pandemic may also heighten many of the other risks described elsewhere in this “Risk Factors” section. It is also possible that future global pandemics could occur and materially and adversely affect our business, results of operations, financial condition and growth prospects.
57
If we are unable to manage our growth, our business, results of operations, financial condition and growth prospects may be adversely affected.
We have experienced and expect to continue to experience significant growth in the number of our employees and in the scope and complexity of our operations. This rapid growth and additional complexity places significant demands on our management and other personnel, our operational and financial resources and our third party suppliers. Our current and planned personnel, operational and financial systems, procedures, controls and suppliers may not be adequate to support our growth, and we may experience operating inefficiencies, delays, control deficiencies, compliance issues or other problems. In addition, we may not be able to achieve any necessary growth objectives in a timely or cost-effective manner, or at all, and may not realize a positive return on our investment. If we are unable to manage our growth effectively, our business, results of operations, financial condition and growth prospects may be adversely affected.
Risks associated with our expanding operations in countries outside the U.S. could materially adversely affect our business.
We have operations outside the U.S., and we plan to continue expanding our operations internationally. For example, we are continuing to expand our commercial infrastructure in Europe and Canada. Consequently, we are, and will increasingly be, subject to risks and complexities related to operating internationally, including:
•the increased complexity and costs inherent in managing international operations, including in geographically disparate locations;
•diverse clinical, drug safety, drug quality, drug supply, healthcare compliance and other pharmaceutical regulatory regimes, and any future changes to such requirements, in the countries and regions where we are located or do business;
•multiple, differing and changing laws and regulations such as tax laws, privacy regulations, tariffs, trade restrictions, export and import restrictions, employment, immigration and labor laws, corporate laws, and other governmental approvals, permits and licenses;
•differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;
•adverse tax consequences, including changes in applicable tax laws and regulations;
•political tensions, economic weakness, including inflation, or political or economic instability in particular economies and markets;
•currency fluctuations, which could result in increased operating expenses or reduced revenues;
•challenges inherent in efficiently managing employees in diverse geographies and different languages;
•challenges in adapting systems, policies, benefits and compliance programs for different countries;
•reliance on vendors who are located far from our headquarters and with whom we have not worked previously; and
•workforce uncertainty in countries where labor unrest is more common.
For example, the U.S. government and other nations have imposed sanctions, including significant restrictions on most companies’ ability to do business in Russia, as a result of the ongoing military conflict between Russia and Ukraine. It is not possible to predict the broader or longer-term consequences of this conflict, which could include further sanctions, embargoes, regional instability, geopolitical shifts and adverse effects on macroeconomic conditions, security conditions, currency exchange rates and financial markets. Such geopolitical instability and uncertainty could have a negative impact on our ability to continue expanding our operations internationally and to otherwise generate revenues and develop our product candidates internationally. In addition, a significant escalation or expansion of economic disruption or the conflict's current scope could have a material adverse effect on our business, results of operations, financial condition and growth prospects. Recent strengthening of the U.S. dollar as compared to other currencies, including currencies in jurisdictions where we and our licensees sell products, has adversely affected royalty revenues and TUKYSA net product sales in Europe during the six months ended June 30, 2022 and could further adversely affect these sources of revenues.
58
Additionally, the U.S. Foreign Corrupt Practices Act, or FCPA, and the anti-bribery laws and regulations of other countries are extensive and far-reaching. We must ensure that accurate records and controls required by the FCPA are maintained with respect to the activities of our employees, distributors and service providers in all of the countries where we operate. In the course of conducting operations internationally, we interact with regulatory authorities, as well as with healthcare professionals who are often employed by governments and may be deemed to be foreign officials under the FCPA. Any interactions with any such third parties that are found to be in violation of relevant laws could result in substantial fines and penalties and could materially harm our business. Emerging-market countries may be especially vulnerable to periods of political, legal, and financial instability and may have a higher risk of corrupt business practices. As we expand our international operations, we continue to supplement and expand our global compliance program, controls, policies and procedures. However, there can be no assurance that such measures will work effectively at all times or protect us against liability. There is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and other anti-corruption laws and that we might be held responsible. Furthermore, any finding of a violation under one country’s laws may increase the likelihood that we will be prosecuted and be found to have violated another country’s laws. Our failure, or the failure of others who we engage to act on our behalf, to comply with the laws and regulations of the countries in which we operate, or will operate in the future, could result in criminal and civil penalties, other remedial measures and reputational damage, all of which could materially harm our business, financial condition, results of operations, and prospects. As we continue to expand our footprint and activities internationally, our exposure to compliance risks under the FCPA and other similar laws will likewise increase.
As a business, we do not have significant experience conducting operations outside of the U.S. and Canada. We might not be successful in establishing and conducting commercial and other operations in these regions and may not realize a positive return on our investment. Our failure to successfully do so could have a material adverse effect on our business, results of operations, financial condition and growth prospects. These and other risks associated with expanding our international operations, as described elsewhere in these risk factors, could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
We have engaged in, and may in the future engage in, strategic transactions that increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
We actively evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary products, product candidates, technologies or businesses. We may spend significant amounts, issue dilutive securities and/or assume or incur significant debt obligations in connection with these transactions. In addition, these transactions, including our recent in-license of development and commercialization rights to disitamab vedotin and any potential future acquisitions or licensing transactions, entail numerous risks, including:
•risks associated with satisfying the closing conditions relating to such transactions and realizing their anticipated benefits;
•increased operating expenses and cash requirements;
•difficulty integrating acquired technologies, products, operations, compliance programs and personnel with our existing business;
•acquired or licensed products, product candidates or technologies, such as disitamab vedotin, may not perform as expected and may not result in regulatory approvals;
•failure to successfully develop and commercialize acquired or licensed products, product candidates or technologies or to achieve other strategic objectives;
•the potential disruption of our historical core business;
•diversion of management’s attention in connection with both negotiating the acquisition or license and integrating the business, technology or product;
•retention of key employees;
•uncertainties in our ability to maintain key business relationships of any acquired companies;
•difficulty implementing and maintaining effective internal control over financial reporting of businesses that we acquire;
•exposure to unanticipated liabilities of acquired companies or companies in which we invest;
•the potential need to write down assets or recognize impairment charges or significant amortization expenses; and
•potential costly and time-consuming litigation, including stockholder lawsuits.
59
As a result of these or other problems and risks, businesses, technologies or products we acquire or invest in or obtain licenses to may not produce the revenues, earnings, business synergies or other benefits that we anticipated, within the expected timeframe or at all. As a result, we may incur higher costs and realize lower revenues than we had anticipated. We cannot assure you that any acquisitions or investments we have made or may make in the future will be completed or that, if completed, the acquired business, licenses, investments, products, or technologies will generate sufficient revenue to offset the costs or other negative effects on our business. Further, while we seek to mitigate risks and liabilities of potential acquisitions and in-licensing transactions through, among other things, due diligence, there may be risks and liabilities that we fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks, liabilities and uncertainties effectively, including in connection with our recent in-license of development and commercialization rights to disitamab vedotin, could have a material adverse effect on our business, results of operations, financial condition and growth prospects. Moreover, we may not be able to identify, negotiate and close strategic acquisition or in-licensing opportunities in the future, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Other pharmaceutical companies, many of which may have substantially greater resources, compete with us for these opportunities. Failure to effectively advance our business strategy and manage our operations through acquisitions or in-licensing transactions could have a material adverse effect on our business, results of operations, financial condition, and growth prospects.
If we lose our key personnel or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would suffer.
We are highly dependent on the efforts and abilities of the principal members of our senior management and other key personnel. For example, we have scientific personnel with significant and unique expertise in monoclonal antibodies, ADCs and related technologies, and our products and product candidates. The loss of the services of any one of the principal members of our managerial, scientific or other key staff may prevent us from achieving our business objectives. For example, in May 2022, Clay B. Siegall resigned as our President and Chief Executive Officer and as a member of our Board of Directors, and Roger Dansey, M.D., our Chief Medical Officer, was appointed as our Interim Chief Executive Officer. Changes to company strategy, which can often times occur with the appointment of new executive leadership, can create uncertainty, may negatively impact our ability to execute quickly and effectively, and may ultimately be unsuccessful. In addition, executive leadership transition periods are often difficult as the new executives gain detailed knowledge of our operations, and friction can result from changes in strategy and management style. Executive management transition, particularly at the principal executive officer level, inherently causes some loss of institutional knowledge, which can negatively affect strategy, execution and our ability to compete. In any event, changes in our organization as a result of executive management transition may have a disruptive impact on our ability to implement our strategy and could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
In addition, the competition for qualified personnel in the biotechnology field is intense, and our future success depends upon our ability to attract, retain and motivate highly skilled biotechnology employees. In order to continue to commercialize our products, and advance the development and commercialization of our product candidates, we will be required to expand our workforce and management team, particularly in the areas of manufacturing, clinical trials, regulatory affairs, business development, sales and marketing, both in the U.S. and in Europe. We continue to face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, as well as academic and other research institutions, and with increasing reliance on remote work arrangements, the geographic market in which we compete for talent is expanding. Our ability to attract and retain talent in this competitive environment may be further complicated by evolving employment trends arising from the COVID-19 pandemic, including an increased preference for remote, alternative or flexible work arrangements. Our failure to effectively compete for and retain talent could negatively affect our ability to achieve our business objectives and have a material adverse effect on our business, results of operations, financial condition and growth prospects.
60
If our information technology systems or data are or were compromised, we could experience interruptions to our operations, legal claims, liability, harm to our reputation, a loss of sales and other adverse impacts.
We and our collaborators, suppliers and service providers rely on information technology systems to keep financial and other records, capture laboratory and clinical trial data, support internal and external communications and operate other critical functions. Despite our security measures, these systems are potentially vulnerable to malware, cyber-attacks, security breaches, natural disasters, terrorism, software and hardware failures, telecommunication and electrical failures, and similar issues. If such an event were to occur, it could result in material interruptions to our operations, loss of data or applications, loss of sales, significant extra expenses to restore data or systems, reputational harm and diversion of funds. For example, the loss of preclinical study or clinical trial data could result in delays in our product development or regulatory approval efforts and significantly increase our costs in order to recover or reproduce the data. The effects of the COVID-19 pandemic have intensified our dependence on information technology systems as many of our critical business activities are currently being conducted remotely and our increased reliance on personnel working from home could increase our cybersecurity risk. In addition, our cybersecurity risk could be increased as a result of the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia.
In addition to traditional computer “hackers” and threat actors, sophisticated nation-state and nation-state supported actors now engage in attacks (including advanced persistent threat intrusions). Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity. We cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our systems and networks or the systems and networks of third parties that support us.
Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Although, to our knowledge, we have not experienced any material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. While we have taken steps to protect the security of the personal data and other sensitive information that we handle, there can be no assurance that any security measures will be effective against current or future security threats. Any unauthorized or accidental access to, or disclosure, modification, misuse, or loss of, personal or other data could result in legal claims or proceedings, liability, significant regulatory penalties, and loss of trade secrets or other intellectual property. In addition, such an event could disrupt our operations, damage our reputation and delay development of our product candidates.
Risks Related to Our Operating Results, Financial Condition and Capital Requirements
Our operating results are difficult to predict and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.
Our operating results are difficult to predict and may fluctuate significantly from quarter to quarter and year to year. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including:
•customer ordering patterns for our products, which may vary significantly from period to period;
•the overall level of demand for our products, including the impact of any competitive or biosimilar products;
•the extent to which coverage and adequate reimbursement for our products is available from government and other third-party payors;
•changes in the amount of deductions from gross sales, including government-mandated rebates, chargebacks and discounts that can vary because of changes to the government discount percentage, including increases in the discount percentage resulting from price increases, or due to different levels of utilization by entities entitled to government rebates and discounts and changes in patient demographics;
•increases in the scope of eligibility for customers to purchase our products at the discounted government price or to obtain government-mandated rebates on purchases of our products;
•the timing, receipt and amount of development funding and milestone, royalty and other payments under collaboration and license arrangements, which may vary significantly from quarter to quarter;
•entry into new strategic transactions, such as collaborations, license agreements or acquisitions of products, technologies or businesses;
61
•changes in our cost of sales due to potential new product launches, royalties owed under technology license agreements or write-offs of inventory;
•the incidence rate of new patients in the approved indications for our products;
•the evolving effects of the COVID-19 pandemic, including those leading to past and potential future reductions in rates of cancer diagnoses;
•the timing, cost and level of investment in our sales and marketing efforts to support our products sales;
•the timing, cost and level of investment in clinical trials, research and development, pre-commercialization, manufacturing and other activities by us or our collaborators; and
•expenditures to develop and/or commercialize any additional products, product candidates, or technologies that we may develop, in-license, or acquire.
Sales of a newly-approved product, or sales an existing product in a newly-approved indication or territory, are particularly difficult to predict. Sales results or trends for such products, indications or territories in any period may not necessarily be indicative of future performance. Changes in our operations, such as new or expanding pipeline programs, the continued expansion or our international operations, additional business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses, may cause significant fluctuations in our expenses. In addition, stock-based compensation expense may vary significantly from period to period. The variables we use for valuing these awards, including our underlying stock price, change over time. Additionally, from time to time, we have implemented long-term incentive plans for eligible employees, and the incentives provided under these plans are contingent upon the achievement of certain regulatory milestones. Costs of performance-based compensation under these plans are not recorded as an expense until the achievement of the applicable milestones is deemed probable, which may result in large fluctuations to the expense we must recognize in any particular period.
For these and other reasons, it is difficult for us to accurately forecast future sales of our current or any future approved products, collaboration and license agreement revenues, royalty revenues, operating expenses or future profits or losses. In addition, although we provide financial guidance from time to time, such guidance is based on assumptions that may be incorrect or that may change from quarter to quarter. You also should not rely on operating results in any period as being indicative of future performance. Our operating results have on occasion been, and in in future periods may also be, below prior period results, our own guidance and/or the expectations of securities analysts or investors. Such results could cause the trading price of our common stock to decline, perhaps substantially.
We have a history of net losses. We expect to continue to incur net losses and may not achieve future sustained profitability for some time, if at all.
We have incurred substantial net losses in each of our years of operation, other than the year ended December 31, 2020. We have incurred these losses principally from costs incurred in our research and development programs and from our selling, general and administrative expenses. We expect to continue to spend substantial amounts on research and development, including amounts for conducting clinical trials of our products and product candidates. In addition, we expect to make substantial expenditures to commercialize our products and potentially commercialize our product candidates. For example, in connection with our in-license of development and commercialization rights to disitamab vedotin, we have incurred and expect to continue to incur substantial expenses, including to further develop and potentially commercialize disitamab vedotin. We may also pursue new operations or continue the expansion of our existing operations, including with respect to the continued development of our commercial infrastructure in Europe and our plans to otherwise continue to expand our operations internationally. Accordingly, we expect to continue to incur net losses in the future and may not achieve sustained profitability for some time, if at all. Although we recognize revenue from product sales and we continue to earn amounts under our collaboration agreements, our revenue and profit potential is unproven and our future operating results are difficult to predict. Even if we do achieve profitability in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.
62
We may need to raise additional capital that may not be available to us.
We expect to make additional capital outlays and to increase operating expenditures over the next several years as we hire additional employees, support our development and commercialization activities, invest in our facilities, and expand globally, which may require us to raise additional capital. In addition, we may pursue new operations or continue the expansion of our existing operations, including with respect to the continued development of our commercial infrastructure in Europe and our plans to otherwise continue to expand our operations internationally. Our commitment of resources to the continuing development, regulatory and commercialization activities for our products, the continued research, development and manufacturing of our product candidates, our pursuit of regulatory approvals for and preparing to potentially launch and commercialize our product candidates, and the anticipated expansion of our pipeline and operations may require us to raise additional capital. Further, we actively evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary products, technologies or businesses, and we may require significant additional capital in order to complete or otherwise provide funding for such transactions. We may seek additional capital through some or all of the following methods: corporate collaborations, licensing arrangements and public or private debt or equity financings. We do not know whether additional capital will be available when needed, or that, if available, we will obtain financing on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to scale back our operations, delay, reduce the scope of, or eliminate development programs enter into collaboration or license agreements on terms that are not favorable to us, sell or relinquish rights to certain assets, proprietary technologies or product candidates or forego strategic opportunities. Our future capital requirements will depend upon a number of factors, including:
•the level of sales of our products and any future approved products;
•the time and costs involved in pursuing regulatory approvals and the timing of any approvals;
•the costs, timing, progress and results of our research and development, including preclinical testing and clinical trials;
•the timing, receipt and amount of royalty revenue generated from commercial sales by our collaborators and licensees, as well as development funding, milestone payments and other payments under collaboration and license arrangements;
•the cost of establishing and maintaining clinical supplies of our products and product candidates and commercial supplies of our current and any future approved products;
•the extent of our investment in development, manufacturing and commercialization outside the U.S.;
•the costs associated with past and potential future strategic transactions, including acquisitions or licenses of additional technologies, products or businesses as well as licenses we may need to commercialize our current or any future approved products;
•the terms and timing of any future collaboration, licensing and other arrangements;
•expenses associated with current or future litigation;
•the potential costs associated with international, state and federal taxes; and
•competing technological and market developments.
In addition, changes in our spending rate may occur that would consume available capital resources sooner, such as increased development, manufacturing and clinical trial expenses in connection with our expanding pipeline programs or our undertaking of additional programs, business activities or entry into additional strategic transactions, including potential future acquisitions of products, technologies or businesses. Moreover, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. Debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to pay dividends or other distributions on our common stock or incur further indebtedness. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us.
During the past several years, domestic and international financial markets have experienced, and they may continue to experience, extreme disruption from time to time, including, among other things, high volatility, significant declines in stock prices and severely diminished liquidity and credit availability for both borrowers and investors. Such adverse capital and credit market conditions could make it more difficult to obtain additional capital on favorable terms, or at all, which could have a material adverse effect on our business and growth prospects. For example, our ability to raise additional capital may be adversely impacted by deteriorating global economic conditions and the disruptions to and volatility in the credit and financial markets in the U.S. and worldwide resulting from the evolving effects of the COVID-19 pandemic and the ongoing military conflict between Russian and Ukraine and related sanctions imposed against Russia.
63
The potential future impairment of intangible assets and goodwill may negatively affect our results of operations and financial position.
As of June 30, 2022, we carried $523.8 million of intangible assets, net and goodwill on our condensed consolidated balance sheet. Our intangible assets and goodwill are subject to an impairment analysis whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Additionally, goodwill and indefinite-lived assets are subject to an impairment test at least annually. Events giving rise to impairment are an inherent risk in the pharmaceutical industry and cannot be predicted. Our results of operations and financial position in future periods could be negatively impacted should future impairments of intangible assets or goodwill occur.
Risks Related to Our Common Stock
Our stock price is volatile and our shares may suffer a decline in value.
The market price of our stock has been, and is likely to continue to be, volatile. As a result of fluctuations in the price of our common stock, you may be unable to sell your shares at or above the price you paid for them. The market price of our common stock may be subject to substantial volatility in response to many risk factors listed in this section, and others beyond our control, including:
•the levels of product sales;
•regulatory approval or non-approval of our products or product candidates, specific label indications for or restrictions, warnings or limitations in their use, or delays in the regulatory review process;
•clinical trial results;
•announcements regarding the results of discovery efforts, product development and commercial activities by us, our collaborators or our competitors;
•announcements regarding, or negative publicity concerning, adverse events or safety concerns associated with the use of our products or product candidates;
•issuance of new or changed analysts’ reports and recommendations regarding us or our competitors;
•termination of or changes in our existing collaborations or licensing arrangements, or establishment of new collaborations or licensing arrangements;
•our failure to achieve the perceived benefits of our strategic transactions, including our recent in-license of development and commercialization rights to disitamab vedotin, as rapidly or to the extent anticipated by financial analysts or investors;
•our entry into additional material strategic transactions including licensing or acquisition of products, businesses or technologies;
•regulatory actions with respect to our products, product candidates, clinical trials or regulatory filings;
•our raising of additional capital and the terms upon which we may raise any additional capital;
•developments or disputes concerning our proprietary rights, including with respect to our disputes with Daiichi Sankyo;
•developments regarding any litigation or potential litigation;
•the evolving effects of the COVID-19 pandemic;
•share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
•changes in laws, regulations or government policies, including with respect to pricing and reimbursement;
•market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular; and
•other economic, social or political conditions.
64
The stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. In the past, companies whose securities have experienced periods of volatility in market price have been subjected to securities class action or derivative litigation. In this regard, we have been, and may in the future again become, subject to claims and litigation alleging violations of the securities laws or other related claims. Lawsuits brought against us could result in substantial costs, which would hurt our financial condition and results of operations and divert management’s attention and resources.
Substantial future sales or issuances of shares of our common stock or equity-related securities could cause the market price of our common stock to decline.
Sales of a substantial number of shares of our common stock, and sales by members of our management or board of directors or entities affiliated with such members, could occur at any time. In addition, in December 2020, pursuant to a ten-year registration rights agreement we entered into with certain entities affiliated with Baker Bros. Advisors LP, or the Baker Entities, we registered up to 47,366,602 shares of our common stock for resale by the Baker Entities, and we may be required to register the resale of additional shares held by the Baker Entities from time to time in the future. Sales by our management, our directors, their affiliates, or significant shareholders like the Baker Entities, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock, perhaps substantially, and could impair our ability to raise capital through the sale of additional equity or equity-related securities. In addition, we may issue a substantial number of shares of our common stock or equity-related securities, including convertible debt, to meet our capital needs, including in connection with funding potential future acquisition or licensing opportunities, capital expenditures or product development costs. These issuances could be substantially dilutive and could adversely affect the market price of our common stock. Likewise, future issuances of our common stock upon the exercise, conversion or settlement of equity-based awards or other equity-related securities would dilute existing stockholders’ ownership interest in our company.
Our existing stockholders have significant control of our management and affairs.
Based on information available to us as of June 30, 2022, the Baker Entities collectively beneficially owned approximately 26% of our common stock. In addition, based solely on the most recent Schedules 13G and 13D filed with the SEC, reports filed with the SEC under Section 16 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and our outstanding shares of common stock as of June 30, 2022, our executive officers and directors and holders of greater than five percent of our outstanding common stock beneficially owned approximately 53% of our voting power as of June 30, 2022. As a result, these stockholders are able to exert substantial influence over our management and affairs and matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may result in our taking corporate actions that other stockholders may not consider to be in their best interest. For example, it may have the effect of delaying, deferring or preventing a change in control, including a merger, consolidation, takeover or other business combination involving us or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control, which might affect the market price of our common stock.
Anti-takeover provisions could make it more difficult for a third party to acquire us.
Our Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock and to determine the terms of those shares, including voting rights, without any further action by the stockholders. The rights of the holders of common stock may be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Seagen. Further, certain provisions of our charter documents, including provisions eliminating the ability of stockholders to take action by written consent and limiting the ability of stockholders to raise matters at a meeting of stockholders without giving advance notice, may have the effect of delaying or preventing changes in control or management of Seagen, which could have an adverse effect on the market price of our stock. In addition, our charter documents provide for a classified board, which may make it more difficult for a third party to gain control of our Board of Directors. Similarly, state laws in Delaware and Washington related to corporate takeovers may prevent or delay a change of control of Seagen.
65
Our disclosures related to environmental, social and governance, or ESG, matters expose us to various risks, including risks to our reputation and stock price.
Investors are increasingly likely to factor ESG disclosures into their investment decisions. We have elevated the degree to which we manage, track and report on our ESG efforts and goals. Where provided, goal statements are aspirational, are subject to a number of risks, many of which are beyond our control, and are not guarantees. Our processes and operations may not always conform to various frameworks for identifying, measuring and reporting ESG metrics, and ESG reporting standards may change over time, either of which could result in significant revisions to reported metrics. In addition, our interpretation of reporting standards may differ from those of others. Any failure or perceived failure to pursue or fulfill our goals or to satisfy various reporting standards could have negative impacts on our reputation and stock price and expose us to litigation or government actions.
General Risk Factors
Changes in tax laws or regulations may have a material adverse effect on our business, results of operations, financial condition or growth prospects.
Due to economic and political conditions, new tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the current U.S. presidential administration has proposed numerous corporate tax reform proposals including implementation of a minimum tax on book income and increasing taxation of international business operations. In addition, as we continue to expand our operations internationally, we may become increasingly subject to taxation in jurisdictions outside the U.S. Changes in corporate tax rates or in rules applicable to the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings or the deductibility of expenses could have a material impact on the value of our deferred tax assets, result in significant one-time charges, increase our future tax expense or otherwise have a material adverse effect on our business, results of operations, financial condition or growth prospects.
If our facilities are damaged or our research and development, manufacturing or other business processes are interrupted, our business could be seriously harmed.
We conduct most of our business in a limited number of facilities. Damage or extended periods of interruption to these facilities due to fire, natural disaster, severe weather, power loss, communications failure, unauthorized entry or other events could cause significant disruption and/or delays in our research and development, manufacturing and commercial activities and could cause us to incur large expenses to repair or replace the facilities. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such disruption, delays and costs.
Legislative actions and new accounting pronouncements are likely to impact our future financial position or results of operations.
Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result we may be required to make changes in our accounting policies that could adversely affect our reported revenues and expenses, future profitability or financial position. The application of existing or future financial accounting standards, particularly those relating to the way we account for revenues and costs, could have a significant impact on our reported results.

66
Item 6.    Exhibits
Exhibit Incorporation By Reference
NumberExhibit DescriptionFormSEC File No.ExhibitFiling Date
2.1†8-K000-324052.19/21/2021
3.110-Q000-324053.111/7/2008
3.28-K000-324053.35/26/2011
3.38-K000-324053.110/8/2020
3.48-K000-324053.14/15/2022
4.110-K000-324054.22/12/2021
4.210-Q000-324054.311/7/2008
4.38-K000-3240510.19/11/2015
10.1+†————
10.2+†————
10.3*8-K000-3240599.15/15/2022
31.1+————
31.2+————
32.1+————
32.2+————
101The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Comprehensive Loss, (iii) Condensed Consolidated Statements of Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.————
104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).————
+Filed herewith.
†Certain confidential information contained in this Exhibit, marked by brackets in the Exhibit, has been omitted, because it is both not material and is the type that the registrant treats as private or confidential.
*Indicates a management contract or compensatory plan or arrangement.

67
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SEAGEN INC.
By: /s/ Todd E. Simpson
 Todd E. Simpson
 Duly Authorized and Chief Financial Officer
 (Principal Financial and Accounting Officer)
Date:July 28, 2022
68
 EX-10.1 2 ex101-seagenxabbvieincxs.htm EX-10.1 ex101-seagenxabbvieincxs
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRTEENTH AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENT Effective as of the date of the last signature below (the “Amendment Effective Date”), AbbVie Inc. (as assignee from Abbott Laboratories), a Delaware corporation having a principal place of business at 1 N Waukegan Road, North Chicago, IL 60064 (“AbbVie”), and Seagen Inc. (formerly, Seattle Genetics, Inc.), a Delaware corporation having a principal place of business at 21823 – 30th Drive Southeast in Bothell, Washington 98021 (“Seattle Genetics”) (individually the “Party” or collectively the “Parties”) agree to the following terms and conditions as set forth below (this “Amendment”). Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Agreement (as defined below). WHEREAS, the Parties are party to that certain Development and Supply Agreement with an Effective Date of February 23, 2004 for the manufacture of a chimeric anti-CD30 AC10 monoclonal antibody known as cAC10 Bulk Drug Intermediate (as amended, the “Agreement”); WHEREAS, Seattle Genetics, Inc. changed its name to Seagen Inc. on October 6, 2020; and WHEREAS, the Parties desire to amend the Agreement as herein provided as of the date of the last signature below. NOW, THEREFORE, in consideration of the mutual covenants and agreements contained here and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 1. Incorporation of the Agreement. All capitalized terms which are used but not otherwise defined herein shall have the same meanings as set forth in the Agreement. To the extent any terms of this Amendment are inconsistent with the terms of the Agreement, the terms of this Amendment shall control. 2. Process Development Work. The Parties agree that AbbVie shall perform the Stage set forth in Attachment 1 hereto entitled “Stage 15: [*]” (“Stage 15”) pursuant to the terms and conditions of the Agreement and this Amendment. The Agreement is hereby amended to add Stage 15 to the Project immediately after Stage 14 therein. 3. Payment Schedule. As compensation for Stage 15 to be performed by AbbVie, Seattle Genetics shall pay to AbbVie on the dates and in the amounts set forth in Attachment 2 hereto entitled “Updated Summarized Payment Schedule (Amendments 11, 12, and 13)”, which payment schedule also includes unpaid amounts in respect of services performed or to be performed pursuant to Amendments 11 and 12 to the Agreement. 4. Project References. All references to the Project set forth in the Agreement shall also be deemed to apply to the Stage performed by AbbVie pursuant to this Amendment. 5. Effectuation. The amendment to the Agreement contemplated by this Amendment shall be deemed effective as of the Amendment Effective Date without any further action required by Exhibit 10.1

 
the Parties hereto. 6. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. One or more counterparts of this Amendment may be delivered by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof. 7. Entire Agreement. This Amendment is the product of both Parties, and together with the Agreement and exhibits thereto, constitute the entire agreement between the Parties pertaining to the subject matter hereof, and merge all prior negotiations and drafts of the Parties with regard to the transactions contemplated herein. [signature page follows]

 
3 CONFIDENTIAL IN WITNESS WHEREOF, the Parties have caused this Thirteenth Amendment to be executed by their duly authorized officers as of the date of the last signature set forth below. ABBVIE INC. SEAGEN INC. By: /s/ Marc. O’Donoghue By: /s/ Vaughn Himes Name: Marc O’Donoghue Name:Vaughn Himes Title: VP, External and Contract Manufacturing Title: Chief Technical Officer Date: 12-May-2022 | 02:42 PDT Date: 10-May-2022 | 12:50 PDT

 
4 CONFIDENTIAL Attachment 1 STAGE 15: [*]

 
5 CONFIDENTIAL Attachment 2 UPDATED SUMMARIZED PAYMENT SCHEDULE (Amendments 11, 12, and 13) [*]

 
 EX-10.2 3 ex102-seagenxcordenpharm.htm EX-10.2 ex102-seagenxcordenpharm
271998166 v2 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO COMMERCIAL SUPPLY AGREEMENT THIS AMENDMENT NO. 1TO THE COMMERCIAL SUPPLY AGREEMENT (the “Amendment") is effective as of June 17, 2022 (“Amendment Effective Date”), by and between Seagen Inc. (formerly, Seattle Genetics, Inc.), a Delaware corporation with its principal place of business at 21823 30th Drive SE, Bothell, WA 98021 (“Seagen”) and Corden Pharma GmbH, a company duly organized and existing under the laws of Germany with a place of business at Otto Hahn Strasse, Plankstadt 68723, Germany (“Vendor”). SeaGen and Vendor are referred to herein individually as “Party” and collectively “Parties”. RECITALS WHEREAS, Seagen and Vendor are parties to that certain Commercial Supply Agreement dated February 20, 2022 (the “Agreement”); and WHEREAS, Seattle Genetics, Inc. changed its name to Seagen Inc. on October 6, 2020. WHEREAS, Vendor was erroneously referred to as Corden Plankstadt in the Agreement. NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in this Amendment, the sufficiency of which is hereby acknowledged, the Parties agree as follows: 1. All references to the company name “Seattle Genetics, Inc.” in the Agreement shall be replaced by the company name “Seagen Inc.” 2. All references to the company name “Corden Plankstadt” in the Agreement shall be replaced with the company name “Corden Pharma GmbH.” 3. As of the Amendment Effective Date, Schedule 2 to the Agreement is hereby deleted in its entirety and replaced with the following: “SCHEDULE 2 COMPENSATION FOR MANUFACTURING SERVICES [*] 4. All terms as set forth in the Agreement shall remain in full force and effect unless specifically modified herein. All capitalized terms not defined in this Amendment shall have the same meaning as set forth in the Agreement. 5. Counterparts; Signatures. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, and all of which shall together be deemed to constitute one agreement. This Amendment shall be effective upon full execution as of the Amendment Effective Date. The Parties agree that execution of this Amendment by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original Exhibit 10.2

 
-2-CordenPharma Plankstadt Amendment No. 1 to Commercial SupplyAgreement signatures, and that in any proceeding arising under or relating to this Amendment, each Party hereby waives any right to raise any defense or waiver based upon execution of this Amendment by means of such electronic signatures or maintenance of the executed Amendment electronically. Signatures to follow on next page

 
-3- CordenPharma Plankstadt Amendment No. 1 to Commercial SupplyAgreement The Parties have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date. SEAGEN INC. Corden Pharma GmbH By: /s/ Christopher Croson By: /s/ Lutz Henkel Name: Christopher Croson Name: Lutz Henkel Title: Executive Director, Global Manufacturing Title: MD Date: 21-Jun-2022 | 09:33 PDT Date: 23-Jun-2022 | 06:41 PDT By: /s/ Christina Simons Name: Christina Simons Title: Director Project Management &Communication Date: 23-Jun-2022 | 06:27 PDT

 
 EX-31.1 4 ex-3112022q2.htm EX-31.1 Document
Exhibit 31.1

CERTIFICATIONS
I, Roger D. Dansey, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Seagen Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
By:/s/ Roger D. Dansey
Roger D. Dansey
Interim Chief Executive Officer and Chief Medical Officer
(Principal Executive Officer)
Date:July 28, 2022

 EX-31.2 5 ex-3122022q2.htm EX-31.2 Document
Exhibit 31.2

CERTIFICATIONS
I, Todd E. Simpson, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Seagen Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
By:/s/ Todd E. Simpson
Todd E. Simpson
Chief Financial Officer
(Principal Financial and Accounting Officer)
Date:July 28, 2022

 EX-32.1 6 ex-3212022q2.htm EX-32.1 Document
Exhibit 32.1

SEAGEN INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Seagen Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roger D. Dansey, Interim Chief Executive Officer and Chief Medical Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
By:/s/ Roger D. Dansey
Roger D. Dansey
Interim Chief Executive Officer and Chief Medical Officer
(Principal Executive Officer)
Date:July 28, 2022
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Seagen Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

 EX-32.2 7 ex-3222022q2.htm EX-32.2 Document
Exhibit 32.2

SEAGEN INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Seagen Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd E. Simpson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
By:/s/ Todd E. Simpson
Todd E. Simpson
Chief Financial Officer
(Principal Financial and Accounting Officer)
Date:July 28, 2022
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Seagen Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

 EX-101.SCH 8 sgen-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of significant accounting policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of significant accounting policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Summary of significant accounting policies - Finite-lived intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Summary of significant accounting policies - Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2108102 - Disclosure - Revenue from contracts with customers link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Revenue from contracts with customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Revenue from contracts with customers - Summary of Collaboration and License Agreement Revenues by Collaborator (Details) link:presentationLink link:calculationLink link:definitionLink 2111103 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Leases - Summary of Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2116104 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 2119105 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 2320305 - Disclosure - Fair value (Tables) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Fair value - Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Fair value - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Fair value - Summary of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - Investment and other income (loss), net link:presentationLink link:calculationLink link:definitionLink 2325306 - Disclosure - Investment and other income (loss), net (Tables) link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Investment and other income (loss), net (Details) link:presentationLink link:calculationLink link:definitionLink 2127107 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2328307 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - Accrued liabilities link:presentationLink link:calculationLink link:definitionLink 2331308 - Disclosure - Accrued liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Accrued liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2133109 - Disclosure - Share-based compensation link:presentationLink link:calculationLink link:definitionLink 2334309 - Disclosure - Share-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2435416 - Disclosure - Share-based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2136110 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2437417 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2138111 - Disclosure - Legal matters link:presentationLink link:calculationLink link:definitionLink 2439418 - Disclosure - Legal matters (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 sgen-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 sgen-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 sgen-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt securities, due in one year or less, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Adjustments to reconcile net loss to net cash used by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Schedule of Cash, Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Provision for income taxes Income Tax Expense (Benefit) Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Postal Zip Code Entity Address, Postal Zip Code Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Lease agreement, rented area Area of Real Estate Property Cost of sales Cost of Goods and Services Sold Shares used in computation of per share amounts - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Investments Investments, Fair Value Disclosure Annual escalations Operating Lease, Annual Escalations Percentage Operating Lease, Annual Escalations Percentage Income Tax Disclosure [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Common stock, $0.001 par value, 250,000 shares authorized; 184,369 shares issued and outstanding at June 30, 2022 and 183,381 shares issued and outstanding at December 31, 2021 Common Stock, Value, Issued Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investment and other (loss) income , net Total investment and other (loss) income, net Equity Securities, Fv-Ni, Gain (Loss) And Investment Income, Net Equity Securities, Fv-Ni, Gain (Loss) And Investment Income, Net Financial Instruments [Domain] Financial Instruments [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation PADCEV Padcev [Member] Padcev Restricted stock vested during the period, net (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Share-Based Payment Arrangement [Abstract] Legal matters Legal Matters and Contingencies [Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Additional paid-in capital Additional Paid in Capital, Common Stock Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Debt securities, due in one to two years, amortized cost Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Amortized Cost Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Amortized Cost Current liabilities: Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Stock options and RSUs (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Initial term Lessee, Operating Lease, Remaining Lease Term Intangible asset useful life Finite-Lived Intangible Asset, Useful Life Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Investment Type [Axis] Investment Type [Axis] Investments Investment, Policy [Policy Text Block] Total other comprehensive income (loss) Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Leases Lessee, Operating Leases [Text Block] Proceeds from exercise of stock options and employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Share-based payment arrangement, plan modification, incremental cost Share-Based Payment Arrangement, Plan Modification, Incremental Cost Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other non-current assets Other Assets, Noncurrent Fair value Debt Securities, Available-for-Sale Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Contract manufacturing Contract Manufacturing Liabilities Current Contract Manufacturing Liabilities Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Unrecognized compensation costs, excluding options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Total long-term liabilities Liabilities, Noncurrent Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Net cash used by operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accrued liabilities and other Operating Lease, Liability, Current Basis of presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Summary of Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Initial rate Cash paid for amounts included in measurement of lease liabilities Operating Lease, Payments Costs and expenses: Costs and Expenses [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Intangible assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Comprehensive loss: Statement of Comprehensive Income [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value (Loss) gain on equity securities Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Revenue recognition - Net product sales Revenue from Contract with Customer [Policy Text Block] Short-term investments Debt Securities, Available-for-Sale, Current Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Amortization of right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Revenues: Revenues [Abstract] Summary of Operating Lease Assets and Liabilities Lessee, Operating Lease, Balance Sheet Information [Table Text Block] Lessee, Operating Lease, Balance Sheet Information [Table Text Block] Total Finite-Lived Intangible Assets, Net Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] TIVDAK TIVDAK [Member] TIVDAK Summary of significant accounting policies Significant Accounting Policies [Text Block] Product and Service [Domain] Product and Service [Domain] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Long Term Incentive Plans Long Term Incentive Plans [Member] Long term incentive plans. Financial Instrument [Axis] Financial Instrument [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Clinical trial and related costs Clinical Trial And Related Costs, Current Clinical Trial And Related Costs, Current Document Period End Date Document Period End Date Total costs and expenses Costs and Expenses Accrued interest receivable Interest Receivable, Current Payables and Accruals [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Payments for lessor-owned assets Payments to Acquire Lessor-Owned Assets Payments to Acquire Lessor-Owned Assets Total Operating Lease, Liability Total assets Assets Selling, general and administrative Selling, General and Administrative Expenses [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Awarded damages for past infringement Litigation Settlement, Amount Awarded from Other Party Income Statement Location [Axis] Income Statement Location [Axis] Estimated future amortization expense, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Accrued liabilities and other Total Accrued Liabilities, Current US Treasury Securities US Treasury Securities US Treasury Securities [Member] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Non-cash activities Non-Cash Activities [Policy Text Block] Non-Cash Activities Inventories Total Inventory, Net Employee compensation and benefits Employee-related Liabilities, Current Variable lease cost Variable Lease, Cost Accounts payable Accounts Payable, Current Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deferred income taxes Deferred Income Taxes and Tax Credits Lease liability Increase (Decrease) In Lease Liability Increase (Decrease) In Lease Liability Net loss per share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Schedule of Share-based Compensation Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Entity Filer Category Entity Filer Category Short-term Investments Short-Term Investments [Member] Shares used in computation of per share amounts - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Share-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies Commitments and Contingencies Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Schedule of Investment and Other Income, Net Marketable Securities [Table Text Block] Preferred stock, $0.001 par value, 5,000 shares authorized; none issued Preferred Stock, Value, Issued Total revenues Collaboration and license agreement revenues Revenue from Contract with Customer, Excluding Assessed Tax Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Long-term liabilities: Liabilities, Noncurrent [Abstract] Cover [Abstract] Cover [Abstract] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based compensation Share-Based Payment Arrangement [Text Block] Work in process Inventory, Work in Process, Net of Reserves Revenue from contracts with customers Revenue from Contract with Customer [Text Block] Cash held in escrow restricted by a contractual agreement Restricted cash included in prepaid expenses and other current assets Restricted Cash and Cash Equivalents, Current Debt securities, due in one year or less, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Royalty revenues Royalty [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Investments [Domain] Investments [Domain] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair value Fair Value Disclosures [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Patent Infringement Patent Infringement [Member] Patent Infringement Summary Of Significant Accounting Policy [Table] Summary Of Significant Accounting Policy [Table] Summary Of Significant Accounting Policy [Table] Issuance of common stock for stock option exercises and employee stock purchase plan (in shares) Stock Issued During Period, Shares, Stock Options Exercised And Employee Stock Purchase Plan Stock Issued During Period, Shares, Stock Options Exercised And Employee Stock Purchase Plan Estimated future amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense Other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Current Fiscal Year End Date Current Fiscal Year End Date Accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Collaboration and license agreement revenues License and Service [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Investment and other income, net Investment Income, Net Investment and other income (loss), net Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income taxes Income Tax Disclosure [Text Block] Debt securities, due in one to two years, fair value Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Fair Value Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Fair Value Option to extend Lessee, Operating Lease, Option to Extend, Number Lessee, Operating Lease, Option to Extend, Number Other Other Sundry Liabilities, Current Finished goods Inventory, Finished Goods, Net of Reserves Equity Securities Equity Securities [Member] TUKYSA Tukysa [Member] Tukysa Amortization of intangible assets Amortization expense Amortization of Intangible Assets Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Entity Address Entity Address, Address Line One Gross-to-net deductions and third-party royalties Accrued Gross-To-Net Deductions And Royalties, Current Accrued Gross-To-Net Deductions And Royalties, Current Schedule of Cash, Cash Equivalents, and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Total stockholders’ equity Beginning Ending Stockholders' Equity Attributable to Parent Product and Service [Axis] Product and Service [Axis] Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Amortization of premiums, accretion of discounts, and (gains) losses on debt securities Debt Securities, Realized Gain (Loss) And Accretion (Amortization) Of Discounts And Premiums Debt Securities, Realized Gain (Loss) And Accretion (Amortization) Of Discounts And Premiums Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Entity Interactive Data Current Entity Interactive Data Current Less: accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Unrealized loss on securities available-for-sale, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Estimated future amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Inventories Inventory Disclosure [Text Block] Accumulated deficit Retained Earnings [Member] Subsequent Event [Table] Subsequent Event [Table] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Total lease cost Lease, Cost Common stock Common Stock [Member] Other Non-current Assets Other Noncurrent Assets [Member] Summary of Supplemental Operating Lease Information Lease, Cost [Table Text Block] Number of reporting segments Number of Reportable Segments Statement [Table] Statement [Table] Summary of Collaboration and License Agreement Revenues by Collaborator Disaggregation of Revenue [Table Text Block] Acceleration period following separation Share-Based Compensation Arrangement by Share-Based Payment Award, Acceleration Period Following Separation Share-Based Compensation Arrangement by Share-Based Payment Award, Acceleration Period Following Separation Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Renewal term Lessee, Operating Lease, Renewal Term Estimated future amortization expense, remainder of fiscal year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Losses (gains) on equity securities Equity Securities, FV-NI, Realized Gain (Loss) ADCETRIS Adcetris [Member] Adcetris Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Estimated future amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Purchases of securities Payments to Acquire Marketable Securities Entity Central Index Key Entity Central Index Key Equity Components [Axis] Equity Components [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Measurements Recurring Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Document Fiscal Year Focus Document Fiscal Year Focus Schedule of Amortization Expense Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Issuance of common stock for stock option exercises and employee stock purchase plan Stock Issued During Period, Value, Stock Options Exercised And Employee Stock Purchase Plan Stock Issued During Period, Value, Stock Options Exercised And Employee Stock Purchase Plan City Area Code City Area Code Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross carrying value Finite-Lived Intangible Assets, Gross Selling, general and administrative Selling, General and Administrative Expense Proceeds from maturities of securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Net product sales Product [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated other comprehensive income AOCI Attributable to Parent [Member] Number of petitions filed Loss Contingency, Number Of Petitions Filed Loss Contingency, Number Of Petitions Filed Share-based compensation Share-Based Payment Arrangement, Noncash Expense Other long-term liabilities Other Liabilities, Noncurrent Document Transition Report Document Transition Report Other liabilities Increase (Decrease) in Other Operating Liabilities Local Phone Number Local Phone Number Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Loss from operations Operating Income (Loss) Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Inventories Increase (Decrease) in Inventories Weighted Average Weighted Average [Member] Rentable building and complex constructed (in acres) Rentable Building And Complex Constructed Rentable Building And Complex Constructed Estimated future amortization expense, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Right-of-use assets in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Beginning (in shares) Ending (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Customer [Domain] Customer [Domain] EX-101.PRE 12 sgen-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 ex101-seagenxabbvieincxs001.jpg begin 644 ex101-seagenxabbvieincxs001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/U'6[#2KBU@N MY9%ENF*0(D+R&1@"2!M!YP"<>@J:RU&VO_-\@R[HF"NLL+QLIP#T8 ]#UH M M452O]5L],>T2[D9#=SK;PXC9@TC= 2!@=#UQ4UU>168A,HD/FRK$OEQL_P S M=,X!P/<\"@">BJ>FZK9ZM%-+9R,ZPS/;R;HV0JZ'### '@U);WL-SYVSS%\F M8PMYD;)EACIN W#D8(X- %BBH;JZ@LK66ZN95B@B4N[L>% [U7;6+!=,M]1- MP/LMP$,+A23)OQM"KC))R.,9H O45!9WMOJ%N)[6421[F4G!!#*2&4@\@@@@ M@\@BHX-4LKG4KG3H;A'N[5$>:(9R@;.W/;G:?RH MT444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 <9XU$A\2>#!#*D4AU*7:[KN _T:7MD9_.I=:_M#^Q-0@AUI?[:CD62 M!K=-@8L?W<3+D\-@J><@'=D5TEUIMC?,K7EE;7!7[IFB5\?3(I(M*TZ *(;" MUC"OYBA(5&'QC<,#K[T <#=WQUGP[X?N#=3I=R:_$MRC$;[68%PT0!R!L/ S MU&#SFG1ZMJ<%O' -4N'%OXI6PW.5+20D@[&.,G[V/7BN[.D:86+'3K0L7\PG MR%R7_O=.OO1_9.FG/_$OM.9/-_U*_?\ [W3K[T ><6YU"RCO=2T[4KE9U\4O M;_81M,4Z/.%<$8SG:2V<\;<],T^_N[F[C O=2N2D'BY;_O7I"Z?9)>->+:6ZW3##3B,!R/=L9IG]EZ?Y4D?V&U\N5Q)(ODKAV!R"1CD MY[T 1ZP5/A^_(.5^RR8.)HIHTDC889'4$$>X-1BRM!:?9!:PBVQCR?+&S'IMZ4 N2K9AW \PB-%<+GK\R2<#^Z:GL,?\+.UW_L%6/_HRYKH?L=KL@3[- M#M@.Z$>6,1G!&5]."1QZT+96J73726T*W#C#2B,!V'N>M $]%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?J6 ML0Z9/9P/#/-/>2-'#'" 2Q52YZD <*>]3WVH6FF6OVF]G2"$,J[Y#@98X S[ MD@5B>(/^1K\)?]?D_P#Z32ULZCIT&JV36ESYAB8@D)(R9P6$V]"%WJ?O1L5#;6'9@&&1VHLM8AO-4O-.\F>&YM$CD=90,%' M+A6!!/7RV]Z9X?T*V\.Z3%86SRNJJNYI')RP4*2!G"YQG"X&23CFL_3O^2C: M_P#]@ZP_]#N: .DILDB11M)(ZHB LS,< =236#>Z/?3WDLL;?(S9'_$RNH_ M_'5; _"JGC#2-1OOAIJVEV6YK^2S=$596I4,W)R,CGUH T%\4V+VD=Z(; MS[!*R+%=>0=C[B I ^\%)(^8@+WSBA/%%G+=W]K#;7TLU@XCN5C@+;&*A@.. MN5(/&>M,TGQ#HFHZ1:_9KB!P\:H+0$&13C!0Q]01T((XQS7)6%U:MXH\V]Y&TL+VT3."HQDGTZ@^W\P+E\S!@N#]TD=\<=2.U='X/N]#3P1!#I7^C6UG"T5QO=1O]/M[A7NK!D6XC'5"Z[E_,5R7@?5[32?@]H^H3RQ^7;Z>N[YP,L!]S MZD\8]:S7%SX/\3Z'K.HM910ZENT^_EBN"PDDR 3QDU87Q#I\VA0:S;2-I /IWZ&N,:]M1XC^(V;F'BPM\_..T$@/\Q4>I6%SX:EAGTB,W/A[6+JW M,\$1R+.WA3?(\AP%%4TU^W,]K M%+:WMO\ :WV6[30$!SM+<_W.%/#;3[5B_$BUN9_#EK/!%)/#9:E:W=U#&I9I M((Y S@ =<#G'M6P=6TS6+/RM.U"VN9)T)A:!Q(5..'XZ >OX=: (W\4ZK $')4$#!R>#4LGB72XM9LM*EGV7%_&TMFQ'[NX M"@$[&'!."#CKBN6\(:C9:-\,[?3M2*07EA;M;75FQ_>&09&T+U8OU&,[MPQG M-9NE^%H[KP_X8\,ZW-Y6HP:1*RE) )K64/ 49#V9>GX$=* .\OO$%IIW]H&X MCN EA;BZN'6/(6,[OF'//W&X'/'TID/B.VG2)UM;T)-"9HF: @.H&>#TS@YP M>3S7#W%_J;^'/&T'B")8;^ST46TDP^6.Y^6X*RI[,&''9LCM73>'H6MO"\5] M-K$ES:R:9"%6;RPD6%.2"JCKD#G)^7K0!87QII3V&E7J)=O!JS;+(K 293M+ M#CJ.%)YQTJ[:>(;"^NKFSA:47UL@DDM)8FCE"GHP#8W#MD9&>,UYKIE_9Q>$ M/A:9+J!!'O:71413&W(4Y.!GTYXYJSI7B'3]:: M^BLI':XL93#Q['H?6N%^'=]:6_@OPR[^(^5&PZ?OB.]FW*J@ M !\Y8'D]N?469=-F::Z\3^&FBFUBRO)XY[='&V]@WDF)O1AU4]C[&@#I9_&. MFVVGO?RPWHMH[G3W]S%>Q6\"Q.[-;,/ MED)5"!WR1CCIWK!U.ZCF^!NH7+ PB;1YBJR_*P+(V%(]><8]:3QS='L>*TVMN&&_>1]/7O0!V6J:Q9:+I,NIZE*+:UB"F1G_AR0!G'N0*;K6M6 MF@:1-JE\9!:0 &1XTWE03C.!R>2.E8>N>5XFU(Z+ +.\MX+>G4H:XS4-;$_P3US2K^[A?4](!TZX(D!WE' 1QZ[EP<^N?2@#UR)_ M,B5RC)N&=K=1]:S[O7;6SUFUTF2.=KN[C>2%43(=4QNYS@8W#KZTMOX@TF\O M(K2SU&UNIY%+A()5D(4=6.#P.0,^I%<]K=S GQ4\+H\T:N+*^&TL >?)Q^># M^1H WM)\0Z?KEITE;2Y\-&4WC,,.!AP1S@]J .X;Q'81P1O()TEEG-O%; M-"PEDD R0%Z].<],HH V=-\::-J;:<(I9XQJ2EK)IH&19 MP!DA6(QG'.#@UC#'ITSS7EOA%DM=+ M\#:AK5R)M%CM0EJX(5+.\(*_O<=05)"DG /4<@UMZQ,+#Q%=^*],'VN;3]16 MWO(+8AGEM98(%( '4JX5A]&H [>/Q!I\WB.?08I&>_MX5GF15.V-&Z9/3)]. MO-3KJUBVMR:.+A3?I;KK37.EC2O'LJ6L<2W?F74BSDN]I/M385V@90"(\$\H3WH M [;4?%>GZ7<^36^NV3JV\89?,SD'N,=Z=XPN(( MO%7@H/-&I.I2-\S 1QR*@F\7:+;II.M8/@FY@\/V M&L:=K-S%:WD&I7-Q(T[A/-CDW$-G.=CK#(DS(,'E3R&'<$CH: /1WU"--4BT\QR^=+$TJL%^7:I4-S]67C MW^M1ZAK%IIT]O;2%Y+JYSY%O$NYY,=3CL!D9)P!D<\BN5\-G6+/Q;%H>L"2X M-A8S_9M1;I=0M)#MW?\ 31=I#>O![TZ_E71_BO%JFI2+#I]WI/V.WN9#B-)E ME+LA;HI8$$9Z[<=J .@;Q)IT,=Z]V\EI]B1'N!<1E=H06EQ%<6LUR#]F6XCV^=@9(4YP&QSM.#@'C@US?CHKJ>EV%[IP^UP:= MJMI=WA@&_?#&Y+ 8^]MSN([8IWC"6'Q!)X0D M=!CY1ZEL4 ='I7B'3]9>^BLY':XL)3#] M_)#>BVCMVN9'%LQ"1KG+-CI]UN.O%QU=;IK&=9A:W#VLVW^&1/O+^M9$VL1V'@ MRQFM[B 7%S!#;VC.XVM*X"K]0"6+:1XO\RXMS&?$GS;G& M""T'7VX/Y&K$5A>^%O$>E:-;QO<>'+J]\ZQD!S]B?8Y:$_[!Y*'MR/2@#J(_ M%=E,U^L5M?2'3Y6AN?+MRVQPH8CCKPP/&>M/F\3V46KOI8AO)+M+=;HK% 7' ME,2 V1[@C'7CI7&Z+>68U3QB[>)DTX#6=^WS80K*(8*]/AFU:)HKHMI**]YMA)V*R[@1_>^4$\9K(\&0R7'B7Q M7KD4;QZ9J-S"+3(-/DT6WU>VD:YLKCR_*D@&[=O(5>/J0/;OT-6;[48[".%I(9Y&FD\M$ MAC+MNVEN<=!A3STK@=3L+GPS>02:3&;GPYJ]];-+#$7((B20[!4.WK@E@.G>L3P!=6_P#PKZZD\^+8EW?EFWC" M@W$I!)[<$'\:Y*0>7\!M&F?5W,6RP'D-Y07(GBRN=N[C!/7MS0!ZE_PD-DNM M2:3*)8KJ*U%Y)O7")%DC<6SCJ",=>/2FV?B.SO9K2-(;N,7BE[:22!E250N[ M(/;CG#8)]*YF[O;$?%#4C,\M>'KS?Y5O,PDGTX+&2&5QR8_X,-R-P&: .TU77[31KFRM[E+AI+V0Q6XB MB+[W"EL<=. 3SZ4MCX@T[4+NYLXYGCN[90\UO/&T3JIZ-A@,K_M#(]ZY[QM= MVUMXC\&FXN(H@NINQ,CA<#[/*,\]LD#\:P_%ME<>,/$4Y\.OY@MM#O+6:[C/ M[N224 1PA^A(()..F>>: .T'BS3/LB7Q,ZZ;(P5+]H\0G)P#GJ%)Z.1M/KBK M=WK5K:WZ:>JRW%\\?FBW@7W& ME_88]/'^N$YCV"/9U!#=?0#/3FHO"X;PMXPU6V\07212WUE8_9;F9\)-Y4.R M1 QXW!\MCKALT =1-XNTVW$?F)=AI+U=/"F!@1.RA@A!]01\WW?>M*YU*.VO M;>T:&9Y;A6:/8H(^7DY.>.HZ^M;3](U.##6=IK=K/H4^E %O0M?T[Q' M8O>:;,TD45(/0]/S%9S>.=$_LK4]426:2QTVX-M)+8022PD,MM=1\>:>P_=;C[F(>M9=[)86W MPS^(%K;30I%'JSQQ*KCA0(0H'Y?I0!ZH=N1SD=:I6^I6,-]<@^)%U#SK;* MQ-)$?)";BSG8!@'
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a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�!KT5S4OCW0+?1[_4I[B>*+3I?)NXVMI/,@?L&4#(! MR,'H<]:TM(U^QUN2[2R,Y^RN$=I('C#9&05+ ;E([CC\Q0!6T[PW]CUJYU.Y MU6_OY'=VMXKEP4M5K<2RE+ H+V6.%G2V MW\KO('H0>,X!R<5=OMG!O#CZ8D]]:ZS,P2>&!V5456)& ,[\KC;C(YSCOHV=]I=QXVO(8;V_.HQ MV49EM)/,6%(]QPX5@!N))&1GI0!T-%8'_"9:-OMF:>5;:ZF\BWNVA802R9(" MA\8Y(.#T/8FH[OQQHEG?W]@S7DMY8HKSP06J3:;YMT]U!<1V\J)9RGRW MD^Z3\O"]/FZF1C. M:EO_ !/ING2722&XE^QJ&NFMX&D%N,9^+="T:PT.WEN[QQ?6RFS:2&262=1'NY8 Y<@#C[Q) M''-6H_%NFSV%O=6Z7DYGA,ZP1VKF4(#@EDQE>00,]<<9H W:*Q8O%FC7&E6. MHVMW]I@OVV6@A0L\SWNX3&JQRW/D1F% M68D*#L3)/H*Z\^,-$-YI-LER\K:NA>Q>.%V28 ;CAP,# Y()!H W:*IPZI;3 MZK7,;!0&SM^;&">#P#GBKE !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_$J MUN;GPO"UM;37!@U"UN)$AC+L(TE5F(4+_%-K?:5YD4 M%II=Y UX\;1AY)E"H@R 3MPS'L.!UK-\)36-]::/H^H^$]037=->(2"Y@?R( M7CP/.60G;T!*XY).!QS7J=% ''_$RPU&^\'L=,MWNIK6Z@NGM8_O3I'(&9 . MYXSCOBLBYU>/7OB'X2U"PM-2^RK:WJ23/82H(F=8P V5XY&,]/>O1Z* /(?" MJ6L>DVGA37/"M_/K5BXB'F0R-;2[6^682?<"XP<]<] 3Q4ML;;2M8U[0O$?A MS4[\WNH37-G)! \L-U%*VX(2#M4KG!W8 '4UZS10!P-A&UI\5BYLI8+:+P]% M;;HX7,*.LK,8U?&#A<5RL]O=/\$-=L%L+XWDNH3-';_9)/,8-=;P0NW.-O.: M]HHH \QU.ZCT7Q[J-]JVDZE>:1J]O UKR^SV\#2&Q9Y1(K.B D;@ #C.#D5ZC10!PW@61Y/$WC" M9K2\ABN;])H7GMGC$B^4BY!8#G(Z=?:J?BYWT7Q]::W?Z9?7NBW&G_8Y'LD= MVMI5D+AF5.=K!L?45Z+10!Y?XLMK-9_/UKP=+!!=31Q:H)Y6CMI&$8 M:C/'H?C[69=;T?4KS3-72"2TN;.&24*RQA&B=4Y!.,CCN:21I/!OBO2=9&@W M4&@3:6UB8+. RM8OYID7>YP,^H44 >=>*VDN=(\.ZG;Z-=06EO MX@@NY(8[5C*L.'!D:-06!+-G&,X(R,Y%7-[R_&*RO/LMVMNV@O"9&MW"K(TR M.$+8P&V@G&:[FB@#S]-#O[/X@7^G00,= U9H]4F?^&.:,@2)]781,?4;JI:M M,F@?$+5I]:TC4;S2]6B@:UN;**241NB;&C=4YYZCCN??'IM% &9X?M8++0K6 M"VTU=-@ )CM /*4L2 0.AYR1V)->4ZI&7U&SULSQK/I4\#/;:F, M( <$8!VG!=3QM.<=:[OQ;IMUK/A#6--LG"75U9RQ1$G W%2 ">P/3\:V:* / M+[U9O%?@GP[HD-E=6VJP7-H;B.2!T^QF$CS'+$8QA2%(/S9&*V [#XTO.;>Y M^S_V&MMY_P!G?R_-\\MMWXQG!SUKN** .3^)EE=:C\-]X>W^2*-=S M-A@2 !U. >*RM4O?[1\<^!K^"SO_ +-&+PR2/9R+Y8>(*I;*_+DY SC\J]!H MH \>O]/U.]M?&S:?874LRZU;:A! \3QB[CB\HL$) SDH>G<"NL\+7>C:WJL> MI:=X?OK:>*$I+=7]N\;Q9Q^Z4O\ >.>3C@8Z\BNUHH YKQC<>?:V^AA;H#5) M1!/-# [B*#DR$L 0NX#8,]W![5S'CS1[O0Y=#\3:?-JFI7^EWB@6ZQ"5I+=_ MEE4!$&.,'GCBO3** .$O;@7?Q1\.7T-O=FU&G7*-,;60*C.4VAB5^4G:>#6' M&DQ\&_$J#['>>;>WEXULAM9 TP>%54H-OS D$<5ZO10!Y+-*^BZOH6LZEI6I M76CW&AP64C6T,ADM9T)/SHN& .XCIU%6M7MK>.+PF^F:%<$9P<@>H44 >2^(=+U'6=6^(MGI\%RLU]IMI';.T3(DS('W MHKD8)P0O7O4^I:ZNNR^")[?2]422TU)&O(6T^8&V(A=2#\O.">V>*]3HH \Q MM?,%M\2@;2\'VN61K<&UD_? VZH-GR_-\PQQ4,XF_P"$<^&J44 >2V?V;3-2USP_XC\-ZG?R76H3W%H\,#RPW<4K MEPI(.U2"<'=@#'6MS35-I\4[R1K2:&V30X+<.D#F(.CN2BMC!P"*[ZB@#QBQ MMKN#X:>%6?3[\-IWB-;FZB^R2>9'%Y\IW;-NXC#J> >M>Q)<*UJMPRR(I3?M M=2& QGD=<^U2T4 >5^!CIMOI_B.'6])N@;K6;N9!-I9"Y&TCY#P>:N^-+ MM]2\"V!MM-OPIU*V,,'V61I?)BF7+LFW*\*3SS@COQ7H]% '"^+9_,\8>"YX MH+J6&"[FEFDCMI&6-6A906('') YK(NY8=#\;Z]'KVBZE>V&KO'/9W-I!),K M?NEC:)U3H?EXR.0:]1HH \P:67P7XQLM4ET.ZBT*[TE+,1V4!F-C(LC.$94R M0"'ZC/-6_$YE>W\*:I%HUU;V=OK2SR00VK-)'$R2#>T: D$E@2,9&X9YS7HE M% '#PM))\9?M7V6Z2!M 6'S7@8()/.+["V-N[:RT._L?'NHZ5' W_"/ MWLR:SYG\*2@X>+ZM(LM>@44 >9:K*F@?$'5YM;TC4KS2]6C@:UN;**2 M4(Z)L:)U3D9QD<=S7=Z!:P66A6L%MIRZ= JDQV@ 'E*6) (' /.2.Q)ZUI44 M >;>&]033_B'XVO+JUU%+:\EM3;2"PG990D6UMI"'.#3ET[5=;\;7GC%]*EB MM=.TV2UTNSN5V2W4AR2S*>44YV@'!YS@5Z/10!X]I]Q<76L^ =3;3]7+V[3Q MWB?8)(HK5VMV41)'@!5#'&[&,#EN*FDTS5+OP[X_T.UL;I=1FU::^MP\++'- M'F)E D.%.[:1@'/KBO6Z* .#\,7VCZ_JEE>6WAG4+6_M5;S9M0@D0VA*D,BL M_P!XDX&%[9)QP#N>-M$D\0>$K^RMSMO HFM''5)T.^,CT^8 ?B:Z"B@#RF:P M\1W.HZ+XH@MYH+W78FT^_@!.;.%T#1OCL4VLQSWK;S02I;.T;HMOM;# M 8SN&,=&YC^&G@"V:QOA<6>JV;W$7V23?$J,Q=F&W( !Z^]>Q44 M>?>'YY/#.O\ BJTUBWN6CO[YM0LYTMWD6XC=%'EC:#\R[0-IYYXXK!L=%OO" M&C_#N?4K:Y:+3+BZ-X((FF:W\])-@(0$X!8*2,UZ_10!Y+-!>ZG;_%&.'3+] M7OX%:U62V=?._P!&"X7C&[./EZ\\@'(KT/PQ=K>^&["18;B(+ B;;B%HFR% M/RL >N1TYQQQ@UKT4 >,>*I[[5- \36TFDZG'>P:JC16EI9.L+0K-&?/+*,2 MLR@DY+'T48)KK+*X+?%J^OVM;R.U?1(8UEDMI%7>)'8KG&-P!!QU_&N[HH \ MR\+>'6U[X/2:'>\D3@$ _W3QVKH? SCTK3U[1;K63:K;ZW>Z;%&S>*TMHK:"-8X8D$<:+T50, #\* .-^)_F/X=LHH;>YGD_M*UDV M00/(0J2JS$A0< 5!K5T--^)NC:U-;WHBZN-?EEB@^R.S2*;E&RN 0PPK<@D<5V?CTO)'X6 MU*"VNI[:UUF&>;R;=Y'2/8Z[B@!;&6';O7;T4 <)I\Y'Q6U:^DM;N*VDTBW1 M9'MG"[U9V9*QU'X;^)[G0M O86U&**-6:UD$]VZGKL(+;0. 3[]@ M"?4+25)[.&6,,$9 0&0J1]0>14U% 'D/C*6^U.R\<::^EZC'WEB+?(\8& MY0P8GIU[=<>G44 >=^(?-2Z\&:JNCW-M96VHRO)!!;,[PH\;JI9$!())!(QP M6P>:+FVN=1^(^NI#%WGAC9)(IXFC93O8\A M@#T(J'POO'Q%\:R-;W$<=S):&&5X'5) D(5MK$8.&XKMZ* /(/"\=K#I,'A+ M7O"VH7.LVIZ=J!N;NYN M[VTGBMG>*>*1./W@&U2H&#N( P*]4JIJEF^H:5=623"$W$31>84W;0PP3C(Y MP: /+[-GL-*^%>M2V]S)86=DT=Q)! \IC,EL%0E4!."1C.*FA:XET_XF[M.U M",WH=K97M'S+NM@@"X')SVZC/('->A>'M).@^'['2?M'VA;.%8$DV;254 #( MR><"M.@#RX^8)OA@QL[S%G$?M/\ HLA\@_9MGS_+\OS<DT4 >6W4!\/:_P"%M?MM!N;3 M0(ENH9;:"!FDM?-(*RO&N2-V.>XS@\\5K^$)VN/B#XRNA:7L5O=M9O!+-:R1 MK(%@ ."P'.<<'GFN[HH X#3+I=#\9^,CJ%G=[;V:&:U5+5Y!31_P"T[R$PWNIO]LFC)R8P MP 1/^ H$4^X)[UNT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$! end GRAPHIC 14 ex101-seagenxabbvieincxs002.jpg begin 644 ex101-seagenxabbvieincxs002.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0L P4D9/0>M+0 4444 M%%%% !112,RH,L0!ZDT +1110 444@8$D @D=1Z4 +1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=80P4N(Y58@$D#. >IH PM4N'M?BSH]ZFE3O>3:-<@VT90NQ$B8!;.T< M=R3 M6;2VN9(]EU$21L)#$*2K-UQSB@#N-&\6VVJZ[?:)) UMJ-I&LQ3S%D62)N Z MLIYYX(."#7,_%2*T6]\(2W/EI')K<,,\C-M#1%6)5C_=XZ'BNE\-7-_?NUS< M^'!HD03;Y[2PU:*\N'1XU M"QJ&!^\P)//04 8VAWZ6'Q)U@Z)$[?3//N_+=I8(KD'.(CR,[!DJOOWQ M74V'C*.[U'2[.?3;FV.K6CW=B693O50K%6 /RMA@<I6FC:_:7]A+9R76I M7=Q#YKHP9)6)4_*QQUY!KG9=$\13?!2W\-_V#<+J5O\ 9H?+\Z+Y_+F1V8'? MC;A>,G)/;N0#N]4\21V-[+8VUN;N\AA$\D0F2,*I)"C+$?,VUL#VYQQFCIWC MO3M;M=)DTB-[B74X99X8I&6,JL;!7!S_ !!CC SW/3FL?5K36M'\;SZ[:>'3 MK6G:I:PQSP*T8FMI8]V" YP5(;G!Z_3F;7="&N6VGVVM^'9-@229+C39 LNG MREAM56!!)*]2 1E>1C% '8Z;>G4=.ANVMY;9I!DPS8WH$+;5[/PK8V^NSM/J M**PDD<@L1N.S<1P6V[02,\YY/6N332-9^P_$*,Z/H?V:T:*A:"XRGZ:.OV&MZC9^')HM ,3P:W#?2VL$D68(45@=QW ,_. M<+GKC)QD@&W'XO9TAADTBXMM3D620V5S+&A1%;;N9MQ&&/3&<\]@36%>_$=[ MS3-"N]%L)76^U==/N5D9 \+J26CQG!)"D9SC!SG-3^)[#6+#QG:>)=/T4:U: M267V&[LPR"6/#EUD3=P?O$$9IOB'3M:O])T"^AT0)-9ZW#?R:=;R1ATA".I& MXD(S_,"><LO$FCPZG8,_DR$J4D7:\;J<,C#L0017,V-EJWA_P B(JZ6UY=:GJ\ES=113*HM$FW\MG&SS+ IV MA$VC*EVX+<8 X.2*[FN1U#2[G3OB-;^)XK>2YM)]..GW2Q+N>$A_,1]O5@>5 M..1P?7 !J>&-0T74])\[0MHMUD:.1/+*.DB\,L@;Y@X[YYK:KB/"UGJ&C^(M M2:32+A(-"J_=3 5LXQVJO_PF]G&FF7-S97EMIVIR+':WLH786<93< VY W8D?7%2 MZK;W?BKP_JFFK;RV-O=V(O FD^%KW M2[BTO;>2VCO)FQY2)"RDNC@_-N"< <_-SC% '51>+;:6?7K=;&]\_1-AN(R( M\N&3>"AWX/R\\D53;Q_IXB\/2)8:C(NNQF2TV1*2/D+[6^;AL#Z<\D#)K(GM M-7T[Q;XR\K1KJ[BUNWA:UN(BGEJ4@\ME K M$JQ!7!SP2:U+3Q(PTO2_M-G<'4;V+=';EHPSA54M)D-M"_,.^>0,/F'?'6F:I8ZUM\,>(8_#,EZMA;/9WFES M^69C&P3]X@R5R&3IG)&.G. #;D^)>E0Z1-?R6=^&MK\:?=0!%9X)2P W8;!4 MY&"I.:DE^($-K>6EI>>'];M[B\GF@MXW@0F0QINR,.>#P![]< $UC^)++4M5 M\()]A\,26;R:A;3I91I&)1''(K,TF#M!(!PN3V]2!;\:71A\;>!+A;>:7_2; MHF-%^?!MSDX]ASCKQQDT 7;7XC:7+IVM7%[:7^GW&C8-Y9W$0\U0WW"H4D,& M['/Z;$25^4JQ&01@@X_$5R^JZ9XA:Z\ M4^)M#M9(KZYM;>TL8G 661$;,DF&X5B&(4-S\O(Y%&EV-_:_$$ZQ%X=U""PG MT7R&>:1'E\P2ECYGSDEB, ;CPGG6_AKQOX'6W2[N5274=D8=I'8-&S*@W'L6P"3P.I K4N[ M._;XQ6.K+IURVG1:4]H]R%&T2-)N QG.,#KC'-6?$EG>S^/O"-[!93S6MBUT M;F9 ,1^9%L7OD\^F<4 $OBW3-6\)^()M0TJ_6+3Q+;ZE8.%\T*$RV"KX(*'. M0U7;/7[&WLM$L=-LIG>[L!<6MJ'4%(%5.I9NHWJ,9.?H":YAM+U1K+XC(-+N MMVK!_L(VC]]FW$8[\?,.^.*DO-!AU30/#MAK&C:E&]IIZA+^RR+BQN%55(!4 MYYP>@(^49[4 =YIM\-2TZ&\$$T'FKGRI@ Z'.,, 2,_C67XMEN7TC^R[";R; M_5&^R0R@9\H$$O)_P% Q'O@=Z?X0BUB#PK81:_*9=25")7;&XC<=N['&[;MS MCOFJ!L'UWQ9BY.!DXXJGIFDWWACXGWSZ?IM]-H.J6T;7,QD\SRKI20&RS%B"O4\\D M>E4%TC5V\#^/;#^RKH76J7]Y+9QD+F5)5 0YS@=#G.,4 =9!XRMI?$%AI6.HRZWX"N4TVZ,6G"7[8=H_<[H#&,\\_-Z9XYK,T M'3M6T%KGP[<^#8]087$K66K%8C"T;N6!F).X%=W( ).,#UH Z>X\7>EI')*D*1@.KAB&5F<#&%Z'!.> ><6HO&.G7.E:/?6:37#:N ;*W0 M 2/\NYLY. % .23@>Y(SDZ=:7UIXZ\77\FG7/V2[MK6.VD5!B5HT<, ,Y'+# M&<5R^D:'X@T+2_ NK?V1?SP :&A:S'I'B MSXBZKQQVB6DLUN"KR +$[,1\V"#RW7OZ\5OCX@VHGTD3:/JL=OJT>ZSN M#$I61]F_R]H;<#CH2 #CKCFL":RUF[N_B%<#0;Z./6-/BAL]YCR[B!TP0&XY M8>PYS@\59N=.U-K+X?*NEW1;2Y8GO0%'[D+ 8SGGGYCVSQ0!T.G^-+&Y36?M MUK=:7-HX5KR&Z"DJC+N5@49@P(!Z'.1BA?&4":[;:1=Z=>6MU>0O-9AS&WG[ M!ED&UCAP.<''UKEM6\,ZKK>J^/8([:6W35;6T2RN)0-DDD*MD'G(&[ Y'3-: M_AF[OKN6![KP0-&N+92;J=HXB&;:1MAV'N0*XZ/0];7X/6&B'1[O^THM169X,+D(+LRYSG'W3Z]:Z MJVM-1M/BC?:@--GDL=1T^WC2Y4J%B9&*#75TB;1=52YGA::R_=IB["D!@OS_(>0 M?GVX'7%1_$S3[W5OA_JFG:=:275W<*BQQ1XR2'4GDD < U#JEO>W?Q&\,ZE% MI]T;.VM;I)Y2H C:0)M!&<_PG..E %F#QYI\GA^^U2>TO;=[&[^PW%FZ*95G M+*H088J&--OK/XA:M?# M0KJST^^L;<)+-(C,&0OGS,,27.1W/N>U &[;^+K2[\-Z9K=M9W M7YF7.!D;\<FW#7-C&/^64UPN63V" O@>DU=EK%M)>:)?VL(!EFMI(T!.!DJ0/YT <%X M1\;VND^%_"-A?Z;J4%K=6=M:Q:B\0$#3&, *3G<,G@$C![<-;/2+>^ MN_L=U=6>GOLO)X"F(CQNP"P+;6*X&,\')QTIEK8ZGX>\1:S97'@X:W;:A?27EE?1B+">8=Q MCE+\J%.>>>.@- 'I5O<17=M%G:MHEI%X8O?!L5Q<6KF.'6"D1MWBS\LCDG=N _A ))'4=0 =1<>/+*TU; M4M+N-.U"*\LH$G6)ECS=*S!5\GY_F)8@=N3CK6I>:ZEK):VPM)I+^YC:5;0, M@957&XLQ;: "RCJ>3QGFN2\6:3J^M7+>(-/LY8-4T&7.EQ.B_P"E@X\S<<_= M<94#(QC<>O#/$,&K/KFC>+(O#,FHP_8WM+_2Y!&9H=S!@Z G:Q!!!P>GZ &] M8^.]+U#35N88KG[4;UM.^PE5\X7*Y+1]=O !;.<8YS4-Y\0+/3M.UJZO-,U& M-]&=!>0JJ%@K@%74[@K*0>QR/2L76M-UN2VT7Q'I/AY+>XTV_:X_LE2B2R0/ M'Y;Y*G;YF"2!D\8'7BKOB6'6O&?P]UVVCTB>P>XM@MI:W3()G8'<=VUBJYP M 3GJ3B@#HKKQ';VGB.RT1[6Z:XO8)9H)%";&$8!89W9!^8=L<]:P_#?C:6_T M;5=4U:QFM(;:^EMTPR,,JXC6,8;)O[:SM[:ZBG M,[1J\9<1@$KNZ9'KDX/&.N3_ ,(QK]SX.\0Z)'IIBO(]8DU&TDG9##<_OQ*B MCG."!@Y ./? !VEOXRLCKLVCZA;S:==):F\4SLA1X0<,0RL0"O<'Z\BN3\8 MZPNL-X+O(M-O(K:?7K1[>YD*A70DD94-D;AAAD=N<'BK@LKWQ;X=U.P3PF/# MLL]C+ \UPD8)D92 J;.2F3RQQQP IRN8XG<(SE03M7J?85PFE>+_#^A^ ].U/3M*O MX=)N;Q[>*%5#O&[3LA+ L3@OD\$GGIVKNV?9$7*MP,[0,GZ?6O)(=#UM/A7I M.D-H]W_:$&KK<2087*QBZ:7=G./ND=^M '?:5XJBU+Q!=:)-IU[87L$"W*)= M!/WT)8J'7:Q[C&#@^U:&KZQ:Z+9I<7.]C)*D$,48R\LCG"HH..2?4@#DD@"N M=2UO7^+7]J_8;@:>VBBT^T%0%\WSM^W&<].^,5)X^T;4=3L=*O=*B\^[TG4H M;\6VX+YZKD,@)X#88XSZ4 7K?Q5"^LSZ/V2:23:-H7KA0IY/!)&,\URMOH6M1?"7P_H[: M1=_VC::C%-- N51+@R$YS@_*1WH [O5_%MOI:Z@\=E)8C)!(456CD$A&%^4'/;W[>A:?%)#I\$76G:?*T5U=0!"J%?OD*6#,$_B('8XS@U'J/CNRLM1 MM+&VT^_U"6]LVO+4VB*RSHH!PI+#G# \X'Z"L#2=,U?0?#/B#PM)I=Q=O-+< MG3[B/!BF2;)&]L_(06.[/;IFI=.\.WVB>*_"$"6L]Q9Z7I$EC/=J!L$C!,=3 MG'RGH.,B@#N[>[:?38KPVL\;21"7[/(H$BDC.TC. W;KUKD$^)VGMH=IKG]D M:JNE33F"6Z:-,0-YIC&Y=VXC*[9VV1L^&.T9PHR3]*\E_L+6_P#A M2O\ 87]CW?\ :?VWS/L^%SM^V>=G.(,%+#:Q(()'#8//2JTWCS3X-.BU>2TNAH:/#HNK7U[:P)<& M.UB1M\;-MW+EAG&#UQ[9IVK>.;'2;6ZOGM+J;3K.;R+JZBV$1,"%;Y2P9@K' M!P#CG&<&J>F:=>6GQ/O+K[%C#G&*Q-,L-4\/ZIJ M>D7'@U-7CN+V:YL=141>7LEN:_P"$WLS_ &=.MC>MINHW0M;:^55*.YR%.T'<$)!PQ'IV(-;TMKYVFO:. MP7?"8BT:[0,C&0.U!3PXYW%BO 7'7 MKCF@#=O?&-O;0ZE7MGIDC1WD]N$(1E +@ L"VT'G ]0,D$5-'XMT^;6 M=*TZ!)Y1JML]U:7*!3$Z*%)_BW X8=N]K=W5QI>$[CP-+#8W&J0Z59SV=U]DVEP\BIA@&(^ M7-9W,02,N'&WD8?!7YUYSGVJY;^+XI MO$7]BRZ7J%M/);O><5P>H:'X@N?!7CO3_["N1= M:IJC7%HBNA#J?*[[N,;#R>/0FNLU"WO;KXD>'=3BT^Y^Q6]G'KS5M6L9K5([R6",!D8,1+Y:1KALELX'( )/7%7?^ M$XM(M2O=-N]/O(+ZVLS?+!^[H)'XUQR>&?$$W@;4M'CTLI?V M6KOJ%L;AD\F[Q<>:JCD\%>NX 9P/7&_8S76I:7?2IX+?1G%I)&RR1Q>;+(PP M%CV'[OJS8[<=< _Q0LH] .NOH6M#3/LL=RMSY*;&WL%V_?Z@D9_$C(P3I6? MCBTG\3PZ#02"/>NFU&QNO$GBKP]?1V4]M#I!FN)7N4V$R,FQ8 MU]>222/E^48)S0!8M?'EC=/I<@LKQ+'5+E[6TNV"[7D7=U7=N4'8V"1VYQ3$ M\=Q3ZQ=Z9:Z%K%S/9W<=K<&.),1[QD.27^[@CW]A7'&P\37]OX:O=0\.ZA-K M-CK"S7\SRQ8*XD'[D;\"/E?[HZ=3DUUOA2TOK?Q=XLN;JPG@@OKJ*6VE<#;( MJQ*AZ'(Y'?'% $&@^.Y;G1-6U;5]/FM8;;4)+5,/&1D2+$L>=WWBQ&2<+SUQ M74:?J&)KZW MFU::8QED*W,$LZG*?-G(0LW.,%1WZ3Z!:ZOX3MMTNI].LIO)NKJ'81&P(5L*6#,%) MP<#CGK@XW-*U!-6TBRU&.-XDNH$F$;_>4, <'WYKSO3;#5/#^K:II-QX-75X MKJ^FNK'45$6S;*Q?;,6Y7:2>0"3V'J =1J7C>RL3J;06=U>Q:7;)=7DL&P!( MW4L-NYAN.T%N.W?/%7Y?$EL9K2WL89;VZN[?[5'%%M7$/'SL6( !) '+6]0U+3GL+NPOM/,?G076S.UP2C MHS @@'OQBL#Q-#K6K)X7N&TB97M]:BO9H8RK&W@5'7YCG!;Y@2%SU(&<9-S1 MK.]B^)?B._ELIX[*[MK6."=@-KM&'W#KD?>'4GWFH)IAQ M>/;;/D;:&*@,P+,%() ]<=>*Y[QIXF^UZ!X=GTB.:[T_5M3LT:6%D EB9\F+ MYF!!;&"",=02*ET.VU/PGJ_B:VETRZOK74;Z34;*:W 8,T@&Z)\GY""HP3Q@ M]:R9?"FIZ'X&\%Z)!:37UQINJVUY=F#!5%$C/)@DC."V .IH [O0="T_1TN9 MK"Q>Q%[()Y;4L-L;XP<*I*KGOMX)K7I$;>BL 1D9PPP1^%+0 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C^(_ M$5MX9L8KV\MKF6W>9(2\ 4B,N0JEMS# )(&: -BBL:/Q);R>*Y/#IM+I+M+; M[5O<)Y;1[MN0=V3SQTXKCO%.KQ7FK>#-62"^A3^UI(O+)R9%$<@R$1B#DC@] M3]* /2J*Y>#Q;I^JZ=KJ7%AJ%O)IBE+VSEC'G!63<"-C$$%0TS($W8>/M?M-<^'^J30I=VM MSIFI6]O/#*2C1OY\8(.TE6!5N.2.:['3?%=KJ'B&?1&LKZSNTM_M4?VJ(*)H MMVW>N"3P2.& //2@#>HJEJVJVVC6!O+K=LWI$JKC+N[!%49(&2S V4]G;!\2.%W9Y!!1B&'7_ XH ] HKF=+\6VDVK66ARV5 M_;37%J9;6:>(+'P=;:\%EJ%XUC;7I5/+DE4L, M8W;P"48 E>WTH ZBBN%T2!6^*?C& O*8WL[(D&5N-PES@YROX8J7X3,S?#73 M"[L[>9<99V))_?R=2>M ':T5YYXAO1I/Q:TJZ6"]NFDTFX_T:V!D9V#QXVJ3 MM'&>>!ZFM[2_'.DZKI$]^B74$EO)9S;W(3+Q$X#J49@1 MG@\Y!JYJVKVNC6LO4@ DD 4 9O\ PA'A[_GR MD_\ J7_ .*H_P"$(\/?\^4G_@5+_P#%5S>F7X'Q?UF:YANK&.+0XY)4NY 0 MO[UB7!#,H7:!T/8UT2>,K(:IIME_Y\I/_ J7_P"*J*\\<:=8I;W,]M=C M3)[D6JZB%0P[RQ49^;?M+ C=MQ[X(-0W'CVSBN=9MH-)U:ZGT@K]ICA@7.UE MW[AN8 C;SCJ<\ \T 6_^$(\/?\^4G_@5+_\ %4?\(1X>_P"?*3_P*E_^*JK% M\0-+FDTATM-0^PZLZ16M^T(6$R.,JAR=V3C&=N,]ZM:OXOM-)@OKDV5[=6NG MG%[/;*A6#@,<@L"V%()V@X!]>* #_A"/#W_/E)_X%2__ !59M]\,/#U]J-I> M'[;"UJ28TCN3M)(P<[LGIQUK7F\2V4TL-I817&I37%J+H):%05A;[KEF90-W M;G)P?0D8/PGE\[PA_Y\I/_ *E_P#BJK:MXHO;'QSI6@PZ7/-#_Y\I/_ J7_P"*K=@GBNK>*X@D62&5 \;J MPJY6)'XIL+NTL)]-674&OX3<6\5OM#-& M,98[RH4 LHY(.3BI?#WB&R\26$MU9B6-H)WMKB"90LD,J'#(P!(R..A(YH U MJ*P]3\3V^G:F^FQV=W>WD=H;V2*W"92(';G+LH))! R>*I3>/M(CMM#N$BO M9XM:'^B-% 6YVEL-[\$8&: .IHK$T#Q-;:_/J%LEI=V=YI\JQW%M=HJNFY=R MGY68$$=.:N:KK%MI$CIM)#*<$<'@]<5BW?CG1M:\*WUS=:-K;:++ MIIN9)OLY59(V&&165N& SGD=.#0!W=%8(U_3["WT6SMX9Y)=0AS9VJD%RBH& M))9L *",DGJ1UK+NO&.BZMX:\0-=V&I_8[!);?4(O*PZ[1^\0%6Z@H,NIVV;)(XC)A5CW!2<_>Q@=^N2<9-.A\>Z4^B:K MJ=S!>6?]ES>1=VT\8\U'.W: %)!W;EP0<E%W9VW7&69B2?W\G4GK0!VM%(RAT93 MG!&#@D'\QTKR?PGXRM/"OAN^-[8ZM/9PZO=K->10F6.W7SB 78G)[=-V.] ' MK-%8L/B:SG\0MHL4,[7/V$7\;C:8Y8BVT%3NZD^N*Y_6/B%M\+V^JZ3IMU+Y MVI+I["3RU,3>:(VR"W)Z@8XSUP* .ZHJ."1I8$D>%X689,&]9O=.M;DWVFB2.>TD"++!(JD_,"VTCH<@G(Z9H V MM(TBUT33UL[4RLH)9Y9Y#))*QZL[-RQ_P Z"K]<-X#TFWO=)T/Q'-:7=OJC: M?&)IVE7%[O16+N%8[N)((_%'_ CYL[O[6UJUW&^$$H:#<:O#8WWEP7)M&@98Q*90X0KMWXSN(')%RE^SV_[QU&R0L?F8*![9Y[ T >ET5QVJ^(?#NI:=X7 MO[F"[N;;4+^W?3WB#*$F;.PO@C@7D-YHIP/4UV7AWQ!:^)=,:]M8IX?+F>WF@N%"R12(<,K $C(]B: -:BN5U_P 4 M7NE>+M T:WTN>XCO_/=Y(VCRPCC)VJ&8<@E22<<# SDXMWOBRVM3J!@L;V^B MTTXO)+54(B.T,5^9@6(4@D*#U]>* -^BL23Q7IACTDVCM>OJP+6208S*H7X'7BJMCXWTR]M]2F:&\MAITIM[D31IY^PW$J+LF(&X+@,64 MD<@,HSTZ\4 =)17+:1XZL];U!;6RTO5F474MI+.;;$<$D8Y$AS\N<8'X9QD5 MM:KJUOI%O%+.'=IIDMX8TQNDD8X"C) ]>I'2@"_17G'Q)U$:A\.=9E-M>64U MC=V\3+*P4Y,D1)&QB&4J_P#.NHL?%MI>^(9M%DLKZSN5MS=1-=1!%GB#;2RX M)(P2.& //2@#?HKF+#QUIVH7&DJEK>1V^KEQ8W4BIY*?B+:F28Q![?'[Y]RYMPQPVQ@M+F_O(X/M$D%L$S''D@$EV47Q[I<&D:O?S6][')I#;;ZS M,0,T7&0< E2I'(8'!]: .IHKF[+QI97>N66EM8ZA;-?PM-9SW$06.<* 6"\Y MR <\@9[9XJ:T\4V]]+:FVL;R2UNIY((;M1&8V9 Y.?FW 'RV )'7'K0!O45P M^E>+WUG2O$\VJZ/>0V-C"X-! MTFZDT_5?*CAW2(72+RBX3YWY? ')..O.<4 =]16):^)H+O5-5TU+*\6\TV** M66)A'\PD!*[2'P?NGJ16!?\ Q ,FG^&+[1]-NI[;6[M8E=O+5E7YB5PS?>.P M^P&>OKQ4%SX[TB"?1HX4N[Q=8C>2SDMH2ZN%3=CMSCC';/..2 #I MJ*YS3O&FFWVG:C=S0W5BVG3_ &>ZM[F,>:CG&T *6#;MRXP3G-36?BFVN/$) MT*YL[NPU P?:8H[D(1-'G!*LC,,@]0<'\* )_$GA^V\4:+-I-[-<1VL^/,$# M*K, 0P&2#CD#I6G$C1Q*C2/*RC!=\9;W. !^0JCK6M6NA64=S="1_-GCMX8X M@"TDCL%51D@LMO&UA%:ZY+<6E]#-H@#7EN8U9U4IO##:Q4@KD]>W. M* .EHKE['QU87NIZ59FQU&W758C)9W,\(6*4A-Y0'=D''J,''!-9'C[Q!!>> M"/$\5G:W]Q':02PR7=LP5(I@O3.\,P4D;L @<^AP =_4<\$=S \,R[HW&&7. M,CT/M[=ZH^'CGPUI1/7['#_Z *YRW\17>NZQXIT6XTRZM[:P5(1(LJ#!,9?< M2K[ANRN ,\=<9(H [155%"J J@8 P *6O-/ /B^VT_P;X1L;RTU#;?1I;)? M&,>29CDA"2=V3@\X(SWZUU6K^+[328+ZY-E>W5IIYQ>SVRH5@X!.06!; ()V M@XSZ\4 =#145M]FMOL]E>26MSA4\OS]Q7& M-V_&X%<[<9]N:6?QO:QZKJNF6^E:K>7FF)&\L4$"_.KAB"I9@#PO?&"0"H/&:TM6\4V^EK?N MEC>7J:>F^\:U"'R!MW<[F7)VX;"Y."/49 -ZBJVGW]MJFG6U_9RB6VN8UEBD M'\2L,@U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *S/$.C0^(?#NH:1<<1W<#1;O[I(X;Z@X/X5IT4 >4OX=\6 M7%AH'B-E\OQ.C"SN5W9$=LZ>42?7#8FQZDCM6_XHTV6+5?!D6GV-Q)::;>AY M#%&6$40B9 3^)' YKMZ* //H;6]C\2^/KEK"[\F_MK=;1Q"V)F2%D8+_ ,"( M'./7IS61!IVNZ-HO@/6K?2+JZDT6T>SU#3T7$VUT12R X#%2@Z=?SKUBB@#S MWQF^K>)/ 5TL.AWL,D]S;-;VCH#.529'9W )"\*<#.>/4X%^2&YE^+-EJ:6= MU]A&C26S3F%@JR-*CA3D9Z*?ITZUV=% &'XMMH+SP[/:W>E/JEK,\:36T8)8 MH7&6&"#E?O<<\<N1>"/%VC6KZIJ6FSPQQZ0EY&QN Q!WI\P#;!\N" MV._X^M44 <+?P7=QXW\&7L5C=FWM+:Y2XD,+ 1-)&BJ&X]5(XZ=ZYB:V\1ZE M8Z!=ZCX>U276+'78Y[TY3RUC#/Q"N[&W!7D =,DD\U[#10!Q>D0W5O\ $GQ+ MJ$]E=1VEQ:6J12^2Q5VC#[P,#MN'U[9J7X8V=WIO@2RL;^TFM;J&2;?%,F"- MTKL/8\,.E=?10!QNN6]U:?$71M<-E=% @3:_8,XW-@]. >>GJM% '*>%98[ MZY:\@\(OH2+$8W>ZMHXIG8D':H4D[!@Y)QDXQT-5_'VGZF\V@:UIEI)?-I%_ MY\UG&1ODC92C% >"P!R!79T4 >8W^FZEXG\6ZV\6E7]G9ZEX:-A'(0C:,%XG!W,S8XP.,Y) M..?1:* /*/"NG7>D6\A\3>/;J2PNQ#?+!]E;R&/G;(/+;;Q_>]<>O2N]HH \I&F:FGP_\ =@= M,O3=Z;J-G+=Q"$YB2+.\GUQD=,Y[5+%9W.@^)M:MK_P7)KEKJ5XUY97L$$4F M-X&8Y2Y&P CJ>QKU&B@#SRVMM5\+>/KJ_DTB:ZT[5;"VASIL>];66$%=FS@A M#N)!Z5H_#>TO[+0KZ'4-.N+*1M2NID6;;EE>1F!&"?7_ S7944 <;X@M;^' MXB>'=6M].N+NUCMKFVE:#;^[9]A4MDC"_*>:QM(L-4T+POXA\*W&F75U/++= M?8)HXRT5RDV2NY^B$%CNW8]LUZ710!E>&M);0?"^EZ2\GFO9VL<#..C%5 )' MMFN9TS[=H/B;Q:\VD7L_]HW*7%D88MZ3@1*FTL.$.0?O[17=T4 >0IX2U'P9 M#X8N7T0>(;6TL)+*_M8(UD>)GD\W?&K?>PQ*]N*]&\-H/[/>9-%32(YI"Z6O MEHD@7 &Z0)D!B0>,G QGG-;%% '#Z^=8G\726">G-Z/INKPZ'\.X+C1K^&32KDF[#19\M?+=-W!/&6Z=>,XQ7KE M% ''>'+:ZB^(7BZ[FM+B*VO#:?9YGC(63RXBKX/L?7KVS1XVTS47U3PYKVGV M[W9TB[=Y[6/&]XI$*,R@]64'('?FNQHH X*\TV?4_%.I^)HK2Z2V30FTZ!'A M9)9Y&W'IC/?I M7HE% 'F>N//9OX*O+?2M2FU"RMY-PM8E>6-?+5'1HF9=REB/F!XVC!Y%-A:W MNO!'B_3;'2]:BUC4(+B>6&_M/+DGEF1D!4#*[<@+P>,<^I[#6/"MMJVIPZG' M?ZCI]_%%Y N+*8*6CSG:RL&4C//(J_IFDQ::KMY]S=7$@ DN+F3?(X&<#H M,G@ #D^IH XDV=\=6^'4W]GWGEZ=!*MXWDM^X+6_E@'_ (%QQGUZIP:=#?$GAA])NO[0O[J]$!:/]P4G9MLAD&5 ;)&=W& ":]/HH \\&F7OA? MQQH]S%IU[J-BF@+I0EM4#%9$D# ODC:".Y.,UAIHFN_\*ZD@?1;L75MX@^W> M0-I:6(7.\E!G)X]<9[5Z_10!%;2O/;1RO"\#.,^7)C:8R5$HE9RF1G/##D<$\ U)\.;6[LM%U"&]M)[:5]3NIU69"NY)) M"RD?@?PKL** .+UJRO\ 3?B/IOB>*VGN]/:P?3KI($+O!EQ(L@0@44 8/@F.:W\$Z M):7,$T%S:V,,$T*IC8'UW?+*3_>45/8 M0W5OX\\87TMC=BUN[:U2WE$#$2M&CA@,#U8?7M72VVDZI#\/O =@^EW MOVO3=4MIKN(0DF)(RVYCZCYATSGMT-:]M/K7A+QCKRG0-0U33M8N%N[6>R"D MQR;%1DDW,-H^48)XQ^GH=% '#S0:BWQ,T74+BRE\J'2IH+B:&-FB25V1@H., MD?*>?Y5/\/[6ZLXO$*W=I/;FXUJZNH?-C*[XG(*L/K@\=1WKL:* .-\5VM^G MC3PGJ]KIUQ>V]FUW'.+?:60R1A4)R1QD#]'\"VJ65[>ZII:SN[Z>JS.B MNO[Q?+9EW(6=1NR,;1T)%23:?_;OA37+#2=-U*#7I+R/5I(-8MA#]J=9%; Y M*[,(% SQQGKFN[UGPK;:OJ4&I)?ZAI]_#$81<64P0M&3G:RL&4C//(J[IFDQ M::';[1#P4VA2+;NDLMU;QQL M7(QLC*\E>Y8X' X.>.:2PUAOACX8TE]#U".\TZ^LS-&8P3MBDR[#!/RX''KG M@5ZY10!YWK6BWFM^.-;6.WN(K2_\,MIL=V\3!!,7 P.>G;K3?"37#I8 M6%]X#%AJ=D%%S?R6T7D?)U>)U.YF;' X)Z\<^C44 <=\/;:[L[77([RSN+9 MIM8NKJ(31E=\4CY5A^';J*T/&5E::EHT=E?Z5-J-E-.JS) "9(A@D2+MYRK! M>G.">O2NAHH \CU31O$)^'VOZ.IU/5;=KRW&E&ZC/VEHE>-WWY . 0P!;!./ M<5TFHQ7\OQ+L=3L[&X>&/1YX!+)"RH)F9616R,C[O)[5W%% 'D5O;:]>7'@_ M4[OP_JTFHV=ZQU%Y=@"LT;K^[7=A8P2.0 ,8ZG-='I,%W;^*?'5W+87:P7I@ M:U?R6_?!( C;?^!#OUZ]*[JB@#E_AU:7.G_#_1K&]MI;:ZMK<12Q2K@JP_G] M161?OJ_A?XAW^L1:->ZKI6KVT,;FQ57DMY8MP *DCY2&/.>M=_10!P6IVFLP M>+?#_BN33Y)(HX)[2]M+?]Y);I(0R, /OD8 ;;GVR*S->T"_O[3QWJ]O97)? M6+**RLK;RR))=B$;V7JN2V!NP<+SC(KU"B@#@;NVO)O$_@.Z2PO#!8Q3BZ?R M&'DEX0BAN/[P(XSZ]*H:;HMW:>(].U+0+;4]*DN;LG6=-F1OL90AMTJY^4,3 MMQM.>>0,&O3:* /.])L]3T_3?'&GSZ3>;KJ]O+FWE50R3+*H"!<'))[\8&.2 M*J'3-5M_"OP\E72KR671YH1>6Z(/,3$#1DX)&0&(YS7I]% '!(NIZ5\1-9O# MHM[<0ZO8VRPR0A2D%-3\3V5WIMY>0:A?RZC936\1D67S0,Q,1PA!&,M@8/6LK2O"^H>'9OAU M8O;SW TI;IKV:%"R1-+&V!GN-S8X[#)Q7J=% 'E&I>'=8U9/'"6EA(L]S?VM M[8K"FT)XD(FENK>.-BQ_@C*G)' M;6(-'M6TBVGG!O8A>+:@&86^3O,>?XN@XY )(P>1QAT MO4HI/B"D/A_48H=6TZ-;,OAR[^0Z88[B=Q9AG.<=R*]8HH \XFL[YF^'9&G7 MA_LW!O/W#?N/]',?/_ CVSZ]*RH[/7-)\$>+/",VAZA=7$PO6LKJWC#Q7"2[ MF!+9X8%CE3SZ9KURB@#-\/+-'X;TR.YMY+>>.UC1XI"-RD* 0<$CMZURMG;Z MAIOC+QF\NEW;VVHB&:WN(U#(P6 (1USNW#&,=\]*[RB@#R>'2M4C^'O@2P;2 M[W[7INIVDMW$(3F)(R=['L1R.F<]N]3Q6=SH/B;6K6_\%R:Y;:E>/>65[#!% M)CS ,QRER-@!'4]C7J-% $%E$T%C;Q/'#&R1JI2 8C4@=%'8>GM7G-EHMW;> M);#4_#]MJ>E3W-Z3K&GRHWV.2/YM\JY^4,>"-ISSR!S7IM% 'C^IVOB/5=.@ MDU#0-3FU6RUZ*XD*[?)$"SY'D+NP?EQDXSUW'I74Z.EW;_$+Q3J5QI]Y%:W5 MK:+"_DE@[1J^]1C.<%@/0]LUV]% 'D,&D:M%\(?#FDMI5[_:%I?P23VXA.Y% M2?>QSTQM]^?SK0FM;G0_&.LO>^#IM>T[5IDNK6Y@MXY'BG44 5=-A:#3;>)[>"V94&88!A(S_=7V'3_"K5%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^.;W2;#P MC>RZXEXVG842BTWB3[PQ@J1MYQSD"NBKD/BA:76H?#O5K&RM9[JZN%1(HH8R M[,=ZGMTX!Y- %_4?%VGZ7KL>B/;WTU]);M<1QPV[-O52!@'N>?H.*VCMM[L$ZJ-I(9N1P"<=\5QNHZ/XDF^'7B'3&:_U:&& M\@?39+F(K=3PH\3N&! +$88 D MCTQ6_>/LC D.O.W:<'DD<\=2!5^T\ M6:9?Z)IVJ61EN(]1.VUA1<22, 25P2 "-K9R0!@\UC:>L\'Q1UZ_DL[Q;.73 M[>*.;[,Y5V0N6 ..?O#Z]JXRPT;5[#P7X2OY/#UQ?MH]S=B^TN2#]XTDZG?745["VES+!>6K0YEA9L;<[25VG(PV[!]:N MVOB^RN]>,9Z9KIJ\]\ M'W6H>&/!VI0W6@ZI+<6-Y5#""TX>=F7RN?FX;.1Z&O0$;?&K;2N0#M;J/ M8T <,NIS^*?B3JF@^?-#I.B01-/'!(8VN9Y1N&YE(.Q5S\H(R>N1Q4?B&]D\ M#>(_#\]I-,VDZK>#3[JUEE:14=_]7(FXDK@@Y X([9YJ4Z3=>&?B/J'B*&VF MNM*UFWC2[%NADDMYHQA6V#YF4KD?*"0>V*-J2)9:K.NERF.\\JT/[H!0Q*X>.UO?[.^)"' M3KX-J+RFS!MG_?AK<1C;Q_>&/UZ52>SO=(N/#.M7?AFZU?3QHD6FW=JEIYD] MK*G(<1MR1DE3CTSZ9 /1]!U^Q\2:8+_3W2 !C)) Y ZD"H/#<42:8TD&BQZ1%/*94M1$L; MX( W2*O 8XS],9YS6%XBM+ZP^(&B>)8K:>[T^.VFL;M+>,R/"'(99 @R6&0 M< D"@"_+X[T>#1=4U*9;N,Z4Y2]M3"3-"V,\J,C!'(;.TCO5_1/$,&NR7(M[ M._ACA",LMS;F-)E<9!C)^\..?P]:X+7]#OKVR\?:O;V5V?[9M(;2SMQ PEE* M1D%RF,J"6P-V.%SW%>CZ.Y?1K(F.2-O(0%)4*,I ((/(H IZ[XGT_P]-81W MRW)-]<"WA,4+.-Y!(!(^AXZGL#6;%X]L9KB_M$TO6#J-EM,EB+7]ZR,"0Z\[ M=IP>21SQU(%0>/(+FXN_"QM[2YN!;:U#L\'Q0U M^_DL[Q;.6PMXXYOLSE79"Y8 XY^\/KVS0!KP>+])N]#T[5K:22:+4F"6D2I^ M\E370ZAIL^I>) M=<\2P6MVMM_8#:9"CV[K)<2,[.2(R-V!\HR0.I[#- &SIWCW2M2M1=1VNI16 MKV\4\4\MJ0DID(58T/\ $^X@;1W]:OZ=XFM+_6[C19+>YLM3@A%P;>Y5<8<;XR&'.><=C6 M_P"%9K/4;TWUIX.DT39"8Y)KRR2WF8D@[%QR5X)).!TQGG !TNH7]KI=A/?7 MLRPVT"%Y';L/ZGV'6LNV\5V4NM'2+FWNK"\-J;M%NE4!X@<%@58@8/4'!'I5 M7X@Z1?ZWX)OK/2PK7P,4\*,<"1HY%DVGZ[<51_M'4/&_A_4-/30]0T=[BQF@ MEFU"+RRDCH5"ISEADY+8Q@>IX -$>-=, T^:6&[AL-1D$5I?21@0RLWW1UW+ MN[%E /XBK,7BBTFNM:M4M[K[3I 1KF+:N2'4LI4[L'Y1GK^M<3/8:CXB^&NF M>$IM,O+35(FM;>X:2!A'"L+J6E63&Q@53@*2?F ]<7I%O]*\<>+R=(O[F/6+ M:W:TF@AW1DI$R,K/T4YYYZCIGI0!M-X_T5;;1)]MZR:TNZTV6S-GY2V#CO@= M!D^U0W'CZV'AW7M1MM-OC=Z,K?:+&=%CD4[-P)YQM(YR"3CMGBN4TJQU*'2? MAK%/I&H1/IKDW8-NQ\H>2R G&<9)''7VJ[=Z7J%]>?$V.&PNLZG9QI9,\+(L M[+;%"%)&/O<>_P!* .MT_P 2&31-+GN;.Y^W7L2F.V4)OE.P,S+\VT+SU8CL M.I&:4WQ&T.WTBXU"X6\B%K=BRN8&@S)!*2 ^#M Y'.<'L37+ZE#J/V3PCKY M\,7FH6NG6SV=[ITMNK3A72/]XD9ZD,F,=3].:E\2VK:AX(N&TGPI/IYN;ZUD M2VCL@D\HCE5F>14^[P#@-SQ[XH Z.3XAZ5!<06]U8:Q;2W%Q);PI-8.ID9%W M97U!' Y)[5)I_C_ $2]LM7N)OM5@^D+NOK>]A,*_ MUY4[I]NF.U(F+X,#<[<;N,YQC/'2J>IV6LOJ?BSQ1HNG.T\FFQ6=E!< M0E6N&4EG?RVP> 0 ".2I[8R =79>++.[U,Z=):7MK=_8_MT<4L88RPYQN786 MY!(&W@\CBL0_$[3[C1)M3TW2-7NX4MIYPXMMD8\HD,K.3A3QGZ>_%9>EI=1_ M$73M971]<^QR:-+!+<7D9,GF>8C'H-\&+[19+&Y@U M%K>^B$$\9C):1Y63&>#D,OYT =#I/BHW&AZ+-=65R=0U&%6CMT$8:4B,.[KE M\!>>Y!]JVM,U!-4L5NHX9H07>,QS+M=61RC C)[J:\_:PM]:\)>&;'5M'URS M>VM@B7MM$ZW%G,D:+N 3+ 'YAR.=O3'-=5X)76D\-I'KLKS7*32K'-)'Y

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�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end GRAPHIC 15 ex101-seagenxabbvieincxs003.jpg begin 644 ex101-seagenxabbvieincxs003.jpg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end GRAPHIC 16 ex101-seagenxabbvieincxs004.jpg begin 644 ex101-seagenxabbvieincxs004.jpg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end GRAPHIC 17 ex101-seagenxabbvieincxs005.jpg begin 644 ex101-seagenxabbvieincxs005.jpg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end GRAPHIC 18 ex102-seagenxcordenpharm001.jpg begin 644 ex102-seagenxcordenpharm001.jpg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�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ex102-seagenxcordenpharm002.jpg begin 644 ex102-seagenxcordenpharm002.jpg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ex102-seagenxcordenpharm003.jpg begin 644 ex102-seagenxcordenpharm003.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\\^*6D11>'+S7(+S4[ M>^62VC!@U":- &FC0_(K!>58]O>@#T,D#&3UHKS3Q?IB>&?^$6&EPWU](==1 MUAGO7E9V,$H #RL=H]>PY-;$7CQK*V\0GQ#IHL;G1(HYY4MY_/26.0$H48JO M)*E<$#F@#LZ*X[2O&EU/KUAI>JZ?9VSZC&[VS6E^+DJR+N*2#:NUMN3D9'!& M:J?$VZAMT\-I>:C+86$^KK'=2QW36X\ORI#AG4@@9 [T =Y17G/@_4KM;_Q* MF@SW6NZ+;^1_9[7%V7#3$'S$29\ED'RDG)QVS6MI_C*\;4M3TS5--M8;RSL? MMZ?9+SSXY(\D$%BBE6!&.G?- '845Y=K?C?Q3=_#*^\16&B1Z;$]JDUO.]Z& ME52.7V>60><8!/(.3CI707>HW)UKPHFL:8(+ZYNYTC6VU!FCCQ"S;F^51)D# M&".,YH [&BO/;CXFF*"YU6/3[5]"MKDP/,;X"Y95?8TBP[>5!SU8$@9Q6P?% M=]<^+[S0].TZUF6P,/VEY[WRI6610VZ./8=RJ#R21DY% '5$@#).**XOXK2& M+X>7L@1I"MS:,$3JV+F+@>]6]*\4:G-XD.B:QHB6%Q+:->6QBNA,'16"LK?* MNUP67ID<]: .IHKCX?%VJ6_B+3=,UC1K6T74F>.%H+\3R1.J%]LB[!C(4\@D M9IB>/M_A*+5/[-QJ3Z@-,_L[S^1<>;Y97?MZ 9;..E '9T5P6I?$66VDU:XL MM-M;C3M(E>*Z>6_$4\C(,R>5'M.[;SU9V,]N8[Y7DS@%4=2JA2P/8D#O5>Q\ M6:D/%%GHFLZ5:6KWT]3OXJOKCQA>:%IVFVLPL/)^TM/>^5(RR -NC M38=P4'DDCG(H ZJBN$U/XA36]QJ[:?IMK, #')H Z[.:*X MGX6RO/X8O9I(7@>35KUFB<@LA,S$J<<9'3BH/#6N>)=0\4^)K+4+*V%C:W(C M#+=[C;@P*P55\L;P2:'<[5?R]OW"W&=V>^*V;CQ9;:!/XINH[&1IH=3M[5C->GRG>2./#$ MD$0H-W. >F>] 'H%%4-(N=0NK'S-2M;:WGW<"VN/.C=<##!BJGGTQVK@_B#= M:QJ&KRV^A7<\+^'[+^U9EA<@32[P8X6QU!1)>/<4 >ET5R>J^-?LMAX>NM+T MUM2_MQPENBS"/&Z)I%))!&.,'T&3SC!S!XZ\0N^KVD?A2-M0T?Y[U?[0 A*% M Z^6^S+,PSP5 &.30!W]%<9=>/4E31HM(M8)KK5+(7Z"]NA;QPPX7EVPQR2P M !Z'IBH'^(Q'AZ*_CTAY[S^U1I,UG#<*V)C_JZQX)DU/05T^W MN-52>"1+L2D PR820;1M;!SQD<'GCD ]2HKSZ\^(VI6]OK.H1>&_,TO1KV2V MO)S>!7948 M&FWYB 02"1Z FM73?%NH2^([/2]5T3^STU&WDN+&07(D8A-NY M9% 1L,#P6';- '645YZGQ-+P1:L-/M?[!EN1;K/]N'VG:9/+$IAV_0VKON,NWRL*277Y3N([ @9]10!TM%<9_PEFKV>E:/!0H-H Z@*>V,YK1\/^)+K4=5U#1M5TY;#5+)(Y62*?SHY8GS MM=&VJ>JD$$#% '19&<9Y]**\\U>\U.U^+X&DZ:E]74'TPV$MP%6.X3)?=+C&P*-V['<<RCTW1-9N;5K?1-35U MDO'D_P"/69<_(Z@="58!@>H''-)+X\N1I^CE=)CAU'6/,DM;:[NQ$L<"\^9* M^T[205.T G+8[&@#MJ*XA/B(BZ+>S3:<&U6UOH].%E;W D6::3;Y>R3 &U@P M.2 1@\<5:OO%.LZ+HD]]K.@P0R1W%O"BP7WF)()9%0D,4!!7=D@KSQ@^@!UM M%8&H>(;BW\3)H5I8)/<2Z=+>QM)/Y:ED=5"'Y3@'?][G&.AKD_#/CG5K7X<1 MZ[XAM(YF9A%;/'<@R74C2L@5EV*L>#@9R>,F@#TNC-<;8>.BNH7=CK=M:6LD M%B^H++97GVF-HD.'!.U2&7(XQ@YZUS>M>(-:UK_A#KF]T 6-A=ZU:SVTJW8D M<*0Q42+M&TD'/!8=0<4 >K$@=3BBN*^*DC0^"&E6-Y62_LV$:8W-BXCX&>YH M;QGK-I?W&G:EX=CAOVL);VPBBO?,6X\O&Z(ML&U^1T!'/6@#M:*Y>+QG!>#P MO]@MOM#:\IE4>9M\B)8][L>#D@E5QQR>M4_'^LZ]I$WA\:-!"ZW.IQ0RE[CR M_,R&Q&?D;"MCENHP.#F@#M,C.,\^E%>;WU]K4'Q3MVL]'AN-1F\/+YD+7>R& M$^>2&QU [)4?E&295##H0>,C'O6U? M^*M3B\72>'-)T(7LL-M%=/<2W?E(J,S*0?E)W?*,#OD],<@'6T9YQ6-XG\0+ MXP!KCK34]5_X6I+-J^E1V=Q;>'97 M"0W/FQRJ)D.5;:".X(*\>] 'I5 (.<'I7*#QIGPSX:UC[!_R&Y[6'RO._P!3 MYPSG.WYL?09]JY_3O$'_ C=]XHO)+;SK63Q/';W$F_;]G22&%1)T.0&*@CC MK0!Z716-:Z]]L\6ZAHD-MF.PMXI)[G?TDD)*Q[U 'H^1G&>317F_B2_P!9C\6>";A]'B?5&-\HLXKO=&,QJ 3*5'&.3\N> MP!K33Q^;;1-7N-4TMH-2TR[2R>R@F$@FEDV^7L<@<-O7J!CF@#M:*Y6P\4:I M'XBL]%U_1X;":_BDDLY;:[\]'* %T;**58 Y[@\\UACQG?>(/!&LZO<^'6M] M%CL+EMXU I+,T>057:N54X(WYSD=* /1J*XG7O%>J^'-&L+NRT*WO;.6*".% M9-19)GE? 6-5\MMQZ@ R.>: .PHS7%#Q^VHV.@G0=,^UW^LQR2QP3S^4D"1\2%W ;HQ"C . M34'P^N;J[\0>,IKVS-G(X=2X5LMNX4 GVO]LWD#3R0W%Z(X+=%P&+2;26^9@!A>>>E46^(Q7P\+]-(::\355TJ:SA MN%;$K$ %'P P(92,XZ\XH [JBN&F\7:[MUO3)]%@M-9M+ 7MNJ7N^*2)B5+; M_+X92IXVG) YP> =.U"XTJVN;Z:V@:-C?!1,K("99#L&SU*@-U MH [2BO/-0\:ZQ/X7\6I!86UOK.C6Q=FAO?,B"-$S+*C[.2-I^4J.1C/-2-K% M[-HGA*XU[3MMS:(PH?;T((;..AJ+5/'UQ!?:M'ING6EU;Z2=ET]Q?B!Y M'"AF2)-IW$ CDE03Q0!W%%<9<>.9KK4].L-"L+:ZDO=.34D-Y>?9@\;'A4PC M;G[D< <<\UV2DE06&"1R,]* %HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KWM_9Z; M:O=7]U!:VZ?>EGD"(OU)XH L45'!/#=6\=Q;RI+#(H>.2-@RNIY!!'!%-FNK M>V>%)YXHFF?RX@[A3(^"=JYZG )P/0T 35@>--"N/$GA:XTJUDBCFEE@<-*2 M% 29'/0'LI_&M^B@#!\1:'<:Q?:#/!)$BZ=J*W-XBYW$=",LIQGG!Z5VE ((R#D4 :[8QD HNP'N,MZ5?\3>'YM=O-!DC:$1Z?J*WH>&M0U,Z?%<:9"1=R2Q,&5AZ@C@B@#S M[3_ E_HSRV5MI/AB^L3:" M0-*3MQ',CGH#V4_C4.J>';N_\66^K0W2P11Z9<66Y<^8KR,A5E[<;3W]*Z2B M@#S'0_AYJEAJ'AR::UT"W&D2EIKBT5S/>YB="[L5&"202"3DDG/ !UH_ URG MQ%;6OM4/]B^:;Y;/G<+PQB(OTQC;D]_T[5-4>QT MOPWJ-M?W;W:RZG&WG0,_++PC;USDCE>N*['5]'BUCPW>:-,1%%=6K6[&-W85-=ZMIUA7]K;SW+;((IIE1I6Z84$Y)Y'2B'5M.N=0FT^#4+6 M6]@&Z6W296DC'JR@Y'4=?6@#F+72/&-QH4^C:C?:7;Q?8'M8[NR\PS.Y7:LA M! "8ZD GGH169X?\!ZEI_B#0=0FLM L8],AEBD&GJWF7!>/;O9BHR!?%+^&[OPO;7NDKI+7;7$,SB0S,AG\[RV&-JX8GY@3G&,#.1K M>*O"VL>(]3B @T:&&&>*2WU,&07MNJD,RJ ,$G##[P&#R*[9W2, NRJ"0 2< M MUVQ\3+K?A]M+W36$=E=6UUOCC7824=-H/3<1M..,3W+2Q*5#>9(6Z'H>>G./4U7L-"U?3?%^M7<3V,FDZJZ3/N9Q/$ZQ M"/ &-I!*@YR._%=2""< BEH X:'P5?Q^ O#>@FXMOM.EW5I-,X+;&$4@9@O& MSN?$ES:)I=W_:MY',MO>[_+:(0JC*Q"G!RN>C#'Z=A10!S/ M@GPY<^&]-O(;@VT?VF[>XCM+0L8+52 /+0L <9!/0#+' %9]G\.["ZOM6U+Q M%"EY?W]X\H:*>152$ +&G!&<*!GCJ37;44 C:K/<6 MXW,6^RNCA$.1]X&3'I@=>U;,'ARZBUGQ7>&6$QZPD2P@$Y39#Y9W<>OIGBNF MHH \X/P^OK:V\.7,,.CZA>Z9I:Z;0>U:D_A6_O M-)TF VVD6$MIJ\-_+#8JRQ;$/('RCUBXFG1+/4=$ M&F?+DR(^^1MV.F,.._45G1^&O%U]=>'#JUUI"V^C7*2D6WF%KC$;)O)8#:>? MNC(Y// %=_10!P]QX+OYO!WBS1UN+83ZS>7-Q Y+;463&T-QG/'. :U[[0+B MZ\4^'M462(0:;!&+RQ@F MS'?7,)^TB+=G#*$P7 . VX=!Q7167AVYMM9\57CRPF/5VB,(!.4VP",[N/49 MXSQ7244 <"O@[6]/TCP<=.FT^34= A,4B7#NL,H:+RV(8*2,<$<<^U=5X@TI M]=\+ZEI)E6*2]M)(/,QD*S*1GZ9-:E% '"S>'/$UQ;:#J)DTJ+7-%=UCC5Y& MMYXGC",&;:&4G&00#C ZUJ>']"U*'7=1\0:W+:G4+R*.W2&T+&.")-Q W, 6 M)+$DX':NFHH Y#6-"\0CQJOB/1)M-8#3A9/;7A=?,_>,Y.Y0=N,CL<\C ZUC MR?#F\DT2VDDGT^YUN/59=5F6XB+6LKR J\>.2%VD '!.5!Q7H]% &!X9TN[T M\7+W>E:)I[2;0J:6IY SG>Q5<]>!CCGUK%UCP;=GQ9>:Y86&AZDM_#$D]OJJ MD>6\8(#(X1N"" 1CL.:[FB@#B]5\&7'B&RTS2-36QM]$AC>2\M+ -&)9OX%4 M8X1\GTWRK.X6?3 M;A0TF]EE,@$R$ 8Y"D GJ:]'HH XVP\+W5Q:ZC::EHWA[3H;NSDM6?2E)D;> M,$[BBX&,\<\XYXK-C\*>+KJ#PY9:C>:0+31+N"8/!YADN5C!4$Y&$.WL,Y)Z M@#GT2B@#GO&N@W?B3PXVG6-S%;7!N()EEE4LJ^7*KDX'4X7IW]JI:;H6O7?B MRWUWQ#)IRFQM9+>U@L2[ M(5WR,6 QPH 49QZUUU% 'FGPYT00^*?$5XDWFZ M=I]S+IVF+C B4R&691]'8+G_ &*ZGQAH=_K5EI[:9);K>:?J$5]$MR6$<&NA55484 #.>!2T (+Q[5P)Y]JYR?X=WCZ?"ZOIT]]::Q=:A#%=(7MY8YF;,;\9!VL.0#@CO7HU% '"7 M_A#4M4\%ZYI/]GZ!I=S?QK'$+ -LX.&1Y&)/&,?.._K6]10!S_B_0;G7])MTL9XH+^RNXKVU>8$Q^9&V0&QS MM(R./6LNP\.:]=^+9='=(N[W2?[/T*\MYD>(2>;-P(PAV]AG)[COJ7/A:*'0_&J: MO<0BQU6:6ZWKD^3'Y*+DY'4%"W'M7:TA 92K $'@@]Z .,^%UC>0^#(=3U-S M)J>KM]NN'8*;K4HX-&OX+FT2W0:HC.;(@MEHU" MD-G()&5.0.:[P# P.E% 'G\7@S7-,TOPA)IL^GR:GH-N]M)'<,ZPS*Z*K88* M6!!4$<4Q_ FM7?AKQ39WNH637^LW:7<4D2,(T95CPI!YQF/&>3CGKQ7H=% ' M+-HNL:AKOAO5]1-C%-IWVK[3%;R.RGS%"KL)49Z*[. MB@#A-0\-^)CX@TB^M#I%S;:99"*""[ED0).1M>7Y5.3M&!GH"?6FZEX-OSXF MNM*VDCDP2%*@E<,H(XYYJ[X3T#5=(OM?4[I+C_1E9 M53$:KMP?3;@'N "<$XKIZ* ,'2]#N+'Q;X@U:22)H=2%L(D4GHQ6CI'@6XTA_"06\BF&CM=27 M3L"K2O.K9*CTW,>IZ5VX50Q8 GJ<=:6@#A]<\'77]K;Z!<1OINK7VFV364\6J(QBF1F# JV&*E2, X.1 MQQ6I<>%;^\T;3;:JTT:VMSH_\ 9VT9WAO,9BV,8QAO6N?;P;XCN? NEZ#=OI$C:7-;[(M\ MAAO88EV[)LKD9X. &&5'6O1:* . TKP)>Q6_BV.Y72[)=>LTMXX-.C(CM\1R M(>"!N^^#G SSP*LIX:UZ]T?PW;:D^FQW&D:C!.QMY'99(8XRG&5!WDG..F.] M=M10!P[^!KEOB*-:%U#_ &,9%OGL^=QO%C,0?IC&T@]";ZSU_5;RP MTSP]J5MJ4_VD_P!J(1);R%0& (1MRG;G'RX)->@44 V^S+''-,)(Y+.7&"\04'@<;1E<8Y)KLK.![:RM[>29YGBC5&E?[SD#&X^YZ MU-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !67X@O;G3](DN;6YTZU96&^?47*PQKW)QC)]!D?6M M2L'Q7X=?Q'96:07:VUS97D=Y \D/FQETR '3(R/F/<'.#0!RUE\0K^71/%$L M2Z=J]WHPB:*?3=QAG609SMRQ&W#%@">!Q74^%-4N-7TQKN;4])U&-F_=SZ:K M*N,((FU35!;GSA8@1PF+(P$W\J0<$4(1M 4C+'/)Z5R7B#6M5\6:1X*OK:&PM_.U MD12VURC2!;F,3*?3% ! MX\?4[#X:ZK)ITT%M=06+L[QJRA0$.[R]I!4_W3GBN;\12>(!I7@F2X-A=:HV ML1&'9OCC(-O)@N26.1R3CKVKT+7-*CUS0=0TF9VCCO;>2!G7JH92,CZ9K"3P MIJ-Q::"FIZQ#<3:1>K6)$6)HPA&\X/S9+?I0!FMXYU'0K7Q0OB&"TF MN=$@AN$>R#(DZRA@BX8DJ=RX)R>N:C\/^/;F]\3:=I-UJ&B:B-0CD(.EE\VK MHN[:^YCN4@$!OEY'3FMC4O!%MJU[XBDO+EC!K5G!:M&BX:+R]^ Y.7!Z<; M>]7-'T[Q):W$?]J:]:7MM$A7;%8>5)(<<,[>8PS] * *GQ#U1].\(SPP3+#= MZC(FGVSLP>&K+Q1X=KAP?J*ZK6_"UOX@UO2KO4&BGL; 2M]AEA#I+(X"AVRU9]WX! ML/[974-(%MI0>QGLKF&WM5"SI(!M)VD8*L,]\].* ,./QGXR%GXTFN]!$3AK/#\:9X4L_MW_( DB??Y7^OV0M%C&?ESNSWZ8IE_X'MM4G M\3F[NG:#788(V1%VM 8E(#!LG)R0>G&.] &3X>\>7%[XGL-(NM0T34A?Q2,& MTHOFV=%W;7W,=RD9PW'(Z0]F=C(PS[ "LQ? FWX?V M_A;^T?\ 4SI-]I\GKMN!-C;N]MO7W]J (+[7_$>J:MKMIH5OIOV/2=L,WVLO MON9#&'94*G" !@,D-S[5@^%]=UJS\,^!-#T:"Q:34=+DD::[W;8?+\OYL*?F M&&/'&3CD;_8EC-9X\G;YV_9\WWCMQLZ<]: .>;QMXQ70=:U,V.C!= GE@ MO1ND/VHQX+&+G]V-A!&[=D^E:/B+Q]]C\00Z/9ZAI.G'[&MY)2%15 M5ER>"2<\#'!K2D\%>9X=\4:3]OQ_;MQ//YOD_P"H\U%7&-WS8VYZC.:6\\*7 M\6L0:QH>JPV=Z+-+*X6YM3-%.B$E3M#J0P)/.>AQ0!BQ_$#5=0T/P[<:98V+ MWNIW\MA(LDC>4&19/WB,.2N4#=#D<=>:BU;Q#XED\->-M,GDL(=5T>S\W[7: MK(J/%)$[94;MR2#:V#DC.#747'AR\OY- N+_ %1)KK2[M[F21+;8LV4= H7< M=H <=S]WWS3)_"$=U?>*)IKMO*UZSCM'14P8@J.A(.><[\]!C'>@"SX1;59/ M#-E)K$UM-F>&].U'2=&AL=2U"&^DA CCEBM_)_=JH !&YLG@DG( MZ]*P;?PGXATS4=6GTCQ):6]OJ-Z]ZT4^F&5D9@H(W>:,C"CM0!D2VVN7'QFO MC&VD,(M)B,7VBW=BD9EDVX^;AMPR3TP!Q61X:UR^\)^!]6UV^CTN5Y=4GAB* MHT;-.]RRL9')/R \],@+WKTF+0?+\8W/B#[3GSK&.S\C9TV.[;MV>^_&,=NM M9(\!Q-X0N-"DU!P[WTE]#=1QA6AE,QE0@$D':2![\],T 8VG_$GR;O48;^]T MK5(;73)=1%QI090OED;HV5F;DY&#GGGBM)+SQO=>'9[Z;^Q(%N+$S1)&LN^W M8@$ G=\_RY&1MP<=16E'H6L7]C?6'B+5K2]L[JV>V:*ULC <,,%BQ=^<9Z8' M-1Z+X=URR@2QU/Q"E]I\5N;:.*.R$3NN-H:1]S9('H%SU- ')66H:HOPM\.W MFNQZ?J@GGTX0^:DC, [H-[DM\T@SG/3/:MVZ\,]-U\WK0QVVS[3:"/*W)C8M$2<\;68GH<\=* ,;5_'UY::Y- MHO\ :.@Z;=6-K#)=2ZAO*RS.N[9&H8$*!U8D_>'!KK?"FN_\)-X7L-8\CR#< MQY:/.0K E2 >XR#@^E4+[PSJ<7B.ZUO0=6@LIKV*..[ANK0SQR%,A'&'4JP! MQU(/%=#917$-E%'=W(N;A5Q),(P@<^H49Q]* /+O!G@70=>\%RWLUHL&J27= MYMU&!C'/&PGD"L'!!XP/;BM+2?%VK7'P[\/:O-JVAZ?+3I4LLSLMO8!9]LCL[*)"Y ^\1G;FK][ MX):&\T2Z\/WEO8/I-J]G#'<6QN(_*;;R!N4AAM'S9YYS0!RFJ^+->U[P1I&I M:='4SJ<=ZUN.)?-$HW(" M1GK@CKVJU=>%]8;5+37+/6K:'6DM/LET[V1>"X3<6'[O>"I!)P=QZT 7?!GB M-O%'A\7TB1+-'/);R&!BT3LC%=Z$\E6&"/K705BG3M<:RT^-M>1;F&Z6:[EC MLE"W$63F(*2=@.1\V2>/>MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C;WQA+- M\0#X1L+BRM+F.T%R\UXC2>82>(XT#+DXY)S^'4U+=Z]KUCX:\1WUU9V<-WI' MF/&!N>.YC2%9-PY!7))'?&._6N?\:>"/#_Q&UR\M1=OI_B+2UC"SQ'):-E#* M67C(!+#((((Z]JP_#]_XD_X5W\0]!\17/VU]&M9[>*]W;O,S"Y*[CR<84\\_ M-@T =%X7\8^*?%?@N'7;.+1H[B=Y$ALY4D'F,F[C?NZD*3TKOK"XDN=-M;F: M/RI)84D=.FTD D<^E>._!K1F/A'P_K[:E,EM92W8FMY)0(45MPWX[$'')/0F MO0=8UD:SX>LX-)Q))K64@W2>7N@QF1P<$C*#@XX+K0!'X'\>V/C:364M JG3 M[PPK@_ZR+^"3\2&_*H/%?CQM)\1Z;X6T>UCO=>U Y5)7*Q0)R2[DX^''QNM-5N;2&PTCQ"##+'%+OC1OE!.=HQAMK=.C&KNL6LN@?M*Z; MK6H IIVIQ>5;W#?<63R3'LSV.X#_ +ZH ] UB_\ %NAZ=]L$6F:JH91*D,,E MNT0) +@%WW@9R1\O ZUC^./'>K^&/&/A_1+2"QFBUF98EDE1]T)+JN3AOF^] MGMTI?B3X[U;P7?Z'#8V]E/'JDQA_?H^8R"HSD-S][I@=*Y/XO1O)\3/AY%), M5D:Z56DB&T@F:/E)[&WL[:65X;._BW!)65R@)W$X!*D=>#[M86N^!K'Q[X+O+&0I'>PZA>O M:7/>*3[1)P?]D]"/QZ@4 ==9WFI2>);^QG:U^QP0Q2QE(V$C;RXP26QQL].< M]JP_B9XNU#P1X9&LV4%M<8G2)HIU;G=GD$'VZ8K"^#NH:[=G6K+Q&C+J6EB" MP)/%WB31_ FF^(+&RLKZ MYN8TDEM1&XP&C+G:0QSM /U_2GZ-\0E\3_#JZ\1:,+=;ZS@9[FTGRP1U4L5X M(.#CAOTZXNV3*/#7@K) R;8#/?\ T=Z\P^('A74/AYK=UXB\-)C1-81K34;4 M#Y(C("N<=ER<@]CQT.* /2_&7CK_ (1&+3;!;==2U_4I!#:VL1\M68D#<22= MJY(]<_F1+J5[XST?0)]1>'2-1GBB+O:V\28_=A8.Q.?3A\_\!/I7LMS?VEG:"ZN+B-(#@*Y/#$] M/4GL!UH LT5D6_B?1KKQ+<^'8;Y'U:UB$LUL%;*J<7@'/(K7H **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ H)P,FBJNIVSWNE7EK$_ER30/&K_W25(!_ M6@#B=%\<:GXVUO4(/"T5E#I.GOY4FI7B-+YS^D<:LO'?);H1QS71:9J&MG7[ MC3-4L[988[=98KRW9MLY+$$;3]PC XRW43QT.P,?7C- ' M4V^H65W-)%;7=O-)$<2)'(&*?4 \4C:G8)'+(U];*D7^L8RJ G;DYXKPU?-L MI_@RVCKMN9HML_E#EXB(C+NQU&"YY]S5OP_X8TGQ-\8/'UEJ]M]HLP8SY&]E M4L?XOE(.1S@^YH ]EOK^&VA5?MEK#/,"+?SF&';M@9!;\*YCX9^,[GQQX3?6 M+VV@MI%N7AV1$[<*%.>?K7%:7!9R_''Q19:S#";6TTA(K**XP4CMPL>=N[MR M23[FN'TR[OK7]F?4#8LZJ^K^7VQDFSY2"5(;77;&XM MM2\.R)]@M+;8A5$^60_.W(!VX/K[5Y?!9VUK\-/AYJ4$$<=\^ML&N%7#D"9L M#=UQP.* /J)PYC81LJOCY2PR ?<9&?SKR33/B=XEU*S\6W4=AI1'AMSYL9\Q M3.JE]Q!R=IQ&3C!ZUZ[7@7PT\/1>)M9^(FGW5_>06.G2O3X+ MRUNFE6WN89FB;;((W#%&]#CH:\;^,&B:=HOAOP=I&GVRP6,.JI&D2D\ @YYZ MY.22>O-3>&8[32/CUXVM+=4LM/CTR.1HX%"*F$A)8 ="-S'\30!ZVNI6+7IL MEO;7LO;=O-4-'ME4[P>XYY%1_VOIAM&N_[1M/LRML:;SU MV!O0MG&:\?\ '/A_2M-^(GPWT6ULT73HWDB$#$L"FY3@DDDC)/7KDU@6NE:> M\OQAC:S@,=FKO;1E!MA;][R@Z*?E'(]* /HB2XABMS/)-&D(&XR,P"@>N>F* M;:WEM?0B:TN(;B(G >)PZY^HKP_^TM/M_A/\/9-1N[H78NXS9PI,L<.OB!%]H@D1KV.11;G]T26ERR#)XZ?I0!W'COQS8^ M!=&2\N(GN;JX?RK6UC.&F?Z]@.Y]QZT^-_&B:8+R5=&EN]F\ZV=F,_G7GOQYTZ[2\\+^(A$\NGZ;M=QX_\ %MSX M8\$2>)-)^R7<Y0>1U'7O7SG:R._[+=ZK,2$U,*H)Z#S$./S)_.NMU"P2R^(_PS;0K M>."XFL\W7V=0N^':I8MCJ,%^3WH ZJT\=:Q/\7;KP4\-@(+>(3&Z$;[F4HK8 MV[L _-C.>U$7CK67^+LO@HPV'D1Q>=]J$;[BNP-C;NQGG&<_X5R26GV[]J'5 MH?M-Q;_Z$IWV[[6_U,7&:72K7['^T_XT444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% &;=>'](O;EKFXTVVDN6()G,8$G3'WAST&.M._L+2/[,.F'3 M+0V)))MC"IC)/4E<8.%!"81X:T@1$Y*?8H\$_3%7?^$?T83VL MXTJR$UI&([9_(7="@X"H@6]Q%<)I%H9H?]5( M\8=H_P#=)SM_"GZAX8T#5KD7.HZ+I]Y.!@2W%LDC#\2*U:* ,FV\+Z!9WGVR MUT33H;K:5\Z.V17P1@CIQU/O5RB@" M)+:".XEN$B19I0HD<+@N%SC)[XR:JZGHFE:U&L>J:;:7R(-URK#T M(J6B@"&[M+:_MGMKRWBN+>08>*5 ZL/<'@UG:?X5T'29DFL-(L[>1,[&2(93 M/7;_ '?PK7HH I1Z1IL.K3:K'8VZ:A,@CEN5C D=1C +=2.!^0]*NT44 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 96I>&=#U>Y2YU#2K2XN4&%F>(>8 M!Z;NN/QJY9Z=9:=:_9;*T@MX.3Y<2!5)/4X'K5FB@#,L/#FBZ7<_:+#2[2VF MVE0\404JI.2!Z GG IUKH.CV-_+?VFEV<%Y-GS;B*!5D?/7+ 9/XUHT4 9E_ MX=T75;Z"]O\ 2K.ZNK?_ %4TT*LR=^"1Z\T6GAS1+#3YK"TTBQ@LYAME@CMU M5)!T^8 8;\:TZ* ,BQ\+:!IMA<6-EHUC!:7/^OA2!0LO^\,<_C3#X/\ #+6T M5L?#^EF"%B\41M$VHQQD@8P"<#\JVJ* &-$CQ&)D4QD;2I'!'I6?I_AS0])N M'N--T>PLYG^]);VZ1LWU('/6M.B@"AJ6AZ3K)B_M33+.]\HYC^TP+)L/MD<4 MR'P_HUOJ,FHPZ391WTH(DN4@42.#U!;&36E10!B#P=X9%H+4>'M+%N)?.$7V M1-N_^]C'7WJT= T0OFCC'WL9Z5HT4 9]YH.D:C>PWM[I= MGJKC -6+71=*LK^>_M--M(+R&=!M;)K*WT;3XK1I!*T$=LBH7'1BH&" M1@<^U26&@:1I<[3V&FVMM,R",O'& =@Y"@]E]AQ6C10!DIX7T"/4?[131=/6 M^SG[2+9!)GUW8S0/"^@+J/\ :*Z+IXOLY^TBV3S,],[L9Z5K44 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56_ MU.PTJW^T:C>VUG#G'F7$JQK^;$"K5<;\5P#\+?$.?^?;_P!F% '06GB'1+^= M(+/6-/N)G&5CAN4=F'L >:TJ\?\ B'J+WG@'2K.;2KS3B\EJ4UBY5?*L2"I\ MS=&S,I.-HX'WNHKM[_Q%>Z=XPT;3I%M6TG5$98;ODMYRKN"'G'S#)!]B,=Z M.IHKG#J>NWECK4VE6]C-);W!@L!,6192N Y<@GHV]>.I3MGCH4W%%W@!\#<% M.1GVH 8US"MVEJ9 )W1I%3N54@$_FR_G4M<=J6M?V3;>(?%!B,L=J4LXN"0$ M1L2.<$?$6KZ'X M/\"B6SLVTG4/(L,B1C.KNI*OTV[JU4L=3L=2:Z6RN8YS:SM;S MA#GRY%QE3[C(KE+?Q+XFU'Q3K&DV6FZ8(]+NK=)9)KA_GBD4.2N%^]@]P ,= M\\00>.)[?PYXFU2[T^W@;2M5:R80%G7:#&#*QP"<;RQP!POXT =[17G7BSQ' MK(^'>O:GIM_ILT4=LK6U_: E75LA\#<=KCC')ZY]ANOKM]#JFE^'T-J^JW5N M]S)+L;RX84P-VW=EB2P&,CN<\8(!U%(S!5+,0% R2>@KSW4OB#J.EZ/XH$NG MVKZOX?V-*GF,L4T4@RDB\$].JYX(^]5P^+-=TWQ5I-CK6F6<6FZP6CM9K>9G MDAE"[@LN1@Y']W@'N<9H ZO3=6T_6())]-O(;J&.1HFDA;M7*\@T MO7]7\,>&?%.KV=G9S6-EX@O7N%FD822(9@"$ & 0#G)Z^GKVVI^)[C^U[K2M M+""XM;>.:226UEG4L^[8F(^1PI)8GC(P#S@ ZFBO/AXYU^?_ (1:./P^EI"2-&/3;]WY0<]2.V:ZV&[U&U\-F\U6"W%_# TDT5JQ:,LH)PI( MSCB@"6]US2M-G6"]U&V@F9=RQR2@,1ZXZX]ZFL]0L]01GLKN"Y1< M#(' R, MCD>U<9\(D-UX&AUVZ;SM2U>66YNYS]YVWLJK_NJJ@ =!5OQ;='P-X?USQ)I- MC;R32M'-/%(Q16;(3?@#DD%7(&2H&,+U)'3K4,_C6[TF_UW2]2LDGO].TXZG;FU!5;N$9!^4Y M*L&&#R>N?:@#M:*X^T\9)_8UYKTM]I]_HMO9FX^TV((8..3&5+'!QC&<')Y MQ3+SQ9JFC0Z)J.JVUK_9VJ3102+!N\RS>4?(2Q.)%SP2 N.N#0!V=%,/ M$LDGBJ.RTW3%.A,"3-,["5?*\S P!\Q'?@#W[=CHNI+K.A:?JB1F-;RVCN A M.2H=0V/UH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4UW2-&>1E1%&69C@ >IIU% &,OB[PT^=GB+26P=IQ>QG! M]/O5L*RN@=&#*PR"#D$5Y1X(U1[#0_%R#P_?ZI"-=OB4MTC97&1\NUF!/Y'K MWJ/PCJNH^'O@J-4TB2TU-K.2666VRY^SQ[LM$,X(9 VNK4W"UAF$[B);9RP, M6?D)R/O$=: +=SG6F:KXG\1Z??:3ID5OIL^KZDV19J'_<1#[\COGA5Z=.3P* .TN+F"T@>> MYFCAA09:21@JJ/UC^_/%<(R+]6!P*M7 S:R@\_(< M_E7F_P )=5FMOA=HD*:-J,ZK')^\B6/:W[U^F7!_2@#T'3]6TW5XFETW4+2] MC4X9[:99 #[E2:N5Y3\.=:XO9;:"/!.9'N' SM!. ,DX!.!Q M6X_C#7+1M2&Y+#&WOG%1^(K2&2*1&4,5F'SIN . MUAR,CU':@#U*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?'.B7WB3PAJ&BV#6Z M2WD?EF2=V54&0<\*<]/:NBHH X?7?#GB+Q'X4'AN=M,L+66..*XN(I7G-+'3&\(Q^'K:^CBU2U%N=+02*9DF5@L+!>N,C!..FX]J[BJ3 M:1IK:LNJM86QU%8_+6Z,2^:%] V,XY- %.73M1TSPH+#0'M3?P0JD$E\&,;- MD;F?;SD_,>.YINH>*]$TMI+6]US2;;4(T!,%Q>)'AB,C()R %3+H=[!O\ E1_W%_*CRH_[B_E0!YWH6NZ)IWBWQ%JMUXH\-?9]5>%XUBU1 M"\?EQA,'( .<9Z\>]4=*UBRTFSU_R?%7A0W&HZL=0B#:FI38Q0/&_'=4(R ? MO=.*]2\J/^XOY4>5'_<7\J /')[#PK-I7BNVM?$WAK2UUN"-$M+;44>".1<\:5UJFFR:QHOB.+Q9X6&L64+VUS;_VBJP30MCY0_+ @C(. MWGIBO4?*C_N+^5'E1_W%_*@#QCQ?J'A\^$?&FHGQ#HMQJ^L01H+>TO4D")& MJ(O0L>6).!UZ<5T#ZYHFL:CHEWJOB7PU%%I1,Z1P:HKF:8H44G(&Q0"QQSR1 MZ<]YJ&D:=JMHUKJ%E! /2@#R"8Z M;-X&\2Z"?%?A59]7OI[I)!JJE8UE<,0?ER2,8]_:KM_JT-GXE7Q!X=\8>$EG MNK6.WU"RO=0!B$64JWB?12",$&^ MBY_\>K>\J/\ N+^5'E1_W%_*@#RW0=6T[P8)].T7Q/X6OM#:5I;:"ZU98);7 M<#=1TI?%_AM;R^V#YM1010*K!L#&2QXZD#. M>V,5Z7Y4?]Q?RH\J/^XOY4 ><^)-6T#6)=$U>T\6>';?6=(G,T:OJ*-#(KKM MDC+#D C^+;QCI3'UC1Y]7U'Q"?%?AJWUF33Q8V2+J2210J&+DLQP6RQ&<*,! M>]>D^5'_ '%_*CRH_P"XOY4 >1FS\&7^HZO&M,AU336LKFWT_4T999" MV?..0H#+CCCG)S5E-0TO4M'T;1M=\6>%VM=-GAE>X@U)2]UY/W 4( 3)"EOF M;H0.O'J?E1_W%_*CRH_[B_E0!Y9%J.E)-XR<^*/"Y_MT?N!_:J_N_P!T(OFX M]!GCZ>]=!X8\4>&]'\+Z7IEWXIT SV=K';LT.HQLK;%"Y&2#SC.*[/RH_P"X MOY4>5'_<7\J ,+_A.?"7_0T:+_X'Q?\ Q5'_ G/A+_H:-%_\#XO_BJW?*C_ M +B_E1Y4?]Q?RH PO^$Y\)?]#1HO_@?%_P#%4?\ "<^$O^AHT7_P/B_^*K=\ MJ/\ N+^5'E1_W%_*@#"_X3GPE_T-&B_^!\7_ ,51_P )SX2_Z&C1?_ ^+_XJ MMWRH_P"XOY4>5'_<7\J ,+_A.?"7_0T:+_X'Q?\ Q5'_ G/A+_H:-%_\#XO M_BJW?*C_ +B_E1Y4?]Q?RH PO^$Y\)?]#1HO_@?%_P#%4?\ "<^$O^AHT7_P M/B_^*K=\J/\ N+^5'E1_W%_*@#"_X3GPE_T-&B_^!\7_ ,51_P )SX2_Z&C1 M?_ ^+_XJMWRH_P"XOY4>5'_<7\J ,+_A.?"7_0T:+_X'Q?\ Q5'_ G/A+_H M:-%_\#XO_BJW?*C_ +B_E1Y4?]Q?RH PO^$Y\)?]#1HO_@?%_P#%4?\ "<^$ MO^AHT7_P/B_^*K=\J/\ N+^5'E1_W%_*@#"_X3GPE_T-&B_^!\7_ ,56EINL M:9K$+S:9J%I>Q(VUGMIED"GK@E2>:M^5'_<7\J4*J_= 'T% "T444 %%%% ! M1110 4URX1C&JL^/E#' )]S@X_*G44 <+X7T'Q1X:M-5A2'1YWOM0GOELO ^A7<>K:G;/-J5[)?D!\PC+XZX MXK< "J%4 # [4%5;[P!^HH Y&S\5^%X]7U&_G\4Z&6G\N*$+?Q_+$BY // M7>\A^A%K^5'_<7\J/*C_N+^5 ')Z+XJ\*Z;H]O;3>*M#>X +SNM_'AY6)9V'/0L6/X MU@>-]8TCQ!/H3Z;XI\,*-,U&+4";G4U7>4R-F%!QG/7]*]+\J/\ N+^5'E1_ MW%_*@#A4\;P75_:BZ\2>$[2Q1]\_V?5Q)))@':HRJ@#=@GKD#'>N.OH[:;PO MK_AJW\9>$5L;Z\>ZMYWU >9AY1(4=>@QSR"<],#.1[7Y4?\ <7\J/*C_ +B_ ME0!YO/K6E#QU:>(;?Q=X7*G3?L-U')?*"/WGF;DP3G/(Y(QUYZ5GZ1K$&G7& MK:G/XE\(7.N:B2/MC:R L$8_U<:)L/RKUQGYCR:]8\J/^XOY4>5'_<7\J .; MO/''AEK*9;;Q+H+S%2$$NHQJN?<@D_I7.>!M;T;PIX(M-$N/$_AF>YLU94>/ M5%"29=FYR,KU]#7H_E1_W%_*CRH_[B_E0!XQIUII$/PWMO#LOC;PY;ZEI]W] MML;V#4$=1*)&D&Y3CCYBO?U]JVCXF;5/#^IVVM>+_!ZW=Q9R6L,5GJ&(/3?*C_N+^5'E1_W%_*@#RA[[2S8^#(!XI\+;M!:-IB=57$N MV(Q_+\O<'//T]ZSKJVTF>ZU?4X?%WA>UUB34AJ&FW4>J*?(.U49'XY5E7D=_ MPS7M'E1_W%_*CRH_[B_E0!Y5J^LQ/K=AXET?Q?X2AUA+7['>VMQJ(:VGCW;@ M0P^8$,21QW_.77M6L-:T/3H9/&/A>2^BU*&_G)U!8XE$;!A'&/F..,9/?)[X M'J'E1_W%_*CRH_[B_E0!@KXY\)E1N\3Z*&QR!?Q$9_.E_P"$Y\)?]#1HO_@? M%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:-%_\ ^+_ .*H_P"$Y\)?]#1H MO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:-%_\ ^+_ .*H_P"$Y\)? M]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:-%_\ ^+_ .*H_P"$ MY\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:-%_\ ^+_ .*H M_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:-%_\ ^+_ M .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:-%_\ M ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+_H:- M%_\ ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_PG/A+ M_H:-%_\ ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 &%_P MG/A+_H:-%_\ ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N+^5 M&%_PG/A+_H:-%_\ ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/*C_N M+^5 &%_PG/A+_H:-%_\ ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_<7\J/ M*C_N+^5 &%_PG/A+_H:-%_\ ^+_ .*H_P"$Y\)?]#1HO_@?%_\ %5N^5'_< M7\J/*C_N+^5 &%_PG/A+_H:-%_\ ^+_ .*JYIOB+1-8G:'3-8L+V5%WLEM< MI(P7.,D*3QR*T?*C_N+^5*$53E5 ^@H 6BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P/&&KZEH/AZXU73;6" M[>V 9K>0LID&0,*1GGGICF@#?HK#T/Q);^*?#*:MH\B;G4@QS YBD'WD<#D$ M=/UY%6-!U*;4?#EAJE[Y,3W5O'<%4)"H'4-C)ZXSUXH U**3..M '0T5S]Q?>(-.NK M%+BWLKRVN+A8IIX \1@!!P2A+;@3@9R,9'%0^$?$-YK7]N+J*6T3V&K2V$?D MY 955""?YN[DG^'9 MMQ[YH O44T2(20'4E>",]*J:3JUGK=@+VPE$MN9)(UD'1BCE"1ZC*G![B@"[ M134=) 2C*P!P<'/-'F)N"[URN.M #J*YFU\07K_$#4=!N([9+.WL([N. M1<[SN=E^8DX_A]/QKI:"Z*RJS*&;H">30 ZBD+ $ D#/2A65U#*P93T(.0 M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHIDPE,+>04$N/E+@E<^^* 'T5QO@WQVOB+4=1T;4;9++6+":13"K M$I/&KE/,C) )&Y2#Z5M:7J%_=:SJMI<+;""RD2-&C#;GW(KY.3@8W8[Y]J - MBBFI(DF=CJV#@X.<&CS$R!O7)) &>N.M #J*0.K%@&!*]0#TI-Z%RF]=X&2N M><4 .HI P)(!!(ZCTKE_&GB34/#2Z0]G;VTXU#48=/VS%EV-)G#Y'4#'3'XT M =3138PXC7S&4OCYBHP,_3)IN#Z5=R/44 +14<_G>0_V)+WQ7H#:I>6]O;YGDA6*(EON,5))/J1T MQ73(Z2 E'5@#@D'/- #J*:)$) #J21D 'J/6N<\-Z_?:KKOB/3[V*W1=+NDA MB,.[YE:,/EB3UY[ 4 =+12,ZHI9F 4=23P*YOQQX@O?#GAO^U-/CMI2L\,;" M;)&V214R,$9/S9ZT =+1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>,?^15O/K' M_P"C%K=JIJ&F66K6IMK^W2X@)!,;_=..1D=Z .!\2V5SX"UV?QAH\+RZ1=_\ MARQB'3_IY0?WA_%ZCGU((&LKBQ^'U@\;7%^VG"6WMI7"VQ @0,\@()8J#\H' M.2>@Y'HHAC$'D%0T>W:5;YLCT.>M9MYX8T/4;>R@O-*M9XK$ 6JR1@B( 87 MVP ,=.* /(9HHI/A1J43/&XL_$QCM_*)58T^UJ/D&3M7!.!GC-=5/X/XN MP62:?"MI>:+++=0 ?N[AUF0!I%Z.?F/+9KKV\'^''AN(3HUGY5Q-]HF01@"2 M3KN([G/3TJT=!TQM2CU$VB&]CC\I+@D[U3^Z#G./:@#R:*^_L7PA2%(R/W>[:",XP2#P:[72O#>F6>NZK*VI6TD.IV.+JPM8A% M!L'R^:0&."02,Y&0#Z5T$7AK1(;*\LDTRV%K>L7N82F4E8]68'J3Z]:9IGA7 M0=&TVXT[3M*M;:TN01/$B<2@C!#>O!QS0!' MK72HK""((L<[.I3'8!0>,8K-U/3/$.LV9M-2TWPW=VY(;RYC*P!'0C*\'WH MZB:YAMS$LKA6E<(B]2S>@'TR?8 GM7C5[H^GWO@WXF7US;)+XY. *[G3]$U_2V+V=AH"/MV^8T\[L%] S D#VJN/"^J"VN[8:/ MX;\B\]>N M?KCTJY:6%GI/Q6U"VM!]DMX_#,0!3)V!974$9]%4?E6A'X=UF*\M;Q-*\.BY MM4\NWE\V?=$G]U3C@>W2I&T376U.34FTWPZ;V6,PO/YDVYH_[I./N^W2@#G_ M S#+I7B#2="\0Z/93236F^'HC$ACBQ+ M.1$IQE4!&$!P.%QT%-M_#NK6L%[!!HGA9(;YBUU&!)MF)SG<-O/4_F: *NJ: M='IOQ/\ #D>DV\<-OJ-K=Q:E!"H5)(HT4HS*.,AF"YZ_-BN$A\.:;)\#&UV- M&36;&6>2SNU=O-B=;IPJH<\ GC'2PTS01((P@VS3,Y4=$ M!8<#T&0!7/>"_"7B72M$@@O-&T>.X@G>8?:;AW#.79@^U,KN&0 2,C H N1Z M5:ZW\5;Z#6;2*Y4Z!:F6"4;HRWF29RO0X/3/2N;T35'@\%^ K6\NHHM,GO;N MWEDNT,D64>58$<;AD<< G&5![5W?]B:]_: MU5_^$6U+^Q7T8Z)X8.FN=QM293'G.<@;>#GG([T AM=-IUJL#74@EG8,29'QC<A>%UTPMO:U!EV,WJPV_,>!UST'I6O#'XMMX4AB@T)8T M&U1YLQP/^^: .;\%_P#$I^*/C73;X[+J_EBOK4MQYT.&!V^NTG!KT"X>VE<6 M,^UVG1OW6,[E'4GVY _&N5U70]=.6?ZL1D_B: /.M.T^+2O@*/$^FV[#7([.6$7B,QD2% MK@A\<\87)'IR?6NP\065KIFL>"=1\-0Q0R7%^EJWV8 ">T>-F?=C[P 4,">A MY[UJZ?H^O:3IYL+#3/#EO9G.8$:79SU^7;CGO46G>']:TF17L=+\.PLBE(\2 M3$1J>2J CY0<#@8'% '/VQGT/Q#IIU73[74],O-5=M/UNUP)XI96?$T\2^%O&4VM1H=2AOKN.260?O+41C,6QNJA0 1COD]S6[;>' MM9M+A9H-,\/(R2-,H$L^U9#G+A<8#')^8#/)]:2Y\.:Q>7TE[<:3X;>XE 69 MM\P$P'0. ,/CMNS0!RUC:OK>O?#N;78/-NKS1KDW8DS^^PD>-X[Y!R0>.3FN MF^&L,=F/%.GVR".TM==GCMX5X6)"D;;5'89)./>K,^CZ_'GO;<% M89S)-NC!ZA3C@'OZTNGZ1X@TJ2XDL=/\/0/ MW>,?^>6A?]_9O_B:-WC'_GEH7_?V;_XF@#H:*Y[=XQ_YY:%_W]F_^)HW>,?^ M>6A?]_9O_B: .AHKGMWC'_GEH7_?V;_XFC=XQ_YY:%_W]F_^)H Z&BN>W>,? M^>6A?]_9O_B:-WC'_GEH7_?V;_XF@#H:*Y[=XQ_YY:%_W]F_^)HW>,?^>6A? M]_9O_B: .AHKGMWC'_GEH7_?V;_XFC=XQ_YY:%_W]F_^)H Z&BN>W>,?^>6A M?]_9O_B:-WC'_GEH7_?V;_XF@#H:*Y[=XQ_YY:%_W]F_^)HW>,?^>6A?]_9O M_B: .AHKGMWC'_GEH7_?V;_XFC=XQ_YY:%_W]F_^)H Z&BFQ[_+7S-N_ W;> MF>^*=0 4444 %%%% !112.H=&1LX88.#B@#S>Y\*2Z[X=35-(F6U\1:;J5_+ M87/8_P"E2YB?U1NA_P#U@T;/Q1::OX*\9ZKK,5_IBAUM[V* [9HI1%'&RH3Q MRW )['FO3-/TNRTJ%H;"W6")F+E$SC<223CU)))]:;/I&G7,-[#/9021WW_' MTC(")N OS#OP /P% ' :3:I:_%=;*2WL;6&X\._O+2U/R\3*J[SP&;!(S@<' M'-2V MT:SBDMXVCAD2,!D5NN#U_'K2_P#"):!_9:Z7_95M]@5_,6VV_NPV*)<">5)5V,W]YN2,GDYK/\.:?8>(/#GAC7 M_P"V[6"\MYH9))[>WQ9YLJLI'&6*\],US^KZ#KNNB(:II?AJ\6([HUG>9@K>H&, \]: .N MNKFWMDC%PR@32+"BGG>S<8 []S] 3VKQB_CM8_@WX\B9(56#6;U8E( \MA,- MH4=CCIBNSM?"^KV5]#>V^B^%X[J'/E2AIMR9&#@[>,@D5%/X/U&ZNKRZGT#P MI)->#%P[>=^\^OR]3CD]^] #);'3Y/C1933VEJQ/A]YM[QJ?G6>,!LGN!T/4 M"LVYT'1?%7B,Z59:?:1>']%D\S5+T1*'NK@?-Y._&2!]YSGKQ6_+X?UN:>RG MDT;PH9;$8M6Q+^Y'HOR\=!55/!^I16S6T>A^%T@?.Z)7G"MGKD8QS0!WR[?* M&S 7;QCIBO,OA#IES<_##298]:U"W5FGQ%"(=J_OY.FZ,GWZUT\T7C"XMV@D M@T Q,,%1+.,CTX%4M/T/Q!I-B]CIVF^'+6U;K##).B^^ !Q^% '"Z+J$NE?! M6&83%+8ZV8[V9EW!8#=8$= M3TFPNK'3]#\+6UM=\7"1M,/-'HQQDCD\=.30!S5GI=EI^A?"[5K6!8]1GN+6 M"6Y'^L>-[=\H6ZE>!@=!VJ*^O_L?C/Q2FJ6X?PQ/JL$6IRJ>8\P1^7O&.(BW M#$<].V<]()[>#QSH&C.]A:Z5/8S-:I/;AX))PR8 701JFV.V+7$3&)!DX49SC/&:W[SPKJVH:/%I M-WHOA>>PB(,4#M,5CQP-OR_+^%.?PSK$FCPZ0VC>%O[.A(,=J#,(P0,O^>>@_\ ?R;_ .)H Z&BN>W> M,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&BN>W>,O\ GGH/_?R;_P") MHW>,O^>>@_\ ?R;_ .)H Z&BN>W>,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ M .)H Z&BN>W>,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&BN>W>,O\ MGGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&BN>W>,O\ GGH/_?R;_P")HW>, MO^>>@_\ ?R;_ .)H Z&BN>W>,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H M Z&BN>W>,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&BN>W>,O\ GGH/ M_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&BN>W>,O\ GGH/_?R;_P")HW>,O^>> M@_\ ?R;_ .)H Z&BN>W>,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&B MN>W>,O\ GGH/_?R;_P")HW>,O^>>@_\ ?R;_ .)H Z&BJ>FG4S;-_:JV@GWG M;]E+%=N!UW '.YH 6BF>='_ST3_OH4@N(3E2 @@$'(- ! M112$@#).![T +13/.C_YZ)_WT*>"",@Y% !1110 4444 %%%1QW$,SRI%-&[ MQ-MD56!*-C.#Z'!!H DHHHH **0D*,D@#U-()$8X5U)]C0 ZBF2RQP0O--(L M<2*6=W. H'4DGH*5'61%=&#(PRK*<@CU% #J*** "BBB@ HHHH ***BDNK>& M18Y9XD=_NJS@%OH* ):*CFN(+>!YYIHXH4Y:1V"JOU)Z5)UH **CGN(;:(RS MRQQ1@@%I&"CGIR:DH ***C2XADEDBCEC>2+'F(K E,],CM0!)12%U! + $] M32T %%('5B0&!(Z@&EH **** "BD9@JEF( R2>U0VE]:7\1EL[J"YC!VEX9 M X!],CO0!/1110 4444 %%1S7$-N$,\T<0=PB%V"[F/0#/4GTJ2@ HHHH ** M** "BB@G R: "BF>='_ST3_OH4V2ZMX51I9XD#N(T+.!N8]%'J3Z4 2T45'# M<0W 8PRQR!&*,48'##J#CO0!)1110 44@=22 P)'4 T$@#).![T +13/-C_Y MZ+^=.#!AE2"/8T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !6=JNAZ=K;6O]I6D5U';2&5(ID#IOVE5>$/"F@:KK7CNRO-'L9(5U(PQ@VZ9B4QCA#CY?7CO75P:E /'5_I<&BQ MC5+?2TD6]E=5,\>\A4)4$A=P)_I5?P9I.JZ9X@\47-_8-!!J=]]IMW\U&^7: M%PP!.#Q[U/!I>HK\4;O66LV&GR:7'9K+YB9WK(SD[^>PK6U73_$VG>)K+Q-HFF1WWFV"V-]ILMPL3C:Q975^5R"S ^WUX -'2?& M4NO>'[+5-*T:>X:6]%I=0&95-L 2'?<>'4<'CJ".E=2Z)(A2159&&"K#(-8A MNO$<6GV8%5$*@<=S@=Z[K5]9C\! MZ5I<<6F[M%$D=J]QYVT6:L<*6&W[@R!GZ?6LCP3;ZOX;T"\L+[0VF>:]GN ( M[J J5D;(!RX^AXK7NHM1UW3K72]6M8DM+S>VH^7.A$<>3MA!R"*HX- O=L6/P]KU[X$U/PI=SK$UM(ITC499D8N MD%O%_ANVT^VD34KZ>[MKPWB!765PVW;U M##D'.!WR>A .IGU_63\3;318;:V-@VEO='=.59LR1J6/R'E>0!WR>14=CXBC M2+Q9=Z;X;$=WIUT?M,0D59+MA&&W94$;MN,#)SZTV6QU9/'NDZ[';6LD1TMK M&Y470'D,9%?=R,L, C@=?3K5CPG97FGZ[XGN;V!88=0OA<6[&9&RHC5,$ G! M^7/XT 7K/Q,VH:3H-]:6L4O]K;65!/\ ZM2A4I=K]HX?8SK#CYE#9_B!(&<8J7P=X;E\.W^I)/.*YA*2(DL3CE6&0P^E>7_"GPOH.J?#.U-[H]E,\DUP&E:%? M,XF<##XW @ 8(.1BO3);I(H&=/WSJ.$5U!;\R!7!>!8/$'A;P7#H\NC1R7T< MDSJYO8A#\\C,,L"6&-W930!EZ'KTVD:3X[T'5H9M"?%,33PZAXA\01S&XDC8)&'="JJNX\(N>_/7Z5*^FZF=5\"W(L?W>CPR)>? MZ1%E2T(C&WYOFY&?I[\4 :$WCB6&-H'L+2WU2"V2>ZLKO44B\LMDB-7 (=L# M/0#D9(S4^G>.+;6[+1WTFU>:ZU2%YXX)W\ORDC(5S(P!QAB%& G^([?6]&\4:@6D]MH[6-TVM1:=<)=2 M,O'FJ-T9V_.CCC=@8!/!KHI/$%R^K'1[.Q@GU.*V6YN4:Y*10AB0J[]A))(. M/EZ#)QQG#\2V.NZ]X9MI6@M%U"#4K>^2P6Y7"I&ZDIYA !8X)STYQSC).9O$D%JEU;ZI9QPWMK#<)YD$L9.QE+E59<$@\@YYYH 6?XDV\7AQ-5CTJ MZDD341IMW:[U#VTV\(0?[W4$8ZY'2NGT>]U"^MIGU+2FTV5)F1(FG67>@QA\ MKP,^G;%>?ZCX3U$>'KH6T$4VH:CKR:M/$LZ!84616";B1D[4'3N3VYKL-=U^ M^TR?26M-.CN;6YN4ANV:Y5'MP[*JD+SO.6YQV4_6@!/'GB"7PMX'U;68%#3V MT/[H$9 =F"*3[ L#5?PYXW,T/G27#LN6)X)(YP!V M& *U/$&EV'B3P_?:/>RK]GNXC&Q5AE?1A[@X/X5B>';G7=!T6#2=3TXZE)9Q MB&*\LKB$+.BC"EED=2K8QGJ.^: .4\3-X>O/@IXB30Y#=6$$CO$98'40N90Q M52X'W2Q''0'%>@76O-%K$&B6%NESJ+6OVIUDE\J..+.T%F"L7?\S''0=<9YK=N-/U"R\JVUO<6\@# MO#()X\[6[AE/!&,@UU-GXRN/^$JCT'6-#GTR6ZB>:QD,RS+(VRZIJ^HP7HMWF ")"R%4+#(W$(23TRV,X&:VKJPO=? M\0Z=K$D*Z8=+M[@6R3R1N[3RJ%W'8S+L4#UR2>@QR /M/'$DM]H45WI+VD.M MF1;7?-^^0JI8>9&5&W('8M@U5\'016_C_P >1PQI&GVJT;:B@#)MU)./E &=\5?#K>(K#1K:TQ%J7VYFM9U M#K(EM/(@W=@71:O:9XR?6?A[::O:*HU2[ M%@8?I)/]3796WBJ=O$%[H5UIBKJ%O9+>HEM* +-C\2);O3-!U9] FATO5KA+43M/?TK8DL=9L?&7B*\L[&"YM- M;M8 LS72)]G>-&0AEZG.01CZ9'4 %'Q;XEO-:^'NA:G8VBQVVJW=GYL'0]6U*6R\.0I?S60OM0G^T-'"^TLJJ'V$,^ >R\8R M:YX^']<7X9>&M$-C"U_87-K+,B72;0D3ACR2.3CH,CWK7UBSUJ^\5RS-96U[ MI4M@([9)[I46SGR=S,G.XD$889(QCC)- &M;^,K>_P!.T*:PMFENM:B,UM;R M/LVJ%#.SL N,''L_#OB;2M#\'ZC:6MF^K:#%):S:>UVH%Q"ZJ#A_NJP*@CM[]J MW?$UEKWB;P/=Q26]I;Z@\\$T%@+E6"K'*CD-)@#<=I]AP/4T ;:>([F/Q5:Z M!=Z?''/5_[-U)M.FBCF!&Y M75-P) )!+#H,TFJ6^LCQ=H?B.VTZ"X*6DUI!W'7FKEQXOOSXDU/0M/\/RW5W901SJSW*1I( MKEN_.W[O'4GT'6HO&MI>ZS9Z%]AM?,>VU6VOID::-2B1MEARV"WICCWI+*VO MK;XAZSK+V9-E+7+R#4?#]QI^H:@IN7NY+R*Y^T>7M3!*8V[0RX&T#KWS0!VU%%% !5 M>^LX]0T^YLIMWE7$31/M.#M8$''YU8HH \MU_P -:%;?%3P190:+I\=K)#?> M9"ML@1]L2[=PQ@X[9K=UN'1/"4&EVT?A^*XM+[6H!%&H18[6=R )%7'&"">! MU)Y&:77]*U6[^(_AG5[;3WEL=,CN5GD\U 294"C:"V3@CG./;-6?'.EZCJT. MB)IUH;@VFK6U[+^\5<1QMDXW$9)[?TH AM-;UB[^).K:++:VITZUM(7 \\Y( MK67AKPIK4\JI'$OB&[MX8@0@+--M503PH]^@ )[ M5N1:7JUG\2;[5XK..73[^Q@B:0S!6B:-G)&WOD-QCCU-<]'X/\02^$]1@BB2 MSU:+7I-8L/-D5HW/F;U5MI.."0?K0!TFE>-5U'7KW1&M8&OH+7[7";.[$\4Z M9VX#[5VL#@$$=\]*W])NKJ^TJVNKZP:PNI4#26KR!S$?3<.#63HM_P"*+Z*2 MXU718--,<1"6HNUF,\G8[@,(O&.Y^;G&.=/3+RZETJUEU:WBL;YT!FMQ,'$; M>@;O0!YCXP4^&/B0?&=HFRWLHK6'4TC7&^"9Y59SCJ594/X>U:WQ^NG0_\ +)?]6N?]M\'W"/6W+9)JFMZ[!J%H/[+U"RBM/,,T9W!? M-WF2>!G@T =+X=U0ZW MX:TO5601M>6D4Y0?PEE!(_6M.JEDECI]A;V5J\26]O$L42!Q\JJ, ?D*G^T0 M?\]H_P#OH4 245']H@_Y[1_]]"C[1!_SVC_[Z% $E%1_:(/^>T?_ 'T*/M$' M_/:/_OH4 245']H@_P">T?\ WT*/M$'_ #VC_P"^A0!)14?VB#_GM'_WT*/M M$'_/:/\ [Z% $E%1_:(/^>T?_?0H^T0?\]H_^^A0!)14?VB#_GM'_P!]"C[1 M!_SVC_[Z% $E%1_:(/\ GM'_ -]"C[1!_P ]H_\ OH4 245']H@_Y[1_]]"C M[1!_SVC_ .^A0!)14?VB#_GM'_WT*/M$'_/:/_OH4 245']H@_Y[1_\ ?0H^ MT0?\]H_^^A0!)14?VB#_ )[1_P#?0H^T0?\ /:/_ +Z% $E%1_:(/^>T?_?0 MH^T0?\]H_P#OH4 245']H@_Y[1_]]"C[1!_SVC_[Z% $E%1_:(/^>T?_ 'T* M/M$'_/:/_OH4 245']H@_P">T?\ WT*/M$'_ #VC_P"^A0!)14?VB#_GM'_W MT*/M$'_/:/\ [Z% $E%1_:(/^>T?_?0H^T0?\]H_^^A0!)135=7&48,/4'-. MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ J"\L[74+62UO;:&YMY,!XID#HW. M>0>#R!4]% &#_P (1X3_ .A8T;_P B_^)H_X0CPG_P!"QHW_ ( 1?_$UO44 M8/\ PA'A/_H6-&_\ (O_ (FC_A"/"?\ T+&C?^ $7_Q-;U% &#_PA'A/_H6- M&_\ "+_ .)H_P"$(\)_]"QHW_@!%_\ $UO44 8/_"$>$_\ H6-&_P# "+_X MFC_A"/"?_0L:-_X 1?\ Q-;U% &#_P (1X3_ .A8T;_P B_^)H_X0CPG_P!" MQHW_ ( 1?_$UO44 8/\ PA'A/_H6-&_\ (O_ (FC_A"/"?\ T+&C?^ $7_Q- M;U% &#_PA'A/_H6-&_\ "+_ .)H_P"$(\)_]"QHW_@!%_\ $UO44 8/_"$> M$_\ H6-&_P# "+_XFC_A"/"?_0L:-_X 1?\ Q-;U% &#_P (1X3_ .A8T;_P M B_^)H_X0CPG_P!"QHW_ ( 1?_$UO44 8/\ PA'A/_H6-&_\ (O_ (FC_A"/ M"?\ T+&C?^ $7_Q-;U% &#_PA'A/_H6-&_\ "+_ .)H_P"$(\)_]"QHW_@! M%_\ $UO44 8/_"$>$_\ H6-&_P# "+_XFC_A"/"?_0L:-_X 1?\ Q-;U% &# M_P (1X3_ .A8T;_P B_^)H_X0CPG_P!"QHW_ ( 1?_$UO44 8/\ PA'A/_H6 M-&_\ (O_ (FC_A"/"?\ T+&C?^ $7_Q-;U% &#_PA'A/_H6-&_\ "+_ .)H M_P"$(\)_]"QHW_@!%_\ $UO44 8/_"$>$_\ H6-&_P# "+_XFC_A"/"?_0L: M-_X 1?\ Q-;U% &#_P (1X3_ .A8T;_P B_^)H_X0CPG_P!"QHW_ ( 1?_$U MO44 8/\ PA'A/_H6-&_\ (O_ (FC_A"/"?\ T+&C?^ $7_Q-;U% &#_PA'A/ M_H6-&_\ "+_ .)H_P"$(\)_]"QHW_@!%_\ $UO44 8/_"$>$_\ H6-&_P# M"+_XFC_A"/"?_0L:-_X 1?\ Q-;U% &#_P (1X3_ .A8T;_P B_^)H_X0CPG M_P!"QHW_ ( 1?_$UO44 1<^&M.5,YS;PB!O^^H\']:L^'_ W MACPN0VCZ+:VTHSB;:7E&>#\[9;'MFNAHH **** "BBB@ HHHH **** "LW4O M#^BZS*DNJ:187LB+M1KFV20J/0%@<"M*B@# _P"$&\)?]"OHO_@!%_\ $T?\ M(-X2_P"A7T7_ , (O_B:WZ* ,#_A!O"7_0KZ+_X 1?\ Q-'_ @WA+_H5]%_ M\ (O_B:WZ* ,(>"?"8&!X8T;_P (O\ XFC_ (0GPI_T+.C?^ $7_P 36[10 M!A?\(3X4_P"A9T;_ , (O_B:/^$)\*?]"SHW_@!%_P#$UNT4 87_ A/A3_H M6=&_\ (O_B:/^$)\*?\ 0LZ-_P" $7_Q-;M% &%_PA/A3_H6=&_\ (O_ (FC M_A"?"G_0LZ-_X 1?_$UNT4 87_"$^%/^A9T;_P (O\ XFC_ (0GPI_T+.C? M^ $7_P 36[10!A?\(3X4_P"A9T;_ , (O_B:/^$)\*?]"SHW_@!%_P#$UNT4 M 87_ A/A3_H6=&_\ (O_B:/^$)\*?\ 0LZ-_P" $7_Q-;M% &%_PA/A3_H6 M=&_\ (O_ (FC_A"?"G_0LZ-_X 1?_$UNT4 87_"$^%/^A9T;_P (O\ XFC_ M (0GPI_T+.C?^ $7_P 36[10!A?\(3X4_P"A9T;_ , (O_B:/^$)\*?]"SHW M_@!%_P#$UNT4 87_ A/A3_H6=&_\ (O_B:/^$)\*?\ 0LZ-_P" $7_Q-;M% M &%_PA/A3_H6=&_\ (O_ (FC_A"?"G_0LZ-_X 1?_$UNT4 87_"$^%/^A9T; M_P (O\ XFC_ (0GPI_T+.C?^ $7_P 36[10!A?\(3X4_P"A9T;_ , (O_B: M/^$)\*?]"SHW_@!%_P#$UNT4 87_ A/A3_H6=&_\ (O_B:/^$)\*?\ 0LZ- M_P" $7_Q-;M% &%_PA/A3_H6=&_\ (O_ (FC_A"?"G_0LZ-_X 1?_$UNT4 8 M7_"$^%/^A9T;_P (O\ XFC_ (0GPI_T+.C?^ $7_P 36[10!A?\(3X4_P"A M9T;_ , (O_B:/^$)\*?]"SHW_@!%_P#$UNT4 5-/TO3])MV@TVQMK.%FWF.V MB6-2W SA0.>!^56Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ***Q_%'B"/POH%SK,]K-<6]LNZ M582NX+D#(!(!Z^M &Q17*W?C7^S-+CU34]!U.VTYE#OD_V@2+&>Z"% M)F SM.UCL8CH#6KJ_B6WT?5])TZ6UN9'U.?R(I44>6C;2WS$GT!Z T ;=%%8 M'BOQ3'X3L(+V>QN+J&6=+<>0RY#N<+D,1QF@#?HIL;,T:LZ;&(Y7.W2Z*,LZ#KM9&(R.XJ2Y\:V=NE_=K;32Z7IT_P!GO+U2-L;@@-A>K*F1 MN(Z-; M#4O"UMKNG6UW=BZ;RH;2.,"9I1D%""0%(VMDDX !.: .DHKFO#GC"/7=2O=) MNM-N]+U:S59);2ZVDE&Z.K*2&';([UTM !15*VU 7&J7UEY>TVHC._=G=O!/ M3MC%5M4UV.PU&STR&%KK4;P.T4"L%PB8W.Q/W5&0.Y)(P/0 UJ*YY?&6F_V' M/J3K,C07/V*2UP#*+G<$$0&<%B2,'.""#G%36?B)9=>.B7UH]E?M!]IA5G#I M-&#@[6'=3C(/J",CF@#;HJM?WGV&S>?R)KAA@)#"H+R,> !D@?B2 .I(%8OA M_P 6?VSJU_I%YI=WI>IV2)(]O<%&#QMG:ZLA((X(H Z.BN3N_' L-8L;:\T3 M4(-.OKE;2VU%MGEO*W"Y4-O4$]"0*ZIRP1BJ[F X7.,F@!U%-YVA]Q49SD \5>U3QS:V#:&;6QN-1AUM@ME+;.@# M$KN&=[#'% '545S4OC.VL-5M-.UG3[W2WO'\NVFN C0ROV0.C, Q[!L9[5%K MGC1M#M=4O9="OY;#33B6Y1X@K\*3M!<,<;L=.H- '545A:9XAN+^]MH)]%O; M..Y@,\4\KQ,AQM^7Y6)!PV>1V/I6[0 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 444URRHQ5=S <+G&30 ZBN1TCQQ-K<%]/8^&]2E2R MNI+24"2 ,9$^\%!D&:U_#WB73?$UI+/I[R!X)##<6\R%)8)!U5U/0T :]%%1 M6]S#=Q&6WD61 [(64\;E8JP_ @C\* ):*** "BN1U_QTVAM>#6I>^("NFVMWI&G7&KM=QB:!+=E0-&0#N+.0 , M$8[G/ X. #:HK&\,>([;Q1H_V^W@GMV25X)K>X7#PRH<,K8XX-:EU*\%M)+' M"9G1P)XH EHK#\)>)8O%WA^#6K:TGMK6XW>4)RNX@,5)(4G'(-;E M!1110 45Q>J?$2+1Y1A:FNA^<(6U;:GE D[=VW=OV9_BQ@]LY&=W4=>CM M-4M=*MH&N]1N8VF6%&"A(EP"[,>@R0!UR3]2 #7HKGT\76D^A_VC:VMU<3^> MUK]AC4><)U)#1D9P",$DDXP,YQ5?0?&L&K7]_IE_I]UI&IV,8FFMKLJPMM2T'5-.LM1F$%G?7"ILDD/W0RABR;NP8 ^H'.. MPD?RXG?&=H)Q0 ZBJFEWHU+2;*_$?EBY@2;9G.W&2=GDDN'$5M!"-T MD[GHJ#OQSG@ @">BJ]_?6^FV,UY M=/LAA7 !U)Q5#P[X@A\1>&+37+>"6.&YC,BQ-@N "1CCOQ0!K MT5C>&O$4'B?39;VWMY[=([F6W*3@!PR-M.0"0.?>F>+/$L7A+P_<:U-M.O[7 M5FC@NX[_ $J-GNM.FC"W"X4L,#.&SC@@D'(YJK/XWN+;7+#1IO#6HI?7T3RP MQF: @J@!;)$F!UH Z^BJ&D:D^IVLDDMC/9312M%)!.5+*1WRI(((((P>AJ_0 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QOQ7_Y M);XA_P"O;_V85V59?B#0;7Q+H\VE7TDZVDXVRK"P4N,@XS@D=.V* (O-M(?! MGFWY46:Z?F??TV>7\V?PS7FG@#[9#X!\%V=W>WBM-]JD33;>JDE8Y25^888;A@9P#75$!A@@$>AKDM5TI[2/2[&PT?5KFWL9EN MUEM;^.,R2 MD2F1PSY)R<]<]:FO=4UJ]LIK8^%M6A$J%#)#>VRNH/=3YG!]Z M '7MFGB3Q)I\O!T_19VG,G:6YVE J^R!F)/][ [-BAXY_P"1B\$_]AC_ -HR M5B6/A>>PEM2FB>+I8;9U9+:;78GA^4Y *&7!' XK7UB+4=:O=/N[CPQK4"1@\>U &]KGB)]$FBC30M8U+S%+;["!9%3GHV6, M?%24W/@K3)?*DC:74[)O+D&'7,@X(]1TKH?[=UO_ *%#4/\ P*MO_CE<]-I5 MQ<>()M7F\*:U(\TL,[VSW]L83+$,1N%,G!'L<9 )% &@+BX'Q>FT[[5<_8I= M!\]H#,VP2>?MW*,_*<<<8KCVU/5W^'MG:)B6:+[44"L3DD M<8_/-=+JME>ZKK5MJ[>%]=MKR"(P&2TU*WB,L1.2C8DY&1GC!]ZSU\,&/2%T MN+PKKT=JM[]N"KJ5MQ+NW@C,A /.!@>N: +]E/=Z!\1]4TY;O4]1LVT1=1^ MSRRF9_-$K*1&"<#@"U;V::YXLM_$) ^QZ?!);V+?\ /5I"/,D'^SA0 MJ^OS'I@GA_#_ .Y_9^\0K=_\?"1ZDEP&Z^;ND&#[]*UM,T.\TS4+>\&A^*[M MK6;RA\OMT))[ $GI5OPYH\' MA;PW';3S1%HC)<74Y^5?,JP7EH6,%S#=V@= PPPYD(((QD$$< ]0* . M/'A[4/$>I^-3I^+VA^=8QVIT6 MPGFNQ'/YNTS@(J,0H /RE@/09XK6LWU+3=-:RL/"FK6P=VE>9;NT:1W8Y9F+ M."]14RN99I'O+9GE<]69C+DG^F .!0!O:3I;:5;W$1 MO[R\,L\DX>[DWE-QSL7@84=A7*:,^L:;\4=1L=5^R7:ZE8_:K>\@A,;1I$X3 MR6!8\ R9!SU)]<"/[%J:Z1<:?%H?B:(37377GQZO )48MNVJWF?=_P!GD5>T M^75+"9[D^%=7N;N1!&]S<7MJSE1T48D R2< #GDT 5?B*^L:=_9FNP?8[O3 M-.O(I)["2$[W+,(PZONY9=^0,=>><"N[KS^RL=2M1&EQH/B/4(8I1-%%?:G; M2JC@Y!SYF6P>1N)P0#U K>?7-<9&4>$]20D8#+=6N1[C,F* .%\*Z5JNN>'_ M !OI5E>6MI!>:_?P2S21-(ZJVT-M&0"2#@9Z5?\ $>D6^@ZC\-M)M"Q@L[_R M4+G)($1&3[GK6EX>M;_PU]M%CX7UIEO+A[J99KZT8-*V-S_?R"<#CI[4S7+* M_P!?OK"\NO#6N1RV$AEMO(OK1 CD8+??Y./6@"'XV^4_PTNK?&Z\GN;>.R1? MOM-YBX"^^T-5_P")@E7X2:VLY!E%D Y'=LC/ZU!%97(U6#5+OPCK%_>V^?(E MN]0MW$.>I1?,"J?<#/O5CQ!_:/B31Y]*OO"FKK:3C;*L-[:J7&* .#^%7_(/\3?]C'>_^A+7._:##\0?B/?V.IKIEG'80137 M_E[TBN=H (7^)@,C YR?6NXT[P-8Z5#=0V>I:K%%=SO<3JESC?(_WFR!D$^Q M%6G\&:"WA>Y\.)8+%IMR#YJ(QW,Q(.\L>2V0#DDGB@#F=)FN_P#A8AT=VU.' M3;K0C.8;J[=I"XE5/,!W$QDACP&!Z9P:Y_PO?2Z'\*?#;6DTJRZKJ8LI'ENG M"HIFE^Z3N$9.W;E1GYL]<&O0;/P5IMGK-IJ_VG49[ZWMS;^=/=NYD0D'#^N" M <=.^,U"GP]\/KX>N]!DAN)M-N'+B&6=F$)+%_W?]S#$GCGUS0!%I6BZW:ZU MJ4=SJ?E:7>VN(;9;Z2XF@E'#21O(H(&&''.#CUKH],L3INEVUD;JXNS!&$,] MR^^23'=CW-96D>$++2+&YMUO=3NI+B(PM,1J\\A=V '5F/4T 9GB;?>:9/H-EM^V:C$\1.,B&-N'E;Z M G [M@>I%Z+3FL-!BTW298[?[/ L%N\L9E5 H"C*@KG@>HK@[_PW>76K7E]_ M9?B^.6Y?+FVUV*)& X&%$HP .@JX;+5$BTZ.TT3Q-9BQ0HODZI;?O<]3(&D( M=B>-)MD\T*Q'S'S-S<\?I M75Z3K#:UIT\[Z7J.G%&*>5?Q"-VX!W !CQSC\#65I][J6F6YAMO!NH@,YD=F MO+9FD<]68F7))_SP*I:W'J6N2V,TOAK7+::RE,L,EK?VJ')&T@@R$$$'N* . M,\/W-U8?!+P;<6MS<6\O]IPQ$Q2LFY'NF#*P!P01ZUVSS73?%6^TQ;Z[CM)- M!6X\M920DAF*[U!R%. !Q5>]TY[WPO'X=_X0G4X-/A5!"(+VV5XBA!5E;S<[ M@0#G\ZKVVCW5KJYU9?#?B%]1-I]D:XDU2W9F3<6R09,$Y/<8&!@"@#GM,N]6 MC\!>#/$CZYJ*)%U[^R_^$=UP MKYHC^VBW7[/_ +V[?G;[XKE5\/3)X?T_0T\,Z\MC83K<6ZB_M-RNK;E^;?D@ M')Y]?I74#7-;"@'PEJ)('4W5KD_^1* (_%-DGB.U/AB, PSF-KYQTA@#!MO^ M\^W:!V!)[#.19JR_'/43+T;08OL_IL$QW8_X%_.LEO"EV9)W&F>-$,[F241^ M((D#,>IP)0*W+J.^G>RFA\):K:7-C&8K>>WO+0.D9 !3YG(*G X(/(!ZT 5_ M #"+4_'%U*RI9KKDQ#N<*I5%#MD]/^)[F(H;BV2RM(W7#"W5 MBQ9@>A=F)P>@"YP<@8-YI,]WH$>BIX5UVUM%E\YC;:G;H\C[MQ9G\W))8[CS MUJ/3='O],N9+E-$\57,S0M$C7>M0S>5NZL@:4A6XZT =!K-FGB;5["S !LM+ MNTO+F7L94!,<0]P2&;T _BXZ&Y_X]9?]P_RKS"W\)36X1!HWC!X%?<;>37X MC$_.2&7S<$$YR.^3783:YK;02*/"&H%O^11T7_KP@_\ M1:UYIH/[G]G36TN_^/A(-12X#=1+OD'/OG%=AH.K:Y:>'=,MF\(ZB6AM(HSF MXMU.0@'0R CZ$9JC/IT]Q+<[_"&K"TNYQ2JD@$ XY! MYH P=!L-0U3QWI5K>WUS92Z;X6MC"8U0N'DPLCC>K 'Y=I..U=#X=DU7Q5X? MUS1-5U.[@N].U-[+^TK$B&654*.K<# )!P0!C%6+_P#M&^U&VU)?"FK6U_;H MT<=S!=V@;8V,H07(920#@@X(R,57N+.[GT";1T\*:W;PS2>=)-;ZC;I,\A?> M6+B7.21S[<4 2Z_KQA\2_9[O1-YB-M%L+S1%%DY)RA/WA[BMLZYK14J?"&H8(Q_Q]VW_QRL_1 MGU#0-"M]'T_PCJL=M;QF.(F\M691RW2CQ) M%?\ BG1Y=)U#PIJXLYL>:D-[:KOP00"?,SU Z8H FN/"=[KGB+0]7U:]M_L^ MD9EM[:VB(+RL -SL3T&!@ ?C5+P5_P E%^('_7W:_P#HFM>VU;6[:UC@_P"$ M6U678NT227=IN/UQ(!6!;:1?V>I:AJ%OH7B2*YU%P]TRZC:#S"!@<;^,#CC% M #)1YW[0T#6//D:&5ORO09$/^O*]_\ 05JUHR7&@I.- M/\$:BDEP_F3S/>V\DLS>KNTI9C]3Q5:]M-0OO$EGKTGAG6UO;-&C@V7MH$16 M&&&W?SGWS0!WM%4]-N[J\MFDN].FL) Y4132(Y(P/FRC$8ZCKGBKE !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37#E& M$;*KX^4L,@'W&1G\Z=10!POAC7_%/B2QU:>.71XI;#49[%(FM9<2F,@9+>9\ MN<^AQ[UJ^$O&-KXE\-0ZM.J6#F1X)8I)00LB'#!6XW#OFN-\"Z);ZOHWBWSM M3U"S1]>OE:2UO&B"C(Y]/QJ'P9I \9_"74O#]Q#;+;VMU-;:;>Q0A%EV$%)P M!WW9R1UY]Z /6#=6ZM&IGB#2C,8+C+_3UI8IX;A6:&5)%5BA*," PX(X[BN) M\&:G-XOGMM5OK4PSZ3"UG+&Z8VWA.)L>P"K@C_GHP[5T^AP:+;VLZZ&+06[7 M,C3?96#+YQ/SYQ_%GJ.U "ZQ>S6L=I#;%?M-U=1P1Y&0!G@?;9I/$?V&(KY$%KYM MQQSN=L1@'Z)(3_P&L_Q+XF;1[W3-)L8%N=8U21DMHG;:B*HR\CD<[5'8YLXK73);9() /*&)(]_S%F.3R!^'2NFN+R"UC1Y)!^\ M8)&!R78] !W_ ,.>E>;?V5I^I>+/B4;ZT@N?+AMMOFH&"9M3R >A]^M 'I 35$W%Q/J]E):ZA9'39('+18W22MQM9&!QM'.>. M]>76EG::G#\)&OH(IVEMGCD:103(HM2=K'N,CH>#^-=%)I.G:/\ %KPW!IUE M;VL8TJ[4)"@7@,F!Q]3^= '=#4+)KIK5;N W"]8A(-XXSTSGI65:^(K/7K/5 MDT6_MOM%HTD"3.0R"15!W$ Y*AFP?H:XG2WO-#U;0H;V&TUG0KR^D.F:G#\M MQ!+*LA*RK_$"&<$CTR>>*K:;;::_@?XCP20VIE6_U4A"J[@JKD8'7 .#[<4 M>H6=P4L++[9=VTEQ+&N9(SM25]N24&>AY(Z\5-!=VUU 9[>XBFB!(,D;AEXZ M\BO+)M/LKR3X4?:+>*7S+-H^C1?$NUNK=TTA;F MS!MK1Q"-TL48.".%!8C+O$C>' MXM,BB:WCGU*]2SCGN<^5"2"VYL$9X7 &1DD(((I;;4YO(C$AV_O K,,'J&PIP1 MSV[T /LY]?A\0QV.H&RN+&2UDE6ZMXFB82*R (REF'1BH M2:EJ%E*D=U(8VA&P0Q<%4V=H/A1\1X1;P^5!K=X8D"#$9!3&T=L>U 'LRW MUHTTD*W4)EB7?(@D&Y%]2.PIUO*:(]'C<,I_$5YSK&AZ4GQ!\$( MEA;JMU!>K< (/WX$2,!)_?\ FY^;/-<]JSRZ1X?^(D&F1F&SAU> S16XQY<# M+%YVT#ID9SCMF@#V2VOK2\,@M;J"IP:AJFKZ:+'5[7^SHXM6TBZ.U_) =@T3]!D,_!&#@] MZ[W2;J*^T:QNX$=(9[>.6-9!AE5E! /O@T 7**** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "FNB2(R2*KHPPRL,@CT-.HH QAX0\,KG'AW2!N.3BRCY/\ MWS3]8&L6FFP)X;L]/>99%4Q73M%&L7.<;0>1QQCUK6HH S]%TXZ7IJ022++< M.[S7$JK@/*[%G('89)P.PP.U03Z;=65L(O#BZ98;Y6EF$MJ65V;DG",OS$]2 M=TIMQI_ MBN[MWM[F\\.S0R#:\%;1\;=T.DR(0 M/3(FZ>U+_P (SK/F7,GE^$]]T,7#?V.^9A_MGS?F_&NRHH XH>$]47[/BW\( M#[-_J,:*W[KO\O[WY?PJQ)H7B";4(]0E;PN][&,)<-I,AD4>S>;D5UM% '&V MOAK6[&X$]H/"L$H)(>+29%()ZD8FX)[^M*_AK6I'NW=/"C->8^TEM'+2'4QH3DJI$O MR2<"I[W1_$NI1"*^G\-748.0D^ER. <8Z&;TKJJ* ./L/#VO:69#8-X8MFEP M)#%I4BEP.@)$W-1?\(GJHMYK?[/X0\B=]\L?]BMMD;U8>;@GW-=K10!QQ\-Z MT9K>8IX3,ML,0.='?=$/13YOR_A3K?P_KUG)/);?\(K ]Q_KFBTAU,O^\1+S M^-=?10!QUAX5 M]\D7]BML=O4CS<$^]=K10!QGMTK2%OXQ M P-2T''_ &#YO_CU=%10!SWD>,O^@EH/_@OF_P#CU'D>,O\ H):#_P""^;_X M]70T4 <]Y'C+_H):#_X+YO\ X]1Y'C+_ *"6@_\ @OF_^/5T-% '/>1XR_Z" M6@_^"^;_ ./4>1XR_P"@EH/_ (+YO_CU=#10!SWD>,O^@EH/_@OF_P#CU'D> M,O\ H):#_P""^;_X]70T4 <]Y'C+_H):#_X+YO\ X]1Y'C+_ *"6@_\ @OF_ M^/5T-% '/>1XR_Z"6@_^"^;_ ./4>1XR_P"@EH/_ (+YO_CU=#10!SWD>,O^ M@EH/_@OF_P#CU'D>,O\ H):#_P""^;_X]70T4 <]Y'C+_H):#_X+YO\ X]1Y M'C+_ *"6@_\ @OF_^/5T-% '/>1XR_Z"6@_^"^;_ ./4>1XR_P"@EH/_ (+Y MO_CU=#10!SWD>,O^@EH/_@OF_P#CU'D>,O\ H):#_P""^;_X]70T4 <^D'C# M>N_4=#*9^8+83 X_[_5T%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1I/# M)(T:2QLZ_>4,"1]14E>:^.= U"X\96&K^&FC@URRL9;A!M 6\57C!BD/<$,< M>A].H /19;F"%@LL\<9/(#N!4M<%;Z_IGC.'PKJ44"B5-5:.>WF4>9;2K;3[ MD8'H00/T-6M<\>8Q2S;BH+Q(5PRC?_>&=K=,4 =G M17+7GBK4$\7S^'++15GN%L!>QRRW0C1@7V8;"DJ,@] 3TXZD8Q^)5ZOA7_A( MF\.E;*UG,&H!KP;X663RV\L!3Y@!YYVT >A45S.L>+H['4KK3K3[!)=VL*S2 M+>7HMU.[.U%.UB6(4GH ,CGFETKQ3=:[I.AZGIFC326U^Y6Z\Z41M9J,@DJ? MO_,,XD=0S%B>HYP!V H Z* M:]M+ISVJ>O,?&&AVGARR\*0V-MYBQ^)XI(8U W M*',CE%)/3<>.0.GI6_;>,KWSO$-G?:*L-_I$"7(BBNA(L\3!B"&*K@_*01C\ MZ .KN+B"TMY+BYFCA@C4L\DC!54#J23P!3T=9$5T8,K#(8'((]:\^N/&E]>^ M"+K7+[P@DNC/I:W>R6[1A+N&6C9"O3'(.#D8X'0;T2ZO++[ M5%%<7'DIM&T!$(4[CST X S0!T]0I=VTMU+:QW$3W$(4RQ*X+H&Z$CJ,X.,^ ME<7J?B/Q"/$W@^SAL+>!-2AFGGMYKEE8.D63&Q"' 4OGH[5E)V=[I>EZ5/X' M^(6F+97=PTHBUF2,-#>.Q)$OF=5?D=3QCDCI0![-)=VT,T$,MQ"DMP2(49P& MD(&3M'? YXJ:N7U?5+>R\5^%].FTF*Z>[:9;>^8KFW98BS%1@GD#'!'!K/F\ M*[J>/5Y]'TQ+ZWTF5H)RUQY;RR(H M9UC&T@D9QR1D@CWH ZBBN+?X@+<77AQ-)TQ[Z#7H99;>4S+'M*)N*L"#CL"> MV#C/0I%\0!%H>L7FJ:>EE=:5?)97$7VC?$&7DDZW5I#%&@1H9X)S+'.K \@[1TQTK2H **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "L.6"^/C*WO!9DV4=G) 9?,7.]G1@=N^!MGQ$TWQ1I#GL!7/S>$=?F^%VN>'?L48O[Z]EFB)G78%>;S.3UR!QT MZX_#U"B@#A+W3_%.D>+Y]?T+3[:_MM4MXH[VPN+D0O%)&"%=7PP(P<$5T7F> M((%TM#;6ERTLK?V@XE*"!""1L&/GP<+S@G&>_&S10!D:W#I&N:+>Z3>W<'D7 M430R8E4$ C&1[CK^%]C19(UX4R(Q#*0 M, XW5TC>%O#SL6;0=+9BKPW]P%N$54C0,-B9.6/S#DXS@GC@"O'/^@!I7_@''_A1_PBGAS_H :5_X!Q_X M4 @@N(/%WBK4R+9K?4K2"&VQ=1Y+1JX.X9X!+<=>!73?\(IX<_P"@!I7_ (!Q M_P"%'_"*>'/^@!I7_@''_A0!P2:/?Q^"O!NDXM#=:-?VUQ<_Z7'M*19SM.>2 M<\ X[YQ5;Q%HFMZQIWBNR?\ LJYFOYM]C?37RAD@RA6 +@[<;3GD DD\UZ-_ MPBGAS_H :5_X!Q_X4?\ "*>'/^@!I7_@''_A0!9MM3@>VC:YN;2.8KET2X#* MI] >,_7 KA[\ZIK7@5_#NLZ?IUW?S6ODM=F^C:!7VX$K9PX8'YL!3R.#WKK_ M /A%/#G_ $ -*_\ ./_ H_X13PY_T -*_\ X_\* .5NM*>VU/P.MK.1GOQ[ M\5UO_"*>'/\ H :5_P" 1+ M(/G20$YV@C(*[CCM75?\(IX<_P"@!I7_ (!Q_P"%'_"*>'/^@!I7_@''_A0! MQ5CX<&AW_@>"RN+:XL]"AN$N9C<(I=I4QE5)_O9)]CWJ6UMKVUG\4RFUTZYC MU2_BG2WGNHRLL.$21&Z@,55B.HZ. M1)4#QNKH>C*<@UE?\(IX<_Z &E?^ >+O$%CXBT;1)] TX7>JI,\1&J.53RU#,&/D>_&,U ML1:AXAN+5<:3:074=\L-Q&]TS)Y'!,B-L&XX(P"!SGTH W:*J?VC;MJ,NG1R M*UY'")FBS]U6)"D^F2I_*LKPAX@N/$>GWMQ=6L5M+;7\]F8XW+C]VVW.2!G/ MT% '04444 %%I['Q M?GQ,/#FL:>^FZG+&9;;]Z)8;I1][RWP#D=P0#B@#IZ*I6,FI/=7POH+>.!9< M6C12%F>/:.6!'!SG@5=H **** "BJNGZA:ZI9)>6;%/"3C9H)&7H'7&X?AG' MU!KF_&OC9O!*Y_&6AMJLFFBPC\YXEB,_F/E#@[OE&.?K0!T]%% M% !1110 4444 %%%% !1110 455AU"UN-0NK&*57N+54:91_!OSM!]\#./0C MUJ6YN([2TFN9B1%"C2.0,X &30!+17):#XQN-7ET9Y;"*&VUFWDN+4QS[Y$5 M0#^\&T 9##H3@\<]:U_$7B&S\-:8+R[$DC22K!;P1#,D\K'"HH]3_C0!K45S M6H:SXCTS1KG4Y=#M)O)A:4VMO>,TH &<9* ,?4#WQGC/2*P= PZ$9% "T444 M %%%% !1110 4452CDU(ZS-')!;C31"IBE$A,C29.X%<8 QCG- %VBBB@ HJ MK%J%K-J5SI\"Y\QQLMY"Z[ M-QVG) Y(QF@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% ' ^)O^2P^!/^N.H?^BEJ M?XD!E3PQ*DLJ,/$%DA"2,JLI?D$ X/0=:Z&\\-:5?ZS;:O$"5TV2+]UOE(Y'8]J .0TK3+'_ M (7-XBF^S1^8MC:2AL<[R9 6^O _*N)KJ8:K EIJ%D M4;2[2W:&,LI ,R_O&VG#!3@#.0>M='I&FVNCZ1:Z?9%S;6\82,O(7./=CR:S M]%\&Z!X>L[BUTS3UABN%V2YD=V9<$;=S$D#D\ XYIHLK_0+"STSPSI.GO86\ M>Q4NK^2(ISP!B-R?J30!@1?\E]N/^Q:7_P!*#53QP/[4^)W@?3K'Y[VSGEO; M@KUA@PH);T#$8'K5R?PYK%QK#ZN_AW3!J#IY;7$?B.[1MF<[?EA&%SSCI5O3 M-/U[1S,UAX7\/PR3G=-+_:TS22GU9S;EF_$T :5XF^ MT/N0BV5AALYQGMG%27MK;>'?#GAN\AN9(&UN>RMM2NKB:21"GE,PW#< H+;5 M."HQQTK8_P"$;U;RM2B_X1G1]FIDF]7_ (2"Z_?$C!S^Y]./IQTJQ-H^MW/A M_P#L*X\+Z#/IGEB/R)M9G,<4 8/B:SO? VC>(M3L=8CC2ZA MA/V&TMC&ML#*D;S(-[;3M8] .1GM75#PUH4>IPWMK,4AO+)K=K.-@8;Q<;O, M&M3\,&1M(\)Z#;M(-I8ZW<2$+G.T%H#M7/88% '):'<+I/PI\$I;K]GA MU;4H+74)HR5)B+OP6'(!("D^A/K76SV?]D_$_3].TQ6ATS5=.G:\M8&*)&T9 M7;*H7&QCNVDC&?K20>%[^WTBYTF/P?X=%A MZFU(PSQ&62X=AL,S<;F>34OQ,61M4\$K$X20Z['M9EW '8W;(S5_1M/\ M0^']/6PTOPYHD%HA)6+^V[APN3DXW0''))X]:BU71]N4\MQT8!8 ,^] %A_!T<6H:OXAU"^GN]3N;(VJO'F!8(A\VV,*%'T./R(]0EEM;RWBX2:,1EQ(P_O*1G=UYP37.G5+G0_"OC MB>&ZF18_$@@:>21Y&AA8P*YR3NX5CW!'J*Z!;+Q'X:?X/L+Z:"/R88EU M^:61(R1E8S-%A1P,@$9P.N!4.A:-XJM[+6EO?#VBRQ:S>RWN>] #=5TNZ\+IJ/B72M5M$8Z3.8]/M+4K%<.B%UFQYC#(XYQR#C/-: M.BZ-H]W8^&M?M[^9)6A >2.3)OS(F"LQY+D')_V<'ICBOH'AC4?# E_LCPEH M$'FKL8MK5Q(=O]T%X#A?8<4S1O"=[X?OWO=+\'^'[>=BQ!&M3LJ9Z[%,!"9_ MV0* '_"O3K.TTW69+>WCB<:S>P@J,8193A?H.*U_%>F6VLZAI6F7B;[:Z6YA MD'LT)''O5/3M*US2;V\O+'PQH,,]Y(99V&LSG;(S7.!&N>!N^Z22. M">:[40^)EGNYT\.Z%'/=A1/+'K$R.^T87+"WSP*QT\(WL>ASZ*/"6AG3IW\Q MX&UVY8;\YW#,&5.1G(P: *=I#-!XH\9::8EL+9M(AN!:V<[!(WQ(-RD!<,0H MS@#..]9=A9I8^&_AIK<,UQ_:-S=VEM-,T[-OBDB?$M"6>2W^S22C7+G>Z<]6\C)/)&[[V#C.*>?#.J&QT^R_P"$8T?[-ITB MRVD8\070$++]TK^Y[06^TE])_<0Q1M-Y,OF'<61#+F]>_:X\&^'W_ +0?S+E3K=P%=^#O $&%;C[PP3ZUA>(O#^OSZT)[ MKX=V>J1B".WMFT_7&@\A%R2K,51F)))R1@<>Y(!9MX=5\/>'?!ND:U=O%+J5 M[(E_+>S/.I.QS%$^7'7Y 0" 2O<$Y/%WAZ70/!?C/9K.8Y;>.ZAL+5'@2S/W M25Q(?E<@G;TR#Q5^S\*ZW+XR>'=):YT]2MK(?$%T3&",''[CG M(X.>M-AT'5X?[2 \+:&ZZG_Q^++K=Q(LW&/F#0$=.* (V\+_ F_AUB"& MVO-.DC:PL(7A28J-PF!$APPR!N'4$ GFN5TZT6S\(_#?7(IKG^TI[^TMY9VG MG&/?KFNETCPC?:%:W-OIOA+0X([E/+D(UVY+;/[H8P$J/8$" MG_\ ",:I_9]A8?\ ",:.+73Y5FM8QX@N@(77[I'[GMV]* #PCIEC#\3/&\L= MM&LD5Q:E& Y4O!EC^)))K7\7>(6TV]T;0K?REO-!)9EW)$BKEVQ_$V" ! MT)/M@TX]*UR+79=;3PQH(U&5%22;^V9_F"C )'V?&0"1G&<'&:;KVC:UXFM8 MK?5_"^@W"0R"2)AK,Z/&P[JRVX(/T- '$:38MX6U34OAU+)-#=WY']C:J)BD M@M68LR[P1@IAB%& S'I@UO?$*"+2M4\#79E=M+TW5ECNI)93(8V<#8TC,2>. MN3ZCUJU=^#+J_P!.^PW?@_0)X]XD\R76[AIMPZ'S3!OS_P "K2@TK6[?1#HR M^%?#S:(OB-XDTK5H5FM;"UM?L5O*/E*R*S/(%/\6["YZC&!C)I+'P]K6G"-8/#^FF M*(@QP3>)+N6),=,1O"5&.W'':I[_ $G7M2U"&_G\.Z.M[$AC2X@UVYADV'DJ M62 $KGG!XS0!Q3RW\_A?3;:ZO;QQ8>,TTZVN//8-+;K.%&XY^8CD9.?NUT,/ MA[3U^*>HZ*%G_LNYT>*\GM?M$FR2;SG3./6[B,(X.0WRP#+ \Y/.234@TG7AK+ZN/#VDB_>'[.TW]OW.3'UVX M\C&,G/UYZT <4K3R_#'0E:\N]UMXD2TC<3MGRA=E0IY^; SG&*Z)/#]@GQ M6O-'47 TV[T5;NXM?M,A2643%-S%M'%K'>M '&122)\/=*'G2DV7BI;2&1G)=(1=%0F[J1C P>P%=:\:2?%W4[0.Z0R M^'T>1(I&3YS,PW?*1AL #/6M'3/!]C+X!0!Y=I= MH+?X>> ]?2>Y.J-J=K$UPT[DF-Y65DQG&T@\C'/7K74W5U)XX_[5FDQ/<*T[(\8 M '^J RH!(X7[O0UZ#I7@;PUHFJ/J6G:5%;W+,S JS%4)ZE$)VH2./E XXJ%O MAYX49)4.D1[)+@7.WS7PDF=VY!N^3GJ%P#WH Q/#NE6!^*OC9_LR*ZI9,KKE M64O%)N((Y!/K7-Z?JMU8?#S18/M$XM[WQ.UE=SF5MX@-Q)D%\Y&=H4G/0FO4 M/^$9T<:P=66R5+XQ"$RHS+\H! X!QD D XR!T-10^$=!@T2XT9=/5M.N&+R6 M\LCR*6)R3\Q)!SSD=^>M '.7-G_8_P 3]*L-+5H=-U:PN?MMK Q1$,>W;* N M-K$OMR,9KBK"S6#X5>&O$"SW3:I#JL:I<-<.2%:[9&7&<8()SZ]Z]@L] T^P M,CPI.99(Q"9I;F224(.BAV8L!WP".>:I#P1X>&BPZ.+%QI\,OG1VXN9=JOG= MD?-_>Y^O- '044BJ$0*,X P,DD_F:6@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK[BC;" ^/E+#(!^E #J*X MCPYXG\2>([;4Y[>PTI#8W\UCLDGD7S&C(!.0IV@Y]#6KX6\6Q>(VO[2:TDL- M5TV417ME(P8QD\JRL.&4CH>* .BHIJR(P8JZD+U(/2JFE:K::UIZW]A*);9W MD1)!T;8Y0D>HRIP?2@"[135='7010 M%<;XD\0^*M,AO M=2TS0[*XTJP#-*MQ<,EQ.J??:-0I P<9.3C('3.I)JVIZIH>GWWARUMI#?0 M+<))?2,D<:,H8 A026.>@XX//0$ WJ*P/!^OW/B+1'N;VQ%G>07,MI<1*VY/ M,C8JQ1NZY'\ZV;HSK:RM;F/S@I*^8"5S[XH FHKFO ?B*[\6^$K/7;J"&W^U M[RD,1+; KLO)/7.W/2NEH **;O0D#(/&'B7P_;/KL^A M6C>'8I )5%PWVQ8BVWS=NW:.H.W.<'G'.-W4-?E/B6V\/:8L)O9+5KV:68$I M#"&"@[006+,< 9' )]B =!17+67BJ\U719VT_3DDUB"]?3YK9Y2(HIDSN9GQ MG9M^8'&3D#&34&@^*]5?7]1T#Q'IL%OJ%I:B]CDL7:2*>$DKE00&!!&,=Z . MPHKA+KQ;XFT75-,DUS1+*+2-2NDM$:VN6DGMGXERC^W:AJ?_ !Y6 MZ/M#J!DR,V#M0 @DX/4 DXK5MOM*6^;Z2 R=28E*JH].2<_7CZ"@"Q16#KM M[XC6<6WA[3[*:18_,DFOYFCCY) 1=H)+<$GH!QUS6;I7B_4]=\(-J&G:+_Q. M4N6LY;&:;"1S(V'W/C[H )SCT'6@#L**X[2=?\5/XKM]'UG2=,@CDMI+EI+6 M[>5D52JC(*CJ6X^A]*N^._$5UX3\)7FNVL$-Q]D"EX925WAG5>".F,YZ4 =) M17'3>+]0T?Q)H^DZY86RQ:QN2UN[25F"R@ ['5@",Y&""?I3-+\2^(-6\1Z_ MI,%IIB_V1+'&9)))!YN]=P. #MX^M ':45Q]AXTN;JZUC1;C2OLWB/3[8W$= MGYV^.Z7'RM&^ 2I. <@$9J"[\3>)++Q7I/A^2STDSZC!+,)%EDVIY8!(^[DY MS0!V]%4-(GU&>UD_M6VA@N8Y63$#ED=>JL"0#R#^!R*OT %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%-=!(C(V<,,'!Q^HH X/X5$#3O$QSQ_PD=[S_P "6N5FNK&[\0?$3Q3) M<747A_['%IYN[)@'GD 56\MCP2#A<].:]*C\%>&HDD1-%M DK%I$V95R>I8= M#^-:WTV],4 >?:59QVWQ66QFM+"VM[CPZ?- MLH,,A F55W\ .<$C.T<''-6D.D6 M:6UZQ:YB$(VRD\_,._4_G0!@:5X;TZS\0:E,=2MGAU*PQ<6%I#Y4!4<>:<,< M$@D9R,CZ5U&D6=AI^CVEGI:HMA#$J6X1RZ[ .,,2<_7-94?A6QT31+FP\-Z1 MID"W)Q-%,&5)%((.X@$G@XJ"QL_$^F6,%C967A^"U@0)%$DLP"J.@'RT 3>( MIXM52?P[#P.FD5I=:.MGIUX;> Q^5#):, MN45?E^0D$<8QTKB[OP')?W263S69F/4D[:M7'A74KI;$2Z M+X;_ - 3R[4I+,AA7 &U2JC X'% $/@]O$&D:#KFEVZIK,FEZ@;>QDGE$/G1 MD(S!G"G+*7;)QR0172:=JM\]IL\06EGI=[,[);VZ7HF\X!O !X&:J MVT'BJSMTM[:S\/0PH,+'')*JCZ +535=%UW6Q;_VEIOAZX-O)YD+--,&C;U! M"Y% 'G^GVRQ_ SP7+-$JR1:K;.KLO**UT3D'L""*[)K>TF^,^HP;(BLOAU?/ M1<#79M&, #;QC QCIBJ=OX M4U&UE2:#0O#$29 C3LK)NZA2"?EZ>U>J-J/B<:]]G70+,Z7YH7[9_:'S[.[>7LZ^V?Q MK%_X174O[.@T_P#L7PW]CMY/-A@\V;9&^<[E&W .>?SK8!\8*H40Z%@#'^NF M_P#B: (=<>S\12MH\EQ"-.@E5]0=G #E"&$(_$ L>PXZDXRK(!/C3&)K& @Q6[&7RT(X&%VX[FJ^G>#KO2'G?3O#OA6U>>(PRM"95+(>JD MA>AP* -.\N-/U[4;:ZN+NW72-*G^T*[R ">=00"/]A,DY[MCLO/37'_'K+_N M'^5>?0?#[[-<1SP^%/""2Q.'1U63*L#D$?+ZUT:Z.#IG[/NOZ=<@B[M$O[*93U\UI'"CZG>N/7(KL MM'M_&5CHEA9M;Z(#!;1Q$--+D;5 YPN,\=J9+HNNS7_VZ32_#K7!=7+&2;#. MOW6(VX+#L2,CM0!RVA>'B?B%8Z?K?GAH/"MM# J3/'G:P6494C)#8R/<>U:W MABRBU3POXDT/Q-.U[HUIJLUI#-=SL"T*%2H:3()VMQG/;':MB^TWQ'J30O=6 M.@O) Q:*03SJ\9(P=K!01D<'!YJ*YT36[S16T>XTGPV^G, &MB\H0X.[IM]1 MGZT ;NK:HFFQ16UOY37TX*VT+M@<=68]D7(R?H!DD Q^&[&QTK2_[/L[I+EX MG9[F52"SS.2[LV.A)8G'8$5S>J>$+W6[E;G5/#_A6[F5!&KS&5BJCH!\O J[ MI.D:]H-F;32M*\-V=N7+F.!Y54L<9. O7@?E0!:\-_\ $PUK7-G>'KJV)R8I99BA[C(VX/2@"PGA&WN]:TW6M2O[N_F MT]#]CBEV+'$S OA5&6QW/3L*Q_!7_)1?B!_U]VO_HFMBWA\5VMNEO#;:$D2 M#:J^?,<#T^[62/".H"XGN/[#\->=<',TGFS;I3_M';\WXT 4HL:[\=_MVGGS M+31]+-K=SIRIF=B1%GN0#D^F*MZ]_P EH\(?]>5[_P"@K6K96?B73;5;6QT[ MPW:VZ?=B@:1%'X!,55N-"UNZU6+5)]+\/27\(Q%<&:??&.X4[>!["@#LZ*Y[ M?XQ_YXZ%_P!_IO\ XFC?XQ_YXZ%_W^F_^)H Z&BN>W^,?^>.A?\ ?Z;_ .)H MW^,?^>.A?]_IO_B: .AHKGM_C'_GCH7_ '^F_P#B:-_C'_GCH7_?Z;_XF@#H M:*Y[?XQ_YXZ%_P!_IO\ XFC?XQ_YXZ%_W^F_^)H Z&BN>W^,?^>.A?\ ?Z;_ M .)HW^,?^>.A?]_IO_B: .AHKGM_C'_GCH7_ '^F_P#B:-_C'_GCH7_?Z;_X MF@#H:*Y[?XQ_YXZ%_P!_IO\ XFC?XQ_YXZ%_W^F_^)H Z&BN>W^,?^>.A?\ M?Z;_ .)HW^,?^>.A?]_IO_B: .AHK.TPZT6D_M9+!5P/+^R.['/?.X#VK1H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ.L:M M:Z'I*25+NW:.(XD<2 A#Z$YXK,U[Q-9Z+HDNI))!<[ 2D M0G53)AL$*>6R7/V9KB$3[=_E%QNV^N.N*J7FLVL&FWMW;2PW36 MD!G>*.49*[2PZ9QD#CUH T:*XN?X@I;6;R2Z7(MQ_9JZG#'YH*R0EE4_-CA@ M67(([\$UU?\ :-EY$D_VRW\F-RCR>:NU6'8G/!]J +-%5WO[./R]]W OF %- MT@&X$@ CGG)('XU&=6TU5=CJ%H%C4.Y,RX53P">> ?6@"Y14+7EJD\<#W,*R MR#,<934+*1&=+RW958(Q652 Q MZ \]?:@"S161=Z_!!>Z1% ([F'4;E[831R@B-EB>3MG/^K(Z\5>_M&QV1M]L MM]LIQ&?-7#GT'/- %FBLZWU[2;J.YEBU"V:.VE,,K^: JN.H)SZY'X&H/$7B M"W\/^'[O56,4OD6[SI$9@AF"C)"GG/% &Q15*SU>PO[NZM;:ZBEN+1@D\:L" M48@'!_ BJVJ^(+/2-2TJQN ^_49C#&P'RH=I(+'MD[5'NPH UJ*KW%]:6AQ< MW4$)P#B20+P3@=??BE6]M7$Q6YA80'$V) ?+/7#>GXT 3T54;5-/6!9VOK80 MLI99#,NT@<$@YQ@52\1^(;?P]H=QJ+>5*T<9D2$S!#*!UVGG/7TH V**KM?V M:3B!KN!92VP1F0!BV,XQZXYIO]I6/V/[9]MM_LO3SO-79Z?>SB@"U15=]0LH MW5'NX%=BH56D )+9V@<]\''KBHK+5K'49KN&SNHIY+27R9E1@=CX!P?SQ]01 MVH NT5S^F>*H=2O-4T_[.8-2T]FW6\C<2H#@2(V.5)!&<<$8-:5KJD$UG933 MR16\EW&KQQ/*,G(!P.F3R.E %ZBBLVRU=;W6=2TX6\D;V/EY=B,2;P2",'IQ MWH TJ*I?VM8?VL=+^UQ?;1%YQAW#<$SPZM[N,R6T\4R X+1N&&? M3(H EHK%@UZ34);W^R[+[5!9S-!)(TH3S)%^\L8P=V#QDE1GC/!-7K?4;>6* MU\UT@GN8UD6WE<"3D9QCKD<_E0!:NW(&2,YQQ@T 6J*KK?6CR^2EU TNSS-@D&=OKCTY M'-0VVIPM9VK'4KS5K8P>4VGW M8MB=^[S,Q1R!NG'$@&/:J=GXF.H2-):V?F6:7DEG)*LPWQ.C%69TQ\JY7CDG MD' !H WZ*@6^M'"E;J$[D,@Q(.5'4_3WIJ:C92+(4O+=A&0'*RJ=I/3//&: M+-%8^H>((+2*QEMA'=Q75['9EXI1A"QQGC.<>E:*7UI(BNEU RL_EJ5D!!;^ MZ/?VH GHK)/B"S7Q2N@'>+I[8W"OCY#@@%,_W@]"#6@]Y:QSB![F%9B,B M-G 8_A0!-157^TK#$A^VVV(QESYJ_*,D9//'((^H-.>_LXXX9'NX%28@1,9 M!)GIM/?\* +%%5CJ%DLWDM>6XERPV&5=V0,D8SV!!-(=2L5M4NC>VPMY#A)3 M*NQC['.#0!:HJN]]:1SK ]U LK,$$;2 ,6(R!CUQ4>GZK8:I]H^PW44XMY3# M(8V!VL.H_/(_ T 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\7Z)<:[H/V>S=%O(+B&[ MM_,.$9XG#A6QV.,9[9S2:B-5UWP]?V$5G-I=Q&M4U>QNYDTKR)9-)BLC:&2/$DBR!@00V-J@, 3@_,>!3]>\.ZHP M\0VMCHZ3VVIV\'V4QO$BV[(261@2,?,2X*YY8YQUKT*B@#AX]#O7UNZ74-%: M[B^V/?6MY]L^5=R;=ACW#YP"4Z;2,9/:L[3?"VJV.D6ENNE[)4\,MITNR2,; MKCY<#[W(X8Y]Z])HH X6Z\)N?A]):P:<6UJ;38K-_,E#-\H&5#,Q 7.3@''M M23:+JL&O75S::0/LDNHP3J4>)711;&-G0$[0V[ .?X2<B@#S-/#WB%;/2X6TKY[1=*9W2>,>88&7S Y)R2/F MVXX()[\5U'BS3+O5)]!%M;R2QVNIIN1U.
\1R(^&3<<#[VULC."V >#6#%X6\20>$K MS2IM*^TR7?AV+3H@)X_]&FC608.6'RL65@5STYQQ7J]% '/Z%97MIKFNS7%J M8X+V>*XBDWJ>D$494@'.04/MR,$]LW7?#M]X@L-:=WNK6Y<*ME&IA(S%\\3Y MY(/F9;J.,#M7944 )@+AB?E!W=.>OI45[X M;UD7,]Q8:<$46>G?N?.6(3R02R/(FY3\IPZX;ID>E>B44 <''X:=M8L+Y?#W MD0^7>O/%+.DSB241XW%F(R2C?=) S[FL<>&/$<7A:[TN72S=R7>B6EI&WGQ_ MZ/+"A#(V6Z%CN!7/).<5ZI10!Y_J'AF]NKO5YAHZM]JUJQO(\F+)BC$/F9^; M_IF_'?/N:8VA:S9ZC+>0Z2]Q:#4KF0V<5TL3/%*B 2*0P&05;*DCAS7H=% ' MFMUX-NH[?5X;'1(XUDL+&"S59D;8T4CLRAF;=P&09/7;["NL\/65Y8WVN"YM MRD=S?FYADWJ0ZM&@Q@'((*G.?PS6]10!QVH^&KS4;*6[M5^P:W:74\UC/(5* MNKDDH^TG*..".HX/451N_#6KRV.KV+6PG74M)M[6&7S% M)41E^;)S@,P<%< MG(/MGOZ* *MD]P1+%/ Z"%@D+[,[*6,B%RSG:2.CJO7^#Z5OT4 L-2\,B^TW^SY+NUDO)KFVN8I(P LKERL@9@00S$9 .1COQ5'4?#VKWC:Y: M/$'_ +0O+:ZM[U)%Q;;!$",$[@5,;,N <[NW-=S10!P"^%[O[7%(VD)A?$3W MS',7^H,;*#U]6Z=:;IGAJ^@U'3I+G2 8+>75"06B.U)YO,B &[^[QCL:]!HH M \PA\'ZW'HNFVMO8I;W,/A_[%,3*@5YP\3;&*G)#!'&[_:^M:4GAV:_GTV]; MPVUN[:HEU>Q3W2SL0L#QEB2Q'=!@V=S+9WVB0S16UU= M3VU\'0AHY2Q"*N@KGI/#/B$>%K#3%TH>;#H]M;L\$EU;3>)+75[+39=+U(7G^F7,,R""ZM@QXD0-EF*8P2N03UP*[BB@#S%M" MU:UTRWCN],VV^GZ=J<$LIEC97\PJR,H!S@A>X!![=ZS]3T(?\(K#K"Z8EO#_ M &796[Q83-PYGB8-P2.!D G!^V6G>1!/JUG<_95:-=BQ+AY" =N M3Z D_**NZ18@>*=1:RFAN-(BD^VQQPL"4NY RNH/3H"V">LOTKL !@#H! M44%M!:QF.WACA0L6*QJ%&242H.X_=7CTSI-MQXDNY);"XN-.36H[DR1RP.4G6%(BI!D#8!X*A6/' M!(.*]+JJ--L1?&^%E;?;",?:/*7S,?[V,T <-#X:U*QTBUGMM'4W=MK-S=2V MT373^&;&[T\:K#=6_EK)J$]Q$^]2)$D8 ML.AR,9QSCFMVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "O/=?UCQ#H6KV$B:_8WLEUJ4=O_ &-':J&\IFP2&W%] MRK\Q8\>PKHCX3A.O?VM_:^M[_-\W[,-0?R,^GE]-OM7&>*+"XU]_+TKP9>:9 MXD-U&RZP4BC6(*XW.9E;+@J"-N.<]* /4Z*Y^\\)PWFN?VJVKZW$^]'^SPZ@ MZ0?*!QY8XP< GRAPHIC 21 sgen-20220630_g1.jpg begin 644 sgen-20220630_g1.jpg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sgen-20220630_g2.jpg begin 644 sgen-20220630_g2.jpg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end GRAPHIC 23 sgen-20220630_g3.jpg begin 644 sgen-20220630_g3.jpg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end GRAPHIC 24 sgen-20220630_g4.jpg begin 644 sgen-20220630_g4.jpg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end XML 25 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
 6 Months Ended
Jun. 30, 2022
Jul. 25, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 0-32405  
Entity Registrant Name SEAGEN INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 91-1874389  
Entity Address 21823 30th Drive SE  
Entity Address, City or Town Bothell  
Entity Address, State or Province WA  
Postal Zip Code 98021  
City Area Code 425  
Local Phone Number 527-4000  
Title of 12(b) Security Common Stock, par value $0.001  
Trading Symbol SGEN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   184,435,456
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Entity Central Index Key 0001060736  
Current Fiscal Year End Date --12-31  

XML 26 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 364,874 $ 424,834
Short-term investments 1,485,448 1,735,202
Accounts receivable, net 438,041 389,256
Inventories 319,354 200,663
Prepaid expenses and other current assets 170,938 119,239
Total current assets 2,778,655 2,869,194
Property and equipment, net 218,901 210,073
Operating lease right-of-use assets 51,942 57,889
Intangible assets, net 249,149 260,593
Goodwill 274,671 274,671
Other non-current assets 57,025 47,184
Total assets 3,630,343 3,719,604
Current liabilities:    
Accounts payable 128,872 114,824
Accrued liabilities and other 479,649 454,030
Total current liabilities 608,521 568,854
Long-term liabilities:    
Operating lease liabilities, long-term 50,205 56,665
Other long-term liabilities 38,805 28,946
Total long-term liabilities 89,010 85,611
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued 0 0
Common stock, $0.001 par value, 250,000 shares authorized; 184,369 shares issued and outstanding at June 30, 2022 and 183,381 shares issued and outstanding at December 31, 2021 184 183
Additional paid-in capital 4,747,481 4,607,816
Accumulated other comprehensive income 507 1,179
Accumulated deficit (1,815,360) (1,544,039)
Total stockholders’ equity 2,932,812 3,065,139
Total liabilities and stockholders’ equity $ 3,630,343 $ 3,719,604
XML 27 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 184,369,000 183,381,000
Common stock, shares outstanding (in shares) 184,369,000 183,381,000
XML 28 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenues $ 497,502,000 $ 388,478,000 $ 923,962,000 $ 720,460,000
Costs and expenses:        
Cost of sales 106,100,000 78,090,000 193,726,000 142,225,000
Research and development 304,254,000 234,861,000 601,913,000 465,286,000
Selling, general and administrative 220,259,000 165,130,000 394,484,000 324,972,000
Total costs and expenses 630,613,000 478,081,000 1,190,123,000 932,483,000
Loss from operations (133,111,000) (89,603,000) (266,161,000) (212,023,000)
Investment and other (loss) income , net (1,609,000) 5,027,000 (3,799,000) 6,027,000
Loss before income taxes (134,720,000) (84,576,000) (269,960,000) (205,996,000)
Provision for income taxes 107,000 0 1,361,000 0
Net loss $ (134,827,000) $ (84,576,000) $ (271,321,000) $ (205,996,000)
Net loss per share - basic (in dollars per share) $ (0.73) $ (0.47) $ (1.48) $ (1.14)
Net loss per share - diluted (in dollars per share) $ (0.73) $ (0.47) $ (1.48) $ (1.14)
Shares used in computation of per share amounts - basic (in shares) 184,145 181,628 183,897 181,390
Shares used in computation of per share amounts - diluted (in shares) 184,145 181,628 183,897 181,390
Comprehensive loss:        
Net loss $ (134,827,000) $ (84,576,000) $ (271,321,000) $ (205,996,000)
Other comprehensive income (loss):        
Unrealized loss on securities available-for-sale, net of tax (2,736,000) (213,000) (3,597,000) (47,000)
Foreign currency translation gain 2,819,000 511,000 2,925,000 274,000
Total other comprehensive income (loss) 83,000 298,000 (672,000) 227,000
Comprehensive loss (134,744,000) (84,278,000) (271,993,000) (205,769,000)
Net product sales        
Revenues:        
Total revenues 431,714,000 347,338,000 814,800,000 649,926,000
Royalty revenues        
Revenues:        
Total revenues 39,109,000 36,296,000 67,290,000 63,514,000
Collaboration and license agreement revenues        
Revenues:        
Total revenues $ 26,679,000 $ 4,844,000 $ 41,872,000 $ 7,020,000
XML 29 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Beginning (in shares) at Dec. 31, 2020   180,902      
Beginning at Dec. 31, 2020 $ 3,488,100 $ 181 $ 4,356,922 $ 565 $ (869,568)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (121,420)       (121,420)
Other comprehensive (loss) income (71)     (71)  
Issuance of common stock for stock option exercises and employee stock purchase plan (in shares)   341      
Issuance of common stock for stock option exercises and employee stock purchase plan 19,791   19,791    
Restricted stock vested during the period, net (in shares)   80      
Share-based compensation 38,224   38,224    
Ending (in shares) at Mar. 31, 2021   181,323      
Ending at Mar. 31, 2021 3,424,624 $ 181 4,414,937 494 (990,988)
Beginning (in shares) at Dec. 31, 2020   180,902      
Beginning at Dec. 31, 2020 3,488,100 $ 181 4,356,922 565 (869,568)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (205,996)        
Other comprehensive (loss) income 227        
Ending (in shares) at Jun. 30, 2021   181,866      
Ending at Jun. 30, 2021 3,391,274 $ 182 4,465,864 792 (1,075,564)
Beginning (in shares) at Mar. 31, 2021   181,323      
Beginning at Mar. 31, 2021 3,424,624 $ 181 4,414,937 494 (990,988)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (84,576)       (84,576)
Other comprehensive (loss) income 298     298  
Issuance of common stock for stock option exercises and employee stock purchase plan (in shares)   359      
Issuance of common stock for stock option exercises and employee stock purchase plan 13,201 $ 1 13,200    
Restricted stock vested during the period, net (in shares)   184      
Share-based compensation 37,727   37,727    
Ending (in shares) at Jun. 30, 2021   181,866      
Ending at Jun. 30, 2021 $ 3,391,274 $ 182 4,465,864 792 (1,075,564)
Beginning (in shares) at Dec. 31, 2021 183,381 183,381      
Beginning at Dec. 31, 2021 $ 3,065,139 $ 183 4,607,816 1,179 (1,544,039)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (136,494)       (136,494)
Other comprehensive (loss) income (755)     (755)  
Issuance of common stock for stock option exercises and employee stock purchase plan (in shares)   463      
Issuance of common stock for stock option exercises and employee stock purchase plan 26,664 $ 1 26,663    
Restricted stock vested during the period, net (in shares)   48      
Share-based compensation 43,913   43,913    
Ending (in shares) at Mar. 31, 2022   183,892      
Ending at Mar. 31, 2022 $ 2,998,467 $ 184 4,678,392 424 (1,680,533)
Beginning (in shares) at Dec. 31, 2021 183,381 183,381      
Beginning at Dec. 31, 2021 $ 3,065,139 $ 183 4,607,816 1,179 (1,544,039)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (271,321)        
Other comprehensive (loss) income $ (672)        
Ending (in shares) at Jun. 30, 2022 184,369 184,369      
Ending at Jun. 30, 2022 $ 2,932,812 $ 184 4,747,481 507 (1,815,360)
Beginning (in shares) at Mar. 31, 2022   183,892      
Beginning at Mar. 31, 2022 2,998,467 $ 184 4,678,392 424 (1,680,533)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (134,827)       (134,827)
Other comprehensive (loss) income 83     83  
Issuance of common stock for stock option exercises and employee stock purchase plan (in shares)   298      
Issuance of common stock for stock option exercises and employee stock purchase plan 14,960   14,960    
Restricted stock vested during the period, net (in shares)   179      
Share-based compensation $ 54,129   54,129    
Ending (in shares) at Jun. 30, 2022 184,369 184,369      
Ending at Jun. 30, 2022 $ 2,932,812 $ 184 $ 4,747,481 $ 507 $ (1,815,360)
XML 30 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Operating activities:    
Net loss $ (271,321) $ (205,996)
Adjustments to reconcile net loss to net cash used by operating activities    
Share-based compensation 98,042 75,951
Depreciation 22,867 19,603
Amortization of intangible assets 11,444 11,451
Amortization of right-of-use assets 6,140 6,356
Amortization of premiums, accretion of discounts, and (gains) losses on debt securities 484 11,802
Losses (gains) on equity securities 7,078 (4,929)
Deferred income taxes (557) 0
Changes in operating assets and liabilities    
Accounts receivable, net (48,785) (54,752)
Inventories (118,691) (47,048)
Prepaid expenses and other assets (37,249) (46,122)
Lease liability (8,533) (7,481)
Other liabilities 50,499 43,395
Net cash used by operating activities (288,582) (197,770)
Investing activities:    
Purchases of securities (1,489,327) (1,788,967)
Proceeds from maturities of securities 1,735,000 1,831,500
Payments for lessor-owned assets (13,756) 0
Purchases of property and equipment (32,161) (22,403)
Net cash provided by investing activities 199,756 20,130
Financing activities:    
Proceeds from exercise of stock options and employee stock purchase plan 41,624 32,992
Net cash provided by financing activities 41,624 32,992
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (2,809) (342)
Net decrease in cash, cash equivalents, and restricted cash (50,011) (144,990)
Cash, cash equivalents, and restricted cash at beginning of period 424,834 558,424
Cash, cash equivalents, and restricted cash at end of period $ 374,823 $ 413,434
XML 31 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Basis of presentation
The accompanying unaudited condensed consolidated financial statements reflect the accounts of Seagen Inc. and its wholly-owned subsidiaries (collectively “Seagen,” “we,” “our,” or “us”). All intercompany transactions and balances have been eliminated. Management has determined that we operate in one segment: the development and sale of pharmaceutical products on our own behalf or in collaboration with others. Substantially all of our assets and revenues are related to operations in the U.S.; however, we have multiple subsidiaries in foreign jurisdictions, including several subsidiaries in Europe.
The condensed consolidated balance sheet data as of December 31, 2021 were derived from audited financial statements not included in this quarterly report on Form 10-Q. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and generally accepted accounting principles in the United States of America, or GAAP, for unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position and results of our operations as of and for the periods presented.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.
The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The results of our operations for the three and six month period ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other interim period.
Non-cash activities
We had $9.4 million and $9.9 million of accrued capital expenditures as of June 30, 2022 and December 31, 2021, respectively. Accrued capital expenditures are treated as a non-cash investing activity and, accordingly, have not been included in the condensed consolidated statement of cash flows until such amounts have been paid in cash.
Investments
We hold certain equity securities which are reported at estimated fair value based on quoted market prices. Changes in the fair value of equity securities are recorded in income or loss. The cost of equity securities for purposes of computing gains and losses is based on the specific identification method.
We invest our available cash primarily in debt securities. These debt securities are classified as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains, realized losses and declines in the value of debt securities judged to be other-than-temporary are included in investment and other income (loss), net. The cost of debt securities for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Amortization of premiums and accretion of discounts on debt securities are included in investment and other income (loss), net. Interest and dividends earned are included in investment and other income (loss), net. Accrued interest receivable as of June 30, 2022 and December 31, 2021, were $2.2 million and $0.4 million, respectively, and were included in prepaid expenses and other current assets. We classify investments in debt securities maturing within one year of the reporting date, or where management’s intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments.
If the estimated fair value of a debt security is below its carrying value, we evaluate whether it is more likely than not that we will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. We also evaluate whether or not we intend to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, we consider whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in investment and other income (loss), net.
Restricted Cash
As of June 30, 2022, we had $9.9 million cash held in escrow restricted by a contractual agreement related to our Everett, Washington building construction project. The restricted cash was recorded in prepaid expenses and other current assets in the condensed consolidated balance sheet. We determine classification based on the expected duration of the restriction.
Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:
(dollars in thousands)June 30, 2022December 31, 2021June 30, 2021December 31, 2020
Cash and cash equivalents$364,874 $424,834 $413,434 $558,424 
Restricted cash included in prepaid expenses and other current assets9,949 — — — 
Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows$374,823 $424,834 $413,434 $558,424 
Intangible assets, net
Our intangible assets are primarily comprised of acquired TUKYSA technology. The following table presents the balances of our finite-lived intangible assets for the periods presented:
(dollars in thousands)June 30, 2022December 31, 2021
Gross carrying value$305,650 $305,650 
Less: accumulated amortization(56,501)(45,057)
Total$249,149 $260,593 
The following table presents our amortization expense related to acquired TUKYSA technology costs, included in cost of sales in our condensed consolidated statements of comprehensive loss, for the periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Amortization expense$5,753 $5,757 $11,444 $11,451 
The weighted average remaining useful life of our finite-lived intangible assets was approximately 11 years as of June 30, 2022, and estimated future amortization expense related to acquired TUKYSA is $11.6 million for the six months ending December 31, 2022, and TUKYSA technology costs is $23.1 million for each of the years ending December 31, 2023 through December 31, 2027.
Revenue recognition - Net product sales
We sell our products primarily through a limited number of specialty distributors and specialty pharmacies in the U.S, and to a lesser extent, internationally. The delivery of our products represents a single performance obligation for these transactions and we record net product sales at the point in time when control is transferred to the customer, which generally occurs upon receipt by the customer. The transaction price for net product sales represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. We reflect these accruals as either a reduction in the related account receivable from the distributor or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management’s estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment.
Outside of the U.S., the transaction price for net product sales represents the amount we expect to receive, which is net of estimated discounts, estimated government mandated rebates, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. These estimates involve judgment in estimating net product sales.
U.S. government-mandated rebates and chargebacks: We have entered into a Medicaid Drug Rebate Agreement, or MDRA, with the Centers for Medicare & Medicaid Services. This agreement provides for a rebate based on covered purchases of our products. Medicaid rebates are invoiced to us by the various state Medicaid programs. We estimate Medicaid rebates using the expected value approach, based on a variety of factors, including payor mix and our experience to-date.
We have a Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible purchases of our products. In addition, we have entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services, which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS, to receive discounts on their qualified purchases of our products. Under these agreements, eligible customers receive an applicable discount which is processed through the distributor as a chargeback. We estimate expected chargebacks for FSS and PHS purchases based on the expected value of each entity’s eligibility for the FSS and PHS programs. We also review historical rebate and chargeback information to further refine these estimates.
Distribution fees, product returns and other deductions: Our distributors charge a volume-based fee for distribution services that they perform for us. We allow for the return of product that is within a specified number of days of its expiration date or that is damaged. We estimate product returns based on our experience to-date using the expected value approach. We provide financial assistance to qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through our patient support programs. Estimated contributions for commercial coinsurance under Seagen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as necessary to reflect our actual experience.
Revenue recognition - Royalty revenues
Royalty revenues primarily reflect amounts earned under the ADCETRIS collaboration with Takeda Pharmaceutical Company Limited, or Takeda. These royalties include commercial sales-based milestones and sales royalties that relate predominantly to the license of intellectual property. Sales royalties are based on a percentage of Takeda’s net sales of ADCETRIS, with rates that range from the mid-teens to the mid-twenties based on annual net sales tiers. Takeda bears a portion of low single digit third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenues. Amounts owed to our third-party licensors related to Takeda’s sales of ADCETRIS are recorded in cost of sales. These amounts are recognized in the period in which the related sales by Takeda occur. Royalty revenues also reflect amounts from Genentech, Inc., a member of the Roche Group, or Genentech, earned on net sales of Polivy, and amounts from GlaxoSmithKline earned on net sales of Blenrep.
Revenue recognition - Collaboration and license agreement revenues
We have collaboration and license agreements for our technology with a number of biotechnology and pharmaceutical companies. Under these agreements, we typically receive or are entitled to receive upfront cash payments and progress- and sales-dependent milestones for the achievement by our licensees of certain events, and annual maintenance fees and support fees for research and development services and materials provided under the agreements. We also are entitled to receive royalties on net sales of any resulting products incorporating our technology. Generally, our licensees are solely responsible for research, product development, manufacturing and commercialization of any product candidates under these collaborations, which includes the achievement of the potential milestones. Since we may not take a substantive role or control the research, development or commercialization of any products generated by some of our licensees, we may not be able to reasonably estimate when, if at all, any potential future milestone payments or royalties may be payable to us by our licensees. As such, the potential future milestone payments associated with certain of our collaboration and license agreements involve a substantial degree of uncertainty and risk that they may never be received.
Collaboration and license agreements are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to future reversal of cumulative revenue and, therefore, should be included in the transaction price. Assessing the recognition of variable consideration requires significant judgment. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaboration and license agreements, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract.
We have concluded that the license of intellectual property in certain collaboration and license agreements is not distinct from the perspective of our customers at the time of initial transfer, since we often do not license intellectual property without related technology transfer and research and development support services. Such evaluation requires significant judgment since it is made from the customer's perspective. Our performance obligations under our collaborations may include such things as providing intellectual property licenses, performing technology transfer, performing research and development consulting services, providing reagents, ADCs, and other materials, and notifying the customer of any enhancements to licensed technology or new technology that we discover, among others. We determined our performance obligations under certain collaboration and license agreements as evaluated at contract inception were not distinct and represented a single performance obligation. Upfront payments are amortized to revenue over the performance period. Upfront payment contract liabilities resulting from our collaborations do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. For agreements beyond the initial performance period, we have no remaining performance obligations. We may receive license maintenance fees and potential milestones and royalties based on collaborator development and regulatory progress, which are recorded in the period achieved in the case of milestones, and during the period of the related sales for royalties.
When no performance obligations are required of us, or following the completion of the performance obligation period, such amounts are recognized upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as collaboration and license agreement revenues. Sales-based milestones and royalties are recognized as royalty revenue in the period the related sale occurred.
We generally invoice our collaborators and licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.
XML 32 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue from contracts with customers
 6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue from contracts with customers Revenue from contracts with customers
The following table presents our disaggregated revenue for the periods presented.
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
ADCETRIS$201,939 $181,912 $382,928 $344,484 
PADCEV123,577 82,405 223,784 152,163 
TUKYSA88,989 83,021 179,464 153,279 
TIVDAK17,209 — 28,624 — 
Net product sales$431,714 $347,338 $814,800 $649,926 
Royalty revenues$39,109 $36,296 $67,290 $63,514 
Collaboration and license agreement revenues$26,679 $4,844 $41,872 $7,020 
Total revenues$497,502 $388,478 $923,962 $720,460 
XML 33 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Leases
 6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Leases Leases
We have operating leases for our office and laboratory facilities with terms that expire from 2022 through 2029. We recorded $0.2 million and $7.1 million right-of-use assets in exchange for lease liabilities, respectively, during the six months ended June 30, 2022 and 2021, respectively. All of our significant leases include options for us to extend the lease term. None of our options to extend the rental term of any existing leases were considered reasonably certain as of June 30, 2022.
In June 2021, we entered into a lease agreement for an approximately 258,000 square feet building complex to be constructed by the landlord on approximately 20.5 acres of land in Everett, Washington. We intend to use the building for future manufacturing, laboratory, and office space. Under the terms of the lease, base rent is payable at an initial rate of $4.0 million per year, subject to annual escalations of 3% during the initial term of 20 years. The lease commences on the date when construction and delivery of the building shell and related improvements by the landlord have been substantially completed. We will record a lease liability and right-of-use assets on our condensed consolidated balance sheet on the lease commencement date, which has not commenced as of June 30, 2022. We have an option to renew the lease for two additional terms of ten years each. In addition, we have an option to purchase the premises in the future.
Supplemental operating lease information was as follows:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Operating lease cost$3,947 $4,063 $8,142 $8,077 
Variable lease cost1,249 1,151 2,321 2,138 
Total lease cost$5,196 $5,214 $10,463 $10,215 
Cash paid for amounts included in measurement of lease liabilities$4,196 $4,199 $8,749 $8,057 
As of June 30,
20222021
Weighted average remaining lease term5.6 years6.3 years
Weighted average discount rate5 %5.1 %
Operating lease liabilities were recorded in the following captions of our condensed consolidated balance sheet as follows:
(dollars in thousands)June 30, 2022December 31, 2021
Accrued liabilities and other$13,700 $13,905 
Operating lease liabilities, long-term50,205 56,665 
Total$63,905 $70,570 
XML 34 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Net loss per share Net loss per share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and dilutive potential common shares outstanding during the period. Potentially dilutive common shares include incremental common shares issuable upon the vesting of unvested restricted stock units and the exercise of outstanding stock options, calculated using the treasury stock method.
We excluded the potential shares of common stock from the computation of diluted net loss per share because their effect would have been antidilutive. The following table presents the weighted average number of shares that have been excluded for all periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2022202120222021
Stock options and RSUs9,824 9,992 10,077 10,229 
XML 35 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair value Fair value
We have certain assets that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:
Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2:  Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.
Level 3:  Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. We consider observable data to be market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.
The fair value hierarchy of assets carried at fair value and measured on a recurring basis was as follows: 
 Fair value measurement using:
(dollars in thousands)Quoted prices
in active
markets for
identical assets
(Level 1)		Other
observable
inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)		Total
June 30, 2022
Short-term investments—U.S. Treasury securities$1,485,448 $— $— $1,485,448 
Other non-current assets—equity securities6,931 — — 6,931 
Total$1,492,379 $— $— $1,492,379 
December 31, 2021
Short-term investments—U.S. Treasury securities$1,735,202 $— $— $1,735,202 
Other non-current assets—equity securities14,009 — — 14,009 
Total$1,749,211 $— $— $1,749,211 
Our short-term debt investments portfolio only contains investments in U.S. Treasury and other U.S. government-backed securities. We review our portfolio based on the underlying risk profile of the securities and have a zero loss expectation for these investments. We also regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three and six months ended June 30, 2022 and 2021, we recognized no year-to-date credit loss related to our short- and long-term investments, and had no allowance for credit loss recorded as of June 30, 2022 or December 31, 2021.
Our debt securities consisted of the following:
(dollars in thousands)Amortized
cost		Gross
unrealized
gains		Gross
unrealized
losses		Fair
value
June 30, 2022
U.S. Treasury securities$1,489,231 $30 $(3,813)$1,485,448 
Contractual maturities (at date of purchase):
Due in one year or less$1,473,502 $1,469,688 
Due in one to two years15,729 15,760 
Total$1,489,231 $1,485,448 
December 31, 2021
U.S. Treasury securities$1,735,388 $12 $(198)$1,735,202 
Contractual maturities (at date of purchase):
Due in one year or less$1,635,307 $1,635,118 
Due in one to two years100,081 100,084 
Total$1,735,388 $1,735,202 
XML 36 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Investment and other income (loss), net
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investment and other income (loss), net Investment and other income (loss), net
Investment and other income (loss), net consisted of the following:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
(Loss) gain on equity securities$(4,299)$4,670 $(7,078)$4,929 
Investment and other income, net2,690 357 3,279 1,098 
Total investment and other (loss) income, net$(1,609)$5,027 $(3,799)$6,027 
(Loss) gain on equity securities includes the realized and unrealized holding gains and losses on our equity securities. At times, we hold equity investments in certain companies acquired in relation to a strategic partnership. Shares held at the end of reporting periods are marked to market in our condensed consolidated financial statements, which can result in unrealized gains and losses.
XML 37 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories
 6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
(dollars in thousands)June 30, 2022December 31, 2021
Raw materials$15,541 $12,181 
Work in process259,805 152,635 
Finished goods44,008 35,847 
Total$319,354 $200,663 
We capitalize our commercial inventory costs. Inventory that is deployed into clinical, research or development use is charged to research and development expense when it is no longer available for use in commercial sales.
XML 38 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued liabilities
 6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Accrued liabilities Accrued liabilities
Accrued liabilities consisted of the following: 
(dollars in thousands)June 30, 2022December 31, 2021
Employee compensation and benefits$107,585 $139,052 
Clinical trial and related costs169,425 122,468 
Contract manufacturing24,211 21,867 
Gross-to-net deductions and third-party royalties95,094 81,316 
Other 83,334 89,327 
Total$479,649 $454,030 
XML 39 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Share-based compensation
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-based compensation Share-based compensation
The following table presents our total share-based compensation expense for the periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Research and development$23,446 $17,232 $46,522 $34,196 
Selling, general and administrative30,683 20,495 51,520 41,755 
Total share-based compensation expense$54,129 $37,727 $98,042 $75,951 
As of June 30, 2022, there was $105.7 million of unrecognized compensation cost related to unvested options and restricted stock unit awards, excluding our LTIPs and performance-based awards, net of forfeitures. The estimated unrecognized compensation expense related to our performance-based LTIPs was approximately $71 million as of June 30, 2022.
On May 15, 2022, we entered into a separation agreement with our former CEO which modified certain terms of his previously granted equity awards. The agreement provided for the following equity considerations: acceleration of his outstanding and unvested restricted stock unit and stock option awards by an additional 18 months following his separation; the exercisability of his vested options would be extended to December 31, 2023 (or, if earlier, their 10-year expiration); and 5/6 of his outstanding and unvested restricted stock units subject to performance-based vesting conditions granted in 2019 remain eligible to vest on March 13, 2023, based on actual performance through December 31, 2022. Accounting for the equity awards impacted by the separation agreement resulted in $7.3 million of share-based compensation expense recorded in the quarter ended June 30, 2022, net of forfeitures for equity awards that will not vest, other than in the event that a change of control occurs on or prior to December 31, 2023.
XML 40 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes
 6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
For the three and six months ended June 30, 2022, we had taxable profits in the U.S. as a result of amendments to IRC Section 174, which took effect January 1, 2022 pursuant to the 2017 Tax Cuts and Jobs Act. We recorded an income tax provision for the three and six months ended June 30, 2022 of $0.1 million and $1.4 million, respectively, primarily related to estimated state tax liabilities for which there were limitations on the use of existing state tax carryforwards. We had existing federal tax carryforwards sufficient to offset any federal liability. Our income tax provision also reflected taxable profits in foreign jurisdictions partially offset by a foreign valuation allowance release. Our effective tax rate for the three and six months ended June 30, 2022 of approximately 0.1% and 0.5%, respectively, differed from the federal statutory rate primarily because we have provided a valuation allowance against substantially all our deferred tax assets.
For the three and six months ended June 30, 2021, we did not record any income tax provision.
XML 41 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Legal matters
 6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Legal matters Legal matters
We are engaged in multiple legal disputes with Daiichi Sankyo Co. Ltd., or Daiichi Sankyo.
Dispute over ownership of intellectual property
We are in a dispute with Daiichi Sankyo regarding the ownership of certain technology used by Daiichi Sankyo in its cancer drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) and certain product candidates. We believe that the linker and other ADC technology used in ENHERTU and these drug candidates are improvements to our ADC technology, the ownership of which we contend was assigned to us under the terms of a 2008 collaboration agreement between us and Daiichi Sankyo. On November 12, 2019, we submitted an arbitration demand to the American Arbitration Association seeking, among other remedies, a declaration that we are the owner of the intellectual property rights under dispute, monetary damages, and a running royalty. On April 27, 2020, the arbitrator confirmed the dispute should be resolved in arbitration. The arbitration hearing was conducted in June 2021. Recently, the arbitration hearing record was reopened by the arbitrator to consider additional evidence. A decision in the arbitration case is expected in mid-2022.
On November 4, 2019, Daiichi Sankyo filed a declaratory judgment action in the United States District Court for the District of Delaware, alleging that we are not entitled to the intellectual property rights under dispute, in an attempt to have the dispute adjudicated in federal court. The case has been stayed and administratively closed by court order.
Patent infringement
On October 19, 2020, we filed a complaint in the United States District Court for the Eastern District of Texas to commence an action for infringement of our U.S. Patent No. 10,808,039, or the '039 Patent, by Daiichi Sankyo’s importation into, offer for sale, sale, and use in the United States of the cancer drug ENHERTU. The remedies sought in this action include, among other remedies, a judgment that Daiichi Sankyo infringed one or more valid and enforceable claims of the '039 Patent, monetary damages and a running royalty.
Daiichi Sankyo (as well as Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals, LP, or AstraZeneca) subsequently filed an action on November 13, 2020 in the U.S. District Court for the District of Delaware seeking a declaratory judgment that ENHERTU does not infringe the ‘039 Patent. The Delaware action has been stayed by court order.
Daiichi Sankyo, Inc. and AstraZeneca also filed two petitions for post-grant review on December 23, 2020 and January 22, 2021 with the U.S. Patent and Trademark Office, or USPTO, seeking to have claims of the ‘039 Patent cancelled as unpatentable. On June 24, 2021, the USPTO issued a decision denying both petitions for post-grant review. On April 7, 2022, the USPTO granted a request on rehearing and instituted two post-grant review proceedings, but on July 15, 2022, the USPTO issued a new decision denying post-grant review of the claims asserted in the patent infringement action.
On April 8, 2022, a jury in the United States District Court for the Eastern District of Texas found that Daiichi Sankyo willfully infringed the asserted claims of the '039 Patent with its ENHERTU product, and also found that the asserted claims were not invalid. The jury further awarded damages of $41.8 million for infringement from October 20, 2020 through March 31, 2022. The U.S. District Court for the Eastern District of Texas also denied Daiichi Sankyo’s claim that the ‘039 Patent should be unenforceable under the equitable theory of prosecution laches, entered judgment in favor of Seagen based on the jury’s verdict that Daiichi Sankyo willfully infringed the ‘039 Patent consisting of pre-trial damages in the sum of $41.8 million, and awarded Seagen pre- and post-trial interest and costs. We will record an amount of awarded damages in our condensed consolidated financial statements when we have determined the payment to be realized or realizable under ASC 450. We intend to request a royalty on Daiichi Sankyo's future sales of ENHERTU in the United States through November 5, 2024.
As a result of these disputes, we have incurred and will continue to incur litigation expenses. In addition, from time to time, we may become involved in other lawsuits, claims and proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent or other intellectual property rights and our contractual rights. These proceedings are costly and time consuming, and they may subject us to claims which may result in liabilities or require us to take or refrain from certain actions. Additionally, successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use our proprietary technologies without a license from us or our collaborators.
XML 42 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies (Policies)
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The accompanying unaudited condensed consolidated financial statements reflect the accounts of Seagen Inc. and its wholly-owned subsidiaries (collectively “Seagen,” “we,” “our,” or “us”). All intercompany transactions and balances have been eliminated. Management has determined that we operate in one segment: the development and sale of pharmaceutical products on our own behalf or in collaboration with others. Substantially all of our assets and revenues are related to operations in the U.S.; however, we have multiple subsidiaries in foreign jurisdictions, including several subsidiaries in Europe.
The condensed consolidated balance sheet data as of December 31, 2021 were derived from audited financial statements not included in this quarterly report on Form 10-Q. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and generally accepted accounting principles in the United States of America, or GAAP, for unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position and results of our operations as of and for the periods presented.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.
The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The results of our operations for the three and six month period ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other interim period.
Non-cash activities Non-cash activitiesWe had $9.4 million and $9.9 million of accrued capital expenditures as of June 30, 2022 and December 31, 2021, respectively. Accrued capital expenditures are treated as a non-cash investing activity and, accordingly, have not been included in the condensed consolidated statement of cash flows until such amounts have been paid in cash.
Investments
Investments
We hold certain equity securities which are reported at estimated fair value based on quoted market prices. Changes in the fair value of equity securities are recorded in income or loss. The cost of equity securities for purposes of computing gains and losses is based on the specific identification method.
We invest our available cash primarily in debt securities. These debt securities are classified as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains, realized losses and declines in the value of debt securities judged to be other-than-temporary are included in investment and other income (loss), net. The cost of debt securities for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Amortization of premiums and accretion of discounts on debt securities are included in investment and other income (loss), net. Interest and dividends earned are included in investment and other income (loss), net. Accrued interest receivable as of June 30, 2022 and December 31, 2021, were $2.2 million and $0.4 million, respectively, and were included in prepaid expenses and other current assets. We classify investments in debt securities maturing within one year of the reporting date, or where management’s intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments.
If the estimated fair value of a debt security is below its carrying value, we evaluate whether it is more likely than not that we will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. We also evaluate whether or not we intend to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, we consider whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in investment and other income (loss), net.
Restricted Cash
Restricted Cash
As of June 30, 2022, we had $9.9 million cash held in escrow restricted by a contractual agreement related to our Everett, Washington building construction project. The restricted cash was recorded in prepaid expenses and other current assets in the condensed consolidated balance sheet. We determine classification based on the expected duration of the restriction.
Intangible assets, net Intangible assets, netOur intangible assets are primarily comprised of acquired TUKYSA technology.
Revenue recognition - Net product sales
Revenue recognition - Net product sales
We sell our products primarily through a limited number of specialty distributors and specialty pharmacies in the U.S, and to a lesser extent, internationally. The delivery of our products represents a single performance obligation for these transactions and we record net product sales at the point in time when control is transferred to the customer, which generally occurs upon receipt by the customer. The transaction price for net product sales represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. We reflect these accruals as either a reduction in the related account receivable from the distributor or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management’s estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment.
Outside of the U.S., the transaction price for net product sales represents the amount we expect to receive, which is net of estimated discounts, estimated government mandated rebates, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. These estimates involve judgment in estimating net product sales.
U.S. government-mandated rebates and chargebacks: We have entered into a Medicaid Drug Rebate Agreement, or MDRA, with the Centers for Medicare & Medicaid Services. This agreement provides for a rebate based on covered purchases of our products. Medicaid rebates are invoiced to us by the various state Medicaid programs. We estimate Medicaid rebates using the expected value approach, based on a variety of factors, including payor mix and our experience to-date.
We have a Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible purchases of our products. In addition, we have entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services, which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS, to receive discounts on their qualified purchases of our products. Under these agreements, eligible customers receive an applicable discount which is processed through the distributor as a chargeback. We estimate expected chargebacks for FSS and PHS purchases based on the expected value of each entity’s eligibility for the FSS and PHS programs. We also review historical rebate and chargeback information to further refine these estimates.
Distribution fees, product returns and other deductions: Our distributors charge a volume-based fee for distribution services that they perform for us. We allow for the return of product that is within a specified number of days of its expiration date or that is damaged. We estimate product returns based on our experience to-date using the expected value approach. We provide financial assistance to qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through our patient support programs. Estimated contributions for commercial coinsurance under Seagen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as necessary to reflect our actual experience.
Revenue recognition - Royalty revenues
Royalty revenues primarily reflect amounts earned under the ADCETRIS collaboration with Takeda Pharmaceutical Company Limited, or Takeda. These royalties include commercial sales-based milestones and sales royalties that relate predominantly to the license of intellectual property. Sales royalties are based on a percentage of Takeda’s net sales of ADCETRIS, with rates that range from the mid-teens to the mid-twenties based on annual net sales tiers. Takeda bears a portion of low single digit third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenues. Amounts owed to our third-party licensors related to Takeda’s sales of ADCETRIS are recorded in cost of sales. These amounts are recognized in the period in which the related sales by Takeda occur. Royalty revenues also reflect amounts from Genentech, Inc., a member of the Roche Group, or Genentech, earned on net sales of Polivy, and amounts from GlaxoSmithKline earned on net sales of Blenrep.
Revenue recognition - Collaboration and license agreement revenues
We have collaboration and license agreements for our technology with a number of biotechnology and pharmaceutical companies. Under these agreements, we typically receive or are entitled to receive upfront cash payments and progress- and sales-dependent milestones for the achievement by our licensees of certain events, and annual maintenance fees and support fees for research and development services and materials provided under the agreements. We also are entitled to receive royalties on net sales of any resulting products incorporating our technology. Generally, our licensees are solely responsible for research, product development, manufacturing and commercialization of any product candidates under these collaborations, which includes the achievement of the potential milestones. Since we may not take a substantive role or control the research, development or commercialization of any products generated by some of our licensees, we may not be able to reasonably estimate when, if at all, any potential future milestone payments or royalties may be payable to us by our licensees. As such, the potential future milestone payments associated with certain of our collaboration and license agreements involve a substantial degree of uncertainty and risk that they may never be received.
Collaboration and license agreements are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to future reversal of cumulative revenue and, therefore, should be included in the transaction price. Assessing the recognition of variable consideration requires significant judgment. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaboration and license agreements, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract.
We have concluded that the license of intellectual property in certain collaboration and license agreements is not distinct from the perspective of our customers at the time of initial transfer, since we often do not license intellectual property without related technology transfer and research and development support services. Such evaluation requires significant judgment since it is made from the customer's perspective. Our performance obligations under our collaborations may include such things as providing intellectual property licenses, performing technology transfer, performing research and development consulting services, providing reagents, ADCs, and other materials, and notifying the customer of any enhancements to licensed technology or new technology that we discover, among others. We determined our performance obligations under certain collaboration and license agreements as evaluated at contract inception were not distinct and represented a single performance obligation. Upfront payments are amortized to revenue over the performance period. Upfront payment contract liabilities resulting from our collaborations do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. For agreements beyond the initial performance period, we have no remaining performance obligations. We may receive license maintenance fees and potential milestones and royalties based on collaborator development and regulatory progress, which are recorded in the period achieved in the case of milestones, and during the period of the related sales for royalties.
When no performance obligations are required of us, or following the completion of the performance obligation period, such amounts are recognized upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as collaboration and license agreement revenues. Sales-based milestones and royalties are recognized as royalty revenue in the period the related sale occurred.
We generally invoice our collaborators and licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.
XML 43 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies (Tables)
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Schedule of Cash, Cash Equivalents
Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:
(dollars in thousands)June 30, 2022December 31, 2021June 30, 2021December 31, 2020
Cash and cash equivalents$364,874 $424,834 $413,434 $558,424 
Restricted cash included in prepaid expenses and other current assets9,949 — — — 
Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows$374,823 $424,834 $413,434 $558,424 
Schedule of Cash, Cash Equivalents, and Restricted Cash
Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:
(dollars in thousands)June 30, 2022December 31, 2021June 30, 2021December 31, 2020
Cash and cash equivalents$364,874 $424,834 $413,434 $558,424 
Restricted cash included in prepaid expenses and other current assets9,949 — — — 
Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows$374,823 $424,834 $413,434 $558,424 
Schedule of Finite-Lived Intangible Assets The following table presents the balances of our finite-lived intangible assets for the periods presented:
(dollars in thousands)June 30, 2022December 31, 2021
Gross carrying value$305,650 $305,650 
Less: accumulated amortization(56,501)(45,057)
Total$249,149 $260,593 
Schedule of Amortization Expense
The following table presents our amortization expense related to acquired TUKYSA technology costs, included in cost of sales in our condensed consolidated statements of comprehensive loss, for the periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Amortization expense$5,753 $5,757 $11,444 $11,451 
XML 44 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue from contracts with customers (Tables)
 6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Collaboration and License Agreement Revenues by Collaborator
The following table presents our disaggregated revenue for the periods presented.
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
ADCETRIS$201,939 $181,912 $382,928 $344,484 
PADCEV123,577 82,405 223,784 152,163 
TUKYSA88,989 83,021 179,464 153,279 
TIVDAK17,209 — 28,624 — 
Net product sales$431,714 $347,338 $814,800 $649,926 
Royalty revenues$39,109 $36,296 $67,290 $63,514 
Collaboration and license agreement revenues$26,679 $4,844 $41,872 $7,020 
Total revenues$497,502 $388,478 $923,962 $720,460 
XML 45 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Summary of Supplemental Operating Lease Information
Supplemental operating lease information was as follows:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Operating lease cost$3,947 $4,063 $8,142 $8,077 
Variable lease cost1,249 1,151 2,321 2,138 
Total lease cost$5,196 $5,214 $10,463 $10,215 
Cash paid for amounts included in measurement of lease liabilities$4,196 $4,199 $8,749 $8,057 
As of June 30,
20222021
Weighted average remaining lease term5.6 years6.3 years
Weighted average discount rate5 %5.1 %
Summary of Operating Lease Assets and Liabilities
Operating lease liabilities were recorded in the following captions of our condensed consolidated balance sheet as follows:
(dollars in thousands)June 30, 2022December 31, 2021
Accrued liabilities and other$13,700 $13,905 
Operating lease liabilities, long-term50,205 56,665 
Total$63,905 $70,570 
XML 46 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share (Tables)
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares The following table presents the weighted average number of shares that have been excluded for all periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2022202120222021
Stock options and RSUs9,824 9,992 10,077 10,229 
XML 47 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value (Tables)
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis
The fair value hierarchy of assets carried at fair value and measured on a recurring basis was as follows: 
 Fair value measurement using:
(dollars in thousands)Quoted prices
in active
markets for
identical assets
(Level 1)		Other
observable
inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)		Total
June 30, 2022
Short-term investments—U.S. Treasury securities$1,485,448 $— $— $1,485,448 
Other non-current assets—equity securities6,931 — — 6,931 
Total$1,492,379 $— $— $1,492,379 
December 31, 2021
Short-term investments—U.S. Treasury securities$1,735,202 $— $— $1,735,202 
Other non-current assets—equity securities14,009 — — 14,009 
Total$1,749,211 $— $— $1,749,211 
Summary of Debt Securities
Our debt securities consisted of the following:
(dollars in thousands)Amortized
cost		Gross
unrealized
gains		Gross
unrealized
losses		Fair
value
June 30, 2022
U.S. Treasury securities$1,489,231 $30 $(3,813)$1,485,448 
Contractual maturities (at date of purchase):
Due in one year or less$1,473,502 $1,469,688 
Due in one to two years15,729 15,760 
Total$1,489,231 $1,485,448 
December 31, 2021
U.S. Treasury securities$1,735,388 $12 $(198)$1,735,202 
Contractual maturities (at date of purchase):
Due in one year or less$1,635,307 $1,635,118 
Due in one to two years100,081 100,084 
Total$1,735,388 $1,735,202 
XML 48 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Investment and other income (loss), net (Tables)
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment and Other Income, Net
Investment and other income (loss), net consisted of the following:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
(Loss) gain on equity securities$(4,299)$4,670 $(7,078)$4,929 
Investment and other income, net2,690 357 3,279 1,098 
Total investment and other (loss) income, net$(1,609)$5,027 $(3,799)$6,027 
XML 49 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories (Tables)
 6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of the following:
(dollars in thousands)June 30, 2022December 31, 2021
Raw materials$15,541 $12,181 
Work in process259,805 152,635 
Finished goods44,008 35,847 
Total$319,354 $200,663 
XML 50 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued liabilities (Tables)
 6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities consisted of the following: 
(dollars in thousands)June 30, 2022December 31, 2021
Employee compensation and benefits$107,585 $139,052 
Clinical trial and related costs169,425 122,468 
Contract manufacturing24,211 21,867 
Gross-to-net deductions and third-party royalties95,094 81,316 
Other 83,334 89,327 
Total$479,649 $454,030 
XML 51 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Share-based compensation (Tables)
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation The following table presents our total share-based compensation expense for the periods presented:
Three Months Ended June 30,Six Months Ended June 30,
(dollars in thousands)2022202120222021
Research and development$23,446 $17,232 $46,522 $34,196 
Selling, general and administrative30,683 20,495 51,520 41,755 
Total share-based compensation expense$54,129 $37,727 $98,042 $75,951 
XML 52 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies - Additional Information (Details)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Summary Of Significant Accounting Policies [Line Items]        
Number of reporting segments | segment 1      
Accrued capital expenditures $ 9,400 $ 9,900    
Accrued interest receivable 2,200 400    
Cash held in escrow restricted by a contractual agreement 9,949 $ 0 $ 0 $ 0
Estimated future amortization expense, remainder of fiscal year 11,600      
Estimated future amortization expense, 2023 23,100      
Estimated future amortization expense, 2024 23,100      
Estimated future amortization expense, 2025 23,100      
Estimated future amortization expense, 2026 23,100      
Estimated future amortization expense, 2027 $ 23,100      
Weighted Average        
Summary Of Significant Accounting Policies [Line Items]        
Intangible asset useful life 11 years      
XML 53 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]        
Cash and cash equivalents $ 364,874 $ 424,834 $ 413,434 $ 558,424
Restricted cash included in prepaid expenses and other current assets 9,949 0 0 0
Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows $ 374,823 $ 424,834 $ 413,434 $ 558,424
XML 54 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies - Finite-lived intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Gross carrying value $ 305,650 $ 305,650
Less: accumulated amortization (56,501) (45,057)
Total $ 249,149 $ 260,593
XML 55 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies - Amortization Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Accounting Policies [Abstract]        
Amortization expense $ 5,753 $ 5,757 $ 11,444 $ 11,451
XML 56 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue from contracts with customers - Summary of Collaboration and License Agreement Revenues by Collaborator (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues $ 497,502 $ 388,478 $ 923,962 $ 720,460
Net product sales        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues 431,714 347,338 814,800 649,926
Net product sales | ADCETRIS        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues 201,939 181,912 382,928 344,484
Net product sales | PADCEV        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues 123,577 82,405 223,784 152,163
Net product sales | TUKYSA        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues 88,989 83,021 179,464 153,279
Net product sales | TIVDAK        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues 17,209 0 28,624 0
Royalty revenues        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues 39,109 36,296 67,290 63,514
Collaboration and license agreement revenues        
Disaggregation of Revenue [Line Items]        
Collaboration and license agreement revenues $ 26,679 $ 4,844 $ 41,872 $ 7,020
XML 57 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Additional Information (Details)
ft² in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
ft²
a
term
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
ft²
term
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
ft²
term
Leases [Abstract]          
Right-of-use assets in exchange for lease liabilities       $ 200 $ 7,100
Lease agreement, rented area | ft² 258   258   258
Rentable building and complex constructed (in acres) | a 20.5        
Initial rate $ 4,000 $ 4,196 $ 4,199 $ 8,749 $ 8,057
Annual escalations 3.00%        
Initial term 20 years   20 years   20 years
Option to extend | term 2   2   2
Renewal term 10 years   10 years   10 years
XML 58 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lease Cost (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Leases [Abstract]          
Operating lease cost   $ 3,947 $ 4,063 $ 8,142 $ 8,077
Variable lease cost   1,249 1,151 2,321 2,138
Total lease cost   5,196 5,214 10,463 10,215
Cash paid for amounts included in measurement of lease liabilities $ 4,000 $ 4,196 $ 4,199 $ 8,749 $ 8,057
Weighted average remaining lease term 6 years 3 months 18 days 5 years 7 months 6 days 6 years 3 months 18 days 5 years 7 months 6 days 6 years 3 months 18 days
Weighted average discount rate 5.10% 5.00% 5.10% 5.00% 5.10%
XML 59 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Summary of Balance Sheet Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Leases [Abstract]    
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued liabilities and other Accrued liabilities and other
Accrued liabilities and other $ 13,700 $ 13,905
Operating lease liabilities, long-term 50,205 56,665
Total $ 63,905 $ 70,570
XML 60 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share (Details) - shares
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]        
Stock options and RSUs (in shares) 9,824 9,992 10,077 10,229
XML 61 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value - Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments $ 1,492,379 $ 1,749,211
US Treasury Securities | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,485,448 1,735,202
Equity Securities | Other Non-current Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 6,931 14,009
Quoted prices in active markets for identical assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,492,379 1,749,211
Quoted prices in active markets for identical assets (Level 1) | US Treasury Securities | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,485,448 1,735,202
Quoted prices in active markets for identical assets (Level 1) | Equity Securities | Other Non-current Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 6,931 14,009
Other observable inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Other observable inputs (Level 2) | US Treasury Securities | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Other observable inputs (Level 2) | Equity Securities | Other Non-current Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Significant unobservable inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Significant unobservable inputs (Level 3) | US Treasury Securities | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0 0
Significant unobservable inputs (Level 3) | Equity Securities | Other Non-current Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments $ 0 $ 0
XML 62 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Fair Value Disclosures [Abstract]          
Credit loss $ 0 $ 0 $ 0 $ 0  
Allowance for credit loss $ 0   $ 0   $ 0
XML 63 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value - Summary of Debt Securities (Details) - US Treasury Securities - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Amortized cost $ 1,489,231 $ 1,735,388
Gross unrealized gains 30 12
Gross unrealized losses (3,813) (198)
Fair value 1,485,448 1,735,202
Debt securities, due in one year or less, amortized cost 1,473,502 1,635,307
Debt securities, due in one year or less, fair value 1,469,688 1,635,118
Debt securities, due in one to two years, amortized cost 15,729 100,081
Debt securities, due in one to two years, fair value $ 15,760 $ 100,084
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Investment and other income (loss), net (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]        
(Loss) gain on equity securities $ (4,299) $ 4,670 $ (7,078) $ 4,929
Investment and other income, net 2,690 357 3,279 1,098
Total investment and other (loss) income, net $ (1,609) $ 5,027 $ (3,799) $ 6,027
XML 65 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 15,541 $ 12,181
Work in process 259,805 152,635
Finished goods 44,008 35,847
Total $ 319,354 $ 200,663
XML 66 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Employee compensation and benefits $ 107,585 $ 139,052
Clinical trial and related costs 169,425 122,468
Contract manufacturing 24,211 21,867
Gross-to-net deductions and third-party royalties 95,094 81,316
Other 83,334 89,327
Total $ 479,649 $ 454,030
XML 67 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Share-based compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
May 15, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense   $ 54,129 $ 37,727 $ 98,042 $ 75,951
Unrecognized compensation cost   105,700   105,700  
Acceleration period following separation 18 months        
Expiration period 10 years        
Share-based payment arrangement, plan modification, incremental cost   7,300      
Research and development          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense   23,446 17,232 46,522 34,196
Selling, general and administrative          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense   30,683 $ 20,495 51,520 $ 41,755
Long Term Incentive Plans          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation costs, excluding options   $ 71,000   $ 71,000  
XML 68 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 107,000 $ 0 $ 1,361,000 $ 0
Effective income tax rate 0.10%   0.50%  
XML 69 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Legal matters (Details) - Patent Infringement
$ in Millions
 1 Months Ended
Apr. 08, 2022
USD ($)
Jan. 22, 2021
petition
Subsequent Event [Line Items]    
Number of petitions filed | petition   2
Awarded damages for past infringement | $ $ 41.8  
XML 70 sgen-20220630_htm.xml IDEA: XBRL DOCUMENT 0001060736 2022-01-01 2022-06-30 0001060736 2022-07-25 0001060736 2022-06-30 0001060736 2021-12-31 0001060736 us-gaap:ProductMember 2022-04-01 2022-06-30 0001060736 us-gaap:ProductMember 2021-04-01 2021-06-30 0001060736 us-gaap:ProductMember 2022-01-01 2022-06-30 0001060736 us-gaap:ProductMember 2021-01-01 2021-06-30 0001060736 us-gaap:RoyaltyMember 2022-04-01 2022-06-30 0001060736 us-gaap:RoyaltyMember 2021-04-01 2021-06-30 0001060736 us-gaap:RoyaltyMember 2022-01-01 2022-06-30 0001060736 us-gaap:RoyaltyMember 2021-01-01 2021-06-30 0001060736 us-gaap:LicenseAndServiceMember 2022-04-01 2022-06-30 0001060736 us-gaap:LicenseAndServiceMember 2021-04-01 2021-06-30 0001060736 us-gaap:LicenseAndServiceMember 2022-01-01 2022-06-30 0001060736 us-gaap:LicenseAndServiceMember 2021-01-01 2021-06-30 0001060736 2022-04-01 2022-06-30 0001060736 2021-04-01 2021-06-30 0001060736 2021-01-01 2021-06-30 0001060736 us-gaap:CommonStockMember 2020-12-31 0001060736 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001060736 us-gaap:RetainedEarningsMember 2020-12-31 0001060736 2020-12-31 0001060736 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001060736 2021-01-01 2021-03-31 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001060736 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001060736 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001060736 us-gaap:CommonStockMember 2021-03-31 0001060736 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001060736 us-gaap:RetainedEarningsMember 2021-03-31 0001060736 2021-03-31 0001060736 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001060736 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001060736 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001060736 us-gaap:CommonStockMember 2021-06-30 0001060736 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001060736 us-gaap:RetainedEarningsMember 2021-06-30 0001060736 2021-06-30 0001060736 us-gaap:CommonStockMember 2021-12-31 0001060736 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001060736 us-gaap:RetainedEarningsMember 2021-12-31 0001060736 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001060736 2022-01-01 2022-03-31 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001060736 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001060736 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001060736 us-gaap:CommonStockMember 2022-03-31 0001060736 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001060736 us-gaap:RetainedEarningsMember 2022-03-31 0001060736 2022-03-31 0001060736 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001060736 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001060736 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001060736 us-gaap:CommonStockMember 2022-06-30 0001060736 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001060736 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001060736 us-gaap:RetainedEarningsMember 2022-06-30 0001060736 2021-01-01 2021-12-31 0001060736 srt:WeightedAverageMember 2022-01-01 2022-06-30 0001060736 sgen:AdcetrisMember us-gaap:ProductMember 2022-04-01 2022-06-30 0001060736 sgen:AdcetrisMember us-gaap:ProductMember 2021-04-01 2021-06-30 0001060736 sgen:AdcetrisMember us-gaap:ProductMember 2022-01-01 2022-06-30 0001060736 sgen:AdcetrisMember us-gaap:ProductMember 2021-01-01 2021-06-30 0001060736 sgen:PadcevMember us-gaap:ProductMember 2022-04-01 2022-06-30 0001060736 sgen:PadcevMember us-gaap:ProductMember 2021-04-01 2021-06-30 0001060736 sgen:PadcevMember us-gaap:ProductMember 2022-01-01 2022-06-30 0001060736 sgen:PadcevMember us-gaap:ProductMember 2021-01-01 2021-06-30 0001060736 sgen:TukysaMember us-gaap:ProductMember 2022-04-01 2022-06-30 0001060736 sgen:TukysaMember us-gaap:ProductMember 2021-04-01 2021-06-30 0001060736 sgen:TukysaMember us-gaap:ProductMember 2022-01-01 2022-06-30 0001060736 sgen:TukysaMember us-gaap:ProductMember 2021-01-01 2021-06-30 0001060736 sgen:TIVDAKMember us-gaap:ProductMember 2022-04-01 2022-06-30 0001060736 sgen:TIVDAKMember us-gaap:ProductMember 2021-04-01 2021-06-30 0001060736 sgen:TIVDAKMember us-gaap:ProductMember 2022-01-01 2022-06-30 0001060736 sgen:TIVDAKMember us-gaap:ProductMember 2021-01-01 2021-06-30 0001060736 2021-06-01 2021-06-30 0001060736 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001060736 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001060736 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001060736 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2022-06-30 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-06-30 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-06-30 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-06-30 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-06-30 0001060736 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001060736 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001060736 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001060736 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001060736 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001060736 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001060736 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001060736 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0001060736 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0001060736 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001060736 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001060736 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001060736 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001060736 us-gaap:USTreasurySecuritiesMember 2022-06-30 0001060736 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001060736 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001060736 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001060736 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001060736 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001060736 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0001060736 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0001060736 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0001060736 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-06-30 0001060736 sgen:LongTermIncentivePlansMember 2022-06-30 0001060736 2022-05-15 2022-05-15 0001060736 sgen:PatentInfringementMember 2020-12-23 2021-01-22 0001060736 sgen:PatentInfringementMember 2022-04-08 2022-04-08 shares iso4217:USD iso4217:USD shares sgen:segment utr:sqft utr:acre pure sgen:term sgen:petition false 2022 Q2 0001060736 --12-31 http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent 10-Q true 2022-06-30 false 0-32405 SEAGEN INC. DE 91-1874389 21823 30th Drive SE Bothell WA 98021 425 527-4000 Common Stock, par value $0.001 SGEN NASDAQ Yes Yes Large Accelerated Filer false false false 184435456 364874000 424834000 1485448000 1735202000 438041000 389256000 319354000 200663000 170938000 119239000 2778655000 2869194000 218901000 210073000 51942000 57889000 249149000 260593000 274671000 274671000 57025000 47184000 3630343000 3719604000 128872000 114824000 479649000 454030000 608521000 568854000 50205000 56665000 38805000 28946000 89010000 85611000 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 250000000 250000000 184369000 184369000 183381000 183381000 184000 183000 4747481000 4607816000 507000 1179000 -1815360000 -1544039000 2932812000 3065139000 3630343000 3719604000 431714000 347338000 814800000 649926000 39109000 36296000 67290000 63514000 26679000 4844000 41872000 7020000 497502000 388478000 923962000 720460000 106100000 78090000 193726000 142225000 304254000 234861000 601913000 465286000 220259000 165130000 394484000 324972000 630613000 478081000 1190123000 932483000 -133111000 -89603000 -266161000 -212023000 -1609000 5027000 -3799000 6027000 -134720000 -84576000 -269960000 -205996000 107000 0 1361000 0 -134827000 -84576000 -271321000 -205996000 -0.73 -0.73 -0.47 -0.47 -1.48 -1.48 -1.14 -1.14 184145000 184145000 181628000 181628000 183897000 183897000 181390000 181390000 -134827000 -84576000 -271321000 -205996000 -2736000 -213000 -3597000 -47000 2819000 511000 2925000 274000 83000 298000 -672000 227000 -134744000 -84278000 -271993000 -205769000 180902000 181000 4356922000 565000 -869568000 3488100000 -121420000 -121420000 -71000 -71000 341000 19791000 19791000 80000 38224000 38224000 181323000 181000 4414937000 494000 -990988000 3424624000 -84576000 -84576000 298000 298000 359000 1000 13200000 13201000 184000 37727000 37727000 181866000 182000 4465864000 792000 -1075564000 3391274000 183381000 183000 4607816000 1179000 -1544039000 3065139000 -136494000 -136494000 -755000 -755000 463000 1000 26663000 26664000 48000 43913000 43913000 183892000 184000 4678392000 424000 -1680533000 2998467000 -134827000 -134827000 83000 83000 298000 14960000 14960000 179000 54129000 54129000 184369000 184000 4747481000 507000 -1815360000 2932812000 -271321000 -205996000 98042000 75951000 22867000 19603000 11444000 11451000 6140000 6356000 -484000 -11802000 -7078000 4929000 -557000 0 48785000 54752000 118691000 47048000 37249000 46122000 8533000 7481000 50499000 43395000 -288582000 -197770000 1489327000 1788967000 1735000000 1831500000 13756000 0 32161000 22403000 199756000 20130000 41624000 32992000 41624000 32992000 -2809000 -342000 -50011000 -144990000 424834000 558424000 374823000 413434000 Summary of significant accounting policies<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect the accounts of Seagen Inc. and its wholly-owned subsidiaries (collectively “Seagen,” “we,” “our,” or “us”). All intercompany transactions and balances have been eliminated. Management has determined that we operate in one segment: the development and sale of pharmaceutical products on our own behalf or in collaboration with others. Substantially all of our assets and revenues are related to operations in the U.S.; however, we have multiple subsidiaries in foreign jurisdictions, including several subsidiaries in Europe.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet data as of December 31, 2021 were derived from audited financial statements not included in this quarterly report on Form 10-Q. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and generally accepted accounting principles in the United States of America, or GAAP, for unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position and results of our operations as of and for the periods presented.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The results of our operations for the three and six month period ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other interim period.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash activities</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $9.9 million of accrued capital expenditures as of June 30, 2022 and December 31, 2021, respectively. Accrued capital expenditures are treated as a non-cash investing activity and, accordingly, have not been included in the condensed consolidated statement of cash flows until such amounts have been paid in cash. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain equity securities which are reported at estimated fai</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r value based on quoted market prices. Cha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nges in the fair value of equity securities are recorded in income or loss. The cost of equity securities for purposes of computing gains and losses is based on the specific identification method.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our available cash primarily in debt securities. These debt securities are classified as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains, realized losses and declines in the value of debt securities judged to be other-than-temporary are included in investment and other income (loss), net. The cost of debt securities for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Amortization of premiums and accretion of discounts on debt securities are included in investment and other income (loss), net. Interest and dividends earned are included in investment and other income (loss), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accrued interest receivable as of June 30, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $0.4 million, respectively, and were included in prepaid expenses and other current assets. We c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lassify investments in debt securities maturing within one year of the reporting date, or where management’s intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the estimated fair value of a debt security is below its carrying value, we evaluate whether it is more likely than not that we will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. We also evaluate whether or not we intend to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, we consider whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in investment and other income (loss), net.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash held in escrow restricted by a contractual agreement related to our Everett, Washington building construction project. The restricted cash was recorded in prepaid expenses and other current assets in the condensed consolidated balance sheet. We determine classification based on the expected duration of the restriction.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,424 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible assets, net</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets are primarily comprised of acquired TUKYSA technology. The following table presents the balances of our finite-lived intangible assets for the periods presented: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,149 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our amortization expense related to acquired TUKYSA technology costs, included in cost of sales in our condensed consolidated statements of comprehensive loss, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the periods presented:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining useful life of our finite-lived intangible assets was approximately 11 years as of June 30, 2022, and estimated future amortization expense related to acquired TUKYSA is $11.6 million for the six months ending December 31, 2022, and TUKYSA technology costs is $23.1 million for each of the years ending December 31, 2023 through December 31, 2027.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - Net product sales</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a limited number of specialty distributors and specialty pharmaci</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es in the U.S, and to a lesser extent, internationally. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of our products represents a single performance obligation for these transactions and we record net product sales at the point in time when control is transferred to the customer, which generally occurs upon receipt by the customer. The transaction price for net product sales represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. We reflect these accruals as either a reduction in the related account receivable from the distributor or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management’s estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., the transaction price for net product sales represents the amount we expect to receive, which is net of estimated discounts, estimated government mandated rebates, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. These estimates involve judgment in estimating net product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. government-mandated rebates and chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a Medicaid Drug Rebate Agreement, or MDRA, with the Centers for Medicare &amp; Medicaid Services. This agreement provides for a rebate based on covered purchases of our products. Medicaid rebates are invoiced to us by the various state Medicaid programs. We estimate Medicaid rebates using the expected value approach, based on a variety of factors, including payor mix and our experience to-date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible purchases of our products. In addition, we have entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services, which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS, to receive discounts on their qualified purchases of our products. Under these agreements, eligible customers receive an applicable discount which is processed through the distributor as a chargeback. We estimate expected chargebacks for FSS and PHS purchases based on the expected value of each entity’s eligibility for the FSS and PHS programs. We also review historical rebate and chargeback information to further refine these estimates. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution fees, product returns and other deductions: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our distributors charge a volume-based fee for distribution services that they perform for us. We allow for the return of product that is within a specified number of days of its expiration date or that is damaged. We estimate product returns based on our experience to-date using the expected value approach. We provide financial assistance to qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through our patient support programs. Estimated contributions for commercial coinsurance under Seagen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as necessary to reflect our actual experience.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - Royalty revenues</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues primarily reflect amounts earned under the ADCETRIS collaboration with Takeda </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Company Limited, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda. These royalties include commercial sales-based milestones and sales royalties that relate predominantly to the license of intellectual property. Sales royalties are based on a percentage of Takeda’s net sales of ADCETRIS, with rates that range from the mid-teens to the mid-twenties based on annual net sales tiers. Takeda bears a portion of low single digit third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenues. Amounts owed to our third-party licensors related to Takeda’s sales of ADCETRIS are recorded in cost of sales. These amounts are recognized in the period in which the related sales by Takeda occur. Royalty revenues also reflect amounts from Genentech, Inc., a member of the Roche Group, or Genentech, earned on net sales of Polivy, and amounts from GlaxoSmithKline earned on net sales of Blenrep.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and license agreement revenues</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaboration and license agreements for our technology with a number of biotechnology and pharmaceutical companies. Under these agreements, we typically receive or are entitled to receive upfront cash payments and progress- and sales-dependent milestones for the achievement by our licensees of certain events, and annual maintenance fees and support fees for research and development services and materials provided under the agreements. We also are entitled to receive royalties on net sales of any resulting products incorporating our technology. Generally, our licensees are solely responsible for research, product development, manufacturing and commercialization of any product candidates under these collaborations, which includes the achievement of the potential milestones. Since we may not take a substantive role or control the research, development or commercialization of any products generated by some of our licensees, we may not be able to reasonably estimate when, if at all, any potential future milestone payments or royalties may be payable to us by our licensees. As such, the potential future milestone payments associated with certain of our collaboration and license agreements involve a substantial degree of uncertainty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and risk that they may never be received</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and license agreements are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to future reversal of cumulative revenue and, therefore, should be included in the transaction price. Assessing the recognition of variable consideration requires significant judgment. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaboration and license agreements, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that the license of intellectual property in certain collaboration and license agreements is not distinct from the perspective of our customers at the time of initial transfer, since we often do not license intellectual property without related technology transfer and research and development support services. Such evaluation requires significant judgment since it is made from the customer's perspective. Our performance obligations under our collaborations may include such things as providing intellectual property licenses, performing technology transfer, performing research and development consulting services, providing reagents, ADCs, and other materials, and notifying the customer of any enhancements to licensed technology or new technology that we discover, among others. We determined our performance obligations under certain collaboration and license agreements as evaluated at contract inception were not distinct and represented a single performance obligation. Upfront payments are amortized to revenue over the performance period. Upfront payment contract liabilities resulting from our collaborations do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. For agreements beyond the initial performance period, we have no remaining performance obligations. We may receive license maintenance fees and potential milestones and royalties based on collaborator development and regulatory progress, which are recorded in the period achieved in the case of milestones, and during the period of the related sales for royalties. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When no performance obligations are required of us, or following the completion of the performance obligation period, such amounts are recognized upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as collaboration and license agreement revenues. Sales-based milestones and royalties are recognized as royalty revenue in the period the related sale occurred.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally invoice our collaborators and licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</span></div> <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect the accounts of Seagen Inc. and its wholly-owned subsidiaries (collectively “Seagen,” “we,” “our,” or “us”). All intercompany transactions and balances have been eliminated. Management has determined that we operate in one segment: the development and sale of pharmaceutical products on our own behalf or in collaboration with others. Substantially all of our assets and revenues are related to operations in the U.S.; however, we have multiple subsidiaries in foreign jurisdictions, including several subsidiaries in Europe.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet data as of December 31, 2021 were derived from audited financial statements not included in this quarterly report on Form 10-Q. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC, and generally accepted accounting principles in the United States of America, or GAAP, for unaudited condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position and results of our operations as of and for the periods presented.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The results of our operations for the three and six month period ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other interim period.</span></div> 1 Non-cash activities<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.4 million</span> and $9.9 million of accrued capital expenditures as of June 30, 2022 and December 31, 2021, respectively. Accrued capital expenditures are treated as a non-cash investing activity and, accordingly, have not been included in the condensed consolidated statement of cash flows until such amounts have been paid in cash. 9400000 9900000 <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain equity securities which are reported at estimated fai</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r value based on quoted market prices. Cha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nges in the fair value of equity securities are recorded in income or loss. The cost of equity securities for purposes of computing gains and losses is based on the specific identification method.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our available cash primarily in debt securities. These debt securities are classified as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains, realized losses and declines in the value of debt securities judged to be other-than-temporary are included in investment and other income (loss), net. The cost of debt securities for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Amortization of premiums and accretion of discounts on debt securities are included in investment and other income (loss), net. Interest and dividends earned are included in investment and other income (loss), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accrued interest receivable as of June 30, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $0.4 million, respectively, and were included in prepaid expenses and other current assets. We c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lassify investments in debt securities maturing within one year of the reporting date, or where management’s intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the estimated fair value of a debt security is below its carrying value, we evaluate whether it is more likely than not that we will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. We also evaluate whether or not we intend to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, we consider whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in investment and other income (loss), net.</span></div> 2200000 400000 <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash held in escrow restricted by a contractual agreement related to our Everett, Washington building construction project. The restricted cash was recorded in prepaid expenses and other current assets in the condensed consolidated balance sheet. We determine classification based on the expected duration of the restriction.</span></div> 9900000 <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,424 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cash, cash equivalents, and restricted cash, as presented in the condensed consolidated statements of cash flows, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,834 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,424 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 364874000 424834000 413434000 558424000 9949000 0 0 0 374823000 424834000 413434000 558424000 Intangible assets, netOur intangible assets are primarily comprised of acquired TUKYSA technology. The following table presents the balances of our finite-lived intangible assets for the periods presented: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,149 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 305650000 305650000 56501000 45057000 249149000 260593000 <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our amortization expense related to acquired TUKYSA technology costs, included in cost of sales in our condensed consolidated statements of comprehensive loss, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the periods presented:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5753000 5757000 11444000 11451000 P11Y 11600000 23100000 23100000 23100000 23100000 23100000 <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - Net product sales</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a limited number of specialty distributors and specialty pharmaci</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es in the U.S, and to a lesser extent, internationally. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of our products represents a single performance obligation for these transactions and we record net product sales at the point in time when control is transferred to the customer, which generally occurs upon receipt by the customer. The transaction price for net product sales represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. We reflect these accruals as either a reduction in the related account receivable from the distributor or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management’s estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., the transaction price for net product sales represents the amount we expect to receive, which is net of estimated discounts, estimated government mandated rebates, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. These estimates involve judgment in estimating net product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. government-mandated rebates and chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a Medicaid Drug Rebate Agreement, or MDRA, with the Centers for Medicare &amp; Medicaid Services. This agreement provides for a rebate based on covered purchases of our products. Medicaid rebates are invoiced to us by the various state Medicaid programs. We estimate Medicaid rebates using the expected value approach, based on a variety of factors, including payor mix and our experience to-date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible purchases of our products. In addition, we have entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services, which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS, to receive discounts on their qualified purchases of our products. Under these agreements, eligible customers receive an applicable discount which is processed through the distributor as a chargeback. We estimate expected chargebacks for FSS and PHS purchases based on the expected value of each entity’s eligibility for the FSS and PHS programs. We also review historical rebate and chargeback information to further refine these estimates. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution fees, product returns and other deductions: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our distributors charge a volume-based fee for distribution services that they perform for us. We allow for the return of product that is within a specified number of days of its expiration date or that is damaged. We estimate product returns based on our experience to-date using the expected value approach. We provide financial assistance to qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through our patient support programs. Estimated contributions for commercial coinsurance under Seagen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as necessary to reflect our actual experience.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - Royalty revenues</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues primarily reflect amounts earned under the ADCETRIS collaboration with Takeda </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Company Limited, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda. These royalties include commercial sales-based milestones and sales royalties that relate predominantly to the license of intellectual property. Sales royalties are based on a percentage of Takeda’s net sales of ADCETRIS, with rates that range from the mid-teens to the mid-twenties based on annual net sales tiers. Takeda bears a portion of low single digit third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenues. Amounts owed to our third-party licensors related to Takeda’s sales of ADCETRIS are recorded in cost of sales. These amounts are recognized in the period in which the related sales by Takeda occur. Royalty revenues also reflect amounts from Genentech, Inc., a member of the Roche Group, or Genentech, earned on net sales of Polivy, and amounts from GlaxoSmithKline earned on net sales of Blenrep.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and license agreement revenues</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaboration and license agreements for our technology with a number of biotechnology and pharmaceutical companies. Under these agreements, we typically receive or are entitled to receive upfront cash payments and progress- and sales-dependent milestones for the achievement by our licensees of certain events, and annual maintenance fees and support fees for research and development services and materials provided under the agreements. We also are entitled to receive royalties on net sales of any resulting products incorporating our technology. Generally, our licensees are solely responsible for research, product development, manufacturing and commercialization of any product candidates under these collaborations, which includes the achievement of the potential milestones. Since we may not take a substantive role or control the research, development or commercialization of any products generated by some of our licensees, we may not be able to reasonably estimate when, if at all, any potential future milestone payments or royalties may be payable to us by our licensees. As such, the potential future milestone payments associated with certain of our collaboration and license agreements involve a substantial degree of uncertainty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and risk that they may never be received</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and license agreements are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to future reversal of cumulative revenue and, therefore, should be included in the transaction price. Assessing the recognition of variable consideration requires significant judgment. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaboration and license agreements, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that the license of intellectual property in certain collaboration and license agreements is not distinct from the perspective of our customers at the time of initial transfer, since we often do not license intellectual property without related technology transfer and research and development support services. Such evaluation requires significant judgment since it is made from the customer's perspective. Our performance obligations under our collaborations may include such things as providing intellectual property licenses, performing technology transfer, performing research and development consulting services, providing reagents, ADCs, and other materials, and notifying the customer of any enhancements to licensed technology or new technology that we discover, among others. We determined our performance obligations under certain collaboration and license agreements as evaluated at contract inception were not distinct and represented a single performance obligation. Upfront payments are amortized to revenue over the performance period. Upfront payment contract liabilities resulting from our collaborations do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. For agreements beyond the initial performance period, we have no remaining performance obligations. We may receive license maintenance fees and potential milestones and royalties based on collaborator development and regulatory progress, which are recorded in the period achieved in the case of milestones, and during the period of the related sales for royalties. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When no performance obligations are required of us, or following the completion of the performance obligation period, such amounts are recognized upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as collaboration and license agreement revenues. Sales-based milestones and royalties are recognized as royalty revenue in the period the related sale occurred.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally invoice our collaborators and licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</span></div> Revenue from contracts with customers<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our disaggregated revenue for the periods presented. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADCETRIS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,912 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PADCEV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,577 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TUKYSA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TIVDAK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,290 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,514 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license agreement revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,020 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,502 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,478 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923,962 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,460 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our disaggregated revenue for the periods presented. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADCETRIS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,912 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PADCEV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,577 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TUKYSA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TIVDAK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,290 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,514 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license agreement revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,020 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,502 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,478 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923,962 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,460 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 201939000 181912000 382928000 344484000 123577000 82405000 223784000 152163000 88989000 83021000 179464000 153279000 17209000 0 28624000 0 431714000 347338000 814800000 649926000 39109000 36296000 67290000 63514000 26679000 4844000 41872000 7020000 497502000 388478000 923962000 720460000 Leases<div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for our office and laboratory facilities with terms that expire from 2022 through 2029. We recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right-of-use assets in exchange for lease liabilities, respectively, during the six months ended June 30, 2022 and 2021, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our significan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t leases include options for us to extend the lease term. None of our options to extend the rental term of any existing leases were considered reasonably certain as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a lease agreement for an approximately 258,000 square feet building complex to be constructed by the landlord on approximately 20.5 acres of land in Everett, Washington. We intend to use the building for future manufacturing, laboratory, and office space. Under the terms of the lease, base rent is payable at an initial rate of $4.0 million per year, subject to annual escalations of 3% during the initial term of 20 years. The lease commences on the date when construction and delivery of the building shell and related improvements by the landlord have been substantially completed. We will record a lease liability and right-of-use assets on our condensed consolidated balance sheet on the lease commencement date, which has not commenced as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have an option to renew the lease for two additional terms of ten years each. In addition, we have an option to purchase the premises in the future.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental operating lease information was as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,196 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,199 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,749 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,057 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded in the following captions of our condensed consolidated balance sheet as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiY2M0NjhiOWFlNDRkNjViN2IxNTEyM2VkY2VhYmVjL3NlYzoxYmNjNDY4YjlhZTQ0ZDY1YjdiMTUxMjNlZGNlYWJlY180MC9mcmFnOjdjMTIyMjFiZGM1ZDRiNzc4ZjA1Y2E2ODk4NWI0ZTBhL3RhYmxlOjUyNmE5MzBjZjZlYzQ1YTViODIzNGRlN2U3NGY5YmU2L3RhYmxlcmFuZ2U6NTI2YTkzMGNmNmVjNDVhNWI4MjM0ZGU3ZTc0ZjliZTZfMS0wLTEtMS03ODgwNg_49e561cd-21a8-44da-9bda-3579145003e9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiY2M0NjhiOWFlNDRkNjViN2IxNTEyM2VkY2VhYmVjL3NlYzoxYmNjNDY4YjlhZTQ0ZDY1YjdiMTUxMjNlZGNlYWJlY180MC9mcmFnOjdjMTIyMjFiZGM1ZDRiNzc4ZjA1Y2E2ODk4NWI0ZTBhL3RhYmxlOjUyNmE5MzBjZjZlYzQ1YTViODIzNGRlN2U3NGY5YmU2L3RhYmxlcmFuZ2U6NTI2YTkzMGNmNmVjNDVhNWI4MjM0ZGU3ZTc0ZjliZTZfMS0wLTEtMS03ODgwNg_e34dabc3-4b10-4572-9854-6f4c41e28a10">Accrued liabilities and other</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,905 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,570 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 200000 7100000 258000 20.5 4000000 0.03 P20Y 2 P10Y <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental operating lease information was as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,196 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,199 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,749 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,057 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 3947000 4063000 8142000 8077000 1249000 1151000 2321000 2138000 5196000 5214000 10463000 10215000 4196000 4199000 8749000 8057000 P5Y7M6D P6Y3M18D 0.05 0.051 <div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded in the following captions of our condensed consolidated balance sheet as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiY2M0NjhiOWFlNDRkNjViN2IxNTEyM2VkY2VhYmVjL3NlYzoxYmNjNDY4YjlhZTQ0ZDY1YjdiMTUxMjNlZGNlYWJlY180MC9mcmFnOjdjMTIyMjFiZGM1ZDRiNzc4ZjA1Y2E2ODk4NWI0ZTBhL3RhYmxlOjUyNmE5MzBjZjZlYzQ1YTViODIzNGRlN2U3NGY5YmU2L3RhYmxlcmFuZ2U6NTI2YTkzMGNmNmVjNDVhNWI4MjM0ZGU3ZTc0ZjliZTZfMS0wLTEtMS03ODgwNg_49e561cd-21a8-44da-9bda-3579145003e9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiY2M0NjhiOWFlNDRkNjViN2IxNTEyM2VkY2VhYmVjL3NlYzoxYmNjNDY4YjlhZTQ0ZDY1YjdiMTUxMjNlZGNlYWJlY180MC9mcmFnOjdjMTIyMjFiZGM1ZDRiNzc4ZjA1Y2E2ODk4NWI0ZTBhL3RhYmxlOjUyNmE5MzBjZjZlYzQ1YTViODIzNGRlN2U3NGY5YmU2L3RhYmxlcmFuZ2U6NTI2YTkzMGNmNmVjNDVhNWI4MjM0ZGU3ZTc0ZjliZTZfMS0wLTEtMS03ODgwNg_e34dabc3-4b10-4572-9854-6f4c41e28a10">Accrued liabilities and other</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,905 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,570 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13700000 13905000 50205000 56665000 63905000 70570000 Net loss per share<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and dilutive potential common shares outstanding during the period. Potentially dilutive common shares include incremental common shares issuable upon the vesting of unvested restricted stock units and the exercise of outstanding stock options, calculated using the treasury stock method.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We excluded the potential shares of common stock from the computation of diluted net loss per share because their effect would have been antidilutive. The following table presents the weighted average number of shares that have been excluded for all periods presented:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The following table presents the weighted average number of shares that have been excluded for all periods presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 9824000 9992000 10077000 10229000 Fair value<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain assets that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. We consider observable data to be market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy of assets carried at fair value and measured on a recurring basis was as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices<br/>in active<br/>markets for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments—U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets—equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments—U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets—equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term debt investments portfolio only contains investments in U.S. Treasury and other U.S. government-backed securities. We review our portfolio based on the underlying risk profile of the securities and have a zero loss expectation for these investments. We also regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three and six months ended June 30, 2022 and 2021, we recognized no year-to-date credit loss related to our short- and long-term investments, and had no allowance for credit loss recorded as of June 30, 2022 or December 31, 2021.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt securities consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,231 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,813)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual maturities (at date of purchase):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469,688 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,231 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,388 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual maturities (at date of purchase):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635,118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,388 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy of assets carried at fair value and measured on a recurring basis was as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices<br/>in active<br/>markets for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments—U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets—equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments—U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets—equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1485448000 0 0 1485448000 6931000 0 0 6931000 1492379000 0 0 1492379000 1735202000 0 0 1735202000 14009000 0 0 14009000 1749211000 0 0 1749211000 0 0 0 0 0 0 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt securities consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,231 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,813)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual maturities (at date of purchase):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469,688 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,231 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,448 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,388 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual maturities (at date of purchase):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635,118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,388 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735,202 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1489231000 30000 3813000 1485448000 1473502000 1469688000 15729000 15760000 1489231000 1485448000 1735388000 12000 198000 1735202000 1635307000 1635118000 100081000 100084000 1735388000 1735202000 Investment and other income (loss), net<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income (loss), net consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,078)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment and other (loss) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,027 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,799)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,027 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Loss) gain on equity securities includes the realized and unrealized holding gains and losses on our equity securities. At times, we hold equity investments in certain companies acquired in relation to a strategic partnership. Shares held at the end of reporting periods are marked to market in our condensed consolidated financial statements, which can result in unrealized gains and losses.</span></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income (loss), net consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,078)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment and other (loss) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,027 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,799)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,027 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -4299000 4670000 -7078000 4929000 2690000 357000 3279000 1098000 -1609000 5027000 -3799000 6027000 Inventories<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,354 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,663 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize our commercial inventory costs. Inventory that is deployed into clinical, research or development use is charged to research and development expense when it is no longer available for use in commercial sales.</span></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,354 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,663 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15541000 12181000 259805000 152635000 44008000 35847000 319354000 200663000 Accrued liabilities<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net deductions and third-party royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479,649 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,030 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net deductions and third-party royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479,649 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,030 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 107585000 139052000 169425000 122468000 24211000 21867000 95094000 81316000 83334000 89327000 479649000 454030000 Share-based compensation<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our total share-based compensation expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,129 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,727 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,042 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$105.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unrecognized compensation cost related to unvested options and restricted stock unit awards, excluding our LTIPs and performance-based awards, net of forfeitures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he estimated unrecognized compensation expense related to our performance-based LTIPs was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$71 million as of June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 15, 2022, we entered into a separation agreement with our former CEO which modified certain terms of his previously granted equity awards. The agreement provided for the following equity considerations: acceleration of his outstanding and unvested restricted stock unit and stock option awards by an additional 18 months following his separation; the exercisability of his vested options would be extended to December 31, 2023 (or, if earlier, their 10-year expiration); and 5/6 of his outstanding and unvested restricted stock units subject to performance-based vesting conditions granted in 2019 remain eligible to vest on March 13, 2023, based on actual performance through December 31, 2022. Accounting for the equity awards</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> impacted by the separation agreement resulted in $7.3 million of share-based compensation expense recorded in the quarter ended June 30, 2022, net of forfeitures for equity awards that will not vest, other than in the event that a change of control occurs on or prior to December 31, 2023.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our total share-based compensation expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,129 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,727 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,042 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,951 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 23446000 17232000 46522000 34196000 30683000 20495000 51520000 41755000 54129000 37727000 98042000 75951000 105700000 71000000 P18M P10Y 7300000 Income taxes<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we had taxable profits in the U.S. as a result of amendments to IRC Section 174, which took effect January 1, 2022 pursuant to the 2017 Tax Cuts and Jobs Act. We recorded an income tax provision for the three and six months ended June 30, 2022 of $0.1 million and $1.4 million, respectively, primarily related to estimated state tax liabilities for which there were limitations on the use of existing state tax carryforwards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had existing federal tax carryforwards sufficient to offset any federal liability. Our income tax provision also reflected taxable profits in foreign jurisdictions partially offset by a foreign valuation allowance release. Our effective tax rate for the three and six months ended June 30, 2022 of approximately 0.1% and 0.5%, respectively, differed from the federal statutory rate primarily because we have provided a valuation allowance against substantially all our deferred tax assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we did not record any income tax provision.</span></div> 100000 1400000 0.001 0.005 0 0 Legal matters<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in multiple legal disputes with Daiichi Sankyo Co. Ltd., or Daiichi Sankyo.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute over ownership of intellectual property</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a dispute with Daiichi Sankyo regarding the ownership of certain technology used by Daiichi Sankyo in its cancer drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) and certain product candidates. We believe that the linker and other ADC technology used in ENHERTU and these drug candidates are improvements to our ADC technology, the ownership of which we contend was assigned to us under the terms of a 2008 collaboration agreement between us and Daiichi Sankyo. On November 12, 2019, we submitted an arbitration demand to the American Arbitration Association seeking, among other remedies, a declaration that we are the owner of the intellectual property rights under dispute, monetary damages, and a running royalty. On April 27, 2020, the arbitrator confirmed the dispute should be resolved in arbitration. The arbitration hearing was conducted in June 2021. Recently, the arbitration hearing record was reopened by the arbitrator to consider additional evidence. A decision in the arbitration case is expected in mid-2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2019, Daiichi Sankyo filed a declaratory judgment action in the United States District Court for the District of Delaware, alleging that we are not entitled to the intellectual property rights under dispute, in an attempt to have the dispute adjudicated in federal court. The case has been stayed and administratively closed by court order.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent infringement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2020, we filed a complaint in the United States District Court for the Eastern District of Texas to commence an action for infringement of our U.S. Patent No. 10,808,039, or the '039 Patent, by Daiichi Sankyo’s importation into, offer for sale, sale, and use in the United States of the cancer drug ENHERTU. The remedies sought in this action include, among other remedies, a judgment that Daiichi Sankyo infringed one or more valid and enforceable claims of the '039 Patent, monetary damages and a running royalty. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daiichi Sankyo (as well as Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals, LP, or AstraZeneca) subsequently filed an action on November 13, 2020 in the U.S. District Court for the District of Delaware seeking a declaratory judgment that ENHERTU does not infringe the ‘039 Patent. The Delaware action has been stayed by court order. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daiichi Sankyo, Inc. and AstraZeneca also filed two petitions for post-grant review on December 23, 2020 and January 22, 2021 with the U.S. Patent and Trademark Office, or USPTO, seeking to have claims of the ‘039 Patent cancelled as unpatentable. On June 24, 2021, the USPTO issued a decision denying both petitions for post-grant review. On April 7, 2022, the USPTO granted a request on rehearing and instituted two post-grant review proceedings, but on July 15, 2022, the USPTO issued a new decision denying post-grant review of the claims asserted in the patent infringement action. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2022, a jury in the United States District Court for the Eastern District of Texas found that Daiichi Sankyo willfully infringed the asserted claims of the '039 Patent with its ENHERTU product, and also found that the asserted claims were not invalid. The jury further awarded damages of $41.8 million for infringement from October 20, 2020 through March 31, 2022. The U.S. District Court for the Eastern District of Texas also denied Daiichi Sankyo’s claim that the ‘039 Patent should be unenforceable under the equitable theory of prosecution laches, entered judgment in favor of Seagen based on the jury’s verdict that Daiichi Sankyo willfully infringed the ‘039 Patent consisting of pre-trial damages in the sum of $41.8 million, and awarded Seagen pre- and post-trial interest and costs. We will record an amount of awarded damages in our condensed consolidated financial statements when we have determined the payment to be realized or realizable under ASC 450. We intend to request a royalty on Daiichi Sankyo's future sales of ENHERTU in the United States through November 5, 2024. </span></div>As a result of these disputes, we have incurred and will continue to incur litigation expenses. In addition, from time to time, we may become involved in other lawsuits, claims and proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent or other intellectual property rights and our contractual rights. These proceedings are costly and time consuming, and they may subject us to claims which may result in liabilities or require us to take or refrain from certain actions. Additionally, successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use our proprietary technologies without a license from us or our collaborators. 2 41800000 41800000 EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 122 199 1 false 24 0 false 9 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.seattlegenetics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Summary of significant accounting policies Sheet http://www.seattlegenetics.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 7 false false R8.htm 2108102 - Disclosure - Revenue from contracts with customers Sheet http://www.seattlegenetics.com/role/Revenuefromcontractswithcustomers Revenue from contracts with customers Notes 8 false false R9.htm 2111103 - Disclosure - Leases Sheet http://www.seattlegenetics.com/role/Leases Leases Notes 9 false false R10.htm 2116104 - Disclosure - Net loss per share Sheet http://www.seattlegenetics.com/role/Netlosspershare Net loss per share Notes 10 false false R11.htm 2119105 - Disclosure - Fair value Sheet http://www.seattlegenetics.com/role/Fairvalue Fair value Notes 11 false false R12.htm 2124106 - Disclosure - Investment and other income (loss), net Sheet http://www.seattlegenetics.com/role/Investmentandotherincomelossnet Investment and other income (loss), net Notes 12 false false R13.htm 2127107 - Disclosure - Inventories Sheet http://www.seattlegenetics.com/role/Inventories Inventories Notes 13 false false R14.htm 2130108 - Disclosure - Accrued liabilities Sheet http://www.seattlegenetics.com/role/Accruedliabilities Accrued liabilities Notes 14 false false R15.htm 2133109 - Disclosure - Share-based compensation Sheet http://www.seattlegenetics.com/role/Sharebasedcompensation Share-based compensation Notes 15 false false R16.htm 2136110 - Disclosure - Income taxes Sheet http://www.seattlegenetics.com/role/Incometaxes Income taxes Notes 16 false false R17.htm 2138111 - Disclosure - Legal matters Sheet http://www.seattlegenetics.com/role/Legalmatters Legal matters Notes 17 false false R18.htm 2202201 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 18 false false R19.htm 2303301 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesTables Summary of significant accounting policies (Tables) Tables http://www.seattlegenetics.com/role/Summaryofsignificantaccountingpolicies 19 false false R20.htm 2309302 - Disclosure - Revenue from contracts with customers (Tables) Sheet http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersTables Revenue from contracts with customers (Tables) Tables http://www.seattlegenetics.com/role/Revenuefromcontractswithcustomers 20 false false R21.htm 2312303 - Disclosure - Leases (Tables) Sheet http://www.seattlegenetics.com/role/LeasesTables Leases (Tables) Tables http://www.seattlegenetics.com/role/Leases 21 false false R22.htm 2317304 - Disclosure - Net loss per share (Tables) Sheet http://www.seattlegenetics.com/role/NetlosspershareTables Net loss per share (Tables) Tables http://www.seattlegenetics.com/role/Netlosspershare 22 false false R23.htm 2320305 - Disclosure - Fair value (Tables) Sheet http://www.seattlegenetics.com/role/FairvalueTables Fair value (Tables) Tables http://www.seattlegenetics.com/role/Fairvalue 23 false false R24.htm 2325306 - Disclosure - Investment and other income (loss), net (Tables) Sheet http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetTables Investment and other income (loss), net (Tables) Tables http://www.seattlegenetics.com/role/Investmentandotherincomelossnet 24 false false R25.htm 2328307 - Disclosure - Inventories (Tables) Sheet http://www.seattlegenetics.com/role/InventoriesTables Inventories (Tables) Tables http://www.seattlegenetics.com/role/Inventories 25 false false R26.htm 2331308 - Disclosure - Accrued liabilities (Tables) Sheet http://www.seattlegenetics.com/role/AccruedliabilitiesTables Accrued liabilities (Tables) Tables http://www.seattlegenetics.com/role/Accruedliabilities 26 false false R27.htm 2334309 - Disclosure - Share-based compensation (Tables) Sheet http://www.seattlegenetics.com/role/SharebasedcompensationTables Share-based compensation (Tables) Tables http://www.seattlegenetics.com/role/Sharebasedcompensation 27 false false R28.htm 2404401 - Disclosure - Summary of significant accounting policies - Additional Information (Details) Sheet http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails Summary of significant accounting policies - Additional Information (Details) Details 28 false false R29.htm 2405402 - Disclosure - Summary of significant accounting policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails Summary of significant accounting policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 29 false false R30.htm 2406403 - Disclosure - Summary of significant accounting policies - Finite-lived intangible Assets (Details) Sheet http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails Summary of significant accounting policies - Finite-lived intangible Assets (Details) Details 30 false false R31.htm 2407404 - Disclosure - Summary of significant accounting policies - Amortization Expense (Details) Sheet http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAmortizationExpenseDetails Summary of significant accounting policies - Amortization Expense (Details) Details 31 false false R32.htm 2410405 - Disclosure - Revenue from contracts with customers - Summary of Collaboration and License Agreement Revenues by Collaborator (Details) Sheet http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails Revenue from contracts with customers - Summary of Collaboration and License Agreement Revenues by Collaborator (Details) Details 32 false false R33.htm 2413406 - Disclosure - Leases - Additional Information (Details) Sheet http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 33 false false R34.htm 2414407 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.seattlegenetics.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 34 false false R35.htm 2415408 - Disclosure - Leases - Summary of Balance Sheet Information (Details) Sheet http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails Leases - Summary of Balance Sheet Information (Details) Details 35 false false R36.htm 2418409 - Disclosure - Net loss per share (Details) Sheet http://www.seattlegenetics.com/role/NetlosspershareDetails Net loss per share (Details) Details http://www.seattlegenetics.com/role/NetlosspershareTables 36 false false R37.htm 2421410 - Disclosure - Fair value - Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis (Details) Sheet http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails Fair value - Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis (Details) Details 37 false false R38.htm 2422411 - Disclosure - Fair value - Additional Information (Details) Sheet http://www.seattlegenetics.com/role/FairvalueAdditionalInformationDetails Fair value - Additional Information (Details) Details 38 false false R39.htm 2423412 - Disclosure - Fair value - Summary of Debt Securities (Details) Sheet http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails Fair value - Summary of Debt Securities (Details) Details 39 false false R40.htm 2426413 - Disclosure - Investment and other income (loss), net (Details) Sheet http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails Investment and other income (loss), net (Details) Details http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetTables 40 false false R41.htm 2429414 - Disclosure - Inventories (Details) Sheet http://www.seattlegenetics.com/role/InventoriesDetails Inventories (Details) Details http://www.seattlegenetics.com/role/InventoriesTables 41 false false R42.htm 2432415 - Disclosure - Accrued liabilities (Details) Sheet http://www.seattlegenetics.com/role/AccruedliabilitiesDetails Accrued liabilities (Details) Details http://www.seattlegenetics.com/role/AccruedliabilitiesTables 42 false false R43.htm 2435416 - Disclosure - Share-based compensation (Details) Sheet http://www.seattlegenetics.com/role/SharebasedcompensationDetails Share-based compensation (Details) Details http://www.seattlegenetics.com/role/SharebasedcompensationTables 43 false false R44.htm 2437417 - Disclosure - Income taxes (Details) Sheet http://www.seattlegenetics.com/role/IncometaxesDetails Income taxes (Details) Details http://www.seattlegenetics.com/role/Incometaxes 44 false false R45.htm 2439418 - Disclosure - Legal matters (Details) Sheet http://www.seattlegenetics.com/role/LegalmattersDetails Legal matters (Details) Details http://www.seattlegenetics.com/role/Legalmatters 45 false false All Reports Book All Reports sgen-20220630.htm ex-3112022q2.htm ex-3122022q2.htm ex-3212022q2.htm ex-3222022q2.htm ex101-seagenxabbvieincxs.htm ex102-seagenxcordenpharm.htm sgen-20220630.xsd sgen-20220630_cal.xml sgen-20220630_def.xml sgen-20220630_lab.xml sgen-20220630_pre.xml sgen-20220630_g1.jpg sgen-20220630_g2.jpg sgen-20220630_g3.jpg sgen-20220630_g4.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgen-20220630.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 122, "dts": { "calculationLink": { "local": [ "sgen-20220630_cal.xml" ] }, "definitionLink": { "local": [ "sgen-20220630_def.xml" ] }, "inline": { "local": [ "sgen-20220630.htm" ] }, "labelLink": { "local": [ "sgen-20220630_lab.xml" ] }, "presentationLink": { "local": [ "sgen-20220630_pre.xml" ] }, "schema": { "local": [ "sgen-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 293, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 2, "http://xbrl.sec.gov/dei/2022": 5, "total": 7 }, "keyCustom": 18, "keyStandard": 181, "memberCustom": 6, "memberStandard": 18, "nsprefix": "sgen", "nsuri": "http://www.seattlegenetics.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.seattlegenetics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116104 - Disclosure - Net loss per share", "role": "http://www.seattlegenetics.com/role/Netlosspershare", "shortName": "Net loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119105 - Disclosure - Fair value", "role": "http://www.seattlegenetics.com/role/Fairvalue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - Investment and other income (loss), net", "role": "http://www.seattlegenetics.com/role/Investmentandotherincomelossnet", "shortName": "Investment and other income (loss), net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127107 - Disclosure - Inventories", "role": "http://www.seattlegenetics.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Accrued liabilities", "role": "http://www.seattlegenetics.com/role/Accruedliabilities", "shortName": "Accrued liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - Share-based compensation", "role": "http://www.seattlegenetics.com/role/Sharebasedcompensation", "shortName": "Share-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136110 - Disclosure - Income taxes", "role": "http://www.seattlegenetics.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138111 - Disclosure - Legal matters", "role": "http://www.seattlegenetics.com/role/Legalmatters", "shortName": "Legal matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Summary of significant accounting policies (Tables)", "role": "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesTables", "shortName": "Summary of significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Revenue from contracts with customers (Tables)", "role": "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersTables", "shortName": "Revenue from contracts with customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - Leases (Tables)", "role": "http://www.seattlegenetics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Net loss per share (Tables)", "role": "http://www.seattlegenetics.com/role/NetlosspershareTables", "shortName": "Net loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320305 - Disclosure - Fair value (Tables)", "role": "http://www.seattlegenetics.com/role/FairvalueTables", "shortName": "Fair value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325306 - Disclosure - Investment and other income (loss), net (Tables)", "role": "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetTables", "shortName": "Investment and other income (loss), net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328307 - Disclosure - Inventories (Tables)", "role": "http://www.seattlegenetics.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331308 - Disclosure - Accrued liabilities (Tables)", "role": "http://www.seattlegenetics.com/role/AccruedliabilitiesTables", "shortName": "Accrued liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334309 - Disclosure - Share-based compensation (Tables)", "role": "http://www.seattlegenetics.com/role/SharebasedcompensationTables", "shortName": "Share-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of significant accounting policies - Additional Information (Details)", "role": "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails", "shortName": "Summary of significant accounting policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of significant accounting policies - Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of significant accounting policies - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i14562ae341cd4ea480b7433207e2620a_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Summary of significant accounting policies - Finite-lived intangible Assets (Details)", "role": "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails", "shortName": "Summary of significant accounting policies - Finite-lived intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Summary of significant accounting policies - Amortization Expense (Details)", "role": "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAmortizationExpenseDetails", "shortName": "Summary of significant accounting policies - Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Revenue from contracts with customers - Summary of Collaboration and License Agreement Revenues by Collaborator (Details)", "role": "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails", "shortName": "Revenue from contracts with customers - Summary of Collaboration and License Agreement Revenues by Collaborator (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia7840155c15543a0bcfb773dcd24fb53_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "sgen:LesseeOperatingLeaseBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Leases - Summary of Balance Sheet Information (Details)", "role": "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails", "shortName": "Leases - Summary of Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "sgen:LesseeOperatingLeaseBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Net loss per share (Details)", "role": "http://www.seattlegenetics.com/role/NetlosspershareDetails", "shortName": "Net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i2ba319b2fae047559025b822a86a06a1_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Fair value - Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis (Details)", "role": "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "shortName": "Fair value - Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i2ba319b2fae047559025b822a86a06a1_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Fair value - Additional Information (Details)", "role": "http://www.seattlegenetics.com/role/FairvalueAdditionalInformationDetails", "shortName": "Fair value - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "if4d6a8a17f794b549d7c4541f82885b6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Fair value - Summary of Debt Securities (Details)", "role": "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails", "shortName": "Fair value - Summary of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "if4d6a8a17f794b549d7c4541f82885b6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Investment and other income (loss), net (Details)", "role": "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails", "shortName": "Investment and other income (loss), net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Inventories (Details)", "role": "http://www.seattlegenetics.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Accrued liabilities (Details)", "role": "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails", "shortName": "Accrued liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i4fccbdec7db3448ba51389ce730403b0_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - Share-based compensation (Details)", "role": "http://www.seattlegenetics.com/role/SharebasedcompensationDetails", "shortName": "Share-based compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437417 - Disclosure - Income taxes (Details)", "role": "http://www.seattlegenetics.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i01d10546c8fe47ef90ac2b01de46d698_D20220401-20220630", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "if6cbf4325714438aa9b3aec0558a09b7_D20201223-20210122", "decimals": "INF", "first": true, "lang": "en-US", "name": "sgen:LossContingencyNumberOfPetitionsFiled", "reportCount": 1, "unique": true, "unitRef": "petition", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439418 - Disclosure - Legal matters (Details)", "role": "http://www.seattlegenetics.com/role/LegalmattersDetails", "shortName": "Legal matters (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "if6cbf4325714438aa9b3aec0558a09b7_D20201223-20210122", "decimals": "INF", "first": true, "lang": "en-US", "name": "sgen:LossContingencyNumberOfPetitionsFiled", "reportCount": 1, "unique": true, "unitRef": "petition", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "i2bca9d070f7741e0b2199b13c8f95cc9_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ie72e7da6e8964393a65f901d2c5705cd_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of significant accounting policies", "role": "http://www.seattlegenetics.com/role/Summaryofsignificantaccountingpolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108102 - Disclosure - Revenue from contracts with customers", "role": "http://www.seattlegenetics.com/role/Revenuefromcontractswithcustomers", "shortName": "Revenue from contracts with customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111103 - Disclosure - Leases", "role": "http://www.seattlegenetics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgen-20220630.htm", "contextRef": "ia6dba3b1d68c4692b844dce08a8d951c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 24, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.seattlegenetics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "sgen_AccruedGrossToNetDeductionsAndRoyaltiesCurrent": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Gross-To-Net Deductions And Royalties, Current", "label": "Accrued Gross-To-Net Deductions And Royalties, Current", "terseLabel": "Gross-to-net deductions and third-party royalties" } } }, "localname": "AccruedGrossToNetDeductionsAndRoyaltiesCurrent", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sgen_AdcetrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adcetris", "label": "Adcetris [Member]", "terseLabel": "ADCETRIS" } } }, "localname": "AdcetrisMember", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "sgen_ClinicalTrialAndRelatedCostsCurrent": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Clinical Trial And Related Costs, Current", "label": "Clinical Trial And Related Costs, Current", "terseLabel": "Clinical trial and related costs" } } }, "localname": "ClinicalTrialAndRelatedCostsCurrent", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sgen_ContractManufacturingLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract Manufacturing Liabilities Current", "label": "Contract Manufacturing Liabilities Current", "terseLabel": "Contract manufacturing" } } }, "localname": "ContractManufacturingLiabilitiesCurrent", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sgen_DebtSecuritiesAvailableForSaleMaturityAfterOneThroughTwoYearsAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Amortized Cost", "label": "Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Amortized Cost", "terseLabel": "Debt securities, due in one to two years, amortized cost" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAfterOneThroughTwoYearsAmortizedCost", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "sgen_DebtSecuritiesAvailableForSaleMaturityAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Fair Value", "label": "Debt Securities, Available-For-Sale, Maturity, After One Through Two Years, Fair Value", "terseLabel": "Debt securities, due in one to two years, fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "sgen_DebtSecuritiesRealizedGainLossAndAccretionAmortizationOfDiscountsAndPremiums": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Realized Gain (Loss) And Accretion (Amortization) Of Discounts And Premiums", "label": "Debt Securities, Realized Gain (Loss) And Accretion (Amortization) Of Discounts And Premiums", "negatedTerseLabel": "Amortization of premiums, accretion of discounts, and (gains) losses on debt securities" } } }, "localname": "DebtSecuritiesRealizedGainLossAndAccretionAmortizationOfDiscountsAndPremiums", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "sgen_EquitySecuritiesFvNiGainLossAndInvestmentIncomeNet": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Securities, Fv-Ni, Gain (Loss) And Investment Income, Net", "label": "Equity Securities, Fv-Ni, Gain (Loss) And Investment Income, Net", "terseLabel": "Investment and other (loss) income , net", "totalLabel": "Total investment and other (loss) income, net" } } }, "localname": "EquitySecuritiesFvNiGainLossAndInvestmentIncomeNet", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails" ], "xbrltype": "monetaryItemType" }, "sgen_IncreaseDecreaseInLeaseLiability": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liability", "label": "Increase (Decrease) In Lease Liability", "negatedLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiability", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "sgen_LesseeOperatingLeaseBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Balance Sheet Information [Table Text Block]", "label": "Lessee, Operating Lease, Balance Sheet Information [Table Text Block]", "terseLabel": "Summary of Operating Lease Assets and Liabilities" } } }, "localname": "LesseeOperatingLeaseBalanceSheetInformationTableTextBlock", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "sgen_LesseeOperatingLeaseOptionToExtendNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Option to Extend, Number", "label": "Lessee, Operating Lease, Option to Extend, Number", "terseLabel": "Option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtendNumber", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sgen_LongTermIncentivePlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term incentive plans.", "label": "Long Term Incentive Plans [Member]", "terseLabel": "Long Term Incentive Plans" } } }, "localname": "LongTermIncentivePlansMember", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "domainItemType" }, "sgen_LossContingencyNumberOfPetitionsFiled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Petitions Filed", "label": "Loss Contingency, Number Of Petitions Filed", "terseLabel": "Number of petitions filed" } } }, "localname": "LossContingencyNumberOfPetitionsFiled", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "integerItemType" }, "sgen_NonCashActivitiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Cash Activities", "label": "Non-Cash Activities [Policy Text Block]", "terseLabel": "Non-cash activities" } } }, "localname": "NonCashActivitiesPolicyTextBlock", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sgen_OperatingLeaseAnnualEscalationsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Annual Escalations Percentage", "label": "Operating Lease, Annual Escalations Percentage", "terseLabel": "Annual escalations" } } }, "localname": "OperatingLeaseAnnualEscalationsPercentage", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sgen_PadcevMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Padcev", "label": "Padcev [Member]", "terseLabel": "PADCEV" } } }, "localname": "PadcevMember", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "sgen_PatentInfringementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent Infringement", "label": "Patent Infringement [Member]", "terseLabel": "Patent Infringement" } } }, "localname": "PatentInfringementMember", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "domainItemType" }, "sgen_PaymentsToAcquireLessorOwnedAssets": { "auth_ref": [], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Lessor-Owned Assets", "label": "Payments to Acquire Lessor-Owned Assets", "negatedTerseLabel": "Payments for lessor-owned assets" } } }, "localname": "PaymentsToAcquireLessorOwnedAssets", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "sgen_RentableBuildingAndComplexConstructed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rentable Building And Complex Constructed", "label": "Rentable Building And Complex Constructed", "terseLabel": "Rentable building and complex constructed (in acres)" } } }, "localname": "RentableBuildingAndComplexConstructed", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "sgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAccelerationPeriodFollowingSeparation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Acceleration Period Following Separation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Acceleration Period Following Separation", "terseLabel": "Acceleration period following separation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAccelerationPeriodFollowingSeparation", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "durationItemType" }, "sgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Stock Options Exercised And Employee Stock Purchase Plan", "label": "Stock Issued During Period, Shares, Stock Options Exercised And Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock for stock option exercises and employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "sgen_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised And Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Stock Options Exercised And Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock for stock option exercises and employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "sgen_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sgen_SummaryOfSignificantAccountingPolicyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policy [Table]", "label": "Summary Of Significant Accounting Policy [Table]", "terseLabel": "Summary Of Significant Accounting Policy [Table]" } } }, "localname": "SummaryOfSignificantAccountingPolicyTable", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sgen_TIVDAKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TIVDAK", "label": "TIVDAK [Member]", "terseLabel": "TIVDAK" } } }, "localname": "TIVDAKMember", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "sgen_TukysaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tukysa", "label": "Tukysa [Member]", "terseLabel": "TUKYSA" } } }, "localname": "TukysaMember", "nsuri": "http://www.seattlegenetics.com/20220630", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r134", "r234", "r238", "r438" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r134", "r234", "r238", "r438" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r132", "r191", "r192", "r234", "r236", "r398", "r435", "r437" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r132", "r191", "r192", "r234", "r236", "r398", "r435", "r437" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r188", "r190", "r191", "r192", "r193", "r207", "r213", "r244", "r253", "r254", "r282", "r283", "r284", "r369", "r370", "r371", "r372", "r373", "r374", "r393", "r436", "r439", "r462", "r463" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r188", "r190", "r191", "r192", "r193", "r207", "r213", "r244", "r253", "r254", "r282", "r283", "r284", "r369", "r370", "r371", "r372", "r373", "r374", "r393", "r436", "r439", "r462", "r463" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r369", "r371", "r374", "r462", "r463" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Accruedliabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r135", "r136" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities and other", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails", "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r44", "r45", "r46", "r422", "r444", "r445" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r43", "r46", "r53", "r54", "r55", "r90", "r91", "r92", "r317", "r358", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r20" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r90", "r91", "r92", "r294", "r295", "r296", "r323" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r256", "r297", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used by operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r74", "r178", "r183" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Stock options and RSUs (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/NetlosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Lease agreement, rented area" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r14", "r85", "r122", "r125", "r130", "r156", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r315", "r318", "r333", "r359", "r361", "r405", "r420" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r33", "r85", "r156", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r315", "r318", "r333", "r359", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r144" ], "calculation": { "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r145" ], "calculation": { "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r141", "r163" ], "calculation": { "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Debt securities, due in one year or less, amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r146", "r147", "r416" ], "calculation": { "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Debt securities, due in one year or less, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r138", "r142", "r163", "r407" ], "calculation": { "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r140", "r163" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r10", "r76" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets", "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r77", "r403" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r71", "r76", "r81" ], "calculation": { "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash as presented in the condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r71", "r334" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r408", "r426" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r90", "r91", "r323" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending (in shares)", "periodStartLabel": "Beginning (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 250,000 shares authorized; 184,369 shares issued and outstanding at June 30, 2022 and 183,381 shares issued and outstanding at December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r49", "r51", "r52", "r60", "r412", "r429" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r63", "r398" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r62" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r143", "r163", "r166", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded", "terseLabel": "Credit loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Debt Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r75" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r74", "r185" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Collaboration and License Agreement Revenues by Collaborator" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r259", "r260", "r287", "r288", "r291", "r299" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Sharebasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r258", "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r61", "r95", "r96", "r97", "r98", "r99", "r103", "r105", "r107", "r108", "r109", "r114", "r115", "r324", "r325", "r413", "r430" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r61", "r95", "r96", "r97", "r98", "r99", "r105", "r107", "r108", "r109", "r114", "r115", "r324", "r325", "r413", "r430" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r110", "r112", "r113", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Netlosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r334" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation costs, excluding options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r53", "r54", "r55", "r90", "r91", "r92", "r94", "r100", "r102", "r117", "r157", "r215", "r216", "r294", "r295", "r296", "r306", "r307", "r323", "r335", "r336", "r337", "r338", "r339", "r341", "r358", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r154" ], "calculation": { "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails": { "order": 1.0, "parentTag": "sgen_EquitySecuritiesFvNiGainLossAndInvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "(Loss) gain on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r154", "r432" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedTerseLabel": "Losses (gains) on equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r150", "r419", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r326", "r327", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Hierarchy of Assets Carried at Fair Value and Measured on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r208", "r210", "r211", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r327", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r326", "r327", "r328", "r329", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Fairvalue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r208", "r245", "r246", "r251", "r252", "r327", "r366" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted\u00a0prices in active markets for identical assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r208", "r210", "r211", "r245", "r246", "r251", "r252", "r327", "r367" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Other observable inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r208", "r210", "r211", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r327", "r368" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant unobservable inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r208", "r210", "r211", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r330", "r332" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value Measurements Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r148", "r149", "r151", "r152", "r153", "r158", "r159", "r160", "r161", "r162", "r164", "r165", "r169", "r170", "r209", "r214", "r322", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r470", "r471", "r472", "r473", "r474", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails", "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r12", "r182" ], "calculation": { "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Estimated future amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Estimated future amortization expense, remainder of fiscal year" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Estimated future amortization expense, 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Estimated future amortization expense, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Estimated future amortization expense, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Estimated future amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r182", "r400" ], "calculation": { "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r182", "r399" ], "calculation": { "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesFinitelivedintangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r11", "r173", "r174", "r175", "r176", "r361", "r404" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r57", "r122", "r124", "r126", "r129", "r131", "r401", "r409", "r414", "r433" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r86", "r303", "r304", "r305", "r308", "r310", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r87", "r101", "r102", "r121", "r301", "r309", "r311", "r434" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r73" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r73" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r73" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r73" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r83", "r181", "r395", "r396", "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r177", "r180" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Accrued interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r26", "r171" ], "calculation": { "http://www.seattlegenetics.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r32", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.seattlegenetics.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets", "http://www.seattlegenetics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r28", "r171" ], "calculation": { "http://www.seattlegenetics.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r27", "r171" ], "calculation": { "http://www.seattlegenetics.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r65", "r66" ], "calculation": { "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails": { "order": 2.0, "parentTag": "sgen_EquitySecuritiesFvNiGainLossAndInvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "verboseLabel": "Investment and other income, net" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r155", "r431" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r150", "r402", "r417", "r461", "r477" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investment and other income (loss), net" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Investmentandotherincomelossnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Supplemental Operating Lease Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal matters" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Legalmatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Initial term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r85", "r156", "r333", "r361", "r406", "r424" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r37", "r85", "r156", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r316", "r318", "r319", "r333", "r359", "r360", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r7", "r8", "r9", "r15", "r16", "r85", "r156", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r316", "r318", "r319", "r333", "r359", "r360" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAndServiceMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Service [Member]", "terseLabel": "Collaboration and license agreement revenues" } } }, "localname": "LicenseAndServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Awarded damages for past infringement" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "verboseLabel": "Schedule of Investment and Other Income, Net" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InvestmentandotherincomelossnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r71", "r72", "r75" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r47", "r50", "r55", "r58", "r75", "r85", "r93", "r95", "r96", "r97", "r98", "r101", "r102", "r106", "r122", "r124", "r126", "r129", "r131", "r156", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r325", "r333", "r410", "r427" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r122", "r124", "r126", "r129", "r131" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r349", "r356" ], "calculation": { "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r344" ], "calculation": { "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r344" ], "calculation": { "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Accrued liabilities and other" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r344" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets", "http://www.seattlegenetics.com/role/LeasesSummaryofBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r346", "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in measurement of lease liabilities", "verboseLabel": "Initial rate" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails", "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r343" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r353", "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r41" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation gain" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r48", "r51", "r53", "r54", "r56", "r59", "r215", "r335", "r340", "r341", "r411", "r428" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive (loss) income", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r42", "r44" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized loss on securities available-for-sale, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Non-current Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r36", "r195" ], "calculation": { "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r139" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r212" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r212" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value, 5,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r70", "r293" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r67", "r68", "r139" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from maturities of securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net product sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r186", "r361", "r418", "r425" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r300", "r394", "r464" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r10", "r76", "r81" ], "calculation": { "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash included in prepaid expenses and other current assets", "verboseLabel": "Cash held in escrow restricted by a contractual agreement" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails", "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r216", "r361", "r423", "r443", "r445" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r90", "r91", "r92", "r94", "r100", "r102", "r157", "r294", "r295", "r296", "r306", "r307", "r323", "r440", "r442" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r119", "r120", "r123", "r127", "r128", "r132", "r133", "r134", "r233", "r234", "r398" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration and license agreement revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r84", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition - Net product sales" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r235", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from contracts with customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Revenuefromcontractswithcustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r352", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty revenues" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/RevenuefromcontractswithcustomersSummaryofCollaborationandLicenseAgreementRevenuesbyCollaboratorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/AccruedliabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r179", "r181" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r6", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r81", "r403", "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SummaryofsignificantaccountingpoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r255", "r257", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/NetlosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r73" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Share-based payment arrangement, plan modification, incremental cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/SharebasedcompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r82", "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/Summaryofsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r40", "r53", "r54", "r55", "r90", "r91", "r92", "r94", "r100", "r102", "r117", "r157", "r215", "r216", "r294", "r295", "r296", "r306", "r307", "r323", "r335", "r336", "r337", "r338", "r339", "r341", "r358", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r117", "r398" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock vested during the period, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r23", "r24", "r85", "r137", "r156", "r333", "r361" ], "calculation": { "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending", "periodStartLabel": "Beginning", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets", "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r342", "r362" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LegalmattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r148", "r149", "r151", "r152", "r153", "r209", "r214", "r322", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r470", "r471", "r472", "r473", "r474", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails", "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r88", "r245", "r252", "r415" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "US Treasury Securities", "verboseLabel": "US Treasury Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/FairvalueSummaryofDebtSecuritiesDetails", "http://www.seattlegenetics.com/role/FairvalueSummaryofFairValueHierarchyofAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r350", "r356" ], "calculation": { "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r104", "r109" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Shares used in computation of per share amounts - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r109" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Shares used in computation of per share amounts - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.seattlegenetics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r402": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r417": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r461": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r468": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r469": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r470": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r471": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r472": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r473": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r474": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r475": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r476": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r477": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r478": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 77 0001060736-22-000052-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001060736-22-000052-xbrl.zip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

3$YFD MB466B/21SUZ@6&L.G)N1)"674AHGO4_.<*:C9M@MGT!G%@-/7[B6 ?QR[A.QC#MJ MK*->)IX<$V#(THSHQN++=(HQ\*\O][TY,&LY,XI:YJ7B6' 3%,,8A6II-A.3SZS MZ@$>DO+!:*:BXRI@)^%#KG8!&BMLI-,KS[ T;GE24QND$T9+2:3$><*FLR9J M8T!#A7*6:+TTHIF-6YZ4F)("]JHQS5,/.976:AN#\@0[+5B\&MQ9!C'-W"U/ M2F09T0,C@G$C.4_!4@-NP!BNG*'RBO N@L69K0*#B8EO1,!"48 "4P8\PC8PH"3RZ5^%H1 M:)I278A^"\P:9G"0PF(NN;+:6!Y)\IIAFUQ8/FN8?4)[)H+6CGH3*(2+$.(' M;+0)N12B#=Z&Y)91T--+:,]$H(Z)O"(E*JN P>:YB2>4P)?A94!I\B<3H*KY1/HS&+@&< R;O&?55'@&*K7^)/7LX7P.1DYJKKS3P M<2$\_.',8N>34XH%'R 06985QMZ:\U,JR5B8K,A(\(182$^)Q&4!&N MK+&B&%>B1B10%[(@?.29J,A,V BV4K+D&'4&9 M)Q69"1?AD0;,I>5)18XM">JZ\=!#%&.R"M,$P147) M1>9)16;"10)Q1GLC)(F<.TD= $7>G"DO;G/?LJLE%YD+%9D)%Y%8^D0(H=%0 MSDFP4=HH@L?PB2J.2RXR3RHR+2[R;>;5O]/M:5>G@][+?.#JXGM/N9+$:"N\ M5! 2\2"]PUCJ ,S7V]UOL3^(#^S<7$RYAUVC[J]00.4]MM))(J K.A5!4(;=6XJB9QXG8 M%+3#S\-J6&DUI=4\*-_$,",L<2,]!]9NK4E* 5$+)((QV86RFE)1EU=1/80. MAKLH)(9_5+).1D)R^0QOJ+(+L)+K;]L"K8B[1S$.WG:]S0LA;XJG6&Q7[W:R M.F:=Z??C3^6SH)',SRQDN-IM\M8Q/;28%\.Q5FM)(8C@EG(.;$@JK6*TF'D; MG6:EX2Q4,%,:SM3"<&H23LXKZUT>77%6$.*)I)ZP/+6]-)R%BF=*PYF6X3B7 MJ)0$$Z\T#S1H2XVA6#.J>(BV M'*$H%>@G<[JLX\S8$)4QW*M@L)616F&X3D8S_SP4: &3]?.B0+GBF@!JJ1RW M7%NA-<.1!F.=MJ!+"U#\:;YXWK-3(.HL(\;19"/F2@B#J7":4JNEQ=(NE@(] M$YE9GZA6Q*?$@2)[[U2,D3L2#/,Z,#+_NQH]4]HQ.0[_;,8 )K?7E%.261HQ MTTIS@Y6.5@=G*7=*B\3%\[":!>1:I=7,T&JL8V =FIK$Y8AS(M(\*.RZPEWXT,6)1K*94U.55U."U MT9PPCEVNW.DM*!+!0;%$#)%Z 11UUMGVN8IDRM3_M R')R."#]B3F+@FR28N M=>#81.=,I*XTG(4*9DK#F5H8SA+SH,R2XJ+&MJ;18LJ9)(%9%FAI. L5SY2& M,RW#83XI;&B007CP/L%II1FCT1-#N:*I-)Q25^=%5PTV7 02I+28.T*U(9&J M(#1SFNFP +HZ7[S^V2E0H,Q[3DU2PG%IJ(V%(B'D/>S(<)D(&+6A, D1/:! M>&V-7BP%>B8R2SQ(JRU121GN!#=!>2XX29IJ+=P"[+'V%#GN>9FVDOUV#%9& MF0SG3CE+'#-.*6JLB7P1?/K<26=RMJ.UQ]2:9(6T/"KC(F.YC3A-&Z *4 M%_PV5I,W&?RZ]]W=H>9.[,?L2M<[82.[RNY)/G?S_ 3NMI0;+D=FF04J[1PA MG 4+AI@(<8"91&$1%Z%0\<((>#9;,'FNG'$"A,FX$=$)20U8-1')6NK5 I3V M6Q@!SVBW/A:BE,JJ7(;/8,LA/B8RP']48146H##?P@AX)B5^-771,BV("(;+ M$#567$ 4HE/@ADF[;#YX-[9:$%V\B1T(:UL@YO70;G::P*W@Y"]Q).DG8%!S MX(UQ,(Q)1:SE/+'@DE".^BB#< X+LVS>>#Y$/9NMB$+2$.<4LX^Y#=BXO*.9 M%]W@',3BNN8:HU@:U"*5S%U#4,_'5 M--& %6&*ZL0=(SHE'7S(*X!MGAH]_[FF]3/;"]]F,Q:%6M]V.X?#F8P^/^!+ M?->RG45),%%L8A24".DU]XH[++D7)&F?C.'Z:C=KH%?HZL.\U1*&SA"(B'NB MUO53'[,_C?0N<4:%(KPH?F@R"S1[8D#".2M'V3T!"7P!_34I?JV\?!*A9?#B M=U=?OCIZ=9=[5V"FTCDFM4W2!,ZE-PQ; B:5HK"2L&];L6IT]:%4C)^'&OJ> MYGW]U/LJQHOF^['=/>S[VAU^/H@U%XT/SR]J?\-=H,V;G/9?:F3RV'J1P MRA$!/"4&'ZV+_E-.PW^[IC^X:('4P+VCH]@\/!J\Y.)D\,=9,PR.7A*,_^]* M<=[:G_T3V[DZVW=;W=[+?X%(<4I_)&@D2K;=;%V\_*\&R*A?J<>SRDZW;3O_ M5>V#HT%]>*W1B?WF980;PS.*KV>CAV+\!U".>-4(0O'__2._.@K1=WN%E$&A MX87S6= F.S=MJ1SU8OIKY5\_[WFULM:PKA4KW51YE27;&?3_?&%!'+ESKTEE MV-MK?[K>B[&#MP17M,NVFH>=E]FU%U7?!\5#1B>X;@]:BJ";6O:D'U]>??@C M-/LG+7L!GKEXV>*B/]JV=PBJX+J#0;?],FO"E]@;-+UMC1Y2/&]X>*0DQJQJ MP;*>#$ ;!^'JP2,56BU4Z,4@W#YF]*K!WS^,5\G78R^*>_>N3AA)AIWD+0O@ M.GBIW$M_K;"5L?<>O0DY&53ZW58S5 I- 0F/C@^Z)W</7S7U: MP_7CH^;VQ]>M^L;.Y_KQAV:=;IW7&YL7-?KA\S[]<+3?_G#\EM5;^Y?=\_UV M_;B^L<_WCUM'!XWW^&!CG^P?AV:ML7=>.ZZW#M[ >1__:>T3??Z6'ESL?_2R M?KQWVXU=P_WK_8;]1$K5%CM<:'X]J;O2_AS0<> M_ON?U@%M?7''75IOP.>/.T>U]GMQT-C"VQOK%]L?_VG6C_\YJEU^/J]=^O/Z MQ]K9P0=]4=O8(Y\XR7UG+4K4:,2U(A]P:N^26&M M4EKQ9*QX8E[VI@E/VF#-O>SUMYKM?:YL=^+O]U2/J2L#\/95/)3I7=IP7:3C MQ^BJ4.I>RO @'9.K0(0?HF/?4Z@KG:$GYY4Q$&_%=+MONB?W5Y+U7M.V*GN= MIN^&6*GM_G+ ,.SZIT?T]Z<0:$(8IN9Y#&C0 M.UU,T'_==&_VY$%C\VS_^/W9?F./UHX/2?W-AZ/ZQRU\\&:G=;"QQ>KPS(/& M/\W]]N;HF@_P+-$Y:)RT:HV_F_6-OX_JC?V+[8T]?/!Q$]JX\_G@S8?/M6-/ MZ_2?5JT-UW[09V\;ZX/:+CY_V_ <' K]% @/\$<@&[$$IV$E,B8$9)D.E 5O MG0PK:__Y+Z.X_&/<;WS%A9&R3UF/)P1VA1:_WUO?:6SNO-VO[&R^V]YI5-[M M[>SNK=<;E<9V!=A[ RAZA;#*]DZ%B-_"[Y7MUY7&?V]6KA'[KZ1^_54C'R:& M\1L]-%^L[7Y.X'6W5QDN>-[F,(%TT_0#_(+: M\,RC?!D*]@)=1-M#L;.04/#+_ \^'WXR0>99<1I9FQ3B5#ID/74H>!V%YYX+ M#Y;\SVDG_N>_B,1_,%RMY'[_)3(HYT=#MW=*>E+2DUG2DT8/VE<,47R?GR3; MZB\R0:D=;Y[O?WS/]C]"BS=JY_6-5GN_\9G4Z.9E_?COX^V-#\<'']^+VH8? M(RC=BUKC]='!1C@Z./9GM_PCMW/A\5B=W$!06 MHDL^"H2C=8A[+9 F$-7J0'"@RL4@[8B@\&4F*(V=]?KN5D%#2H9R%T,9?+7" M*XJ2>MWV5V\V]9;]:%AGZ(&G__?,.F-EK3+HEK*X2Q8+0K->==OM9C^/2E=2 M$TC4<._EIPP -HMAZ=?PL/IPG^=%])Z/RNE>?(HN!&,)1D]U7D%=NO]$^BS[.P0J79J30'_8H_*E):OS\) M3-YKMDV)DW,V_+8X=0>_B53?_!G7T#;CNN7GTF]L"J*UM]LGM4N_SD&YWE< M/_Z,ZV]J;+NQ!]?ZLSHXR4RZZQ_?7]R9BM+6,4Q(0H0Z#PZ4:F2\%(A+$6V, M@0:G5]8V8LN>V5Y\^ES4$$J>W-?>G5<=\UR_]%+/S60;]GQK-!E\N!QI@0/; M:=OBUMBXM;0A;UR(F &#Y"(IY#2$R,X:8VFPQ#JZLF8((EIQILT/K7$!G(Z^ MEP;_5OB!2K=7Z>92E)7CTUZS'YJ^R(H"(VY>]QG%:;U#VVE>%M]_7Q2$&N^+ M)0"H>XIW:W5G=7>ULMD^:74O0+XWT:12[Z[^_H!\_IQD%I\<=M=#Z,5^?_3/ M6V@ 64C(?50N47PRE 7,,4'!466C MU_P2*[N;]Y\A\,PTZA5\W.XUNF>+2:)4KVB7L%"& " MRJ6Y$=<.1,DI2)99IH*-FF8V]6T%R&U$F)(PWW5!6JV#YLDPR'UNDKK\9*+T M,:2$J, :0-Q[,+HDD&6>N B6Z"T&WJLQ)0L'V[^-A)R9ZDD/C+5Y8EN5>![] M:5[+#S\#TXG]:J:QK=/,V2J7S9-*GB9TKRGJF1/W1KPQB M*YX<=3M78ZO7W]/VHAV^Z,O*;T]H;-FCK<.SGJ=Y\4\8 LF\\S3B42K$ \-( MBP"4B0GGHXU6:+NRQNFML=;?1^'&TXDFES!IO)Y_P3< H>%:N40IPX#^D%_.9LDY9%1D<+*FJ @.C#?Q9G9>O?@T+- M?TTL7_$T69C[Y%1_-.^JT1P,2P1$ZX\JOF7[_:=(ULSIR_=LX==W+]JNV_JM M_\CGTT.E^(/9[[(]LYA!\ZE;.C)OSR#>D6+47[4U!_ZD&&D;^X(-05 MQK60#&&T'NYXC]0VCIH''_=X_=+3^IO:6?WRD&Y_/&C6+M?Y05XGU][YO+UQ M:SU<]K'Z"-XV-\ M*1HNDHN(4*(S"W1(4Z41DT7E*,-]CH3S9$C0V-U!UW^N5DYLK_(E;SY0^8^\ MX.-6X+6XMCUU%1[AXA 62_V]A_YNCHU1QZ"QM!P)%T!_(5Y!SE@-ZFR")U(3 M10TPRS>;]6EHZ3*C[.;(=0VG$XXG%;-C6^!\XK2U>&QTEZGDH_00XJDBSI,, M:0-AN%5><$>5" ZTN '!3MWV@_WW$(DKN6!!'%3>OGWU\^'>.2F]<'?DM]4) M>4PO5MQ%Q1]%>+5VKL5P=A2+8=T!8_#2PG+P\'#A4.C./):^'FEZSFVS(?SPJ%*.,UU MYXI33WK1QX+0$EHI%N3V*[_!_< J*OU38'7]O,?#E;DIHYL56P$5+2E::ON# MBL&58"_ZJ]]=FO'4V>Q7PPTBA\L%L[\;V,%I?R&1XC$9G?VS3RI0RDG$B&'P M4IS1@!PV$04NE11@[C97H-V/_7&+?L2RIGLN,+WO2H=1:809K[6X_7>].U=] MQ.^[XFD1(#=C#\!.NSD8 %K%%L!/K]O)S*=U48G @BXJ6YD065^,7&S8@:WD ME4SC8/SM'M?3>CNG<";'(D/M3CP\;0VG=^RBQE.#[K ]7V$T]G^?'4A>Z\#< M?R/,?'X@>?[):>GRYBF(X.@1#T8CHQ5'GB:0A-?)LE""9 F26PUST;'%T=7@4>&XN6A9B:G6*!>#'"G,==*;SD=]I7'"9_7)WVTQ.^ MW[ZK$S-Y'9W\G;9>G=GL#%T H0[1*SI^G8.O/HDEC9=QG,"2I04:3B)FE9E? MJ[GRXV."T8F/)@FZJI19D,;.7<_^> 648O>[RK#BI@%4_.FFA\V:UC?#YX'CK/!_;_[C)ZQOK^*!Q! 1OZWR_<="N;\"S MVC6^O?%^?%7$69WNM'.QG=IE.-IO'.+:QDYK^\T6K1V_/JJW]S&\5WO_\I#7 M7]^Q0BE2+SA-"OF\BP/7CB%+L42&KS>RNV5ZQWF1V^3MC/]QUXR$!ZQ2OW,A M>GGJ\O"H^EVAZ^Q-H33O^YGWO+Q;Z4SO\V:[PX3+\-6^9EV&7T?YE.5ZX7D1 MXL+49QW&GH6>_'W:AR?W^TM9FG4ZT>;%V\;^V%PY'BP/5"#&\X)2%AC26BM$ M5.#."(65$/'"YBA%/D2]89Z\!/<2W&^"^Y66O"GTX]50,TJ0 M_V60Q[>FXAD6I2<6HQ@B01Q;BJRD"26ON% N\"BF67][]C;Z8$M] )8O3"?\ MZNLOP-3+](/!Y+PD]\X1\&:Z:X90,2\HADJG6TSK.>T/!Z)!N,/=4^XH6=[M M%<]J7>2'GS7AT?#82@=>K9O'EK\T^T5>H6,[/@.U]3X7?)^0DIWGE!T?..(FB-3IR[R*S M\J>.>@965,G_S=DT+#G?P+->3&"ZJY><]9_!99UV AJU)17__3&EEOUSVKH8 MRI"*J^VE9J99U8RAO5@YB[D:Y_QUUG3VP_@A3K\N)M@"_SCM-(]\ M[P*YB/- @+4S-@(#EL(I1P2A+ (;MB[Z3VKEZIJCWK=X^C BUXOV,[()E.FE M;9W9B_[*BYLJ"!HR>EU.5U76DKL;>X>MI?0KMG:OP.!'!2'^M'/3ELI1+_N[ M?]U+0HW"E $_7F57V1GT_WQAUVYAP\]48PZWT=B-H&J=RE;'?Q_JYJ6M7[>& MK@P74^9"(J^!1%2&^]S/>>NO]JX;O45ELT@+W=ZC]5Z5JPB=1NFJ>[[95GUC M\W^7;Y& 6@4F//$)\EJL\GO6AGK0MANK1"W/5/;I5?U>QG?JY?O-YJ4>6B#J M'7B?G]=^,G-5E>3GJ%A(\MWZ3J.RM5IYO55?K[_:6G];@1AY>Z>V7FS>^MM> MQYZ&YB"&.ZJXSV8OYHEN&;(UB."75Y_0.&?!;G^BS5-EMS]NR_W9+6&YQA5< MV,G#3?"I",&*.:VOOXX]%86UVW<3WZ>1[1WTK<"U[^MS*?0'"%VNK+'OB/*> M$/2$0]VE:4].RM\Q[;]M"TP[5G:/8BR->GG$71KUTDO9?->HOWGI8:JJ?=*+ M1W!>+DOSMMLOS7QI%("79K[D4J;BGF9>#*\>=5OPB/Y_53;_?=H<7)2&OBPJ M($I#7W8IZ_OZ<]L_JKQN=<]*/[XT@I>E>2^YE!G):\4'T*9!MU+FV9ZA]-7C M;'PA4OVC>:!EOG_^55*JE;6:[=C# F>^SH#;:/;]:;^?YX?FXH7K'=NZZ#<+ MXO$-GC)^#=>PY'-V8O^T->0FVR=QV*02MY9&2<@CR%E9@U_^I(L"RF M?^59Y<5$S@)_X(?6U?<,7ZUN_S1/\UUWW=/!U081.\W^YQ*3ED8)V",3(HL! M2KP$I470Q^%(S* 'LBD Z5VOZV/(&%0BSM)(F/V$!HTM/"#BUF*(V]/7?E[' M98&GO&VM5K8;_[VYF-O9[,$@.4 )"IU#\"@)\5X;BJ2O$D=3CND/Z45L'? M76&&CO72+Q4#(;BL!O(,JX'$FK6R5&;Y(C;U?STY^UOSC M)MC?/3X[NTHLN69K)U:N*DU-K:[]_/7#1O2Q[6*OPDC1%^0A ]2W*VEZ'R/P MUCG,K-[]^NO]_G67]WVA_O15[Z$8W[W'PTL_+D0C'ZP]HSJLF#1%5MHT](HSJ@#WL-VA;M<@/^V'\0+DR7L7HE?! M,VU\M;KGS(HUQ[ ML\?K=/^RWGC]>;_Q7NP?'[1J[=KY6[8#SSMO;1_[\_KE4:M&-UE]8_VL?OP> M[U_^W=R_7+_;C>V^'[#XZMKX%FG!W1/UB\WV?:;OZ$A;E(D;/V+;;9R.O9UM[<+2+4;_6FO.6C&_D9T@V_?1C%E"7:3 M KOZJUMTS+D4C+$6,:P,XE@Y9)TV2&F&L21$,!%7UDB5:U$%F3\6[GX .4]% MR$KSGC*#*A" ][$^,Q(>CM?A5>/ M@Q+=)HUNN[?(BR=<&D$$$L( Q&END2% 8ZSU3NH8HLGE 3C35L;5EF7.9 MSMJKSA>P@VZO&,&3%5)AZ=,BYS*/-KN9,B(J7E/I'ECA,/@IEBV@>P5R7!&1&U569EC6)4^J_3(NUX\L<[^L+!6=W 4>Q5_ M8]Y9F2]9!%HR$N?F4)KKG;"=13F0H+LSHX M897*&U/0JI:F2LRDLJM/;O9+M)[T>TF;[@FTY:)(UN1U7R=YBFXYK65AF,V5 M -^U;&< 0=WFE0S+G/0D$>_VM!9!N1, YX2"<$P;9X"6*DMOHL#)<<4 \ MHJL&E]-:EMB2)Y>?*2UY*I8\SEV82CX9(E @6"+ 8H4,H18IRYP4S@:J8K9D M7,7JT:-+\Y>8F5]R,MJ;KG-8:47;CY6B3U WH5/X,A^YF>6&MDF1E*^"?)OE MN),;LYWV^K&(STILF]@RR<;ZH-;$YQG?ZI>'O+:Q_PEC"C&7=(CJ0! 7)" 7 MC4,RFA1XT"E(M[(F2-7P>5I84)KRG+*4TI2G9LKU5S=-.5&?\A 2\B TQ"47 MR*8$/"518PDVVA %IJRJ6C]Z_&AZDV"FM;?"#/9K6/STT%9G8#N'S5S)<'&!OW>)>VF!K/4[(L,@1 M3S0@C3E%1M,$:N("S^LE*#=5PN=IQ+\TZ3DE7Z5)3]NDQSF8-5YHBBTBR6'$ MK;3(&*50TD8JX37#.H%)2UP59H%R1?-'K9Z0A"U:&NS*LLMIG?DUX8F-JY4F_-0F/$Y&!->*^US$1A.+N"44K)?DA(XC5LO E/;Z/.TBC 4N __@]U\:1)_LFK,2PB<'X?MWL+!DI.<< M.4P(XH$(I(7D",2%(=!T.GF]LL:J(*PJXY,J#;(HJ\U*<"O![4E7UI7@-DEP M&^>G6&L*V!91X)$.J[X[@PWBC%M&;<2$LPQNBIBJQ.6:NGG9H_%MT[IFJZB> M7BRKVQUT_>>C;@NZM?^?_]*4J#\J>7''X&*.]G%D(,W0/9X(\?[MG+I MQX2O=G)L?=.UY/K(Y2Z.Y1YI,RNX_VZH@V45AHE3 MQL^WXN%$G>/<8Q189(A[XI$+Q")FK+:<.P9T?V6-4%W5ZM'+?>9O6*+$I"7% MI$EO'5!BTM-ATG@8*R.V/I>OE)1&!/$L0UIKF;]*;D!JDH5<]XY7-5W6<99% M8(R]TQBNQQ/?ZO>6$T\7A&]E$5[+/I3P-FEX.[Z]P%I)$;&G!OF05P2 &(%R M!8IXH$G1Q(!WV3R*;*KR\8M\RIFH\VO'$^0HI1T_O1W?HBF<$,4#1U%&B[A@ M"CFO-*(0-R5B#,4V;U,F>!4S/$=V7*[LN1?[6Y"9+OYV7G?64W"_.R"TY'@^ M*5Y6 OE3 OGM5=61-2 M5_7C]W:;BM$O_1#VVV[G$ UBKSU7@]CWFOXRZQ'NAS>RC!*68V1_O"3F-=.I M5EI7%C7KD&&Y.<+35,6\8@P7Y?*?IZ ,MU?P11,X:+!&2IF >.0V[V:=UP"I MA#GQ)EH*E %7*2Y7\"VQ.3]-9>2H-GE7->:M]\IYN[+&=%4_GJN48\SS:\<3K390VO&3V_$X M27'1:BA+% 6YAD;_Q.,RI;&_S3&/\YX-,=2XB"1BDH@[F1"1@B,8F0\,6)R?7PP M?E&5Y,DG8Y1#L_==7=QMMYN#O/?@.SXI\[43'KP\VD(QGF_^;+3 M;/VU,NB=QG&0N=9YZYWPZGK7E6CR(#0YO$4EK# RV4 1,SPAG@B!^$EYY ,1 M-'"(JD3*:C6&(\NFJP_QAX_655SJZKUT==SS>6]- LD@;6E>B^L9LCQ$Q*E, M3"G-!(CG>[JZ1$52[G8Q=Q5%B451E%^; C3!>B-S?8^IV1[<2(AQ5;]]>UMFT>M*33Z MG>UM]W8'=A##!]LZC=^>7J+I_='T88>, M(A$)FN%"JY@,7EG#JQC?CF9O_5 YL;W*ERS>:N6[JM?/8N]/1^L*%>NOGPZ. MNCT Y%"F1N94%2_K[S\)*5T@$ LIXQS$0HDAPR @HLDD : &[HS^ -+NU*LG M\HJE7BV07@4;K"4D("RQ0EQ2C%Q* 6DI)'$>N^#RO,@JD+Q[0-Q0S2KVJ^S_ M>"#4/:E*;O7[I^/JF)KG,:#+V.N6SG9VFDCJ9Y\HT]&F!%0-NX1X%!!+2V.1 MU4[**#@F#T>X)_63_ZQQQ-="J-=TY'[DOC?3KC'1^XH-%R0Q5%),I<=]Y* M9"(G*%$=O4XAV4CGT7BG-&;R]:'?RXY3/,OL>![2ZW8>DQJ?&$4>-J7,9T[. M6#=_QHEYO?V>0MO.:I='QP=O:KC6^-#>/SZ$^T+??7Q]7#O^T*[1UZWM#_I\ M>_V3CE1YZ2BR*A?GU#FZ2DRBJ(CBQ*?D5/JEO/C$PO92B>9>B9PTR3J)D<)Y M(SV=9V50*Y#W$@<1O.;"+E)2_)K*E9G+!='#R]KA)VZ4,R2*O#:*(0=YHC+J5%SB2*J \F,>ZC(7G3$,VK M3-ZN8/U=A!MFR(=5Y+\A2\4.*O^<=F*%X6HEZU1QPC1\<3#3BBR$E G..4)],8 MI+$25'D;!=<9 UF5Z?L$L3_%P(WH8]O%7H61 @?)(X82RU)/4QY*O&;GHZ&( MTGP?9K[CXX46*V:"1=8K"4%6+M]*1 ",QY((2JU-LJ @"V=][F$>LAK>"% P$DCSQ750BJB8F&=;(ZL\UG555N'-N?^MJW* MB6T&U.Q4O#UI#FRK+*NV"'SBF_S>@?BV.J^&PKL&9&7T,#F N[UEA#<4&RT] M@O"1YU%08!Y1621$#)8'SZP**VN\JKBJ\COX?SEA:6E,>F*[>)4F/563'NW_:/FWE M61W#[4;AK=LGO7@4._WFEUAI=N#[DVQA7X9>3[ 'Z94LBQ*3KZY+B,9)91D6O8JSF* MS$KCG5?*\E#C+?G+Y"S[UG:D)"2OO07MRG.94N8OF%I$B(_.FNA-XBMKI$K4 MHS<5+K,NCR_&WJ="4/KPG?!J'O)TXL-"BL&E['>BW_C61 M;@PE6J+W$"P:F$I)%(7&/>(1/3B6-@HM&)BJ8R%.9"$1HHLKD[>EU MOY!Y M._7;#&8F=OT,J]SWOUN%;];YEF=<[7I2R9CK)18W"Z&6H# MH[68\B8]1N?BM"%7SQ$A):YE3L;0JF$4" U=E&K7I?$O8C*G-/ZG-?Y;^1KC MI4B&(&R21)P2 W9O&$H^PS8SWG.YLL:J6(HJN8/QS*GQ3S*ALR"L*#Z4TDL&71NZIZX5OTK]<=@Y=Z.#__'02&""';0T3N4)-D]: M[X32Q3REB[F]"21F*2BA-=(ZK_OCV"$7)4.!6W ^#">:='8Q\+'*^*,G8T[< MGF:<;RN1M436N:7K);).$UG'R7MRPBMPC\B'0! G\)?3'.!5*,:]-P8+DY%5 M$5.5^-&+4.8&60MV_V)@X:%7"\^N%;5JV]YALU,\7MW$,A_!!'K3MTY:L/2C M6+$^SQ&SG8N\FJ[3'62JWH.?.Y4FM.RP5TR$[PTJW509',5^S$8;8JMU)KAQ&Y7K2?D4WP@B]M MZ\Q>]%=>W-1=4-RQ?A_OLN]V3$I/UC%#(P+8[O9L(5! A=C+9T&;[-RTI7+4 MR][M7S\7D0)[S/"1+2UO'Y4-Z,\7]K8Q?-]2?FYFPY8VLP4/7C(YA=)ZZDZE MWHV@>YW*5L<_'".FW=977P'OU77 V_T*A">_R M^_RW=:L#[J=["O<(_6HEGOL(COHD]H;+PRNV#:Q@T/_^BUSSP,."DH6K_N8> M"GH ;].R)_WX\NK#'Z'9/VG9BY?-3M&FXJ(_1O<:^90,B.-YM]QKP\/?L'(5 M#_%RE (+4X-$9WAL>X6*5(QI_DM7_JBQ>:89_K7;_OB8 M8-]_Z+-HK%G5]K!/39!?,A^ MB0^(BN>[DW/2_3YC2 _91/:Y=!R9A'$N:=^42C41I5KZ/7AWXI?8.8W]F>^X M.S%E+!NYG(U\5NN*ZG%0.>EUPZF'OK&MV)_%/)-G,)ZYG".2P?%$I!::&,]3 M=(8GCXWCP@LEE!:?-HJY'AP3=+])'R,O\;K7;><,;V["Q^;@Z-5I'_HC]C;/ M?>LT]^-ZOQ_A_[ P2T.W=T>CEU]_ A<> *SFKJ?,8":, O:2AR#(B4,"!"Y"S=4ZMK#&NJHSI$KA*X%H0X,(* M&ZRDX-8P+I2UX(:=T-@PX['&?L2X2,FX%@2XZ!AP:6>T!(GFU:P8<2$(K$L)3@T7DT1K.8+%868^JQP+I,CRT2YM5? MW4J/8I"<6JM20R0GBB&O4DQNC+]LF"&/IY^ >"6 M 7."M**YE'O>UEEIFNOJ.$/ KQ,!ABX5&/JCLR^EH<^OH5,N8] Q< G\/ FB MB>?"$A6BTM@X7:8K%LS0Q],52MG(HY:(9T,PX(P4F8R%@H.=V]E,I(*02OF48PA(:Y9WAZ31B1U$-*Q M2*G@*VM45N7C:\#/WZA3:>A?>8\DV I)/'/@'O,PLXXXX6B$XJ /LU5IOH3S^4H[_VKG(@2B&"&2 M@9U+;3%Q*3CMI/56IE0F,A;,SL<3&<%0C_,F\RQAGXDT"PX-+K M%+F*R6 ("U#XO M+'.:\^ CUE8'(TBY!&?1 &(\=1(%Q49%CK#2"F"!:.2T"D@(975,Q#H% &$H MJQKYY"2B1(?%0@?,1/"<,,5QXHIQZPTVB5O++%7P\HL.$YI3,;_[E5;<_&.ZO%,]/ M\OR17ZQ"==^D\SWN\72UD\I&+D4CG]6RM&R@N4;XKU>@*B>VSBH%FF6WG=YT MNZ'832;VOC1][.]V6Z&D(9.B(=NWEYXY(976CB*)$T5<:(D,#P81[PVG$*$& M%E;6@%]6R>/K!)0SU>?7H">>KRP->BH&/9Z6I!%"!R$Y,B _Q!E$HCA(A MQ@L&TL44X@I=Q>7*DV6VYXFG%TM[GHH]WRKD([506@9$9"*(XV21IDXAY2R/ MFA'*(P8';5A5/;X>1FG0\VO0$\\(E@8]%8,>3_R)P#G#P+BML]F@&4,Z*H4< MU=X&HB1)!@R:TRJE8HX,^B>9A*L-G*"Q\<<84)[YJV<^JU5[.[$?;<\?%0G7 M$+_$5O8]E4:]92,>GO,4ULI M(M$J(II<1-RJ@+0S#!%F-,"VQQ*;E34N197JLI+QC&QS-[;@Q\-JY3!V8L^V MBFR##>UFI]D?Y(I!7V(YD62A$@XCB;X9RA-P;_V&-$OHFSCT;=[*/ #,<1.M M023F\H=1:N2(C"@9%Z@UF ^(IB-*Z9V#=8[Y;4\&B MS&M2(A@VH+5$!D>-#(].2SPI893R M&IPW>&PK$(@5F+E)"AE"122@UD)%L&[*J^;Q!;WFM&#Q@A3Z\;>6F\UZZL,S M+N?Q).M=\KR[$>KU2]B;'.QMW4I(F!"C3CY"AR8.L&8RE5$BP%,BP'C2XO]G[TV;VDB6L-&_HN"<>.^9"!53 M^^(YEPC&R[R>.X 7/!/V%T>MT%A('"VV\:^_62V)10(;C(1:4!,Q&*3J[NK* MS">7RLK42B2K(D8L"8H-!*_5[QZW>21QW&'Z;!<2],7V[!R^[ MOG<<,^$+)BX.$W?F8R,N>?!F.8HV9Y0;"W81DQX\HX0U)DDESL N8JQ-R+QG M]$NI8?JXD6 !<9&"!*M!@KD8B<[ES0$)I*,.<1DCN"7A(VK0E MGC>."A \\&R7,2< M$MK&5X1,FX<$]U2D>*6B^K+[.0Z&=5OKG#W2&Q[&?NL_'9"57UI5+3>M=JL; M2R6-=0N1# YB]\GS_XVJX>G;Z$?]:EC%P8O/N]4?MNIF+-SNAG/BCR%R-PX+ M0BX.(5_/A4^224DX[!"CTB#N,U:&1!"36,N@,?>YD#L!GVG^I,O-\;$#(CR9P!UER$EB$0=_%AG&-))4LYBH!0_7;&P)L']4@P[Q M%B%O?GBCB'L3Q'U&G7N&&?6< <-%B;BP 1DN--(.*R^3$P2KC2W65J:H\S62 M]%6D>!3Y;H!\SP8TM!$N2&51BHDA3D-"6EB.DCWVM6&(_;SXSP_.NP M;X$85=?V3U\.X_%@M]?-T^WWZH.%+V'B?4#3 J"+ ]!W<_$.Z;Q4*1"PC81' MG+&(+$T2,:&PQ,XPI6E.%^%M1>=/_S210Z@H\-B*)Y6ZCY.FD%4!XYH"PO[:0 RKH RFSAN@51'CFB+"]]I2#*FB#*;-0H MI[]BD0R2 @?$E93(,:40ED+J0'DRQ@"B8-$V9AULE!5TDEFI^+_J]SY7@RSW M("5WCRZ56/JJRJ:<(>/DO.3OL1M3-2P =RN >S\7U8D:%)MR%,7@#>(Q: X MRY"*(8@$M!),Y3[ 30J*%VEM:B++#Z7UHJV2JJ\QH&^QWRM2?$LIGHVDB!I; MO48DGW'FEH"9XH5 A(J G<21$+4 M.<1Y(2PC7A7.I<:+G-2J>GARS,"Z\Y4M3RVEAKELP;N.#RTO+J %.+JS<:5@I1)"\U1=%0@4%0>N90P6+&: M"2&PL-0^O@R= G<%[NXO&ZG W?+@;O8,6 P*G'2+P)@CJ*X7:@/\8(D#Q4A* M*KF-+:I(F]%'5/ZFX%W!N_O+E2IXMS2\FXU/1B.E]"JAE.NA\\ D,HP0A'T" MTYUZK-UCS&YJ-#I-XY:MD]AO#0YM/[90R]E!Y>NB/Z'JC(8Q+".[Z1;UKAD0 M,/1&KA,?A1ZX_0*LL2)X%?MO,]LM-KY)K]4'SVV_"^LVF#[W]\SK9]"/"_3? M /H/YB*9)'IBI0:LE\;EC!&!-/4)>>& 3X5R\.7W-RM7S0?/QDA7..&.G,"Y MDLGELU>>T]S\-2)K(T5*@S-$M-:"QXTMO*GFR_S=O1#&S2%SQ5D)1?D5Y7<] MZ-TQV%V4WW(A;S:L39UC)MB(M N@_)*BR#%G$18*1^=H\KFX:9/YH"B_Q7"" MP\9%KL'N89$@SKQ'FCF!K*.:.$^"(#XK/SZ_FUN47U%^1?G=?>NC*+\E0UXU MVQ U4D6P1L'FNK664623YDB+7/D_ &$$_BGE=V]\4)3?8CC!*DH8,1P%Q20H M/^Z02S*B**.G7G!K WA^9)/KHOR*\BO*[\IPU]WVP8KR6R[DS>YX<2XIMER@ MB"5%7.-<;4@$Y+#VUMM$@_0_%_:\+SXHRF\QG""Y\@3L'<0]C8@K IZ?#!HE MST-NB!@"MEGY$;Z6RN\'6Z&A&IQT[&E^B_A]?5E&_NS(!9VB&1L-N.%60XU- M@]9H$$.KZL+['I^,AG5IFU8O7=BKML?PQL/!PO:LEU/Z:$8H']0YPYH.@V77 MZ_BGGDL,V[ F]B#NCHY=[.^EB?8:<\O>:#@8 @/ RI8\GX7INJ/MN2T^[8CP MG'E$D[+@Z$G0=3Y8Y%7B41H;B/Y>O'NE'#/'*A-#N/#+\OC%,:<%#P9)@$:P MDIU%AN. (MA*,@1M4LKGSS5O$RY^;![=\B#K[>!X/6OK/3H%L_ 2,T7!K! P M9K?19$@L&!C#X:9^583ZZ%@ MRA[BRD=.2# =,E5?HM;@BRZX>4_WN-GF=YGEHY[E8RA!^;1W?-*/A[$[J#[' M^E#WDZ7N@9=[/*Q[/*9R!ZLH:/ (QT5M(<$-R=6:%7(* M*\0<_">](CPNI'QI :8"3*7.: &F:X%I=K/,M(B^3\YYO9+"4>7>]Q[.+H65TJ: MWUO\7;18Q] MZLE\9>,B\P]"YI<7UBQFP%H PNS!=IV4EYXB'F1$G N-+ X628%%8,EC[NC& M%FN+*PZ%%$AX$)"PO(!B,0,:(O6SX<=@5=#<:*0-U0A8*"(7I$0DQ4A\\HHP MM[%U18GG=8X\KDT8Y46O#W]V6R )_=CUIZUA'^[6&=>..@!1675=J#4$Q/N- ME-P,!C/B36C]=$+J_4SI\12WNV'_G.[;X6@T&!['[K#818M'R/F^YA%3[XCB MR%B;P#C2"7PD[9$)RELF77"Q#H]H8A9T=&E-#\ ^;"Q8>,F596%!$?=;B?ML M7$1IBC&A!ODZ+L*"1L:("$0%=UE[8D)D&UN"S">)%&%_,,*^\/(71?&O 1+, M*/X0K'"@XA&X01AQHC5RV%(DH[8B$L$)CEGQ&SI?YZ]@P8/!@H57*BB*OQ'B M/AL)2388[<'.MUY;Q*/*#9\]0X$*;I2-Q,64,T3G:YZO3M@7F59"://C(?N] MH>VT>C_*S5IU LG-F]X_/+2\SY!)P;Z?PK[Y/K?*)Q<%>#D\LI1;_8&IDVP" MST<;D22FX/UN;.GYO>!;0M]MY6.-MH8>L\C$B4@8*>-8 MKAHKD7/:((>#%LYJRBC>V)**+K2C4Y'\ADI^4P,B1=Y_4MYGPQO>J'RX+%<, ML;F[GPG(2D*18-%X&Z@6(:O[*ZJ%-%3=/X93:/-5T):1\''#4IKCE;BJ2MW= MP+!QJW[S\\6+7Z!F:XEF'#.Z0E64';'%ZY!/\ZDP3F>K$0AFK4"<)Y'3!B-2 M%EQ_3P1G=6%?QMN*SX?);VXW+ERL5KR95@"V .PZ'=HJ 'M/ #M7/4L2XC!F MB/&0$#A7'AD=# H61Z\X*1E,KE['F#-(X$67(-NJX*9'?1MIW5B^^.:3(=Q$+/H!A"HF#5*MUY(.X0_4M6U75_!\,$0/L@I MJ8/-,SK.+LAU*[#U7]?_=>O:RR:SYW13Y13%D]Z@R@SSI!]S.NSG^-N7*@P/ MIUM9%RZ<< 8^O\0ZF/MH>/TE32$2O[P:%W_FV=;PE*LJE%AV>=DD[L042N'^TG9!.\X!/;^6)/!QN_7N9=8-R9=9]= MLFL7)J6E+_TZ$_H)H$+LYU$P)]N8N;0.^UG'_>O') (\W,_PD27M M:5:/($#__=7."\/UDG)C,5L>#ZLK>?AM!%;KMD #WQX2[GNN3\_P[>E%?'M[ MAFJ90&^'/?_IL-77= WO1'< M(PRNG^X%Q3KI]U:+T!GJUUH?YMRQ)X/X9/K+;],VTU41<:Y M&8U?K\WXZW,(W,1C&)SL0$^>//EZL_YJQHH9?\?TIA'ZVJ_Q)OG)[P2[_J'? MN_)[DQ6;2OWL?.Y[KG(3'(0UF:O:U&1=>(# A4*MR63-IE!T?>:J;S:?'Z2Z MW*)J[0^'FKFA5\1CQAKB?N(.^D=J8YHHH\L>2%N M>0MOOMG\.FY+?9-DKIN\\J-:NNWCWJ@[7(Z0K\<"P%RSMVD[K=H7/+%50%6W MY>U)-;2=Q[PRWH^.1YW:;[O^D&A9H'J!0DR5KQZS((U/$P\NN?3QLDN_]HG& MLRMQ]:[-[[9CNSZ'@.LHQ[/HX[$#\6&DW:*8XE67F5N;TQ8W6^YK]\@&M5DP MLTU&G;_/Q9281H8Q\_YC%V$:N(UAC\V-O-!P, M;3___::?OCC3_CNPZ>=HY=D[]ES#'/[ MM///[J>Y7;']#T<[1YUC>(_3#__D^7[X]/[X1?7A^/7ISM$[OK/_YNC#/Z^_ MOJ=OTDZ%3_..V,Y;S/:>'7S9/?C(*%$L>8>DRN5U)4O(,*&14M0&SD-T.*?- M:MPV>/ZXU<]5EWA@F06-3QRXF>#_;-Y <],"[@AX\TD!BT*[BY'Z<9R^P-CM M8 S/P)A.EB5,,"(XU\.R,2(CL$4L&1R\%@I'G6%L497Q"H05"&O.>]\"PAP+ MG 1MN(P\%U$;G<&WZ(.GH'N0H0\1D@"Y@39X5 1.131"%1Y*PA*'!022Y@K[C]\F M YTEJ9CES'H>.!-$:PT20G7 PFCX['H,NR;QO)AL2T6ZKSNS^>;.@_;A"7E" M%.*42&1)LL@RH8S'Q.+ZP*0T;2$7=V*R(%VC)/ZQ(MTM@,YS:V@"9!."<^6= M5L%'S5FD7D=J:7%)&X)O,P<6$Z&!,4R1L)0C+A)#+H(I9UA,+&!"F&>Y*1_7 MN@U,L2X&W8+J5C<9E';C\.<+-CW0EH4W6[G_\R]-"?WMY\J.K6DYP4*E0J5" MI4*E0J7F4NE6M4,TBYKZR*((W.1=;":Q%LS0:$F(:O9H.[MQA 'LBO/JJ,7X M7ICQ?3H?7/!$:"J,0TX'A;@W&#E*-")!VZ@99=:DC2U"29O3>=.[],1^"((< M%8TJ6!FUD9P99J5(!I- O5!8^% $N8F"/.-%8TNE8M*AE%UIKFE"SE %:JG$QI::3SJ^]>9N$=X"L85*#?.2"\0N'F+G_&,K&-9 .,2I M28"QQ"!--4$IT* %24XXVQR,_8%K/*WQ!/.,WQ?X,O*ACWP$>08O!X-1/KN= MSVW["U5PC M2(I(B>2UYXXG@3>VB&DK4T!ZS<2_@'2A4J'2_:O2N\?_BBI= U4Z%SD46%"F MI$%:6H.XH!(9IC$*5)@0@TM!^@;JTA)"+".7%4*\8R+6A28'DUN@//Z)F=ZC MRFTJAD^0J571"O3"FS@8]BN?:XB.8X>?X8-<4+3&ZMPMJ'52 W:[U8WG]47' MG4K*]ENS(XJ7#GI>%U0\YX!ZV/87VP_U9MR+7C_%:CBJ)UA4ZXU5Z][3N3@B M3UPR&\!+%30A+H5#3DD/FC5293QUC(6-+;VH(Y]E6[W1OD^A4J%2H5*A4J%2 MH=(#I5+QR ^N5K<++[M-Q[ZL:-6O0?'H!,]_DICZ#:AC?QO[GRL=Q M*.M-]+V#;GV7>F>I;!0M[ CV_O9P=V:CB%DO/34L]PV 'UQHI!V-2"DG%4N) M:!4VMIAN4\H;M%%44*%@=Z%2H5(C->RBDBZ*AEU'#;NS_S+O%X&6]7SOV3;] M&)B7,AF)L,VY&%$*9'(BNA0:]*N/2@G=0!7[""J=S+17W+%]?SCMK4A67>[D MVF*O#PD]K]PTM]@;HA.UAGANC'/6PO^8>V.D\1+719%O@)NEL>+]8-[SX6SZ MF;;2&\XH\I8JQ'70R 8I412,4)H(!D2L6Y*U&67++HZ\KGL5CP( KBC1N"#I M+_UK[BS6NS.%%[%3C@:KD/:1(QY40#J1@'!(05";J|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

=Z1:-:U2P MYR@0V4'@IE=(XZI#2=/:D)=&54_1!=$"&)/'BJ[8@@]E "^".]+HLN#X7YB: M[F)/?''F/]RVW--<B?CFDEA+8K\JQR3)(5%7O5<&]?8K>2D' M]OOS??(?>Y:9/-M6F^'/'^5+X>S9I[_:6D"L]8?GOU[I.QV;9Q^?PPU$9<\2 M>NXT]BVHTJ?-&J?EQ62^$DOI49J+BXJ2 _M+T7,E^H 2\(EM*W7HYZ?9?;C9 M!?M67UENN^"\.-?XY1]6,^&/T#67 /R0"%L\DPNEQL'*8Y'W=VNEP6D8/N(R4P:P0"+*" M!C"E*KNG,Z9"O3&G6;['%XIY.=^A#,^YZ56Z/4U]AH.+/&%$'B#,RC]'<,)8 M@'JWJR]_#LNY)B-)5=>E8(+695DOO!-IL)50&*UW9Q!0)#C,&&%J5>5!6&G67S 632J MB;#I5^HZKE*%43T)6)I;!;_53.1VY#1=#SA=A,[G$WQ@6$SOZI_75?DN;[H/ M,<,V%M3CSRD$F:N; M)B8#'YBO&#HL)[FN 'G&#.8X4S=[.E,,_XA69Y;V(@ M$ ,S8W>%268 !\ [X^D\?-B9\ST+,0+3-!\!:BP:BSE:M(FQ";;82ZEYK7UL M&^SO2,C5TP3^4A.X*-?E'ALJ)HBE,ZI8+*NFVJBSZ<(M*ZUO0#^ATV=!TFGZ M'G#Z/.5(,'=K8.PNVR0&W91=9"4+(?.:H!J#4CL@-QI^LC.R1$IG4[=@Q7) MA"?9'I[3ET\S^7 S22..=LZ$SRK)37.&@2/&L0$)9RVT*HS%>H+9YR0M;$EW MCSZR(+B1D)WQ?2'0)A\@W'O:>9WQ',:.Q[!+=FT_1*E.%0/QFA^M(Q]J%F_& MOJ_+8@X/JK0E1#8!7C-JQ-D2A>NR&JZIQ8%_C'?X_AU1%U8*7P%#H:%7@#46 M\E=2L6M+HIY%FW4PS1U#$7VD(AIYO=TR1Q;24$3"*C=*U6X9UD);H8ITP9E1 MYPL7=")'C[F_K#>F,CHAO=J5JZXUC]IJ3@054Z8@_T=S\ZKW'%UI&T-2FQ2' M&P1WE^G3>)^=?N1W2L+"-P.]GG)]W*^"P;"PUM$I780#$=D:]32%!U+$].8E MNR9UD:2 F:)0JSZ\M$F]X$&U*< &W>-3.^T1PXKX31\;6U (_Y5X"M]4*VZN M"8]R$1ZP$6IBV^QKPG=W"5V/CK,NF3J+S>VOM$,]&Z%/PTHM2?)B5+2GGH?8 M=@;EJVGCH[(6)[/*0FQA70U9[VZL1SE6H+Y^3RT'PR6AMXE+&7SI'WW Y-X. M?WRT=9*Q@$8.NK&G.<')$CC9IR-XEL<-)_O5W)L7!B*B>I69O.#UA&\U MX?T[LMZ+U^"/H:T.5?5@R;]X^?J%8YD.AU58P?6R"E[&;!TCMF?'XE0G^';3 M_@Z1P%G8!JO+8*A8B6OLJ0FP9^VM$GU5T?CH&T0JSG&X;#OAXG2ME\LL)O$E#:&\M]7X66-]V:"E9E* R\^WU6T5R_.I"\GSJ:,@VMH MN!JWY&*IBQRNVJY[!M:+2U@P(761^9"YHQB)#M!S(5!T7A^\ \WEW^M6A+C M=>5A*N-&5E/V %BOIU>2A$VN! M1H7=KAZ&V*_G]C8I7@S9'B^R;L=6((XBH1MW_8[LJ"S1RMF;V,%!5E$FL(8, MQ[6V@K!,-U\AC-!EQ6MY3^(8$+%)).(! *@E"MB 0$'W!6\[D&ABH4:Y#MPM M82 !OQ'I(]:7;1N? L,/O6]6#!'LZ]+M1JQ->5/ZU)OR](X,_!2A6A-U4N%: M/078_%RKPA>C(*-S7UV6VTTA_*O$/VS=X\?.EM3NFG)N-+UX%+RI_"'M;BLF M]F35U40VPMM&8%-HO0A81,:%OVNVJO;"1&8][D3+1W&Z'9@.8H\&. M;$.-:-@N9(AEW>";MAWV72T[WYU\DS-' (EM+Y+#SB8P*"TU^6[A:U))/XY@E)T:0CA-U&%SR2/")AU,*_VU\KHO\NTU/I M9O&V:6+E^-%9WM 1AG&DXT;ZQXM?Z94?Y5[ZB0*;4?0Q(MC33F0Y--"/2B*( M82&O"/C4]-8S24=;R@_.#E"L+H+BXRLJR7T M*LB3V:EUO4 AT$G#<&L"@W?YUVX)/LYINI7H21VRBKJKA7H23;Q'!A^+U)+/ MR[*OD^08Y[NP[Q+R]Q5-C%@P<4XI9QWS87,*UHE2A^N^=4K._41:J-R1IT / M16T;O C(U$E26.;Q]W&RF;N"%DG25D,+(ICABVA9YU5F_.A,>UBS+^3B#!VG M)\/J4/D1XERY539'E%&H7D#$D"7ICEY5ZW:0!F)R*2=:-9B#7A00V\Y-5?J$ M-#7!'VK"V'2T$+"Z/=K\5(A[P)+J[&G6AVGO-P?-\ KWEBMO)&I?'(+[3!).LOK,:=@?<-@3O6CE=?;TJDJF2E-BU4<.(H-G>UGOD:ZD/(*= MBP9;/,W<+Q26:*8L,E#SK$5*-* ,5<]9B4RHPI^0NE!7J%078PK-*H0RP:=9 M?JO6@HDB#8;]TA?;NZ+#NAO\]RU&%'JAROY(!.30X/WLD9N:7[04'5X:YG M!&X?=UR_4);D!-(?RTX_UB5HQP\+^Z82%?1S/\HJLTK41J7LCY3UQ'O$)?%$+2=@D/6YDQV.V6Q"%^7HG@+V/KBT55=@U+ MJIA'WA\: BQZ]CGKA#3_+7H3!0)FJ:=;2I),W*8K130+P#O B'0\C+J.RZ"" M461FHU@YHI:^:\"BI#,AW+_AMKVU?P:49L,I!Q6/'D[/H1T%LJ?QA"M#1M!) M;TV NY)%!NFA(."=0@04TZ9R+6M&HI% 0;V)?RUBH@"P84L#Z)04_N9)CC_+ M[.&&UG'3C]I@K(,!*,!F$UP!P:KU@YLQZP=RS4LI+%7P@&BC8DF)OJK>8<7P M>50YIK#,8XRG6C*RG @YFR_RAJ?LVO&"2!-W+04&>$Y:.;3ZUEPVKR\(XN05 M3Y;''D.7(F5=I2J]4M5%P?[2;[-72A#HDBCV1Y!*N#V4T1&VDLG/ :)D1<>=KI8>KSOQ:(R"EASA-5ZN 6 MEFH3]E*:,9?'SA)OR1IKPZP=E<\]8VF/FX*&7 M9/'O"VQC-E7L$1H=RJ?%ZB^=MPG/:CD,Z/+@8Y47=F3Z!<_W:J+A"V#*]>_FZ,G X09[)_2"L M-A$S6Z=/7S5U>X05.9FJ*44H[_$H19C5])-P'J=,_<]1.*8'QD)3%V8;S"?C MS(=ZV:YA3UZ\>JF.E=!\)H5GQ7*;91, >%9^9 $Z56!%XR>W+EGFEOH&;AL@ M'AG:[H5_6?-=:) @YR?2'ZQ)-8J6!-D M]_39^>)M34TT()]F\2O2[0Z7>TU_6.N-5\/T$O4M??=.&MUV\"NNT"B?=-^>OSGF'\>6_$4U+N7A8 M!W3I8*PIQVH/]A4TD7;''ND\?& \CJK/K&;;.N4)1(GF+&F!@3Z$=4+(/?6\ M(KFFRNZSK:A!GY+TD&I:K'#T^'[TXH@H5"[ B4M6P>[4JW>2#TG\(P4S. FY M)=THEM1S8:"9A^2CAAT&[:**O6F6[P8/(M3]W+OV"VH&"M: ((EA!DCK)/SO MAEZAC59H[0'3>)'Z@Y)TZH^RR^0^'8NKB1*=U@<0A: M6:);+(: M ON"#M*-"<:RNP@>CXJMI?%R=?.@^!XW+;G?1(!@I0U!9[L).6'L[ZSDG*KE M\"3S.Y*K.>--J$N^K%OG18?OD!?.34+!,,8C2/P.V>ZF7 JAREQJC#V;PMP: MVENM2*_*H=Z_"W$T1>+)[:TBC.79=F@[2C494J1.JM\K["#2?EC=(3I+)8 3 MQ+EKF//RAZ[#*C+E9-9CJ*B-,K$-,MHEP3X%^#!2+\G(0I@3<42/$MN$N+?S MJ2#W7H70/T2&0%P/.(D9:2NFB."\C!O4\"253OD-BR=JN\NA;\#P+&)"6V$R MLRZ&4647X?VX:X 6JZOKWGKC]KE Q'AA!M+E=UUS*'D,2DRK;! MF%$FQUH>G,:5\?22_E>#0[+N$SF]&0G(F,$H/3EA<-1$E!LOR -%?8K2!W6% M]-J&B,PI,IF,X*3_R\>E?NBFP\'V>UY/,)$F%)C;*6#_E%SVQR&\7Q757MGVKTS ?(8BHWW<%_M_A)@ M)&X7UD)A@E(&IF+F#$-6[79C(SK),E5"-"!D"9V0Q&W&1EL!7U7]OM;^4V6D M4RX!;0XT#O;. 4TFY",[LJK@,3@LJ^XL^"+EZITGNEN"6(EE=L&7R*XIWT(NJ\A5X[CM5OC'W+.XZO;*GE9'H?PQX$AT_&KF#^A F"% M+$A+<=M$PR$F;RY:_)3>"-Z*N@>Q,\(.]]MWF&P7;%YR/:)TM?L4FZG(^O6# MZQ9;K2!G3ACPRBYEA+,)NP-V+M,"._1RF.%UGM<:7"8NN%Z)MCC+>4W7W&0D M6(],@W&-3I+*13?72)*D1E,Y\;1)6J1J8HA%.^6*J1[#B[N:-#T?YQ=O55X5 MO6L0/2%>:-%.S=E;=M-OV!S=7$EE\$JA# M[,,&E\D-?J]YV)?M3@U_.FZTYVRG49$Q2WK-?TDNM?3B0?\B&D]CYM($LC%L M&C.IDNCPCY\B'X<;8E3QNC)11!RIV":"O9?!&E91JY='!QK*2MS0MWOJ^Y"P MBYD@@G>A-<[D#W(45&OY]8+TE8V58"'&=_%;%WIQ^H$3+>$VB.'X <+.Z$:H M!OSN?/$F#$>[8_NK)CQ>9;BD(A)S)7,FCF"@2E23O9!_XO[V=RBP,2] V$< 2-ICY8'">67XZ 5:^2>*3\C_ *QKL:,)'%*"@2GL>ZP\3(:(*Z) MMA3[)EB_RWI9"WF5WOUW5)W $4?9DHUP_JN!*L*D'93#1M7%PR&X;>L! MP["NQ+13"'TA!?3\4"K%M8!U[GP[E9S07D2F"18K6-1>B:'F/]O,T<.I_S7V M3]%6)7Q>89>!7X1& ,<=%0;[\&9"+:07+-M MK=OU^>+%-@P;L$NR GVIQ)'(IVJ_A^AH9D\!\P$.,:,OE ]X+\2MA;O9.M8S MV'LW\"K7RH^GYS_/+D66^W$9C!"K_#$2"HXK/+OPVV"$P]@I! QO,@2S2->M M]CT3=3--'I=[Y3VTQ@NW1KU+Q]=5-<+VE#AB@KL*RVJ]K6[E],/8Y$&,Y>RO +'*Q1)S&&>9E $=S>V#VY; M;]+3?1,542DS_:TQ:+SAG&^Q^,)2 2^3+.]+X89ZXX@U'N4)<\]DU[=Q.: L MPJEO.@IB2=U1^VLI7T6.*D3K[=&++,/:N78XXLC&F! IE=N#8%T92@M?$RND5 =A.87C4!^%+FN$R=43S&[]W)'/@G1X_***0K_3_Z3?':H2?Z/_Q;$: MI@5E$QAE&E+YMO@#P;\<6<=]6@@QW6WEFE\>B&RT#(B>OIE=,?" M=M@A_;)65<>!$HZ,%$VKW!%[>D5)@ID5Q/Y1I"H^]04^<%\@I0#3R1"#)AL)?"EF;VH!%HBH4XJ MMII/,LBIK\HP<11+84/.R@@E9-.09CU-[\,*S"G"#4@<<$/R7@6E+AV+/%D= M.>]2/(C[-<[A&>WMDK/,2P8+<7/O$FD@+A/T8*G65$H8 AAK30@0X7M$A@*B M$I>(_IBL-]7]$?S[_A3.,-FKS'Q?CGU+:+/K9;_D,(JQ/T[HD*P7/(5QJ TB M1<"49F G#_^Q9=_;/; ,0_;F*+#%05?-X6 :%8QS6O"_!,F@K1-67R($Y[:^ MJ 5_0]9+W0_.*XQ=F+4^Q=8IME5G-RP!-__BV')!IBEQXXF.97^-N M8V1*@'FW^['32.BT/!Z2F81$'B@WU0)Y/\_Z'-D0DWF.K;2+\J*K>(XYB^<[ MSS;.%3Y.Z7P#*]Y_)/SNV0E^]SB>Y;'![TXF[J<' 8J#B; [<8@]R<^UY+X4>,T>,. M.@E&8C0( )6T."BV+P_L3W/UT-D7:X"X!6HVQQ!%R-] M(F+F8&1#T3GUYJWK\J)I^Q.IX2\6@\#\(D#0O&DD83&DR[2]R5".(G!'8)$D M6,5O3K/X2&9QIK=-6KRX0.UZV?8=$;!E37I%VBSGT?$1#;H\4">Z&.P$:'[B MTGMX0LN*JNR @5!",?*J_YX)*SVU.M$^19J+FT5_S"UYH\#H9 YHT MJ,[5J\\7_$Q60^ZT'Y%<(X9'NLI6])S\GM@BJT '=.12T!YU!X#1G 3Y=BI1SYB#>E_14)LHAS9(<_/KVJO9=[<) MQ,5U.P-(Q^RX%,JQ]$GT7&Z19;I;KH3Y';BJX+%)"C%0;T=$'M'WD".-"(IQ MM@1H%37(ID_H2.]5:^9> 8(24/@+'C=Z-%HP)"L6*;K*ZQ*M.:D*%L?:!V/: MY-RR\A,PGS'19)PO4D5K;HP-'Z">$OXW(@ -JT@4NVVP7F%^=W1;&OSP^7Y; MBK//>?$0M'OE6,/VR?=[;5%:1UW,7J^"IH36%./0'<_,][R:"B/%I;6 M&HL&JLSY%H68:D6ABX(D]3B 1Q,QE- (%GN1'1")I/$D^:[I"$=8)[7K2'!9?1^=_$#@T;/5@_.%__;C@Q%[B^Y-QU[A?L,ISBN]-P*6XF[ MC&X_J>9A8;!&=*-5F&>45JM*^-!JJ%W$2X$9QW#32T#)"807K&&KNT2ORUU' MQ$!M RBNUT^![(4SG^9"GUF SQ'%/H?E(Q>/(<^K=^P! L\'[.UEN>]3?KS' MN;OO";E4$=-21&0.G%D:;&/\H$.?$Y@PLVK\JH$"P9(J5 C&MM+3.<$[?%.; ME#S<+^I1X]U#/2W,Y?HHA_:V_F#MFR$;M_9KQ8\2=:QH\TD8/T)!IJ#&PF U M)9^Y $QRP\"KX&J"$NRC9P51CGV ^4GOR]9;[F8<3NKF:,>D?%D+'=_YD./H49T1T/,(/XQ7*C@_%Y*'2IIO]V)'X+2(CITO>N4?C M8T+#H$TJ4N@CH/B4&,PPB?J>:5 UTV_@Y,JG+6U,2Q3I#N'+JJ8R5(./B-PG M>N>)K'T($%;D Z.Q,5N6-YKCE%]ZSCC?VRI;HQ(]1G1_E3%:$%J\F&.^\SI[ MZ[)K;.>RYY_FNN#P69&2*D]>^.Z;]?/$Y_;X& M]^DZDOFD0Y/Q_\[3#LNXB@HS=UVGEZ$W=#!W>,- N4-\&FT,UU7.LRH/A Y, MN4-R5S/#:8PF/VXID= ME2&M70F!^ICF6TG#F,67:K$,W@WV^J?I=F=NVLQKM^, 'A+DP%I'A9$F"=2? MX^0<>%O?#]SM'B["GGK)B@XDCN%NY/)LOI!WNTOFTZY.:0-$=2MAA"[4%0/! MV[9=E6VWC6777\%RTNER&B() MD-3D=*TER[+CCN.NMMSIO&6!Q*6(&"18 "B)^?JK*-PH+'IZ3PD/ 9LK1S]BH&]E+;_^:@+@ M%_D,[D5TG>5& :K'3J1.16 M[SOO,B-T<:XJ0DA?B9W?]@ _>TF-KJ!QDC].2.RN]$];\O3T)4^2"4F&@[%@ MDN5\4SEA MNN)^L%&N/43/(!NH*[9 ,#PPT0RGH.%8-SBNC%K\T.Q8Q3.L?5P5=K2J_:5[ M#QCY(5.XX78%LZ,%ZL7(#;0BRQ+YJC3]1KM[SZ'?T9'*Q@E)>(JDK>\$N;\X ML\J8J+E[T78S[JO+UZ:%@1/:L)6&?LV-&WJN!X\>6/+5'JVGMC'(S2<#WC'> ME5]M*W$GQ&/:%%IM_HR="'SA7$%0AZ!,F4P9]JS=D2>^0$;X-DMI)\6 U>@* MBGLB8LH@E=&M:-MXGKPUFM'',,6A=9KB\I+%$98=M(TY3R>/5^D$IYHZ"M_@ MZ4/-S#2?#S-L,?WK@R][-V7!U63 M>Q4,IZP&CEN(Y#(J92!,Z9)"T]1TOTNL=4J4,DY0(\Y!Q9E1:B1LGWU3/(BZ8 M2-5-2,B38+(BL%B1@313^,G(!E-%)%9GT")Y6V#/'K('4O^8P6+&RM=DM-1I MQUK=%5>#42(CE^#)F!H3,3.V/W"M>0]5(F]=Y*6Z5.NR4%8ZAW*")J>#P[\_ M=T,)J2L$_K?\BH=DE+90ZKYC(4>6 /IC3EV([\6P?LC&(=L@[-X[TSK"UUIV M4%AH[CJ=OF(YX98SR*=\8OV!#;4I"QIZ4"S&B B.WY6!:20,<"0N]:XSK-^K M(X'+@D#)*:S[UA2U%?)H4(\EE7HC"G^:P/&)$XFC-<9:RE)I%E--2C2><$[S M[$;Q9%4;-11#F!(FUNOJPI O+97[X-^S:DVG3/@VE0+-[:.(YY2[;:G 51,3 M?P=?+PVX1K_HUG%71,E:0:I0C?D+-=#:;PM<-V,L;8'K PMI=U' M$CG+8JH.X2!E$X-O,[*\*PG5)=]"N^6,9O:7Y5S\RS\%A[TW_1ZUCH5,"@I6 M(C+<_?,P['>.40*GLGROMIP^-9HF:.,%.$"77 M\-RS1Q&U"A)A,FLJ>XNYRS/A&BNT1)A1A(M5C1,\3O+QQ)A^02VNG,' MR:Y,WYCN%\>1V%71DD,0KUNU/=\,E4R86, 103RT-+FF)G6>TUW3P#0[FANI MX* ^MGU@/>H%3^8J(=V9)^PGVO.G+A[XTBFC'!,AG]3,%=IR&-BR*%5Y*A-T M,3L9=KJ(F#?C,>>^H:M72$GQ'80LEAN G5;2=#3EV 6YE2$[WN>B]40U6E*0\;WM6"@2AQJ3*KR"9TD=>UH_O>*EO6Z+P'+_;%[(\-5<,H;* MXDM8GZ+D C/P0PL,#$FH!95=PO5<97/%L#PO\RQM2S:?N633#FZVZ'-/ONY- MS,=P0>?9_,#\7"G/61.'PW@#!G&0&5RD=?C/7(<2ZN$\:51?BK]IP\94K+3:I(PZU=\B=<DT- #( MYB:T=\! &0N2H+Z)"VMWM(@FPCQ4KQ3 0R39<^Z7[>VV/R6W3%$L*4@A\;1U M+"'6J%(X\N#H#1*2$E@OQYWI-B,?#&E-(Q^6[[!BV7VR[Q M)$%8O'8;G_J>8N%$O1S0KAPQ!>_4#LYE'0J4@%VZYYPZ^RR6PHM M)<5BB;UEQIM25U#C![!JO0M;AH!VU)OHC^^B!+8[\2ZC^;=5UF[I><"3;++X#LOOG?1?5'+UL,KK(2HX6)(% M%P-+K&KY09.I,7F_=@.?AVPOC6X*#0"F8@ V@W"& 4)QI\+"DZ#:)1P&]COH M0MM=_.%=K%<13PPJE>F3IFV6N-826$IXHR2SB!%1G346W$B.&,,#T39[/;4W M0*7MJOK9]RC.GK+!@8;&F+KUU(ZW9C+'L;QGPO258J@Y)-R)H MT:SXITH2:\V:W4%GE)?$)S8O':20[*]F5@U.+R(Z8$#6^ MG!QGHKQ 0RA@RN0P^%)!I<47>PFD;=D)(D; MA)82Y]?$[;6NJ2%RN16V1B,L:#.W% /#@@723'C,F[&48P M9,= BXHJ3>&##)HANX'7#OAM] V^]FV>%5CN?YT4.,-/OVGKG_]^(3_N,_D% M#H.^:+G (0Z._/[AH7_8"^\ZNQ.NPR/HUU7CNRWPX%JO+G^E*D&*V JP&]OY MBZ6QXLF4 '+F%/@RRBJWWY1&>=*?IJIQR;;N>QKHKFW_I:J<W?MDPAJZ+U\F M?_%MW-#0W,]9!5LF[53?+.EXWB7-FA';44Z*[[CQ=WZ5':\ '8;*B?HSL$/= MIXIN(5C7J>DAX)/SL0:$!X56?1>>@EM$X>#^^OK+7'C^O+'&CA0TU;47PE(F MNDW%V4R),' MK$TU[;:R.>PAAP4,"CC9 .%)BE, 8P-OZ#*FK(;L*>+:;+@IG6+ M@8!MS=V@N?NK70?DH% P2(8EN63O08,J)&S#R01N_C;B%[Q53)3)G)P.MC%= M A O6MLLV*!-L!I**$1^+K@9\^W"0Q5S3?MM,F->T/#P#\T7R!%R?-"++)5D MEG0',V9;Q3VX'$]!DJ.2"OH?:$>"_CM,O-NUE9<7Y[ZNUZO_3<*67DI1%1PJ M)^+27*"+6TG!>3:F>QB<] =4RQ/-B(I/ZR[[05\W12%P8BF1;8Q(=@3!^J7F MHC48BZ3FA&55J G& L.?+*T()E!4*M; "16KHE(U2)#VB)QQW+MQP[[>N.N, M_5:$<5@[ :?1R9=\A,Z=HU9&>>A0#):.,H/SF2X)$H:(6-9?0NE4@L.4%])4 MJEQOW5;A$-.A\$WEYCM6+;W;:KQPQ8)B0W +R!1"TDR 4<(&K^J!5?D!VP)P MM9 D8" [@CHAD3-Y7L!4!#)3^^Q14WI\KHQ>?%[+;)>[F$!;&"G)#%<5NY M MQ7JC!L.##:(*4XC[UDPCR(A5 NN&*C$A]\V2#*5EE5W5$VX;H?+H6$R00IV+ MHA:$80J;QC!>/_ TBIJ-^1I<;!(X;\O@RA8H$&M'CEZ0\"046 M'F%%;*0Z>:2./8,5/="[0XPEQ?UH+<1,@^<<7$P,@*VXIE.A.FWFRMRI:-'6 M>*M#4F7+8NWKB;>ZL@@.?38N8%QU8W'$=FE_]0T_+K1HYMI0 MO!0@5^865Y&*.5BW0%W[*;-YQ]EX*:O-;3Q^_;BB>5$:2U-'3ESQC8X\T9[I M#;R!PX41:92;2F-2B]\#7L4NK-*I&*\AST\6VSE/JU,D$0M@J,A>\ M\&5IX"DM,)$MM.P^JDX<\F E)FZ"Q-P6_@PNJ%&*19)K .LJC)$5999[3C ?\"./#9]OPO @KUK"@%XM(T0+ M%8K43:('2(#)"D,D<963_"1$P"R?V>=NDDRJ_O,'^( \;%'2IO?QUXT(#0SFL;/&C&4$8*AWO#&UZV1R')I9N MB+,ZYB3G*P'_IA/"7%KF?$YDBUH!@R@F*W/'&X9B&6"Z09KQGS3^[?K+KRAM MC3AQR\6MDDI%;KGQB% ?N#+%0V0H[SWCWFRDC'ND&CDWMGD9W>KR"KL(5AO[ M#X9+]9N+(_S&6@H"&:X@JV[DRMX#(,P!3P75RH0N]2I%GUJ-U5*S^;^D'&N. M@>]:^7&&/1>59)>8,PZ;E7%W':=:LLO!LEV/!VFI^8"6VX0K ^V?+&7T47?(L^T8%_9)S MT=@-^(3^G(L9W; 5%:7!3.2/9KZVH,!I1(X58ZE[/32X]O\+NK2($\6I7"&% M\LYMY]U9-\7OBO!@E+2A#1RKV#]7,EAT4Q/"F(Q5L ;?(1$"V;640=<*82[% MP*R51#99T,2>L#".V)C"I'%BHA^:G: 9\)FUF0HF$)"=\M@;ANBO,00RD -4 M:H$1ABL9F)/\\X;6%M\CA^/&FUNQ^FB%]9'W" QQW&FJ^,&X3#2+KEB,W$V/ M62%>KV49+)LUET(+\;4I)[ATLA&J\D"0%96BCLQG(M[,1;Y3=_V#) W57,PD MS: S5P1;YR C2U%#O2RWH..]H_6G*I1;2J\X%:IZ&?%@LFB 0VYMH23&F"0Y M2'@09\N<>"**"&NB?(E-#[(M8I7$*4IPOB@C-YLMYP8/C2UA'V$4.1;_?\A= M3[W_IK2"P7SL>D(')]\@\,/YZ3HX:8\Y7>N!H4Q="G\[6\G,(,$%4%IZL8-! M!4ED1K'2RE_\LQ7#ME70AF1"2-)K P"1?#OI2:T^M+4GFX%!1@)>Q<7$G MY[5=4JZ,>I8389Q=1#<*\YVX)T)1AU+VU(7L52I,CT,E%2JW"$/=]'&S%[[: M!4UM_/U7K=,?;I!(^X3%?QQ$ML9Z\3"5S%K5G'ZZ;)))8LB F\9F=**?=?MV^1J!&5 M/V9!:9K5#DS;#3Z'#HN(A7R_)FL/UR1H<;A+_^=7]Z8,@#%X]88I' M/0J3'!\@M0^!_OC5>6V>*4[2*&*M"B(H>-."!XO$4A3M7_O,$>.+#( M3I,YC8L^5%D8O!I4;SZ.4BD[:)OYS^;6='I\<\H<_HG5-\L_=^A/W3*N_^VX M,^B%:__:ZP3?^;=A?_UWWO7)N\8Z['5.!H=;,MA#,)&W9:PGG4&X+6,==@[# MX9:,];AS7;#_Q_6)MC#Z;UJ_M@FKT5-1_<8 M*@(UREU+\=#I@_WU@/FSI;E)I^'C7,7!T1%YN_*^8+@82]J=5=GM*_&9HH"/ M. 9;L;7RHGOO1#'.$XHZ_8R3;AZ5IA0:6O"L1Y7OGIK65BW5^RR?/6!M'C3A MO5JXRXMSEJ'ODU3VUGS..NU2/HU>;M=NW?TE-%OO750VJJV?I*)@H9X_2$3S M"SL!H5H-?HJM\H,+\!(EO[U-#_GN6:J\W)T[/OB/9[MLFS9W>/M!/QSTAGN[ B!Q]W;N)]TP MZ**XV$E=VG_&G6V5Z-,HT>_2H;WCL-_KA6$7E&=?*L_W&1:&>F>,E$!:\(N@ M5H/8.\=]FS G,VA2-U*B6\](77J_3+K?NA'^"A%1/*RO+JEROZI,7^+$O^[L MN2H/>@=_VUMIWNKRYY3XFS;W(.@>@2[O'>^H+@];7;Z/NCP(@F%P-.B1+N^S M+J_H:]+IJB&_U?/[(.Q:EWV_U7Q_;^<^[(:'H.:#7779GV]G6S6_47'O7G@X M/#D,NO'18'C2MSSW%]?VK]L@>:MQ]UWC[K%CW>L>8Y"\MZ,:=]!JW#W0N*AI MZTHWA-\=#X^Z<;\W[ V.+:W;J%+?KAAH8])FD%OEV"K'5CG^.N@&0U2.X4XJ MQT&;0=X+Y6AK1OY?4(SX0]@5MP>#$'%($A@MJ\9+^@FTWR5AAUE^9JL+*07; M*L/]58:#9TS4;=K\+CJ"HU23_ M99FNN$N$"I)[?2^:9?.K1P1=&;9"0M8C&!-\BT,!T.K:MMQIWW7M_N9!=[O< MZ3EWMM6U&Z1K@V$_.!X>][IQ&)X<84 VZ,F([!>;97:-VKT4BY((:UGW!L1^ M%@QU-] CU:_D02T0ZBM%HE?BZE-T=]X9$D]%^!,^F8LR:Y5R&PS>;YT<]/8X M&GS2#;"?*!CNI%+&K?U3VYV[_=J9E"J\''7A;30:72>LXP6H?\\-)'U5]>J@\UQXP=&/J=US M&HKW&XXE\C[,1O_>\5J=VLK4=O[M_'=7I_;_M56F6ZQ,?Z#O)@R&O:.C7C?N MA^'Q,(C%[[@VX!3YN$-6MCX2GQ!12X/2):V*S,YOD4%:7$5I MZH-^[;QKH\5MM'B_H\4G)WL<+1[N=.UP/^@$?VJ5ZA8K57%[T \"/*"_A]56 M5-E#2@IL6V?S$<5!LM53F&WW#IQ/$S'Q+F[%>$EI@[].X'"!Q45DV!&G';Y@ MICWH1P?!X)?H]4LCC^P[\$CK!K?S;^>_FV$0L-C"UF+;>HLMO--B8Y7[7C,N MWJ]RVRA%*_;:^;?SWUFU%[:!BNU7>^%.!2K"[0]4N%.8;?7HM_OX/"3*$AQ[ M?^]<=LX[WJ4@*GO90-$?]EK[K]7_[?S;^>^P_=>&/;;?_OOQL$>K UL9V,Z_ MG?\>ZL"@][) ;T]#J?K R7^="F^2I6EV R/V)EI'$.@GUOT5WB3/9M0-?I[- M8(2K/Q;>WY917E)+VA>QR+ I;>XAN[*'H"3POIR>_YV?\AA,E KT^SU5,XA- M;5&)%84)E@KBR+S_?OOETZGW2_(:O@H^,R\0R3N;$V4M8Y!&*8Q/>)=3(BRD\AU[@IZS@3S_TXY<6^,P?O8O?ETFYPA=(FX\?Q>5$6B-5'#+>)-V96 U^(((?D-_E(3TH+F#UZV>:.??SK^=OZ4G MNF4T2H6*^\"_U,AJDX&1T[/J@1'VTN8',(,T6A3B5/W/FS@I%FFT.DU(+!W0 MA][,HOPJF1^P+W0Z7-2E+7X?__G-31*7T].3D\[QL/^'5UJ9R2_FOP8=G)?> M'N=O@\[1\'#M7WN=8.W?[GKK2;_3&PP>]-I=4<&/"1UO_&3>D[^$6&8W23GM M[*3-]'CPA&T(8IQ+I%@P;"8)N-(E.LW)G(T@#(([%D\Y30IE]O@>")YO\/O1 MRAN!'?5-@+].SPCSR!2=;6QLS&8)VE0^_#2.EH7PP&Z"=\'$%O*5<+^-#PX/!Z=1&(P MB ^'HZ-1, S"OHC'(H+K_3]!.'BE/C7-S5G4DY5W M7J#:-7(-T<,FL_W)S_51X[F^_/CA\]G7OW^Y6"L"UHP]P?!R>1H>D,(C(8_A*_IN V/ ]_7^8@FP0J[O$49:=W-B8LO."D M/_#IH2]&MZ+&CI?IRB,U';/*SSE5 4,8@9,"V\F(MH@M/Q+3*)V@$8 OHJ/( M#_@,;KNP%:;32<<[?$X ^,=*V+D&7C]$,LI;"VGGWGHWD6E>(SM M]//OW"R)XU2\T/21#\T+C[GR[1$IMN>,Z&U,\.YX??"N.\KB%?QG6L[27_\? M4$L#!!0 ( (&*_%2+,.Z%X0L #IR 1 7VZU:!PR$":G);)%DLI>Z3))*LB_W:4O8 E1C+%:2 M2=A??]VR 1N#, YL9=>9FDG 5C_=ZJ?5;MFRYM./+^. 3)E47(1G-?>H42,L M](3/P^%9[>>G*^>D]N/G#Q\^_N1Z17WVF MOI&!%&/RJY#?^)0ZSFX MY72/C]N.-_"IWVEV^@/J_C \]4^Z':_;[3C'W8\#ISU@'>>DT^S#IXY[TG5; MK-D\,: OZE1Y(S:F!#H6JM,7=58;:3TYK=>?GY^/GEM'0@[KS4;#K?_V]>;1 M-*TE;0,>?LNT?NG+8-Z^5>&->QUXU. MJS$70DAN4<)#I6GH+93X6CIZ-F%JO0R):(^4,*9WLI#DM$VM/CNQB02I.W6ZW6W_!P%MOP=H0,NT=_.BX M3:?E[J!V4RP6UPW?G+G-K4RQLDS3?54$SUH_7@DZ8 M"V#OCW=1J)AW-!33NL]XD28Y-)CPL M/;#!/(OEDO*:H6%^G5+I21%L&4?UB103)C5G*IW0#T M?P26S)OD%&1##T_7080%-\N>S&61?8 ' @(6^^8M=WPBV:X=!Q$%5PI#]-^^ M_QX-=NT_B'A1\,_HOL\&NW8?1'C(2_0>I9_@/.'^6>U"0#5Z3X=@'1[_^>%Z M:TEAM"_EYN!S^*5=GQM0]\%?XBSK6(<828*BG^JK BM0D6+^7?C9?%Z-]D0X M:6(17 F3PG)9_ZX52P[.'6IU<^BS$(3A@Q(!][&8/ZCB"-GS*;H3:RQBU*["3W&HTVL5(7FHA8D R>@@J M>J=YR<*C%MZWD0A\)M67/R*N9_OF>8T&.]%MF$>4(3JMZ-\D5O5.=6K 436Z M"L3S_D?R MA.['&CT2DU@@&?& 45HO,Q&H^IG(F!XL.0#^#Z!%WQ/!&%FH?# M";C*@_IZ1RH+@EIH;+H-UXVK6JZ\0*A(,N0T!D:V4M!DB4WFX.\4KGC[_I!4 MWA>AU$S$7D$IE%')IRI54,4(>*+]X$#<)M V9EN-5NMUS,9*WGE==7[/]XU" M&ER' R''QNA+IBD/#L.V5:$M!MJ-=OM5,>"0I6Z24DZ^2]2_1\/9VVN3%3/GIB"QQC EG: M0&(CWB-F\^5B+*3F?QI;O[Q,<(YUT*O39G7V"/G8-G=U7G%M2FDFB>I*QL4# MF[(P8K@PQA.AEM33"A?,>)'28LSDKL1OQ[-/$T_<_)4CP8Q7[RQ0XW4]"]QW MSI8^+C5]*(IJGSET6R7YJ^*D8:O+%VGT0@0![0MI#(8JZ(9[F+)Z0\G,':\$ M2?5GRY9"ELO=?Y55UA3O-MKF?FZ)0,I<"C(FFOHQ,9(LK)S#*M*?D;2AE;P@ MW#"J=LX=B9 UM<.??%D7"U;.O:42=$;4FH5=O(6SWM553+-QS_=X[Z4 H#VY MM=KFF<8Z?M[OF^28,S\OA-*O82L'8F>H#9.,C0R9#P3!*LS*H@I(+\#8T] J MBFWG\+C=.-G(8:I&R"SOJ/R8NV4:O*4F4$J-J-QUD=NJM+TDZ+CY>3P@$(0@ M@$$,2'6=7ZI.6(]A+Q@^MHH04<7B8<6;Y;+:!A![^CII-[I%.*E@CKJB7$YI M$.V:G99R]KS4=?.33Y0E1KB*CBZ5B5:EK3FHV6C9G%[%W+/PWZ(>PB._X)'_ M<":I]$9P+'ZJ<4&EY,RG>M&$AOY7J'; D3Y,)AZ8%T&+<'A.%2_Y_.?P]E@S M8M-MNPU+A&2*.G/$ U\C<"H5,.+S/I"VIY)+U]2-&-\=7;O:5$-:CVGELM=W<,X--PQKQ MR5)!);F\#J=,:;QU#?E*Z!&#_ 24,"P,@:$=.=R&9JV4\$9][D[6$M$D5(-) M8E#R'<)^_P,!Y'?&YCXN55P5P[277,>MTNQ5L1[;XO)R.;0@J#V%=MIN[H9_ M82(KFD)#+>3N*ZC3DO;4^-'-WT).25?3VZ5375;>GM9.6E;/5S5U)=TOGZ96 M .PIJ=MV<[<4,R14,.WT/$]&S \X[?/ %+ [LK &P)J$6@TW_PPD 2$IE$IS M4"HG;82QIJ86,%*$CRJFJ+Q'RV6JS3C6A-7")X:%J*E@XGK$1PVX888/;L;5 MLL:>71<%KP>Q)["6FW\*8H <@T324)4GI-Q[8S8H>S9KMXJ34\64MMZU)9?4 M6['LJ>VX[>;F^9MYJF!^NS;38DU?2LQ-EI+V3-9Q\T\O8FEBQ*OI[K*SD1R M?01\;+MKIH1+YUX'U O]'%VP! B_3K9W0 ]C>^<89-[R<8\&@/+M*_,^PIGM0$-<&L[W.#R MK+9?)2''UQ=P)SPM<76,V#.CV12N\?G^O'BQ[,::/$Y;N 9 M@:%<1]CH)RFBR5DM;LDU&]=(O$U>?&0L(#JIG%W#&41?[J>9\^4#1@H8=A[Q M +=N!JMQBZ6 O> 6+F LOM"[T4D%I7?I?:%N+O8V/H5:B1;H)G(&)N'KABST M9K?1N,_DW> >"$1%ZHH'EFX6E-Y[-Y,CH89\(POTTNR9=*T4S(PO(UP<<6]T MFXI2F9-W$V/PEQ6II+Q\MA87 MD;?XV'U#&)>!>K-Y_ YLH,B;64C?"\.(!E\47-&-,0I&J(>Y>L@VNF,'A .& M_R164RBEA\,G)L? #ASG4Y-,E'T4VV7^)J,:0A7J+#.(U"O&=A;F4#FXZ+B^ M@/H0=^U\DIP&/=S=),"]X_!='G412=S7QI!(J'HZ=G\3]&Y7RWDGC %YS/ MO4Y%>3?ZK'\X+R8/Q0!0J2=QBVN4?)B!X0C!K"AF-"@23;O"O-6@NA4A;D35 M ].GAO2DI&4O^CR Y+#1 =L%#YB"]5Q+D1*(*<58MG"+4^*3^/*B6>C'4]7- M$]O" #N0?)"I[:N&[^)5A\-DAQ3\&\T,4.]*Y/:2Q;^O0T/U_!(QV^B7[8)O M]J)Z3WV/3>V%5;;-6RBL>F 0U,Q;YC&KK=Z"Y?=0<^-<>8#%ASFWS?>;VK^% MWIB;6>?X$/8B]0RV)R5-C#V?+9OZCU3B;>% 2PV+RY7KT00B&?HY".; MT+G=FRK> ZL]T#1O+E0H3(S14%GTO#\B+AE>@X2\>PZA?#?O@&UT3A'1-YN. MUEUJ-^RB8&ZZ;2]37H'X5]^0MLU\]G/S]B/]-D>S.(\-;,O/S_[_.D-L<_^ M_LL//_SM/PCYU\L/[_9>S^/Q(Z]:\ M(>]^:Q<'>'PFZ/_=R.S_<^V/> M_ME\]83\TO_1J_G12=M\.5CL<FWGZV^_OW:][^)_MO,.?>\ M_^W95[OFIB_B9=GS?_WV[F,\@$-/FEFW\+-8;M U/W7]A^_FT2_Z.;\7U]ZM MWRCOR.G72/F(,$X$^_%[EY[]\L/>WG(ZVOD4/D#>*S\_?WA[Z98=2G$QA2\P M@T43NQ_C_/!Y^=[S5_-9@ED'"?_3S:=-*M)^Z:=E(!\/ !8=#J>__.+D"'Y^ MUC6'1U,X_>R@A8R?X65)D3O5@A90_[G&59^? X]^&H^G_3R]P_>K:Q=XPXP! MOB\ _V(Y=Z<@IO-XZ4O3(KEY>_J74Q]@VG\Z.>[(%^^/)B^Z#B\]H3$Y;CTE MGHM(9)"9^, ,899!#,)*F?3E^2ICZG!0O92S[T(OZM5EGY>)? [317?Z23^U M_;1>OO-R"K?%_^JX;?%!GSCJ'*,2GS4;-9$R)N(S*$*3\Y"#BERR08:Q G!Y M-!_,V08MZZ]G>-RA:9J7"EFA\&Z]QY?(#M/K&\^[X\+"_)FD6<'CZ M]T6?;2W9Q;S6Y"[%AY"WE>_[=GX$[>+D/3X(BQ>S].O_'3='1:G_#HL)#3DG M@9H$>$)8@ K9>R&)B,Y(3[7*4506]UUXUI$^?SK2KS;UU'M#'V5+TV8+D%T2,Q?O\?I!2\6)T6#1?<^*!)TT2-#,VT6#73HC7QY$>K^:SXYC"+ M"&WB-'?&*R"^$%/F "1(*4D6$ATPR%R9VCKB#CAC"H0&94HN3"R-U0@J:8B(NHN2DYY8XJ0.)./+B MR](X\-K0#:!&ZD-MR(^[EXNVE4G=X/'FT8(V7BJ52!(,"/IVDC@M@ @P+F;E M(/$P1 3YE#RJ6N2H(X4A[20Z\0R2+"M4D2([E<(0-U,2(L\>O(XRJ!W;R4UV M3R #SNO2K/W33X]ADC/#>!V-6&99H-PT)XXR1X %P,%9(:%VS' #C#$IORVE M?WW?9+M)KQHAS&<74%!(.*:<"7?6$FD2>J-1) (F.66]UUI#9=%?Q3 FO599 M[EM-=S6AOTBI*6/WT_>^26]GK_Q1L_#3"^ F2FKFDQ>$"8^:6P=%K'>69!^< M8D'G6'W;]'Y48PH2*Q.CLDCJ427&X\,RRY!Z@XR CEHX@%G7?(6WLS@_A'?S MKFSE[.=/_OLD!V=ESIIP5&=$<@3IP I2EC>DSF7=MW;H^$"(8XHK:Y-H0&%5 M8]0'6/AF!NE7W\[0]>\N@'X-N8G-8A*RLY0Z03*/: E-,#@'7A&9'?4*T!J* M5)E$]Z,:T_Y<9=Y4%DD]Y7,IMRC3E+A5D2AJD:U0UEB$521:F[WU2K-4VS.Y M(W%K U?+=P=ER0]_%)E]]=-^$7#QRK?M"4[[TB%0,0N=LB4L.T-DA$BL989@ MK"NI"R)'5=OU7@O8F)SQS7EQS1^K+I-ZY/_J&_QX"F_F[4?$]1$P_.TCX=<0 M%N?O3J*1D625$!D HM6 T=O.?J5)@6\];T]*KB:7C',P0!A%+U!RG8ECH10D!,J]DPP#C.H9<.?W M'Y-37D_F&\]PQ=1H.,)X\M?O1Z5N "W=A5R=TQ$&$P.:-T>HUAJ!<4V\YVCB M-&@'FIILS8=NIOT*#OSV_.DOO\/T0A8(?%_C:)^W,\Z55M;*>=AG=%H6#=]]E MZ$+"!XRQ4F'A6HN4,OD4/5I"F@#-;4)+Z%CRQ#) O]@6#3)(TO:#EI'KC?WS MK 4_;?X-Z;_GT[XRPC>SVF:>SA=ULV4>HB0R MEDSNG#D)#!6L\MIP+6GPMO:F]%!C&9-9K,[5&_,='IL0=7-H;IFN-_,6)39; M&H!X\JGUL\['7JZSU+];23G][W&W6%43+L<2E?#! 4=WH8R%Z40"=Y1XDX3C M2H!5NU0&FX]D3';^T:B]0S+4KR\]'\+$8D2ORVY(\!2](I<4\30*?,LH1"$0 M9NU4ZAM@;+\Q]Q5FQ_ &^5'2DEN4PA_-XN 53CO>H3TKU2O1*OY+101*"IXD M6)*,'*K@J@7?)2,PP"LQ9*N>RJY]M>Q?! +4R>%#.VFO#AQ,X8!QH] M$*=$(1^:%&=5(#A0H\ :J7AM__1NL6\VIOU<*ES[<@!HOS81NH_HGDUB##(P MDPE&M8I(CR%MP#"6@/'>9\&X34.,[F8T8])[6_'@)FI7$$#%G!8,M=M8MI)? MHSZ>SOL>&*NA(B1A'8NAY&(D=)UD(E;CP*.STD "&V7]=)8[ (W)]ZQ*BWIB MJ)I,-FUG2+HNJ_PBDV#3PX1$.0O4"0P S';P,Q5"B9 M(QB7:]<5K(=L3)NQ5;DR@&"JD08CG L^@*;6&X\:31B-L8Y2EMB0';'21J=! M&@:UU<BLGM9D=X]2O_)WYK'L)&:/ Y??0/X7NU^\H!F17,_/M MR5LD15_]4=S;>2^UM[,%M- M)MP)RK,4J.U+OREK)7&T+"-+PZ6,*L4!&K<, M-IPQV>O-.7A]%WP<\J^8.+$"NE(2+U&'Y&8Q23DJF@/:%E9JG$KG*V==1O^: MFR"X NIJ*_%;H(PJKJG-I.TFOC(+AJ$UQN&LC\^$*ZY*L)IXZ]&)A9"]]AG0 M[#U5M;;^3)==L\DRO?E\I?O-U]^;TQ5PM-HEQ6:Y++@$5C)MOH4[T*<@R[SN@R*EUHM(?'V M4GF/QL;AR+,T.LF[O.=C=,Y:SS!FML&@=\;*LC.WA%FG.7ANDJN^ M.U:I#G!WJV##4*2Z?,:1@.6[@S?3^;>!$J_.KK[3A*N;QU0IT:I<_4J-TP>T ML6T3$<:J!NKR!Q>^N4PG0>*TI4O+:UC^Q/?+C<5?O\<#/_L"'W POZ(5C8N) M $,=U9*8"!B/26N(2YP34$(ET(PY7CN;?(9J?%V M=N:VO(B+YFOO'T^R9MED0+L:("AKU CI"IGHM[/KH1F5FQ\OQ M&RSW$.*ON?Y\$[YE<'897]0*(@N,N.PCD=0(XF0 HF0(P5"A1:SMQ*Z/;E0F M_LG3LHM")I=JM_M=']VH M]M:>/#VW%7\U>BZ'N)\O#GM_MM4$3X*GQ@ ^9UJ%TB:HG*L2,-B3.(E"YUP. M4ZC,XP&&,:8JSR=$^,;JW8DW M]2LVJ,KU)WW8]VG^(J),6KCU&)V)S-9)$1EA!@-_67;*0E")^ZS+)*6J:129,B_[Q MC\25)'J/2BEXP[FNWF5F+6!CV[A^%$9M+;&MR=1OU5W#]0ZZ;M[N?YM!6IT: MPB'9R$,@65")#.>4A%+ J2&[H#+5YFJSR%MV6N^_UP.=Y2?-C"&FO^9I>Q$@ M]3M^O_G%BI]]8X.3L[;V?CKM]O/MK7$F.@0'(1HB&47=Z-%'1Q<]$,]]HDEY M=(AJ.[15@(_)A=V5?MJYP(=V.&]::!/!!RY20M5:\L8S+741:+M-$-9(T$;Q MVH3<=)WUX?/PXG#>+II_]Z3:SU?/89L(ZP4-.A/@&))(Z3WQ1BNB/-59N&QL M=6?[;D1C6E<>B$/7NB/4$U'-%+MO^\0<0$\:&+DA1AH:P$,LE) M '17I"TE1]Q%KFIWBWD O#&M!.^(4$,);T!VG?;+ZL_"X3&J<@*X!WQ9UO%P M:XG)9>D.C5G2M?<0[P3T%/S/X2FTJ82JD>;UJF_^A8RR4B?NO[_"#QM4E#ER MH46RI5:#$NE*&K"SF>@HA8_*.5']E/+[,#T!G[$VYW,ET^=F7 I M35(F8?A4<&F?B#6@280HP(%T--'+S+DEF+WO3@]L;?>D54G]J:^W3W-#*O*' M5:N5TY3DB0I>,1<88] M(L\#W\)+WZ=W'9;*E'[6)HEJ+JCEI-R82%Y./[+,$JZ"DUDSI7CMS>>;D:S# M%O/7,D 51#)0.:=D(?#,T6W*"2U?+'O2"1TH*I@W^#M!1>TJL0>G1MN_%ADV M%T#]>I+>\GTH<[N?<;1]>'\Q]C\M/$XY>>^CQY"L!&+48$BFE4%_R60A@I": M#GL:X?T8UV&2^VLQ:5 QUO%S+W>=OVH@2Z%[1"^L%].E):?73;?LSXE?>=_" M87-\V$TTQ_C?!DLR.NPX5U:3D+PA&9)RU@(#:=;RB6NB6FMUD/Y%O)_'E>F MBSVK5MBGD>*-+;$G3H1LM,3 (+A4=@V 6"& &,I,UM&@*:_M?F^&="U./G8N MQ/#K0]6%6G'AZ*B%V"S=P*B84-)20C-W.'**;J"+FE"?0F I'_=S'WMWG&;(210BSTD^IM&F[,20O:7/=6>9L?[#=_E%?.EZ:S2M9B@MT M]&6-N+0JU.BW:)!"\H!^=*Q_,,F WH"N]K;,OBNW)'')<@N*E<_ELEO3^:Y M:[[,FMQ$/UOXI>3 @_XK%K#K;?6^-J=VY_ZM>GH%[0 ;K9+^7 M2'U)BLVE'R1(0SS5!I@ 8ZN??_% B&-*1GH\R@TIU_$8>W2H4 !3='#0>[F< MTS>XC5_CWCLW[0^=CTH6?7G;=^6V5U,K2XLQR0$+9A<&M=]2[?K7TNE["_-XRY4J&KMUL%8R76P^Q,]B,N48 M9$."M$"HU"$FFL!"[1Z!UU&,*?S;3-)WIR@\>*:KF89_^K8I*_3G,'@2H&FF M1%')2K-N=-XAH\&R.!ZFO4*C55G@UT",2?G7D?=V\[P[Q7X6'[STT[(,_/$ M2EI6GK?+R=I:WZ][@^IF8*.1U3I"]=+3?IY1[50V*KE * T8F0OC,%JVI7.R M=$X9Q8*NG3AQ"Y2ZEN/LLN?'!QMJ8C1$^;Y[)2CBI#+$NN@U^.B3'=:*7$4T M)HM2@QUWVY>MY#%0=N49IM)9>@4KH;IP1FG"F'=%PW*$A;ZO]#9996/65WO" M#T63I+;^MBV[KJ_L[[G+=2*.=U-K/] M&?P/^+8(;;G@+9V@@M)(F"Z-GT%+$K2DI0]T3)XIQW/M!;GM$(_)\@W"OVLU M^[L3\!"YX5?AKP"?O,@+:!'MIX-V?OSEX-.W><'=G0-77"@>8B":.53;D;IR M EO&V?.!92]4\.NU_:F#9TQV=%#>/98,J_EI5]%>&SK\%QS$P+MT)A [4TQ1DKITU\%", \_)^6I_OVK[>=9>R/Y?GJY2 MFOAG:Q,3(J D2U$3)$VL!']6&SJ#TO,]X#"_W73W& MMT(OQ2KGT#G8J",(PH74)34X$=0Y'$?BC32&6U7]6-PJP,=L;D;)V,W%/AAC M;S7+,MUWXH_*NBO!VL9QP?IJ= MGZ5YJ8!J^C+D*3X0^-TM5A/6O'+%Q81-QK+E6L*F!P8RF\%':U#NKC2802?7 M^XAQE;-"L,15X&&M\&3;\Q\?KJ?NNN/$)Z,]M99PC!")E$&0 !@Y9JU-3@89 M[FHO"-R%9PSA_BXHLDX?DHUD5+&R[?H( \TZ2R:)2SZA<>6&A. S<52&'(#3 M5+WN:,/S4(?VE1Z#(]M*9%?6:=7+;4M+=.4JE:W.71@KK5:?WN:DR D4.@Y* M>6)U+')WI:*0!9*9099T_3/ES^]?0QGTU_ICWOY9*K+G$5:G_7V #EHD MYH2B,P3"*1)T.3!;:D];OA+;R-VR]6T>E8$W&MG?+EW2ZT8SY-I>$> .DF MB(4 1+KHB+7>$$C9:70=0PJU6X#="F;KP!:E.S\!I$^_0GC#:+6TTCD.I9JP M/!<)'67-2S=0X4*4Z'3KVFKD7E!C\DCJ\.1:,%M5+G4/%O]X/$OMR0V0<@[, M4:X(,"8(XM/$EW"[''(AR[%F)M6.;>\$-":79!B:U)-'G42&U2C[C89/\]_+ M^F,ZCGU7B%*P.C_QTTL"6R-X);*?-]IF>#^X[) M!ZG+BZ&%4(OCXC<_.\[X\[B]?.[!*3(3<,#HA)$(2I2-*(8J+I6S M-I),1@B?!%^+'FO><$P-X0?@Q1#37HD0^&F#\_VIQ%=]97MO]&UL[7UIWO_X>0_WK^\>V3ETVC_;UZ]=?OH7) MZ)=FG7W[Z>+KWY:^_U5TWV;.N6?=I^=?;88LP3@3[Y5N;GO[C;T^>S"WG)W'2C. CY">+7__\^&89Z7 \?9:&)\\6 MWWGF1R-$W%UA>OH9?GO:#D\^C^#LO>,)Y)7HSYI<0*D"Y_^6JSW;&M,Q IG$ M60""[\*X"+PBQINNOCWF\VN1!-G/1M.*B)>O715O<^*'-0V\=.D*:+L+D1,X M"3"I"?7*=2_A/ -Y'6&Y9(O=YW0$1S"&Z3"VO\3FY%F'\D4S3MAR2/A+VXR& MJ72SAU/\6?K=MLDOFI//$S@NUOD";YNVO;LI+=Z&E Z8:D$[S/>XRZ6&H8*& MXV'IE-[BR\6M"OK=-!&^30&OD)X^&:;?G@YY!A^U\%1[+X7+%@(US@LJ+,^6 MQ<$][E?:>M;:41.OW'Y4.N3F7$$C'V#4O3N8M>3(^\^#\VNC>> -_MH.HJ84 M:#8$!/Z0V5KBI/ $@A-"1_S'TK+^VC,]9]^&3H&+6SPK;#Z#T;0]>Z?CM^-V M-8HYA_=OUT?X N,9M >AG4Y\G Z2LZ!#Y,0Y&XETVA(K%8[+*6CFP07/9.56 M7<=PM4T7RCR8G+5N\?S?LX,H7DU5=J=-1:/.F<,&/'W23!),?GM**Y'\&MN- MSTL'Z9_HY+V8M=/F!":OOL71K/B'!VT+^%_ZY+\-M$U4, ,$O/)$JN1)H)IB M"TR4QD6OK>M'!YO W+U4MN/V9J'T1LRREMBV6GK1M-/V8)Q>??M<.N +.V2! M]\XJ$1\M(]*&0&Q$8_C(. M6P ]$CG4,_JR(OBVBCB$$7YT]#N&!A,_0H@'Z03-7)H]11?\#*7D5DM/ TG6 M2"(#X]A^HXA1-'"G*?."UW::UT+V2#32 PW+8A&UG8A!9,[8A&U4@0'B@81X MHL:.30!V:];JQ'IV'AZ) +8R[3+5XK:FK3@*E.FHP:O_F0VGIX<09Q,T M)+2OO[P;_HYV*\]W=+_RYLW4.??R'2LW!W.)ZA>!Q=@Y]BH-QTH]R;\10FV,X!2]SDR!6)D64B!8YIP4,F 8Q) M/*'O$VSE#J7'YGRWRGQH5/F.*P"^>Y;O;\YE;O6VW+[RDS%V,NT'F!P>^PD\]^TP#B2ZVDY8 M[&HT0I&986RMJ"$I !U$4#7CE5O!/+=<[V]>99\[B.W[V;3D]I15E[E,,8[BT>&(PSJ'(TF&#H?@)&N3;?(IVEA[:F(C M@-^]2OJC8UD[KB?M+)2]A'D@PU5L0XB/ M53]5*+EAZ63KU?CSYK_/T#:$.)W+Z$^*;E!0ELOOUUUGC7'"(CY0$!)1:0.@%TBODQ*2)%3 MTA)J+[?=$HO<8XIX>@R3&\Q=KHTW>I\Q%D078M@D?'\"OH67,/__.2%>2PP. MG2;9*D$DUY&$*"A1D)CE@GKG3&43;(]ZCX]-'SJ_/CN]6U9[6-)C,J0->Z6E/6.Q5%#QD=MYGU=3-!'VO\8C:9P#B> M?IKX<8MV+#2/4_=JU$WK'J3_GLU7' " M2U[7CI[Z:]>$#OLTR\;=9"U5B)G2Y0J6YA$$OA0NDBH$LE;R#9"W(,W M\5."VY+52RK+$KP+:"XG*C0E261.I-226*^!T,!]8BE(&FM[I;? >=SN9BT> M>I#(N1D^^3"" 8M)92DE85Y(%&QDQ!L<]QFBHR'Q$$WU%+@K""H*X=(VP=T% MZ9N;\29_ZO<=2TD'Y[.IW,X.+-9CR%;]-7H^Z&OSUMX:C\R/S@,:*.;1R]6&)(_NIW0TE>8!8I,Z,VH=(JL\I%\! ML#O7KB(I32V+]K%CLCGUH^GI DS2PM* ,46.)A(9M"9.@20F>&8RS2J;V2 ML@+*8Z"\AI573@']_=DURV"0\5??A1H.ITW\Z[@9(9!VGH%]%6>E2@TWW&:' MI1KN:N2U6@V2)P4&'UF7I#0& SEFL8<&'S@$H_3=M1INN&'U8@U>Y 1@%$88 MV,U(HP)Q*3J,/B$)F:@WJG99@_K%&JY/LKT9+YON8S,:O6XF7_TD#3P^M,8Y M2K0M+6?"$)ML(-DHGW@N0;>JGY2\"<0'D3FPB39N2%;NC9(>_)H7SX MG!@CG- F<.SF*1CLZW7QN70F42W6NC5S*7YROK,-&#>[3< MZH$-'LGSB?C$<,P.AA,?A2(^!Y-T@JB;"YK%;KK%CMT63/6QYVR?[];=W#BL5:"V]2:H8#)R-& MVK*J$C,)(I95%>$Y \&HVD?.U>.6275F*NZ1ZS:F=DU_T[8S2)?37.9C7/?A M^\_=%L!7WV 2AQ@6E,WJUIP#=YQ]FDWB,9OPP\N,!%YPI#XSM"_/JP?3XD[H*^'+8:W/E8?H9U.AK&;%\&O'12[=;TY MVC##<#K#[PR,CUP9$TA0M.Q\+H7FJ) D2!U25E+SG/MPP;]@# M>9&?UWYJ#E+JN/&C#WZ8WHQ?^,_#J1]UK2DUIKO4'?0YNLR^CX"6;(=36$SM MSEO^$6)S-&>X>TH'G)N2G26)8M2B'TO1NID#.K,R6Q#*>EAK]7,#S?;=ILEB![V?MXZ[:*9H!$0F\PE.\EY2:R+E@ Z,#X%8Y7M(5]OS0FP*M,XI4B& M$=YA9%!*0'DKB4LY$ZJ2Q8Y(41]JM_"N:9RM\^FL<\P5?9IB: MZE(]0 9??5[BP>33;3-UO849]YU/M]2$N;!*=]2,2]_5)9U8R:U53!!P7I>T M3X]V00NI #8GZQFEM6MTW KH@63<;43T*LUL;? >IJVO85JL8*\#:I/TNPW4 M<".@W:;A]4#<]2(/U:R^,TF -A;][K*\8@"?@.Q)",*2I*F-7@CFH/9BQ@ZE ML"(W;U]*V,38O92L/G>P%NDG.4?I6<:N$X,O(H%)[/\@$V&"]I9B#\AK5Y]< M K'[(*(".:M7,.]AV1X6MU>$*PMPE($TE&7B3&FO+A.16LMR.!6&28 QB:J] M$_%60(]! O4LWL.3?Q#C[&0V*ME&JU9-SK(100+&?F6!Q$4B$5XIIFZ(*+44 M $-4[:K/4JP+[E'(I!ECP_@A3;"NDL\)59PF+7JL<$A >8CGB@VKBP'%$ M)9-VWF4<*VOG_]Z(Y#&(H8*-5ZYX]Y$4>C@[.?&3TR:WPZ/Q, ^C'T]]C,VL M5#4]^MR,AK'L[#_O"=^,%N]9+&:UM@FL9I#8KL()E M[0U(IIQ7"7^A(C.3F)-N4.'^VZPBSN_^/A]>W/W@_.X?%G>_F)/1COKLP9'L M +V@9"D) B*.@D)2BL&URN(N^N]SXZVS?1:%LS["YV8R+5,%A_-9FG;@G(Z! MEE)K5F!4H*(E(25/K+!!L:BC3K6S9U>CV6%J?-_T+R4!U:&@C\31N6?7E>1- M\\4K'+A+_8?T?#9]UTS_!=/B PY,TL9TQV&9,B.9^/$&'XI0A\7D-D.A!6LUCJ-B@1$)@+@EAF/4&+2,>E M,][7+^&^ LPC%DH= GIQO<^6RU_XMAQQ5/Y7O,\O?M3-3DU?^,GD% TR7T>4 M@I8JLHQ05_:- ].E!#QVC\'QS(V30=>.V3:$^(A5U"=9/:2SOBZ6A[<8;";4 MOQ\?#5'WY4S%Z9\MY-GH[3 7C%)[C:"LH:4TA<,!-C-/,.;,44E/9?4CB-;! M]8A55)V6'LY[6(VQ/3A!'VWXOUV8L3BJX",4"Z?BPKT>MM&/_@5^,G!>2I&2 M(B9J2B3CBE@>#=$B)BNCLJ9ZXE8%V#^D\/HAM8?3*#9KPCN,N#]]A=$7^*,9 M3X_;04Y,,Q! O)5E8PD^4%XG] HU]3H'QS34GM':#O%/-=:@LH>\ULW0ET?G MT]=F8 55/-%(&-48S:94#JODE.BD> 1K >)^];< ^E-V6Q#70\+J/4"C?&!@ M'+5!H:&B=/B00$KX?)A 1.0T9N<=8[5KKMT3ZD_%;45>#RFCF\-^WM_)V*6 U$>4^KS2GZ 9 MLO"""%I.%O'[#72=5]TEDLZU!*U>U[$ L M\C/6@5&QBNFE6^^^;ND]C7^=OBTLUR.12=J4R@Q\I-AGX5B#BA3:ERK\(+ ; M$SK4*#G<.X&WE""MR]\F!JO,V[6CS1: DT^9"9($AK''VT,NJ=2$1JRX,9Q MD]):F[CN8/#&F^^V+N&]:6AJVG!E.D4?Z68?X0N,9U#LT!U_[>.T_3J<'L=9 M.VU.8-*>)T.]:$8HEV9^HK8?I[-RBT<8,Y?Q?'&E-IQ>?+.9;)&3MBMH]1+7 M]F+,:]EMM)QY(7(YWS9*)=%YQ*X^9N."<28'-M@5R.V"TI?#UA_AC8ZZFY<4 MI>Y>%UXQIX)+PB/\]L_23CJ3>=;3()L;=V>$2ZX#Z@8X6V8BCM4Z9N(^!=\:^44$);X!XX+KL MPM'$=L4?C!8F88=HJT3R#_QHD?JD;V+7WH\6B4[9(# \Q7^42"HB<5;AX*>L MP]'0,Z-K'TGP((\6V8B46X\6V<2BO1\MHC7ZFN RL=;',D9YXJ))98SB!E+B MBM7>+O$@CQ;9AM[[6W2'1XMH+:E6"5W7D&.I@ZE)8,H3;LNVQZB9=[6+JS_P MHT6VH;R&E2MN8B@-_QSU-I*3Y004$X[+(DK*1&=71*>EY!E MK;F .P;HY3L_*G=\2\-6IOF=/X'W^0JFA9[7 571&5\)9/?.^+8,-7V9M[(K MOAIVGZ]/LK]/6GP5D@:$\(!'CE4/1:$N<-XK$9+T74*2S'E>7K_K=#H@;_[SY<%_G#W@,@M3*CD)Q3%X%HC&RPSE[#X=3#(EUVD]KBY=]?OGZKXF MVFDEF]=^./G2%<\_6U N[W0[=/]]"!-$<8SOS;-5R_[=(20_/?^*'Z<_P+>S M":1F[#]"J2XP'!\]]^VPW2*IH']0]=()=FS :XD$V%\G(9(!1[6$%&V,GG&M M?(C!6Y,&_JIW$;HMVG'.Q/;\M5-ZIQU<., M= T[+;*=K3!)>D6,TNBF."Z)92!)L,%E$)'16'V;72WPNTIR>#BJW _O^TZ? M6&K]\]/E8?(M?('1?'DQ6Q\P?"6<9X4&!HH!$OIU(>%0+'C2O+]AYE9D^YKC MW9-J5FFW'GL]+ :=0UO8Y>H(<([W+-E@#; ]5:K?".A^*MCWP?@J4?5&U]XU M1H.P8*TGAN92WSV7(VZX(4(HY14.)"'4SM)] -JZHR3^@Y/6)BSU*:DWX\^S M:=M9@)UMPPC8/9NR&1H H6EE2- YD!B42")X;5GMU-1;X.PQJ*A/Y"K);,E" MGQ'#)6A\ 0^+.RH!Q$+ M:)XKRPV/V'E2-L^_"JELT?,Q!1]ISK9Z.;35<'XT@=R'A1[*?5X:2M3VG=!'#Q M5*T#<8>AUC5X>P^PZE"[A@M<@Y<=Q537H5*;&(4$"!!_R+)YV":>B0?&G'*4 M"U][@GUOTED_?MJ;M$V]NPT4<,-1S[<1R6TTK:Z616('8/2J8T<,(K MVU+H&*-813-3L21JU9Y=>OA*O^A"W834'@3ZY^&G23>JG!Z6,60QS'0^ M@HQ*&*\12HAH(B.!!$$34=FH@#X"X#!266ZKT>S>3]L?RTTO%/7@QLT/2%Q" M)1P##\$241Q7:2TZKB8K0K7+.1BK0_5EDIN1_,"BJ4!-+T=@G>6"E=9W'3'X M0!,/#(/A'DF:N(7O@I'#63 M1?W@A9+70=B3^WXWNOTXY=OR>*LLJI'0>[=R(U*3 U#%@<0L I&1>GPT#"W; MXY40@2NK:_O.^Y+)'1[Q[E6RB>U[4,?A<3.9?H+)R:5,Y+/M*M8)+[0BUK-0 MMA9AKRER)%X)&J07V?K:&4&KT>S>6ZG-7=.+X7MP7)_[$3I=<'@,,'U;OEW, M7)X$;H(,/B3TI94A$M"K#@4VM(8@O3]S#2W(90 ]:>#\]A@EVC'%^Q/"\,SU+4*/1V!05<:E,VZ3,B%/X M4BEGJ"HE)$1M,=P"9_=^1RW6FGY,OM.:Y\L;5U]"F%Y,W%3=7GSSI?O<)+Q& M8ZYM];6B//9!<1:C9,%[EZA)B0D7);4BWK#5]^:;;!DUQ&-(LQ&\SP=?\'+% MH7G=3 []""[N]/9\*QKV4EEK7\HO&H7R*@65M4459\LU54&B$UT[D-@$X+:] MV?5;7+7XXG@G2"^:=MHY@(-L$Z4&'UP 4\H+^G+L2W#$-9GM(>M[M9&N-F? HO3< ME-F\&+"7IX@S9,Z(EYY)#0;_U3Z@8UUL/Y+(JO#30W[=[3C_\-/%JW*^R'#\ M?MP=XGG%F1@XEB7WAA,N/$;T/)5@WI4=HXYS<#H*WK??MSGJ'U=[U3GM83'X M7BTXG\4>,"&SXJZ<*ELRO52,Y9G2Q'+F-.=>25L[&V4[Q#_56(7+BI/_79V[ M:Y[!M88LH)\>Y"E,$/>GXTDS.SK^]+4I+;@:<0V"=-YB5T\BR_A :714Z6"T>L5$JR'Z3&*;I^T+:M/[T]]EQZ@4D4O6?0M (TGF77$46D()*8= MU\"]COTK[U%W=?NB:UEQ9NMSVFYMQ7R15WO! /M>HAUZ"+(3"FR%0GZC$KL9;&S-3Z6JK^)$QN$) !!4AJ3 ME;1V7N@#VPI6G?$U-WEM8OF'OF5FG;;\W.2U0H!5!-+GWIG[L/O0%2NDHR%R M2ICGY8FF@7A##7'!@:6>0I3VAU/J/3=Y/1BA;D+J;C=Y>>]E,S M]:/+GY>)Q7?-]%\P_0BQ.1J7R<:!T(DKRP316JLRS5WF"0008!S;Y#67U?-# M>VO,#R?>AR&+'KS(WAIV<:7Y'W5YO)^._?C]Y_(G[6XN,L;WP'.'T;L#XWS'I*' M+B*?VUL7KK<.W;GAY;8-;!+9E((FS*B,<73.)!BARS&-)H$Q1L7:.435P/\P MBMXO[3VD&=W;CA]&?OQ'DX9Y.-_)]&8H 4^&4R8ED5X8(C-'2U-N MB8B"1>VMUZSV:NDNVO5CJOXAB:6'K&>$NB\UIR 51#[36-:N!WEDFP9T'OA>R'DH0PAW]6#D5:JK0%3[)EB ;"OA(,]:>#ZY-^]N>BE=LQ]#7'1C''7Z9>3EQ?K M1.NTJ:>DA#[:LY_DA"UDLNE8OBN.OQ?]*@5&=(3,%Y:U4*[,[EY3OO\@##F-Y);/I@H(?5-L34G,#AU$\[N[R] M7$$F:83#DB **$*+RA(/^"-DP9CDQMGJ9TO< N?'=M]J\=3#-MD5T,ZJ[:X! MKK>"HK< VU/+3CHI9[H;2"Q5Q79RXP]GS5$"H/XC/&$.H4 G?04 MY/ M_IA9V=_TD7K[%H[\Z 0_A,DV%>)NNDR]--L[05Y+KJ4,":1"4QM!6L5M.8TU M!A5"'MQTP2T?U%EHNZ/7IJ^^%*&=SZ5G%T$Y[$"$I67[98EV)/>$Z0A4 M6.F8J;X&O0++ED%UV[YH,)A#SW\<3]_-BJ[?YP](59<$\WHX*IEE+DC#&2?4 M=)F4U!(;\ >3V3DI+1/7J[6MC*[7N-T>PNP:-%\+E6O;M8=AZ"UB.>IZSD,H MCV@7YITTLT6P!^DU6JI+B_K@)]/3 7"5@XLX3#(J,,1/D3BF'.$J04PY94]K M^RX;0OS.I;,+8OJ81;YJ@_DD@;#62!T44=)((GE9;0252/8\NA@ L"/OMX?< M[?IL'SK8VK#[7D!M)]-+8G[AV_F\=@JY#-Z..!]+IG*B)-" OEKT!K6JG%DO M@PLO?TD7^.I"$S??>6]S;UL3V50S:,UY^24T9<;Y;+)F#4R;3)AM1/8%CMW. MC]7@9R756QIW5\1[(U'91<@2,+B.*.[ 5"#*":G1:\_6K#7=_J (7S'?M2N^ M-[%I[86W#QAFCZ=OQKF"!" M%OFJ.^S.G:MG_*:VY6KOV5WRK#K[ *239Z]*P-T.<7!Z-9Z=+#+*WP[;Z1JS M!QMX;^6&[<7#7&Z]V;1"A2:0B_2.X+T*JB0A$Z )#01$1%00) N1:3W(AU14!&DBE11 M0!$! 2D*"JB(W!#K^YWW._?<<^Y]OO]Y_F]P[SUKULQDUJR95?9>'CX[G" !WX)^J((@+( M2,O 5*1E5*3EH3!9%1A,!28+' '!-0 @/GI*R\C"\D&_[<\'__K=_'S(+_R[ M% 0@2 _>(G^;!\(_;M]H+-_M@\,^JD#=!'\2S>$\X<^PQ_Z\<_#9X<; 6^ M3:=U3 'PX29 A2\!B OX^AG@$D!!0D)"2D)!2DI!2TY&3LM(34%!SC^_!6/Q8TMPSN;1CZQ84DU':\NCIFUU% SOWX-C,LM;>J>4]6@ ,QEE+ M@+>)F(A0'F\"#XR. &=! "\]H4QD,L.1!0\L1]_+\KO.HR^FZ%@QPC%R6P)$ M1P80"\IWC>&,*&)&Z-DH8)&O?YGPSRT0^FW"X31 <'_)BV@ :P1/NX.LCT? M46[4,0$?>48=7':/>ZJY;*1,2N&KS^GF+\^Y1]]_>W)*+6*/]W''^0R=MRV] M%O #-J>'.I$!E!]?O LN']CY=O;=E^VGCW=*\C(K[KQ0S^B__.[M(2!BJ7I@ MA]H1\NXP6_E 7U?U>4;C/3^Q\4;9G@-!OKH'J_&!P16?$X7[:#40LJZA\9W/ MR)N;RPJ-$V4SW\B_4:[<;*V@8%*/=QQW#KK!YI+)W)+BU*MR[_WY=V>C%+]@ MU^>D#^Z$4[_4,/"[]^VYK=>^6:E&7M:>W\_]B9NWK'[UN"D4 _.!)S^'S MPPV*[-^)+BLI#2AI&YD2$. #28CC*-4 @ -,"+!K(>!(+-H3<]H(Y86$8SW] M4*=U=&6E3UL::'^7$<#+T#B-\HBYE[4XGXK*NGQK$.R+KU/!QR7U4?V/U 0 M@QLM: M>88<<6A[8H]D?NM$HD^X^"*M]>RM<20F0 =P 5" '^Z" N: )6 &2 P0!I7 MP@!( UXXNX87$D&;]9WU>9H/S\W*R0VT-_,U0N.(U/@1-$X)7Z &X[5"B>" M!0(!?[P(F?\O[I^MT_;!HG[83N$:Z.F#]43A5>+*I'AN'5.'X]_]IGK$#Y;X MBV_H_O"-F?^1LS$X*O-1E8X_%O6SN8".CROZ5\'2'6/ZNP:-TOE=0&%_%TQ< M?3"_"B?WQ/A@\73S$!]- M]/V?9+(@7$SZH75=L"Z_XL?M<7']YHMQ_>HSJJ,(29Y.V'Q;KY^OCAW+_(4+Q ML^;(A#_HE#_IEI[N'G]6D/^LP-GVBWP4.9"-[S: Q/'= OKYQ$>5(+Z.ZG<+ M-"Y\ER*@Q!>/,IP+7V;]:QGR 5\F_2D'PDL)T7QW,_!KDL'S[N!Q0T#*S0U7 MXX.[$_T0^DXIR,K^19'!WQUQ]Y\4>?Q=XC<%K_,3'L=ETN'? F3EJ/K_?AW> M%R3?/8JW"P!K?K]^U'']\M/W,ML1!L'\LOX['"UI\G$7-Z %( X?IPX&F(P MP&G "#<$>>$HN[>[ KT3["_Q)RP=^ M+Z#^EN$G_!Y6 %2@SU%X'JT'B5S] E$(S#]D-1P+^]G(HU3X(PR!?XA70/MW M7./-L/P=MD>F$6%\/.%(C*V/R9&+0'_Y'4)\'0ZAPUW$^(*1[A^ZB=W1?H'^ M?R$1^:$]W3U_C:EZ5D="9G@:KDSI$HCU,T"BD&@7+!*!MS[4_^?D0?:=^8AR M5/-C"OE_W7Y((-KGQQ3TA_/_2C'%N"/_0B%R\<%:N[C_A48%1^+DD"%8(XRA MM:G)S^&-Y"?Y+\RD'G[HLUH^GNX_/47]O?&&/\E'WD4@W5P"\>,;:1 2C?T; M=MN?Y+^RD[NZZ_CY^*'_<"[M=P%M@U\51V:<\$,=/4FQ?OZX20R#_--Q9#XX M1_X'*H4K?J#\#W1R]-%P^ ]D?/X)?Y?#76"-]\!O.@,>Q6\)\.4C#@"B_,-% M@C]D<,TA],=O&5C^O47X]Q;AWUN$?[I%^)Y5//BXL0/P[RYPXP1^>O,#7''3 MV=&JV@.'8W$7!H\=+8,9_C<<1^MM:=P% WZN,0B^SZ/$ GH:#4#',ZS,GA@ ML?XJ4E(HC*3+43Y*POU\I4)<_*5@DM)2P#&-$'\7N#<2"W5%XN8!-=YW=^[Q M0CT1:KQV\J;2IOXZ2 ]/P[-HI-79$];PL]YP902OACKT6(A*B*^_+Q+K @WQ M]4%A5$+4>/'*57#X$5F*%XIGP7JK\7Y_%6)O:@[5\4,CH0J2TA)P:6EYJ**R M)$Q!3EY96APJ(RTC+063D9)6EH#!5.055>3DH#^ %_=K:(2;BJ6N_H_?PI74 M>'\T*C@X6#)85M(/[2X%4U96EI*6D9*1DOB[N2"DO?Z3[D2Y_%5- +CY_:@T,Q*F3UY615E*6D5.6U=;7U8;!E&%R6DJX=-65 MA._':)BA76!8W;W>.V\&Z> M/C@'X[=[O% T"SH4BG/BD<]_MPV_2,)U*DZ% M[)]T(QV=7[J/4AX7/UA/K _R1_9K^6!_8#Z>1P&IXN."J[)(A (2+HWK M%5S/2LA)X_I'6=[554)1"8&0=5-$*"F[XASW71CQ1Y<\WW^_:[\K0/_3KI7ZU69# M3PRN>T-_.-<*&?#;S?@A2<4%[TLU7HP+SC6\/XB>?Y<#,"5I&$Q13EI11EI! M"88K*C(PV#R,KAA6_;O[,?Y7-9: M6ED%9[F\]+_:_W^3O]K*.MI:^GHR2K@!YY_8KX"/?YS]2O]B^^5E7FB 4XL>VXX_EZ?_E84]+5TM;5TE.05%65NOOW0:3/AKV9&1Q*Y=_ M];#]7]IZ_+4-_W0;]9^TX9\?AO@GS9'ZO:"4^L>UIM0_[.A_DBQU]?'L/]]/ MJ$/_#?^&?\._X=_P;_@W_/\/?G_A0*)P2XM@7@WUP]<4]D8Z.J?-+5S"T!P*!?[/@!;NC\;BU)CC<%D$;F6#PR_A<)]@ MK/\1_>C[+(.K]Q$./OHRRX#&&8C#68YP]^^X.)[G.ZYYA"-\40@(? MCOI/*_^+<-2WW[$/%O@^ S$-_:;]'9]?(0 H[>!\<^TWS34+ %JC 8!E^C>- M/Q\ J'']UO+DC_8P'<7+'Y^L/)%PR2.'_H+_+<-_ ?[X/N0WN)^/7R :BL'E!!(J\8]!_-\6_'L[Q"V1;D@T$K?A@-KBHLP3Y8[K[A^O ME*&>J'_6B?]-L7^ [W&- _KB;P##:4F Y@D# -D8 @CHR0&(4QZN!O2KWTQ( M;8&CS+/C7OX>]WCXFZ- X*2C&\83?P &T+&TAL(#T4'?Z_!G7@@!,H :8 !8 M 2Z #Q &) 90!%0!30!/< 8, .L 0?@% '/ !? T$ ^> 2" &B >N >E M-G 3* 8J@%J@ 6@%[@(/@$? (# "3 (SP"M@"5@#W@.[P#X(!"(&48+H0:P@ M;I 2 PD U("J8/T0"8@2Y #Z S('80"!8+.@:) \: 44#:H %0!J@?=!CT M]8-&0<]!\Z!5T#;H"Q@"I@ S@#G!@F IL!)8"WP<; UV!KN# \!GP9? B>#K MX$)P-;@%_ \")X$OP*O@7<@ (0)H?F-LT4S0XM/2V,UHS6ES:!MI*VGW:%CIA.D$Z/#D%WB:Z( M[B'= CV$GH]>AQY.'T5?3-]#O\1 Q"#$8,3@Q1#/4,,PS/">D8Y1CM&6,80Q MA[&#\143A$F0R8C)ARF)J8'I*=,79DYF+68D\Q7F6N8QYCT6=A9-%B1+'$L= MRR3+%U8HJQZK-VLR:ROK"S8"-E$V"[9@MCRV'K9U=@9V578X>QQ[ _LT!YA# ME,.2(XRCB&.(8X>3B]. TY\SB_,AYSH7$YY&WCO<%'QF?$I\;7QI? M%]][?FY^4_YS_%7\TP*D DH"'@*9 KT">X)"@G:"L8*M@BM"+$)&0F>%JH1F MA2F%-80#A N%)T2(1)1$O$5NB(R(@D7E13U$7/*@HJ6)4&E7>J$JK> MJI6J*\>$CB&/%1];4.-5B:Z ;ISNL1Z=GHY>M]U*?5]]=OTK_ MO8&\09C!?4-"P^.&R8931IQ&<*,*H_?&BL;AQMW'*8Y;'<\^_MI$U 1MTFX* M-C4V336=/2%P G6BU0PP,S)+-7MA+F0>8'['@LC"W"+'XHTES/*<9:\5O=5I MJTJK76MMZR3K&1MAFT";+EMJ6R?;"ML].UV[%+M7]E+VX?:##FP.G@YMCL2. MMHZECCLG]4ZFGUQRDG>*<7KJ+.0F\LQ7 M%S.70I<=5R/77-?W9MYEWH<^=CYUOB2^9WQOH^A0WJAN/RZ_$+]1?S'_ M&/]7 2H!Z0'OT=?S71%\$99G@LN?EX2NR M5[*N?(M#Q W$2\=GQ']-@"<,7(5=O7[U,-$M<3A)(2GO&M$UU+6GR1K)Y2FT M*6=3%E)-4UO2H&EQ:1_33Z?W9\AEW,PDRPS,?'7=Y'I;%G_6M:ROV1[9DSG: M.76Y'+E7VN=M7VYCN2=\KN\MS-Z6#L2.HDZ[S4>7CO[+V=^_[WUQ^X/UCH.MTU\]#^ MX42W1?=PS_&>OD?ZCQ[V:O7>ZU/KN]NOTG][0&F@=5!AL&5(?JCYL?SCYF&% MX98GBD_:1I1'VD>/C7:.:8P]&-<=?S1A-#$X>6)R]*G-TV=33E.OGB&>K3SW M>;XU'32]/W-AEG V[@7-BXR7'"\+YT3FZEXIO.J8UYT?>FWU>F8!OK"VB%G\ MNG3I#>6;C&7NY8H5F96[J_JK(V]/OEU:\U_;7X_9H-W(W13>;'JG^6[HO?W[ MI2WTUN%VP@?6#V4?Y3YV[9COO-SUW=W?B_O$^JG\L]+GWB]V7Y;W@[\2?[U^ M('+0_NWXM]E#W\/#PTV Y\>I1\VC]0,$H(& (7\>;@;P!R%!_W4 _P;(+_A+ M/>C/FO\B''8='824!?(A(-J?!R&[@2V?@$64EX^&4$: M:9A6@&)K9+VN_%,A^Q"R4#H ?"0)(2 @(J/_(4I+ /#0$1+!Z+5XB=];N$32 M!!3(C%JZ\C&02&LFUVNCFR8"@Z /YE,:QF0QC>/8M&Y&^70FG"'?#RV"\(<6 M >!ES*V5%=F6NUQB[@]DGZ1LG"8+>GJM)4(R$M<0&J@F_F%%G8[J\#M +A[T M[MY))#FAE852>?'LVJGU,29DR6A",E0ABSL(R;R*Z+J6$AWOH(VN4\M9P DW-!M&J"8927:;S71I A"+$?=@? MW>6N[K24>KTW>IKL0;^D>-S DLUJF/JYG6F)$]^Y#RB>O(S19O/5TZY:S>O MU#H=[U6_SH.:-0GU6B648KC85H+B(&2DF*Y135[5([)2B.TCH_%PRFOB%U5Z M3E')DJYU/Y72JLF:\:&83'F!:%2VFRRJ("9P5UVA5>NB88" M\0_2)GE;=;RZ^GE(KE+NM'F5L'L!@U7H C7R;_[&!C!V"SPS7&W,*V=7$*E<%-$SM1ZNF_; MI'5DI_+U=$[[C'W)FYB#>4.U,![REW3NT3O]^9#9X- M'ODTGC_R:6=D#>]IR)&GS3U4+'UFZ3Z8VG*AC]L^K32]XRZXB;VC^[;S ,V7 M?":VLOUN=A5]O+T(*'DLV57-VPIHIQK#6R$AHIL?CD$:&L?6F9H''.=.+GN&ES, MM1QM/;V2$3+RQNIN1R\Q..!RR->W#M[)5Q/CQ\=XA0:Z&GGI SNN'0*/EOB: M4I-25$J\%Z<_.#I][(ZXK82")/ 0VLI;G'.\@V"0, M@[U&3UBV740?RSU7:W66$3"/!@Z!L"6_S?CD"FZE5X^P9A#G.R?)*LDMOQS/ MT'"(B61G2F"57Q/MH7YAIZR ,G;!&5AE+W)E&5Q17G'X;4%,L[,XIEAZ3[+LE4ZK9"LP M!]J?IM>0I'GO91+4[_-%H#PW;E'Q]43&YA?JQ(6:WC-/OZS5]&H55/FB5-_= M(HHZN:ZZ(@J:RM%4/3#H/9V_]I$2.^)Q[JSO/N0U&W49OJ^.#IL#;L.WNF/* MB,_L!FLY-?3=':*5NN=:/B><25^_J^.O3K*_Y&("(S[5=UL@S>G!HB37/ -[ MM _I*>_;C4Z7%QCLSVO4MUILL(^5' _VNOPD^O7X9%4Z%4-\YY<:1^VKN?WK MAL_*1AO?/3L$2CEJ@N_;RQ,$Q%R-ONO2O!!= >M01=MUSFUD('N11%AHMY7AI MZ%PNK\[W-"G8GJS_Y)E5Z)W92I=%]M7CR;$3"T/W$J(>J4$6OK-OM] =<>:3 M[^?G&E>/MWP3==\W.-\6QCSV.MAK[V/1QB$@G?I,K39V^OP']MWEVPH'=UK= M_."?":X=I=[F3EK5G@/ ;-//X9I,)$&D!KG>S[?%X,6N-;[C%XXR-_# M0DR+SQJKW4LWG,^8_&4B@S>-K.BA"IG;,7UWV=O;Y$FCXOI8.2JMU8J<0H;0F?&0X=(]D@.P2(LN!9&ZJ374Z=3^X.(CG' M$)*T/!>]&E)ZD-&E'@(?I*58B^BH-R@'X[=/DW_;GTR.=S9"XE^2[/2CN'R,E7E/K\"9YVF@YZUZT^-B= M@66>BLOF#(!,VV=LEYLA.-7YW\,FWM9$I>/F9M;T0& 49>CG Q :SL@&IV MSHF&:GK;R#(.[VM.VQ)=]JAUEQQ#CWG;S>YJK74]^K'BU0\39-8I8I=F=M>L M+](%>NJJN[DR6Z439,+W;@R7%KCQB]$F7"JVBQ+R*KI$T5X?;HBXIK M&":^5Z]&_#0,"WGM(9TJE_]H8LRVKO+V51X(TZ"&L++U1X)7W.H1R4*?;I_; MXC<\Z6B97U7G>$&_A"W&0+Y\;X=1BC6<)PN3J)5=;]M7OJ+%N'(V+N$]@U?% MUPR(U!5S]=FOL!*3>;RG ^81^C&Q[0IY^AZ6RJ MIS41&9-"J)-:5AJ:(%#:/LLXJ4DZ)EN !I&P7>)!%PS<,DZ''JLULN%^0+&Q M;4.8- 'J>DQ1/BH30T$"K6"D("F')CQ@M2*'#-57=SKKCH!M+J:X/!6 M(4@A63,K-.XAVZ/;5-7:";&6 =@[,?,H263_Q$"SA4GJ.Q$VK>&T#W0&3OQ^ MPLGI>AQNM4W]D15KHQU#E*)-@F:[.3>7Z%[!$05])UY%,#>JWTQV/-=Y^48Q M^$/+ SL'@A(["]JW!07C=F/&3],9"U(NC'W5/(23A,(E9U/ MUV36W@U"34$S\)AY9+2+9FUAW"L#S?O6(]+#Z7)U3D9R/M4)%PC43TOS9SR% ML-%X%A<,64M7$*PVM$[.?][C?K^\'T+ID\U'\=;V@BR:/,B]V M2,T^\J:Q M;6GQY];!EM.TQUU.9\]44=?8^8=TH+T):X"9^ MMLM4%%VQ&ATTZQ;(N)U,23U5*N#3'B?]!&=B-GB]8*1&3U14Q,)<3\]+E*3. M7-]^*'6K9^BBOMH4A58)B.2*7CY1FB:&?R)W51/F[LWPI)#1AF"UBM 9JIB1 ME3!\K;1#6*9WU<*,'\U(-HVEF?>99R8$,G/'ATD-*^NBI"!<6K&%;V6 MUWVXI\5"J]MD8;7%G^)P9'*4(K96'YBS2?8"$):6&4*&'^Q_XR FBV\ M(V#\/GGW)S?NBX>#^=4MBBTB=/*IP*EDE M!J6UCXD=Y]3KJ!-EZLQBFZ75]ZPV/OFK? KKZ*SF[AB??[?[^=7.BEIG-5>G M^KO@YO,L6[N[@^13[\*L%J*>-GT*.^@,.=^I_G8_;&MA7:W3_E2'M,I^V*VS M.SBQA5[(V][OB\FC^2#)?[;M8)9)'$1WS(0>9F'+>^':638.WV,DOC)Z NF% MEZZ2]9*T M764;E^5-V&J=0Y/'R,3))6=86'V*Y $+G*:6=8)!AM8#&F8=F[W%>0;YCN:+B"X>)S6('53M[B1 MT]%B,U@LW2:4!&1MP:<'LI3C(F4CU./T(#225]IZ%%B62#SB?>J>FUB>S$'T MAC4G_22"KSS:NBGM:QFD15TJ_F1XUW/2ER*$TR/6_ -T2A85-L?A,QMQ(S+, MI:5"S"WF&TQ5XF@9)M%M:=%N:U+.:]BOQO"('6I7;T]Q\:P%W3PCR[#2*ZI7 M&;/%I5C)S>,XYY/:IAD^GS:R9>!C=WZT\):;LM%[T+"6+W$A((,US+(<*< U MPM%HJ6=G>\LGGA>+_;AN+Q80-9O[5*MF$GNWHE)9&_= M=&ZZ]B"PP_'D<#POL?:6L7;GDB27MOJBU^:YR@#O5M_SA>_#:AZ%,BD5Q(8WAB*3KS(I+5#6 MO$@TSO<2@L)"_<+?:A#';;^X@;C2.L,C:L2I\VCT[02_+2$9#8F+CC%'P*9S MP$#(\/-F5'W?[D/_%Q+K)>DNZ07)&W% MS;4ZG_7+#3^*YS"J]@H2C!,5#7BRRS]C23F7L+%GU[IE\O8JAP*"]"-M!<*E MG&',N(\$X4K"OYW:[C.CR*!("3ZUV3KR;&90I;8TCH]'QO!^2#'2BU6'R8", M=Z;C],H\#;>H:ELCS:"< R\/.DMIO;0-:T'0_AX MPJ(/0- M#5TK$'B3U;4\>=61D*@8/GY"8Z6L3/7>-]"#47C2!Q?XK""R9#91B[-O M^*C.-7,A)>72V;E,CTR'L2MYU.?Y>N=SIEX" 9D??2FM':TVN<<")" M1=(F0I&M\:SW@=&,QICS0OSL!FKMMD';C)R>6+FAH':T9UZ-="YJ1\7MR M:1Z5C&05@57@"=4HS,'#+(,!C:7]B,"@_?"6X^8:VE$&OK62\+0;;(%OM0PF MM?5@/!^W]Z\;]8=5%*.D-T9G@MZ&I2N,#TJV6^D195]DKS$HOOE4C'H)MC!Q M<_7@X6>G9P=.B#>=53J]@O&HV6[#_?"=U>L*KZ:OL^N>R18&46GY.MC&@JI(XG.UBFU4JR7CN!^$7ET$SJ ;12TL5Z9+-C*>JZ:HU MMR?&.>XEG?I@J)B3,^J+SKF4,=J44IR13.Y]O;OR,4'77$O"I?9>.6]1I@SA M,I9KA8!SO#RA/.QM[TM36:%C&*O>D*^F0XK>LKY4K\>2!1),J#J[PUL(GW\T M*F_[T,.D*T)Y"#1^9CX8^' 0I%Q7>NZUFP\Y%@B M<2RZ^;8E-(^Y\)+Y/7\]EO5N$JR]0Y'P)$'$9SCB$ C/_-S"\_%)[)>PUH!: MUB\A=S/$W#U/A5Y<)5Q$) VFI,@Q50=@%MOB?M"L,D)]M,& 0FZ.>.W5H-=+5P:POI1Q)2 ME? F& Y?"LASA%']O2M&AWA7E3_#EN"G.\$]K\XEM:Y%1<:YM#+M/B-<> ME ]R:C2\[WU"7$K=VMK+Q?)^+8F"ZKJ:"GPY8F%LJ_^,7C>]O,4"X M1<(IIOBT\HSG0:];+67 C^GY/QD_#V27K)0XJ6SA3CGJ3$\S4$ID0F%!Y1=; MT[,YR#<\SU)3=K)L_3-7?]M)??V,]+ZHJPZWZN_%]8P&]I?1;EW_1A@5O+7A M]DAW4$O?0#,]I)&__D*X1*P&=UJWS,,R8RF.*?\,)57&F"A9WI&+H4%M4O1/ M&:YV++?>J@A8,ZS,1107E&S%W,=:A&.<$R#]$8[?", M$D(-@FY,L_4PG[5J#)1VJTJWL55!)=OPF!^H!WR[QV?]02]T'D;QQN 6\ABL MW8.TU<8GMM7RN&ZK!!T8Y0-[#E (B1D#!$+<9" M]OX)WQ-7_7-]!GFGLRIT#63&JE".ZM%]=R[ZLL4S[1D]HBWWMZ5I$>\8(QY%G,%,D>SGVX]Y_*PFI$TT.=*R\(M6(X(^H4[&[M6 0);% MF9'(;I+ A,JW.13S7;#6Y=NE C;"K M+J$E?B-ZA/:.;K3$\=);#"P&:+J*[M*-B9*++I9UREX-)IT8F'N+F;(P0]70 MB M\SH,WPBE!39>26NN3N!E/M,0:X19W99'F+#L2:Q,C1ZP61;,.X!J^!C MX]I\JMDJ&B'?9N&:;FG_&GKW!I.K9[,'@ZJBY'R>VW8/RJ1\.%5H/_S6*_Q8 M!#/;R>/VIPSZ82)*9&(3F M;\,.R LIM[''LWPF=')(R>2-R]6Z9Z'UK;#N,FQ[K:5E5KPYQ#)F8 M7JFQ!%M6Z,2KBM@OYEY"I-5P59'ZG9NMJ"6$,%GPQ0(T-(JT.PF[5\_$Y%4< M7Z3K?HZ<@T_/RO4XQMQX% )UF/F@%WE0D)X[EBHJ9[.6J?WRE(4^9<_ *P$5 M<(6U28\RE65N+,^%;F4*P/5ZJ?!EEE+0:S WB-J.I+WS6>N[<_K)04WPS[>G MB5XLU,K?KY\HR>WN;]%VH^91]>Y>1I&79G<( 2^LAPJ-KMS6,HK?G6X]2*@4 MG_"AMZMZ.<5?^%;^Z6:NX$12&;^#(R)7SH-4J_"%<.8PK3YHGX M9%%!D<%/-2H3G2$"CPOI$=L=+-0A+UBU9M*:>;E MUP:D2:KL>\K-D#5W9:]EL]34:I-CD;E^C/#(Q%"6K_ 2>]&X#GD"*_-"*X"% M $S-J;]1=:XIN/'QYM32\9FZ=,([0'*YABG'ME]6CO-L'2%'Y TC4WLWKA[! M+D%!6#U%42Q9.2F_]I6$8Y"D MHVX[IC?;PC=NB=\TL\Y2<[NX+9TB8"%3T2?(, $L]/&M[L2MMB3UF;(5D#UW M(!<8FZE?7V6UK=)I$2[?13WD-_Z0*GWES!4]O:>K-TNU+U_VISX)[Q=JO=LT MLA>>6E\J^* E#B&[NC+#>%-"-N3+]:8DGI.W+U[VCV($C0VG\B:D@4P1?>CK M)<>)4RINR'8&D#6J#I5RSZBSM;Z)[W#-Y-TQ7%E3ZU#Y@'A569]"30>C(7YW MS5ES24E0I#PKL>EJ'4(C507I>U&L([?EF<+),%OP;8;']+>O9>>HG=<.LF@R M\=9-;%@3G#0WY6695>>Z)3?ALS0#M6YE!4>7<3G#7A"=[STE$?K0@16X=@N4 M#%=D6&JRYDCMM5AR:RH2#$AB\G_.JVBNLS7>OFU9[4!,[Q,1)N?4V/:)+4$N MO? AZ47D#9TRW[[%"EU8N,B9"[WOUJIOF$"L)_V')?1>D.FCHJ)*9#6G2RT+ MEN*#YKT?&I8^@8O)$6G&QU8[I?(C4Z%]*G6&&F>&R>XYA"R=\9_7'66&9I_3 M?=BG4-T:[&!3$:+*95 ?'S3[N8NIN_QG4*,\KE T3 M(T&A9<[3=S*G%PV"5<,%5R)XD_C+)'SMVMXN^U/JJZVT]\A?+G:F->.Z95E- MNV((T:[HRV$*J)Y\8TH?N:FJT&6QY MG.7T]>?FJ:+NB8Z@25L;5NQ<^AD9[:$AJGR1(?"I$\?"(S[D#WC8!=,D?MTC MR94-GEUKD/,6[S=WN))B>AZA6R/ <6S%_QOD _IKR"&@)_A!UE^5<_=YRZ24 M??E8V.RJ1UJS3721""I)D(^;8@L0)>D8@#D-< MBIC=P< M0I(:32BB$J@#GF"RV/N43U* ')KZ&.(.O!M)'YP)$3I9"_ S/'QU MAG/;_Q#H.;;V+?>9FJ_9(7#2W_V+B]W.9U??"RT8U79;C'(LJE:\ <8Z2.M* ML#H\[?NV,^U<6,QM!:.HK,:!_(I)T83[JX6DI-8TTIF)#M>%7I]X-=6Z,(B) MYJJ[HW;7B>:JC[W0_4V'L^F2^B?FO(P%;F4]*.*=*?^F2;_"-Q (+!T"RV_* MC/HLGCM6#T:PRT907^-U1>07^5RV/QY1+SJ?*]=OF16O5U2!9 =3TQM-AW.1 M"V9?0 S>SEVM/_EM>#LZ2GQAG9CR=C5Q'JK5GOR;7%Z^W;K%]<('A#P)KVO> MB;UOC;L4%1U=/1OF'Q14ZM 0QYQD:B>Z471&YG*+J1UQO$O;^M"PMO5EF@$* M;%@_A0)L@^O>TFIQ41X)S1N0N>9=7>D8LZI7I%\AI#J8Y*VF6I(+=X=ZNFS< MO94MAWPR$]TRJHSDXEHG)_HJ^MI,7Q-Z%2? =QRKK9_?#>7RLQP8%;9NMTQ] M9YURP[+$-JHFSTL/R>#@OMT;X]HW9F;C8,4Q4#.,8>GB/:8;[OM&0WCIN:T2 MG,@Y!WD2-;O@4C3[\,V5EDVR:=*PV8:&%:/FNMY&U$Z<$71"2W?N&%49;$#D M:U!\"^TAP$$<=V]5XV3(2Z*7BT6[S8%=_7WWG45#DK@G73P^W^,^+LKV)7J8 MC/^6">MM52')$?YD6N?[@>RY/;#KS:N+^I^$MJ-O.\F;]SE8[J4O>EJ?/:%^ M@K$F>TLRN$%TAZMR8S#6H\FH4:=24,BZQMB%A_AC=$K.]4- *J>GT?4.A^S* MG8.0K6=O:E]Z52_1B@\A+KWV=8(HE54KCV.)35;*(Q/TC!%#Z!R_,'1OXYX3 M4=Y$6?XF.Z;_TXL/>IM-8G(6=C;=8\,EM#;*/3XI)U33XG(?STH)ZLXF(X8L M( 'X_<6LVN>BL$8E:F MDDJ<-%+7;9NKH;LYJ>+--RRI1^?ES&+)F,%(QK) =MXX6.-J_;BW0-<3^A,Q M^;XOM1*.KW5D&$\I6?.+LW2=\L1F9J;9:!+FEEN2]EXC _.\K0EJ_Z:GR)HM M.B+65R41O]GD0TIOUR*XS?,5@Q H]F)Y2M7]7&FY=CSD>@LV.:$1S=#%3\_P M/(*X[]F-;CO9$W*W%SS)U;#VZA',G %1$:="1>@KQ2XO4[,*ON\U88 ("DE! MB*G4ZTNY+M^0&U":XK!:M:B]6=TG6,*S:AXPJ?_!+%N68$RT]HZG'IP_RT+T M$5UF['TUU!VUIMLFAGV;#0M7-YZ&9'7I-EXJO]/[TTFD\>EK^+%HL,YD80/$27VM3T&).!H&=<&?B>34V=H MW@"O.=1\#/R6^Z=J!V^M]UR1E9"YG\.V*E"7RI(@N(]0JX' 5 4#+!<4PC4; M1;W32$[I7-CBMI48]OV 98WP# V#CJ\QY+;L<7;!XSMT1!^--E^Q%)!(J[YI MT]@3*F^KHN=F>KI%AHPQ*U+]] )LUJ#OVTE%%ELI]9ZQHK:%'N)P7"6P@("4%?:$CPBOA'J4"8@.A^ZC[AFZB2Q>Y)_ M*#IC!M,Z=)'RN BBR7[)Z2ZVP-*(]\:I;*/2*_0F]T9SWV%S^CTQS]80TGNE M>N+6_"GT2959Y&+V#K &.N>BZ+1J8?OF:?$<&[::!UO#9)%]-PFKXSO*V>O. W2.'U 5[+__UT:!' MO%H*H_0$:(D,*LMD58&S7 N\VZ(V$7W1GZW7):!C *1Z@TM7ACMNAP?0%>,W>I.ELH@9\R@F0F) MZ^Q]:.NQ)==6O$V$4B,[ZRZL<U(9W_]<2I M*DI?@YRR)>BL#U]:/&:V+YXMK0MJ]A5_V!5RY:A #O5X]":%('@Q\T*C7TS'.%P4*F# 9 MMJN1J#"_P@I/L&7*:'^VFKZS^934C2Y#* 0=(7NW;BK &>TSL4\G-]HXGI]3 M$Y(K5X2T]:)>="$A22.YP&K#M_X^.%P8N]TV[/,UD256<7(^Z;& MT@F>DJ_KN56O"A6R/\X6J1+^S,HR_HQ!QUI_)0N18C+ 8+.LW!#H-F<3%&W% MI6]3EMG0H^JQT\5XQ3#-+KMI\%'E/#$!XFF/^".)*OUB_QVDRB:%=OZ),\6- M*87/QC'8WJ0&D'?Y;N#R&=?7UJ8?NSZ8[4\';N\.[,F4HEZXDXNOD,6YHE!^ MIH4\W@KD_&O/'8R_>KHZE+"R2\'K[CJ?5 N_\WSO*IM^_P,[,H-\NZI\NT>$ MEBA!%;=Y11[_PB?W\\!2 ]4TU<)^FT"^:U1#^@)I;K7MJ?F-=32N!*J? MSGPZ<_:F9\?R+=^<^I"RCE,O5N\6/B_?NB&US:U(Y>?Q->G-?DM5P=;BQ]K4 MC9L6RVMK=ZC;V]47]BXG<=.\BS"9KUG=VI@SWA.J>[BD\K*5>'17-G.3'W=CI?;DZ?YOL@N5>XU=V>)S_VF=KK ML\:;LT_*/36B=K9V6%]TM$^\G0M6.]U^8[#@!6?0\-Q\A/$>Y.3CQ1=%;\*D M=$YOY^95'Y@U=;8J?U91WPJ9"E[B]+N^VFDP?<"MZ+G\12AH=?6\=^KDFNG\ M5[7>QIV[&NWHG<_P+WE&+R+L,G!1V5BP/?>@_^#;O3R4 M[_LX^HRQ[WO(,G;9QT[V7[\_[\SV?W_=USC_G?"ZOYWZN^]J>^[KN_9[;_OC^&S)O@S ? M3P P-P?$ 0"@!&A! #&8R *,WP".L#!,_B$A(B3XI^;(/(#.D"&3YA_X'A% M$-L/'"\%XB)P"53@#NCP+[P<)/9#A@2?0 DIP(]_:D%R1)P5_XQ=\"%^AR"_ M@G\)XLG#PT#_2[_'DDO[Z;EP?^A=L! M!T . O^0)?_3/Q#FMW^@B#_](P']M &*)?EE&_SJASWC'_:)[_WQ_56 ENB1 MNYXY/K\&T!-S .(TD3\)G -H*2DIJ2AIJ:AHF6BH:9C8&&AI&=@X6%C86%@X MF&B)\./USP"BHZ&AHZ=CI*=G9*6GIV@%,Z-&CW%OFQ^MSCH>#93X:B5PO/ M/[CV9/C=YNV:IR-S6_:>(7'7[]1VC,YO*QLY>(5>2"^JZQQ;^,P$D)#@2TM* M+!,%.9DBL0C\4&92? F"!%C(Y,ZDL!)*T&8]\$%>R.,-)C95SX8-CE78$"8G M%(!"1+%]$%^(@D,( SLE'/+MKR+\^Q*(_B["_@1 "R9^DPG0 M9>;L5&#"R5 ME[V9;-9HHI_>C1Y8VJO>T9IHZ=Z9O-^2.[X/F+^/:"TMJEX.U2]^23(I6;'R MZA8VQSQY'S J_=[2TI^IA5$W,N8CA726M"K5PQHRSN1[::U# MKS>;-;ZO)I"\2HH[L7-CT*-)+N=:0.R+N.7SU]W<7EI4O Y0= E(=[![57!D MCZ'HVP24Z7 FW^R(T&O#W9;J37O/J)2QMCB6<+]FT/L'TWINF74K+[9*4#NM M)NO[P.7QV.BZS;C9D>0WR:.(A]4<1WE'U?HYMY/LKSMVH(L&/N-E6DM4IFE MZ?TN@V6*BC7#XK6?-?,FG-][!W_IPR[7?.F)*;(H:_W$]VW..Z;21V7+;EO] M1?V:3 >VVE^FQ"_DZ-V2,8U=B0#W_,W/,4/']]SC>0JVD@H3G"Q*S),J-^/( M59)W*HJ*'/G +W=&3QR->CVSLK4/9.X)&'/4UPR,R&/?+_5Z&CJ5-;#OI+HO MK19?V7RU?JRU?[5Z4\O":REJB7]IPV:_?\O._'55E!%J5ZNX?BTGK>E3T5?3 M>=94F\U/K0B?II5OE#G9(<;?GTUY]4_?V^/\;EN186UB,=3Z[LIKKT\[W*A] MH'C+VATJE)J[_W)_E<[P]S@E+RT+J.B:F).2$GL"/S=AK ;A(R@,U21U_/ MP-[=VAP_"CB9NAOJN5NBL0?2PD1IQE/ZR5MN%!/6^6(9-]U4P2@B3XW8I1@( M_!^C"@#0!&+P Z%%,"XP&(?/$H8HP!*+L_% H_V)$B8H'!*)"@[XB1/? 5X0 M_(N!J&OC$T:0T/7!$71^VT1BCL,"D+8&CK9X$CN@!\ %(#&/Q# $K &+ I M K(XG-8 E@ !]\BL7GY(C%.C!MB4&C/6V0N.! "P]?.)Y,BU?%X(V@ 4^\ MJ U>!0<$ X%$%>K 7](_O=/UQZ%^E)W6(]C''^>#(IK$YZF(TH3P'<3M*$&> M1.HOL6'^(S86@3@?- J+IQXBL/0"<:B?[@)Z_AZ87QEK+ZSY;PX&I?<[@\+] MSIAY^&-_98Y[X4)^90P"_/5_9? 1_VU:%^[G]2,0/P9(:R-=/>!@,@:L$1 ( M AWLH8V> 7Z"$0;U+S1=_W^5T\4@;.U0.$-!:W\<\ ?H^B,@_T2WQOKCB'3+ M,']MS*.?9.H0)!R'QNC#<+!?[ M,1:4!Q$EE@L@T3YX?O!X?\7I(,]%P,#(7Z4_ ,)J+ __<.#'"QU 'S_X& #V M@#M^V#''IWKXU DPQ6.&>-P=+X/&#SU2^,$("OSJ6G^!/VEYP._5WC\*_(3? M PF "O8G-$C"XI7< QV,0F#_UH_A..A/MPB-_X^&!_RMA0*ZOULRL1C6OQLJ MH6CD6'\?.!)K[V]&Z&J@OWR'C,C#(\SXAX*8,='_PS:%%P8='/@7$CD:X^/E M\VL4-; A*%D0:?@\'2P8AS9"HI 8& Z)()8^//#G=$%]($R@$#@_)HW_M_T' M!V/\?TPZ?P3_KQ1SK!?R+Q1RF#_.%N;U%QH]'(G70X;A3+#&MN9F/P:,Q$3K^/EX_(\5PX+SQ3S(AN@BD)RR8.*)1A2 QN'\0M_])_JLXC8>7 M'MH?C?DCN$P'"KI&OQB$8AQ'HPAO*APZ$#]M89%_!H[:'Q_(?Z'2>A"'QG^A MTV ( ^#?R,0>)W:@AW](M#X O^FL1)2X?R'F"1( >.='B @C(4$"[PX5(W%_ MP_'?_^*4[81_@C<=Q MQ.F7@ 42!XG_68*P0Y#%/P=3-?$;!S,_!4 )(JR_@/TWC*'>.%R@FHP,"BL- M(XPGTG!T@$P8+% &*BTK ZAKA07"X'Y(',0#B9_'- 36FUH%(#X(#0$'17-9 M\T ]I+>/<00&:1-QW!8>X0=710AH:4+4P]3" @(#D#@8)"S 'X55"],0(!I7 MP^,$LHP A"B"\],0.#AU?RZ/!BG M(2#PPRP"_LMJ('[>)-I$P&60_L@ ) J'Q8<+*O-3%N_9+^%_C.L?@N;F_[-H M0, O:2S.&NGY/TMC"=.;C#42BP[&P)%X<<'?R@8AN/\398,0O%^_U'W\_8.Q M./S:!8WY9R-_"/S%Q4#$ORDRGH$7E/\M^',__V_$?[)_6$? U3S1F 8WB>? M )@74L8W$.E%L!6H9HYO80C\Q@J_N4)J"! .+:5DY:1D%6U_'EI*R:JHR:C@^Y4*S .AJ*HL!X7*R_ZT=K!VA?G_:34X&&].45].5D55 M3D%57M=07Q<*584JZ*C@>ZJ^/%115D5/Y:A/R?=!,]O5^VL=9&NA 3 STEJ*J2DI2<-)30 M_?%M">>#\T?^& ET_'$_,'\?0N-4\X>AO/ 5(O5CF2F@^8^G2NHR!RIX79G? M9F3^,/ZCDI 8GQ DPA"##H 0N[2:SQ_53@PP JZLY(E059%2E%66EY+S4)## MUY><+P"' Z7DU) J'I( M>>"K6LIY2"++[?J2IXRDGA MR2I(I((\'*;Z2S_4&XDB=%6HJA2A)RO8XF3DU67Q752!VU0,Q+-H3%PK# M('6\\.[_4W?5TX/(R?^]QQ[HPKWQ;0.)GP]EB-[^[WSZS[KX7WWZMR/5_^#3 MO_]IY]^X(_.[MF3^7I$R?YLT?Y+P,S%1_.<20!/R7_@O_!?^"_^%_\)_X?]_ M\/L0 ;]2U! (%=#2W']+ZXA?EKM;6EL8FI@9$$\\:(W-?%!H$D8 "$#A,(1U MNJ.3,X2B%R !J !RPBD&#(X--+D1OH00B+>> WX&ULCQZ<,@])&5M" M(,#_&3#! S$XO!E+/"Z/P*]L\/@Y/.X?B@LDT E'N*P>?@2_GC5,@'"9D M">9^A0>B?[!SA!#B!L=O4X,Q$"R^3R A4G]OQ/]KQ7\NAR1^AX;$[]#P&O;X M5N:#\L)7]X_]&L0']>\J\7^I]C+4'(&6A <"N M-_$ $> %!0 R0 N0 9> HH T8 ,< "\ 6< ). '# &P@ ,$ H< HX M \0!"4 R< W( G*!0J 8* >J@#K@(= &= #=0#\P DP",\ M)$$D$23G2*Z09)#DD]PCJ25I(^DF&2&9(5DFV0(#8!HP.Y@?+ 56 >N!+<#. M8$\P!AP-C@=?!^>#R\&-X$[P$'@&O +^2DI.RD(*(94B/4IJ3&I'"B<-(HTF MO4R:17J7M);T">D0Z1O2#Z3?R>C(N,DDR-3(3,@27Z9/(>\@OP1^0#Y+/D6!04%)X4$A0:% M!06, D<11Y%)<8^BE6*08H[B"R4-)1^E'*4AI3,EBC*6\CIE"64+Y2#E N4N M%2.5,)4:E045@BJ<*HFJD*J1JH]JCFJ7FHE:E%J#VI;:E_H,=09U.?53ZBGJ M3S0T- (TJC16-#XTIVDR:.[3=-&\H?E*RTPK3JM'ZTH;3'N%MHCV$>U+VD]T M='0B=-ITSG0XNBMTQ72/Z5[1?:%GH9>F-Z%'T,?0WZ"OI1^D7V.@8A!FT&$X MP1#!<)VAFJ&/8861BE&$48\1QAC->(.Q@7&,<8N)A0G*9,$4P'29J83I&=,B M,P6S"+,!,X+Y'',!\V/F618PBR"+'@NPB[";L_NQ)[%7LH^P[AW@.Z1Q"'KITJ/S0 MX*'/'('B.>0)Y,GL<\*[SLO-J\OKQ7 M>5MXE_A8^#3Y?/BN\K7RO8>P070@_I ,R!/(!WYN?F/^8/Y;_+W\NP*B G8" ML0(5 M."U((J@IZ"5P7;!3\(\0F9"YT2*A6:$*825A'V%DX7[A3^+"(JXB!R M0:1.9%&40]1$-$*T5'1*C$Y,2RQ(+%]L^ CY$94C?D=RCO2+DX@KBGN+WQ#O MDR"14)+PDT%G2,ZOCKW=-9T974QNC6ZG_74]*+T'NF#]8WTX_5[ M#9@-[ RR#%X9"AAZ&98:?C!2-(HT>F1,9FQJG&(\9L)C C^X[SE8N!RS67.5=$USG743=0MS.W9":X3_B>: MW1G<8>[5)\E..IPL.?D-9@'+AVUYF'AD>WR Z\'3X*CYY/EL^%K[)OK^]G/PJ_(;]_?P;\B@#+@9$ # MBAGEAWJ"YD6'H0<")0+C F>"U(*N!7W F&+N8$%8-VP]CA6_F.H)%@L^'_PF M1#/D1LB74/O0ZC"F,%183[AX^*7PA0C#B-N1I)'PR/93_*?.G'H3I1-U*QH4 M[1'='B,8R_)7\J\]#T>$?\\03;A>L*WR_#+SQ.AB1F)^U<\K_0F M*27=3"9/1B6/IFBEW$UE2HU(G4TS3ZN]"KD:?W7SFONU9]<5KN>F4Z<'I\]D MF&749PIE)F=^R_+.&KFA>Z,BFSO[4O;G'$3.X$WMF^6Y/+D)N3MY/GGCMXQN MU>:+Y%\O("\(*9@OM"_LO*URN_@.UYV$.WM%J**9N]9WGQ0K%Q>7<)4/A!]DU[#4 MQ->":L-K/]1YU\W4.]4/-!QK:&\\VEC3)-U4])#_X8UFMN:D%NJ6;7-MKNW3SYV?#S\Q.I)[U/3IUT=AAV/.W4Z6[LTNAX^4WO6\%SE M>5VW4G=MCV)/S0O%%S6]2KVU?(IN*GV:6OS=G(6/KO\#OONV]RY>;KYZPM\"\6+78E; M95K-7A-;>["NO=[SP?'#W 9F8__CY4^7N M5Y6OG3L..PN[H=\HOF7L'=EK_&[Z?6H_8']_?PW@_W$Q0INP?@ #C& 2\)\W MG@#B70G0?PXDOP'\"_["!_W)^0]AOYUP5\(.R .#F'[>E7@"#!$NQ)$!8-#O MA0\E&3D%%368E 9$ OIQ3>*W+R 2,"DY!1DEX:8(*05!%41"0>2#\&H $YY- M2<4,T>9GH685D(<*"BFP*W&H,A',X&-#"@*3'?P? MX.X;(%$S,+P,I&)0#A M9]>&Z@H>$JX-90:(%Q](*,!4Y!0'GV0"#FX^L)"16PDP0F!!9VZU::?(?:@< MV-"U%F2ED,7$5K&QO_&0M\%6BQS<7 1;RX P/K,3Z^*GWTV-=7Y/-\Y.'7_ M8%W'\S&QFQ[K5LT0$.WZ[%-)^CZ@]TF6R#+@-6H,K-NAZ8-&GPHU_SHY&%@W M,$$AT+S+:[5<=M;/(9^B^?AR^-8K]Z-*DB5C$N-W2K&N+L$YWS#+W\RCV!); M4? 0M8BK6S5/Y+ZZK7QIKCKU*;.,IWR*[W/9)EVOG,*GAX[O]!9I#D_,U:G6 M+8= X]PTL@/]ESU+5/O?CTHOVVR2? T].I;Q-3PJ;3Z$J:VJL"@-&\=0&-AR M1DMZ8672HAXX_WV+@V$D\<+[D47!.^/)T4B<:>7M5PE^V.Q7[Q;'I#'3+S>4 MA[H_*AP>D?*447Q) >Z>K6OQV"SH^BC"VVH)9C?35\M7-3,QOA%XETU J>?X M,=^G:1RH$XUR[XY[7(J]]F0]'WE;#K@8K*]4DO':VLRZDL;0X1*GIQ+4P+*Q M$?/PN(JA^:7/#,>LR3-?NK$!LO>>^)>HS_7[2)+A5/&7UF/+LSS$GFIO'3OBKA4[+4/Z/9/Y1^4PX"N-$D1":$[; MY6<+3[R>@:[SQ^?G>BRJD:U^Q5J.>TK)W0QQ?=Z6X+I]4@S;''OFJDG)]:[- M,X((\W1=V)K0B>5!LZ6P5W#XO.3U!"%GA;D3F<;%EI>S7#A6-N:.,T^)^WG(-JC6(TF#.][BAFK7J;>U9UG/ MF&4_M?!\;=UL?]$X<*8 PDI.O4W#SL[-/'=O[I&R[X>DT2M7F(J9K:01 MML/)!8D2 2]W':!3G7>U'5:O2&U^\AZB$UF]8ZCQS?3S!B8(ABII-Q5A[575 M^2I_,J]8K>JI?@S/X(G 96_2YMG[1) ??Y_9>&_/E.9(C 0_T+GJF M*+6[G4Q7<;)(8;<;2=X?\M[C?$=Y9!'/-J-)GBJ+E*@LE#27@NYM&<[%+W%ON9: M=\)@H!:4&))7:?Y>=WRZGM]/L%O(-[^Q]$X6].%[CKOJ1^J.CLZ*[C7?;[)3 MNF=G'HJRVD[<#79KVGOHONJ^#\AM;="$/M+6)B67FMPMJ;FL5-IJ/.*-BKE3 M8S2&'@A)JIHNC;$35'6JW#*8U G4+&G)JO1BOV>#DLB3MOGF\N#I#7Z$5L+& M-RO0Z8[O>87:421R#&(?OWX\7;KP7+V@^YT^B7JLB/S')#&FJY2/:/<42=NM M^)./8SA/TU+2OI/C[+7ZI$JI'TY/B(#^ ,J4>,_*4G"_A@]L;( M)_%?>@YXO4_6CQ4",5,27DR02Z24QPDO?(9WC!A:XK"]W21:52\YG6,\(6F4 M>70EI-3/=#S;4#CM>-T1L\&.)B_KB-D:$]&+K>,\OFFF 1M+1L="0EN;#"_9 MKE?,602_?*=4N3K/@$N7"!E*S7ZP(&.EEEB:/?%:\]HB@X>6G09PXOU:V7>$ MW.3<>W]8E:$-6&%]%-FT;6.);R/>Z%!?T8_:C;F*^;CN>^K6\'?#8, M2G)KS"E/C(ZMW3-Z'S+E5T$1*3#BK[Q4_&BJF?25LCS.&47OYHT47!?2#1%3E6_D4M*Z!;J^]&6\5DXN#QLW[5 MJSM4$VO%[[=Z)[ZG# O%KW%^=RR;*K@2DZ=,QM^T-[S'XI!6&K5J()6R=LQ M8"8OFSJ<(:_<02^T2$_%K=(YH*9Y;\CT1FGW5J?]LFUTR)?5.WJWLAZQGS;KGTXJ+K,QYK)F[K<_CEEK;KH:6'%NU:O MU&=KSA]HS!LB[BPJ'U6LOGW97G3.*&1B^=2E60F-9T)QZ'?0N8X3T)CTQ%O> M[N*+^:MT%>\R'Z(_)UX=2]>HB=9@\&M/.NG\L.7LR9EIA=>TW-.7"_(*Z[^6 M:7[AY2P;X1%!&2<$[M#K(OV["Y2II\?@&!?[<'V_@?E,U8QSTQ3:M]_:X!B$ M.S5-UDL@E>:5NR$WQK 70-L.=\=67KU51I^I*(CBFGO<=[=KWK'KY4AST:3" MR<=* 8][&R:%_3QW;U^CRO%^>;CK E/:>.RUO&61P<+,%TUC18JX;>[W9V-1 M4\@T+0?W!]$/_./I2.W*^IHKQ^E4]6O*3=5?%;/*H&XN3R:_]*\K@(T6O9C4 M.OY*O$19:>+\=*/UI-E=*TGGZ8+ RY(SK5>014IEY>Y>L4THLV-5J2X"=P/I MF8Y2KK'9P0/M1M<+7K/%5RZAMSDG*QV^]]B_G6P/MUJY:2.R#XB-EKHUEQN8E-+I''<\[LK+Y):O.8R.WV=BL%\XC: 1KC\=M]S44'TPL) MN1:P*S8Y;C<5JK@I\B*SC?4D^M5E^\',,V?=8+<$>YY]'UKOOMX9<@ON%5A2 M[!?I:V+-INT2><[QD-1IL Z"0ZYBW+Q49'IM]N&YB0<=;(>DHS[2EMU6I:(+ MCCN7)"]42M/:MR0N-9F-,:14I=_7>=QB&U M,EE9EE 49608%I".U2O9.WO[PR==OKILCFH3TS23(N%_VN.6<6NN"\4EE9V%4F)$JCL[G:JF;-O%XMF-&- M7M0TF;P)37KVC1#/L?=-FC5CVWWHX*JIA*;$YEJ2T84@[U+'IJ#KG$X\NI') M,MU%"4I?';O$:>;QF-MW/3R$"W.^U'_=#Z)K$HP087Y[][Q+&!0@"PIT=>MT M6?94(Y^83Z42EY8%99K&0L2K^C)-1B!?G1PWU]+&:]&;PQ\_4;O4E' MG\X4=-+5-[9Q,>_TP6%K[*W'8A"^\#D=_W#6/(XJW1SG4Q-TG4N']]:]_#_3 MA5\+G!P790M)@YCY) VY&2%K5C2:.T.+:Q MR,ABW(OJ8)J32_4!+GY33;>2/CQS,Q@YV_V>"U3+3DE>MOVTK2#RVVO^;ZRE MBR&:3V*??*$JOS29(UH8< \UCN6Y/D@3._'\[OQYVOV93IN@S4#P# MBQ[/'-E5QZJ2KAX?63*O7M0&@DEI+1EUS[OIF, DW\P]9D,^2<,BA\)-1C]O M)Z0%GLY[#8#ODG1MK_I\;/LN_/!, WO69&I>S'#MVC%RD>D> MW2<^M:>500.2)W3K4NJH'\US.#92:O;K.UB?O5:J]8YM+"+=D7QT8GGZX<7O M;L:UR<;D]$5SM=XO<8UGU,^\U$:7LA6;YBITIYPAO-R-*-?\/2E6M$[/,GUET_[ M')H(D#O=R1QP1.KM&,*(OF)XX'& >?OU B"@Z)HC+=SU\#F3..S[S>]5(?.+ M]WMP9PLS#5V[O!-M4IY+[,&41%&J.@J'QM*.FBVYO[I<;S;K8CHY2;[V0OH( MCL($1\INV8][SRQ":]96?@,.JVVJK/0P]7EH4F\,,O5V\57XVDMSY2&M3 MKQQZP^N!55GS*'A#@ISL[.EVZKDT7JA1\W8.Y]/8WOFV1II##3YE35C5(,D5 M5*X(XG)QG4-,T:A[) E/Q1%_N4\81=CZMN4$BB1@YZ3*1)UFC-*M'G]%/9W3 M;";43J;B*>CBS=("1T%KA:N!*K*D?$R06) +.-PY,W2\1"98$C>(9')5%MM M\55_Q8?W 8XW]A4GQITF5\MZSYD=%\J5?Y1VF;DDZ[2;4G'=S9$(Z^URY[B>5/71S03CB'0VV#3L?BKA@G4V6D0-D$U1H&DHQA(WSH M[H"V9KFGN)I'V?=MGXTF#Q:*I8I$H#HZS5T<5I+D3U>-ZZ0"(L=5OO5JWJ/. MT167'5',B&<,LX=OC;UELNJ(OBK8$2>XU7]VXYZ'YZ646:?AC.YEHQ'2.7UV M;@EU12X)E<[1.'6!.'6C^7L;'47V1DOFHM/'$(:\.T-WD5O%-P6J9V(T.&$E ME7NORR2]WC_U^L&R MF3A3'6D.3RQ/\KD@M\ #OKQ=I:\M>6E\PM+^P"KRN MP5_8J2.U-4@F_+D M25\*_=J,;.GD(&H_ZU=GA#RHNCHOEMM4^NP\(XV4%: 7.,*JP!SMOB&KJ;#] M\I+J]Y2O29VO+4C/KN0_BR!-21$%<_95MS>$FJAL;+_S$J _ 7FCX[#!]/64 MR2,K&=SRY]QL1H9'#(E,P0N/MW;#Z'E%ZN,'+>KN"DN+1[*?; MP2(,K=#+1@\LI@V>?3RCT/MNM[F(91/-;ZV2RU^Z! *WDSC> M;'WF,UA?RU)/!PE]F%79*$=V7'^S8U$K^X%;'H\G^&I_[E")B1?=K1]3&S+F M2$GY("*OPO>0VG6>J@,6ZH_T(I]PF4=R.I3YR*]*Y6Q+S&I]C=!4WQAV&[O:(+[QO- MC..'Y"]IA6=!?>GG9/3:3+K8WN#\;8#EZ]VGH[QOC9Y[W#%! M=T-D.Q-U=K_$B]<9YE[\U@-\ :UF0:!" UR]B#>"R6W-^P\;':S8!FY^#R.MUSQ&I^AP&6& M%;DMN4WD4O>JUL&>!81OU_N J=VEKK/TC^M0'JF2FE))V%O4%*K])O?'- \) M+LM=LU;LQ6;?"TB1:,9MX?*//>B?XF54T-Z?Z02QH.=,OU%R]_26EF_?J M%:ZFD&/R[ZXH*4(DT2:P?<"'HV]3,>RRF__A\JVF6,7>]]_[R60GZU\&:E0_5CZGI%^23 M;=]A4[V>2N66-L^L9X[/!JY$1?D(/R=;HK\* MA=3!=:N#,XS?5?:2#?SSFY5[TSF M#;1V'/*V-Q6@C9L49H!?$,22.O#TM?:I!+W$KA]N&$D3S,H_O7@8YN?1-B]D M$N!YKY3T5)_QQ9;7;](Q&9%1@O*!3.8O=G.DO&$&,?7SEE/H&_(BJ;XS%9=T2,9OU[T6O;';@JX>Q;[H\+L:&XWUB>N?1&Q=)=\' MLM\9!>$:Q07:ZDI$=.ZDBIJ0#C3#4UYL;=KMB#Z;REU+>BXM1\MS-*CGQJ66 M5Z%E;;XHGAKZU ES@*=)AC70J:S:[OX#Y496K\^1(U',K5O\"^FG:CYV'JIK MH:!RNS?DSE;3W./R_NO4GF :SM_^U1>5.GE+'U_RN-IE+9P)E8MD179HZ2T[ MB80OL^UJAITW0AG$&A&&+'?F)XYFMZR=3<&\Q*\4)\UC,B6ER*@F-;9Z(THX M^;-DFNDL^+Y6(M%C&>YE%:IJ7@XO0[C"YA8YWD2&&K8N.E^.6\C@D)9_@.5: MGA8NZWDJY]SM&WFF@]DSONN12ISB:\'76W.>GZ]NTK5*O[(R?3J:ANZM<0@K MBU+C>Q6>$W#6=S-SR&]-8A+NB'ALL6'6=S4\]W"S\YS!LZ\)S_8!W GMCTN; M:@%[9+P4R.&'\8TW6_IN^JU\1&<-.3D,6B)BQ^-S&[V>VA[38RV#IQH)IBVK M[C3MM;B+VI1,+6.X]P'^\54>-Z_B9U.;Q=%#J6B?'0T[)..>2P+.Y>UA5\1G M@:>AVJ[Q:2]8EKM!WUX_U6*:B47+'%T%;VXLVY\.N)1]XV9FE,A1M6AW=@09 MJ&0IAP\&8AO6NT8E0'LZ1?+Q\P7:>%'_CT;;JZ.J7LGICQ[?8LA1S@]9NSAU MZPYL>B9(%ZXJJMD7(^G.DF48!GYH37FH4]?W%^J9I>M/SS:9 M[0,T3.>3&@87#%Z.4C))?FN4?>JE?JM M-]F1VU'O0CDD4M+Z=T@[5H^^3E9Z(&0I7SGNX;=XY'3/"G_4J5O%M%BKY\FU M[)$>=>NB7HY6 MGQY^G:L3&D>^E$F:O_RP?CP.0@4^92\WDB/T3+2Y*RM)\U;EEJ;;[S$SN[G8^/7ZR+JE]9W].B MR>'_5L1P:7*K_$S>O/LNA8["\_[VPYSR%*^WFJ$K=W88V[IR]!UD2LB MG2M>16-9+<[1+0\%VH.U9!OO!FT&H/2.<&2ZM/15WV46'QYP5T%>>6S6$+_4 MTWSCZ/$WDHKL?"%MUZ16>6VO)NP&;C!P%MY+SS\?<+%^THLTOV3]6EAD3?7S M;O7CVR8V\@S#5#DD15JBHV6=.B<$ .H52"QZJ!SC('ZLF5%W,.+5OT2 NVGPH(/;DX MPN+12*OZ%7=O,5]8($ F/[4[%O?V+7GW F>_Z+NLBY4EM91[42?0*P[;T'?- M%ERU"J7EDO$9@R[ MU#0&KIP=^6PA(JTP<5YC56_;#J3NDA>Y'V,0>768W$VJQA+O$CJ\7BZV([ M6JET.;3"5![1H'N81G>$?^B1O7MAGM;^85JHCFAH* M^+Q__T#Y[;@=#L4I)'VU+R4U&C;8:'QSR^_UG$BUO*?P*[2%S6SO!2T,::NL MTF:ZV^M4)SNG\W("0OF\(&CWX=9WG?E[044:27#/94U#$YKL,<6JCIQT!^IG M7"4"&IO";=N#[1&OYPP7R&5]-/X9WC==\Z5GI4FH_RA.06.]KX5;>@WUIZ,%MVJYY"6DCP0LWX$?&/(P14OD&A5;A=Q?)M%%/KVD' MED8]22]?*'QE_9A9]>;7%<>6ULF!<*_EF2B'J2WG"M%G\SOJR_'BYFQ]%\<7 M9]?5/[P<[]+@<_#K7Q?_& NMBBB0_ZB]'>GZ.C114VO2(>J"/M\A/MV5;DDJ MJJ$0Z5SY[:8!2>Z+\?H-"4=QA;$&AB7G'4C$18OR8XR2-87.-)W-/#0%?8SD MGT[+B:ZBG6C++VP.JEJ -_2UC%3)W?+XTC\PHFD1VO1EYX@FU'D;=#3(9JMY M_?@^H,C )*IUOG(5=BOQ0;>>2*[S7#*%C6JWUG2^Z<<=(7_#?2#Z0O:\*92"]DQ9,5^BH^=:L^9+FO)JF M/[=%7W"K+Z5TP0(-$,I;X M4^Y5G+^T]MFX-/-=AHEJ7\(>!=N03P1]: E2I1?SRFM,SR(R>^CM6O&2?R6I MD^62.+K%0;%C%Z[ 7VBOP7&W9A\H7CLSYQ8PWY(F<69AB]?XZ-6LRGW@[,=7 M%3JU;2,\O92+-A9'6.O]^YV>1*(&V,[>S[5P=[RN3L>WIE4&_YH]Q#K[8?R$ M7S\V''GE.?+FR.R[4O44L/QG=AOCKZ(.#$OJY0[/UC EI3NO7/="0SX*^UXI M*%O),50+2J>Q"91O[R?K#E(@23)(2#MV>)2E+V7[$,NCKR?U'*&D>D?49;I6 M]J[F@T\V\L;T5QGJF ZJVK?E/V>-R%;\]B87>/)--%Q/!5==-XN,><_8=#;9G'R^V]RK\J,=S M"E%2FG,XZOGPHL#;B 7KE6:^BI;4Z,R*L:S,GO!W7N-Z?H7='QOA-+=N\;,V M\$#GF0(PNEWS#T4[^)2"D55:;N_ MS^;"'"6D3V"5C)F'LN8*TV#7$P1%7#!M2#;<+QK40#\C>N?3.!9-;OE&6Z3+D+W']5 M89P!OWMW=9P#D5Q#YU/SN"&7%)7V9;NEN&Q5.;*GPE3$YU-]P?.'84Z>IKZS M<>>_)5M-M7?P-$"#O)PK)[4(RG MS@4J&RL3 _MG_+N[I9.EH,?,HB:L*(&0R'=PC;X 3^TD[J.ENV<:>6\E';T4 MGSV<,,&C);L0KGG?-F3B,_K-HWT@<2GPJ/.L1$!G)<1$F+_ 9".YE6\DU%^A M9=GE[16+-FZ9Y(:>+;IHXXBRFG7_T?%!J[Y[SQ4&%3]/E#JU\MSL'2LFN4*V MV&FJE5?UQ!D_/GV+6/?8CCQ>%_3D7OT+NQC-?I]/3;ZO8'8OGZCLSBB_>'HH MKF8^E,FI:M&4L^,\UQ=A/U&OCN9#HJ,-]G7J$NK#-YZB7*)LW+._.;&,(_/M ,SUYN[E@48YGK&"QLV_$ MXY9G:/:7EQ.2]7UNH\Z9V-I23BUNI [[-6WMZEP,BZ:*@&Y4?YV-/05H;1#] MN&'6[MNG'":;9/9/1<.?=Q(#.F5'R#Q6L9^^1 BW=2 MJ/_)IR:(TXFANQO;?/3%:II-62.#\,Z:=Z%.#((1,G27[<)+S9%K\BH<"$/)*IQ9;VJ2=] 77C*+=PK,@V-VJ=)]4L%5E6UTN<_5 MFTXC<]UY,X+XPY[*>C/5QC:(N$<.Y+!.*S&4#'V:"F# /GB.JQT<<+3<*HWA M"O#HV[YWG;W0G*9&]I77)E9,L:*&NEZBX;Q4>V\E?9565W^(>D'5M*_T3A+% MG+K#TP6FGL-W>_WOJ0=7OM^CA-7TOXE@\MY]AKU$FJ/6ALUTUM M:1,:.@[.#V)[C3TJZYIOIA4\XM#6.OM*TWOW2MP-3C(6M5";V2_?T_MR\W9Y M(-OV1WUQ.<9IY3%%GDM?3^ZT6PS MG_ *RKN5F[9PY5;OT)?7-Y>'3X5>GT[?2*/@K?1_Y&.6,<[\KJ1>AL3:XU2^ M_G<+\Z2^@ OWW]?3EPUPDHT$.TH_'=Y8NV#U_,&,7^K16%>-2I<;=HPJYW5O M2!CDK..\GWR.,?*=__8J,TNC9HL-JN T5\=U.N%K=>/4=EZ)VN00XIR:7VG$ MCM,%TF)$/+0G5;31>&(D,DS99"Y:Z_--]'43]7JMTJ:6Q9FZQ:=^6U.AF1Z! MGS_KG\"].A.J&+7BU/J49/1Z,9>#1"ZKE=H1!(68LLC]!"NGG:<;+!FU-Q_K M7:59CUC@6:OC.0SOAMT/&.!G*$0"E;4DA1C;A[$>!A(3J1+0[\9\3^NFUJGN M?W3/6V0JS'@QQ M-W%Q._D#_;52BISO T'1+E32QUVMUI9^_IDH7 L.Y&M!T5V)![]C*R07>8XZW[&8?4;#=;7H<,O$Q,?9)FVAUQ3XP%%;C+1E+.7]C M'[B.*66ZN64AW7"+5VW;A4%(V"LC_>'C8L=UV<)"5>0Z7CN03_@XV%B'_JLFO,8+LOG-J'(^(F_:U(%G&U[H"[G2D;@M!:TILWZ+2UAFALO5?G,QA0>T[D6$ MYSPU=YWN51NG#QYN+#*J7N%X>'-SZ8'=BS.2[RF1SCPGAMJ_]>T=VSQC>2Y6 M(/QV#[Q[X?6%:=D'+F:#^1][C!)<_7(WW8[MHD9>D"08&<#=U0,VE4PHL#.7 M5AS?A>*7B70;CQ]L:G$4S6K475V6U53#N3Q_T1S25[3Y]J7))6NBF$-YJO>4TH+RE\MT(>U]&K-VV4B'+N%. MY66NY3[^'?D.2ALJD5JU5V5- C6"6=!K2ZY7#%5+QF*.5R,S)4^BBI$O5#Q, MJ8]2F)6)6)#&^W (^A5\\X'9NQ_-Z!?E$1K/PN/1]J@,O M7A!OJ#WI;(&2R@DQG^"LH>WD*K?BH<5]2&%)Q;Q-&"XL&6!)NEW09GI6XDZ* MXO%LE^DSPS$[[/2E$ 79PS9D9*>X+L^G>CI5>559SFV&Z21%T[8[%]/;P&8?!,0:DTXOZG"+#!?M\]4LY"@@^Z8V7Q1FV9?8U M[,8G1OR?+24'1.,L_<17EE&;(>?=[=@BZY^0Q4\_\Q2W:\OX9N]EX%?=H[\/ M7*'B8P8OKV1Q\FW45+4>\C&Q)$^]SR3*NYV*#;'N+)]^*R/^-G8B19\K*_^3 MG$*(-;W17'MX2) M:,&JJV52PMSME[BL>9AK83"OTI:2S2::,=_BSB.$E#)?\9,Y7.,;3D87S.WZ/&WC=1I..MWWV) MCWO2N2:G*U\LR"M+#6%>85T>"OC=.+9^[>HTY"Q-:N.B&)\48ZK^'+.6KU % MSOYA;'8DDVBEV(;V4N)]3OF&,O5P.K?3<=V)H,&))+0ZAD3P#<* 8+K\I=SQ- M;WZ&U+'0NM;0X*.P <^<6*#]"O!RN5JYT/$*%?/(V8)42%7P"%Z$?=N)&G,^ M?M A!X21[$]G_)@@<3MAASI_8'CLE0W/AZ@YM[S[62!W?WWAI$_Q>GRLK51Z M588[^3L:%XOWAMYK0#D773=\/XUL#=\7TK&R8\EL: M]NWY6)Q"8"2S5HH0(@_K']9[^05H,6608J-8[090AK[VH5%93Y*=7;'@6*5J M*0NW^HF.&D$/"*/G?:>($'NABS1GB]FJ'U53>9-6[*97ONN6S',[!+[YN6&9 MBL&CHB9*,\W$*K;;X;42-7_^ _8\XP1>VBZ6D0%#P4$M'>;:^O3VODLZ1\^/:'ADY3QAUFH"B4 MPKUIL!/V>D95J0U":J\I8G6ZHRS$?03C;??>T+?>,0VR:(^IF<=.[W7S'.#YB8B MKR Z\.'EFK+;5"<%%6$V=&R)JII?!G?AOB\=[<7R2?*1L60W>.!5>7)(E:AXYV&N"9T5,<.2^'0K MF]+/EF0VKK#Y(:=K(6+G7I;Y;WN -1J2LL_1PY YKO,M!GY3"24M,6I=SX+J MN/JED.>NWNHR^."03*(Q;M2PT2!$OR1!D5R?PBQG?+[ZV)5,C7W *MVN]^.9 M-%YIZ9"7\!*>7E=7*Q.*&:&O3$MB:3H2!9F]!M?#]@X+9@_K'RO9-5NL\1A] M+UZ#*3\E7O)8,O%NC<@.Z%CU-]RHQSGS@>.0I <9/D78[+&NLL@4U-N!&:-D5S])OG]$532ZGPAX6&Z]HKUC^)>.RP78,WV;K_LO_"U!+ M P04 " "!BOQ4/ &Y>OE! "?7 % '-G96XM,C R,C V,S!?9S,N M:G!G[;H'5%/=TC!\0@?I39$J112D=Q"0WGL3%*4%") $0D(5L(*B@(""@((* M2!,0I%<5 >G2I(0B77HG0"A_@O6Y][GO>]_W^]:__K7^.UGGG-FS9W9F9L^> M7Y&_P/'"8*8?N"X.^@D0'R$ T :B/47_AITY@]9,?P=.(6[BD#B1S@C M[NH-@P!$/_@7< ]>G%[XGU##.P#@I_WY5'&".X"YC%WA2+BW*]R32UQ<6(SK MC(&](P2&IYP%Q$7%Q>1%Q>5%I;C$).1%9>4EI0$\$#T$ %+\4U1<0NPYZ+?^ MSPE^_>_SYX2_\(O =R !$?[@)?G3/A#BMWV@@#_M(P#]; -TD^!7VX0)/]K3 M_M'^T?.P_W 1H#RRZ:J: :Z\!% ?E0"GZT?U:. V0$E&1D9.1DE.3DEWC.(8 M'1,-)24-TPD&!B8&AA-TE$?PX_'W *(Z=HR*FHJ6FIJ6D9J:FA%_HV;\+D+W M[S1P^ Z@(P.8@-.$(&Z @ Y$2 DLQORR\=5H]UMQ)XT,J4OIX ME\4X>.WM[;INU,2Z)O^CM#M%CS_V3&ZD%]?W3FU:.ON$QKTJ:?@RO26C9>7B M&Q:?4=K8-X.A P@(<-H2'>E$2D(L=:3"*3%Z(IP&7MP,Q.(WHAGQ&KPW[5R1 MX'480]R,43-CEKJ0Q=.B=3C3AH6TDCP^"\5_K4&_+]5.!P$ M* F/_I,.4 86"Y3>*,CP]?:BJ JK*KUL;Y(%8<^4;Y>]+Y M0*SP0?D;O;F*A43"2[ON'%N7]I93-_:-3"AC\N-D,L9K24XD2;2\1_3OON3! M]M4? F+?Z"]/G=AN:VG!@MMJ.446F4ZRG:.Q"ZI/3A94.XF1.37:49TREIG3 M6; 9(DYH ,TG_K"[U/3Q#3KIX7X'=5%90+NC(FD )C@+ZC<2NYK_JE:K:]^R MP[!A50]C37+.ZLJW];'N*7Y,;^'N1ZHRU$]IF.!T@'1_.6I6,SL$P+$[4SJ1;5G$EAI4NKN[*CAY\W MS>.;LW@S9GV#DOH4IF5J>T:W@BKY4O1\9X-H+AV4SX?ZUSKB=$-.1PX M7*0\^)UD)(1% 5E5'0,BHJ,@YF(#V0"$K'Q:;/CA#@!L!,0 I;F%GK69RE73 MJZ9:JD>\?$>\M*U]_NKR4"7*8B$BM/(;;?A1G?Q1W0Z^_D2#P99HC63.('YY#%8+$ MR_QN$XPPM(>"S34NFN-)@!F@"1@!0K@G$D !3@ $@!\I\+T18P0<[FP&1J(\ MC1S<''%D2L 80.!8X( SP(43 A^)>1Z)4'C^XOYIAZH'$O9#2TH'%,0#"8$= M-8DKDQ]QJQE8ZWWWI@*>GT#H+UZ@_\,+1IY("!SFC:,>/[+5$PG[:1C.< ?$ MKX*IB[?![QH$3.UW 8;\7=!W\/#^53!T0?K\*FA /=1_%7"^_=VTJJ.[RP]' M_,AAN/Y5 [[/B8"I$Q>7$QSE< '^%?@)6@C8/]%4/?Z93Q7A9&X!0VKRF'H@ M@3] U<.)Z^_HIMX>R".ZL9_'!<2[GV0*'[ C$HY0MT?:_XH48Q=C[Y^1@L=_ M/-6.G !V1OY=\^:X./\[NIFCQW>Z,<+Q@O4O,JTC NYIY0K&=2ZNOR PEY\> MH\97F.)T4H4CD7"H!QSF\D.$\F<-7H4_Z%0_Z:80%]<_*X[]K,#I]HN,CQS" MQ>\Z@,X==0OHY_,HJDX?U5'_MD#Y^@^IM>\. X##(_A.):(ZHN)'-L=1F>6O M9<+UHS+YS]9 1U+\M#_:^C6Q'?%N'N':@(BS,Z[& W75J *BZS MG,%YY"RN[(:SU07X-=S^ G_2G@._%VE_R_ 3?B<7 (;RP J"@*,\_T(B@2,@+I!?F57##"]D=$3#E:GL44BX M%A@&1M@CP4Y'VOM[_IPL*+XSXRGX&AVH"]?_"_83HA >/Z:P^DN;W+7VC4CF"<'-@/J>.M;6Z@_S/)D?TD_X69W!6."%#Q@+C\]!3- M=^.U?Y+QWG4".]NCCK(^*F,F_PGXZC\, Y\I^HE Y'Z?*?Z,<0^*3X#^2CD7;FNQSN M(E!> 7[3&8]0?!>2'97Q' !A\0\7X;,C?CSCS"&_?;0M.?&?;3]H)Y0,-*>RP_J ?.6]U/D/FI<'H?CR2+<7$S\AF#?/SQ;4P=Z.",C17H0+7\:MLU%(16[N'\TZ M.?YJU1,WYQVUZ>0H O8 0\$PI#?.76(B/WEQEOUB_EN__L%H8/!?LT*AO[B] MD:9@Y_^:VQL_-8F8@KWA*(0C&,?.\UM8PP?Y/Q'6\,'9]4L !=A3KB-$FZS!%;DQI\4"HF*"XE*F?\\*13"W45%?S##G2#. M_O\6JQH"C&/[Q2J*JQ,2D_B#5>:OK+B% FX5\S/"=7X[B$M<4ECTS^/,(R$# M WD=F#?2'H9?)BIRXRC"$(B3O!387DS604I,2 KL("XD*>$ %I*5$@,+V8LZ M2DA(BSD[.4A)_917ASNB\.&(E_\^X)S@CK@V?CE/7D(,+"DM)BK*!1>)75Q45DY<4DY"55- M=54Q,3DQ2159W$A5EQ"3$I55D_W9@"D8Y@3!#R@U#WMO;T7N'TLL7 +Y[0MY M,Z0] HGR-$; G2$>.,\>[33_RO+#FV8HAW_A4&XN7#3)XYIP0CF"$3\9C'$Y MP0/B@+!'^'.)20GC^^:W(_3!+O:._CK&YFKJ$!>P-RZ,U-34963D)"4E5*35 M)31$U52EQ-5%)=55)315125EI37_E#Y:!N)"!Z>OQ)]T'36U7X9XFVJIX!])1\4#^0/S@.#'@;R'/! MTWF1[YPX$9'?TB)_M/DC#, (B _821,!AW(=)0UYR-\$EHRDC*R]K*2HD).8 MO820I+2LLY"#F(R4D*R3G(2#HPRNBV7%N'_(._T1 GAYI_^A//Q_'TK?&T#\ MBU 2^66T-L0;%PG^/]QI!O;Z[=BCW"=O[XB7Q_6+/S$A,2&S@;B, MN9BTO(2HO(3$SVSPG 55QPQO]=1E!3XQ*7^,>D\%W6T147$V#< ME"MR9.W_SJ9_+XO\U:9_F0S_"YO^]2N;?V&.R._>$OG'CA3YAWGY)PDWV1^Q M_UQE*'']!_X#_X'_P'_@/_ ?^/\?_#ZGP*T3%;E]N965#L-38TT M=?0UC@Y5*+7U(3 X 2T 0&%(!'Y]?M':AHNT'2 R $2_$&)O:.WIX&9IOG1 M$;J&&A=^$0_\!;:^?#^$[A;2-N;B OYG0.?HB4 " ,@8ATLXX58V./PV#O?P M17KBZ?@37D8'=SQ.@#_;943@%,3A)_"XRW?\W!'/=_P"'G>"PIQP.%YG3R>H M$Q[_B,/O^J#P+PD(]7%XJ \$[(O#>W XKP<*"L'A^#=.C%"PO3< ')T>\R+! MCJ[X+V?PY\T( ,@H7?[ '?[ D6"_HW>(:G!/_Z/S:ZXSCF>YQ.3D M9+FTP;X>8"12R!C7*?8()RXU.-33'N8/ -]M/@+Z?]H@_>&H_[+RWP1\WW[' MUDV.^@S$W/J;]G=\\)< (+N)\\W#WS2'! HO0, )P9_TWB? P -KM]*.OZP MAQD?+W\']YHC;GJ(07-ZX M,0'F$OK'(/Y?"_Z]'N=P^S,P;G^&D[#$11D$YH+K[A^[-2X([%]UXO]2[!_@ M>USC@"'M &"\*@S0=C "A(NM !'#,8#P]T?P M-R\3":+P-V_(T2LT0,W4G,L1A?#Y7G?TUHP8H !H $: !> >( S@! @#L@ M"L %0 /0!8P <\ :N (X JX %$ OL UX 80"MP''@*/@40@!4@#LH \H! H M!:J ]T #T )\!GH!-/ 5F +F@15@"\""0"!2$!6( <0"X@3Q@01!XB!9D!)( M Z0/,@59@^Q +B 8" 6Z!KH%N@^* 26"7H"R0 6@$GPFJ"$X#U! M"T$OP5>">8)-0H#P&"$SX2E"(4)90C5"(T(;0F="!&$P83AA'.%+PCS""L)& MPF["KX0+A#M$)$0,1%Q$0D0*1-I$%D2.1%Y$P40/B!*),HE*B#X2=1.-$:T0 M'1!3$;,1"Q++$^L07R1V(?8E#B6.(WY%7$Q<3]Q+/$6\14)"PDS"3R)#HDUB M3>)&$DCR@.0923[).Y).D@F235)24A9205)%4B-2>U(D:2AI NEKTEK2+M(I MTFVR8V2<9.)DFF0V9#"RFV1Q9-ED-61=9#-D6'):7(CDH!2C7*RY0HRDC*#,IWE .4ZU145*>I+E#94"&I(JFRJ.JH M1JBVJ1FHA:EUJ)VH0ZB3J$NHNZB7:,AI^&A4:*[0!-#$T;REZ:!9H"6G/4VK M1FM/&TR;1%M.VT>[2<= )T9G1 >E>T"73==$]XV>E/XTO0:]$_UM^E3Z.OH) M!D(&'@8U!D>&6PQI#/4,4XPDC/R,.HQNC/<98Z)DDF2R9_)B2F*J9 MOC(3,I]FUF'V8(YB+F3^PKQ[G/VXRG'P\7O'\XYW'<><8#UQX03X1/B)_!.] M)W99N%@T6-Q9HEE*689/$IT4.&ERTO=D\LGZDPNLC*P*K(ZLX:R%K(-L!&P" M;*9L@6RI;*ULF^P<[%KLGNP)['7L"QS,'!<=1PS'(R<"IQ0C@?<=9R MSG$Q<:EP>7 ]X?K(M7**[93V*=2I%Z?:3V&Y^;DMN&]RYW,/\U#PR/(X\SSB M^<"SPLO):\![C3>'=Y"/G$^6SY4OGJ^1#W.:_[35Z;#3I:>_\9_@U^$/X,_A M'SI#=4;YC->9EV=ZSI*"G>>( MS\F=@YU[>:Y/B%)(1(\$E82F1(A$F<2JI* D6#)9LE^*0E:&5\9.YJE,GRRCK+'L ]E/=GU#D5K17?*'X58E+R4[IN=)7Y5/*]LHOE<@T+C42-$4UN M31?-',T5+2FM0*UWVL3:>MK1VGTZ[#J..EDZ*[HRND&Z'_4H]66S>4GCTN-+4Y>E+H=>_F++;^MGVW3EY!6/*]57::[:7WUK1VQG M99=MMV=O9/_2?M-!Q^&IPXJCFF.\X[S3!:='3K-@17 ,>,99T3G&^9N+HDNL MRZRKLFNX'WI8>>1#R:!VT'(8/# M=WH*>H9Z?O62]WKLM8+00[SR!GG;>I]; M/SH_F%^KOX#_/?^9 ,V ]$"B0,? #]=.7;MQ;2Q()>A%,"C8(?A#"$_([9"I MZUK7,V]0W'"_T793]&;,S8U;5KC_N_MX#QP?-$6(13R(.(YTCVZ.DHY(?DCR$/?P2 MK1R=&4,7$Q S$6L06_*(ZU'XHXW'5Q\WQ4G&I<13Q*/BOS[1?U*6P)OP,&$O MT36Q-TDU*?\IV]-[3S'/G)YU)5](SDMA3[F?LOL<\KS_A=:+DI>G7\:EDJ3Z MI$ZG6:8UILNF9[TZ^>K^J_T,6,;73-/,CUDR65G9;-E1.00YJ)S9UY=??\Y5 MSRW+$\I[D<^R;_.*^(J>%C,4AY> 2OQ+5DI= M2[^669=UENN6?ZA0J"BN%*[,J#I5E53-5!U50U%SN^:P-J!V\YWGNX7W+N\G M/ES]@*Z[6-?ST>1C>[U>_:<&S8:Z1I7&VD^*GZJ:Y)O*FV6;2UND6TI:I5J+ MVZ3:BMNEVTLZ9#K*/LM]KN@\WUG3I=SUOEN]NZ%'IZ>EU["W\XO%E_Z^RWU? M^YWZOPUX#*P.^@QBT=>'B(?"AVF'XT;81EZ.GAW-_RK]M7I,?:QUW&P$X M,3_I/;DW=7N::CINAG,FZYOXMZI9S=G/L2&Y\6'3>'-D"[J%Q81OLVQG[LCN-.Y:[#G=Q.@?Q\(?@/A+_A+/>C/FG\3OG\W<1%X M3@BB^_.["<;#CR#VMHRF@YGK&PM#I9 M^*%K?,WI%C+V-CCU;5WWQ%E9YW64@)R\MHXN;K'FX@IQ\_'U\P^X$QIV]U[X MH\=Q\4\2$M/27V5D9F47%9>4EI57?*QO:/S4U-S3^Z6O?V!P9Z@V>:";3 M%P[,$N0%O.\[U1 KQ\=N2O+%F)UP5%]]67A:BL5<6L.)G\+[5JPF$J^O!1AE M*7/[SI'"ZV=//DHKPG]P\?C[%Q=GM*R<97]]=/'[FP_MBZY^=Y]DEGWJ_[8M MIV,-\;^7D%7>-#"[(R"O:^,6$)Z87=$\.+?[UT\S1B=&*S!7,$O5?=78?-1R M\/QPX/\%0LCAYZ.&+8*&.>6P/+D*CD$+E(:-_0-LSKW-7<8F5I.%J6K[([V8]RG%%CW*[K6],HM=1AC !L*L1-YURKJ M1#QKUJX--[.MME;EV[<$>GSQDIQ7=1Q%4*(39)JA*_)XOQ. 0Z M*N93]G9A5]T/@2Q6W[U7'=CCST/VF(?6#P']Y.Y#0$Y87H*3*?CB_>EBF\!H]Y*!/%>EO;>S]Q)N/-%3IJU867$?\/1=J*^"\]S]2Y>A]>DJS M)]15=6V^CK$-*K&CN3!K)]P',]R# M*HX;1[_H"J=T;=0^P>1PL;LU.<+?!5VC-CVN+%VS%R MUEY8MH70ON>-X9RV($I$HA:B)4@V[@/BW$G[!K_K+%DKX[9=:(R5.Z5Q/ MO9EWZY36K=SDR)(XU^@K N$VMZWI;HP]"LE=N.4Q4@HI925+'P*[#CH1,4MR MO2'BC&8_CHN+8HY!Z+6(=H6XT4]H)ZO/T'AQS7D"$JV+EW.R"%X\OLZU0]?) M@AY;G@FOP9RU3$2YO7R$;1%POW*OJ0^$M,1XE[^:Z MEE;:$*77QP)"))6G9M!H(Z]-F8O7WG^KWAP(>G:[V8.CLA_K'6CL),.\/H+- M"TVE*I%^-?I<3]$'KOPD)SPNCDLK!F(!$PFQ=S?4G\ZMF1O M<,V\BY(06Z-X'A-$:K3>)[:0-,J[[M-9!"/WJKB\6$JG1F]>%=/"JL7F>C8N M1M/<6)OX"8$61Y(2\:81Q$.I>SC!8+TO*6 15EH+/&8S!Q0KKIJW?81_L5&(*6F!?#W!5OXIS+D#PJ)@:@4#>M M511S8/3BY---;*U&5^-7POKPU8F#,+YKU6>3I>H%0SZ?&14TZILJ;8S:/SX< M?0CT&2&L=O<6.3<P1=\?LMA^:FOAK)-U%L&T MT4/%**Y+Z;IPC #$T8RI#?#)[7,>]ODXL,2T))3^@+[I@I.FL:$?@5N ;']0 M1/E :42IMT*BS TOQD=?#*[)F:J>_2KD1GMC2-S]2E[IC)9OB(1P];* 8NTJ M?P;)WAQ$'@N?S/;.R!?#IFAN9+7"SDB<6!Y_? D#;:Z%/TA_$7(1 M>>?=0?!H4"?:]]MBN0)X-^(YFN?XBMK!"Q=**1:SFW#J 9@N&Y.1RFT(XBGV63U^551!?/?X .]23(Y@0RAR?SU;M, MVIPM:OYH+@K0=935P3%:P\\&UR;@@PNY2R)CE%3KG9_=+533!.!10[N:7V*N":R MT[?&7WG@C_%M''G_R4,W\FU_RNQ;;*7!K8'N<1F*$*] "8;BDN71Z5%%6W:7 M*)J+XX%F6M./PDY",_H)HW>P";[+GC(CMD-.I0JVM3W?R%FL]L_VTN>^[BM* M_&H^P^XD4JOL"W??K\&6!X8LN9Q#PP3;DJ*6\MG3R^E5@_,^Z-W;4#^E6OQ8 M,W(]W:U\HC/[P/D0X%4P&V]LJ C^/#N76ZI3F;:P'U9\Q;;W1JR7PR%P"T81 MOEWH*K;JM*HOD #I:^2/:^I(&^VO'19V'O;7BSN.&D@4\X.]C*I&Y<5GRF:V MDZ88SPP+#M888L*&(?Y:R:+!O%@3>@@E_'0W,M3H MMF(I;@DP'J*)BRF'MKN9(U@,N.[ID+>=5WY87=/#:W>")*1(Q'6;,:FWZ@UK M;DD^'1I-<;E\OVIDG?3,PJ4OXV;SL%-?=C4?Y[TZP23YCAU4LW+Y\9M [V7E MLLO1S;/R:P?H8(?K!EQQQC?H*BEA-8J'&A@7#KR)K;7:]<4 MJ(,+!HQ&W*^_^N QNZIPC^3#@H?F(#HD\&G0>UMVZR@&:Z[,8LE@B,>$1A$V M4DXDQ3_VVLS^3+POBU!['VFOZS%\'SS^HP]2J@\!WUJ/@,+9OYUJ72/WO7+D@ M1$R$T)8R3$E0;!_U%78IF3*"G;HY/GOQ=:Q\_(,W=9]#C=_4'=R31BGR/&!8 M/8%UQ%A/ITUS Q%\W'6PE7AG+ MK6_)3M3RZJ^N'7RTK\4QU+QU^CC?4,C0;B)+I3#[8RIJM,*(&\MMUIM"M\LA MT9[F_G)T<3=R!G7.3GSNGG?D+T\4#!KP\8(*3T94^_'Z'="2CS]T/6!.[3_Y M+''NP@NWF==\%4/EJH9(A?3\Y)X0/U-M@_12=*5[E_Y!XM$EQ_H'.UHI:R4ET7EB5YAB0^!4]Y$W=(+[$]ZR GNA3Y M,II1];H>NYZF6^L)/7:^.W>D $T]$>LZS!UL?B"\)%"YY6 KD%AZS+NY03)Y M5OCT<6J/)6WM/"M]DR,EI9VT(ZQOW#(CU;HSUDD.'&P'OAP"7+LSXREU M >PORBM#^*P>I(VH>7UUDQ$Z,\S:),& 4)B^3*K1$)-5+T^/(CO!^8@IY*E)8?MI.3G!1[PC,EG,\UZADF;/_1P@ M(^'9J96J;U/D9R_H9+$TC$+WWY9@ND?<@W4GW?VEDR]55R1:2,B5!PK5T'95 MQ931)4Q%,J4SC_K MK51Y:P,_'9.4I:F\T.R]NIY$YI$3BZ5E9V9]I3N?9S5I* J83)Z$#'45S?*H MG5-O2Q[U%EYMNU;-O%BU,-[N[&/QPDTW&S).Y,DA:I/--&?X[,)CGM?TV$:L M;=.5S]A85--0='MC0$'DR%G>-*SP.+L-$9<2@5NRQW MV_EORDH?+VVMNK=@I6>J1SA7W5UM5!5=15.G%S4XQ>4C%*LG<]%#P;Y3,(W^ MKLKDV4"FBI/F7#[+CVM?, :DAZAK*II$K4T>0!27AT=Y70,")^/,[/3N+015 M)H39U?0/WG*KH7FS\M*@G@.=]%O!%FD08RD 'U8XL9 M%=@#;&N!1U4;7VV8-^NV!D-=MSCF-K])#POA=;^8EPG\>:'[L\'?.(8#0Q8M M&L\'6KB4'VO+GN/QWSS.:0I9?H[)BD%6MA*4[^Z69A\SK6JH8(_,X7OS@'ID^[[-19G+PF MF21=5TF\3B^PO:\=7<9(RWQI/D=2S7N6R"Q"0\=6:& W\9KNW 7-@(^CGD$5 M6UB[K76WT1+%+JUI$MKM\*Z<+)$Z'8"WYAPJ9>_R)Z&-)Z_ B./YASW_?"K@ M3KCWHG9Q7/GL(; RO&QT0/;4JLIRR_L@V0J7P=L4\K'Z5RIF,$.'P$>[K<"# M@)(H;&'3EXZ1M8P\3=1KY34T^-6!1\CIK&P:=$_S*'^7O/^-_RAQ8BP#9 M$$DOF\>)^YY4^^.U)8K)R]ZZ2FS[/C1LE],#YL-&,EF"ISFZ#6A[:5E!Y\0! MA?F%7('8; MPX5=NC#I]UY.!C?7CCD>4&Y&*@]OO ["EG/9(9;&C3Y![KJL MKS3U.??=Y@6T.,?S'S=7B!Z\>'R#LX?3 >Y6.SN"2-E;B]I>1S'M+]6N\BE^ M/032WX:>>V_#2^-2HV*&BU(DG$8N!9?3_GJ=V*E^<)NM\G'DR L:2G MGHX0W/>T:")6:@[7M:VD-WHB_FZC4RQ6O3&!S2@J]GS]A"8=!^H%BK)KE1[+LXJ<-_IVKW84X]: MI,>;/O245V.+I(OMZRT79&?G8^2?DES-1'!K"[QYU?.'O6\$)Q6]2]=A<=,+#SGQ9-.ZDYMI^Q&]](@6S/W4E8/C4E(A7 M+F9 9/\M72/GS3!SRWB98^-" TY\SE%>NN=]#4Q9@I-?7*-%LP0V49?']AX[ M!.24[Q=+]BB8S5RUZFDL]<483I:@E.TM.G68B(."63DKO-KZ%.8YY;<'@[K[ M C\4DBT,#N8P6:X6?TGDE=U?OBH@KP7I0.MM7XJ(U3S-0Y3]Z3R+RGH,"QEG M5\3=/2Y49T=91F6GGE?5_G!Y#0^J)7#!2L@I[]A+W:WES2^1$GJ!:+!//9$O M70X%B^TMJS7X]JA9Y3QFN2.R/\^VKS_H7CFFAM/>RNJ)@&!F>E9K;Y=/Y$&N M^5T-C3)?GP!RL4?WR")._N/Y:^3:VJL*F5AKMR!,7RY \>.FY:8FJ M8F5528,F9?MPTQ=']8W1CP4I@09C.;<^10B=ZR("!YTK'%5 %)V?:"FM9(O= M-BVWBM2U4K^KQL.4V5/,:&]BGG?78+JQ)L/"@!!.Y:AW8 MLEAB%R5J5A&] MKD^A.L:-@FW):._=]1&T+^_6?9)9M[G"[)C.-YZZ.BQR73WV:5/6VEF,_$0' M&\J^5MA:;\TV>"E<',:67JG&&Q?3?%/A[N!Q;"?*>0-'S2Y MQ?V09B9_C>1EE/MF?'UU_N5H)\P=TZU\.S?(G?.L[AY?JJGK&IRHSM](2V]9 MMH@]QJB."#?6+8\.N+@5#2X8_CE M^3??61&[1=?))K$+=)_[LU04XI M&!\LA!%;*XU]7XF.A3BD5+[>=H,LT2I.WLNT?UF<)M +2/7S1O!GM^V8]->> M+##GI/'5JA/"/FWR"6D8SBW="G4H%2O :+;H#P_K-5WK=3]?"K%T6E@6Q^?[>RY&=RXU"Z/KF\WW^4JTZ3,/5G?>$/P\.#637 M\WRS*%[AX.?B;O$@.YG""M\@]5@,QL[6E"T-9[#132@HN-K+"/*Z*8U'5KB9 M4)L=NR1\.\:FK3(N_&6HK54W+R4IQSI-O&^@H?V 3]M6*PW%'%/($\G4LSNI M%D:M'&492U9\2P?H]3[)-9*-5MC6_5F[K*^?3A8TWTPC3A:/R97-N1EPV/O/ M,Y8)_]K,MM6:X_,:9]\9Z-:7#Q\7:ZI'MF%?T@9W*H26BS'$AJJIWA@ADL7W M:?W7-*":FM/_3F8 M3F T]U86KP5(;NS=3%[X_JPB=BMI*,4AJ'0R3V]:)V\G"9X"<[^;V#7.I''+ M/1"B'6=N'B1!>_VL?)AG]DP.&J.,:L\K7M]YME=>8PBMC4V@>:),ZBWVK*-L M;6UI[V P8^AB6VEER9?U%'JQI%B^DHRA3.PE'ZCM9E0&(4]H?ASG6E;Z&3X= M"[M&0]^M[D2H_RM#[TFY0Z!ATIOG.4J'7K7"]F'M;!/;<]^&25\&W5OH;D[[ M@XWD+EA-UZ5 3LSM-\H50G;,G]L_-RD6;;TTHB>;H0UY<&G(1F[_6*9%K8&Q M=*BJ$TB&\Z/(=/$Z&NG1JM7\X &[>Q^K+^^TQRO+H/MWT]!>'8R/!FSK2^1' M[:RFTH=9IZ\9Z/?T6%C+9V9!$J^P\(@+ABV52PQW>,(67DP/$.<-,("??'PA M&(H,I1_A3=>Q<+'+N7K*V"DH?V2YO'2XSG4TO_I9,12="'OYT>M^^4D$F>O7 MLIHJ[?KJY]&6.HZE$6F>Y93O=1=R^Y)HH)L^=0/5T+>9M6&+MF$EHH%:<).8 M"%[9B-K(C ;C\'OTLG$!&3>?2';-DECKR4U%526C?;"V&?!"]+E8@_0JO9,T M&AH4@G.NXM?: Z;X)=8YYMOV&FO6+;%>X\L*$4.E$M*NX(1!K>>\G2H.3.X: MQHQV*-U:\AKFO:39T6EW(=&C%;$,9L.^A?% M!7'DLQ*9$47:8YJQ(^2")E<*0D2CIEJ&60YV!E*$@FFZ)[R"*K!1[$]&^BTZ M[$MB3)?/L?,\X'6C.F9Z-B=EWN8TF-*K1. 7AK&)$U"*]%MZP.UP5-Q M5_28\]E?US"6GLQ-A_>B)^E(HHE@P:\:4$3H3Z^?9]+>*1=.'%*,K0AH<7'& MAMF;;4:Y6MA_M5TOS/3N'^X(KUL2"'S_\( TN=["TG3RC45A(X81=K6]:"U; MG]G"\_2SQ!E$)?KB"A&%9%\3ER@4/?YMX=F.JASMU^8=08?V"MJ]=LN MKF#+=C.RWSRJO!\":V;/H1ZMLW06ZZ=P&Q!+FO=PSK'4+[%Q%=MP. >3AX"B MWSG16SP0M5B M"VY1/_:I:JK]TJW!M>%'\2002_Z$1SH0+WI3V?<^KR-3B^Q./B7L\MWQ0*8X M[P5N/RZLJ"Q=84QR";+'\-M/BLN<V+>)F]UTD>91EJ/VW>/):1^3PAVZNX M0+OYM8WXH$TK35%-O\>E?&%$4&AW%?KUI9LZ8F#J/,#?-KYR M=<=0^I)+]>7W;7O1Y8JCPAWN3O<$ZWDI;5BU'1Z>F**8T ]_1W_FG;G=1LE. MW>?]@C6MB>FY.5CR8D$/:Y1GF\Z>%C^?D,L ++>6/+KP$NO9IW4ZS-.#3YY] MT!4R5#N>76RO>5>P_MS=EIUENQ&Y^'A8R;-8OUW!++(R2@K+> Q@*IR5BO=_/@6A(-//+92\UAO_#FDT_YF'>2%'H"\R54(K)USMR.]K'T MY;\UQ/C6[!V0J*;7U4\(E.KV0*NI1.#9.;$*UV5SWRH@FA=>]9X_? M$]Z2EZ"64W2YC8["(-:99_;]G^ZSSVD75C\/0Y3>&]8.8#WA&,=,M&?R7EYU MQX:8/X?EP"J%1(;SPT'N<)>/L!:-]:!MUJ/WDQAF06BO430:*P$J\7K[&1J1 MHA:7E9&>)&.KCF!"26W>E!V+RTYKI'5]J<,;4YTU*9BL/9AO."4@/>\SUYZI MH]T)HFLXOD];75,R.L[IB9I](:4X'6$Y/[R2R.-W5Z>/O, M#,>6A*](.=/Q?(LX==],O/&$RZGAQ[H<;0=7J]%K:C.C'M=N[.3TGC@)B\@/ M.Y\D NY;-BBO..XYX76:*K4W*5 P:K"UW:6:>([W M)5>&EZO:ECB66R^O%FE*,].,J3OI2&5WR=+=AAK32>GV'@+J\/.;,O!:_^ + M6V^7!IJ"!P-)VZU$EMB@Y!45>M:+>RR\O=YE!JQ#FDR#UJT^T;-$]UWO+68G M1X:Y'@("(:$*27DR7T;[V>D*I$EV6Z'G-TG:1OJU!6<1@9>0'1&9^B2(1(C M7"IGW5K-678;&:L'X@]5MF2'J],F[^>^]2Q!EP>/C.R/>;%ED[E."B!%I*]5Q7N4_&-2@6CU7)K>G83/B6CJ4-OEI4*/XV7M@^-2*XV53@\QHST M=X9],N_];-(%$S :-X_@=8VA?)I]KO/QENTB=5/;7G'QD@*_!'2>*;ME_$*+ M@+:R&=;\98$ 883[97:/\Q5T^QMRRP,A2/_2N)V9P3RGN'7OF,^#HVEQL6AZ MH4_,ODR/F6P3259X0?>N9J@][)T__/)OO$ZWS_)/S4C6]=,P4/=L7C%+L*0[ MW_R@4]79KH7V\3M;==K2VEK44E;?COM>V,Z=P4ITC:=B;:\U9?*[%SNZ([4FN3FY1EF.W%B@,-Z)WYT>4B)I$J+547 MQ!.+7(-6Z2$QNX:% ]9)NF)VHX'Y+IM+EWL:M=3S:953+E$9&\A;8VC:JZS, M-UP:874OYO:;^I^]7WO%'A8QJQR%U1-YH+^%B_<.UZYE^3VPX5QSO=:]C]"( M^- XZ[6$A#$Z%2+=$?HN@<"N=.L[KJ0,?3G7 V@/I#!:GY*;6I:K<]98QTNL M)KYX.ZN4YH@E17$.*#@6R:-#S):8/GV";"6/UYO92RC7;\U]SIY\GM70R"@D M&7 :L6NESVB<8Y5/<*U10T]Q[Z-";59I>Y=1]"% Y180GR$3[PZ-?!X5\K5& M!17F!AN.+9.9=KY,>G4JD"%/^K9S*=7UX00Q6GHS2XMJ^AZNA&NW&N!C-ZGC MLS(R;/(S&U7ZFJY&IXB6R*S+S+47SU&7-/L(MZ1,Q&VTC55X[XLL[-\KKO1* M0D"U,2*0J4*YU\2!BY<[C'MZA*7C;D)8"E:5U,=TA3< M/>&ZX4,I<2E>+>*]IJ8-D,<44O47E.ADTT-ZDW.O?)4G]%5>/[<<\""CV>9* MXK9R6: +U>KQ$@RL<6&XC=-S,2C_0?X@5HO)*#XK?["H7)^R_.F7G:SGOMGQ M-,22/1N2FBPWGZ[DE&3^68_XVG_ M<-^:X_@K-6?3!0YT^\:KKQ^=2J<=_%8M%!KY2\_.)_E"@VHM)._%H6,XW[1N M;TA6$!1D9UFB)#-)9_KNC7T.69,HQ>J]/@02\UIP\7*_5B$?"8/?DGO@W#Y; MI;2EH&7?43Y:+I#CYCMJ!Y:P0$"%7I2NG+A\^:$YN(W*V6 R,R/M5;C+(TV/ M;$I]'>H1+D4F7K!SR\B]==E_ M\[#OW_P*QB)Z53#MX.(UGQW2-1X(>*O/<$;IW-:RG\_HI\O*+EUP@_?'H9TN ME2P^D_V+469O6*'"U+KG4!J4\XI>G[),3IR)\;]PK_%,@A48V0"MZA;%W-G*GUMCX.[S#!2R)V]6AL+ M*&5P?_:'QH3<_+S$2,K)7I(DMLA>#H$(L0OQ-"QG)I^I/G.+>"B+A&'SQSJ0 M2QQ)VRJ5NV%R!2LI C4TCM*A6F[COH\-#=]F8[J5K1T#L,7RH\J/&TPHZZEE MD(ZS%(YK*]T[$)=0.4JWO'J!/)"GECNJ4#8@,A26<6LFS 5:,Y^ZPQGQ;>E. M&,K#OR3>Q&'WDO?22-U(DH2WI8-WD;7ANR'64;&HP6VW2>SK9VQE,C3:>8!*::KPVQJ;J\Y=E0E&+CF[M!IQS+!.>/E8C@[+ M]J2^PV6: /^5,(;(1TVF;IU=MF=X[%!4)!PL5^4W*WP)/Z,Z0Y@#0_)7E5L3 MH[SJB^GACVRGAA0.@")T M_O7!HL;-.?U]0RW_DH&V0\!W;Z=B\M6CH*>FIEWA<6.)ROFUQVT1,M'Y%EVN MJ=TO%":M5/8:C9X&ND_E-[CN!O(]&%0^(5B1(_)60<_+1?2SCRWJJGW?4D!N MG. ;/\KB*ZVQ'S=0&RR?!<8CLZ.S7-)=72 ,S4W/4ZVB+*5RM?24PVK9 [$, M(XJ;ZZ13R$I"JJ%]=.D6YR7H0<%<58F9E\=(WEQP49*,=>A'\Z6G-3)T%A6E M2KZ*R=EYV5DVKO;W;$U(,]-L?&P$^%SE5]AT)OI^?$#VWX])\^B!ZO<#9=0Y M2U4H?N>M"\U0SGA_-OUG306ETM\Z[#'2>F>+99+7YZ^\1C/ZGV.R&RB236YZ M.8B60"PN!'30Z@NK M[BWVI1Q0NU'G()W\[8.I_9PGRJ1G\I$5>>L-@I1 @RZF5[M2MI=+K/XRP%:T(ETC MI>'C0]P8J9[O#7' "I9^\U*XF5NIX NSK2\+B5_6]SFFH56&N3QP\"(Q/,G9 M$7O,:PD:NNV,?@.O>?=JR/]<.Z=T80ASW\W\.[,G!?R:JDG$MBN^A,1K7CV. M#KI77$,UIL#@ZI*#2?ZF.W>.I'$D\! @CQ_:L6TJ0"@V[7_JQ\YX37P[!"K] M@]JBFSL MM90B_3[VDO"-W.'MJE+N^)+MU9FZ3/UEA!TZ(KF6-]MJLKE_O%YI951\8<^Y M)6,(,2-3TS&LB"A;6)(OM'GM;1"+EKWCU:D!IF?15E^86'A'^A\8ZF;+86YO1W2H]R2P(<8' M(&Y3X=9SA*V/O6P\W_XS2A9C*XQ-@8ZYC"!E$SPE%5YZH,Z5-[-)J;>9F$6\ M;-)AM3 UM=#O>^P(IN\G*0-HS%?6YH>5571T=#=-S4R[NZNA*CFO_4Y%'L_) M$:W3=\M.E#)35,EX%:D(]^D\F;OPG :UE!:(N3(_LM]7H;?JG;K=>QF;"CV.V9"A+CBSV MP'0MW-*Y>GDX,/]G4X<#_P]02P,$% @ @8K\5$L#F$=?4P N5H !0 M !S9V5N+3(P,C(P-C,P7V_ZK_6_ MF+7N>^]KUZO]KKUG;B9OY@&4\JY@*V:![[GJ63DYT8#X^M([>)&=04Q V$VO"XFMCQ\''S\@ DI%WM3( 0D!.# M*<@";"O)N%O;R,@ -I-DU!94Y56UDP59@A7='4#OW%]K -TA0%$S1FDI!@E7 M,5<;.QN0DPF#JXVUK:.8JR3C'YV+W3[_+N9A9/B#Q0DBR2CSNX)!1_4-@RS4 M <0@S,W'!>3EY640%N4&F9GPFSXS-P%R,O#S\O/Q\-W^"W/Q"8OQ/Q/C$V7X M.S'>#NA@9B[V5N[EWX>[?9-D_/NZ8# 8-^P9-]3!@H=/5%24AY>?AY^?ZY:# MR]'-ULG$EG/'N1 CD 'L)T3&&K+\/O=Q!3J["3)R/CG*FSL5%7_T?%_ MNV$V-CQ_O)1[P<)&8B7R]Q<6-1<\!F?Z6TYX]\;F_TWJP>!0.:FHD+"7+P@$5,N@6<@ 2Y1 MX5L=!0%%381Y145!)H+\C#RW,S(#BCF!G:Q!?]'6:F^V 8IO+*&_]Q!JQ_",FQ<@\D)) M%1O[#]]!2(.A!\"B9E&@P00 ,&___JAC^:..Z'*>_G-79;8S+)T.B;F+_@;&4 MU$DXHIC?H<21S%D([UOS"U,_)H&AMY'?6YY%"9)3#,N^&V'6^%JFJ44ILC:8BLJJ#\^<-7 M:4%6 6.6(WS,6&H9U>>B-1(38\V>#@$V-8WW,9_R,4[Q(";MT\$8:]9LF,SYCQ4 1+ MYE>5]!4WX<35W0HWR0&%*R.UD2L5;RV'59%Y!DRE-!JE)X\;4:<\U_&4$5_! M28TE)($2S7D)[\JSPH?/)(_M6%]A_B\)WV@]I!PQT;\C9WR)27L6JXDZ.G;R MC+IT/':M]L*97)E8R-L7S;W4[+2!L&!<.[#9 SM7[Z"S99!N[H97!K!%B<+V M#?>PQ->Z\'20JRJLXK-\C8 M>K ]K'^V:G(C9(+N,*&3L&5L;V*%H,+@.O,\>^[<:*;9I_*LA+MRP&6A#Q'+ M+RSNGQU*7A>V#)%9, B#QM<4O)9^:78#>#KO _5?S;::GX!J5ZXU=&8U?^JN MPAHDH5'S\A2 'L1<:XZ,C5O,Y#?"4(,N"!J1T\E4T"%EG^3'Z@?)K5S6\V21 MV@D$>U@94:.X#QN5W6!BCFQ)U9(]H(Z%\LFYL_*6LH0YGPWB/7VT?Z=1ON*G M@E^3B"!G5(@GJ)I7L,G J.XMY8=U;IAN]E+8$[&3:;H6U!-GBA,5B&!MQCKI M3UWM[_]+8>#1'<\0>D::YJ4J)B[-*(H9N$^*M^:[2L>+SR @(_O&O=(Y%S> MSOG=\Q3_"B=^I>[*RM[]E\4Z'I>9G4 P78Z]9Y _E7@!1[^39&-LSNQ(IY1P MCZ=AMOKH>GN!R\_,<.[]H2+J[HR4UQ4EH1:+L'FCD4RT0I#N#8![ G+DJM8^ M='":O'O4S<1M&%"9,BT8^=+'<^JN=,N92.4;-IZ/,H M;)R_E"QLM%]>F BG/EN=DA@[64=19WNN,)$$]1EL"XGTVJWR16\ [R@GN2-= MSV(WH,S%+O0S5[M;NZ>0,F'_Q.#/*'7T.O70ON[.\=.H^Q6M],#PLK"!#KSM M?!,J8"!KH&!Z'6;PZ?/_'JF^T&:YD_-7.;KN_6V"BTZ: MKC;*+:L2LA4"(PZN:)_LA #FAK0;\W9_0=!T:/X3Y_7#9KO7B*OC+,CKPU7 MF ]BI[?%4#/9] 3.)QN5%%5.C/];Y_,:YJ!C,MTLXA2E>#>,E>"+B$94TYW1 M4ZG]]J'NS?[I"V9',:,0;ZA%"8/NU817W/N +6NA?)>*-A1K&I&@R-%1(=:, MQRZ/KJ20JE.LR"7T7))0Z1>XU5'"QEJ#WR*L3Q(A8BUMX55UGS_^L0+>4WV=P7;I ;J+*EC-""O)]I - M3:W+B1A@7,[HEUBM])-W2$,USX7$(\_(&T"EM'9(_"_H^LK$XJ6F9GG;^ 0Q M\L4V?]O)?"RO]:[I@_T)@A)+9U:[/1Q5ID\J8=[J.K-W5=S+;0H M&.X;!#G%F,Z?Y^#]2=(T*^69 PP"]R)= 9@$H!4V$4=7\ZJQ=!;,U]/C,)R4).@FPI5Q)JV+K6&7W<]NMB4NUQ MU0X.W9IK*Y"Z+XOD'3HIH>]I9%G?8Z\7+E41S<_KYD2F,?P;[3LO(1D;=^))OH+V6N/ MZ(8?;X:O&U_D6DYN]W7H(H+()XR0H@6UOD0@-^Q'U+-O7!A[/OU>)M]N\;CP MD(NV';^YLQ6-@N]1^,-%9TDV"JF&%%7SD9/S5"-NF[,=YRH98?-?%1UZY\Y) MX7P0?$^>Q0RQ.MG:Z/EV5Z.+28'UJAN =MCL:WO0P>#(A:?A#0"Z(^ZPO3;M M>C&IS[A=@? C.GPY,"%K=%%5.>/XW( GIN9SYS@D=2?6N'4[O-%I\=@.Z>:: M?^?!& MIJ58OWBS-WCH:"(UT4AT?J/*/<5;MS-S&LV9I-7?,JF^(JV4Y -/"/NV*SP7 M<*X@>W"JVKP8;H2Z:B0$]AZ>A9:DN:N6:]>VFY/AMJ&#< O-IK&I^: A*N%,1J [5X\$Y1]7T=?+:4:4$>Z MX8FBF.J,-WXB1"\0/&VTN*?0DIIPVV7N)6Q]I*%@D79>VR!G^#S&@FXN^4'P MORO07N-5X.)*ZL$K A9]T";X0D.:MN%,WF6AY1/>/TG$S2:FT\;K>[O[R M XV'[?863FNH!]I$4D$_ROLY#FB/9H,B>]&P\:OBK6.$X7'??K3%=G(GCM$O M7!&A MCE1 &"W?J-[?>365%(&LVZ#/F[.]@S]VF;BE6;)\L[CP>HH-B8PS?-. M#$DHK(6I2<1U G20*F-[F@HU;Z"Z]+S^.7^!--H?!>IV2EQ:N==O#OZQ1TQ) MG1=W4H\?7X\^*EWRI[W\R/P_JEM%W56K6!T0$6^H*>+R6[$8A4M MDP[U_#>5.,/))"UIDK#*CL5Y(EV$L!R?\ ^GT:BV2-=(]U?!O?\ED,[[7.!W M]DLO?:5Y5=$[/G+RPUO<:R]XNSW@KS[ [@#!%39](1]\W.LC-D8V?9_]#ZT8 MLU4=^HAPG3#C/^7R(VZ&KT!\(.57/GCWA0+A6!_51G_&DFU( M:'1A=E16- SL:EL+2=:'5.5*TM1ZX;OQTQ;=\#[C@ZC"W+PCU?([65UX.% MW+&IQOC'*=(JJ1Y5V\DV(^!.GZP+J0"?!X7:K M,6ARH]I#F@XEABB<[HV-?QMSG=.<#W,>CB6T$\R-;1P0!Q[L=WLGEYXJ=!IU M2YQ<2"=(QB+CK0NC'+D>Y\L1HSE/Q2XA@\Y7BS\VZH0;8Z]*6WRD45LUWB'A M(><6X?7HRJ+"WB7Y'ZYP.#A2VWD-&RN[L?WU"*)0N__XVX9U-IJ5H]IH9D-S_+7>Z 10A/4>NE63:-Y?!.*:SQLO7P1-I$6_\K?S5:T%;%&15Y3G6V$6T F)\\LW\-HR'H> TGY]#_J#CVYJ9[X7FZTG*[C!"/?$B25VNF_3%:.E9*?//8>.GIS2NZ-V'O-L?:_ MA^ZSX4S>.2+T[>-6/MHD'>OKES8C<95XIZIP'PL/\0'T]).*K;+@NT(ULPV/G'G^,9_1 MMAO P:'/]"#Z:W-T:X4CFW#E/AI(\1Z:9K9"M.WN'#RB26UL+V^=G*LTC.$L M\<7UWNFOM\(^KIN;RC_S;840NI*U,Z1]PN;Y'G2WNOL]AN +&) MU^,^?5D/\J]^5C$@Q5U:GV%Y"!G)T:WEYLHV?W8H5/(VMX''E= _G\Y_K=%Q8\^=KTU>:C[>)?FJ_N\BXY MZPN6R9[F??<,D:QN2*Z)*7&A\_I>S * M5($I05]NZ][QF?KAM" MZ->T+%!K)QHDFGBDAJ=\6,))B$.*2+B*G#Y_=V]9,\NH(K5<=A^Q^U';EO/) M[7+I:ZMS2T]:9Z P!ULH8@1HA1V)A5[Y%KHG.K;+\4%WV?O #587JL6(PO%6 M+DA!?]X=2H9+#L>IE$$OF@XQ!GXXI^/NZN,2MBQH-L>T4I_"9^SJO!Z'E]9^ MEMB8NO![J=?+5 S;3;.FD,,1[?P9&WND4[:PW M^QM?_Q7%Q8B 2 ')L+F5*DS"CV3)1XDJNG$E4X[TSP$ 3%\[ )?2Q]N(XAGW MG?^N,I69Y>/"M%&,=4#>C&#E6#B]^WD!W]*YGLQOQW2'_C3^!G Y>P.X#<83 M6BSJO8JW,6>=I[9S4NG*&RK\L-^*\Q@#E\E1=IK 8WSV+.8[XT9ZH2CD!!=C M0]TS.GCXE7\\^K#B.A@5UO@YP<;QP5%@Q!!"*#3.8U#ZD16+5L_WRXNJ'3K$ MHXBF5[O4D;NUB-[E;N/@UQ&H^_C,BH_K!E;(*@9:[U)2"^GMY!55P.05 M6B*.+@.U.UQA[5\<4/H\D;VSO5^Z#:16#AQSE(RL/+%^8(SB LI"Y60P<#/+ M^]OSVV#DPV*/%L32HS^6]S/E$04?RKE/>X\1=D(;B VKBFYE;)%4-UW5V<^- M0!RZP&RH'(3[I#2<;P!DCV@)LUM@VL\7A\SD[ZV*#G#;L[3]A@A:$6>_#75N MZ08@S)UGFX:80O=5K7\*[CF0O65NSO,(5[%(TYX[$V,)7B.+_F]A08%H?Y_Q MUCC]6I]G6?^2CBS-2 >>&JXRRG[-HG8TSS]>B7GT*)\_WJ'VO5KMX7;8FY4% MSEZS+A41S?(#4_#5X?H"&;NF,ZB^CGQ/ 8I%34I4ID!J30K1&WI9AC&*V=/P MZZ^HA,C*$?'.=O6",,L:6']DXQ4$-F8KR\IY$Y:,@2WL>8 PG;3>ZE_.HL.S MS=]FB7RDGY/OH:?(F&F0'A\3P;B\(M7+5%]T(EPLY*$>P-O< MC-NL*.PVYVC*OP&$7S^,USJ][]LZM]6?PCH6XU+@]J6=%IS?A.D:-?HK;?"Y M3!?RUXE_RG'E-M7<-%LRY-^$JKS(UGIX""PBB"EA4KR!M#Q2\*JK0"J)S?RE1JROGT( MI D= YMZ"6W44YDP%-'#'UON/=4 V#3!/6I3G"OS<"J M&1=L9$.%."7Q_?AE1;QA+9('Y<14FN0*W**"D3.\PFQ?XA;W!J1S7&W,$P*# M2G']]=&=;?=B71"/%+#?1?5^KVUQI2)X&T-:?T#E:FLD7R'_;4WX'<:/U>*HG!C8* M(JA(]0C^+I(C^5=<@E/J:&QF+71UA1*:.G7#^V9?5@FO0:XKIDM$#&,(2B[1 M.'X)9^B="I2)+#D>Y$YZ/2&D:BMH;^>,KZ2O4$"-']EO-M$?A.^\"N2L,_1*XF;>7O QIX5Q5L1Y"68,C,Z\UPNH4!%=9?6_AP M$H%GT,6C(\WQHKH;P-U^%I4Z*;WO3[I/[U[6:+[\J>$<^_24IOH*'EY3 M9>^%!$PCZ_99]I(?MYT:]#.?CD.4W'W]@V*FK%TFICFU"_31XS\*?NEJI;KL MA+I,-1LL[X9'X&6H8RDH? YQG1)&XZ-'(N?YM/B M Q7>Z8GL;KEP MD@;WI_R!%H<2.^'GN<"%NPSQW_9Z)A28"&43YE\0?F18M)GP2\2H.J!T@^B+ M)G6('-4\6WZY.VQR!TR5IBA(@[?&GEY403Y'[6\)Y,^0QLJ[N9^87'*MW\DG.:V-S[*_FQ]?F'TX^JIP3$'^"E4QD;:= M&(KLRT#K/B66E/R(7>9S][R^J52+"T1&NI)E,IG\(:X:6-;++ 4GIA4KH&'\ ML>M[H.D?J15O>Z*%_+=8$@6WE']RLN.)F?B1\X&@E1:!9(8_"RW.>.3PKKZ M#*[J)B.<#Q)YU9]W-KE".U8(B2-ZVG)4P;04I_:.87V-X+5'%!&+?F0)Q9 G MWPGH]$'%"&/+8J-JZ*K>]UHQ):8P824F?Z;WW!Y(2P!F1J2[7T\U)%&B.X->5J>[A+)9=CNU!Q[^'>6,##GIF=5;/VG2VYP\<@5-M]3U^@<3@W K M2QZY@;,&<+O&4WM<28$^2DO8-&![B0F2;OMG(2OQ Y$**;&B'1FI=_45&MBH M';]V3P/S7^:&=.MBRQYFV%FRU7&TXYJ;VL=,UAEF"8V^10V0RU# E*FHW\T* M+!3EE9$9H[BWVDOR&<"+]CZ4L':SM^*SWXLYDF(B+*]FMA*%SJJJ[ J_3_:< MT"VF,ENCN1VB@1GD&O\YRP8[)DY8O?]LJ_T4"GFR8,(SQB4%3D@](Y*S1=\ M>M=HY-1J:[ .OOOYW@!>K?54\7?< 'XDAUSG?[D.Y#G\^;%W1:W.O NB!$J1 MW]F @O#H^,U5'FDD]:W(#QPW5,#2[RM3$^U#\)WKX@4V'6=D1M+L:.]U/0Y. M_^Z]0P\\H->1[I.[-94 4IG67NL*<<@V.<<$U^6FAN;@8(KI";$XV'3YRBF- MIBQ?^DY0R/L?FS#E"Z183R29;#[CU!*4VSNVT7:IN]T %'4#^+5@-R^P?5EP MP22U67='64OL\7_-3(D'@%=^@^>A-P"&#!J_BA[-GD%+5QY=>N:?FN.;OT\5 MEFPM/60&W1$W@(>C 09X.X M"\CK71N*F"8I08&S80)9?1#;^W3NB"2?4CN;40U MY,Q)O>BPY7G9HC-GZLS<&%59A77Y51K[-EX6KN4^K$:#R2MG=FW +6%Z@1M Y!M[=@2/OMKTM[/MTQ:.2G)2F7U[ M"?(])7L)>#!>@C%G.(-@ON5/>[8T@'\R.F3P0866F_V%@_:D:8(R/H(=\?EB M?H:O[!BCLQ:I%\&?D[0JV3[ ,F"?F^0:J::K2?\)#T_2&.+4Z[IC?!\!Y7,T MB>]_',Z9E39!A_OZFQYC700MR:G=!?V7\^9K4Y:$8NO_XA@R+Y MP^CB>%UZ"9*Z6/*>Q1S%E,6.M(3@HW ,18YC]:&DS[,54RK/A&8&/I6(=*U; M4V')C<\=^4IS11_4UDN.)11;_?@O]VUXJWS7S197+WV^O"60T0>Q+UN425#D MA4=JY&PZ_SX7=! 6D$Q;K;>Y 7RV8N3.$3N,:7QO1Y=)T:V3S_P##T]4.E$? MNH9_Z .E%IB>J1WA$@O\_)F9X-#X9\,MTG+XL=F@;TN??:+%PW!J5;7U45BA ML#SH&,JV"!Y;U,D7G4CT"%F?.8U(#ANSL=R5K=BD8F 6"3O,&-VE&I43U7"V M8#N9^"5.U1[Y3'5F[PB1<#3^_C[&67%@^+U^L. ;(HU9UPN'[-Q?YDN\^$!&XVI9IVL>80V4 MI9Q5P8?( P R38"\5^DQ$4/2,,)B-&$>_0JC;BYY2S##_'*%/FWY20C99LRU MJ5/4-#KMF%",**:%KAMA?%L:PN M]XY]-U==S^6AIF\@$I#ANL _<1::7/&JY1W^3&Y;A*)X^H^P(@5,L9;T_ JA M_:*91&^:S/)'/(>PF+&?P>\ELL[$IMU;6C+P_IW^IR/3_P3!&1A^2NU30T>$ MCK-$G.DJM*"DN9#;F.;TJI*;V%R_1R4DERL#Q]%+%O- M4 :L)]K0&P /,$%8/9\PF.HVVRON>U#E[%C(_)7IU,S"CXG<9;N&.T?0QZO M7*V6$GZWD0_V3ER^;%"HM&H/HQ0.B$)">I5N,?LXA/WWJ6I=ADA^Z=HV@'_H^-2_9'@$X(OF ;3P'K#A@9!=<0KF:N.LP^BK?#(% M@X.6EONT'_R"B;#,RL+FCS8]%\OMI83SM"(_8F.3!J$LYFP&\5=O )C%[' ] M!;DKI%3GDE213]QG\SS]>T_^*S#5M!_PODV)P'8W *7%A0(H38O.>#B[JP*% M_*S=FU!FNFW"8IV4\G M#=9H)_"2GI^^L1]&<&6-]3W@7NH &0ROZ!IT!VX[B>%3D<1<5NUK9: M/>);SGTPK1)?74XSXLX?IWB;N)]TM?0P,0E>K@25T9SF-^YSRI^?H[%EQ%UQ_#V^&MSOHS"I\O"^RW49(YR!-2^YK1C$^ M_87[&YLOH8U:Z!_(E6;W%-[>C;-1U/7A/+%7AJ[P2I%NV[@](E>=/4N3]E%7 M_Y5)1%-S)?>RM:Z!*VCK%^G7$,=AU6;)[1M2NJ4 MQ9$V,\^'0-> 2@*K1NT-S1M'->'J<$B=@U:QSG-@)]!#'7O8+O(==_+KVSE= MYX%I)5%SHY]N(?[_K)[JN.*'@['&JO3!MJC@EZ$.Z-7J6 :1%[\2I54G>2G M6QRV)1D0?VYAOL#/,IV1, 6/GYD"TB:E=IKH@!MDB%9BNJ_';=QL& !F^6H9 M.B)[>7!2OBBDAZNKI7NT_U=;KM6*%&6/3S.D^R(E.BGW#28$?OD1RMP!T_-U M,SL(*2)UF? 4 MF! M( _;AHE;O(C4U!S\(C+GQ&!OFCXXB4:;DE!MIX@%=@G?J6V>Z9E#>;I M,42>M Q/77TFEEI8F<.I[H/748WC8LY !;_9,0!CE0X!.8DK M,/E95A]*,,SHKD#_<61\Y(R0M"O]F8'?K M_E0X_30;9 3TI_//1Y8J*KBR* M@$-719!KZ0; C]5N%[DGX:-+> :.&.N]C3TK5[>B "<347A5_Y5X58"UV8^S2S7D?1[(TP9)]Q2A[2EOP_1XFRW\X%AKI^Q MR_M)&=.^E.1O_,: :L(57AVKT_PR( J;J+*(6')K;,P%B=B2C _M85*\9'X! MUZOHB!L =NRYHD^K]I.8@]JOM=\GW'1G5XL'RHN+\EL-3E_.K<>WL/IVBNS9 MCRTH*\CD_?@CT3E$$Z@ +;)/@\Z MJH[KU&W9W9_(>(Z[)GZTV\?GFN6ED;R++ P5.3,G>RKNG[0 M5X]=O%.7N D4HO+[2M>CR>>;PT/3PD<)9#V,SV0$^"E7X$.*8CI[>@J?F?SKRR5)Y=:3:AX[?7B M5D-%CM=#0W&+A0-*WU(##$(LHFFR4-10!]F$KFX;;$Q1QI2A0OY7*_5UN)$" M=J[@,\-7>MRWZ6;W#0!YJX+2,;'*1Z^.C;_MT MF>]7!V]#-_V>DD]&T*6@ SP&N7P#$*JX-D=PA;?V]"9:: 4J.M5G^\?-3]M# M@C#C:7$Y'"BT3M!">E)/5RIY48LI*W>?>Q%&;IR ]FO*R!)EJ%?PNLL^ISL@+/M/7XJECU2BL:]1HGE$C>&( M6GP.6%!B2\.FJPKM6$8T/ M:$5)NT>?''7T.?,>.+U!M4W%4Z___+90)O!#)N7/LQ]_Y3IAU:R)IO[XFD"E M^0]]D/3@A'#+O695.8(R:AK#2[<'H,Q+&\ZP \I5(*VJ3$F1!-;KAB?\;X@\ M505XY=!9'J;!O(;,X8_S(0H/E20 ,F@;1QOG^Q85T5%--X /G+:$)M^R<872 M]F76_C;",WX,H,:>%S:%C2QRK^4+:S0+Z#_U#&(E5 MFN::M=4'@7J6N,Z\S"2SD_J#I"3(=M+#!!D2U'C]ZO=0L"#LKWOVC[W3VKK@ MB#^F3N5?(C:2]Q#NO-SN3'$H"_<&VQA1QQ#;P"/M+O)2_[YM9L@1_^I!NA*^F&?UH-_)#2O?B?&?R,&FN,3 MZ!X&>0,H![\&$^^43ZIYA_!-U2&(8?S <:J 9$%Y=4DK MG-OT=B+09Q7K!(ZL=@QU=+]*E$Q,'.?)X]?L("CB*NOK-5=LVO+S]?CS4O6/.Z5B#T M9*GGRS\)O>SX=1[7D9X3G5LSJ.=WM^\V74 0CA,FPW5"=.6)_IU>H$,^(+7C M+@.VP^:B:('X'[][.C*$O>S1Z:QNZUK\63/MM*>%9_RT8F"S82I&V_5J1$BH M?U@YJSVF^-50EC:NFZU877H[.W/= K*ZC[8!?S(W6Z]FXTS63H]J6X5I#BW3 M3<8S\VBR2-S]!L#'(?YRZL4ZMG-6MA-?^<;H J9?8Y/-@,E.GL:CR["M5-+- MD[O;G-9 S"<+/I3';JICZAU!X4XY<%03TNTPMF=;LI>)F__L2[=) U!6OKWL MZ_#!D(S66/G>2(9&3G%U4 V,XB2(I-2E+Z^\9YG*O*K!0[:6DCHW1 9;XQ/* MTT#L+;X+S,J1PG8ANW]1V'G@U4)SH$<(1U7K]Q@A_+9&U^Y MDS=F2=)QN0N0I)<4A!UKRJ<*%LPU62F9OXP8FX=^400S=!/6E#@>R/[C6R MU*.N^S+?VW>\CBM.G:][8Q1VE']^MZ[23_1/*ZOY6#-_:3A57A-2%:7URY/Y MY:QHJ9O_$6C@#?1^:N8]?4MY!.EQ=<2 M;W0WV)GZ];=6Q,V,S>PJNJ>KF^Y;1C65 D/J$ MRHU/Z=>/BQ67O7X@6]OV=HT.&=W5\ZH>*U?9FU#QI")-XW/[7\"=0SV)L^UJ!_R*C>6X^XRIFNJ+8H+IYY MN&:[:-'\L,-R6W##+CTHX-4/KY5W,*C-=G3SW,% R_L].7D8#,M9E?F8B[$< M?*9J1VI'2K:0(Y TW+I;1]=?6U[?$WI]#]::L^#R:2<_98IJ971L)IWF94K" M&$/9R0R2W(.: B9>U@P-]=,U1 *YIE?I[9[\()@.\3[$N5MZL+K29,HRZMZB7<'1'/?'#@&U]<4-^1/R==/W2'=DA\BR[<+ MOYQKE0\K/'17H,MX5#?2M/-T+SXIH&$N7K0O:@<"]V89JA6X2NSW59<,">*9(Y/K-N*N=X0(C8_I$-<9O,3(2 FM9GF@3^I\QFPO*7E' MPW5[JV!K^K+7W]*\I+!OL>3+HZV";/H\H+_1?%LL75S2,+M[.#9Y33!#'KK9 M#\F#0._1;RR M?S'..-!=D/MMFR,G##/Z%5Q8G)(^)=FU=T"5_UI0+;.O$*H?X*LL M)^"&F8LXV2MJ-$*V5=>QM6#"X@WZN<+ZZA4O!U@QIE_H/QJG4=M SNV$"<@_ M%QZ?08[7;H+U4+9*T$+NK!&PYZ9KW"9PFM<*0N74^+F05/Z+G7@OA6]_@VJW MT%OT>+B+Y$!E, GI4/D -G@L5SUM@=C8(!L9FQADICMKK(J8+3YH=7X*>'@B ML2Y@B35'GDDI,8^LSI-B>F3C7R4T99!\Y+(O^:U [(GS&Q$13\:F+VI,8#,; M2)*1'H!'DOG#L&7:^;^>)^7,I((=Q=6MD+W[@ M0FOE4$!9@QJ$Y@6<F))H6V$,CQD5B>;+#DNAGV#09/AR)"%'H_SFZ)>M_ MM%:0^A&72E/&2&Z1!T7U_EHR4 #O8@R>C089,^NZF0N>U7:(:!;X/5=P+?J1 M<[J#YD@M,ABV8JR/S]\C+Y[MT +1FT$$_?NPR7268 M-@@.7K0%#V6N&A]?=YQWH;L>LEBC#[=6=E>W+^<4RY\A9D3#85QU6HD2LI MH+T=R*4T[U2$X!X>!4K(PZ1L?]\EC\+T*E*!_-LT.1Z(P ZJBL$47,RNW-]) MX=#+OSB\9BJU-92A!?OSTB:3:,L9%3X2OQWTEO?(/6Y?,':&\'YU[N%65B"6&H;Z=U=NJ_#V84(Z)NU M,KP=:$[Z9BC"%EDZE-IW-J7OSO8^540X3DPUR*[:7!Z^Y?):R70R^!K1+\"& M2RVA5@E1FWOR3%26TH)KSP;3M^W4=>89TNOHNV#_L.FL9WU\'8W#G8_74*CU MTTO3")+7IE[^2+IO]BL]$7JHUQZ"+9Y*GI?!0S2K"M,V0<<1AQ7KQ&PKNZ6A MJWVE \6,)6Z@K1L UH;]18\Z(8INQB4V1_P&4)3#6IL81ZUFC6RU2:@7*GT] M,,SZ*2LR'U<50DTG]B).JZ(WR:"VOKZRI**' HGLZGIOD8Z$JT4TYY/Q^;*K MZ571U4V?.":A/ZQ2??%P:)PZP1U[=#;\Z08@?94J/3YW_5;NYPK%>4KKV (: M0UZK;O DN>CJ/7IR[%/Y5TW];OLC(VV7;<>E2EIO\TJHBZ@@?_H1T*(F7V'\ MD%[Y, 1L*D6J,YG1U8N$Y!A,7W_%/WVC=^_)O]P*^VO62O6L>+U<[:O&UHXP MZM^_ 8C;KR;E,ZD/SDZYS(ZKGD:RZ/6P,S6*.L-G>$L6A!,?;.?3 J."\ST, M1K3*E\M8RO?#"JZZ)@Y6/4!0'MN3K-50V>IB8(_K'"(N0%IGVBX?3T),YL?F M=[ADX54KRDM/ @E>"A%FN3)T/N3WC/R>FUK;)#TI6GMZZ%85G>$J_@][8E83 M;IRLNP&,57J;;+"+=]T S.,*X8[7^XQE8+>)*Y_BAA(I!^S/^E*>%Z*UZ L? MD8=<*B>GQSC/QA@.;=YHQQJ?WK4XUD7S*FVLH[WC7S]CZ#A6QRT_[F+N%3[&=)U%@DE2[6% NZ M!X]R$\_B8=&U;IZ#.(\,]-@MQ\?2@^:?$ILZ6DP%&J\P'A9G:+7^>57V]A-4 M"$.B;?F,?K/I(JI)\U/YJ/H=D]X$$W1(O1V!&- SKUN_,@U'43GY]3'K^WT. M]>-N//1?5\<).IEL>W-%BP>V M&;YH%@SWQMX+.TS4." IW.F-O0'L44NOM<1KM=H"73JD4)85EUI#S\WRMLNX MN+8!6#W#:E0,A6B,5OHJF?5';!K>P>5,T$%CW7XR$INJ*SXXG2$W$9?Z_A3WAX%;2896951*OUWJ0V-I MQC(%T:&31),K,\_M&CDE=.W6HN@AYV&>8EZ*KH=TTWF2]\%7V=.@2L/,C; ; MP!9[B-1"2\=R\P3YOLI*L$!71]T'U ]VCOZX4&6ZB9(>G/H,\BJY)AD:F=]7 MT38>H@.>38=P+4);[0NIIO-T:2IU^M4;0.GJ.9*^1S%:HN4&\&[2O+JOYJ).U,' MQI,+TEN"AB+-"8\7R[H@@ 4PUX7_=67)= ZR+8M?O)S6_=P92H7>5#Q"RB MN%1P3Z1$EL86YPT-2KI_=.\M![ 41ILRCW 1%0?+!>HD<%/A*[,"[E+NS!-< MC1)Y]L6<&J";A>ED=SCS,L_5^Q8H6[J=*EXYHX$S]]!,@T)G>W6G[;,S(O+@ MN!*AK7@D];3O"H[&Z73SN8S$QQL ;#G?7AS(YN/( /^"4,J(4E7C>@RG/17Q M)=4 1DQV6[O!S-;U]"ZZ66KP)<6,MCFEA(K(P%3ZL16$=9*55D[N+\6^3 2F M3S6FG]V1B'B_2VF6:+DR'VH5:> U0CDTK/S-#D->WHT8AHVL+@D6#E*R$6QS M%*#CJ?'42@FR*L+"H;?_"E_,1-M/*KJ[D!5"E+YPQV1]P&75V>C5"V47&8>.5'91RB=Z*T=AI\Y/0G;B MF08<2VT6;3Y%5^DD.[NN[!/7AGXHV$7SW0#P&+F<2664#ZVN+H">\LFAY*5< M0;7%CD%H<[YIPKW4A\4D*$W3AM#E$W)DL)3BG=Z+\BI66RG WL,A0>/HX25.3-^X0AH M1)/I7\WF6U#?8M?''/>IOS3&Z,AL O7&1[WC[/8YWO)5*W&ZPE?KA/I;/\+H M8M>U(FH_>.HEMQ%^6J&G4B]:1;UJP0^2#"TMCHUU:%T;7T)#'WP1;1/.\B5@ M^_98/PH>R]9C#ER@RJINX1?1G_DR#</1NTGM(D$=ZI%961U^ M$.>A(!E->R+"PJ36:$QGD>@A3F@]SSQ967.^)1QNCA7_A"!;)@-KAG94;C:. MT_&$VRN?##9TRNI?3Q(>MK$:*+&_#$2$A2A %2.C-2P0&MR592(%2G#^31?7R6)S1OPM'O?WDO7>R65:O/GL5H YY\ATO M6S#=,ZEVH/Q[AK[5/!*2L'B&*8/N^;R0&!LG_')N#N'=/[JHP-=>0+>F!:?_ M;X.HY[B'#3JD: 3QW"\/R]QWYZ_:].^QEZQ2=[ QE0L;XIGS,##6 M<)&Q/O)U; RA#H+KA'O+(UYMY\+BDWPRS MWN)-V-F7+/"NJV=M#_^TG?41X MWQ8(%64PKY>%WO&;GR.&MS&^O-I49./RK:(UQO8#&^7D1MTE7YTZ,^SI?0FB M9DH$"4-QS0\&.>T67T?C[&9B/[P!1(F_\EB'"0U]O M/1^/L4Y>@2"CJW_Z0I^V8C^L<[(!;.(9%K];[6-UL H8T7[C+, 0TMN-G^! M8HCH];(@:QX3A)==)=?F6+W\,N/N>F2UQQ&%WS_!51&Z;VH"RDZ7"8BM+ [& M)<=XS&7O>*[Q@+WNQXU_-+)T/] M(.-HUDU:KZ?<*?J/Y S3PY63:":"4^H%]BP1I@\ MW)A!3M4'=&P9>VLJ\!,H5GC?O$7K+*Y8SSS<[$/!\ +5W/RRJUY:J+$#S-*@ MW1KAZ!R6,LV*"*E]6OLT ^X'?_B09H+*.6;, %[P:Y+:T>K_U'+EWU X[GJ4 M4)86A3%,BI3L^[Y][4TBJ2P3,28&8S#&TN1C*Q1C*_N>HH6QSPQ&18RQ$QEC M9I0]Q=ABR-+M<^XYWQ_N/>=S[CGWWN=?>-_G?=_G?=_SJ,&2'[.;2/O/U\-" MGQK<:E J =Q.!9P^I<$M+LBJ7075\8>KGVQ=;L06'\7-I1QI3TC\KF%*CN4K MB=4Y'Y#SW,\9A,7YE("G!23;B(&[<>)[ 2YTHE;UN0E;L[RIH7D=^\;VUG/< MJN3D"2\UN96Z;*WK::X>BI_O D( 8[5X\'G\U8L$+:U0D4"Z<_NX(G("**!P MVL]%#V!OI8U2U*(L-*?\VJQW]?+DJGS7$ 772A\Z>JY?X[O,32CN 327;EO3 MU$B"=\[2[G-S..JBS*S:MK;2GUS/RW"\IZFYX\ZF,!@*'L 7.R9K=D*VPAPI MB+2+OG2.'F"W#-DKH,LC4*JB8=S-4]N+NRGT[MD E(L$RBK+ELZCBZ6U33@-SF8HI:&'TD_="F) S0Y?PV=M M_@;HV <,G8A@,MK0*,7&CR %8=7A7N%'+O,ZU_NE2::FQSK6T3[3P4.SE>X1 M)XG/[,Y4!USE6M;\TZ)3<3VSUAQ+6F> OS,%+LYQR2;\2SHTP1>.Z AW!,F' M2Q.)3_A^T#LHM9G3/L,F<=>;MT)Y,3 &/#N:2F7A@4[3W=*82Q"H?MD+,)^! M5GQG!_)ZB.H&="!@5U4>_W+9^J3O)U!;PS:<)^ /U:K^4$WY4I?1F)7F@ED# M23>^)($;O&V@&"\LC'Q2@X"_?!MB3I.T?)@M7E1G8UKP7W],_[>(@Y YAPE; M8]1Y9[$LB$ZC!>CMB]8.U;S7E+R"RW'.M<[O+A+CY(J[&4R&NPO!9\F#>#+' M73:;N!F]X^@AM;KH"/G[#"L&W'O5<7<=>$/47P$Y1U+Y/E)=YQ%:Z*A1I9]H MI#7@XZTB @PZ7I;TS57E88M;X1V75Q.[B5K6?-*DJDG&_DPNPW.4LF1V+HWE M-RJSG$,;L4POSVMYR?WX[S4\-@>4M^"_K,_\W*!0Y'?CA+^#H\;64S7U.QJ& MQZVU0V\T3P\<90)":FMGA:*A0_8^!+>U@(6DB])(P8IA6IU3FON$WU*TW@$_ MPN6G5/I_-HXD]-E EJ?68I*$33]7$)%!CY&IVI06DIFF-[4NE3Y9&(]Q0H&C&7K%WUF*\(. M8ZQ*FWTGGG;%"L)3=B;S$^VPC8&$3QX>Z6NF89'Z99CNY.$!' YL76T1%0*8 M7*KZVM^-")%M##662\EA>%6"OVY(X'X(G1ZEV0^]TN#-6X_4S&MO2\S@R'L$ M*JYMW1IXNP#0>>YS_5!"&PK;RYN8*P2=FVVPY6UW",9HCO8W\-#JEMY\?YI34*C0U-N>CBV9(7F5>, QFE MQ)8?AM$BUSN6H*$KVE6:#UHKD1@)C2>(S]&=Y=ATO@?:TKPAH24[+2O0&>Q69+$9M5:)W\FOV'R%'!I9ED8B%%9$4RL7-\_V)13U/[IQ$G',[+LSK#:FBXC.,H/O). M^Y;HQ50"B_06ZR=1T-\8)PU7?Y&B^V45*._&)=[R!N=N$$ 4F]"%A(Z;!#YT M%?T"I.;H$Y.'S"I2,TU7,RY<(42REXKX8+TSBDM+#/^/W*O,W**%ZR6\*K5Y MOI.&E^4'[[*SV&+!@\CD4*.8M*RAQ'ZLF1AO0UC&I.R;X1A,*T<68IC6@52 MBOIWD"RBTL@YG7SY>%G-Z*;.!JGBO3? ?,A]-Z]U&B-*\ZYJ[A(6I#[E55CI MT/Z=2^%:R=3M8W_DYD/ QVZTK)_A I9PKM,F$B-PLM>+*CG7+Q-3 =D$4'.& MIJ$<_=B[X3A.\QHV513'W$["0A1&"Q\5]E?.>W;C#CM?,/-S^*IS@Q+[H$2J M.JCZX#-:[X?TZAK(%E]?_\-OY>5!Q,RT!H)SK&PAK6A@>=\S*NM9*NX;!NT' MH[ 5_5 2O%'U!E%/3CA]/_;EZ.P&+; A\)3G%+9EKC7.ZJNC\S$^P0JUX%R! M=["C2>WYY"*]Y:WA@WKS0[*G]!%S:)^>]#;K+[Q\>/(QA-%!TLL[;'4L.P-@;S[% M>M#75 ?$1M8C?Z(9$YVP"\.B@XE/8GD*N3K)(46&5Y(+M/_HG@;M4%7D$I26 M5?TIF):1+A!ZOQFF][X@LQ6)_H?W:).# 3M:O;O69/W?-MR@^2GYI[5 MU0RO34&WTD==$?8EE#D!I+>2"M*G1*5U4OL*YVS[S;*;]:GP_OZ5@(&3K5D. M:7J:H5*T[3G>047/U%W,>_@G_>N1PF:+WF@)N0*U)F+[*Q*9*7%M;G #IC.#YAE#+BB27#1?PM"E^(:I>X7T\8_^[3*S'XX,W M]3N)[TSL32+D=I46?K$7)GT;(M=-6>7\VH%LM<&\E@3UH;-6$)4?7Y#KV2%T%=VL3W$=-W@I0S+]BY M%<>Y?;TBS7RX%8;Z(;S7B !C>R<.NG=:WFO-BOPKEOAQ-VPP\H9H3\QUKTOR M[-O[)5^,H=U[+WUV6$4T@E6_^TZ"U#@ZE8Y'35LLS%AK&%#+MI0^Q;K3E=3$ MJ"OR0YZJ.FGL31/K) L+$UT7K 'A)R'I48'SZT)A*Q/L;T#!X;87\N;[_^PP M)+!PMA[ZI2-ID%()O%VE-!>R+&'31N:::KA\7,GA1 0ZKF*'-Z)+WK(8(0B= MGL1+'@+)%A_W'&2:[O:Z$QB[M"G.RRL*-WGBAE]DO_S;T#6;!FD-XK(_+#9B[KO]0IIY]\R,J] [O.I-L0A_+15 M.1M*'EYX87I3K&6"O0C$Q3&L_>@U;T7"JK.$;55GFJBN7PSRWK9'\F)&65)J MAHL!/JT$IX-8Z)7_Z,;??9!S,/W.^AD*20>/M1549E&^'84]_!?-1X:*<$EC M/SI3]N_TN' WQS/J3>6!IW+:Z1/@*W_U-AVT-''RJLY"<=Q(5I3'U' ,W6\$(UNR0U*K@EZD Y]S? _S=@]?9Y]6Y% M7 KYPW@ 4%G9&7-D- 79@$80#/-)OJEVXIMK5Q[S;$D6:VEI#'[M2J*V[;$' MGAWH6/Q=\WCG-FA!AF1S)ZIT5,3 $I27]*KN]!F._,$0JACO=>#0\( ]Z,>0 MGJ_>^YCFK]NU1-->.[^Q]@+LBJ<=0?=0+/)RQ[:*$@*^S2?[IM?':W32B?$5 MHD,WJGADU>4&S!*(A&Q^+U2QL$FW'?J%1GK;B,G0@M_99^((QU.&J8T@0DW1 MPYW]R[^F;[.\E*@5?D%R;UG7%@"'8DW^>991[>NSM%*MK2,Q_66GMZ;2$SV. M5(VZJDN$DQI;!0T1/ Q@JC&]]RIFYE*DD#XVY_OQ[9(NPO-2[N/^_:V$:QK+ M]-"?.V\A-C*_U,\A%$R,Y,!N('DWWW;^U .=/!Q-:6OR7H__ %8?)-7GC0=I M9%4&AL>*M9VTJ@R4X14?(6>ZYX.XLBGLPB]8;(!'8_>DE6+RH[XP'\I6I@9" MYL&Y$7-A"Y[B""?6K%;1/36^SA&->D(/+XCTO-\6/7$1S9ZEEJ[+*G"Z,^GRR+B]=C7;T MVZH@W%G<$'&[IP%N2KXURV!\7PB9"NI23NTUE="%B!6-SWNE18]=^?"+-T+Q MI<$E@YFN@$@&.7#G0;G<-E26NUN3K'U*=6,P%YOQN-A3;7? 9].$(P9P1'J[IQ6H/YO&NTPD?/BGT^OB M1W_Z#EM(K=-U<;T8E&2*]V$EN;&L)1C>72-8S5GLL#7,^4;72Y[C\J%;,'Y4 MT;UK3$;SAKQA?XT2K-%\E:6TSO_:!;-V"X?!E2_2=?MZ_0,_W:L!^E6X,_*= MI?UK;)4WDD-0Y\NB2R5->>Z-MK,E4C;(D\Z[JCC9SP2Q2G017<9+K[%I7625 M.V\H;#!9335<@&PPUC<_1U3L9#F9<8OJY9B]0'F_;C8=-3JZR&<4D4[< &); M:_8P384$H(\2GHH&/19Q9XQW($6RA4'\#HA>T'@V3-GD1X(4@ MJ0\!NU\$B4MPNG;")9X,H(;;$_=AMXERW&] I[W7^@H"7AL,5X_@U.[LS3YW M+3?WI<+@(>8C-%LH8E("X?C\7DG\DH*0*S"7%28Z-B\6K*O-=-9IPB^?URPC M9U@O_G#\*T!!R&4E%W1;&17@GM)E%<[HWE3A 7HH>F=8![TV-.7Q5E<%2E H M/3-!-?E)C'C+M572N'B;;U@>D!J)NWQ#SA-P"D>Z1O[#)-=3IF*>S&^_7*4S+_.+'\&^*L#V$G M**3EK8F6"Z^;CW!\SHVX7VXMSG0)D1KVOU.$&1SLS2/B-INQ:FA*1VPQT MGEM-9Q,P,S*FE_#HNK+]?WNQ^ANF'+9R4!=)1;]8\)Y:L=E],R75YH_@>:B* MRKOS;/'HM9^7C8W)N^VLP_?8QVV^#?E_2'FOCW^V,JQBJ'4-% @AJ3'J#?V9 MD0-7=*J6@ZK"TX=-14TS9V*PI'#C0T??_!^H\?]/Q/VF_P=02P,$% @ M@8K\5&C2#S<-A@ 0W(% !4 !S9V5N+3(P,C(P-C,P7VQA8BYX;6S4O7N3 MVSBR+_C__138.3?N[8XH3/,!DL"V;N;,>& L^RSJBD.J14 M[3J??@&2DEAZ4 %L'CF8;M*)#+S!^&'!)#(_)?_]>-^ 1YE6__;?_]B__!X3_^]67#^#-BF_NY7(-7I>2 MKJ4 O\_7W\'?A*S^ 52YN@=_6Y7_F#]2"/^M?NGUZN&IG-]]7X,D2I+#3\L_ M*1XSS#""<213B.(LA23+$.1*4)$G.5,TOKG[D\ DYX3D,".%@DC)'.(\8?I? M>8Q)G,HDP76CB_GR'W\R?S!:2:"-6U;UC__ZA^_K]<.??OGE]]]__^,/5B[^ MN"KO?DFB*/UE^_0?VL=_'#W_>UH_'1-"?JD_W3U:S4\]J)N-?_G?OW[XRK_+ M>PKGRVI-E]P(J.9_JNI??EAQNJXQOZ@7./N$^0EN'X/F5S!.8!K_\47]6)/G%//'+4MZ9GOTLR_E*?%W3M MK9\>Y+_^H9K?/RSD]G??2ZE.-[LHRV>M&BV)T3+.C9;_=$[8+U>H[TG?];&N M'I2KS?WH2\<^3#]Z4_>;Y@<97N&.F*M5;KY0;Y=BK._N3M35JH?7V-?78K6F MBQ&^%GLQ'947YA =I0^SVT+49*CG03-SXE^6]%Y6#[1]0=MD7(S& MS'\S.H-J9\(-$!L)YDNP6DKPI!4'JQ(L9*4_4-H$\&AL^)=?]M@$[[[%Q#IE M,4)_?.WTQ\XRJ%8E-+;= *,XJ#6_ :UM3_K)Q<+X-MHUI$L!OFI'A1@( M3>=K@_Z@Q[^0I5Z@G #G>*B+?]]4:[-*J;ZMOD@#Q'PAM3OT7J]L[N6'5:5_ M_YI6WS^7J\>Y9O]73W^II'B__/0@2^V5+^]N^7K^6"MXRZIU2?EZIE24$IDS MF$C,(:*9@B12>J%2X#S.)8LQSIWX.X"24V/UCHU@O0+EUDJ@/6FPT!::WYI_ MWO!;UN+_S^/$T/ #O$U7810<=Q))"#(1U-+ M2%G#)APMN92TDF]D\_?[Y=?UBO_C^VJAVZC>_L=&>SY?5HN%G@Q_IZ68%5FL MBJB04#(6080SO18HJ-"K DJRC) H1DYSB:/\J4T36_7!3UL#?C:^?]>&_PD: M*\!OQ@[0&G*>)KQTDQWC!P0_,)D'P-V9G@>BYXEY7:6/2JH#H3GDRZ'-#*-" ML^4M-@OY21D*OET*\Y<1HI?L-66;1<$W^6/]2IOZCYDB:4YQHB EB$*D"((T M-G2813EEC.6*Q2Y,Z"9^:D2XU1ZL5.T[W30>5$=_-\)S[ P[O@L'<6"Z.T2W MWI\X!!C\5NL/C &@ML CV0V#SA/7.0H?E>J& 7/(= -;&>SS:6_S&_WQ]L># M7%;RE5Q*-5_/LB*+,%<"*D8)1"07D$:Q@#'",D$J3M-"./IVI^1,C;IJ9]L< M(@.U*K474:\$U_2'Z]+]'*S6OMBU8(7WN0PR6D70Z@A^:K7\V:M7U8>#/^_I MI)2QO:0^4T]X0[V/#R.#SQI06992U*[59UI^*K^NS1YXO9WY699?O]-2SA"3 MN,B0@BBE2',#EY BP6%#)I MF@C">0'7Y:RIIUV7\X^[D8&0\]G;Y7J^?KH50G]+JL^K:DT7_^_\X?5*:%[U>,ONH%FZ.M_[$?\A69'&?!VIFW' MN^730V,CQ-S$'=/%9SH7[Y>OZ<-<-_ZKO&>RG*DL9U$28Z@B4D"4I!PRJ<<_ M)2G)1)+C-+$:]5;2IC;X]\KJ%#N3[Y,U\N&ZA=G'I^0V+PWCD%=T8:XS?/TNY7I[C^'- MZI[.ES.BUPI*0:-2QF6##_G"X@WW]<7VLMB[ M><4U$=7W)-[IWU4SA8LDC4@$BXA*B'*>0\P)ACB/99+2"!6Q531\KY2I4<3N M[ERC*6A4!;6N]DN-\Z!>7FEX@2HP*PQ"R6F5<1&%08N,\ZV.ML:X:%AWB7'Y MX8$KC%+23^J+I(NWE=FK^%R:@-[UTZR(,TX2GL!<)!PBEBK(*,D@%]HUR"(< M4^QT,GI.T-2&_8E;+>M[D!I?[37(_0^CNN+,Y!:[FH\ !8Z/6$5M'$ M9Q@E0:,EV*KI<2%Q 0A?:XAS8L9=/EPP]FCE<.GY8;3P>E6M/ZD_KU:BNEV* MK[)\G'-9?5TMQ"S!(HERSF%2$&*< 08)QQDLS!<;_=OZQ+/ZM%F;) HF+\6L0$E1 M))Q"E& 3-$KUXH$IO9800K \12C+$Q>^<)0_-1)I%&RN3YD]R]7]PV;=+*7U MR-F%40!ZO]J8"$<(1&-9'6Y1?U8YQEBX]I@=(P7LA\ TM=4#?]L[ M';UO0&N1/_8:B)PG2G.5/BK/#83FD/R&-G-M%/W[Y:->+:S*I]>;TJP;#D*V MHTBD."DHS"F1$-%8:2I$"M(X2GE,XY10I_U66\&3X\!.;/=6<^=KH]:HV]%9 M""P#\]@I&)]N0*OV2+'Q=FAYCXJ_(/:%XN'MP#@?"6_Y_M! LD?97L77 ML]U5['IO]':YW)C=)DX7];*E^BSUEVNYUG[6K!!%GD92PJC>&Z(\@H0+#.,X MSHE(,AIC9<,A;F*GQB6-JD#N=;6C%$>P^ZDE'(2!*6:?:Z)6^@:T<';T!GO% M@R KVL.6^H,70/B9_,DC;4WLPP!K"-Z\6[-VI FF9F['UD9A\&$6;IE\X-M7 MWHCM\YTT^>Z6OYY5KMV'. MYS/[,%_*]VMY7\T2C A6!8QD?U"FS<. ML)S?P7%I9!C-F6_0OM5#>2:?Y^\F-E#__+J48KXV*;8^KM:?2_DX7VVJQ9/) MPJ7EB5FD,,^Y7J,5&4HABE(!:4HI1"G#"%&:9S)UH4!OFDV-'AMUZQR(;LSG MKZ_L6/%%>N#E&;-)8UN;5B>T:/O+6'<#M'U@;R#86NB/6+V#[HET_>DU*B%[ MA_.0K/T+&!IC=7^_:M)[-5FKXY@SD10$1@6/(3+9!G$J,\@*E.:15*B03DG' M#P5,CE9K_;9Y)?Y[],.PJ_IM,",W';7VVJBC:5^/L:/Y^A7:?M]Q;0==#\R&%+?4O-OIW[3[4:KG/J4QXE$8HY9!C$[X0(PXI M2A6,1,)((I6FJZ)%3TJ-2J9^@3RD8,^M#SAV;9*][CW5=X\?YW^F M\Z7Q1V^78G_>VVRI:H5G<98)GE %112;BWHIACA*,*11'L5893*+K&(X!LJ? M)A77U]-J_V[]77MS/RWJA/=MTL,;4]' X1!Q0*L)E*2) M@HAHQ[Y(LS2E=+;>E4UZT4XY4R/*9Z?4!:(T_)>Z9H2>Z9\@1\ [\$S89@/O M;IZ\>X0?YS? F+ M_:#- )V1\KY%_V-H]!U.V5TC/E[@J/\3+4N_F2+OF<+MXOM9NQ::IK M: G5Z8_:7!24*!FQB$#%LZB]B".*%!*<*I'RHE#,:7O)IW)3\QQVFH*.J@/3 M@WCM1+LUW4MU3>#Y;&"O."_10L#G::'F5;51EVLA0#US+_I+ M*]L,8HE(2:Y77F93'T&4H CB3"_)9(1YP@DE4EK%F1RT.S7"-(DNYWIA;'* M_"JI">MIDHXZ4>8A>!<<].&0!":JP6C8NW*G;>]C&?U*AV'T3WMV.6QM',_L MM D[C^O,QT.C)AY*J<=YL]:0:49PH6 ADP*BV*S(,R9@JA?GF+(\RI%3'9MN MXU,;F%W=7(,7.I#9QA\, R)X"($%!@/._8^-]79TWVEZY-/W8Z..#]!//#-@ M@_,S%5P^;N?)+-838L3T%!E)B IF\@WI,5G0/,F*)"$TMTHK_9IG M+XRW$W-*SV=[+"W98_22&WU!\: MF^W567_$.10\3SSI+'Y46AP*SB$+#FYGX+[4[A;D)_5Z=6^J'-;+CB]R80J) MF2Q^5H?:,<3O.B$3&H.UDO"5T1*T:H+;LC2[A,%*7/D!S]?& MT'7*C+N5Y 6XH\TG/ZT.&ZT?Y!U=_$K7Z^:(J8G\TZM6/I?5/N$8XC))"YG# M(B*F,E\J(:4IAS'!!%$1RQ0[5>:SDCHU9Z16&MPW6KOY'G8HVU&?=^P",UP# M6ZMP4_.\JS+X+4@Z-R>4/%&9G(V+>Y>V5"EB,^!$J0$\9&P%RP]?,[P_I+#9]_R6FZPA_ $/&&+$78%3J$BX0D +,L2GGISX!5X6GTW_S>!U8]T859J M^XUF\X%VI)[_HO/D3!22)5F:0(2DT.LL5D"291$DA2PXST66231KCI^^KFFY MMF.DJW1R&6F'FH4;=$;)&\U2U7<@][K>U,N+4*9(G$'&<^/%FHJV*I*0I#G.J. Y37';K6^78I*=NM5K,ETJ MS1VKE^C,#'-,,18P29DP=\9UMZ:20B9H%&>I5#0O;"Z_C=Z1XUV%XRY=68$' M_;NF))F>.\T!NYX&A%R:+5']KVJUF O:G,>WI>O;@E]TW/";3\(&LK\P;5^DR;IH.'[ = MY?3PTNC HW5SO=;LEI?RNZ:*^:-L;JB9BVOO5J6)T6L$JCR/-4.6"$@)1F".8O2)&9%RMP2 MR(51_^(]%OK4O[Z8_LS"]DYN>V'W M!FS[(.@0!]%)825-B!X MOS^+WJ]T;3YYNE6:43\MY;?OY6IS]_W;[ZN_2UI6M_>KP!8B/-&F"UE&"] M NO?5^#)&'%C:@62Q<%CI_;/'R_858$GC)YTI>]VZ4JWMNE/C75 MFP=:^X V$/R]Z<>=C>#UB_6CPWV+E^G/D6YKO$"_NMT \8]^[_T1C^+&NWWB M'Z-G=U<"-#\P3FE.V7S19"=K*LGM(@9C&4FA<@JC)-)K-L1RB&FB8!YEF*,L MCUCFE,3QO*BIS9_;NHB+O<:.>1E[8+5;+OD!*_ ,UE&R4TPR0&3E931\A1J= M%S1N?-%%@X^"BBZ_<77RZ2:(H+GX,8L4$UBQ&$I%,^V08P29S"*H:,)I1BC. M8ZK_[63[H[96R@ FA3^'@/R_T M,RDOE1[ZE*D]6:)//CXX6?1^;V&FXDBFN>0P+@H!49Y+O39/%921_DYDD8B1 MPB[G=\]:G]IYG-F0T92".40I'G*(ZSO$"9G"VE902'.V"D M 6PK8=I@V4T?@[\U@2<-@\"S#71PNUZ7<[99U]7*UROPF99>K\V=1,)?WNQ. MVV.GOSXVZT06ZQ,/#8P.7:[G8K[8K.>/G;)6;W_PQ49(\4XK:#:H-\U&S"?U MEI8FALA4K*QG)[V^W2S7,T5S2I(B@0P1!1&3)H"4%9 RJB*:HRQ)I5, J0^M MIN:.-G?Q5P]-%OHZ7.#K7ZKAGJB?KK,CGM$[)#!A=>WI; ""K47 #$W0L &\^XWO7;^.0UKT#[BGWUHM.XX;$^83R*H/7:^- @VSIJ]^V/![D4 M3:8&/2>8W03Q:K/^N%K_7:Y-?.\L354J24[TVI\AB 23$&/.H>($)XQ(@5*G MV'Y;P5-CWUO.RTT=<5?K#V3' -?H.4OH+;<$ @ :>H^@Q;"K,]@J#;375]?G M>]).H5'<9^2;&U3>@MPLQ8X4?G95TY[[:JY-K< MQ^Z M47?>[Y? CA1?K&L#D^B+]*HS_09!WQ-=^]5M5'H/ NOA=!!&R+#IHRGT8Y;F MJZ6>FEJW*$M(IK! $'.6Z?6QRB!#3$"%6:18HA*>*Y=IX*24J=%Y6[5JI^5 MA_,THG:<>C5.@;G1'2)G8NN%P!-!G98Q*M'TFGE(&/T/NPU\(>>S6^V%"N.) MOEO0NQD5:8)HDL$(F:$:K_L1^8QRV-,AC/&K = M@.3]CN5"<4@%C;#: *$)Z^E4YC#G"+$N3 M F&G59B=V*D-U_=+[1#1!="R[EW3ZEG!;#DYO#]PTTJVMY8?YHRGTO=9?GCE;-*N1 MOU12;18?YDK.N""H2"(3(!LE$&6QN:PF(Y@E*<=2)DIF3HL &Z'3XZ"MHH : M3<&F5A4LM*Z.6S0VD%ONO'@&,O2&2JTNK/4%'4!KC6] HS/XT(>H^_:( T2^ M=CUL1(Z[F>$ PM$>AZ'S^7J<2ZD>/6D6];"FMK"9MN#K^>/]9[( MC"6(P8'%]U;^ 1*;ZQQ1I#L-) MEG.WC#%'(J;F*^W7&XMZ>6%_([\'1CNVN0ZV(S( 8FW/&>PNL.1(P4Q#%E"LM8.!4U M.2MIN@/=*>!0S@LQP1ESSQ/" MN1?\)Y#XK M&>=44VM^.H%[ W@+?P#<+==BGM$,O3J[G/9R[.R5+Y"+S#_/U M_*Z^[?&:5LW&1\01(A'-(#,9Q.NBF3CGN5YN%D0*CEA2<*LDL">;GYJCLM?0 M'*VX[1Z= ;"?)*Z')3 O.")BGQNSU_"^$:[?[(QN_=-^9)]I=)Q$EKT&[?)1 M]C_E+U"O4Y$U3QA+<8X@%9A!)",$F2BT'Z!AXZG(D' +C>D7-[DA7:MW?4C> M@!*WOF */<1/A^"%*VIK@TO D+N7*V-K8[A-B)W'PK4K+J6H3,8+DZ6.:D,^ MJ29KW5^6NAWM6FCO3OL8MTM1_[HN\MXM\/U9?Y?,M?/%1FCUZ@PYGYH$.3.5 M"T1H@J'*9 R1J1U&8\I@2@K!*9:8)DY7PX-J.S7>VAK;Y+&1/V3)YWK^U6YX M=92%2-X_+%9/4K8?/6@=OIO)^D&WZ%I0-^07PHXX)]/-@7EW:V>3F]-8:7IW MFZ^S_AO6ENDUUE-];G=;EKH!V>SK[\P#C6G@;?L=\5H%>(2N\%9$.*2N(]<@ M'@'VXQ+&8P@=-D^=%M<9#J^>]H^TH^7V=UH*H]&O*S%7\R:+@5:NK%^HRZ7N M6FI**@B11:E>Y:J$2(B8BO2B%V.8TRC.6@#"L4;X:=A/7U#H\\/QU<88R9H%?G_5UQS+/D65C M@N]IQAI%Y5$GKC$[X7#^&E7VP%2M!Z5'#@J3<+ZYWRQ,E=@_EZM*3[JEI M3 M>N3/=+Y\)=6JE.;8@9!4)11S&)&T@ BS".(T85!R)'F!8I5S[)2JU8=64YN( M:EW!9J=L7<'1<1O(3W?9S1VC=T+@R:&G+I/:U67JF 6:#ML;!HQE-X#5MOD] MSO:*M:\,K5YT&C=#JT\8CS*T>FWO$6[W263^UQ5V^R =3!,HL:>AZ4\TX M)U+FFG(I5ARB"!?:Y44,IIPAH1*%.;$*NKPD:&JDVNBZ*SZTTQ8TZMHGJ>A% MMY\P?6(6F .'PN64T\(&BT$I+GH;'BWCA8UYW0085L]?$6S99,'ZN&KRK"[7 M,\HBFIG:J)PG"**4YI"PC,(4;"N:-_ M=1I0.W_I:I@"C_T&H4;!&[!7T7-0WCD$?$;A'2NSDGY:%(& M7K?<.@OTL!65#_A>?M$4;A5T"9] "YVS8E]T+7,)C$O+E8OO^[BZO4W$N75W M=CF;/ZEW\R5=\CE=?%Y5<[-[]?;'V@0+:@T_S*OU+.8T5EFJW92"88AH6D J M6023.)*("KV,B9W..GPI-CE'Y_ Z],ZT70W6FTX*\Y4".P/!UD+PV]Y&\':Y MN:^;7+FFZO36]Y8.U@OT:&B?[$4Z\\H[\M!]_.O![+_%[Z%] MQZAM4]_\]6I9UQ[^E2XW2O^],8F7CTL4SVB4LD11#'G*"42H4)#AG,.$Q 5+ M$HQ98K5MY2)T:H2^51O<=_6VC/!V ;N?94-!&)A!=^@]4_E9NOG7%]:YPQ$5 M*[ZIC^7,Z!D=V6?2)XVP?0S^ *B:R<2\6<\049Y&3>B]2UOC!.0/L&X7IC_D MW6$N_9MY1>_N2GG7UIK[(A_ES9&K49XZSM[K7:1.VQM7QD=4-D#^VL=_M-0#'JA\O]I6Q(]K_$E^$ MP"Q^,;IR9S^H;;EI*Q_O+P0TN?MVA3SW*/BO>?SB'>:KULJ+V3%N/9>7[JZC MFC$OKM# F[?[U4#G!#NG-)(%3B')\PPBI&=(PO($$B*S#*LLRG03#@>!)Z5, M[=2OR;"T6"WOH*F! 19[I1TOWY[$U&[BN!JIP*3>T2],4$ O +[NU)Z4,>Y5 MVCXSCV[0]CX\\$+2?F/7)&U^MUC]7MVRJMXOL+TMTM/$A+ZRS\Y#ZGSCM:;@ MMZVN'I>3-I#XNGO1)VK<.Q,61A_==;!Y9VC0ZZT0^@M4U3(^E74^1"#*[WRX?-NOH@ M'^4B_E7>,UG.?3/#Z5>ME1@OFR*FDAP3\M_F&K,2G_OY\+JN\D_<\3S,E"PY% MCO4:6_("T@PCR/,\9S2BBE/D=%E_B!938Z2M$<95WYH!6CM 8\@^Q8CC-?M! MO62Y$@J-?>@ED@OL[2%][[5*;..+E6=?&C80#U377,7OM^I M&:L$3BDO$H@1BB%*100IU8O, BF!E$Q2IKB'^KTG1$_M3'=7OW=3->5E5[L; M-)YK]Y[J!SM."(-N8,*X4+MW?U%IQ-J]/8B%K=U[2O 4:O?V &)9N[>OA:&G M<\;!*1]6S:VS>I__M8GE*I]>KX2<25-S2=ICYZ>Z=PY@&HU!T9UUU.[?MQM#^^\H3G.&=Y50 XXS;."YXI# MO?[V1S[;LS+V^(C/[K40]\MG!&415PG2KI#9,XJ1A(SC"*I<2AD7F.;8Z;"O M7]S4R.66\W*C9^A.9%N=?;VN*NCS+K>7&]H3(A.+>]=CW9[VO1/3+VQ"-YW/ M[J#8O36,3E[1:EY]4GK@&(;20IKJITP W*L\3O5C-Z0\ M48^ET%$IR V(0RIR?'O@;3FE)%]_4F]_\._F+LT7$RAE"G%]-_]_^Q^;^2-= MZ-%7?9'5NISSM13F@]NE>/Z+SI.S7,1IIE@.JP:$\U@E:V1H#1KB^;?>A0OZXVGFV;[2>X-N:E=KG)G9_V X^VW M %\!.TI]X8X-O6;<]>G6/O"E7B_6I0-U7]8[7F^[?;DWJWW$=.[!+Y^_82[E MSY>;YI9;FWO'X]Y8P![R=44M@(;C7CX+!_'1M;* H@877-/?VO63J3FPUG), MRP\FD/^C7,\0X7&""PQ9'$N(>"P@B44"4\H3R3*51MPJPMY&V-0FA*VN33VS MK:(W8"D=Z\'T(FQ'T[YP"\RW6S6;0BOK&KFW>^0^]B WI!#814C\U?$Z+VKL M,EP7C3Y11>OR.P,SQ3Q/@7^0D .ZH)!6M@ZK%(5!LTSG4(;+[R MT+B('CY0E6PT[9=@*:2]1Q4E,->60"10 MI#U+FD*9(RGS5$DDV?#CFB% CI+AT:P9'^AO:)WIQ-S,,LE1ZO@*<*_5 MWY2[2\T+8\WP? 5GP!]RAC,$TK'/;K8ZACJQ.<0@R$G-3L@+GM <&MI_,G/T M]##2-3E2*N.6_C!I4^0^9P$3.9&)(A!%<001C3@DBF&8%2B6N>!92F(7KC@G M:')L8?1L%IVMIHY1_6<1M2, 'S@%IH ]1%LE@X397T+"$Q&<%3,J%5PR]I , M+CX_](!V8SV-H>OUZ/6/ #UR%@#3A>[4?"VX'J&3$C M'Z'V&WM\:'KA^:%^POV]B2[3R[SF^N+M9OU]59J4:C.%,6%%0B%->0$1R7-( M>)I#KIA,"$%ZV>&T3=TC:VKTT*@**J/K#:B:"[UTIR[X2:\NFM\ZIG;HP]O6 MD?""8G!?H@;P:P-@>R-ZKZE/;^(B'-X")Y# LB4XCRE$+,E(0\HSG*S2^YTV6Y MBQ*G1B9[A=N\, -.NR[#;,<>7L$+S"$=W+;U%1MU8:WO.#%?UH!Y8IG+\D;E M&FOS#QG'_D4?N\H'&1F^R'NJY;4??I/E?3Q+A2!Q)&.H,&(0(;/242J#E&2$ MHHQ&*G:KW^JHP-18:9? A+8)3,JMSNU&JLT.J46?#-D[]8OTV+NJ1VEC M=OHW3X!O?:A?N>5J#UV0S5@+\2^X36L/3O\&KD,[5Z>D;9(@W"[%B=0(N_U) MD5":$"HAQBR&*"($,E)(6"@91YG,F5).EWD/6T M?Z0])*OS1GR8+^5[K6@UDX0@IH2$FNT(1'$609S%*8Q0@F0:,\95ZD1T5ZLT M->YK:HVPNM9(UZ9NP1&3H:#[W*XF29W[Y#=C&ZB-<]PF]]#!EDPZ:K>%)M=. M=9C+/?9J:(^YTZ\WD'TQ\O4*C4O2W@ \XFU_+0_,E<7YYGZST+.'L,G;-5.: MI?4XB&&2FD@PD2C(BAS!G,>,%REE"7.Z%NHH?VHDW5&_N7)^,C6A8Q(NQRZQ M8]J 0 >FU2[&3HD'/2;\&@:>KY1@CM+'31HV#)JCM&(#FQF:L>?HD.739EVM MZ=*4:ILA3CG/<@EY;DY!"$XAC92"0C)5%$F11L**Y.S$38W3VC0S)T\%.VJ[ MYNKI1;R?P_SC&)BRKH5P0)8>&V2N2-+3V_S(.7IL3#U.T6/UUI6U.'[=!S%7 MNU_^GW-9ZB:_/[U9F>W%&1/M7\%NCL^/BU:TW[+RG8!@')J+KX!U>ML,%)M^%/*QD MOTQI#Q=8SA;[<&ID8*19<^'ZTH7L@\_;X 9*\@0)8F)(N*D"P@BD5$90BI0G M&1&((;>H]2N4F1K=':11<(Q'NZ97['AN+*P#TUY]W>&B-:Q0?6 MOL+EKE%EW'@Z#Z =!=SY:-,GT=ZN7].R?-*.:)IG29+I/ZYGU .I4Z/.W6@]S#[D@T0/$;^&+:_ \>5HD9K^KSY1XR;NLC#Z* .7 MS3L#CQ/K^.%MRF3!$EY@GL",Q IJ)X9#4M 8DC@3E!:\2,R%1?NB'<]:=V*) M$>IR?#,R0%O)OKT\X'CP]PP\RV.]H9"$/K1K+P%X3R5]TF!?!VW/VA[W&.V4 M64>'9",P'SY**MU?[(A+UU@Z?Z$ S8POUEDZPOA/0W#RY=_ MY2A]7 ]L'/MK 9H:F+I9*ZH9$)Z[A?55MI-"+KXC&*L)0I%0OOIC*("LP M@X5"$F=)''$EW1(7GQ,U-;K::7J0$V)>:SL\'T0/V'9LY0?"P,2T1^]YW%*C MJ,_LQ9? \):[^*R@D3,77S+X.&_QQ3?&PE;ZPBV2KJ&#C]'\/(XO!*7T,D,R)S:T.YH"G:J>HS9/83I=AD@RDR&).TV0)8S#*5VV261@JC$J92(JP)3(Z.NBN;Z7VDL@"L% M-Y4<=!CKW"-V]!02Y\!<=90?ZO/&7?FT/7:3/75G5S. M/NB%EI3/R:*;^/K]4JW*^YHH#JIP12G&3'$&E>"YN5Y-("$IAD+&"F<*B22Q M.IFX3HVIT4"G(-K!3-MF5*TCMS^X5L2YLJ_Z266\'@A,/8T--X?(WX#GZ?0[ MIKB44O/9(:+=FJP_FT#'/-/GOVH'6<\F?G!MYAS35CV11'D:U9/)E:V/,N7X M06 [,7EJ;> ^WS[-\6$&9%.7EC F4D2U]YGC#")41)"JB$'!<$H52BFF3M'+ M_>*')Q(?^ZUU*\=*KZV[OJ%C;MK9V7X MT8:=W5M7'@\T#;9[@N+3\HL)[BDU@[VBU;S:3]EYAA.:1AG,""L@RF0*29YF MD--8TTBB(ID[[=6Y*C!A3_=D?@K]^];C-=?;YB;M^;K[I/&#MT:;"UD4[ P' MM>4#SQYL^]/Q(") +X6FMAW6-]N>Z.)]@';0HL)#4?1]BF$K_F6.-!S!.7N^ MX=K.@&V#;^__^N;V__Y5WC-9SA*2J2Q2'+*XX%#[6CDD*L,P$4E!(R4+E%K= M*CUJ>6J4U^CFL$!\!I/%(GRH\8&9I%$+_-8HYK)"?@: PZ)W*! CK6,O?!'< M%J*G;.U=6SY[8;SEXBD]GZT 3SXP,#?Y_&XY5W-.E^M;SDV=:4U?]6V2N>S, MX3)6"M&$PR1E"J)(Z,5=FL408YRCC L5Y]0I_[B5V*G14L<3J_8& +JS #RT M)CCF#[?K!#M'RC^T@4FOHS#8:PRV*FM_*82GY :3KTS>=D+'S=;M!,111FZW MMQT]H'(]^]S<$#6%@[_*\G'.9;5-#)FI@BK!81$14_6*QI!)2:$0B40YRX7, MK-+.]DJ9&@6UBM:+NE93QQBR?E O^$Z^H I,*8-0LGQP?Q,:\G3]B]?# ##OW#XO5DY1MHZ>3_W]Y_M+4IE.C MG[\LRYUN=>[^7=$.KK5WS.P3K'OM'*5)=%IHW^I4[91]N8P;L+.O*:ER XQ! M^K=K\"378&]3':JV\7FW-CC\OI(7!=-SW,Q'H>$^2IL47."P6>6C7)N\<'K2 M>IP+*5X]_:4RQQZ[\]1;OIX_-G>.5\:;W>C?M1^NEOOPL2S34P>))32AQ1"E M<0RIX!DLA-#+89(1)ITJ (P27;J M])5;DTQ%K9^,56"^_+D3'[*W[ ;L;0-[XX*$&?K%VQ/C>U)J5'KW"^0AEWMN M??#5T.]R44\/=/DTDP(7&5(4QI%)V)#B'#(29Y#%22&PB..<6ETI.]W\U(AT M>PO2J A:'9WOA7;AZ^?#ZT$)S&M.> RY%'K"[&ONA':;&_M*Z E33MP(/?74 MD#CGU?+.E()^K[73#3_*S[K?JO9@*J:Y2A*I72692[WN3@3$(B60L9RF2N0I MCJV.$2Y*FMKP-;K6]<_!3EM0J^L2!-N'K,69IR^\ H_LLU -.1;MQ16 .NTG*E1YDY- ML-=3KT&TIJZ7Y<_@:KQ\? M1@::7TH3V/]&-G^_7[;'J]47R>7\T800SFC*).(BA=JEPA#%VI/"&>,PBK*" MBCS'N$"SI;PS94+MN,%&K-57GS1?_:[P<"-@JZ-),-PJ>0.6/0'EPR&W(PUO M,([#(%MUP4];A7_6C@/8P;I7VA^AN$#DB5VL1(Y*-2X@'/*.T[ON.RYMZLVG M.&'?YFO]S<^R/)>Q*F A>0H1UZLXD@H!B9)*YC'#$;8*RS_5^-1\CUHI$^85 M)S^QG[=Y9QTV7([0N[S=<@TF@?G!%0ZG_99S=@_:;3EJ;+2]EG-F='=:SCXS M8)_EM?Y@SNGB6ZE=C]NE^"+K:N#FP&R7%)HGN4@00R9390)1FL00(Z7] R2+ MB.:IX,@J-82MP*D-XZW*8&UTKJ.!RD;K.ES!9?/%!FZ+/1C/( 8>]SO\:G6! MUA>T"M=A A;U2H8!Z; QXQG0D?9GK@?6;;O& :7>71N;=L;;O'&PZMD>CLM[ MPQ,&?Y;E?"7>+L4;W?@,2\P+5@BHW2C-QZFBD HE("_BO$@HHRFV"E8]*V%J MW+O+HMMH";2:P.CIGDWX.9"7':FKX0G,JL[(#$HU?-+ZJW(./V]Q].3#)PTZ ME87X](,#"\X:3M 4T>;NJF8T$5%*.(<(Y;%>!2D&<9HQF),H1312L3*7D^VS M'!P*P78,V;[*O9Z MV/RX=5W/&'=4PO7<Q4O.BLI*G-T+>@Y;V]U2#X@%WR)M0?K2V6+V M7F_H(A+>=D+/R1EY^_."N<=[GI=>&%@7B#Z9Q@S?U*."+EP#1WM:F-"W>*ME M/7%M]0P2V&F!AZ]Z-3V2QBU8<]GDHXHU%J\,O->]856=<7O]]E'_\6&^E._7 M\KZ:X:A J9[48(XC/=TA1"".HP1R)1E'<5%$A=-T=T[0U&:[O9Z@5A3\9E0% MM:Z. 05GL;6C"A^(!>:)86"YW\&^@(2O6]?GQ(Q[S_J"L4[6J.(!DD$NN5KHPQXS)&J7"Z'FDAI*E7 MW"9R,0SJJ%WO2X7\+P(J#/!.$#DB6ML)(Y*.PX0'#*0RZL#3C#; M^ZC5M]4M_X_-O)0FL>FJ_/3[4HHFL]:,BR)3 J=0)JF)%X\4)*:@.HE3O3"7 M4:KY:1O@],WR'/.R6*M1\SS Z=L8J1]:Q8$>+V!1*PU71FNG@AVVT/=SD$\D M1UOZ-.BM5Z!5%S3ZPEKA-G.?7Q =#C+]@CG2.>:UH+J=8MI#U'N(:=',>&>8 M]C8].\)T>,U'A:5M&OVG&8U%*A,50:K9UYQ_:$;.:0JS*(_26'*6T\SE_.., MG$D>@UQ3$6F/H)USYP&7P(1ZE%I^IV2H D9'* 2I4[27\H+EB(Y,[:\Z=/SX ML%'?3ELLRQAF,8>*FSVB3*40(\0@19RH(F91FBF70>X^?XUWM#FDV)F5BS3< M^, #U]>S1K;B?+^=FR]=< M)ML>=K87%!67>9*02,^NE$*49P@2/?@@%C3-DU1/N"AVVJMUD3ZU'9E6^1MP MUZA?GV'09P8X;N,Z]87EWFXHA$-O^&[!_7,'W.>Z[P(=+M_#==\('@*;K]UA M)]GC;AD/@>5H'WE0(P,S]M%RJ655GV59YWO:':*F @EB(M$)%05$%!%HZL% MF28F74=!(F95P^R2H*F1UE9/$^L':DUM3EO=L+5C)A^(!2:A86"Y)YZ[@(2O MO''GQ(R;]NV"L4=9VRX]/S3\RJ1YJ[OZCXW).K+?7MY^G0G)TSQ- M4BARJ2!2LH LUHL/'(F8T$S21#BE&K<7/37RZ&A^ ^KSDSK>L-:^."',%Y#A$S+F%893V03=V5^^O?Y7K M]:+.I]KD2*US64KQ3EOW:?U=EI]IN7Z:%2(B)%$*IB)*M M$$DB+S.RLL%@D M^FLJI5/@C:/\J9%;JR00])[>R>90ZX%6:S!?*E-"I[;'C<]<>\2.U +B')C9 M]IJ#O>K;1+Y@VP%F$():?U ;X(_=!B+GB>)03Z40N MON*];K#FJG(]_\]:4KL1]7=)RV^_KV:FXKU$A,,HS3--(T1 J@H&,ZH7@4F& M52Z<"&60%E.CFK?5>GY?7Q-7F_6FE(!V5-_>S;L!^HN)O-4B[NDC.SX*CGQ@ MINJM7'Q3;XOSNH!"QY@;8.P VI!1BAI?QC%\K>,>':92 ODR3 Z5D2T:&[JP M; [SY_6]D*_K%?_']]5"OU\U*]G=I@PEG(B",)BDL5Y1HD28Z$@&D<0IRQ.& MA;)*[^(J>&JLV-&[J?C4T?Q__!-.XN*?V_T_$WSPJ<$T8AQVD.D:E9 M3*F(H9(JP9QP/2:MTIUJEX13O6]H)-8)K>?NDZ2@:XG'X1"5^A M7V?EC!L-=LGI2(M9H^R9"M;HCTOS.7[WA49[FO_EZ]@JVSGH,Z-'GK I31A,L(* M*ISH.2Q)(X@5B2!/.:$I)A)1I^@[/]".4N4Q++!VQ.L'KL#,>QJI !%RE]'P MQ+X]@D:EW\L&'_*OQ1L#W=R#FX\']R*;?8 F?^ K6LVK&9:HT-3!H,QB"9$@ MYL:BC#4WYS%'1,A8YD[^F:,"4W/;=AH.J!+K#+ZE6Q<0TL"<8W&3^@;L(7_= M![F[$S@0-U^^H:OX<5W&@> <>9)#VQEX0$/GY5_I8K/=V%QV?=A?:TJ5XM/R MB]' A&;H!SZN3"'HYL=:A29Q098B0HC0/A+7RU&$A8(D9122!*B MJ-XTFYJ'90P#M64W8*=]O5'0U7]8A@E_W6EYOO,2G13ZS,=/_[B?\?C&TM>Y MCS>]QCT+\@WGT?F0=P%>BUJWM8FZ!5IG(LX09WH=2T2L-$>3'.(DX3"/D8P) M*^*481?GU%[TU-Q24QN9F]K(#YW:R&JK=Z=BM9>"U:?ZPHY@PR M*=\I/!V\K'0/8F%+1Y\2/(7RT#V 6): [FMA\*&2"6#437Y>+>:\>PN!R2(K M,BQAA'$*498I2)EB4"^KDX3*B*38Z6K(>5%3\Q?WFH*MJH.O??0 ;'TDX@&V M\&&) ^3/M1AI#VO%,W_O1-_EB_ MTOK^8\9H(13G#%*JEZ HT\M2K->A4(DDIC2+(J)RZ^I'EZ1-C3"TOK#V;5R] M&#ML^XG".V*A?14-5NVK[)4%OS7J J,OJ!5VJ3M]$4"'S& ^@1PI+]@)0#WE M +,%HS<#V,5&QLO_96O/L^Q?UB\-OZR[U'WPI'V^&(Y4*II"@P9$6"(4IB 3&-L?92$U:D MBC-52)<%]F#$IAF0\PPK.X=S* *!IXV=6C?@8T^QX4&W@@_-]7CO=]?TZ#=[ M#XTZ=7?WZ)F!F4CN'Q:K)RG;VFXGPK](1&DN$8.)X$0/4R9-GH$$7"(Q>]Q,+J6:NV9%NPRYW6CW"F1@"MCJ"K=U M1<.&X%E#XRN'R45YXR8SL37_**N)]8O#V.:OM)R;7?PZ&:,YEIVI5,DD1AA* M%IG(O)AJ=I$$DHPPRB(<9;'35M61A*FQR59!L*@KR;L'>AQC:$<75R$3F!YV MH+0I4OW&8IRUW-/H/VY_U-%^UKS#T7W^P:MVH*NV.L]V]F)1'.<$93#*"A/5 MQ0C$PL1W99(G*6-8$B>'X;28J8WKK9;@H5%ST%[S(91.^\Q7 #3.'G,%6@W# M!-WW8.!W:_E0R$ML*Y\Q],R6\KFGK\EO\6%5529MQNN5V;+>S)=W;:[EU;)Z M)=6JE,USW^@/6;W]L2ZIEC%?TO*I+L_S49NKW]2F:TEWVX)ULPA3SA,50TE3 MTQ&"/UDL18 ^9-UHBUL6=(7HTPG6N[ MBS&)+@N^*5+WT$_&SI^;Y$)[4\'>UFV/ML_7YMZ Y^:!K7V^DX$$[02OR43" M:/H"R4B"0GXZF4E8D0,3@)^_18X+6JB8$EA(/3L@R?22,2D0C*2@>1QE*<[= MLGW_E[G ?^K"OJPU_I-C2N]K[^C_E[B5WU7R?V[OY-^NU^6<;=;U1KNJ<"$2"YE38Y16Y6U*I,X=?, ;C0<5_K!!WXYH M/&,:F'&V<+;JUF@V*2,;C0,L?!T \E5(VD+BN 6E[2$X*BSM\.K0.K)*ZG9$ MQX728O3?K_4OY^MJEF&>)'D20Y%0DYT(YY!DE,,\B5B21D51"*? @4L"IT9! M6WVO6+->Q-B.:WPB%YAH=J!UEX4UW>A_@59?G_5A[9#Q5ASV@KB1*\/:&7]< M%M;RO0%!G;I-&52B"--93 M! MMA5A^WG%2I[5T'A>"C;T;EA]O+9-+V29T=K:\RS,T_HE/\6: M]L')VFOC5"429FF20:2B'#*>9E!('A&6D9A<5ZUINE'S<@T6YKCA02]M*J/J M=36:; /FO0(5F%=/56FR"9*_ND[3F1COZX.Q7 M^N^K\O6F6FO/KJSJI/-I&@N!< %%84JW901#EG %HXB9DL\\EY&PND9SLOFI M,0N^!/78U'X(%N"X7]S-YK<=]HUF]V1K+^:3^*SS0ZSM3>:]!N M+N]_:N#VR[SB>J;:E/*3JD?_*^T9B->=2-[;LJ1M&9WJU=/^F;9T?%T@I#/E M,QYQ; HTHIA#%"$&F90,HD+&&5FWX;KZ0Y6NZEG>K\FG& MHD@0B@3,<$HABIF"C$@,8\Z+#)F,V0[Y2X\- M# SZOBK7WV1YWRE@N4U$'$D2$Q5!E9M22"A)(>;:09.*9%FL1W.29TZ!06=% M36T@UYI"+>D>='1UC DZ#ZR=C^0'KL#CNT'JVP%2 1(17T;#5_#/>4'C!O]< M-/@H^.?R&\,XXF]R?O=]+<7MHRSIG?RX,6VV_D;U:;.NUG0IVK1R?,:RK,AE M1F#$S0$\%04D.%(PIDG&<(K-QHX+;3A)GQZ3&"W!ILD_5E]YW30G)F9YL-ON M-075ZAL=$#!C!OA)/UQ_4OWL1CMN?67'1,%Z(# Y;?4&K>*@T7RW,*M 1_D; M4*OOC[$&H>:)Q-QDC\IK@V YI+IAC0SUD(8NJYJUE99ZNQ2?]3?SH_ZNOEG= MT_ER)E.2)UG"(8Z07AGE>GG$BB2'41JA@B2)0)'345<():?&IDIOUCNQ^ZUNFJ@X23(*\UP59G=+0HI,O#OE:5H0AN+"R=$=H,/4*+I[/M%; MO]9U,3V@>RR).2SHH9??UG@'/4>X D1?!#Q @W'Y=3A$1_1Y15,#,U,LZN^ M%*>9NPWWG]$HI2A")D:#F\-]'=GY!S3X]N*)8]&]GW"SO1GD,?&%$T2^$F'8"1TW,883$$>) M,MS>'D9+NL7[>;//J?W!YKKUG5R:3,\S(F5,E,AA'J<,(J;_(,IX:)G*92P9 MYL3I5G./K*D14$?5^@H+[RKKQCY]"-M1CB?< O/,(62OK2!S)A<+,#PQ2I^D M46G$PN1#[K!Y)72YFE.Y&_89$U ><1D+2)"((4HX@8PE N;:XTER(5.5<1=N M\:/6U&CHW8F*-HYY%3SUEQU3C=\+@4EM0"F1XHS!)DRE0JB7$$JD82"TSC# MB$4LMDK1<$[ U 9O&P2Y5])Q\)X$\?+@O1::P(/7$94!L:&G3;\B./2@P9&C M0T^;>N:Y84NF7VGY#UEG]]I7@MZ?L2"$TEAP!1-S\(4XSB#!&.GA'!6Y M+(H8(S1[E"5;V:Z%>N6Y?'N[4LVEP7KDFJTN=N:XN:3QC&'.:Y0C* M.N[<7!BA.4U@I)! M.#:=7"*C3HA8VH>PDY%4!D=;\!_C_X813%XH"5X;,J! M9S=1%+4QH8!NUM]7Y?P_I?AGL%PM)9A7U48*YZQR1]C;\I=,TVPM_F MZ^_;Z\QZA;+8F"!/<^"M_V=20[6LQYD]7RKI3U_+&8HSK$PT/TVC"*(4FY/"3/NS49(R0K,HQ5;LUR-C:NS6;N:T M>MX HZG&$1A=73>ZC@&UW>NZ"J9QMKO<$!JPZ746@ROVO8[;''GKZZQ1Q[M? MYQ\=YH76N>_V9\DQ3I#4G:V'-:IWO KMV= <$J5(C%A4%,PIQO%Y\U,;UHUV M-L>_-MC9.1W#$0D\@NW!=>D-5CL MU7:,R>F'UW*(^P(M](CO5M7=:QJ& FPP\<4(O;+&)0@;LX_XPNHE=X?^]>I1 MEKOO0J3P3/(T)2ZW=^&TFC.]TD#NB[WZ0>&S=OOZ+RLMXW?+Q\VZ^J# M7LHOTC9CCHIBR5(90ZJ''D0(48ASE4 BLR(K)%>1<+IJV2-K:H/SZ_QN.5=S M;@(D-LL5JV3Y6)^+SFO5P4^U\B!US!/2A[;=).X)P\ CVVBY.P"J%;T!+6(! MLA198.)I"N^3-.H$;F'RX?1M\\KUZ6F[]XV^R(6YC&2*=%='-\L[815%1K"( M$((*"Y.PD"C("BST'TRS#$L$2MC0=+0#])D<%YVYVC@\Y>R03K*CIQ&A#TQA M%RY!!DJ#[PF_ +E@AVCS8KE?KX"N+]?K-+_\7*ZX MK*J/O%7H+R !3+G,D6N(%%1 BDE>5P4"!7**5[0 M5O#4J.=9O -O-:^:@ >^K0'A-;3$U2<+@6Q@:K(((@GD@+F"-4ZXR NY5*Y@ M. :&^'*2-/6MRSDWWABMOIO;Z_HO4XC[D2[J^^SKU[0LG^;+NR;<5B8TCA*6 M0!89AXF+&!*&$118*HY32J1[N**3!BXC;9Q0Q?K&\G>YJ//ERDI_2WX'Y::78]PTV'SI8FL:I(Z3SA3E0>+OV)S-= MSI>?EO+ODI:W]ZMR;:Z?F$V'FQ6$1"TDC/9:G3 MLO]ZE:9&ET9O4.W,N %B8PYP@+FZ\Z25-X& BWJY2[=FZ$FN;3NFZ^=OME9!]6JA,8^_;M=MQCM;T!KXY/^9)OIK";@KWI4+N3N8_!& M?W(#C/E P^ Q39VW'O"5PNYZA<9-;^<-P*/4=_Y:'IC+>*V_=,8CKA.$FBPM M=/%Y5_)A!XA\91NV$3EN>F$'$([R";N\ M._26S-M[6=[IR?'/>CV__FZ.K^CR:59$.&<(,T@9IA#AI( L3@GDC%.DOVV( M$<>;,B?E3(UXVKL@6UU!HRQHM76]+W,:VGY^\0A88$H9B-6 FS.]2%QQ>^9T MNR/?H.DU[O@63?_C S='5T]TL7YJ@\P*5<@TRDV"7A5!5/ <$LP1Y H5>8PC MA'*W4YMNZU,;\*UR0R_X/@/.VT[.VQ]U4.F76 MT9;1R8>&9]5>+>LL#I]I^:FLW0-1;S5]EF4=8#++,H6(HASR3)E,_QF"5,_5 M,"F8-!7_$.%.MV@L9$YM2#YT\_^RR*F1S+,*WX,J<%K ;,\U_L ;@6NL<1M$*W90>*25"P)'IQ4[ $[1 MBN6;WBL4[:/Y=T<"4I$DY91"$<42(I45D"81@SBFE,HH2Z-,>:I9="Q]:F33 M6Y('[/4??$KCUC?VRZT@B(^P\/(%ML^J2.=!"U\GZ83LJ51..@^+0RVEGD:N MO,"];[ES:R^3(J4L)3#!)IN"T)X3C6(*$U2H3)AJN<*I(%NOM*F167T+N=X? M&GA+^R2D=ISD#:C '+2_J=TAG"I0<+T5*+ZO:I^4]3*7M?O,/GM=N_>EJY,U M:7ZJMY&^KQ;Z_*IE3K_$]^9SZWW.//OE64I/P]>O3/5LM M9I1J!LF%A$66:2>$R1PR(1(82TZBF"#"&+*--WG6\M0BU 4M&0=!HZ!K0U0'N\@B\ M!H[ @] !B0'A6L MIHYIM]QCBC#+:09ECCE$!9.0%2J!E(LB-O_+B-7)1J^4J0W31D_05=1NG/9C MV3]@O2$4>.2> .=RQ)8#2F+%-^;'>J<]/%K/Q$WC*V5->%8@-,QG'JW)+27%[5*\O7]8K)ZD M;"(:]=?P.ZWD9_V=F@G]'Y0G"!).8XAXDD.2I QF:<)YI&)&E+V7[%>WJ MQC"JOT,FCHYWXJ2!6I7MOU:U>4"VYC6;L;(UL'WFH341/.C6Z\#JIORE931U MB"^!S93T8ET;>MZJ.Z6Q##2F@<:VFR8FN[II0K=!:R#860ANS5;[MG>;A[96 M F/FR_6HRT3X8CT[UFSY$CWL.+,&Z8/^Z=>OR!'GZ"!8/9_(PX@8&( R7\[7 M\L/\48KW>JPL[^;:@[BM4TVU^17J\?.VR4METBZ\TT-G%N&LX!(I* E#$&68 M0)P+"F.N$DJ3#,O,:L5WG1I3F\/?5NOY?7WS1FW6)O2+=G3?YO:Z 7JXY(XQ M+<-ZR>XD.CSV@2?9Q@!86P#V)M352=>F7.F#K%-^=:UI$\P82SQ&R%R%I*_0 MF6%*C!M3@.VHS1ML@1GL&6(= M34&KJM=4A)<1\9=XL$?6V&D&+YM](JF@Q4O^*CK=B4>*C8E#A=FO*$76@/Z&S%IF2D MBDU)D&M3?9)>O&)3TG]1RN:58=SQ5BGMT&IWY_V2K^[E-_KCBUYT-!<5-GH] M^>E!EK7'4\UX1#(A&(81D;EV1B(,*8L)C!**:,03PJA3T@E[T5-CEIWF)N^R M5AVLZ0^@=76\7>" O1W!A$$T,-_LP6RT!EIM8/0&7Z094?/%O%UE?99:I,]< MRNYX>>(B!\&C4I,[((=,-:"% 75BFZ3:[^85IPNS!GNKO2HM9H91:M)GIC#- MS6T%$F6:HB2!^DLH:2PY*Q*K,Z(^(5,CHU9/T"C:;$6\-:Z_-1_U0MK//+Z M"LPQ@S!RJS5[ 81A96?/-3I>!=H+9CTK1GOIV8$)TIMSZ>HS?3)>O%Y Z=^4 M&RDZMQ;V-Z,Z98D2@7!.&8PECB"B2D"&:09SC) 0>9;QU"G!W4 ]ID87K=+= M*TV.6="S,"RH&Y9FL!:$VH]V&VJ'>O/W6O=0>Y9'DEEKXRDP_48MQT MY-=!=92#_,KF!J[E:+G4+E:U3?SU9K[8K*68Y5&B.,IB2'"F(.(H@BS._S\B9&M.91%(:X$X:0 "!:'3UDB;P'-Z6B[7K40R],FLUW&?] MNP&MEA[78/TP^%IPG9$R[NJJW]2CI=2%QX=FVGI^JJ5'R=L?IGB4R3:\6HG? MYXO%#*NDR"GE4*^FZG54H;DC4I!PF2B4Y#E"3KZ3C="IT4?G\+%R)'3<=F#<)R0 MR^'=H1DGN#GR,O?,9?FH?VB/4*(\0I'(.))7#@5 ML3HC9VHL\]KX(&S5[(G52X5%H_B^L.+ K.7G@+:C&P_P!6:8#UN<3-FG1L< MYU,7IPTHO_Q,+?$],+IPWPIWZ_E?36+B>0)5QF,.<<0 MF0PU%&N'A8H(B[Q(48:M3J2&")\:D5C>M#$;#[\9(T!MA>?+3<]ZIY]H0F,> MF'VF![??&V5#89_6O3)K^+U?+SN%W[67S)ZU.:FK9J>L=;UP=K*-@4<&XM\W M;<+?;ZM;(>I26G3QF<[%^^5K^C!?TT6]I&:T,B7_[DT45OV-_6*R>%7SM6SG MM":1(3N9LLCBPEU7NBSC<_O7[=7D>"KNO<^TZ=ZC7);EK3- M%F#"QG@IS<4C<]_05-0$'9L\GF^,!+RO@Y#0ZHY[8C(2^$='*V/)O3JA9GL> M/BL2I7@6%3!EG$"4Q0AB7J>U0(AF*I=Q7@Q,H=F*<*+WT9)F\C;H8O!)\PDL M;3G^,UYN!;Q4CLL# WNR6AX^>6V1DB:X[:-< MSV*!D]R^]ULA>P@L5 M%SDR\7PUD>-'KQWPU?NEJ1Y_NQ2_TO(?Q*82_7=Z/Q8*5["Q@CZ_[;F]GF 0=[0\%/=2&4QE:PS2?<6/MS M^-BYT+WBG9\]J_E")!\&[/,S12!Y0Z>;]LK$*3+AN,#_?W/?VMLXSJ3[?7^% M@ . U\5G'SNM+3V=__2$EV99O M$BE3BC[T);'$JGIH%HO%ND D,Y")S-9%3!B@62J!9I @B&.MA%=SJB9BXU/[ MVRPKWR-D(Z2N^CD,4+WKV%WRU #*L1V28 JN@=3 2JI=Z%-%X_!.AXMRJ[-J M"NH'F\ZLYOJ\6'YG,_4'6]M/WF^U69P/<_7TLEQLGE^>_EK8K(S5+IETDIC3 MJU$I&,1)BH!1*@I;9;43ZR:2&YOU&2WF M1A\MHO5?B^C="G 3:<\>4R$GTN&J??CIZ5GA%3/SO38S.YF $0I8J6ZBK5SF M4RM99$2+*MDB(UR1"69>W>>\#S]W'O?VP\_A0-?Y \^EWVU_6-0;@P "D1HN M-B L-@*01T MAKC91Y,8Y#FA0(A<9$SH7.?<>1]UI3JVG;+DT6Z*JN#20Y,Z ^VPS_4!7]\W M0@7+-]&.Z:C@^B;:0UIR?N/5T,8/6H]MJ ^(!]IHPD'MMX?X0M:X2S@/-MP^ MX"O?@:;W?KF;>Z6H!_5],Y?+]S,WRQ@KF:18 (QS#;"6%-"8M"WEM_RA;$$L$B>QPD 16ULO(1AP MKB$0:Y$1(!A5( MX\Q8)@HA0#&5 %,NN68P9H9^UQ>E$> M/NFQ&810)1G.$QFV(D.CH"<%&9J?[N!A>MK\]_N*55_0G":)MD8$BQ.SQ'DF M 5,( JZ50@DRB@ [W?">C#RV]?WTMW__K^^W'DZ, Y@]YZ99L=6GD M>0" AZ>F*Q #>6-*]@*Y6,[)VNA&.7AA.%?).3X/W"%G'^B8"%=K6?"@CZL[ M3'*=8T6X[2>048!98I1-G!)@V[% BJ'(_ XPS>3&IH;JW%JK>WI<\,4S&ZT9 M:\4)H= 6M,B9#?F,(9KG">0QDGZ!XN'0'B9F_/9, YN@$+M9>.%@ MZWF[./Y^GI34"9A)YX1)J#RX9F+#9K$Y"7Z2@^;V5I@J?K^QU51,,I:3/,$* MY# VZ@,KHSX41$ )IA-(-::Q5T6NLU3&IJ'/5O#CEM->ZO>52#N>$Z_%K^]C MXIG:?06/_57N.X"@I[I])8T/K=IW(&9;S;[#A[LIA//9K+6$Z]_>]X]4^=BW M?[&EO/_Y-BT+2Y6IKA-&8P8A-U:>Y G -,\ 9>:8F0NB598F-(N]8HB#<38V MQ;/GSRH7PZ"?8@DW8V[*Z$/FH6<%5B\R4)>J7FD@XN_GBQ%8V8IF?=M9_-8\ MB]ZZ+SCB@?1E.+X&U;'!X3S6R^$)^'>MN)^O;<":E&:9K*I_OD[G*IFDV!P, M408!1"0#&%$$N)*I^5%"EFI"C>J>(RC,W*,A@X?5MN M![C<;/\363YMS&N8?A6M2'1J6'%YU,$Z5K0*5F]9T?YP!Z=^5>K]]Z4YN3PM MS!GFDY(;4?2\N9W+Q\4[F]5#932%5*DX!91K9-M[:I#'&08R3G"B6)I1XN[V M]Z,]-I50L W6"S W!S^YX[S(%5V_3)<2O+&E61O+K1P>+G3/67&X9>@/Z[X= M2U4SBA+NIP6PY^P]\T4K^1W[[3%.5V/M<:'1'^8#77D$QM[OBJ0;>HV7*)Y# M#G?-TDW6@XN8CD-T/.6+%S/Z3!4A)>OEU'89OV,KVS#6_F/OGG^P65'V:I? M"C.4*'-L!UJSU&X=N3G/0P((03QE6DKBUQFZ P]CVT*V(EB'N>7YIO@[JK%^ M4VPG>P&+!SS/]QWFRO$DW^\,]+RQ;'DN-)DY=1?0%V40*1L)"X1T*?$WBD)+STW6(F]58W/__V_*$S(_XE4P:^G0CN%E(J4 MQ6:S!UF6F6-)3C3@1"<@@[&DC"F5).FD=(Y^7QNK? A@C\GU!^]OZGDZMY[\ MJW$DY@ G4Y("D7,.<"8HH-C@R!77L68T19FJ<+R?R^%0W!+KTY$A0P#HN'%> M!4G?ONP:<_^\+75TNS;:DF_*\D?K1?2-AOIWENO)M^7"G@(>EE49V=N?T]5$R(1G><* 4C:22F,)F-;0MDK72HI$(^;4 MO>82@;&9V16/A\U7+*.N48V7@&SQNP2 I^>UW@$9]T-\B_A-"]N\6UO4YJ?] M@KXX[#"G]1:A=D?RMN>Z69/-909N9[/%7\SP;WZ^6RHY77]=K%83"6VY5Y6! M6(D,8)A(0.,L!22#-BHG8T8!^!R\NS Q-I6PX[*H^BX*/HOH'3\+H--\N-D( M?:/AE"/ZVC0+WH;%-3 &,CTZL3"H<7(-2,?FRU5C75U= M[%&QV?1_E/R=3>=VY*J9L2HNT \"(6V1LZ+ML7GDVU*]3C>OJXDBG(B<<6". MX,(FR:: HU0 $J>48Q&+6.K)7#VSM9)/G4J-7<>@TP+/RP5^PF:/VO0H^/>M M8OZ\EO@<)TV^*1^D-;> M2A99T:)?K'"_%M<^._FB7^H2_FJ;7.V$+)[%F0&/(F97$ORH4F9A<&HH:!:(0+=#SZX\VKXNZ>J6K]9+)M83@HAF.4N! MQ(D&.+7.]"2. 3%'G SE2:+]FILU$1O;(69?/+!617=E#O 5OX[N#2>9OK#ISW^<,%D4#GC$92@YXG7(0^/CE877>'J$./:C,458:X7!AXXTK59O--@UY;G.]H3T_ETK;Z:,>5Q M-J0Q:C:OFYD]-]?-F@D2B29YID","3)6!LL!1= 8'4Q1EJ$LDY!Y^ 6ZR"3I6 >%-R?)E??1#4)HEL7[/TM MF<[PA;)O_!D8UNKI#-")+=1]I"NJC=IDHZ5Z4?.5(5PV@_C;?%F=_/YM,;,! M$ML#X,.\YN-=3E?FHT_FQ_ESF7A45!M[8C\G&C$18YH""&VR$$7&UE)) CC2 M&28$QCGRNGOJB]&Q66A[>-V,%=RJJX2YF7U?C6[&>'TJA]3+V; M4A[#A/:LNA_NOMQ$3O=AM5FOI*Y[YFXBKLRS1N?ON@K?1*SH+O#4,.O=JKKV M."4A"\+VP>;PM61[!/ML&=H^Z77N)E8T8?^DRG^_S'<5MJLVV3M/E!2I2'&6 M XF5!I@3LZ5D60I89DQT26-(D%/_ G_28]LD[EYL0G#1I7"Q*Q%?5H,J+M@Z M][+VF TW+=\/QCWK[2W3T2];MG^U4.^K\5>L]^(W]$ YD4!RG2"8D5AQKZ)V M[J3'ILSJN5#;O,.O7168QPRX*;!^<.U9@;5 .E!>DRM@P=.96@E_4!:3*R"7 MDY><1PCO(*WY'.[+JHBVA=63F3PU@<3H+*X@0$3;LM^: )H8&TU*B!D7MDZG MUV&_(Q]CTVSWJ_7TM7#,Z+:SI,9FWJHWV)*I:=BZAB,TH*FFX*X'J.>5<.6 MP6A7,#=\.Y5F$ )I@PM$!M4#S8(>:X"6ISLZBC9\I?ZQ,:KEWNJ7XA WR1*5 MI<8( ")'"<#8QIK8%%U.$TX9)IP+O[JW9XB,;=WO>8P*)BO7A&< ZUDX'?T[ M5X+4MR?'%Q]_?TT# *$\,^=(#.N#:1#RQ-O2]&RP4\'N'@5RHC(,S8)/4G,H M0(R G&83G5#;009X3>;IXN M4_KH$T+[W5+[*UV#UY_8SR_2C#XU]G#AK*B:H%.$)> @]A8!3Z/8VU[H9DT4G>?O%JOU)"$LDT13D!)I;(\#<#(%.,/2\D N>;J*[)N&]M_@3 M00-MZ/MQ!]V^3\0YWJQ/'^BV N\6KZ^+>5&O:^>U8Y H3 $6"0=8LQ@P313( M4 +37$-AUJ6/%7]"86Q;<@N>V*J^"I.?56:%1,->#:^ZBZ('6 MZ^GX@Z[;B^(=K]_+#UZ1_?"G8;),+RMO!ZLO99)1I(6]IXL5LJWL$G,N)^9P MGL8$DBQA,/-:T0VTQK:V"U8CPRNHF&WKY.@-KMN*#P19SVM_A]8A6#VH 0<\ M0H;87Z T?)1\L\AG ]U;7KG2\#Z*))0IEA*2%%":F_-XHKGMALX!3))8QIBE MD&(?57&!SMC4Q/?-ZRM;OML@P^^;M[=9T:'*F.G[..E"D.C+7"^6KQT20B_A M[6G%CS9,LV;3]QJ2V8)$:*/_(X,M6T2]>" (&D99GO)MJ?FWQ;*HG/Q=/=O% ML9IPG0E&,P$HH2G A)AS H'(G-A3RK3F1/KUPKA,:FS:HN34*HMEP:O5#ZN* M5S^UT "OFV8( UK/RF&/UY[-Z'L;8-ZZH1V+0.JA@="@&J)=X&,EX?!&UQ81 M;%ULFN6%-<=<2<@E@)0EUJT? \YQ!C*429:C3$N6>=W_'PP_-GVPXZ[CE?\A M=FX+OSLB/2]V=S Z%-@_)W.PXOH'@P]<6/^<8*=%]<\^U;$*]W3%GI^7MKQ* M4?/N4?U0\XTZ,D\102K/10J$K;B-A;:Q?&:CAS)6.DX%0<1K'3M1'=WRWA\. M[A8S(\ZBZG%L\U._3H4-NHYNC53EU[Z2:65[)>^?7SC>Z/G-CYNN"(YZSRKD MD-_2;B@X[O5HX852J++:3C2'K:/M \-)X6ROESM4RBYZ1O_6WE;ZM^.VTK=" MJ)FJ-Y;^O+!UO(WM_EV]L?*#B!V;EJPS'94=CR*]9=LY10[GFRFY7GR*:P;ZO-2@$*,:*ZJ%%-5KNA MU9^KY(T*@8OJ7?LO0"ESM!,Z^C["+X!'5>WQ?!$&JK,]AB^$7]GM8::HL1!W MSRP,5YI[&"P/BG4/1+)K@E-AQWPV*-TMYD5(Y'].UR]WF]5Z\:J6N^A<%,., MB 0"+9+,WK2FQG[(&8"9-)_P%*G,*^_!D>[8;(&MN6Z_5=&6\>@OPWFT9;US M<+3K5+@=C7H N.>=.A"V'7*JO) *EF3E1G7@K"LO*$[3L/Q>[WK#NUHIM;O M+*Z''M5<_<5F3VKY.DE@SCA.8B H,JI*"V8[^.9 ,JYSF"4Z5\SOIK>1WOA4 M5,%:9&B]^E[E-@/K>J4;#*[>KW8MIS?'=^&V\TH)X5,3A!UN>)V "7;3VTQM MX!M?)]%/;W[=7ANBD,ZC>F73N;1W3)^G*\%FMAK%!,9I)J%6 ',N;;-6 9B, M8Y"0!*.,"HVU5X6P #R-31\Y%MA9;F6Q7E%=2!.]&W'Z++IS?D[=U-S ,]6S M*NQ6C.>Q/F>E7$6!GH\JS=.(\H>4Z3G/T8A+]C1">%WYGN:A_?/O/E7^HO^[ M84NCR&;OY=W_!*8QREC& "&( 4QD#&A,.> XYHS(-&.Y4W&.!AICT[%;-J,= MGU5 BGNRW24TF[5A((SZOG;SALAY=VZ/=S+-2 MCU1-97;.#Z:P4C 5@-O;*YR1%.1Q2@!E5 H$M2"95WWILU3&MKPK]JKJT?_B M9Q*=Q]'-R+D:G9X7]K:_RA:@/MQ#C1@$,BK.TQC43&@4\WCC;WZX8Y[/P3%O M6SWU?9\D,"&,,,'C', <SU8O]<_^/S?0'F]E _4=E M[(BI=3/9#V[G\O 7M2?+R_#3CA%BMK'-<>Y_BJ+WRB-;JWNME3%W%4^@),9@ M4-(6/S=6!,A)EAO[ 2ML5C_B>>Q3A&-8]KV4R0"5/OY4ZTA6;-NF*\+(=U/\ M':F]F#=%&/%RAT+Q@&<9@F&_)6Z6SGCGOF?=>5=,L_T[NJ]/\U[8J'S$SOO1 M+P_?J&*FSO3PN8EV6$1;,"*+1E3"$;!>PX=,8ZAB$,,R/VREB0^9F),R%A_# M1;?=U))>O^];P7W^\>?TL>H8MVT5-TERD?!8:$!0I@ V?P.&L01I(D@>)T1) M&G=HD^Q"VTF)?4!C9,.:6D6_/!LV5[_:-IZJ$*;6S=-OOW*:![==)ABL ]6P M*X&K]]#\_!_@SR]V=ZB:9M::98;3XCXP!=*]3B0'U9@^(!SK.:]W.^2UW$JA MC)+<%I4AFB#$!03T(E;_P2)C>';7V%9_*[A43"FG"B:0 ZR)4U-A%>193('%F[QECA+'7 M;6([R=$IJ= ]/YM+_Q"EAH(#9"Y5+P&BUWS-Y$<^6I81KA==,MH4#KVV;:XO58PXMI,U71 MK4W\8F:E1'JQC.Z62D[7D;7-=\$/ 2,>'- *%?C01&K8^ <'H4_"(%S>&:K+ MZV?S["1#).68QX *:JP:A##@.1> I)2S&',F,J_"UF MR4UI]8]]S^KLB@ZO5I*/;/!:1_+#^KL63(PX5OP8J.N[NQZ,UDUQ5@G4JZ?% MK?C'9KI4?[#E?ZNJ(MS6R35)8HHQ)@B@1,4 XX2!/.$)2#*5FJ.@HH*Q#KYP M)^(C=89_,P.],.L/7^C.#G W]-WT7S@PAU%W6WZC]2*J.([V+-=[:'.J(P.ANL;')4<1D5;$:&3]]V4,= -NN2(/#T?77FBTR' MMD\7I+^BW=/QB .W>;H@T&E[ITL/7ED-MKPVLP5=%G.K/8J02 6S.+;.G1CG M.< )4H EF@$H42XTIFG"O0+4&ZF-;H&7-\![)KUB2]T =C,<@L'6]\+W1:Q[ M7=DF)$*7F3U+ZV.JSC:)?;$(;>-+';TY;+K\#S;;J-_>:T''GY=%"UOQ7GRW M)4V%A P#3@>;85$@]('O':"4\<: XK*?$'8(3MXC'JU>JF]KXUDF]62ZG\^4+C/ 8J9L2& V)S N$I0 E"$,4(:NAT O$A.C:%8WF."J;KR2#%_4O)=D>M MTX2[I]H)A&;?KMX=D#=[\'KHKN4#2VC5TT3R8W2/ P@7E8_+N_Y9=5^GZVE9 M(ON.K=23&>#3PE;]F#"9(X72'.@8F:.1LDWZ:,9!F@HJ66K.2KET3;*[1&1L MVF7/ITV!4-'?2S8]LNTNPMFL1$*!U+/2\,;'*PNO#8 KDO(N#CU8CEZ;7*MR6?6&2F"4I-N>=6%(!L/D_X$G"@4JS.$YC M03P+-@;C;&P*92M8TN./7V"3;NC,^-]:UHL;P$YH#B6"JU!9JRC,"8*8) MP%CD@%+.@2 8RBQE-,WR_N(21]Z%K68-U)F/*N[[#$GLU'5M*/#[]EDUA2>N MSDY%KVW:0L#Z(;&*']G4+01HU\4M!FP!MS8#?%FM-DI^VEAW7%E&H'#7%9\] MO%FZJ_N?:BFFQGZ[GM;$I8"M7D5IA%+!8O+Z:];ZR/!>I%N7_%F]5J'@IWJHH M<:(J :MGWBH1HSF@K9/3M(Z?3IY/;1TWK4(W;/F!Z/1NU]3$#S7W9@E(@XX''MJ-:WB++7&2Y<_=Z'(#5[NKH"D'/^Y"C]%X^C7.B=G)D' PTF/?B M'/MUE\79SZ\,T?TZG:LOYK^K">8P13030$MD3&$)<\ @X2#+XH0G/):0>86Z MG)(8VP+<<1C]W?(8%4QV#<7= ^EX97,5/+T;B5[(= ^Y/1$^=)SMGL#'!->> M"'@QHO;TR6M:0NQZ&$"[?'.9 J12:99U+LQNBKAM<9YK304FQ,NI>#C\V)9T MR5V7W@^=FCZ,MMM#CTT>>NWN\)%M'=SZ.01JY+!;]@^Z,*1?%C/S\JH,J]]] M%SG)8R49 BFT-P(H(2#73(&$R93F7$-(LDY[?M_]Q;6).$_J.%Y'!,>W[RO$*.*_)TG% )WRB3A/1C\K5<0"B M(5W'Y>W@P16_+VW1:$@30A"6(,X4!UB)!%!)(( 4\2SG,16)7[9."\&Q*:*" MJ4BPY?+=^OU_V%D(%AA10NRHV:0QPN(D*?@>)7SA IO\8A9+<6.(0 M#H3WB#4X?*_C64S-S*?/OZNY45BSV[F\E:^&HC6DUH9F%<(PT01QI>(8Y$D: M TP%!8P1&Y"OF50<*S8=$S%]4WT7/)=[,SL@'//0Y@;^HZGL."8 M]GT,V\+Y>PW.0Z9;0]S\3V%>*(4ZAKD1'?8#@?>XENHII,A<(LI++3]$GQ]4%_E9V@0"^6P(H:L+!<2+Q#%9X+PM.PA>E" MPGA2N"[HX!UOY(X&ME_2_>"U2NN%,?NW^;+J+&,K5_^FS/=6/;&?$\BS3$DN M02IY C","> DD8 FFE-SUF4Q23M4XPS"G)/2&+Y:9WD>WNQXCF9%+RO/Z\$@ ML^=XJSC89 R4Q-2NCLWO:CTARAG;"U95;^>%;)$1+N!M9DBL0UV"!N%IV+O3 MD#">7+D&';RS 2XW8ET5IL%)*C!/N='"# (^Z>/W^U;40?I\\OZP?]MU7I)YQHE7.<)@A FUO:YH"JK$ MN4P387Y,D'9*]'&B-K9UO&,VFA6=A)>67;#08&-^8!U"IIJQ=EOIP1#L>>7O MP2L8O8D>M^@99LMK@G#*P F40,JAF=:@RL))[&/EX?92YVY56]/B8?VBEK90 MQ%*]J/EJ^L.V*%Z\JFI;XXQ!C@4&62P9P+FTN81Y E".8*Z@U!KZQ5>Z4AZ; MDJF;\0O+N4T3W+,>30O>O;M:.4Z#X_FJ#W![UC^W#W=?HMOU>CGEF[))PGH1 M?6/+(CH[N#7BC5"X'E>.=(=N>.4'QYGN5YX#=,B)ML>=N\7F2NNF'=K([Z0;!G/63YC6H,WT05G \ZVC$=?>X%3H\$W^"P M#I2X&P)>OT1<+Z0:$VS=1AHN<=9+LH.$6+\W.X:;G"T_-A$REC!).8@%0T8] M(P@H$RG(M,H$I8CDR*\OQEDR8U/)]<*+HL:G9PS)>4C=C,+K@>I9\YXM:KBO M5F MH]F>:4^/U65T'=U503#KVU=5P%7CLM0-H7L?MV,1RD5UF="P_JE6@4^<4^UO M="\?^F1T_ZHP2![5VV*YGL0Y3I7M8YS9TJ$8JQSD4&) $=0:$IXJZE0XOHG( MV%3#KD#FGM&HY-2_@.@)H,TZ(11,/6N##@AU*B%Z"8*K:HB>##IX$=%+8IVK M(GKQV6ZVP)>Y6%JG]B=5_OME7NB3O<=[KU@FB8:)0G$&N#(K'L"#NIO1T!.6/>N-+=?1+UN^?XVF\ZA$MW8= MYH"SMVG1 ;% MH8/Y4&-CPZ0'%LC78;P-T^^FMF=?7M9S%7I-YE(F6,J- *) M(.;P0C(":(P52!/%"48R9HBXFB7'@X]-]Q3\106#E>?.W0PY :[=_+@&CMX= MQ)D;ET3N9&:<##:8>7%)C+I9+;*&,W>\*=N--W^#"*N.=% MO2UO6.06O%5\EV5MMTQ[AL2YSX2;A1$8W8&"Z;:Y&^M%5+$=;?F^*6J-KF\* ME.];4?8/M_,&+%0LGCOA80/UO $YB>+S'^'*$+_RXMQ>UDPTPUFF(0>YH,PH M+)P:&T-F0"&:0D%43(28K!=K-G/TC9[2\#(U=I1ZOBHL=?XO1J0 MCF[0Z^#IV_^Y.YR4[$6_6 9_[2$^[U3\T%%Y-0H?$XMW*N+%"+PSCW9;X8]J MI6S-$*,T/MFJ(8M";53W6E6HE\A3A&2N@6:*F!4/4V.=< :@3K'"BN12>H7@ M.] M<0!>C5^]PU,@H?5>0 42(^X4!Q4 MKWA <*QG?%[MIG<^35?L^7FIRA:@#_K1D)EOU-==45_$H5)"8L!B:LY%!!) M$PQ!FDI!>$:IS*"/TFDC.#:-<\BO/0Y5'%]1.[D5=#?E$Q+*OF]DKD/16^VX M0A-(Y[22&U3AN I_K&VK#[VA<<$NP(W,&4QZNX.I MT_K@6Y_*>RV4U*WOXP!Z[G7>J1)@1FF ,5VX)D6F' M4\5L\S*%4I)SD:9. ?V7*(S-"-DR&55<.L:97P2P62D$@:5G17",2,"C2ZOX M36O>O%Q;[^:G_5J_/.XP >)M8NWBP5L?[)"I\V@3"?A,_;:9SN1T_FRKSRQ> MWV;JY]UBOEHO-\)0FRB5\8S;/&6=*H"1S %/F 0*:Q(SG7"5.955=BJA%W![=WU4N&X9+KJ^52Q' M-9Z#@^F1PA,*X'UR^!QPNGQ@0>MY&&2^#QDNP@@OI:))'KS7JS5!&KMYA6I1 WD?D.HSY[?I_,FML!/EX&&)CP>^9M.Y M9>3^IWBQV7"?%\O#HB#;N,9W%H-R#J35"5(T>"[K!O4.;+ZFIESO($<9C[Z-L]/2@M%6TGLE-S7 MI^2H+M$N'/L]X*WE]:"&NLV\@I-A;SFOA^SD]C/ D*&N*HK"N5/Y26FU7"I9 MZ7EC9!?QY.5&,&%A<2#/,/O239SL$VV,-.09G:TM(\-,#-B0^"O5VI M.#'QP7#!& IT8K*A(G"&F*./(*'FDB-C;KLN0U6EEF;Z)5P6ZTV/-;.'#+7SMZ M<)T@SS*64NNE,'W4AF4G-Y$-5[#;;XNB 3:8AM)#;J1N@A]O%TZO=-M M4_Q]L9!_36?FZXL0%$8=@$11;K2$W0HA5X!E2HH\9\(H:Y\-<#OPV#:[+5]^ MZW\'D]M:[R)\S^NZ56[OY7LL9*"ENAMVT&5Y+,SQ$CSYW#]"Z$\S.P_Z#_;_ M%LN[C3&V7M7RT^*53><3FB<)U"D'1%-J=V@&J,X0@%HPGB"E6.94^;R1RM@6 MXI:[Z.\E?XZ1ROR*GYG6\ M,O:EK;NO*96INK*KE#22JNOVO,!B\9!P"P34 *@4^]>/!TAQ7[#$P0E6FV5* M(@F>X\L7'NX>'N[_\C^^G\Q^^H;+U70Q_]<_\3^S/_V$\[3(T_GG?_W37S^] M O>G__%O__1/__)_ ?SO7SZ\^>G713H]P?GZIY=+#&O,/_TQ77_YZ6\95W__ MJ2P7)S_];;'\^_1; /BWS2^]7'P]6TX_?UG_))@0MW^Z_.>2>'31*> ,)2BN M)7BM%:220S;"Q!+X__/YG[/S)GEO0'M;0!4TX(R(]"_#G><2A7";A\ZF\[__ M<_TCAA7^1,S-5YLO__5/7];KK__\\\]__/''G[_'Y>S/B^7GGP5C\N_W_G\'W+S:>Z]_WGST\N/KJ;W?9 >RW_^W[^_^9B^X$F Z7RU#O-47[": M_O-J\\TWBQ36&YD_2==/#WZB?@4_/@;U6\ %2/[G[ZO\IW_[IY]^.A?'O.4]=E7 M_-<_K:8G7V>7W_NRQ$+?H]^&JEYF)*OO_K^O?OGG*S*^+G%%R-FP_8:^C6CNO.Y<1/O1_6,U?J+/3F26!D4V0%0:4!@%N&@U+92@B\E:":X.(OOZ MVVY2?5VU+Y;II\4RXY+,R8_7A66ZH^:;4+[XQ,]?PY(>!.G+=)9__':U*RUT MM5XTD-RY6HCI.Y>@/0L/M M-VZ% MTO"@Z28!?:_X"?IU4(\_7;<((3KI)57C$H+%,<942 $+(%7H)!R35# M81L@X.9;MT*!Z1T%!TBR"R2\I@!_229L(_B/)']\N3B=KY=G+Q<9)Y@Q1L8) MSMQ4LR8-!.F))RT9(F:!^;#H9PLBML*)[1TG[>3^O,XEO6J;GN8L+ M2TC>D2TFRBJ5FI$)Q @Q0<&44.B<"$D<%GH\^OJMH.)ZATH+V78!DA(@5322OE30. W//JK<#A>P?'H3+M M"1@OZ9_OEI\6?\PG7OH2D,(H(QVC?9-@';5&T-RBS?1'4BWLQIT7;Y>Z8L\$ M%7L*M"=,;+;&=\OWR\6WZ3SA).<<0[(<)&.T,VJ,X++4H$-)F:4HI./M@''K M[=NAH^/,9C/1]@21]XO5.LS^O^G7C>OD#$\FJ Q"_>#AX=)SP;B75D<%2K]V*)84,W!=M)UO1FL_=?%O,?&1B#F@EI"YA<2 B%7!:DA2< M\B%ICD4GRRJN\Q.X M"FG2P>EJ$F1!QE( K9(&E7@]J"<9Z>B4M4PY"FT:! 3WOWT[:'2?@FP@VBX@ M\GI.3R-Q3+_AKV$=+MB:A&@C_:\@,55 J:#!BVA(5L*8D(-VF!M Y/ZW;P>1 M[A.1#43;!43J,>[R95CCY\7R;%*T+LH5 :;4\SLA73W')\!;M.0&*32RA?&X M\=+MRJ:ZST'N+\@N5GVO+^LES\L?[R^=V:.@XYWB@&+L 1%^4LLX%NGO'[^0 MW%;O3M?U7D>-K"?%6NUT/5))-77.3 GK8' K=;><.^R; "*QVC8#B0=9R<; MBWEDT+PXP7FN=:.O9N'S!&N-<$0'S%H$A2Q H. )1%2,W"86F#HL877C==M! MH>-,Y?["ZZ3\^M5TE<+L/S L7]%WR"622OC$+"15."AO,H3J*3.F!%JKZ"F' MU=L^\.+MD-!QZK*%0+O"Q/G-@G,F9"E9,?3 >: ]4#!BPA8/63GFE$?EW6&1 MYX.OW@X7':"V%B&V>MYQN__"\\F6A:GN?+@,^%;28/@0K"@E=1H M//G'"5OX$C=?NQTB^L]B'B#,L6L:SM-I5Y;NQ_4C%0JZ2$3[*#8733AXIS,D M$2)WUB/A^K#ZA@?>O!TF.DY;-A%I,UC\R\]WY/B&OG'P16W"^GR%F?ZQ6LRF MN5[+_R7,ZHUSBKAPO;K)R+8WN)]\:MNKW;LQ<>"=[],5? [AZV13'E>WD7?E MU71.+YO27K(XO^5U"3ZG;8E2&Q#&*8H\LH<0:I5ER=$Y2*S0H(15W #C MXJ7G:Q!GZ]6/[UPMQEWHVM?4_'C'B]6*Q'K)92G(.:?-,L8<:-OD":)3"41) M+"=:@%H^=CZR#Y\1]Z2;U%^;TD@D16= B!.#H"JC( M2!ZRGB%+H9B,V=HT#&9N$3(N= [1[+T@.43,'6#E95A]>3'/]:_?_O-T^BW, MB)G5B_7+L%R>3>>?_SW,3G$B>521IPQ6.$],T8**MCC(AB/+H3##'[M_N ]V MMB*L!RP=!(#%T-KH &(OOH4I?7N&KQ;+C\3117'+%%>_8EQ???7CA-HH)Y'; M!,4D6I-.1XB%@@)MHTCH4#C7W%#M1N(X?32&@]V0&NH!@"G5JYRK#YB0UA3Q M^1;7/WAQ(=O,G(,"*U6LN\ M1Z_GWXCJQ?*,6)@(A8:)($%IHXEV)2!D8J!P%K4E\>CX6$'[/KBY_OYQ&G4, MAY.]9=L!+MXO\6N8YM^^?ZU1,>W?[]9?<'E#1A.M0C$R1N(A9'(T XDE, 8R MA5*\5(7IQ[+'^\!E"[+&:?0Q'(I::Z(#<-TD'F4J.I%P?+"T\Y*K5POW%"2E ME&=!)AD>*W,Y.(@;IR?(@-O3WM+='QJ+=9@ULCN+K[A0X6M- MBU0;ZH(EYTR3+- 1S).P))!$D6TH%DUM=J);>]&/T=.#R]PDZF\F] YLRSOB M)-3R\3<85OBA=GY]5_Y*AK.*:X)<2Y\<64;RT4 I6^\;% -<1N-BTDZ:UEO6 MHP3UX!HW@5 [L7> H=>D@_GG*3GVYQ*B9?#;]S0[K25 ?UDL\A_3V6P22^$F M*P,L60]*9@_1^@)>L% ;]6;)6'-G^6FZ>G"BFR"JN1(Z -8EW=QQ43@6(-N* MH'BM([/"08XFRFPQ!__8%;)]P+,30 ;VCYL 9"]A=@"":_[[V\4\7>8-C"LR M>2A:$)*#=Q "^?'U[A-3A&EA'RNZV&MGNH^0'KSA-CO2P6+N "OG]$\4E[9D M150G3E1GC^<=_B06&4IR0CS:$F__$&FFMSR M34WRE\6,A+ZJ+OKZ[%(TS+&BK?%@'+&D3"@4+[("QB,> MEPZC_8(&7>S&PY #43? 8;NX< B,RAL &Y$(@YL/9:S!7RVCK@( M(>;6@?B>J!DL"S@0:@X4=E_>]U4$>75$DSB6FFMBI>;%F0X0&.WMHK"D!/-" M8>M-ZU&"NC$]1W&$#E1(!\;H9L;\!VMGUW(5)5A:8DC!B,@2E$.*?$VQ(+2W MWFEI@QCVL.(>HKKQD X%P*/G%X=JHP=XU?37O?*:Z*2%E(+,L)<.%.W@X%0N M0+NU3+XXFVQS7#U(33=FJS6@VLB_ R3=SX21T6H5 Q13,VE<^#I' D$+6@OD M^PET V:<=L3/,7RGQO@Y7.H=>%"UE\)T?;(I^)[7JU75PN(\$5.38%3!D 18 M"A5(."*#8TI!-I)< 5NR;A[T/T).-S :SGMJI8P.3-(C$A(NJR@U0DE50A8I MQJB#"*Q+:.J][!1:)RA2&'?U1HH2 MI38)$N"RXT#41RZY3XRUKSB[0\;8-Q/;:/AN7>M!XNX ,==:!9W3[XIE%IT M4ZQM9$)R2XDCNLX#06\ =74 0H_X#I,YYA_"\LY M11:K:^S^BF6:INN)E%9*@Z%V8J5U%;,![X(%DP7/S'*>2FMWZFFJQBV(' AK MC971 ;SN"FJBE?-2905)($6MCEN(2M8(1A(/,3HA6Y=@WZ5BW(+)@>!SH+ [ M2#T]%?Q.&#>TG3.$&+'.%<@4]-8K4BAB"=XX[>5C0T&'*)D;UQ(=^PCO<+4T M@]E8C;'>;Q3SI?Y>F-WDJE67K)NO.&[+K$?8.V;_+%73[W6CT](8\J.< Y]0 M0>;.";)F$DO[;6+X_EDW$R@DZW?+S6OS)D1^C\M-^^*)C"(GQQ@P+D6M\XK@ MT$8P4A:.4HOXZ%2!PU-8#U$V=E:K,7(>SV\U44\'7MA-KLX;9+\X77]9+*?_ MA7F"P3N1_:8KMJZ'Y!P\BQFX85HS5D0IKJ4 M.&$FHENI8RQ=:SY"#EC)[R.AZV#%-$CIB[,,!=<2I26 MZ-9U:K94X 7%XM(CTR9)YGCK!/X#I(R=_3HVEO900(\XNC[3)CEOF6+U'FVI MQPR:=G>#%(L4U,**HCAK70YZ\!BAP:X<'Q]1^ZKB.7:%OY3N:E%NG'[5XE3'6)27@K@M+G5:569O'6,4!RSP1NC;6R= M^GF E,,/?RX>^*E>89SPE'512@$/9'F53!R"E09XEH7B6Q&3;9UFN$G!N+FK M%OJ^>^*SMX1'W.!6RW7M7I9/TYJ""%Q^FR9\\7VZFO"H&,M%0C#TAPI>@V:0Z9R#U:^+DS"= M3[*QB66?H61:'ZJRXY!"@&Q1:%DL5X].-]H1&7<)& <>;71Z%R '"K@#W_B" MD=_Q).)RHGE0Y,%;R*'>\O(L5W$@\:),XL$C'.4 M,1PT]I=N!]!X0T(X;\=\(9$+-A+W(:7DP&I'"%>.$"Y2/7:120KM>6Y^M_(! M4L8YI!@.+BTDW@%P+OTS"CCQ-?US-4F&,63% I((*-:OZ00E V#T4II$__/6 M59%WJ>CDH'1_K[61@#N R ?\AO-3O&I\E[U#$Y, [UWMFV$<.*4C+:!H>$!/ M)K+UM9+;-'02U.RITSO%L0<(N!^ O"(YU6N"P_"%JQC5(;;1]#X0:B+X#$'T@;1 !=;S@KV1M9XO-T(H+84T0%286&(3( MR9AF"B8]Q@0,O9&I"!%YZU#L48+&M4.#0*F= CI TT>IL 9SC,LR(I1?Y M9#J?5C&MI]_P!U=*.*,"BY"=I=@D!*-M;:VQ?!6U5$7N8 KJN;3!(LI9N=DZZ9)]Y#12?US&X_Z M4#&/B)1:#S,YOS=W-=#VU;>WT[^$Z;PR0NBO0RA7FZY/Y_QM9E'F6$(DYXYE M3ZO*)UG;NM(6G;@4$IDL[%:/I+N5-WN^NY.ZYL.@D\+,\V J[-ZVKZ8['9R5_/B3R2 MRX1G84L2&E+B!92D?3L&+!#1VBPR^8;1-39D [+3245U&X/8B]H[V((O6;SP M(7XA1[1,:2%K5F?V"N VNNJ6&(@E>V 4(I>0A>.V_>RW>TGII/ZZ)?(.$W<' M=I-,_35?(D5EC/(:9*B)%1L4!.L0)&8;F3:E-$]GW2"@DWKJ-@C97[0=6),? MO5A^W'#Z):RF::(HC/'2D4DT1+HJG$'0S$*.B,A\0C2M\PGW$K(53MPSP:)\5D[4_BLF)E"H'$4G20 +Z*1#Y-:WOOWS "E;8<8_ M4\SL(^X.4/,WK,-W,;_X1N[:9WQ[6JMDWI4[ETW.EP3%MR)YVE7YQB'+BI-# M)@448XO+(2>76J>>=B)PN_,7]DP@-IQN^@7>Q3*Z>]E)H52Z=KL%1DX MJ8B]A+:47(S/K8^(=R1Q._ ]EZJ7(?73 ?RNW=P[=Q$W3<[O=%B\3"U[79S, MQ=/J0G(&F"<#SS& ]8HD+)/3J?4NNB.)V\'ON50N#*F?#N!W,S(Q@D)3'B*@ M5AJ4B4BFF[[,6BI9*:]%9$[:UL?&0S%R[CF^=B8W'))'!4@'2^4S^OQ\<&8Z^[0,\Q7)O0)DGC=?S<[ADO_/Z?DIXZ44G"A*H**-S]4MT 9- M6V *D S7T4>>@VD=T0_#R;B;1*>+Y(C@Z'R)7/)4C-&R% =:(XE99DD&P"=@ M6N;@L+B$K>]E-AMA,%B13,?PW4MQ'3CK][!SQ8HOF4G#(,LB0"FCP 6#P*(( MF>>H6&KMA3]"3B?U64=PKUOIY#EV$K_>9^B>7O(W.&O43>FAEO7':J?T%)OM MNXH_U@8?LR)[6%ME" <*"5_16PY)*9<\1N]DZWUG*\(:]UIRWG.?781Z/Q]4 M8N15HT,PS-1C=A4#;SV8JJ=>2^VQ\$3GI5WDW8&+=DG]N42J05[,ZVK==)=Q M2CBGN03TP50;',#7"Y0ZHBO9!<8*N:)5A06DC28X1NM*##%7^@81XT*F@6(?;EJZAY0[@,D# M,Q\OF&$IO:@JSGDBB8-;[U9(&MB1LW13 Q ;12@=PNSW( M\4?7JV!TB1E!Q%0[DS #'KT@+E0V/OA"_D!C;-U/R;@7NMH#J8&\.T#-/;4[ M09:,6,< 252@+'F)/B=/_B)FJ3(+5K=N(M5YE[$F\==^ NX (K?S_J_G=_,; M'Q:SV:O%\H^PS)-0LK'>,S"N\LBE!5>%5ZP.691: M8Z#[0CB9T$:GLBXNY= MJ,'4TP'Z'AV#(+TT-HIJO]&"JKTBR> 62"9+,KKH9&J=63UX(L60S=Z' \(N MPREVT"/NZ.9.DM;1<-]H([TR8=3&0^D.&D+D$%:V D*2&4*+-OBB4OGV[ MS;U&_0ZV$1X34P=JH!LDW2PTC9X+DXJ&$LF@*V$9676FR)4HM?#(4,S:>C?< MO!@E:M'U:E E*F&J#((CI(S/481[[BQ MW3%!UEQ+8XZ_J-U)-J(Z'U9VO5;R?%??_/#=UTTOA]^^XS)-5YAKIZ23K[/% M&>+Y7,;39?I"8G\_"_,)DSH$11%U5K4Q*:LYNDRA4O!1^<23R_J6N7N@8TQ; MNL;MNW$,@(ZMS$YQO)D4NCOGF<54!,M@/9(&M)2T@G4!IR-G*'3&_&213'NR MQNWA,3:*CZ#*#N+=1Y?P!URME].TOIBX_*+*>;/KD,P+3M>G])F)#4EH:R-$ MS6KKG-J+FDD%49F8BU9&E-;#W XF>MS>(T>/." ;\-] M#)N"OI/:T6>C^@](DE]-UWC1>OA<4A\P+3[/-T_96(2)$+:6!RO0G#GR]!EI MHP@D=U\5AU*[T'PN]] \C=MBY9C+H2MT=+!:'DVL&2Y90N)%E7JKV@<%SB<' M2$Y:R-$Z[08H'C\LW3E84Y=NTIV[:.7 )-5O\SQ4LK/VU;,R>(I9:Z?;X!3X M7 HPG1UM-YJ%V!I;>R8[AVOB,G*VGWF M^^7BVY0D]\O97TGLK^>7;9A?I/7TV^:N[WVM1R^E8B2*P%4 (50=)5<= &'( M<38A)57/\5WK,\(VE'=R2GTHTNY)TQ];K1WX=3/I&N[,TW2&-QCZM-A2 MOI>RK-WCG!(:HE*2)$"R]$Q'B$8G+:+36;1NL38$'^,>EG> Z]'!T8&I_='' M]6:Z8%*RY$%P46M1(H5IM-R]TX'^<"6*Y(LTS=IG&&=!;I>35S,D5E9DYM&@&)10JA=[%).4"FE-S4Y]J$VB7U72( ;;JZS^F/<6M$\Q"0" M,*S\I11(:BC!.:V3:-!^LN"N-XU8N=0?8054\=HG(KQC75PWB/ESTD+LV MBNE%2DO.B;>@:M]:I&R@/ILI^4/KKQ=NOC0FK[0G#]Y?T MS2FY22SKS%4H8#EGH#BMP&!2@1QY8"3 S&SK>[MV# MX$O)7=2D7(HMVA1-M@)RO1:JM$P0JA=D0['0:>EMCJ[=9D M&TP\";T#%73H_CT0[.HTVSG]$BW92=#<\D#T1R]=G;9NP-NI-O=W&;(JI]K+NU,YM5L)5 M/O:"M7,C;E4@%H"I1&+S%%&YVEPO49#OA.",L]:-"W<@K[>KED>R:&W4U4$H ML7T5RT23?4XA() 8+2B!#@*Y$$"&F07IO'+8>B+Q]M2-N[-V4 LTD"([&+#P M &?5T5WM(%QI.!J9R;7P!D'Q[&JKM@(<^D.=J1*H.' M5&L']O9]./MQ_2W]Y^ETB;^'Y=]Q71,"5^G^BPOF!F$[N=,UT'MH39 M;/6NO/@6IK/*]*O%\F.XP7L,EB$9 2@6#:@8-7@M.(@<<]9,^.A;WT=O0GB7 MQ<1'A?;1U3]VAUE0M_]6C\R\0HU M+\9 B*YFP'@]-LVU^VRP5M=2:-[Z4N[VU(V;9NK!/@ZCR"[R4=N+=Y*=#8Y; M6H5,:E#(R, GY2$$5VJQM=&B=0'1]M2-FXWJ *0#*;+?+,"KZ3S,T_;"M37/ M%Q(#4V>3*,60%BDF8/56(&TA(>@C);%VI+R;X8U'R0(,J=8>L@#7?.W:'8IX MQ7?EO-G(7^>DRM?T#6+W6STDN__*5-UU5O2QV6EM2W*]4=I$8R@A10%HZA"> MH$@8.2A@GEE1!Z-__(^D$+SDHK&;-19]=X.1R7PW%#V<%62L-95CGV6M9TTX9 M@JN.7$HV*F.Y$:W]_N$W@\$N??4)\9V4V,T0E,-8SL$@UI%!660&J@A)+&<. M/!L5D\Y28.O*\>%Q.]AUL$YQNXL2GT$[RX^G)R=A>;8HJ^GG^;1,4Z!GG]_A MH)WFZV(V336&N\'0=JTLMWQRRS:6^S#3J(7EB\O7O+]XS156I53,U2[](A-6 M@Z;84>4$/";G+,]!NM:SDAZFYN V5%>2O?N23R3,7^C3?Y^($J+6:( G5T!A M,1!3\<"]S%@B]QJ;=^O?BK*1VU2U0MST=I1U:\YV0-'(;O;:(:2_;#C*, MYT4,-?*YS4@P)DH?*J)%(6X') DYIAB7/+@6W<>>Y"8D7OB#6-YVHB^ M PQ=A+%/A;FW\XX;IB=.Q5"B5^!DB>2/%F(S;>)<3=^0WLKF0S,.H7?D9G?# M(/%H"NP K+<[2+Z:SJ=K?#/]AOF"(<,*2A$,Y"AJ>Y0ZC$;*#$)@$"1A%7SK M>R)/$C5R5[JA#&!+572 K0_X#>>G6"M*Z@%_%=#?INLO+T]7Z\4)+F^;^6PY MU]D%0"VJF2^%9,$S&"I&Y)I+$#*:\_EFT6H.F968#4H*"IJ/5APN(9N^8#Z=X?DI MR5V78"/BJ[63T&G&/#'K3 +ED@!ON 61':]] BS/K4.(W2CL-J.Q"VKN)&B' M4U('>^P5=T_YIU;!ZQBA*($L&>%2\[SV'F1VFW9I M@\AAU-4!(A]A[)X&]+=X98$Y",/'/(+E0+ZC M UH ];*EB% O68*6(?A$@A:V=1UQ^YAG<]QS(?MWY>&JA[/-\IMX&7.214"4 MMI ;+0WQC+3FBT^TVD- FY\"WFZO[#9XV47]-P[7AI'VF,>QR_7D0ZV>?O%] MNII(5K#(($$RJT %H\BO90I8,-HZ[YR+6X7#]-1K2X*^NEH.-UXX#D"&U.3B M4+'V@(7?\23B4!A:+%-8+F_-6 MT=\3JK_WY2.#8!\5+EK*<^SBG"TL(^VEY"CBZS6>K";&LU ">B@>B;?L&%E* MK.<=4C$6N-9%MO(KKK]XG&S4,3:/H;7000+@[6E=%S7G]I6BQ?-&>I\WC78F MWIL4F>(0J[24)CRVZBC V!=-(#> M)!XHWCPEC;V>I]-*R2^GZ[>+]7_@^GV8YHG-9(5C/4NP2/M\+A&BK5=NI2HQ MQ\Q\:@VS;6GKV[(U ]T@JNH @J_G]"Q*C M!,== )*@\D)Y&T+KM,.#Q(R3.C\ZR-HHHP-4/74Z]6+],BR79R3 ?P^S4YS4 M,P!R8CDP+XF]ZLI&M&3&HQ>%?$X53>MC_1U)'"^[;L-7>.4+1X=@\U5 MU(%!W.T(Z@.>A&EMFE5/55_K3W_@[!O^OIBOOZPF)7/#42($5ZM.(RW> M8'(MEV+!E.BYP=87\PZC>)R>"ITC^2"U/CL0UV7ZZ8_%Q$FF168).#.&Y)L5 MD* 9F*Q%0N<0T[C8O2!TG'&[G4-V'R4^3Z02]'!B/7-1DV"3JEO(:2*;! _TC M6D/.3S:MDZ3[4;H=6I__X= 1]/@/4>5Y3R>U<+MWVN!%G[L0:.2QUZD8F5T!$@JNT""4)YPI+AOO6F^1PU^"VRS0[16O?&PY!I RJ6 G1 MBUP+P'G@9"VX;SU O=W!P!AUH[M@9+L6!H>HI(,M?M>S#::C*)X["-S3-I1\ M!)\=!U26:>-"3NDY'$J-<J12SYD?,IQ-%W;J$ Z%M5R7\ M0_A\]^1:A[]"_O [1[A OJ4 CC##P!D9E!(@;5&@HJWQ1DG@11!)9JN*>#ZY MPNMB?5=N+[6)5L&8'"RY$;5,.A*;9-')EKO(K?=6!-7\JORC%'7KU^V"BMO& MKJ$2&M8$#V/N+OH;5MFFB_Z&JS^FZR_IHL'A7O;LZ8>V-%@[LM#((CW1&/*J ML8LJ0=7Q9\K5H3P<;6T^Z8#K0E:5BUQ4ZXS6EJ0-W+_T6L\X*[*U0@/Z7'O^ MR@#1<0_2F^)U0694Z_95V](VKOT: D,[-C#=3TN='Q$_:1'V[UJZ[:./:N & M[%6Z+41ETD'ZP@ C3P316&BKM1(HM@C&"V-\],_3S/TZ787/GYO MO=5&JS!E4K81N%&T>@K3X"6+M$ZCK(U_M?>M*V:W(NQY&+A=T'/;P+77SW.W M;I<1W,O%C "].)\8'N;YS3350.T%26LSOO#B2:MX=O7)Q?* 0/98I!W5N@XA MSF-;9VL40ZTAT0*K5[4Y.&\B%"D$EJR,4ZV'%'1@G2<)BQ$Z%5G8HMWP,HNMG@G;8SL;,U[@^.'.1Z4=TFP15JS^UVB^B)/DSWO7M>VBM!;H?XKEF:R=RC6YI-IY)D7@UK0^,;U!P.CH.%2A MBU;2[0 :'Q9G8;8^NR#>F% B^E([V:=J2@/X9',UI<)BSD+SUEV0;A P4JNC MP:"QOW0[@,:/X.)2(I=L*&9T=A#JP8-BR4#D.H!PNL2<# _-Z\0?(&6DID6# MP:6%Q$=V2GX/_V>Q_.'1KRY:J"9#+GL +26"*J[>JLP93/%9!D$BX:&!-W+W MS>-6W0SBLQXHWI'!\3:+51.=]THH 4687&^*)PC2D8O&2[69)"N_ M5<'@$QAYD(#Q?))#-;IH+=ZQ&\Z^R G7R^GJPO9Y74+4I0"+KB9F"[GQJ#DY M[QBY=)JAW6[V\\WGCJ?P1EI:M!'9V-I^'XCV;Q>$"^LMPR0AYYKX83I#J/<& M'!J3@I,FW-XI'M#U]:>.YU,.H.F]Q36VGC^=_OUL%7[$2)$3%#&##=H30(T# M'^IP^NQ"D%AANIV>KS]U/&=P #WO+:[1]?SZWW]]\;]^&")5I#5)@]2"8F%9 MJ\]50:! V$2;;6V%O9V>KSUUI#Z1 ^EY7W%U$!\^X."^N>PR()@42M9[@[*> M>*H0(01.\:Z*U8=A(;'6D[F>HFGB,=5N%F>U.&.\CL\MSE#UQLEN= MU\%*Z[PHX@V&U7X571>_V;*DX#YB&IWXGS_Z\K 6K9$8A06M' 6K1@C"#GFB MJ)5,1F5E;\\1.SP;>(."@].<%8SX[BO6JHKYY_.'7QNE2<:7!>,!DY"@D@L0 M?+:0:9D8Y6(0MG59U>,4C6M!#M#^G6QG.\$_"].P?\GGC=]O;R8&+-Z\!1>9 MN%4E*V";R@YG,SB32*?!A\0=;3>N=:?$UL:"GO9RL5K?*NYSTH4LC 6,DEQW MVD;!N8VI=Y_, *5V9AUWT?=<\'"[JL:/A^TS<+V$6Y@D_?D%< M7QM]>HM+$:1$7:\R&K*N"K4#)QP)TBAAN78\WQY)^D#HO#<)XYZ>- #2$37P M+/:?UF.'MWAJ^[WJZ&.#;P%1*:$B8PY\*;5%K-7@'$:P3HC,)<=H!S'TS7:P M#W4@X;ORU]7Y9<)WD40WKW>J*3[[4B<>OEHL;RZ7-],0I[/I^FR2DC6%IP R MU%7H;03O,T+43',DZZM$ZX3. >1VM1/N@IL[@?615-9!XN?%$D--2X39;RO2 M%;Y?+H@QXD,5*X10FF( 37R(["$4%N=?WX0[1TM3$>@JLFPA[; MQ?I0A4\;]R^G)+::79KGEXNZ?7U_N9B3D$YKA[")#HC>AP F"@V*?$6(&!%" M0"F4SY+E[=RIK5XW;I:Y 4(&DFP'!N:FG7P?SL['6C)#((]*0#"RM@_19":= MJ!56Y&MRI9GGK2\/WD_).*=; QB7!H(>=9S99@G<9.+%?'Y:;66B^*%J9/4> MEZFJYS-. D/EG## @_44H'!1C^$EK06RG$5(SS%O96"V?N4XL\I:&YEA)-R! MH;DO\#P?2O7CJT^X/)EPD9CAGM@PSH%BT4-D08$KR2H*;H-.K7O';$?9.%/% M!C!$ RAB;)_G/I;>?=WD,!:_;<+>\PG.$Z^X,]$)T*FV;8A20:QCZ[7F23DF M%.W4>V>1[GOC.!.\6ANE0>3;K4V:XQ]AMED#69&'3\X]EM.:0KAB &UTQ<8",CI%7KP/ MX ,C!@(+@IN28VQ]^?0.$5TE\ X!R&'B[0 ?5X0;(X1DF0,*67M_15:C.X3H M">A1(%-QD,J K?%PK'3=(7C83YS-VN$VS\K%[)SVDN!;4] JN0Q1"P-!F%!R M9DKFUM>1GT%6KMV6LI>@.S ;-[GX&];S,IQVGKNZZ IUJP5$BLP2H#1J%3H@2KFQ>][4IC5\F^P1=Q]V2ON@2JG@\/Q M;5_0/DK?B[5A@G<;Q.88'+)%\J^36=DZRG8?9^L9J>]]HG@:YJ-_(WT^II2L^P* >)R3KFRW&( M.0O@UF,1H0C%6S>$;T5[5XF"71#UN-4[DC*[VXIO\SUQMM@<,0!C*H"2A4%4 M*D+PS@K/M4KIN-#L*O$P'.!V$GR_,'J[F*<+AI(WB+PDL#P94.080$R1^#.) MA^B*1M7Z;N&31'65M1@ 3'N*OU\\39AD:"6YL^AU/2TL"KS$ EERBRH5EDWK MVN%#2F./E<\8 #L[B;KS<5!O<3U;K%;$Z.H+B7QMO.Q&CQ9/8F.+AM0MH(OO/B5GYF+Y@ M/IWANW(K&79>P?2N;-ZVNG7W+?CH::L,@)$Y4#Y)"/7.G2S2Y"(=Q8*M[>I> MA'9JCG;!SVUS-+S"GI>I.B!?^<"3!C160V8@'T1;UIG97!QPKFGS*X77837""AY!:'[@T(;Q3:[8+ONY<,3NZ M0CNW;J_"=/DMS$[WBN.N?KFE#7N I$9FJS[]W^O3Z^D;V?"*_';#E.76))5YZY7Z&#T'#PJ_Y]G7]NC:4ZLP#CD948.4 HXS MI(W:1/Z MRIM[\8UBGKK&7RV6'\/L]MQ+$QWR*"5$5P69>0:?'=E>;;G*:'+0K9?A+O2- M>R8[& 0'4]%SV10OBX4N1?P_I[@DNK_0]\[7Y; MJ_6 1,3P1 VR<1]'A,=P!9+!G-$E0*$)UM)%@GH*@$ZGY$*2CK6N!#FB*_"B M#H(]/_FDM7[/;D,?>+N8+V]N/INFT]Y)FU708+7QH#SM/HXCA=%S8/@;>=#GM"YH4<-Y=F[O)W,0R"1>G0 MN0"6E5JM5$A^7EB04FMRI(R)S6_1[T1@)SAMB)"'0-A<73UA\?7\Z^EZM9$8 MOQ@@DB.M42L1,B*Q8K2%:$J$%+7,,@;C>.L"LT?(Z01G[4'P$-P.U$BGX!(7 MK+A8G-L!*&= ML"*1D6?\?&IRS$&"#"G'D%@IKG7%S2/DC%M:/2ZX]M%(3^#ZY>R:V%XM\3]/ M<9[.-CZ%]Q@9Z@39UT)CP2P$YA$2#\9H;V49,G)XB*Q.+%DO84,3[?4$R/L8 M^K%V7>8,,Q(C](<*9,!=%@4"\X$>H7.@XZ1>/*L@%>VCJ&G+<.I%$-H/;5]&[HZ 5LK,&P3B1ZBF1[0 M]N,.Z>M-$^C*TF91%L:B\)Q!2;04%0NU-6ND+X,KV5"LPU3SX^;[2>G$?1MW M1VV@I0[ ]FD9YJM2!Z//\T=\Q7W*T^T2-7]__H8B576:)6#(3+ M-1@O#KQAY.%J5KA.=59KZPBV)?TCF\H6@%ITHMT.D/W7CY^6&V-P=G5,?[$A MJ*2E#89(CXE$:A5"E"R#+E9'VA"05G]CG#Y,S;BH&P\ABT'4-6I+^\M*[_\\ MG:[O\E$[J >,CD)\\G&4<^3CV**!&5]*M,[$YMGC^RD9-R+N!G(-U-2!G7L] M_X:K=95)E=9FR\ 061:14[PF%?DUM=L*<:_ ]^$D M'JB;[M#U,JSQ\V(Y_:^-'B_6BRT1F18(J=16F(D%DHUEX)/54D:AG6GM]3U- MU;B[ZJ%Z?Q1&!RNA UA]_+)8KFMWPBO6?IA?[[P,TFAP@<=Z-8'6FRP)@I8L MJB"+:WZ+XV%J>H+1X7J_?1.VC1(Z@-/U?G5OZJ>K@NJJ$S:J&&(FKU'7&:/D M/\;*#/+H*70J7*G6;>0>HF7<_J-][(=-]-0IWBX<4F&$R@$=Z&C((<5ZR=O62M25-ZW[H3[,#7CFJ\VVMX"0GN(O@,0O5M_P>55$ZX?5UG.*P]8LBXG M#3[7D#<7#E[3EUI[RS19=I3-^RD_3$Y_,-I'X[<[6S42?P=(:F'6.8M&2..&.\5OP<"XO9;[V&C'0T0'R^&:.WO/ M)8*)+#:'$A"$MV0TO)'@C>(@LV'!H>',MRX*>)RB3HYHCP^5!\/<@_7V7"[1 MO** *,5O569\E1 M#5:-,<"%M,=OF[Z8S19_5!^)OGY)2)^2G[1:O5VLWR_QVW1QNIJ=T?*MAB1/ MA$])>9*$](I\[SHI.!I+BRJ$: NW16#K]$HSXCLQE(?B;;>KQ$,IMX.->A_& M)XP[X;P+D)1BH+0WM U("89[PU2T,976,XOVH;.3JM,>L+J3RI[+SGUY=_NF M1)I>8K__T<->1=^"G6/LW\5P[@HYCHYMQK6F#-X&"9M2?%X;)OCG=*%\BVX1 M$U.'\!A!Z]!; 4KP6*?)*4@A)^^8+"J/T,>CXSUW%XSLT;YC)X5TL)L^5$#& MF>(EJP V) ^*9P&N#M)&C(JQE)UBK:L!#JD;'0Q+S56^947H+O+O $9-RW.D M\BPFP8 '4>7)(@3++/CHD58MPZ1:F_%__(K0G0 U9$7H+MKM -F/E!@&QCDZ M:TBD]<*+8C5M18QYJ81 %DW$UM+L M*H4:"B_&A$ [C]6@LM$4Q#L'NCAAF(X*6>NSOYT('#>R'7H7'TY7'0#Q-DNW MA'FR6*ZG_X6Y3KC>Y/4GQ67&K-2TMUA::#I8B"5Z""+DD&N3/-WZSM&N-(YK M+0>$R^U.WT/JKH,1Y4_PE]+IR>DLK#'_9;E8K?XZI[UA5AG^"^TSOV!9U$DF MWR>&?"/IL0!+M1^(K]&J89][03B2U;FT\FQ ^KE'M!L4#:+E_L_L@TS5Y M>L6T9!H#L01-0%;J%X9Y,5Q9KF,V.:$#[N;='^H;V_EG>'MC^']AP_ M5T(^#8;PZQGDZU*8\*2"L+5>.47:E!BQ%VO+W: "5P8M_=]ZT.>VM(U[864\ MG#;158<.Q$V^?@_KBZ_^-EU_F<[?S?$_,"QO^$T3SXL2@6(&(6M&6>1:F.IK M>SQ/<:4W28JAW=W=J1ZWL+P7W#;7;X=^PU8<7QZ93+A410L?P-MZO M 2>XI^@X:.5:WS<]C.)Q*S<[1_)^>AT1Q?6$^XETS06K9R\*O8[X_/1EN3C] M_.73'XO*\C=\_8&].T%6#M M\P7LF"I\ULB]MEBSE#D[\I^0A*VX\^"9LH"9&R\,BF#2\*C=S<2Z_\Z(W4]U MG9U)LOTSG]$.ML3?KL/N5*3SVR99G23N0W*D^Z5HU>\?1BGF_W MB[B:(Z-*9&@8&,\)*#%:B):B)32IY!!BP#AR6;PTF+MS5;G M3C*;A[R'T9277JZ)-T7J(]Y;U:7%?/OEHU@FEB/ L@?CFHX!E$1 '" M>IF9EC'JUFU7'B7HV=C 73!SVP:V4TG#1F6CF+(#"MVW?/(1C=F09>X[[,S<,L9*!=J3D<6T-Y+'K4O3K6^VG(\:W;[N:^^O9W64]W-#1'MZJ5.I<$H M8I^<@4\25I4ICC.6_=I>8R>9V/+=D',4^WO]E9(!YGR*Y&]WJSKM[B> M\""KS;%@HDF@A NUG0.O4F+&D+6/O/45T'O(&+>PXTA0.E3\HW;MW*2,'EL, M)+7[&+3(M-4<*8*J;<4U+19OA ?DGH(I9%(D]=16N.>[QRVI&!A4Q]!'L^/J MX7RO.:%UNG^P^./76WM1]Y+5T%6JSS^[RA)<(BE;+2T3!7AQ%E0RDKQV+<$( MC3II5!);WXY[A)P6^]6M1U^%$2F6%$6)M:OES24#//QP =F#.Z]92!3-#0N: '<>70JUP\ M>*5,Q55M8A_J=0U7%%>"F]BZ]O 8#LZ'\,?O@9 V#;,5>>GOR@=2U9*\]TF2 M1I5B!+"@-3',;66XU([[M)7K*&5HW6?P::HZMCL[X.-!9Z>--CI)^&PX^MMB M^??7\_?+1<+5+98$Q9@8LP.?0F4I!)*=4V2N10A*"IO8$(WIGR!K_(30H AK MI(^>(/9J.I^N:./^RV*1;[-D@G4\)]#"1U"U"C-*CR!HRZX]U&,Q0V3LGR!K M_/30H!!KI(^>(%;S5RIR91@%LI9=7OP]DF;?!BGC=O)-_F M$CM1*X^Z.!"Z6% B, CU%,(849*U/L3FS10>(>?@"R$I+4[GZ]7%*WZ\ :^W M[+TOGV5E9*(P!%?GSB@OZS@/&P!9XCJQG'5N?G5T/U+'];];(>G.A8\CZ*WS M-,!=6[!_.O+!9PUKO 9,3CX&/"TT2I[J3)]ZW2?S2,!# Z;4M+=52?/6U<4# MFK!K5P#N+(%;23"1!(^;JZ>"!U"UD:V7R*$H6P1/Z*5N712R/77]&JI=\/)( M]YN6VGEVMNF 3.7##QO6.@V9MWP,;@R%]$4F\J+K$7])&9S#!#9SKD+1C*G6 M![,#FJ??2,6+,R0,;5HU7(/_1:)^8I4-RL8 85-"KZ(!CW6:GPH!10FQB-:G MLT\2U:\QV@4==PK4FNIB[/N$+^F[TQ1FGVKRE41UP56]%WG)C\CH4E(2<=TRQ>.FU\SY-54U5=A\69V%VG36AD[2Z<$"CZS U[6JKN$3QKDG(O&2";U?/ MN-M[Q\T[#@*F 07?0=)Z,SCOX^D\+\_N62")LU@;6(&149)]+18"YEQ#$*MS M1HVE]7R91PD:MSO.4*Y1.QUT *B[H>:5M14B; 8;UUM52H0(C@<.,3L1BPDE MZ^8=;!XB9MSF-$,!J8WL.S\L^?B%9!S#"C-]ZRO.5YL'[Q/$LZX"G.@7BU20HM5;W Q#6HVKN> MPDD.5A-:A9'*V-:GM/W8TZO%=)V.%\MEF'_&S5M_.;NSX%[\$9;Y:M%)G6QQ M0D)!\H%4U &"ID7'O) R>QZ#;)V:;5)U((2]I6@II@(F9@O*90;>!PU!!A0L\^C^P5S:JP/? U;=9NA*\,JC MI'@Q1<;K;1A1Y_(Y2#X8)20R@ZV-;S/BG[79W06S#Y_W'U/]/>2<-I33AS<3 MU91CVC@,4!RONP4SX(KS($/.0N82-6N-W1L$]#+#YJ@@N)V)VELC'^SSQS6+^^1,N3U[/$W$V_8:5EQ\C^5A(W(3 P6"N,[Y%AAB\A92C M#\[I'/F3CNF3;QG93HX.@,40VNC ?)XWD\D/!KPR%HI0V5IC,U.MDPQ;D-4EN/8!P6)8 MC70 LH\XHQ]]_@O.<;DI='R13^J=V/4R5$?@@K6",1^=HF8;FW>EW(G#L"_%# 6\X+?4 P:?\CX?7XSV2R#P)*\!(E+1G M1 9.^ (AJTANJ^)9MW;L#J>ZEV&68_I_1]9]!VA_,=M\!O/]K%\LY8FPA2F= M$'*HK:<^"EML!0NB)5C)XWOV:[%66=Q\V-\7([L=A>>1U \L?EF(^X_#9- M>#]O;Q>;/JEXGH!8?:K5=M=_7H\6WB[6_X'K#Y@6G^=U4-=$FBRTXQ*,,;J. MEZMCER0"=_]*F+/O3ES!_]W53 M[3\)2@;MLH)@4@TL+ >'Y$DB*<_DS+B)K>>3C,;LR*[1/^A::PJQL4\0]E;2 MBY1PALO-Q]_CU_X^1I1:A<2D MU%Y[<>ONR0-G$,/2.?*@\7$62F_Z[V!;NJKI>%P:\;8TR&6=7I?%Q&59;"3? ME5M=0(E2(%IIR!IHF]%:JU/KWJ'-B!]Y?/FXV\8X$.@%^_O(O9YR_K[(TS(] M3]2]GJ?EYA?N;J43D:U@7*G:0-G6;H"D&28]@ MQ?0$G,ZKA\_SV^OP?=_._U>_WK;A]@-D->NT79__*7R_IY\D.JW)+29UYJKB MS;S11'K.%+E*%Y@W PR-?)"<-D?8-QY]508?A.8>/0,\/U4P!9Q-#DC 62A- M<4-IG9%\C)X>SA@/Q\3]!]@--/!\3,E!G?SO/&4@PS)L)_^'L>18D2$J ]X* MBL@+_2L*+T!J"DE\<+408O:2"<56C%87.9!W:=U>_EY1^KPQMIN9SH_I?#] MW=>+L'XUR;U,&&-MBV*=$ZFYZ,;7\SSN9Z)C'2C__#5!7JL M/=(Q ,OUF,=E3:9&1@CH1)$N\\);GP3N1."AMFDC[M_/Q7W[;5<>G&>EN,(* MH,D$?,,(^($\.(Y&%,5Y#+%U7_ZM"!MWVQL.2;=M5'LM/2/S=("C?=]CAC)6 M0[K:NR%-6A8],@U%*W*/#!+(F"J$-%MTBD6HYF[I46W6Q].XPO\\K26L=;+% M>367=,XJ$S5H92EZ%36AACI#"2+Y%!&E:=U8YCXZGI-%V@4G=W*0A^I@S'/8 MY7KR9KJ>?C[/=H;5^<6X'(NKEX.JT:P5'9E!9+$.50VV!*:]W>X$B1Y_#3WT MU15R[G_SR*5I!VMRT4RL78&B7E:[J($.5I% *O\*?4V-*8A<1]!>*B-<*LYN M5:>[$S2NWC\.0%KH\T%H["GNE]H;=W-T[A6?4'O&03H6 M06&]>ZI$ %Z[V4JG/+?-BQ$>H&7D\L]6FTM3D8]M1=XL5JLKY^SL[6D%_[OR MGJ*+3:+IU716*TQ]5%9P RJ1L];JNG) ]U;H8 M5,8=&)PK4_P1:T2Z.=D_J7.U-N?[F%^19#?ED>_#*0 $ M @ $?" 97@M,S$R,C R,G$R+FAT;5!+ 0(4 Q0 ( (&*_%3: MV +GHP4 *T8 0 " 3(0 !E>"TS,C$R,#(R<3(N:'1M M4$L! A0#% @ @8K\5*Y]?/V3!0 11@ ! ( ! Q8 M &5X+3,R,C(P,C)Q,BYH=&U02P$"% ,4 " "!BOQ42PFP>C0) #F& M' @ '$&P 97@Q,#$M&%B8G9I96EN8WAS+FAT M;5!+ 0(4 Q0 ( (&*_%2)^(<$MP< /04 < " 3(E M !E>#$P,BUS96%G96YX8V]R9&5N<&AA'-D4$L! A0#% @ @8K\5-6#0FE]& M%N( !4 ( !W)<" '-G96XM,C R,C V,S!?8V%L+GAM;%!+ M 0(4 Q0 ( (&*_%1=N5@V-2( )U6 0 5 " 8RP @!S M9V5N+3(P,C(P-C,P7V1E9BYX;6Q02P$"% ,4 " "!BOQ4B9A^6VQ" 4 M8@ % @ 'TT@( OE! "?7 M% @ $,6 , &UL4$L! A0#% M @ @8K\5%WH5SY43 (DL# !4 ( !"'0$ '-G96XM,C R C,C V,S!?<')E+GAM;%!+!08 $ 0 !X$ "/P 0 ! end